PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Duverger, N; Tremp, G; Caillaud, JM; Emmanuel, F; Castro, G; Fruchart, JC; Steinmetz, A; Denefle, P				Duverger, N; Tremp, G; Caillaud, JM; Emmanuel, F; Castro, G; Fruchart, JC; Steinmetz, A; Denefle, P			Protection against atherogenesis in mice mediated by human apolipoprotein A-IV	SCIENCE			English	Article							HIGH-DENSITY-LIPOPROTEINS; CELL-DERIVED CHOLESTEROL; HUMAN-PLASMA; TRANSGENIC MICE; HUMAN-SERUM; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; ACYLTRANSFERASE; METABOLISM; ACTIVATION	Apolipoproteins ave protein constituents of plasma lipid transport particles. Human apolipoprotein A-IV (apoA-IV) was expressed in the liver of C57BL/6 mice and mice deficient in apoE, both of which are prone to atherosclerosis, to investigate whether apoA-IV protects against this disease. In transgenic C57BL/6 mice on an atherogenic diet, the serum concentration of high density lipoprotein (HDL) cholesterol increased by 35 percent, whereas the concentration of endogenous apoA-I decreased by 29 percent, relative to those in transgenic mice on a normal diet. Expression of human apoA-IV in apoE-deficient mice on a normal diet resulted in an even more severe atherogenic lipoprotein profile, without affecting the concentration of HDL cholesterol, than that in nontransgenic apoE-deficient mice. However, transgenic mice of both backgrounds showed a substantial reduction in the size of atherosclerotic lesions. Thus, apoA-IV appears to protect against atherosclerosis by a mechanism that does not involve an increase in HDL cholesterol concentration.	INST PASTEUR,INSERM 325,F-59019 LILLE,FRANCE; UNIV MARBURG,ZENTRUM INNERE MED ENDOKRINOL & STOFFWECHSEL,D-35043 MARBURG,GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Philipps University Marburg	Duverger, N (corresponding author), RHONE POULENC RORER,GENCELL DIV,ATHEROSCLEROSIS DEPT,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY SUR SEINE,FRANCE.							BEISIEGEL U, 1979, EUR J BIOCHEM, V93, P601, DOI 10.1111/j.1432-1033.1979.tb12860.x; BISGAIER CL, 1985, J LIPID RES, V26, P11; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V836, P279, DOI 10.1016/0005-2760(85)90131-6; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; DUVERGER N, 1993, ARTERIOSCLER THROMB, V13, P126, DOI 10.1161/01.ATV.13.1.126; DVORIN E, 1986, J BIOL CHEM, V261, P5714; LAGROST L, 1989, J LIPID RES, V30, P1525; LEFEVRE M, 1984, J LIPID RES, V25, P1603; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QUIAO JH, 1994, ARTERIOSCLER THROMB, V14, P1480; RADER DJ, 1993, J CLIN INVEST, V92, P1009, DOI 10.1172/JCI116606; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; VONECKARDSTEIN A, 1995, ARTERIOSCL THROM VAS, V15, P1755, DOI 10.1161/01.ATV.15.10.1755; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	28	220	227	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					966	968		10.1126/science.273.5277.966	http://dx.doi.org/10.1126/science.273.5277.966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688083				2022-12-28	WOS:A1996VC67000066
J	Pierce, M; Crampton, S; Henry, D; Heifets, L; LaMarca, A; Montecalvo, M; Wormser, GP; Jablonowski, H; Jemsek, J; Cynamon, M; Yangco, BG; Notario, G; Craft, JC				Pierce, M; Crampton, S; Henry, D; Heifets, L; LaMarca, A; Montecalvo, M; Wormser, GP; Jablonowski, H; Jemsek, J; Cynamon, M; Yangco, BG; Notario, G; Craft, JC			A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; 2 CONTROLLED TRIALS; CLINICAL-TRIALS; RIFABUTIN PROPHYLAXIS; AIDS; SURVIVAL; DISEASE	Background Disseminated infection with Mycobacterium avium complex is the most common opportunistic infection in patients with advanced stages of the acquired immunodeficiency syndrome (AIDS). We studied the efficacy and safety of prophylactic treatment with clarithromycin, a macrolide antibiotic. Methods We conducted a randomized, placebo-controlled, double-blind study of clarithromycin in patients with AIDS in the United States and Europe. Entry criteria included blood cultures that were negative for M. avium complex, a Karnofsky perform ance score of 50 or higher, a CD4 cell count of 100 or less per cubic millimeter, and a life expectancy of at least six months. Results After the first interim analysis, the study was stopped. M. avium complex infection developed in 19 of the 333 patients (6 percent) assigned to clarith romycin and in 53 of the 334 (16 percent) assigned to placebo (adjusted hazard ratio, 0.31; 95 percent confidence interval, 0.18 to 0.53; P<0.001). During the follow-up period of about 10 months, 32 percent of the patients in the clarithromycin group died and 41 percent of those in the placebo group died (hazard ratio, 0.75; P=0.026). In the clarithromycin group, isolates from 11 of the 19 patients with M. avium complex infection were resistant to clarithromycin. Prophylaxis with clarithromycin was associated with an increased incidence of taste perversion (11 percent in the clarithromycin group vs. 2 percent in the placebo group, P<0.001) and rectal disorders (8 percent vs. 3 percent, P=0.007); however, the frequency of more severe adverse events was similar in the two groups (7 percent and 6 percent, respectively). Conclusions In patients with advanced AIDS, the prophylactic administration of clarithromycin is well tolerated, prevents M. avium complex infection, and reduces mortality. (C) 1966, Massachusetts Medical Society.	VANDERBILT UNIV,NASHVILLE,TN; ABBOTT LABS,N CHICAGO,IL 60064; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; THERAFIRST MED CTR,FT LAUDERDALE,FL; WESTCHESTER CTY MED CTR,VALHALLA,NY 10595; NEW YORK MED COLL,VALHALLA,NY 10595; UNIV DUSSELDORF,D-4000 DUSSELDORF,GERMANY; NALLE CLIN,CHARLOTTE,NC; SUNY HLTH SCI CTR,SYRACUSE,NY 13210; INFECT DIS RES INST,TAMPA,FL	Vanderbilt University; Abbott Laboratories; National Jewish Health; Westchester Medical Center; New York Medical College; Heinrich Heine University Dusseldorf; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								BACELLAR H, 1994, J INFECT DIS, V170, P1284, DOI 10.1093/infdis/170.5.1284; CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; DENIS M, 1994, CLIN EXP IMMUNOL, V97, P76; FERNANDES PB, 1989, ANTIMICROB AGENTS CH, V33, P1531, DOI 10.1128/AAC.33.9.1531; HANSON DL, 1993, J ACQ IMMUN DEF SYND, V6, P624; HAVLIK JA, 1992, J INFECT DIS, V165, P577, DOI 10.1093/infdis/165.3.577; HEIFETS LB, 1992, AM REV RESPIR DIS, V145, P856, DOI 10.1164/ajrccm/145.4_Pt_1.856; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; LAKATOS E, 1986, CONTROL CLIN TRIALS, V7, P189, DOI 10.1016/0197-2456(86)90047-4; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MEISSNER G, 1977, AM REV RESPIR DIS, V116, P1057; MOORE RD, 1995, AIDS, V9, P1337, DOI 10.1097/00002030-199512000-00006; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SANCHEZ T, 1994, TUBERCLE LUNG DIS, V75, P386, DOI 10.1016/0962-8479(94)90087-6; *SAS I, 1991, SAS US GUID; WU M, 1980, CONTROL CLIN TRIALS, V1, P111, DOI 10.1016/0197-2456(80)90014-8; 1993, MMWR-MORBID MORTAL W, V42, P14; 1995, MMWER MORB MORTAL WK, V44, P11	23	220	225	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					384	391		10.1056/NEJM199608083350603	http://dx.doi.org/10.1056/NEJM199608083350603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8663871				2022-12-28	WOS:A1996VA90400003
J	tenCate, JW; Prins, MH				tenCate, JW; Prins, MH			Major orthopaedic surgery and post-discharge DVT	LANCET			English	Editorial Material									UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL BIOSTAT,NL-1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	tenCate, JW (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT VASC MED,KRUISLAAN 403,NL-1105 AZ AMSTERDAM,NETHERLANDS.							AGNELLI G, 1995, THROMB HAEMOSTASIS, V74, P1092; HOEK JA, 1992, THROMB HAEMOSTASIS, V67, P28; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A	4	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					209	210		10.1016/S0140-6736(05)65540-7	http://dx.doi.org/10.1016/S0140-6736(05)65540-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684194				2022-12-28	WOS:A1996UZ28600004
J	Mead, PE; Brivanlou, IH; Kelley, CM; Zon, LI				Mead, PE; Brivanlou, IH; Kelley, CM; Zon, LI			BMP-4-responsive regulation of dorsal-ventral patterning by the homeobox protein Mix.1	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; POLYMERASE CHAIN-REACTION; XENOPUS EMBRYOS; MESODERM INDUCTION; SPEMANN ORGANIZER; EXPRESSION; HOMOLOG; ACTIVIN; INVIVO; CELLS	IN an expression screen for factors that pattern or induce ventral mesoderm, we isolated a complementary DNA encoding Mix.1, a paired class homeobox gene, with no previously known function(1). Injection of Mix.1 messenger RNA results in extensive blood formation in the whole embryo and transforms dorsal mesoderm to a ventral fate. Mix.1 expression is induced by bone morphogenetic protein-4 (BMP-4), and a dominant inhibitory mutant of Mix.1 can restore a dorsal axis in embryos ventralized by ectopic BMP-4 expression. Mix.1 can form heterodimers uith the dorsalizing gene siamois, which encodes a homeodomain protein that is structurally similar to Mix.1. Furthermore, Mix.1 blocks the duplicated axis induced by ectopic siamois expression. Our findings indicate that Mix.1 participates in a BMP-4 signalling pathway to pattern ventral mesoderm, and suggest a model whereby dimerization of homeodomain proteins regulates dorsal-ventral patterning.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Kelley, Clair M/O-2688-2015					ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9	24	127	128	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					357	360		10.1038/382357a0	http://dx.doi.org/10.1038/382357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684465				2022-12-28	WOS:A1996UY95000053
J	DelFavero, A; Barro, G				DelFavero, A; Barro, G			Health services: An Italian market	LANCET			English	Article								One of the glories of Italy is its capacity to surprise. In out-of-the-way places extraordinary things are suddenly encountered; and this is hardly less true of science than of architecture or music or painting. Italian medicine can boast excellence in many quiet spots. Yet Italy's record in medical science and practice is perceived to be below par, and one reason may be a lack of central coordination-forgivable in a country that had fifty governments in half a century. The latest administration offers a rare chance of political stability and the prospect of reforms. In this profile of Italian medicine The Lancet's guide was Dr Giuseppe Remuzzi, whose central coordination was exemplary.			DelFavero, A (corresponding author), UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,PERUGIA,ITALY.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446					0	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					167	168		10.1016/S0140-6736(96)05024-6	http://dx.doi.org/10.1016/S0140-6736(96)05024-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684159				2022-12-28	WOS:A1996UX78900014
J	Ruediger, N				Ruediger, N			Bioinformatics: New frontier calls young scientists	SCIENCE			English	Editorial Material																			0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					265	265						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8669000				2022-12-28	WOS:A1996UW78700049
J	Andrews, K; Murphy, L; Munday, R; Littlewood, C				Andrews, K; Murphy, L; Munday, R; Littlewood, C			Misdiagnosis of the vegetative state: Retrospective study in a rehabilitation unit	BRITISH MEDICAL JOURNAL			English	Article							PERSISTENT	Objective-To identify the number of patients who were misdiagnosed as being in the vegetative state and their characteristics. Design-Retrospective study of the clinical records of the medical, occupational therapy, and clinical psychology departments. Setting-20 bed unit specialising in the rehabilitation of patients with profound brain damage, including the vegetative state. Subjects-40 patients admitted between 1992 and 1995 with a referral diagnosis of vegetative state. Outcome measures-Patients who showed an ability to communicate consistently using eye pointing or a touch sensitive single switch buzzer. Results-Of the 40 patients referred as being in the vegetative state, 17 (43%) were considered as having been misdiagnosed; seven of these had been presumed to be vegetative for longer than one year, including three for over four years. Most of the misdiagnosed patients were blind or severely visually impaired. All patients remained severely physically disabled, but nearly all were able to communicate their preference in quality of life issues-some to a high level. Conclusions-The vegetative state needs considerable skill to diagnose, requiring assessment over a period of time; diagnosis cannot be made, even by the most experienced clinician, from a bedside assessment. Accurate diagnosis is possible but requires the skills of a multidisciplinary team experienced in the management of people with complex disabilities. Recognition of awareness is essential if an optimal quality of life is to be achieved and to avoid inappropriate approaches to the courts for a declaration for withdrawal of tube feeding.			Andrews, K (corresponding author), ROYAL HOSP NEURODISABIL,LONDON SW15 3SW,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Hagen C., 1980, REHABILITATION HEAD, P87; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; 1996, J R COLL PHYSICIANS, V30, P119; 1994, NEW ENGL J MED, V330, P1499; [No title captured]	11	558	572	2	40	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					13	16		10.1136/bmj.313.7048.13	http://dx.doi.org/10.1136/bmj.313.7048.13			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664760	Green Published			2022-12-28	WOS:A1996UW66700022
J	Smith, R				Smith, R			The importance of patients' consent for publication - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	14	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					16	16		10.1136/bmj.313.7048.16	http://dx.doi.org/10.1136/bmj.313.7048.16			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664761	Green Published			2022-12-28	WOS:A1996UW66700023
J	Emanuel, EJ; Fairclough, DL; Daniels, ER; Clarridge, BR				Emanuel, EJ; Fairclough, DL; Daniels, ER; Clarridge, BR			Euthanasia and physician-assisted suicide: Attitudes and experiences of oncology patients, oncologists, and the public	LANCET			English	Article							DEPRESSION; LIFE; CARE; END	Background Euthanasia and physician-assisted suicide are pressing public issues. We aimed to collect empirical data on these controversial interventions, particularly on the attitudes and experiences of oncology patients. Methods We interviewed, by telephone with vignette-style questions, 155 oncology patients, 355 oncologists, and 193 members of the public to assess their attitudes and experiences in relation to euthanasia and physician-assisted suicide. Findings About two thirds of oncology patients and the public found euthanasia and physician-assisted suicide acceptable for patients with unremitting pain. Oncology patients and the public found euthanasia and physician-assisted suicide least acceptable in vignettes involving ''burden on the family'' and ''life viewed as meaningless''. In no vignette-even for patients with unremitting pain-did a majority of oncologists find euthanasia or physician-assisted suicide ethically acceptable. Patients actually experiencing pain were more likely to find euthanasia or physician-assisted suicide unacceptable. More than quarter of oncology patients had seriously thought about euthanasia or physician-assisted suicide and nearly 12% had seriously discussed these interventions with physicians or others. Patients with depression and psychological distress were significantly more likely to have seriously discussed euthanasia, hoarded drugs, or read Final Exit. More than half of oncologists had received requests for euthanasia or physician-assisted suicide. Nearly one in seven oncologists had carried out euthanasia or physician-assisted suicide. Interpretation Euthanasia and physician-assisted suicide are important issues in the care of terminally ill patients and while oncology patients experiencing pain are unlikely to desire these interventions patients with depression are more likely to request assistance in committing suicide. Patients who request such an intervention should be evaluated and, where appropriate, treated for depression before euthanasia can be discussed seriously.	DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; UNIV MASSACHUSETTS,SURVEY RES CTR,BOSTON,MA 02125	Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Boston	Emanuel, EJ (corresponding author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,CTR OUTCOMES & POLICY RES,BOSTON,MA 02115, USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1993, J FAM PRACTICE, V37, P123; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; CLELLAND CS, 1989, ADV PAIN RES THER, V12, P391; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FOGEL BS, 1993, GEN HOSP PSYCHIAT, V15, P203, DOI 10.1016/0163-8343(93)90033-K; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; JACOBSON JA, 1995, J CLIN ETHIC, V6, P149; KINSELLA TD, 1993, CAN MED ASSOC J, V148, P1921; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MOINPOUR CM, 1989, J NATL CANCER I, V81, P485, DOI 10.1093/jnci/81.7.485; Owen C., 1994, PSYCHO-ONCOLOGY, V3, P1, DOI [10.1002/pon.2960030103, DOI 10.1002/PON.2960030103]; Quill TE, 1993, DEATH DIGNITY MAKING; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Ware J. E., 1993, SF 36 HLTH SURVEY MA, P11; Wentland EJ., 1993, SURVEY RESPONSES EVA; WINOKUR G, 1975, AM J PSYCHIAT, V132, P650	29	283	286	3	71	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1805	1810		10.1016/S0140-6736(96)91621-9	http://dx.doi.org/10.1016/S0140-6736(96)91621-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU469	8667927				2022-12-28	WOS:A1996UU46900014
J	Dreyfuss, G; Hentze, M; Lamond, AI				Dreyfuss, G; Hentze, M; Lamond, AI			From transcript to protein	CELL			English	Editorial Material							HIV-1 REV PROTEIN; PRE-MESSENGER-RNA; BINDING-PROTEIN; RIBOSOMAL-RNA; HELA-CELLS; CAP; CYTOPLASM; NUCLEUS; TRANSPORT; VIRUS		EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND	European Molecular Biology Laboratory (EMBL); University of Dundee	Dreyfuss, G (corresponding author), UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA.		Hentze, Matthias W/V-3980-2017; Dreyfuss, Gideon/D-1218-2013	Hentze, Matthias W/0000-0002-4023-7876; Dreyfuss, Gideon/0000-0001-8129-8774; Lamond, Angus/0000-0001-6204-6045				AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Aoufouchi S, 1996, CELL, V85, P415, DOI 10.1016/S0092-8674(00)81119-8; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Bohmann K, 1995, J CELL SCI, P107; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENAMI K, 1994, J VIROL, V68, P1432, DOI 10.1128/JVI.68.3.1432-1437.1994; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; FORTES P, 1994, EMBO J, V13, P704, DOI 10.1002/j.1460-2075.1994.tb06310.x; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FU XD, 1995, RNA, V1, P663; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GRAY NK, 1996, IN PRESS P NATL ACAD, V93; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIU Q, 1996, IN PRESS EMBO J; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; LU Y, 1994, GENE DEV, V8, P1817, DOI 10.1101/gad.8.15.1817; MARTIN G, 1996, IN PRESS EMBO J; MARTINEZSALAS E, 1993, J VIROL, V67, P3748; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; MICHAEL WM, 1995, CELL, V83, P415; Moore M., 1993, RNA WORLD, P303; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; QIU Y, 1995, RNA, V1, P304; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STEBBINSBOAZ B, 1996, IN PRESS EMBO J, V15; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SWEET DJ, 1995, TRENDS CELL BIOL, V5, P444, DOI 10.1016/S0962-8924(00)89108-4; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; THEIL EC, 1994, BIOCHEM J, V304, P1; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WAHL E, 1996, IN PRESS TRENDS BIOC; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	86	59	60	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					963	972		10.1016/S0092-8674(00)81298-2	http://dx.doi.org/10.1016/S0092-8674(00)81298-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674124	hybrid			2022-12-28	WOS:A1996UV48400004
J	Beaulieu, JP; Lamers, HJGLM; Grison, P; Julien, R; Lanciaux, C; Ferlet, R; VidalMadjar, A; Bertin, E; Maurice, E; Prevot, L; Gry, C; Guibert, J; Moreau, O; Tajhmady, F; Aubourg, E; Bareyre, P; deKat, J; Gros, M; Laurent, B; LachiezeRey, M; Lesquoy, E; Magneville, C; Milsztajn, A; Moscoso, L; Queinnec, F; Renault, C; Rich, J; Spiro, M; Vigroux, L; Zylberajch, S; Ansari, R; Cavalier, F; Moniez, M				Beaulieu, JP; Lamers, HJGLM; Grison, P; Julien, R; Lanciaux, C; Ferlet, R; VidalMadjar, A; Bertin, E; Maurice, E; Prevot, L; Gry, C; Guibert, J; Moreau, O; Tajhmady, F; Aubourg, E; Bareyre, P; deKat, J; Gros, M; Laurent, B; LachiezeRey, M; Lesquoy, E; Magneville, C; Milsztajn, A; Moscoso, L; Queinnec, F; Renault, C; Rich, J; Spiro, M; Vigroux, L; Zylberajch, S; Ansari, R; Cavalier, F; Moniez, M			Pre-main-sequence star candidates in the bar of the Large Magellanic Cloud	SCIENCE			English	Article							HERBIG	Candidate pre-main-sequence stars were observed in the bar of the Large Magellanic Cloud during the search for dark matter in the galactic halo. Seven blue stars of apparent visual magnitude 15 to 17 had irregular photometric variations and hydrogen emission lines in their optical spectra, which suggested that these stars are pre-main-sequence stars of about 10 solar masses. These stars are slightly more massive and definitely more luminous than are Herbig AeBe pre-main-sequence stars in our own galaxy. Continued observations of these very young stars from another galaxy, which are probably at the pre-hydrogen-burning stage, should provide important clues about early stages of slar formation.	ASTRON INST, 3584 CC UTRECHT, NETHERLANDS; SRON, SPACE RES LAB, 3584 CA UTRECHT, NETHERLANDS; ESO LA SILLA, SANTIAGO 19, CHILE; OBSERV MARSEILLE, F-13248 MARSEILLE 04, FRANCE; CNRS, ASTRON SPATIALE LAB, F-13120 MARSEILLE, FRANCE; OBSERV PARIS, CNRS, INST NATL SCI UNIVERS, CTR ANAL IMAGES, F-75014 PARIS, FRANCE; CTR ETUD SACLAY, CEA, DSM, DAPNIA, F-91191 GIF SUR YVETTE, FRANCE; UNIV PARIS 11, CTR ORSAY, ACCELERATEUR LINEAIRE LAB, IN2P3, F-91405 ORSAY, FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universite Paris Saclay	Beaulieu, JP (corresponding author), INST ASTROPHYS, 98BIS BLVD, ARAGO, F-75014 PARIS, FRANCE.			Rademakers, Fons/0000-0002-3571-9635; Beaulieu, Jean-Philippe/0000-0003-0014-3354				Arnaud M., 1994, EXA, V4, P265, DOI [10.1007/BF01580786, DOI 10.1007/BF01580786]; ARNAUD M, 1994, EXPT ASTRON, V4, P279; AUBOURG E, 1993, NATURE, V365, P623, DOI 10.1038/365623a0; AUBOURG E, IN PRESS ASTRON ASTR; BERRILLI F, 1992, ASTROPHYS J, V398, P254, DOI 10.1086/171853; BOHM T, 1993, ASTRON ASTROPHYS SUP, V101, P629; GRISON P, 1995, ASTRON ASTROPHYS SUP, V109, P447; ORTIZ G, 1994, ASP C SERIES, V62, P128; PALLA F, 1993, ASTROPHYS J, V418, P414, DOI 10.1086/173402; Schmidt-Kaler T., 1982, LANDOLTBORNSTEIN NUM, V2b, P18; THE PS, 1994, ASTR SOC P, V62, P23	11	18	18	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					995	997		10.1126/science.272.5264.995	http://dx.doi.org/10.1126/science.272.5264.995			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662586				2022-12-28	WOS:A1996UL61900040
J	Orton, G; Ortiz, JL; Baines, K; Bjoraker, G; Carsenty, U; Colas, F; Dayal, A; Deming, D; Drossart, P; Frappa, E; Friedson, J; Goguen, J; Golisch, W; Griep, D; Hernandez, C; Hoffmann, W; Jennings, D; Kaminski, C; Kuhn, J; Laques, P; Limaye, S; Lin, H; Lecacheux, J; Martin, T; McCabe, G; Momary, T; Parker, D; Puetter, R; Ressler, M; Reyes, G; Sada, P; Spencer, J; Spitale, J; Stewart, S; Varsik, J; Warell, J; Wild, W; YanamandraFisher, P; Fazio, G; Hora, J; Deutsch, L				Orton, G; Ortiz, JL; Baines, K; Bjoraker, G; Carsenty, U; Colas, F; Dayal, A; Deming, D; Drossart, P; Frappa, E; Friedson, J; Goguen, J; Golisch, W; Griep, D; Hernandez, C; Hoffmann, W; Jennings, D; Kaminski, C; Kuhn, J; Laques, P; Limaye, S; Lin, H; Lecacheux, J; Martin, T; McCabe, G; Momary, T; Parker, D; Puetter, R; Ressler, M; Reyes, G; Sada, P; Spencer, J; Spitale, J; Stewart, S; Varsik, J; Warell, J; Wild, W; YanamandraFisher, P; Fazio, G; Hora, J; Deutsch, L			Earth-based observations of the Galileo probe entry site	SCIENCE			English	Article							JUPITER; ATMOSPHERE	Earth-based observations of Jupiter indicate that the Galileo probe probably entered Jupiter's atmosphere just inside a region that has less cloud cover and drier conditions than more than 99 percent of the rest of the planet. The visual appearance of the clouds at the site was generally dark at longer wavelengths. The tropospheric and stratospheric temperature fields have a strong longitudinal wave structure that is expected to manifest itself in the vertical temperature profile.	INST ASTROFIS ANDALUCIA,CSIC,E-18080 GRANADA,SPAIN; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771; DLR,INST PLANETARY EXPLORAT,D-12489 BERLIN,GERMANY; BUR LONGITUDES,F-75015 PARIS,FRANCE; UNIV ARIZONA,STEWART OBSERV,TUCSON,AZ 85721; OBSERV PARIS,DESPA,F-92195 MEUDON,FRANCE; OBSERV MIDI PYRENEES,F-65200 BAGNERES BIGORRE,FRANCE; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822; NATL SOLAR OBSERV,SUNSPOT,NM 88349; UNIV WISCONSIN,CTR SPACE SCI & ENGN,MADISON,WI 53706; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; UNIV CALIF SAN DIEGO,CASS,LA JOLLA,CA 92093; LOWELL OBSERV,FLAGSTAFF,AZ 86001; CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125; UPPSALA ASTRON OBSERV,S-75120 UPPSALA,SWEDEN; UNIV CHICAGO,DEPT ASTRON & ASTROPHYS,CHICAGO,IL 60637; SMITHSONIAN ASTROPHYS OBSERV,CAMBRIDGE,MA 02138; UNIV MASSACHUSETTS,FIVE COLL RADIO ASTRON OBSERV,AMHERST,MA 01003	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Helmholtz Association; German Aerospace Centre (DLR); University of Arizona; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Hawaii System; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California System; University of California San Diego; California Institute of Technology; Uppsala University; University of Chicago; Harvard University; Smithsonian Institution; University of Massachusetts System; University of Massachusetts Amherst	Orton, G (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Drossart, Pierre/H-8670-2013; Ortiz, Jose L./L-3192-2014; Bjoraker, Gordon L/D-5032-2012; Orton, Glenn/AAD-9862-2020; Goguen, Jay/E-5389-2018	Ortiz, Jose L./0000-0002-8690-2413; Frappa, Eric/0000-0001-5327-7781; Stewart, Sarah/0000-0001-9606-1593; Ressler, Michael/0000-0001-5644-8830; Hora, Joseph/0000-0002-5599-4650; Lin, Haosheng/0000-0002-4504-3165				ATKINSON DH, 1996, SCIENCE, V272, P843; BEEBE RF, 1996, SCIENCE, V272, P842; BJORAKER GL, 1986, ASTROPHYS J, V311, P1058, DOI 10.1086/164842; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; LEOVY CB, 1991, NATURE, V354, P360; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; NIERMANN H, 1996, SCIENCE, V272, P848; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; ORTON GS, 1994, SCIENCE, V265, P625, DOI 10.1126/science.265.5172.625; Puetter RC, 1995, INT J IMAG SYST TECH, V6, P314, DOI 10.1002/ima.1850060405; RAGENT B, 1996, SCIENCE, V272, P856; SEIFF A, 1996, SCIENCE, V272, P846; SROMOVSKY L, 1996, SCIENCE, V272, P853; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; WESTPHAL J, 1969, ASTROPHYS J, V157, P63; WESTPHAL J, 1974, ASTROPHYS J, V188, P111	18	57	58	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					839	840		10.1126/science.272.5263.839	http://dx.doi.org/10.1126/science.272.5263.839			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662571				2022-12-28	WOS:A1996UK75700045
J	Geist, NR; Jones, TD				Geist, NR; Jones, TD			Juvenile skeletal structure and the reproductive habits of dinosaurs	SCIENCE			English	Article								Skeletal ontogeny in extant archosaurians (crocodilians and birds) indicates that the morphology of the perinatal pelvic girdle is an indicator of overall developmental maturity [that is, altriciality (nestbound) versus precociality (mobile and relatively independent)]. Comparison of the skeletal anatomy of perinatal extant archosaurians and perinatal dinosaurs suggests that known dinosaur hatchlings were precocial. These data are consistent with the overall similarity in nesting behavior of dinosaurs and modern crocodilians.			Geist, NR (corresponding author), OREGON STATE UNIV, DEPT ZOOL, CORVALLIS, OR 97331 USA.							BARRETO C, 1993, SCIENCE, V262, P2020, DOI 10.1126/science.262.5142.2020; COTT H. B., 1961, TRANS ZOOL SOC LONDON, V29, P211; CURRIE PJ, COMMUNICATION; Duellman W. E., 1986, BIOL AMPHIBIANS, P13; Gill F. B., 1990, ORNITHOLOGY; Horner John R., 1994, P312; HORNER JR, 1988, NATURE, V332, P256, DOI 10.1038/332256a0; Lang J.W., 1989, P102; Magnusson W.E., 1989, P118; MINTON SA, 1987, ENCY REPTILES AMPHIB, P112; NOBLE G. K., 1933, AMER MUS NOVITATES, V619, P1; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; NORELL MA, COMMUNICATION; Parsons T.S., 1969, BIOL REPTILIA, VI, P81, DOI DOI 10.1093/ICB/ICP063; STARCK JM, 1994, J MORPHOL, V222, P113, DOI 10.1002/jmor.1052220202; Weishampel David B., 1994, P229; 1989, ZEITMUSTER ONTOGENES, V114	17	37	38	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					712	714		10.1126/science.272.5262.712	http://dx.doi.org/10.1126/science.272.5262.712			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662567				2022-12-28	WOS:A1996UJ05100047
J	Cauble, R; DaSilva, LB; Barbee, TW; Celliers, P; Decker, C; London, RA; Moreno, JC; Trebes, JE; Wan, AS; Weber, F				Cauble, R; DaSilva, LB; Barbee, TW; Celliers, P; Decker, C; London, RA; Moreno, JC; Trebes, JE; Wan, AS; Weber, F			Simultaneous measurement of local gain and electron density in X-ray lasers	SCIENCE			English	Article							INDIRECTLY DRIVEN; IMPLOSIONS; AMPLIFIER; COHERENCE; OPACITY; TARGET	X-ray lasers (XRLs) have experimental average gains that are significantly less than calculated values and a persistently low level of spatial coherence. An XRL has been used both as an injected signal to a short XRL amplifier and as an interferometer beam to measure two-dimensional local gain and density profiles of the XRL plasma with a resolution near 1 micrometer. The measured local gain is in agreement with atomic models but is unexpectedly spatially inhomogeneous, This inhomogeneity is responsible for the low level of spatial coherence observed and helps explain the disparity between observed and simulated gains.			Cauble, R (corresponding author), LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550, USA.			Celliers, Peter/0000-0001-7600-1227				Amendt P, 1996, PHYS REV A, V53, pR23, DOI 10.1103/PhysRevA.53.R23; CABLE MD, 1994, PHYS REV LETT, V73, P2316, DOI 10.1103/PhysRevLett.73.2316; CAUBLE R, 1995, PHYS REV LETT, V74, P3816, DOI 10.1103/PhysRevLett.74.3816; CELLIERS P, 1995, OPT LETT, V20, P1907, DOI 10.1364/OL.20.001907; DASILVA LB, 1992, SCIENCE, V258, P269, DOI 10.1126/science.1411525; DASILVA LB, 1993, OPT LETT, V18, P1174, DOI 10.1364/OL.18.001174; DASILVA LB, 1995, PHYS REV LETT, V74, P3991, DOI 10.1103/PhysRevLett.74.3991; DASILVA LB, 1992, PHYS REV LETT, V69, P438, DOI 10.1103/PhysRevLett.69.438; DITTRICH TR, 1994, PHYS REV LETT, V73, P2324, DOI 10.1103/PhysRevLett.73.2324; Elton R., 1990, XRAY LASERS; JAEGLE P, 1995, PHYS TODAY, V48, P109, DOI 10.1063/1.2808000; Kalantar DH, 1996, PHYS REV LETT, V76, P3574, DOI 10.1103/PhysRevLett.76.3574; KAUFFMAN RL, 1994, PHYS REV LETT, V73, P2320, DOI 10.1103/PhysRevLett.73.2320; KODAMA R, 1994, PHYS REV LETT, V73, P3215, DOI 10.1103/PhysRevLett.73.3215; LEWIS CLS, 1992, OPT COMMUN, V91, P71, DOI 10.1016/0030-4018(92)90103-X; MACGOWAN BJ, 1992, PHYS FLUIDS B-PLASMA, V4, P2326, DOI 10.1063/1.860203; MATTHEWS DL, 1985, PHYS REV LETT, V54, P110, DOI 10.1103/PhysRevLett.54.110; PERRY TS, 1991, PHYS REV LETT, V67, P3784, DOI 10.1103/PhysRevLett.67.3784; RATKOWSKY R, UCRLLR10582094 NAT T, P63; RESS D, 1994, SCIENCE, V265, P514, DOI 10.1126/science.265.5171.514; SHIMKAVEG GM, 1992, P SOC PHOTOOPT INSTR, V1551, P84; SKINNER CH, 1991, PHYS FLUIDS B-PLASMA, V3, P2420, DOI 10.1063/1.859613; SKINNER CH, 1991, OPT LETT, V16, P1266, DOI 10.1364/OL.16.001266; SUTER LJ, 1994, PHYS REV LETT, V73, P2328, DOI 10.1103/PhysRevLett.73.2328; TREBES JE, 1987, SCIENCE, V238, P517, DOI 10.1126/science.238.4826.517; TREBES JE, 1992, PHYS REV LETT, V68, P588, DOI 10.1103/PhysRevLett.68.588; WAN AS, 1994, OPT ENG, V33, P2434, DOI 10.1117/12.172898; WAN AS, UNPUB	28	17	17	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1093	1096		10.1126/science.273.5278.1093	http://dx.doi.org/10.1126/science.273.5278.1093			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688093				2022-12-28	WOS:A1996VD42800034
J	Lloyd, S				Lloyd, S			Universal quantum simulators	SCIENCE			English	Article							TURING-MACHINES; LOGIC GATE; COMPUTERS; COMPUTATION; SYSTEMS; PRINCIPLE; DYNAMICS; INFORMATION; DISSIPATION; COHERENCE	Feynman's 1982 conjecture, that quantum computers can be programmed to simulate any local quantum system, is shown to be correct.			Lloyd, S (corresponding author), MIT,DEPT MECH ENGN,DARBELOFF LAB INFORMAT SYST & TECHNOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							BARENCO A, 1995, PHYS REV LETT, V74, P4083, DOI 10.1103/PhysRevLett.74.4083; BENIOFF P, 1982, PHYS REV LETT, V48, P1581, DOI 10.1103/PhysRevLett.48.1581; BENIOFF P, 1980, J STAT PHYS, V22, P563, DOI 10.1007/BF01011339; BENIOFF P, 1986, ANN NY ACAD SCI, V0480, P00475; BINDER K, 1995, MONTE CARLO METHODS; Brockett R. W., 1983, DIFFERENTIAL GEOMETR; BRUNE M, 1994, PHYS REV LETT, V72, P3339, DOI 10.1103/PhysRevLett.72.3339; CALDERBANK AR, IN PRESS PHYS REV A; CHUANG IL, 1995, SCIENCE, V270, P1633, DOI 10.1126/science.270.5242.1633; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; DEUTSCH D, 1995, P R SOC-MATH PHYS SC, V449, P669, DOI 10.1098/rspa.1995.0065; DEUTSCH D, 1992, P ROY SOC LOND A MAT, V439, P553, DOI 10.1098/rspa.1992.0167; DEUTSCH D, 1989, P ROY SOC LOND A MAT, V425, P73, DOI 10.1098/rspa.1989.0099; DEUTSCH D, 1985, P ROY SOC LOND A MAT, V400, P97, DOI 10.1098/rspa.1985.0070; DIVINCENZO D, 1995, PHYS REV A, V50, P1015; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; DOMOKOS P, 1995, PHYS REV A, V52, P3554, DOI 10.1103/PhysRevA.52.3554; Fetter A.L., 2003, QUANTUM THEORY MANY, Vthird; Feynman R. P., 1985, OPT NEWS, V11, P11, DOI 10.1364/ON.11.2.000011; FEYNMAN RP, 1982, INT J THEOR PHYS, V21, P467, DOI 10.1007/BF02650179; FEYNMAN RP, 1986, FOUND PHYS, V16, P507, DOI 10.1007/BF01886518; KALOS MH, 1984, MONTE CARLO METHODS; KIMBLE HJ, P INT C AT PHYS; Kraus K., 1983, STATES EFFECTS OPERA; LANDAUER R, 1991, PHYS TODAY, V44, P23, DOI 10.1063/1.881299; LANDAUER R, 1988, NATURE, V335, P779, DOI 10.1038/335779a0; LANDAUER R, 1982, INT J THEOR PHYS, V21, P283, DOI 10.1007/BF01857731; LANDAUER R, 1986, FOUND PHYS, V16, P551, DOI 10.1007/BF01886520; Landauer R., 1989, Nanostructure Physics and Fabrication. Proceedings of the International Symposium, P17; LANDAUER R, 1989, PHYS TODAY, V42, P119, DOI 10.1063/1.2811186; LANDAUER R, 1990, PHYSICA A, V168, P75, DOI 10.1016/0378-4371(90)90359-Z; Landauer R., 1990, Proceedings of the 3rd International Symposium on Foundations of Quantum Mechanics. In the Light of New Technology, P407; LANDAUER R, 1996, P DREX 4 S QUANT NON; LANDAUER R, 1994, P WORKSH PHYS COMP, V2, P54; Li Z., 1993, NONHOLONOMIC MOTION; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; LLOYD S, 1994, SCIENCE, V263, P695, DOI 10.1126/science.263.5147.695; LLOYD S, 1995, PHYS REV LETT, V75, P346, DOI 10.1103/PhysRevLett.75.346; MABUCHI H, 1994, OPT LETT, V19, P749, DOI 10.1364/OL.19.000749; Margolus N., 1986, ANN NEW YORK ACAD SC, V480, P487; MARGOLUS N, 1991, SANTA FE I SERIES, V8, P273; MATSKO AB, 1994, PHYS LETT A, V192, P175, DOI 10.1016/0375-9601(94)90240-2; MILBURN GJ, 1989, PHYS REV LETT, V62, P2124, DOI 10.1103/PhysRevLett.62.2124; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Negele J. W., 1988, QUANTUM MANY PARTICL; OBERMAYER K, 1988, PHYS REV B, V37, P8096, DOI 10.1103/PhysRevB.37.8096; Palma GM, 1996, P ROY SOC A-MATH PHY, V452, P567, DOI 10.1098/rspa.1996.0029; PARKINS AS, 1993, PHYS REV LETT, V71, P3095, DOI 10.1103/PhysRevLett.71.3095; RAMAKRISHNA V, 1995, PHYS REV A, V51, P960, DOI 10.1103/PhysRevA.51.960; REBBI C, 1983, LATTICE GAUGE THEORI; Shor P. W., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P124, DOI 10.1109/SFCS.1994.365700; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; SLEATOR T, 1995, PHYS REV LETT, V74, P4087, DOI 10.1103/PhysRevLett.74.4087; STEANE AM, UNPUB; TEICH WG, 1988, PHYS REV B, V37, P8111, DOI 10.1103/PhysRevB.37.8111; TEICH WG, 1992, PHYS REV A, V45, P3300, DOI 10.1103/PhysRevA.45.3300; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; WARREN WS, 1980, J CHEM PHYS, V73, P2084, DOI 10.1063/1.440403; Yamamoto Y., 1988, 3rd Asia Pacific Physics Conference, P779; YAO ACC, 1995, P 36 ANN S FDN COMP, P352; ZUREK WH, 1984, PHYS REV LETT, V53, P391, DOI 10.1103/PhysRevLett.53.391	66	1442	1464	7	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1073	1078		10.1126/science.273.5278.1073	http://dx.doi.org/10.1126/science.273.5278.1073			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688088				2022-12-28	WOS:A1996VD42800029
J	Havlir, DV; Dube, MP; Sattler, FR; Forthal, DN; Kemper, CA; Dunne, MW; Parenti, DM; Lavelle, JP; White, AC; Witt, MD; Bozzette, SA; McCutchan, JA				Havlir, DV; Dube, MP; Sattler, FR; Forthal, DN; Kemper, CA; Dunne, MW; Parenti, DM; Lavelle, JP; White, AC; Witt, MD; Bozzette, SA; McCutchan, JA			Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NATURAL-HISTORY; INFECTION; AIDS; DISEASE; THERAPY; PHARMACOKINETICS; CLARITHROMYCIN; BACTEREMIA; ZIDOVUDINE	Background Azithromycin is active in treating Mycobacterium avium complex disease, but it has not been evaluated as primary prophylaxis in patients with human immunodeficiency virus (HIV) infection. Because the drug is concentrated in macrophages and has a long half-life in tissue, there is a rationale for once-weekly dosing. Methods We compared three prophylactic regimens in a multicenter, double-blind, randomized trial involving 693 HIV-infected patients with fewer than 100 CD4 cells per cubic millimeter. The patients were assigned to receive rifabutin (300 mg daily), azithromycin (1200 mg weekly), or both drugs. They were monitored monthly with blood cultures for M. avium complex. Results In an intention-to-treat analysis, the incidence of disseminated M. avium complex infection at one year was 15.3 percent with rifabutin, 7.6 percent with azithromycin, and 2.8 percent with both drugs. The risk of the infection in the azithromycin group was half that in the rifabutin group (hazard ratio, 0.53; P=0.008). The risk was even lower when two-drug prophylaxis was compared with rifabutin alone (hazard ratio, 0.28; P<0.001) or azithromycin alone (hazard ratio, 0.53; P=0.03). Among the patients in whom azithromycin prophylaxis was not successful, 11 percent of M. avium complex isolates were resistant to azithromycin. Dose-limiting toxic effects were more common with the two-drug combination than with azithromycin alone (hazard ratio, 1.67; P=0.03). Survival was similar in all three groups. Conclusions For protection against disseminated M. avium complex infection, once-weekly azithromycin is more effective than daily rifabutin and infrequently selects for resistant isolates. Rifabutin plus azithromycin is even more effective but is not as well tolerated. (C) 1996, Massachusetts Medical Society.	VET AFFAIRS MED CTR, LA JOLLA, CA USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; SANTA CLARA VALLEY MED CTR, SAN JOSE, CA 95128 USA; PFIZER INC, PFIZER CENT RES, GROTON, CT 06340 USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC USA; GEORGETOWN UNIV, WASHINGTON, DC USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, TORRANCE, CA 90509 USA; RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Southern California; University of California System; University of California Irvine; Santa Clara Valley Medical Center; Pfizer; George Washington University; Georgetown University; Baylor College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; RAND Corporation	Havlir, DV (corresponding author), UNIV CALIF SAN DIEGO, TREATMENT CTR, 2760 5TH AVE, SUITE 300, SAN DIEGO, CA 92103 USA.		Dunne, Michael W/AAD-7418-2020	Dunne, Michael W/0000-0001-6186-5196; White, A Clinton/0000-0002-9668-4632				BENSON CA, 1996, 3 C RETR OPP INF WAS; BERRY A, 1993, 1 NAT C HUM RETR REL, P106; BERRY SH, 1994, MR341NIAID RAND CORP; Bozzette S. A., 1995, JAMA (Journal of the American Medical Association), V273, P295, DOI 10.1001/jama.273.4.295; CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; DUBE MP, 1995, 35 INT C ANT AG CHEM, P241; FOULDS G, 1990, J ANTIMICROB CHEMOTH, V25, P73, DOI 10.1093/jac/25.suppl_A.73; GIRARD AE, 1987, ANTIMICROB AGENTS CH, V31, P1948, DOI 10.1128/AAC.31.12.1948; GLADUE RP, 1989, ANTIMICROB AGENTS CH, V33, P277, DOI 10.1128/AAC.33.3.277; GRIFFITH DE, 1995, AM J RESP CRIT CARE, V151, pA477; HAVLIR D, 1993, J CLIN MICROBIOL, V31, P1794, DOI 10.1128/JCM.31.7.1794-1798.1993; HAVLIR D, 1994, ANN INTERN MED, V121, P510, DOI 10.7326/0003-4819-121-7-199410010-00006; HAVLIR DV, 1996, 3 C RETR OPP INF WAS; HEIFETS L, 1993, ANTIMICROB AGENTS CH, V37, P2364, DOI 10.1128/AAC.37.11.2364; Heifets LB., 1991, DRUG SUSCEPTIBILITY; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; KLEMENS SP, 1994, ANTIMICROB AGENTS CH, V38, P1721, DOI 10.1128/AAC.38.8.1721; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; NASH KA, 1995, ANTIMICROB AGENTS CH, V39, P2625, DOI 10.1128/AAC.39.12.2625; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; OLDFIELD EC, 1996, 3 C RETR OPP INF WAS; PIERCE M, 1995, 35 INT C ANT AG CHEM; SKINNER MH, 1995, CLIN PHARMACOKINET, V28, P115, DOI 10.2165/00003088-199528020-00003; Trapnell CB, 1996, ANN INTERN MED, V124, P573, DOI 10.7326/0003-4819-124-6-199603150-00006; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; 1995, MMWR-MORBID MORTAL W, V44, P1	29	243	247	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					392	398		10.1056/NEJM199608083350604	http://dx.doi.org/10.1056/NEJM199608083350604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8676932	Bronze			2022-12-28	WOS:A1996VA90400004
J	Vongpatanasin, W; Hillis, LD; Lange, RA				Vongpatanasin, W; Hillis, LD; Lange, RA			Medical progress - Prosthetic heart valves	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ORAL ANTICOAGULANT-THERAPY; BJORK-SHILEY VALVES; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; THROMBOEMBOLIC COMPLICATIONS; CARDIAC VALVES; FOLLOW-UP; PROPHYLACTIC REPLACEMENT; THROMBOTIC OBSTRUCTION; INFECTIVE ENDOCARDITIS; PORCINE BIOPROSTHESES		UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV CARDIOVASC,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Lange, Richard/AAM-9594-2021	Vongpatanasin, Wanpen/0000-0002-7531-9388				ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P669; ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; [Anonymous], 1994, LANCET, P619; BAUMGARTNER WA, 1983, ANN THORAC SURG, V35, P87, DOI 10.1016/S0003-4975(10)61436-1; BIRKMEYER JD, 1992, LANCET, V340, P520, DOI 10.1016/0140-6736(92)91717-M; BLACKSTONE EH, 1985, CIRCULATION, V72, P753, DOI 10.1161/01.CIR.72.4.753; BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; BORTOLOTTI U, 1985, J THORAC CARDIOV SUR, V90, P564; BURCHFIEL CM, 1990, J AM COLL CARDIOL, V15, P32, DOI 10.1016/0735-1097(90)90172-L; BURSTOW DJ, 1989, CIRCULATION, V80, P504, DOI 10.1161/01.CIR.80.3.504; BUTCHARD EG, 1992, REPLACEMENT CARDIAC, P77; CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776; CALDERWOOD SB, 1985, CIRCULATION, V72, P31, DOI 10.1161/01.CIR.72.1.31; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CANNEGIETER SC, 1994, CIRCULATION, V89, P635, DOI 10.1161/01.CIR.89.2.635; CARPENTER JL, 1983, SOUTHERN MED J, V76, P1372, DOI 10.1097/00007611-198311000-00011; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; COBANOGLU A, 1988, ANN THORAC SURG, V45, P248, DOI 10.1016/S0003-4975(10)62458-7; CREXELLS C, 1972, AM HEART J, V84, P161, DOI 10.1016/0002-8703(72)90330-4; CZER LSC, 1985, J AM COLL CARDIOL, V6, P904, DOI 10.1016/S0735-1097(85)80504-0; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DALE J, 1977, AM HEART J, V94, P101, DOI 10.1016/S0002-8703(77)80351-7; DANIEL WG, 1993, AM J CARDIOL, V71, P210, DOI 10.1016/0002-9149(93)90740-4; DANIEL WG, 1991, NEW ENGL J MED, V324, P795, DOI 10.1056/NEJM199103213241203; DAVENPORT J, 1990, STROKE, V21, P993, DOI 10.1161/01.STR.21.7.993; DEUTSCH HJ, 1992, J AM COLL CARDIOL, V19, P1500, DOI 10.1016/0735-1097(92)90610-Y; ECKMAN MH, 1990, JAMA-J AM MED ASSOC, V263, P1513, DOI 10.1001/jama.263.11.1513; EDMUNDS LH, 1982, ANN THORAC SURG, V34, P96, DOI 10.1016/S0003-4975(10)60862-4; FALK RH, 1979, THORAX, V34, P746, DOI 10.1136/thx.34.6.746; Feigenbaum H., 1994, ECHOCARDIOGR-J CARD, P239; GAGLIARDI C, 1991, J CARDIOVASC SURG, V32, P800; GALLO I, 1984, AM J CARDIOL, V53, P1061, DOI 10.1016/0002-9149(84)90637-4; GINSBERG JS, 1995, CHEST, V108, pS305, DOI 10.1378/chest.108.4_Supplement.305S; GRAY RJ, 1984, J AM COLL CARDIOL, V3, P321, DOI 10.1016/S0735-1097(84)80015-7; GREEN CE, 1988, AM J ROENTGENOL, V151, P455, DOI 10.2214/ajr.151.3.455; GROVER FL, 1994, J THORAC CARDIOV SUR, V108, P207; GRUNKEMEIER GL, 1994, J THORAC CARDIOV SUR, V108, P709; GUERET P, 1995, CIRCULATION, V91, P103, DOI 10.1161/01.CIR.91.1.103; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HAMMERMEISTER KE, 1993, NEW ENGL J MED, V328, P1289, DOI 10.1056/NEJM199305063281801; HANANIA G, 1994, EUR HEART J, V15, P1651, DOI 10.1093/oxfordjournals.eurheartj.a060448; HERAS M, 1995, J AM COLL CARDIOL, V25, P1111, DOI 10.1016/0735-1097(94)00563-6; HUSEBYE DG, 1983, J THORAC CARDIOV SUR, V86, P543; IBRAHIM M, 1994, J THORAC CARDIOV SUR, V108, P221; ITURBEALESSIO I, 1986, NEW ENGL J MED, V315, P1390, DOI 10.1056/NEJM198611273152205; JEGADEN O, 1994, ANN THORAC SURG, V58, P1721, DOI 10.1016/0003-4975(94)91669-1; JINDANI A, 1991, J CARDIOVASC SURG, V32, P503; JONES EL, 1990, ANN THORAC SURG, V49, P370, DOI 10.1016/0003-4975(90)90240-7; KAPUR KK, 1989, J AM COLL CARDIOL, V13, P1561, DOI 10.1016/0735-1097(89)90350-1; KARALIS DG, 1992, AM J CARDIOL, V69, P1310, DOI 10.1016/0002-9149(92)91227-U; KATHOLI RE, 1976, AM HEART J, V92, P162, DOI 10.1016/S0002-8703(76)80251-7; KEYS TF, 1993, CLEV CLIN J MED, V60, P455, DOI 10.3949/ccjm.60.6.455; KHANDHERIA BK, 1991, CIRCULATION, V83, P1956, DOI 10.1161/01.CIR.83.6.1956; KONTOS GJ, 1989, ANN THORAC SURG, V48, P60, DOI 10.1016/0003-4975(89)90177-X; KURZROK S, 1987, J AM COLL CARDIOL, V9, P592, DOI 10.1016/S0735-1097(87)80053-0; LEPORT C, 1987, BRIT HEART J, V58, P66; LINDBLOM D, 1986, J THORAC CARDIOV SUR, V92, P894; LOWRY RW, 1994, AM J CARDIOL, V73, P1089, DOI 10.1016/0002-9149(94)90288-7; MARTINELL J, 1991, CIRCULATION S3, V84, P700; MCANULTY JH, 1978, CIRCULATION, V58, P159; METZDORFF MT, 1984, J AM COLL CARDIOL, V4, P50, DOI 10.1016/S0735-1097(84)80318-6; Mohr-Kahaly S, 1993, J Am Soc Echocardiogr, V6, P12; NUNEZ L, 1984, ANN THORAC SURG, V37, P84, DOI 10.1016/S0003-4975(10)60717-5; OBRIEN MF, 1995, ANN THORAC SURG, V60, pS65, DOI 10.1016/0003-4975(95)00223-8; OKITA Y, 1991, ANN THORAC SURG, V52, P1158, DOI 10.1016/0003-4975(91)91301-B; ONEILL WW, 1995, NEW ENGL J MED, V333, P414, DOI 10.1056/NEJM199508173330703; PEDERSEN WR, 1991, CHEST, V100, P351, DOI 10.1378/chest.100.2.351; RANDALL PA, 1988, AM J CARDIOL, V62, P973, DOI 10.1016/0002-9149(88)90907-1; REDDY NK, 1994, ANN THORAC SURG, V58, P462, DOI 10.1016/0003-4975(94)92229-2; ROUDAUT R, 1992, CIRCULATION, V86, P8; RYDER SJ, 1984, THORAX, V39, P487, DOI 10.1136/thx.39.7.487; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SARELI P, 1989, AM J CARDIOL, V63, P1462, DOI 10.1016/0002-9149(89)90008-8; SCHOEN FJ, 1985, HUM PATHOL, V16, P549, DOI 10.1016/S0046-8177(85)80103-9; SCHOEVAERDTS JC, 1987, J THORAC CARDIOV SUR, V94, P375; SHELLOCK FG, 1991, RADIOLOGY, V180, P541, DOI 10.1148/radiology.180.2.2068325; SHERMAN DG, 1990, AM J CARDIOL, V65, pC32, DOI 10.1016/0002-9149(90)90113-F; SILBER H, 1993, CIRCULATION, V87, P30, DOI 10.1161/01.CIR.87.1.30; SKOULARIGIS J, 1993, AM J CARDIOL, V71, P587, DOI 10.1016/0002-9149(93)90516-F; SMITH ND, 1981, ANN INTERN MED, V95, P594, DOI 10.7326/0003-4819-95-5-594; SOCHOWSKI RA, 1993, J AM COLL CARDIOL, V21, P216, DOI 10.1016/0735-1097(93)90739-N; SOULEN RL, 1985, RADIOLOGY, V154, P705, DOI 10.1148/radiology.154.3.3969474; STEIN PD, 1992, CHEST, V102, pS445, DOI 10.1378/chest.102.4_Supplement.445S; SULLIVAN JM, 1971, NEW ENGL J MED, V284, P1391, DOI 10.1056/NEJM197106242842501; THRELKELD MG, 1995, MANDELL DOUGLAS BENN, P783; TINKER JH, 1978, JAMA-J AM MED ASSOC, V239, P738, DOI 10.1001/jama.239.8.738; TORNOS P, 1992, CHEST, V101, P37, DOI 10.1378/chest.101.1.37; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; TURPIE AGG, 1988, LANCET, V1, P1242; VANDERGRAAF Y, 1992, LANCET, V339, P257, DOI 10.1016/0140-6736(92)91328-6; VANDERMEULEN JHP, 1993, CIRCULATION, V88, P156, DOI 10.1161/01.CIR.88.1.156; VASAN RS, 1992, AM HEART J, V123, P1575, DOI 10.1016/0002-8703(92)90812-A; VOGEL W, 1993, AM J CARDIOL, V71, P225, DOI 10.1016/0002-9149(93)90742-U; WILSON WR, 1982, MAYO CLIN PROC, V57, P155; WILSON WR, 1978, CIRCULATION, V57, P1004, DOI 10.1161/01.CIR.57.5.1004; WOLFF M, 1995, CHEST, V108, P688, DOI 10.1378/chest.108.3.688; YACOUB M, 1995, J THORAC CARDIOV SUR, V110, P186, DOI 10.1016/S0022-5223(05)80025-X; YU VL, 1994, ANN THORAC SURG, V58, P1073, DOI 10.1016/0003-4975(94)90458-8; 1978, COEUR, V9, P915	99	509	544	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					407	416		10.1056/NEJM199608083350607	http://dx.doi.org/10.1056/NEJM199608083350607			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8676934				2022-12-28	WOS:A1996VA90400007
J	Hayden, FG; Diamond, L; Wood, PB; Korts, DC; Wecker, MT				Hayden, FG; Diamond, L; Wood, PB; Korts, DC; Wecker, MT			Effectiveness and safety of intranasal ipratropium bromide in common colds - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						ipratropium; common cold; rhinitis; administration, intranasal; sneezing	EXPERIMENTAL RHINOVIRUS COLDS; NASAL SECRETIONS; SYMPTOMATIC MANAGEMENT; PATHO-PHYSIOLOGY; ANTIHISTAMINES; RHINITIS; KININS; SPRAY	Objective: To determine the tolerability and clinical effectiveness of intranasal ipratropium bromide for the treatment of symptoms of common colds. Design: Multicenter, double-blind, randomized trial. Setting: 3 university student health services. Patients: 411 previously healthy persons 14 to 56 years of age who had cold symptoms that had lasted for no more than 36 hours, rhinorrhea subjectively judged to be of at least moderate severity, and documented nasal discharge of at least 1.5 g over a 1-hour observation period. Intervention: Either 1) ipratropium bromide nasal spray 0.06% in buffered salt solution, two 42-mu g sprays per nostril administered by metered pump spray; 2) control nasal spray, which consisted of buffered salt solution; or 3) no treatment. Treatments were self-administered three or four times daily during waking hours for 4 days. After receiving their morning dose, patients stayed at the study center for 6 hours on study day 1 and 3 hours on study day 2; symptom severity was recorded and nasal mucus discharges were collected and weighed hourly during these periods. Results: Ipratropium recipients had 26% less nasal discharge than controls (P = 0.0024) and 34% less nasal discharge than untreated patients (P = 0.0001). Severity of rhinorrhea as judged subjectively was reduced in ipratropium recipients by 31% compared with controls and by 78% compared with untreated patients (P = 0.0001 for both comparisons). in addition to being associated with reductions in daily assessments of the severity of rhinorrhea (P less than or equal to 0.003), ipratropium was associated with reduced sneezing on study days 2 (20% difference; P = 0.03) and 4 (30% difference; P = 0.02) but not with reduced nasal congestion compared with the control spray. Ipratropium was generally well tolerated but was associated with higher rates of blood-tinged mucus (16.8% in the ipratropium group compared with 3.6% in the control group; P = 0.01) and nasal dryness (11.7% in the ipratropium group compared with 3.6% in the control group; P = 0.021) than the control spray. Patient assessments off the overall effectiveness of treatment were more favorable for ipratropium than for the control spray (P less than or equal to 0.026) or for no treatment (P less than or equal to 0.002) on each day of inquiry; (study days 1, 2, and 5). Conclusions: Intranasal ipratropium bromide provides specific relief of rhinorrhea and sneezing associated with common colds.	UNIV COLORADO, SCH PHARM, DENVER, CO 80262 USA; UNIV RHODE ISL, HLTH SERV, KINGSTON, RI 02881 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, RIDGEFIELD, CT 06877 USA	University of Colorado System; University of Colorado Denver; University of Rhode Island; Boehringer Ingelheim	Hayden, FG (corresponding author), UNIV VIRGINIA, SCH MED, DEPT INTERNAL MED, BOX 473, CHARLOTTESVILLE, VA 22908 USA.							BERKOWITZ RB, 1991, ANN ALLERGY, V67, P593; BERKOWITZ RB, 1989, ANN ALLERGY, V63, P336; BORUM P, 1978, Rhinology (Utrecht), V16, P225; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BYE CE, 1980, BRIT MED J, V281, P189, DOI 10.1136/bmj.281.6234.189; CRUTCHER JE, 1981, J CLIN PHARMACOL, V21, P9, DOI 10.1002/j.1552-4604.1981.tb01725.x; DIAMOND L, 1995, J ALLERGY CLIN IMMUN, V95, P1139, DOI 10.1016/S0091-6749(95)70219-9; DOCKHORN R, 1992, J ALLERGY CLIN IMMUN, V90, P1076, DOI 10.1016/0091-6749(92)90126-M; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1987, AM REV RESPIR DIS, V136, P556, DOI 10.1164/ajrccm/136.3.556; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; GROTH S, 1983, EUR J RESPIR DIS, V64, P490; GWALTNEY JM, 1992, J INFECT DIS, V166, P776, DOI 10.1093/infdis/166.4.776; HAYDEN FG, 1995, ANTIMICROB AGENTS CH, V39, P290, DOI 10.1128/AAC.39.2.290; HOWARD JC, 1979, JAMA-J AM MED ASSOC, V242, P2414, DOI 10.1001/jama.242.22.2414; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; LEUNG AKC, 1994, J OTOLARYNGOL, V23, P125; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; PAREKH HH, 1992, AM J RHINOL, V6, P107, DOI 10.2500/105065892781874685; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SPERBER SJ, 1992, ANN INTERN MED, V117, P37, DOI 10.7326/0003-4819-117-1-37; SPERBER SJ, 1988, ANTIMICROB AGENTS CH, V32, P409, DOI 10.1128/AAC.32.4.409; TURNER RB, 1982, J INFECT DIS, V145, P849, DOI 10.1093/infdis/145.6.849	29	68	73	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					89	+		10.7326/0003-4819-125-2-199607150-00002	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678385				2022-12-28	WOS:A1996UV92100005
J	Macbeth, F; Stephens, R				Macbeth, F; Stephens, R			Marketing clinical trials	LANCET			English	Article									MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BW,ENGLAND		Macbeth, F (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					111	112		10.1016/S0140-6736(96)04094-9	http://dx.doi.org/10.1016/S0140-6736(96)04094-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676679				2022-12-28	WOS:A1996UW67300017
J	Smith, GD; Phillips, AN				Smith, GD; Phillips, AN			Inflation in epidemiology: ''The proof and measurement of association between two things'' revisited	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; CORRELATED EXPOSURES; URINARY SODIUM; HYPERTENSION; RISK		UNIV LONDON, ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Smith, GD (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314				Armstrong B.K., 1992, PRINCIPLES EXPOSURE; BENNETT S, 1993, J TROP MED HYG, V96, P267; Bigazzi R, 1996, AM J HYPERTENS, V9, P24, DOI 10.1016/0895-7061(95)00268-5; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COOPER R, 1980, CIRCULATION, V62, P97, DOI 10.1161/01.CIR.62.1.97; DYER AR, 1994, AM J EPIDEMIOL, V139, P927, DOI 10.1093/oxfordjournals.aje.a117099; DYER AR, 1994, HYPERTENSION, V23, P729, DOI 10.1161/01.HYP.23.6.729; DYER AR, 1994, AM J EPIDEMIOL, V139, P940, DOI 10.1093/oxfordjournals.aje.a117100; ELLIOTT P, 1988, BRIT MED J, V297, P319; ELLISON RC, 1980, HYPERTENSION, V2, pI78, DOI 10.1161/01.HYP.2.4_Pt_2.I78; FERRANNINI E, 1993, AM J KIDNEY DIS, V21, P37, DOI 10.1016/S0272-6386(12)70253-6; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HUNT SC, 1991, HYPERTENSION, V17, P969, DOI 10.1161/01.HYP.17.6.969; KOCHAR MS, 1993, POSTGRAD MED, V93, P193; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MERTENS TE, 1993, LANCET, V342, P418, DOI 10.1016/0140-6736(93)92820-J; PEIRIS AN, 1989, ANN INTERN MED, V110, P867, DOI 10.7326/0003-4819-110-11-867; PHILLIPS AN, 1993, J CLIN EPIDEMIOL, V46, P1203, DOI 10.1016/0895-4356(93)90120-P; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905; Sharma B K, 1990, Indian Heart J, V42, P66; SIERVOGEL RM, 1980, HYPERTENSION, V2, pI83, DOI 10.1161/01.HYP.2.4_Pt_2.I83; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1994, BRIT MED J, V308, P1025, DOI 10.1136/bmj.308.6935.1025; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159	27	50	50	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	1996	312	7047					1659	1661		10.1136/bmj.312.7047.1659	http://dx.doi.org/10.1136/bmj.312.7047.1659			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664725	Green Published			2022-12-28	WOS:A1996UV48900031
J	Mead, GM				Mead, GM			Raltitrexed, a new drug for advanced colorectal cancer	LANCET			English	Editorial Material											Mead, GM (corresponding author), ROYAL S HANTS HOSP,WESSEX MED ONCOL UNIT,SOUTHAMPTON SO14 0YG,HANTS,ENGLAND.							Conti JA, 1996, J CLIN ONCOL, V14, P709, DOI 10.1200/JCO.1996.14.3.709; Cunningham D, 1995, EUR J CANCER, V31A, P1945, DOI 10.1016/0959-8049(95)00502-1; Cunningham D, 1996, ANN ONCOL, V7, P179; HERRMANN R, 1994, EUR J CANCER, V30A, P404, DOI 10.1016/0959-8049(94)90266-6; HILL M, 1995, J CLIN ONCOL, V13, P1297, DOI 10.1200/JCO.1995.13.6.1297; LEICHMAN CG, 1995, J CLIN ONCOL, V13, P1303, DOI 10.1200/JCO.1995.13.6.1303; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; Slevin ML, 1996, BMJ-BRIT MED J, V312, P392; 1992, J CLIN ONCOL, V10, P904; 1992, J CLIN ONCOL, V10, P896	10	6	6	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1568	1569		10.1016/S0140-6736(96)91068-5	http://dx.doi.org/10.1016/S0140-6736(96)91068-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667859				2022-12-28	WOS:A1996UP66100002
J	Lanzerotti, LJ; Rinnert, K; Dehmel, G; Gliem, FO; Krider, EP; Uman, MA; Bach, J				Lanzerotti, LJ; Rinnert, K; Dehmel, G; Gliem, FO; Krider, EP; Uman, MA; Bach, J			Radio frequency signals in Jupiter's atmosphere	SCIENCE			English	Article							EARTH	During the Galileo probe's descent through Jupiter's atmosphere, under the ionosphere, the lightning and radio emission detector measured radio frequency signals at levels significantly above the probe's electromagnetic noise. The signal strengths at 3 and 15 kilohertz were relatively large at the beginning oi the descent, decreased with depth to a pressure level of about 5 bars, and then Increased slowly until the end of the mission. The 15-kilohertz signals show arrival direction anisotropies. Measurements of radio frequency wave forms show that the probe passed through an atmospheric region that did not support lightning within at least 100 kilometers and more likely a few thousand kilometers of the descent trajectory. The apparent opacity of the jovian atmosphere increases sharply at pressures greater than about 4 bars.	UNIV FLORIDA,GAINESVILLE,FL 32611; MAX PLANCK INST AERON,D-37191 KATLENBURG DUHM,GERMANY; TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,D-38106 BRAUNSCHWEIG,GERMANY; UNIV ARIZONA,TUCSON,AZ 85721; UNIV FLORIDA,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; Max Planck Society; Braunschweig University of Technology; University of Arizona; State University System of Florida; University of Florida	Lanzerotti, LJ (corresponding author), AT&T BELL LABS,LUCENT TECHNOL,600 MT AVE,MURRAY HILL,NJ 07974, USA.							BARNUN A, 1975, ICARUS, V24, P86, DOI 10.1016/0019-1035(75)90162-1; BORUCKI WJ, 1992, ICARUS, V96, P1, DOI 10.1016/0019-1035(92)90002-O; COOK AF, 1979, NATURE, V280, P794, DOI 10.1038/280794a0; DOYLE LR, 1989, NASA, P384; FRANZ RC, 1990, SCIENCE, V249, P48, DOI 10.1126/science.249.4964.48; Golde R.H., 1977, LIGHTNING; LANZEROTTI LJ, 1989, J GEOPHYS RES-ATMOS, V94, P13221, DOI 10.1029/JD094iD11p13221; LANZEROTTI LJ, 1992, SPACE SCI REV, V60, P91, DOI 10.1007/BF00216851; LANZEROTTI LJ, 1989, NASA SP494, P374; PRINN RG, 1976, JUPITER; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RINNERT K, 1979, J GEOPHYS RES-SPACE, V84, P5181, DOI 10.1029/JA084iA09p05181; RINNERT K, 1985, J GEOPHYS RES-ATMOS, V90, P6239, DOI 10.1029/JD090iD04p06239; RINNERT K, 1995, HDB ATMOSPHERIC ELEC, P27; SAGAN C, 1967, NATURE, V213, P273; SCARF FL, 1979, SCIENCE, V204, P991, DOI 10.1126/science.204.4396.991; SENTMAN DD, 1993, GEOPHYS RES LETT, V20, P2857, DOI 10.1029/93GL02998; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; UMAN MA, 1987, LIGHTNING DISCHARGE; WILLIAMS MA, 1983, REV GEOPHYS, V21, P892, DOI 10.1029/RG021i004p00892; WILLIAMS MA, 1986, THESIS U ARIZONA; Zheleznyakov V.V., 1970, RADIO EMISSION SUN P	22	21	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					858	860		10.1126/science.272.5263.858	http://dx.doi.org/10.1126/science.272.5263.858			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662576				2022-12-28	WOS:A1996UK75700054
J	Kukla, V; Kornatowski, J; Demuth, D; Gimus, I; Pfeifer, H; Rees, LVC; Schunk, S; Unger, KK; Karger, J				Kukla, V; Kornatowski, J; Demuth, D; Gimus, I; Pfeifer, H; Rees, LVC; Schunk, S; Unger, KK; Karger, J			NMR studies of single-file diffusion in unidimensional channel zeolites	SCIENCE			English	Article							ONE-DIMENSIONAL DIFFUSION; LONG-TIME LIMIT; ION CHANNELS; MOLECULES	Single-file diffusion is the restricted propagation of particles that cannot pass each other, The occurrence of this phenomenon should be reflected by a change in the time dependence of the mean particle displacement in comparison with ordinary diffusion, Although this process is considered to be the rate-controlling mechanism in a large variety of processes, so far no direct evidence of this phenomenon has been provided, Diffusion measurements made with pulsed field gradient nuclear magnetic resonance (NMR) in unidimensional pore systems (zeolites AlPO4-5 and Theta-1) reflect the expected time dependence of single-file diffusion.	UNIV LEIPZIG,FAK PHYS & GEOWISSENSCH,D-04103 LEIPZIG,GERMANY; RHEIN WESTFAL TH AACHEN,INST TECH CHEM & HETEROGENE KATALYSE,D-52074 AACHEN,GERMANY; NICHOLAS COPERNICUS UNIV,FAC CHEM,PL-87100 TORUN,POLAND; UNIV MAINZ,INST ANORGAN CHEM & ANALYT CHEM,D-55029 MAINZ,GERMANY; INST ANGEW CHEM,D-12489 BERLIN,GERMANY; UNIV EDINBURGH,DEPT CHEM,EDINBURGH EH9 3JJ,MIDLOTHIAN,SCOTLAND	Leipzig University; RWTH Aachen University; Nicolaus Copernicus University; Johannes Gutenberg University of Mainz; University of Edinburgh				Karger, Jorg/0000-0002-4046-7698				BAR NK, 1995, J MAGN RESON SER A, V113, P278, DOI 10.1006/jmra.1995.1095; BRECK DW, 1974, ZEOLITE MOL SIEVES, P636; BUNDE A, 1986, PHYS REV A, V34, P2575, DOI 10.1103/PhysRevA.34.2575; Callaghan P., 1991, PRINCIPLES NUCL MAGN; CALLAGHAN PT, 1984, AUST J PHYS, V37, P359, DOI 10.1071/PH840539; CALLAGHAN PT, 1990, J MAGN RESON, V88, P493, DOI 10.1016/0022-2364(90)90283-F; CHEN DP, 1993, BIOPHYS J, V65, P727, DOI 10.1016/S0006-3495(93)81099-3; DEMUTH D, 1995, MICROPOROUS MATER, V3, P473, DOI 10.1016/0927-6513(94)00060-9; FEDDERS PA, 1978, PHYS REV B, V17, P40, DOI 10.1103/PhysRevB.17.40; FENG S, 1994, SCIENCE, V265, P1839, DOI 10.1126/science.265.5180.1839; GIRNUS I, 1995, ZEOLITES, V15, P33, DOI 10.1016/0144-2449(94)00004-C; GIRNUS I, 1995, ADV MATER, V7, P711, DOI 10.1002/adma.19950070805; Hodking A. L., 1955, J PHYSIOL-LONDON, V128, P61; KARGER J, 1992, J CATAL, V136, P283, DOI 10.1016/0021-9517(92)90062-M; KARGER J, 1995, Z NATURFORSCH A, V50, P186, DOI 10.1515/zna-1995-2-310; KARGER J, 1992, PHYS REV A, V45, P4173, DOI 10.1103/PhysRevA.45.4173; KARGER J, 1993, PHYS REV E, V47, P1427, DOI 10.1103/PhysRevE.47.1427; Karger J., 1992, DIFFUSION ZEOLITES O; Karger J., 1988, ADV MAGNETIC OPTICAL, P1; Kehr K., 1984, APPLICATIONS MONTE C, P181; KORNATOWSKI J, 1991, ZEOLITES, V11, P443; KUKLA V, UNPUB; LEI GD, 1993, J CATAL, V140, P601, DOI 10.1006/jcat.1993.1109; LEVITT DG, 1973, PHYS REV A, V8, P3050, DOI 10.1103/PhysRevA.8.3050; MARLOW F, 1992, ZEOLITES, V12, P433, DOI 10.1016/0144-2449(92)90044-P; Meier W.M., 1992, ATLAS ZEOLITE STRUCT; NEHER E, 1992, SCIENCE, V256, P498, DOI 10.1126/science.1373906; NIVARTHI SS, 1994, CHEM PHYS LETT, V229, P297, DOI 10.1016/0009-2614(94)01059-5; NOACK M, 1994, MICROPOROUS MATER, V3, P201, DOI 10.1016/0927-6513(94)00044-1; RICKERT L, 1970, ADV CATAL, V21, P281; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SCHUTH F, 1992, J PHYS CHEM-US, V96, P7493, DOI 10.1021/j100198a003; SHEN DM, 1994, J CHEM SOC FARADAY T, V90, P3017, DOI 10.1039/ft9949003017; STALLMACH F, 1993, J MAGN RESON SER A, V102, P270, DOI 10.1006/jmra.1993.1104; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690	35	278	281	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					702	704		10.1126/science.272.5262.702	http://dx.doi.org/10.1126/science.272.5262.702			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662563				2022-12-28	WOS:A1996UJ05100043
J	Wachter, RM; Goldman, L				Wachter, RM; Goldman, L			The emerging role of ''hospitalists'' in the American health care system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; MEDICAL OUTCOMES; UNITED-STATES; HIV-INFECTION; PHYSICIANS; SPECIALIST; VOLUME; GENERALIST; MORTALITY; PATTERNS				Wachter, RM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P856; BRANDNER J, 1995, MANAGED CARE     JUL, P19; Donaldson M, 1994, DEFINING PRIMARY CAR; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; GIPE B, 1996, COST QUALITY, V2, P6; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; JAKLEVIC MC, 1994, MODERN HEALTHCA 0926, P64; Kassebaum DG, 1995, ACAD MED, V70, P1152, DOI 10.1097/00001888-199512000-00024; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KILGORE C, 1995, INTERNAL MED NE 0301, P1; KILGORE C, 1995, INTERNAL MED NE 0301, P33; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; Moore M J, 1995, Am J Surg, V170, P55; MOVSESIAN MA, 1990, NEW ENGL J MED, V322, P1602, DOI 10.1056/NEJM199005313222211; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Robins NS, 1995, GIRL WHO DIED TWICE; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; Starfield B., 1992, PRIMARY CARE CONCEPT; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER BJ, 1994, MED CARE, V32, P902, DOI 10.1097/00005650-199409000-00002; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; WEEKS WB, 1994, NEW ENGL J MED, V330, P1280, DOI 10.1056/NEJM199405053301807; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WINSLOW R, 1995, WALL STREET J   0721, pB1; WINSLOW R, 1995, WALL STREET J   0721, pB4; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; ZEIGER RS, 1992, J ALLERGY CLIN IMMUN, V90, P278; 1992, CRIT CARE MED, V20, P540	41	493	495	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					514	517		10.1056/NEJM199608153350713	http://dx.doi.org/10.1056/NEJM199608153350713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672160				2022-12-28	WOS:A1996VB84900013
J	Bartlett, JA; Benoit, SL; Johnson, VA; Quinn, JB; Sepulveda, GE; Ehmann, WC; Tsoukas, C; Fallon, MA; Self, PL; Rubin, M				Bartlett, JA; Benoit, SL; Johnson, VA; Quinn, JB; Sepulveda, GE; Ehmann, WC; Tsoukas, C; Fallon, MA; Self, PL; Rubin, M			Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article						zidovudine; lamivudine; zalcitabine; human immunodeficiency virus; CD4 lymphocyte count	HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; COMBINATION THERAPY; PHASE-I; INVITRO; RESISTANT; 2',3'-DIDEOXY-3'-THIACYTIDINE; INHIBITOR	Objective: To compare the safety and activity of lamivudine plus zidovudine with the safety and activity of zalcitabine plus zidovudine in patients with moderately advanced human immunodeficiency virus (HIV) infection who had received zidovudine. Design: A multicenter, randomized, double-blind, three-arm, 24-week study with a blinded extension through at least 52 weeks. Setting: 21 sites in the United States, Canada, and Puerto Rico. Patients: 254 patients who had received zidovudine (median duration of previous therapy, 20 months) and had absolute CD4(+) cell counts of 100 to 300 cells/mm(3). Interventions: Patients were randomly assigned to receive one of three regimens: 150 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (low-dose lamivudine group); 300 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (high-dose lamivudine group); or 0.75 mg of zalcitabine plus 200 mg of zidovudine three times daily (zalcitabine group). Measurements: Immunologic activity was assessed primarily by changes in absolute CD4(+) cell counts; virologic activity was assessed by changes in plasma HIV RNA levels as measured by reverse transcriptase polymerase chain reaction. Safety of the treatment regimens was assessed through the reporting of adverse events. Results: 78% of patients completed 24 weeks of study treatment, and 63% of patients completed 52 weeks of study treatment. Changes in absolute CD4(+) cell counts were significantly better for the low-dose and the high-dose lamivudine groups than for the zalcitabine group (median changes at 52 weeks were +42.5 cells/mm(3) in the low-dose lamivudine group, +23.33 cells/mm(3) in the high-dose lamivudine group, and -29.58 cells/mm(3) in the zalcitabine group). Suppression of plasma HIV RNA levels was similar for all groups (median changes at 52 weeks were -0.48 log(10) copies/mL in the low-dose lamivudine group, -0.51 log(10) copies/mL in the high-dose lamivudine group, and -0.39 log(10) copies/mL in the zalcitabine group). No significant differences in safety were seen among the three regimens, although the low-dose lamivudine regimen appeared to be better tolerated than the others. Conclusions: In patients with HIV infection who had previously received zidovudine, 150 mg of lamivudine plus zidovudine resulted in greater immunologic evidence of benefit than did 0.75 mg of zalcitabine plus zidovudine and was better tolerated than 300 mg of lamivudine plus zidovudine.	VET AFFAIRS MED CTR, BIRMINGHAM, AL USA; MCGILL UNIV, MONTREAL, PQ, CANADA	US Department of Veterans Affairs; Veterans Health Administration (VHA); McGill University	Bartlett, JA (corresponding author), DUKE UNIV, MED CTR, BOX 3238, DURHAM, NC 27710 USA.							[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Berry DA, 1989, STAT METHODOLOGY PHA; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; CAMMACK N, 1992, 8 INT C AIDS 3 STD W; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P130, DOI 10.1128/AAC.37.1.130; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HAMMER S, IN PRESS N ENGL J ME; HAMMER SM, 1996, 3 C RETR OPP INF WAS, pS24; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOOPER C, 1994, 3 INT WORKSH HIV DRU; JOHNSON VA, 1994, AIDS RES HUM RETROV, V10, P907, DOI 10.1089/aid.1994.10.907; KATLAMA C, 1995, 2 NAT C HUM RETR REL; KOJIMA E, 1995, J INFECT DIS, V171, P1152, DOI 10.1093/infdis/171.5.1152; KURITZKES D, 1995, 2 NAT C HUM RETR REL; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PLUDA JM, 1995, J INFECT DIS, V171, P1438, DOI 10.1093/infdis/171.6.1438; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SELIGMANN M, 1994, LANCET, V343, P871; STASZEWSKI S, 1995, 2 NAT C HUM RETR REL; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VANLEEUWEN R, 1992, AIDS, V6, P1471, DOI 10.1097/00002030-199212000-00008; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; VINER KC, 1993, 9 INT C AIDS BERL GE; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; WAKEFIELD JK, 1992, J VIROL, V66, P6806, DOI 10.1128/JVI.66.11.6806-6812.1992; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WELLES SL, 1995, 2 NAT C HUM RETR WAS, P230; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; [No title captured]	42	95	95	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					161	+		10.7326/0003-4819-125-3-199608010-00001	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686973				2022-12-28	WOS:A1996UZ28700001
J	Russo, AA; Jeffrey, PD; Patten, AK; Massague, J; Pavletich, NP				Russo, AA; Jeffrey, PD; Patten, AK; Massague, J; Pavletich, NP			Crystal structure of the p27(Kip1) cyclin-dependent-kinase inhibitor bound to the cyclin A Cdk2 complex	NATURE			English	Article							POTENTIAL MEDIATOR; P21; PROTEINS; PROGRAM	The crystal structure of the human p27(Kip1) kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 Angstrom, p27(Kip1) binds the complex as an extended structure interacting with both cyclin A and Cdk2. On cyclin A, it binds in a groove formed by conserved cyclin box residues. On Cdk2, it binds and rearranges the amino-terminal lobe and also inserts into the catalytic cleft, mimicking ATP.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408; Jeffrey, Philip/0000-0002-4351-5341				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JEFFREY PD, 1995, NATURE, V375, P159; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUSSO AR, IN PRESS NATURE STRU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1570; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	38	771	803	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					325	331		10.1038/382325a0	http://dx.doi.org/10.1038/382325a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684460				2022-12-28	WOS:A1996UY95000042
J	Richards, S; Gray, R; Peto, R; Gaynon, P; Masera, G; Pession, A; Rondelli, R; Valsecchi, MG; Reiter, A; Riehm, H; Schrappe, M; McIntyre, OR; Bleyer, A; Cairo, M; Reaman, G; Sather, H; Trigg, M; Auclerc, MF; Bancillon, A; Lepage, E; Schaison, G; Clavell, L; Datton, V; Donnelly, M; Gelber, R; Sallan, SE; SackmanMuriel, F; Santarelli, MT; Perez, C; Solidoro, A; Bailey, C; Burnett, A; Chessells, J; Eden, OB; GordonSmith, EC; Lilleyman, J; Land, VJ; Mahoney, D; Murphy, S; Steuber, CP; Vietti, T; Crist, W; Hancock, M; Pui, CH; Simone, J; Mittra, I; Shetty, PA; Allison, R; Baigent, C; Clarke, M; Duong, H; Durrant, J; Godwin, J; Greaves, E; Harwood, C; Peto, J; Sinclair, D; Wheatley, K				Richards, S; Gray, R; Peto, R; Gaynon, P; Masera, G; Pession, A; Rondelli, R; Valsecchi, MG; Reiter, A; Riehm, H; Schrappe, M; McIntyre, OR; Bleyer, A; Cairo, M; Reaman, G; Sather, H; Trigg, M; Auclerc, MF; Bancillon, A; Lepage, E; Schaison, G; Clavell, L; Datton, V; Donnelly, M; Gelber, R; Sallan, SE; SackmanMuriel, F; Santarelli, MT; Perez, C; Solidoro, A; Bailey, C; Burnett, A; Chessells, J; Eden, OB; GordonSmith, EC; Lilleyman, J; Land, VJ; Mahoney, D; Murphy, S; Steuber, CP; Vietti, T; Crist, W; Hancock, M; Pui, CH; Simone, J; Mittra, I; Shetty, PA; Allison, R; Baigent, C; Clarke, M; Duong, H; Durrant, J; Godwin, J; Greaves, E; Harwood, C; Peto, J; Sinclair, D; Wheatley, K			Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 randomised children	LANCET			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; MEDICAL-RESEARCH-COUNCIL; CANCER-STUDY-GROUP; CHILDHOOD; THERAPY; INTENSIFICATION; RISK; REMISSION; RELAPSE; DOSAGE	Background The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worldwide overview of all randomised trials that began before 1987. Methods. Individual patient data were sought for about 3900 children in trials of longer vs shorter maintenance leg, 3 vs 2 years), 3700 in trials of intensive ''reinduction'' chemotherapy during maintenance, and 4400 in trials of various other questions, including 1300 in trials of pulses of vincristine and prednisone (VP) during maintenance. Analyses were of survival in first remission, overall survival, and cause-specific mortality. Findings Deaths during remission were increased by longer maintenance (2.7% vs 1.2%), VP pulses (4.0 vs 3.2%), and intensive reinduction (4.8% vs 3.3%), but these increases were counterbalanced by reductions in relapses. Total events (relapse or death) were significantly reduced by longer maintenance (23.3% vs 27.6%), VP pulses (31.2% vs 40.4%) and intensive reinduction (27.8% vs 35.8%) (each 2p<0.001). Many of those who relapsed were successfully re-treated, however, and only for intensive reinduction was overall survival significantly improved (18.5% vs 22.3%; 2p=0.01). Interpretation Intensive reinduction chemotherapy in these trials produced an absolute improvement of about 4% in long-term survival; if the extra deaths in remission had been avoided, this would have been a 5% benefit. Further improvements in survival seem more likely to be obtained with intensive treatment than with longer low-level maintenance.	DANA FARBER CANC INST, BOSTON, MA USA; INEN, LIMA, PERU; MRC, LONDON W1N 4AL, ENGLAND; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN USA; TATA MEM HOSP, BOMBAY, MAHARASHTRA, INDIA	Harvard University; Dana-Farber Cancer Institute; St Jude Children's Research Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital	Richards, S (corresponding author), RADCLIFFE INFIRM, CTSU, CHILDHOOD ALL SECRETARIAT, OXFORD OX2 6HE, ENGLAND.		Pui, Ching-Hon/N-8076-2018; Schrappe, Martin/ABA-6144-2020; Schrappe, Martin/A-8109-2010; Valsecchi, Maria Grazia/K-8891-2016; Pession, Andrea/O-3200-2013	Pui, Ching-Hon/0000-0003-0303-5658; Valsecchi, Maria Grazia/0000-0001-5574-3504; Pession, Andrea/0000-0002-0379-9562; Mittra, Indraneel/0000-0002-5768-3821				AUR RJA, 1978, CANCER, V42, P2123, DOI 10.1002/1097-0142(197811)42:5<2123::AID-CNCR2820420507>3.0.CO;2-5; AUR RJA, 1972, CANCER, V29, P381, DOI 10.1002/1097-0142(197202)29:2<381::AID-CNCR2820290219>3.0.CO;2-P; AUR RJA, 1971, BLOOD-J HEMATOL, V37, P272, DOI 10.1182/blood.V37.3.272.272; BLEYER WA, 1991, J CLIN ONCOL, V9, P1012, DOI 10.1200/JCO.1991.9.6.1012; BLEYER WA, 1989, AM J PEDIAT HEMATOL, V11, P371; BLEYER WA, 1983, J CLIN ONCOL, V1, P317, DOI 10.1200/JCO.1983.1.5.317; CHESSELLS JM, 1986, J CLIN ONCOL, V4, P1758, DOI 10.1200/JCO.1986.4.12.1758; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; CLARKE MJ, 1994, BRIT MED J, V309, P1007, DOI 10.1136/bmj.309.6960.1007; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; HENZE G, 1982, KLIN PADIATR, V194, P195, DOI 10.1055/s-2008-1033805; Henze G, 1990, Haematol Blood Transfus, V33, P483; HOLLAND JF, 1972, CANCER-AM CANCER SOC, V30, P1480, DOI 10.1002/1097-0142(197212)30:6<1480::AID-CNCR2820300611>3.0.CO;2-3; LEVERGER G, 1988, MED PEDIATR ONCOL, V16, P389; MAUER AM, 1976, CANCER TREAT REV, V3, P17, DOI 10.1016/S0305-7372(76)80015-1; MILLER DR, 1989, J CLIN ONCOL, V7, P316, DOI 10.1200/JCO.1989.7.3.316; NESBIT ME, 1983, J CLIN ONCOL, V1, P308, DOI 10.1200/JCO.1983.1.5.308; PAOLUCCI G, 1989, MED PEDIATR ONCOL, V17, P83, DOI 10.1002/mpo.2950170203; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1966, OXFORD TXB MED, V1, P21; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; PUI CH, 1984, CANCER RES, V44, P3593; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Riehm H, 1990, Haematol Blood Transfus, V33, P439; ROWLAND JH, 1984, J CLIN ONCOL, V2, P127; SACKMANNMURIEL F, 1978, CANCER-AM CANCER SOC, V42, P1730, DOI 10.1002/1097-0142(197810)42:4<1730::AID-CNCR2820420411>3.0.CO;2-K; SALLAN SE, 1984, CURRENT THERAPY LEUK, P35; SCHRAPPE M, 1987, KLIN PADIATR, V199, P133, DOI 10.1055/s-2008-1026780; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; VANEYS J, 1989, CANCER, V63, P1466, DOI 10.1002/1097-0142(19890415)63:8<1466::AID-CNCR2820630803>3.0.CO;2-I; 1982, MED PEDIATR ONCOL, V10, P511; 1977, BRIT MED J, V2, P495; 1988, BRIT MED J, V296, P320; 1982, MED PEDIATR ONCOL, V10, P501; 1978, BRIT MED J, V2, P787	36	88	91	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1783	1788						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667921				2022-12-28	WOS:A1996UU46900008
J	Lee, CH; Saksela, K; Mirza, UA; Chait, BT; Kuriyan, J				Lee, CH; Saksela, K; Mirza, UA; Chait, BT; Kuriyan, J			Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain	CELL			English	Article							PROTEIN STRUCTURES; GENE; KINASES	The crystal structure of the conserved core of HIV-1 Nef has been determined in complex with the SH3 domain of a mutant Fyn tyrosine kinase (a single amino acid substitution, Arg-96 to isoleucine), to which Nef binds tightly. The conserved PxxP sequence motif of Nef, known to be important for optimal viral replication, is part of a polyproline type II helix that engages the SH3 domain in a manner resembling closely the interaction of isolated peptides with SH3 domains. The Nef-SH3 structure also reveals how high affinity and specificity in the SH3 interaction is achieved by the presentation of the PxxP motif within the context of the folded structure of Nef.	ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute			Lee, Chi-Hon/G-9190-2012	Lee, Chi-Hon/0000-0002-6138-711X				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1992, XPLOR VERSION 3 1 MA; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FREUND J, 1994, EUR J BIOCHEM, V223, P589, DOI 10.1111/j.1432-1033.1994.tb19029.x; FREUND J, 1994, EUR J BIOCHEM, V221, P811, DOI 10.1111/j.1432-1033.1994.tb18795.x; GOSSER YQ, 1995, STRUCTURE, V3, P1075, DOI 10.1016/S0969-2126(01)00243-X; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	40	385	397	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					931	942		10.1016/S0092-8674(00)81276-3	http://dx.doi.org/10.1016/S0092-8674(00)81276-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681387	Bronze			2022-12-28	WOS:A1996UR60400016
J	Sudo, K; Owada, Y; Yabe, I; Kikuchi, S; Tashiro, K				Sudo, K; Owada, Y; Yabe, I; Kikuchi, S; Tashiro, K			Syringomyelia as a cause of body hypertrophy	LANCET			English	Article							CHIARI MALFORMATION; HEMIHYPERTROPHY; GROWTH	Background Among 26 patients with communicating syringomyelia who came to our out-patient clinic from April, 1989, to March, 1995, three (11.5%) had hypertrophy in limbs, hands, or feet. One had crossed hypertrophy. We considered the possibility that syringomyelia caused body hypertrophy. Methods We searched MEDLINE for articles which mention body asymmetry or hypertrophy, and examined the findings in our own patients. Findings The site of hypertrophy in our three patients coincided with the site of the neurological and magnetic resonance imaging findings. In addition, the horizontal and vertical location of the syrinx corresponded with the site of all four hypertrophic limbs. We located ten articles in which a diagnosis of syringomyelia was made, and five in which other diagnoses were made. Interpretation From studying our patients as well as those previously reported, we speculate that some types of body hypertrophy are due to damage, accompanied by stimulation, of the sympathetic neurons in the ipsilateral lateral horn of the spinal cord, Although there are many causes of hypertrophy, we suggest that the possibility of syringomyelia be investigated in patients with body hypertrophy, especially in those with any accompanying neurological abnormality.			Sudo, K (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT NEUROL,KITA KU,KITA 14,NISHI 5,SAPPORO,HOKKAIDO 060,JAPAN.		Yabe, Ichiro/AAU-2495-2020; Yabe, Ichiro/D-6458-2012	Yabe, Ichiro/0000-0002-1734-7997; 				AELVOET GE, 1992, BRIT J DERMATOL, V126, P603; Alavi S, 1993, J Postgrad Med, V39, P219; BARNETT HJM, 1973, SYRINGOMYELIA, P1; BRYAN RS, 1958, AM J SURG, V96, P654, DOI 10.1016/0002-9610(58)90467-7; BUES E, 1954, Chirurg, V25, P443; DELAPORTE C, 1991, J NEUROL SCI, V105, P183, DOI 10.1016/0022-510X(91)90143-U; DORING G, 1949, DEUT MED WOCHENSCHR, V74, P754; FOSTER JB, 1973, SYRINGOMYELIA, P104; FOX JH, 1974, ARCH NEUROL-CHICAGO, V30, P490, DOI 10.1001/archneur.1974.00490360066014; FURUKAWA T, 1981, ANN NEUROL, V10, P199, DOI 10.1002/ana.410100212; Gesell A, 1927, AM J MED SCI, V173, P542, DOI 10.1097/00000441-192704000-00013; GUILLAIN G, 1925, REV NEUROL, V32, P778; HANLEY TB, 1984, ANN OPHTHALMOL, V16, P342; HENRY M, 1973, BRIT MED J, V1, P87, DOI 10.1136/bmj.1.5845.87; HUBAULT A, 1982, REV NEUROL, V138, P1009; LAPRESLE J, 1976, REV NEUROL, V132, P567; MAERTEN U, 1938, DTSCH Z NERVENH, V147, P196; MAYERS LH, 1926, J SURG GYNECOL OBSTE, V43, P746; MILLER RW, 1966, NEW ENGL J MED, V275, P87, DOI 10.1056/NEJM196607142750208; NUDLEMAN K, 1984, BRAIN, V107, P533, DOI 10.1093/brain/107.2.533; Osswald W, 1983, REV PHYSL BIOCH PHAR, V96, P53; Panday S R, 1966, J Postgrad Med, V12, P79; PFISTER RC, 1975, RADIOLOGY, V116, P685, DOI 10.1148/116.3.685; QUINTON PM, 1983, ANNU REV MED, V34, P429, DOI 10.1146/annurev.me.34.020183.002241; RAYNOR RB, 1986, SPINE, V11, P343, DOI 10.1097/00007632-198605000-00009; SCHENKEIN I, 1974, NEW ENGL J MED, V290, P613, DOI 10.1056/NEJM197403142901108; Schliack H, 1967, Acta Neuroveg (Wien), V30, P512, DOI 10.1007/BF01239930; Schliep G, 1978, HDB CLIN NEUROLOGY, V32, P255; SHAFTON AD, 1992, BRAIN RES, V599, P253, DOI 10.1016/0006-8993(92)90399-T; SUDOU K, 1993, J NEUROL, V240, P75, DOI 10.1007/BF00858720	30	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1593	1595		10.1016/S0140-6736(96)91078-8	http://dx.doi.org/10.1016/S0140-6736(96)91078-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667869				2022-12-28	WOS:A1996UP66100012
J	Roy, S; Hughes, O; Mukherjee, K; Stephenson, BM				Roy, S; Hughes, O; Mukherjee, K; Stephenson, BM			Knot Crohn's disease	LANCET			English	Article									ROYAL GWENT HOSP,DEPT SURG,NEWPORT NP9 2UB,GWENT,WALES	Royal Gwent Hospital								ALVER O, 1993, DIS COLON RECTUM, V36, P1139, DOI 10.1007/BF02052263; KRUPSKY S, 1987, J CLIN GASTROENTEROL, V9, P467, DOI 10.1097/00004836-198708000-00023; MALCOLM PN, 1994, BRIT J RADIOL, V67, P964, DOI 10.1259/0007-1285-67-802-964; STURZAKER HG, 1975, BRIT MED J, V4, P338, DOI 10.1136/bmj.4.5992.338	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1528	1528		10.1016/S0140-6736(96)90675-3	http://dx.doi.org/10.1016/S0140-6736(96)90675-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684106				2022-12-28	WOS:A1996UN47300014
J	Newton, R; Ferlay, J; Reeves, G; Beral, V; Parkin, DM				Newton, R; Ferlay, J; Reeves, G; Beral, V; Parkin, DM			Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye	LANCET			English	Article								Background We have investigated the geographic distribution of squamous-cell carcinoma of the eye to assess whether solar ultraviolet light is a risk factor for this disease. Methods We used routinely collected population-based cancer incidence data and published measurements of ambient solar ultraviolet light in our analysis. Findings The incidence of squamous-cell carcinoma of the eye declined by 49% for each 10 degrees increase in latitude (p<0.0001), falling from more than 12 cases per million per year in Uganda (latitude 0.3 degrees) to less than 0.2 per million per year in the UK (latitude >50 degrees). Solar ultraviolet radiation decreases with increasing latitude, and the incidence of squamous-cell carcinoma of the eye decreased by 29% per unit reduction in ultraviolet exposure (p<0.0001). Interpretation Our results are compatible with the hypothesis that exposure to solar ultraviolet light is an important cause of squamous-cell carcinoma of the eye.	INT AGCY RES CANC,F-69372 LYON,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)	Newton, R (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.		Ferlay, Jacques/ABD-5058-2021					ATEENYIAGABA C, 1995, LANCET, V345, P695, DOI 10.1016/S0140-6736(95)90870-6; DIFFEY BL, 1993, MELANOMA EPIDEMIOLOG, P81; *EUR NETW CANC REG, 1995, EUROCIM US MAN; GOEDERT JJ, 1995, LANCET, V346, P257, DOI 10.1016/S0140-6736(95)91309-2; *INT AG CANC RES, 1992, INT AG CANC RES MON, V55; KESTELYN P, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91562-O; LEE GA, 1994, OPHTHALMOLOGY, V101, P360; MCDONNELL JM, 1989, NEW ENGL J MED, V320, P1442, DOI 10.1056/NEJM198906013202202; *NCI SURV PROGR, 1994, SURV EP END RES SEER; NEWTON R, 1995, LANCET, V345, P1378, DOI 10.1016/S0140-6736(95)92583-X; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; Templeton A C, 1973, Recent Results Cancer Res, V41, P203; *WHO, 1976, MAN INT CLASS DIS ON	13	109	115	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1450	1451		10.1016/S0140-6736(96)91685-2	http://dx.doi.org/10.1016/S0140-6736(96)91685-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676629				2022-12-28	WOS:A1996UM48500012
J	Brandon, AD; Creaser, RA; Shirey, SB; Carlson, RW				Brandon, AD; Creaser, RA; Shirey, SB; Carlson, RW			Osmium recycling in subduction zones	SCIENCE			English	Article							SPINEL LHERZOLITE XENOLITHS; OS ISOTOPIC CONSTRAINTS; PLATINUM-GROUP ELEMENTS; MANTLE OXIDATION-STATE; TRACE-ELEMENTS; ULTRAMAFIC XENOLITHS; ICHINOMEGATA CRATER; NORTHEAST JAPAN; OGA PENINSULA; ARC LAVAS	Peridotite xenoliths from the Cascade arc in the United States and in the Japan arc have neodymium and osmium isotopic compositions that are consistent with addition of 5 to 15 percent of subducted material to the present-day depleted mantle. These observations suggest that osmium can be partitioned into oxidized and chlorine-rich slab-derived fluids or melts. These results place new constraints on the behavior of osmium (and possibly other platinum group elements) during subduction of oceanic crust by showing that osmium can be transported into the mantle wedge.	UNIV ALBERTA, DEPT EARTH & ATMOSPHER SCI, EDMONTON, AB T6G 2E3, CANADA	University of Alberta	Brandon, AD (corresponding author), CARNEGIE INST WASHINGTON, DEPT TERR MAGNETISM, 5241 BROAD BRANCH RD NW, WASHINGTON, DC 20015 USA.			Creaser, Robert/0000-0002-7672-035X				ARCULUS RJ, 1994, LITHOS, V33, P189, DOI 10.1016/0024-4937(94)90060-4; BALLHAUS C, 1993, CONTRIB MINERAL PETR, V114, P331, DOI 10.1007/BF01046536; BALLHAUS CG, 1986, CONTRIB MINERAL PETR, V94, P192; BALLHAUS CG, 1985, EARTH PLANET SC LETT, V74, P56; BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; BOUDREAU AE, 1989, CONTRIB MINERAL PETR, V102, P138, DOI 10.1007/BF00375336; BOUDREAU AE, 1986, J PETROL, V27, P967, DOI 10.1093/petrology/27.4.967; Boyd F.R., 1987, MAGMATIC PROCESSES P, VVolume 1, P13; BRANDON AD, 1995, PUBLICACIONES I ANDA, V1, P8; BRANDON AD, IN PRESS GEOCHIM COS; CARLSON RW, 1994, EARTH PLANET SC LETT, V126, P457, DOI 10.1016/0012-821X(94)90124-4; CARMICHAEL ISE, 1986, EARTH PLANET SC LETT, V78, P200, DOI 10.1016/0012-821X(86)90061-0; Chen-Lin Chou, 1983, Journal of Geophysical Research, V88, P507, DOI 10.1029/JB088iS02p0A507; CREASER RA, 1991, GEOCHIM COSMOCHIM AC, V55, P397, DOI 10.1016/0016-7037(91)90427-7; DRAPER DS, 1992, J GEOL, V100, P766, DOI 10.1086/629627; EDWARDS CMH, 1993, NATURE, V362, P530, DOI 10.1038/362530a0; ESSER BK, 1993, GEOCHIM COSMOCHIM AC, V57, P3093, DOI 10.1016/0016-7037(93)90296-9; ESSER BK, 1988, GEOCHIM COSMOCHIM AC, V52, P1383, DOI 10.1016/0016-7037(88)90209-8; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; HERTOGEN J, 1980, GEOCHIM COSMOCHIM AC, V44, P2125, DOI 10.1016/0016-7037(80)90209-4; ISHIKAWA T, 1994, NATURE, V370, P205, DOI 10.1038/370205a0; JOHNSON KTM, 1990, J GEOPHYS RES-SOLID, V95, P2661, DOI 10.1029/JB095iB03p02661; KUNO H, 1967, ULTRAMAFIC RELATED R, P337; LEEMAN WP, 1990, J GEOPHYS RES-SOLID, V95, P19561, DOI 10.1029/JB095iB12p19561; LIDNER M, 1989, GEOCHIM COSMOCHIM AC, V53, P1597; LORAND JP, 1990, GEOCHIM COSMOCHIM AC, V54, P1487, DOI 10.1016/0016-7037(90)90173-I; LORAND JP, 1993, EARTH PLANET SC LETT, V119, P627, DOI 10.1016/0012-821X(93)90067-J; LUCK JM, 1991, EARTH PLANET SC LETT, V107, P406, DOI 10.1016/0012-821X(91)90086-W; MARCANTONIO F, 1995, EARTH PLANET SC LETT, V133, P397, DOI 10.1016/0012-821X(95)00092-Q; MARTIN CE, 1991, AUST J EARTH SCI, V38, P569, DOI 10.1080/08120099108727992; MARTIN CE, 1991, GEOCHIM COSMOCHIM AC, V55, P1421, DOI 10.1016/0016-7037(91)90318-Y; MEISEL T, 1996, 6 VM GOLDSCHM C HEID, V1, P396; MORGAN JW, 1981, TECTONOPHYSICS, V75, P47, DOI 10.1016/0040-1951(81)90209-2; MORGAN JW, 1967, EARTH PLANET SC LETT, V3, P219, DOI 10.1016/0012-821X(67)90041-6; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; PEARCE JA, 1995, J PETROL, V36, P1073, DOI 10.1093/petrology/36.4.1073; PEARSON DG, 1995, EARTH PLANET SC LETT, V134, P341, DOI 10.1016/0012-821X(95)00125-V; PEARSON DG, 1995, GEOCHIM COSMOCHIM AC, V59, P959, DOI 10.1016/00167-0379(50)00143-; PEGRAM WJ, 1992, EARTH PLANET SC LETT, V111, P59, DOI 10.1016/0012-821X(92)90169-V; PEUCKEREHRENBRINK B, 1995, EARTH PLANET SC LETT, V130, P155, DOI 10.1016/0012-821X(95)00003-U; PLANK T, 1993, NATURE, V362, P739, DOI 10.1038/362739a0; PORCELLI DR, 1992, CONTRIB MINERAL PETR, V110, P528, DOI 10.1007/BF00344086; RAVIZZA G, 1993, CHEM GEOL, V107, P255, DOI 10.1016/0009-2541(93)90186-M; RAVIZZA G, 1993, EARTH PLANET SC LETT, V118, P335, DOI 10.1016/0012-821X(93)90177-B; RAVIZZA G, 1993, GEOCHIM COSMOCHIM AC, V57, P4301, DOI 10.1016/0016-7037(93)90324-P; RAVIZZA G, 1992, EARTH PLANET SC LETT, V110, P1, DOI 10.1016/0012-821X(92)90034-S; RAVIZZA G, 1991, GEOCHIM COSMOCHIM AC, V55, P3741, DOI 10.1016/0016-7037(91)90072-D; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; REISBERG L, 1995, NATURE, V376, P159, DOI 10.1038/376159a0; REISBERG LC, 1991, EARTH PLANET SC LETT, V105, P196, DOI 10.1016/0012-821X(91)90131-Z; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; ROYBARMAN M, 1995, EARTH PLANET SC LETT, V129, P145, DOI 10.1016/0012-821X(94)00238-T; SCHIANO P, 1995, NATURE, V377, P595, DOI 10.1038/377595a0; SCHIFFRIES CM, 1982, ECON GEOL, V77, P1493; SHIREY SB, 1995, ANAL CHEM, V67, P2136, DOI 10.1021/ac00109a036; SNOW JE, 1995, GEOCHIM COSMOCHIM AC, V59, P4219, DOI 10.1016/0016-7037(95)00239-V; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; SNOW JE, 1994, NATURE, V371, P57, DOI 10.1038/371057a0; STOLPER E, 1994, EARTH PLANET SC LETT, V121, P293, DOI 10.1016/0012-821X(94)90074-4; TAKAHASHI E, 1986, J VOLCANOL GEOTH RES, V29, P355, DOI 10.1016/0377-0273(86)90051-X; TAKAHASHI E, 1980, GEOCHIM COSMOCHIM AC, V44, P1643, DOI 10.1016/0016-7037(80)90217-3; WALKER RJ, 1991, CONTRIB MINERAL PETR, V107, P150, DOI 10.1007/BF00310704; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8; WOOD BJ, 1990, SCIENCE, V248, P337, DOI 10.1126/science.248.4953.337; WOOD BJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1277; WOOD SA, 1987, GEOCHIM COSMOCHIM AC, V51, P3041, DOI 10.1016/0016-7037(87)90377-2; 1981, BASALTIC VOLCANISM T, P288	67	235	241	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1996	272	5263					861	864		10.1126/science.272.5263.861	http://dx.doi.org/10.1126/science.272.5263.861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662577				2022-12-28	WOS:A1996UK75700055
J	Seiff, A; Kirk, DB; Knight, TCD; Mihalov, JD; Blanchard, RC; Young, RE; Schubert, G; vonZahn, U; Lehmacher, G; Milos, FS; Wang, J				Seiff, A; Kirk, DB; Knight, TCD; Mihalov, JD; Blanchard, RC; Young, RE; Schubert, G; vonZahn, U; Lehmacher, G; Milos, FS; Wang, J			Structure of the atmosphere of Jupiter: Galileo probe measurements	SCIENCE			English	Article								Temperatures and pressures measured by the Galileo probe during parachute descent into Jupiter's atmosphere essentially followed the dry adiabat between 0.41 and 24 bars, consistent with the absence of a deep water cloud and with the low water content found by the mass spectrometer. From 5 to 15 bars, lapse rates were slightly stable relative to the adiabat calculated for the observed H-2/He ratio, which suggests that upward heat transport in that range is not attributable to simple radial convection, In the upper atmosphere, temperatures of >1000 kelvin at the 0.01-microbar level confirmed the hot exosphere that had been inferred from Voyager occultations. The thermal gradient increased sharply to 5 kelvin per kilometer at a reconstructed altitude of 350 kilometers, as was recently predicted, Densities at 1000 kilometers were 100 times those in the preencounter engineering model.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; NASA,LANGLEY RES CTR,HAMPTON,VA 23681; UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90024; UNIV ROSTOCK,INST ATMOSPHARENPHYS,KUHLUNGSBORN,GERMANY; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Langley Research Center; University of California System; University of California Los Angeles; University of Rostock; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Seiff, A (corresponding author), SAN JOSE STATE UNIV,DEPT METEOROL,SAN JOSE,CA 95192, USA.		Lehmacher, Gerald A/F-2653-2013					Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; ATREYA SK, 1979, GEOPHYS RES LETT, V6, P795, DOI 10.1029/GL006i010p00795; ATREYA SK, 1981, ASTROPHYS J, V247, pL43, DOI 10.1086/183586; DELGENIO AD, 1990, ICARUS, V84, P29, DOI 10.1016/0019-1035(90)90156-4; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; HAAS BL, 1995, J SPACECRAFT ROCKETS, V32, P398, DOI 10.2514/3.26628; HUNTEN DM, 1977, PLANET SPACE SCI, V25, P817, DOI 10.1016/0032-0633(77)90035-6; INTRIERI PF, 1977, ACTA ASTRONAUT, V4, P789, DOI 10.1016/0094-5765(77)90013-3; INTRIERI PF, 1987, J SPACECRAFT ROCKETS, V24, P127, DOI 10.2514/3.25885; LIU W, IN PRESS ASTROPHYS J; NEFF JM, COMMUNICATION; NIEMANN HB, 1992, SPACE SCI REV, V60, P111, DOI 10.1007/BF00216852; NIEMANN HB, 1996, SCIENCE, V272, P847; ORTON GS, 1981, 1625125 NASA JET PRO; PRESTON R, COMMUNICATION; RAGENT B, 1996, SCIENCE, V272, P855; SEIFF A, 1992, SPACE SCI REV, V60, P203, DOI 10.1007/BF00216855; VONZAHN U, 1996, SCIENCE, V272, P850; WOO R, COMMUNICATION; Yelle RV, 1996, J GEOPHYS RES-PLANET, V101, P2149, DOI 10.1029/95JE03384; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837	21	89	89	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					844	845		10.1126/science.272.5263.844	http://dx.doi.org/10.1126/science.272.5263.844			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662574				2022-12-28	WOS:A1996UK75700048
J	Emerich, C; BenJaffel, L; Clarke, JT; Prange, R; Gladstone, GR; Sommeria, J; Ballester, G				Emerich, C; BenJaffel, L; Clarke, JT; Prange, R; Gladstone, GR; Sommeria, J; Ballester, G			Evidence for supersonic turbulence in the upper atmosphere of Jupiter	SCIENCE			English	Article							LONGITUDINAL ASYMMETRY; ALPHA; BULGE	Spectra of the hydrogen Lyman alpha. (Ly-alpha) emission line profiles of the jovian dayglow, obtained by the Goddard High Resolution Spectrograph on the Hubble Space Telescope, appear complex and variable on time scales of a few minutes. Dramatic changes occur in the Ly-alpha bulge region at low latitudes, where the line profiles exhibit structures that correspond to supersonic velocities of the order of several to tens of kilometers per second, This behavior, unexpected in a planetary atmosphere, is evidence for the particularly stormy jovian upper atmosphere, not unlike a star's atmosphere.	CNRS,INST ASTROPHYS PARIS,F-75014 PARIS,FRANCE; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; SW RES INST,SAN ANTONIO,TX 78238; ECOLE NORMALE SUPER LYON,F-69364 LYON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Michigan System; University of Michigan; Southwest Research Institute; Ecole Normale Superieure de Lyon (ENS de LYON)	Emerich, C (corresponding author), CNRS,INST ASTROPHYS SPATIALE,F-91405 ORSAY,FRANCE.		Clarke, John/C-8644-2013					ATREYA SK, 1979, GEOPHYS RES LETT, V6, P795, DOI 10.1029/GL006i010p00795; BENJAFFEL L, 1993, GEOPHYS RES LETT, V20, P747; CLARKE JT, 1980, ASTROPHYS J, V240, P696, DOI 10.1086/158277; CLARKE JT, 1991, GEOPHYS RES LETT, V18, P1935, DOI 10.1029/91GL02091; DESSLER AJ, 1981, PLANET SPACE SCI, V29, P215, DOI 10.1016/0032-0633(81)90035-0; LOUCIF ML, 1982, ASTRON ASTROPHYS, V112, P287; MAGNAN C, 1976, J QUANT SPECTROSC RA, V16, P281, DOI 10.1016/0022-4073(76)90070-4; MAGNAN C, 1985, ASTRON ASTROPHYS, V144, P186; MCGRATH MA, 1991, GEOPHYS RES LETT, V18, P1931, DOI 10.1029/91GL02545; MCGRATH MA, 1990, J GEOPHYS RES-SPACE, V95, P10365, DOI 10.1029/JA095iA07p10365; SANDEL BR, 1980, GEOPHYS RES LETT, V7, P5, DOI 10.1029/GL007i001p00005; SHEMANSKY DE, 1985, J GEOPHYS RES-SPACE, V90, P2673, DOI 10.1029/JA090iA03p02673; SKINNER TE, 1988, J GEOPHYS RES-SPACE, V93, P29, DOI 10.1029/JA093iA01p00029; SOMMERIA J, 1995, ICARUS, V119, P2	14	25	25	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1085	1087		10.1126/science.273.5278.1085	http://dx.doi.org/10.1126/science.273.5278.1085			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688090				2022-12-28	WOS:A1996VD42800031
J	Lepor, H; Williford, WO; Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Machi, M; Narayan, P; Padley, RJ				Lepor, H; Williford, WO; Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Machi, M; Narayan, P; Padley, RJ			The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSOCIATION SYMPTOM INDEX; MULTICENTER; MEN; DOXAZOSIN	Background Men with benign prostatic hyperplasia can be treated with alpha(1)-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. Methods We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year. Results The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo). The mean changes at one year in the peak urinary-flow rates were increases of 1.4, 1.6, 2.7, and 3.2 ml per second, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo). Finasteride had no more effect on either measure than placebo, In the placebo group, 1.6 percent of the men discontinued the study because of adverse effects, as did 4.8 to 7.8 percent of the men in the other three groups. Conclusions In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazosin and finasteride was no more effective than terazosin alone. (C) 1996, Massachusetts Medical Society.	VET AFFAIRS MED CTR,NEW YORK,NY; VET AFFAIRS MED CTR,COOPERAT STUDIES PROGRAM COORDINATING CTR,PERRY POINT,MD; MASSACHUSETTS GEN HOSP,MED PRACTICES EVALUAT CTR,BOSTON,MA 02114; VET AFFAIRS MED CTR,SEATTLE,WA 98108; UNIV WASHINGTON,SEATTLE,WA 98195; MERCK & CO INC,RAHWAY,NJ 07065; VET AFFAIRS MED CTR,COOPERAT STUDIES PROGRAM CLIN RES PHARM COORDINAT,ALBUQUERQUE,NM; VET AFFAIRS MED CTR,MILWAUKEE,WI; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121; ABBOTT LABS,CARDIOVASC CLIN RES,ABBOTT PK,IL 60064	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Massachusetts General Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; Merck & Company; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Abbott Laboratories	Lepor, H (corresponding author), NYU,MED CTR,DEPT UROL,550 1ST AVE,NEW YORK,NY 10016, USA.							BARRY MJ, 1995, MED CARE, V33, pAS145; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; BARTSCH G, 1979, J UROLOGY, V122, P487, DOI 10.1016/S0022-5347(17)56476-9; BEISLAND HO, 1992, EUR UROL, V22, P271; BERGER BM, 1995, J UROLOGY, V154, P1060, DOI 10.1016/S0022-5347(01)66976-3; Brawer M K, 1993, Arch Fam Med, V2, P929, DOI 10.1001/archfami.2.9.929; FAWZY A, 1995, J UROLOGY, V154, P105, DOI 10.1016/S0022-5347(01)67240-9; GILLENWATER JY, 1995, J UROLOGY, V154, P110, DOI 10.1016/S0022-5347(01)67243-4; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GREENE DR, 1990, UROLOGY, V36, P293, DOI 10.1016/0090-4295(90)80231-B; GUP DI, 1989, PROSTATE, V15, P105, DOI 10.1002/pros.2990150204; KAWABE K, 1990, J UROLOGY, V144, P908, DOI 10.1016/S0022-5347(17)39620-9; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; Lepor H., 1995, Journal of Urology, V153, p274A; Lepor Herbert, 1993, P170; MADSEN FA, 1995, UROL CLIN N AM, V22, P291; MCCONNELL JD, 1995, UROL CLIN N AM, V22, P387; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MILLER RG, 1960, SIMULTANEOUS STATIST; SCHHLUCHTER MD, 1988, 86 BMDP STAT SOFTW; SHAPIRO E, 1992, PROSTATE, V21, P297, DOI 10.1002/pros.2990210406; Stone Nelson N., 1996, Journal of Urology, V155, p575A; 1993, PROSTATE, V22, P291	24	586	604	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					533	539		10.1056/NEJM199608223350801	http://dx.doi.org/10.1056/NEJM199608223350801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8684407				2022-12-28	WOS:A1996VD30200001
J	Graham, BS; Keefer, MC; McElrath, MJ; Gorse, GJ; Schwartz, DH; Weinhold, K; Matthews, TJ; Esterlitz, JR; Sinangil, F; Fast, PE; Wright, PF; Dolin, R; Corey, L; Belshe, RB; Clements, ML; Bolognesi, DP; Stablein, DM; Chernoff, D; Duliege, AM; Walker, CM				Graham, BS; Keefer, MC; McElrath, MJ; Gorse, GJ; Schwartz, DH; Weinhold, K; Matthews, TJ; Esterlitz, JR; Sinangil, F; Fast, PE; Wright, PF; Dolin, R; Corey, L; Belshe, RB; Clements, ML; Bolognesi, DP; Stablein, DM; Chernoff, D; Duliege, AM; Walker, CM			Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120 - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article						vaccines, synthetic; human immunodeficiency virus-1; acquired immunodeficiency syndrome; HIV envelope protein gp120; human immunodeficiency virus infection	HUMAN-IMMUNODEFICIENCY-VIRUS; RESPIRATORY SYNCYTIAL VIRUS; T-LYMPHOCYTE ACTIVITY; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSES; GP160 VACCINE; TYPE-1; GP120; INFECTION; CHIMPANZEES	Objective: To evaluate the safety and immunogenicity of recombinant glycoprotein (rgp) 120, a candidate vaccine for the human immunodeficiency virus (HIV), formulated with a novel adjuvant, MF59, with or without a biological response modifier, MTP-PE. Design: Multicenter, double-blind, randomized trial. Setting: University medical centers. Participants: 49 healthy, HIV-seronegative volunteers 18 to 60 years of age who were at low risk for HIV type 1 (HIV-1) infection. Interventions: In part A of the study, 32 participants were randomly assigned to receive either 15 mu g of rgp120 in MF59, 15 mu g of rgp120 in MF59 plus 50 mu g of MTP-PE, 50 mu g of rgp120 in MF59, or 50 mu g of rgp120 in MF59 plus 50 mu g of MTP-PE. Participants were vaccinated at 0, 1, 6, and 12 to 18 months. In part B, 17 participants were randomly assigned to receive five monthly injections of either 50 mu g of rgp120 in MF59 or MF59 alone followed by a booster injection at 12 to 18 months. Main Outcome Measures: Local and systemic reactions; laboratory measures of hepatic renal, immunologic, and bone marrow toxicity; and HIV-specific serologic and cell-mediated immune responses. Results: 13 patients in part A received 50-mu g doses of rgp120; type-specific neutralizing antibody responses against the SF-2 strain of HIV-1 (HIV-1/SF-2) were induced in ail 13, Nine of the 13 had crossreactive neutralizing activity against the MN strain of HIV-1 (HIV-1/MN), and 2 had crossreactive neutralizing activity against the IIIB strain of HIV-1 (HIV-1/IIIB). Twelve patients had type-specific fusion inhibition activity; only 1 had crossreactive fusion inhibition activity against HIV-1/MN. The monthly vaccination schedule used in part B resulted in decreased antibody titers, indicating that a rest period in the schedule is necessary for maximal immunogenicity, Lymphoproliferative responses against gp120 were induced in all vaccine recipients, The stimulation index to gp120 was persistently greater than 15 for 6 months after the last booster vaccination was given. CD8(+) cytotoxic T-lymphocyte activity was detected in 1 of the 11 participants tested. Vaccine that contained MTP-PE caused a greater number of moderate or severe local and systemic reactions (of 16 participants, 4 had local reactions and 13 had systemic reactions) than did vaccine formulated with MF59 alone (of 16 participants, 7 had local reactions [P <0.01] and 0 had systemic reactions [P < 0.001]). Conclusions: The SF-2 rgp120 vaccine is safe and immunogenic. Three vaccinations with rgp120 in MF59 can induce type-specific and crossreactive neutralizing antibody against B-subtype laboratory strains of HIV-1. Human immunodeficiency virus-specific lymphoproliferative responses were induced in all vaccinated participants, and CD8(+) cytotoxic T-lymphocyte activity was shown in one participant. A trend toward the augmentation of lymphoproliferative and humoral responses by MTP-PE was seen in the participants receiving 15 mu g of rgp120. However, MTP-PE caused a statistically significant increase in the incidence of local and systemic side effects, which was felt to outweigh the small increase in immunogenicity provided by this biological response modifier in an otherwise well-tolerated vaccine.	UNIV ROCHESTER, MED CTR, SCH MED & DENT, ROCHESTER, NY 14642 USA; UNIV WASHINGTON, SCH MED, AIDS VACCINE EVALUAT UNIT, SEATTLE, WA 98144 USA; ST LOUIS UNIV, SCH MED, ST LOUIS, MO 63110 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, CTR IMMUNIZAT RES, BALTIMORE, MD 21205 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; EMMES CORP, POTOMAC, MD 20854 USA; CHIRON BIOCINE CORP, EMERYVILLE, CA 94608 USA; NIAID, BETHESDA, MD 20892 USA	University of Rochester; University of Washington; University of Washington Seattle; Saint Louis University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Duke University; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Graham, BS (corresponding author), VANDERBILT UNIV, SCH MED, A-3310 MCN, NASHVILLE, TN 37232 USA.		Corey, Lawrence/AAE-1796-2020; Graham, Barney S./AAC-5898-2019	Corey, Lawrence/0000-0002-2179-2436; Graham, Barney S./0000-0001-8112-0853	NIAID NIH HHS [N01-AI-82500, N01-AI-05061, N01-AI-05062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005062, N01AI082500, N01AI005061] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELSHE RB, 1994, JAMA-J AM MED ASSOC, V272, P475, DOI 10.1001/jama.272.6.475; BELSHE RB, 1993, J INFECT DIS, V168, P1387, DOI 10.1093/infdis/168.6.1387; BELSHE RB, 1994, ANN INTERN MED, V121, P584, DOI 10.7326/0003-4819-121-8-199410150-00005; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BUI T, 1994, J ACQ IMMUN DEF SYND, V7, P799; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; ELAMAD Z, 1995, AIDS, V9, P1313, DOI 10.1097/00002030-199512000-00003; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GORSE GJ, 1994, CLIN EXP IMMUNOL, V98, P178; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533; HAIGWOOD NL, 1992, J VIROL, V66, P172, DOI 10.1128/JVI.66.1.172-182.1992; HILLEMAN MR, 1983, J INFECTION, V7, P3, DOI 10.1016/S0163-4453(83)96465-4; KAHN JO, 1995, J INFECT DIS, V171, P1343, DOI 10.1093/infdis/171.5.1343; KAHN JO, 1994, J INFECT DIS, V170, P1288, DOI 10.1093/infdis/170.5.1288; KEEFER MC, 1991, J INFECT DIS, V163, P448, DOI 10.1093/infdis/163.3.448; KEEFER MC, 1994, AIDS RES HUM RETROV, V10, P1713, DOI 10.1089/aid.1994.10.1713; Keefer MC, 1996, AIDS RES HUM RETROV, V12, P683, DOI 10.1089/aid.1996.12.683; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; TANG YW, 1994, J CLIN INVEST, V94, P1953, DOI 10.1172/JCI117546; VANNEST GA, 1992, MOL APPROACHES CONTR, P57; WALKER CM, 1993, HUIT C CENT GARD, P321; WEINHOLD KJ, 1990, TECHNIQUES HIV RES, P187; WINTSCH J, 1991, J INFECT DIS, V163, P219, DOI 10.1093/infdis/163.2.219	37	84	85	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					270	+		10.7326/0003-4819-125-4-199608150-00003	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678389				2022-12-28	WOS:A1996VB68000006
J	MacMillan, LB; Hein, L; Smith, MS; Piascik, MT; Limbird, LE				MacMillan, LB; Hein, L; Smith, MS; Piascik, MT; Limbird, LE			Central hypotensive effects of the alpha(2a)-adrenergic receptor subtype	SCIENCE			English	Article							RAT-BRAIN; MESSENGER-RNAS; EXPRESSION; GENE; ADRENOCEPTORS; DISRUPTION; MUTATION	alpha 2-Adrenergic receptors (alpha(2)ARs) present in the brainstem decrease blood pressure and are targets for clinically effective antihypertensive drugs. The existence of three alpha(2)AR subtypes, the lack of subtype-specific ligands, and the cross-reactivity of alpha(2)AR agonists with imidazoline receptors has precluded an understanding of the role of individual alpha(2)AR subtypes in the hypotensive response. Gene targeting was used to introduce a point mutation into the alpha 2 alpha AR subtype in the mouse genome. The hypotensive response to alpha(2)AR agonists was lost in the mutant mice, demonstrating that the alpha(2a)AR subtype plays a principal role in this response.	VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA; UNIV KENTUCKY, DEPT PHARMACOL, LEXINGTON, KY 40536 USA	Vanderbilt University; Stanford University; Stanford University; University of Kentucky					NHLBI NIH HHS [HL38120, HL43671, HL48638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038120, R01HL038120, R01HL043671, P01HL048638, R37HL043671] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1988, MOL REPROD DEV; BOUSQUET P, 1992, AM J HYPERTENS, V5, pS47, DOI 10.1093/ajh/5.4.47S; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CERESA BP, 1994, J BIOL CHEM, V269, P29557; CHABRE O, 1994, J BIOL CHEM, V269, P5730; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; HIEBLE JP, 1995, J MED CHEM, V38, P3415, DOI 10.1021/jm00018a001; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MACMILLAN LB, UNPUB; MCCUNE SK, 1993, NEUROSCIENCE, V57, P143, DOI 10.1016/0306-4522(93)90116-W; NICHOLAS AP, 1993, J COMP NEUROL, V328, P575, DOI 10.1002/cne.903280409; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; WANG R, IN PRESS NEUROSCIENC	20	409	427	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					801	803		10.1126/science.273.5276.801	http://dx.doi.org/10.1126/science.273.5276.801			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670421				2022-12-28	WOS:A1996VB42900044
J	Collins, S				Collins, S			Using middle upper arm circumference to assess severe adult malnutrition during famine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC ENERGY DEFICIENCY; MORTALITY; CHILDREN; PROTEIN; INDEX	Objectives.-To examine the use of middle upper arm circumference measurement (MUAC [cm]) and body mass index measurement (BMI [kg/m(2)]) in the screening of severely malnourished adults during famine. Design.-Nonrandomized cohort study, correlating measurements of MUAC and BMI. Setting.-The Concern Worldwide adult feeding center in the village of Ayod in south Sudan. The area had experienced several years of war, leading to severe famine during early 1993. Participants.-A total of 98 adult inpatients belonging to the Nuer tribe. Criteria for entry into the study were prior admission to the feeding center and the ability to stand and have a BMI measured. Main Outcome Measures.-A comparison of the ease of use of MUAC and BMI assessments, and a correlation of MUAC and BMI measurements. Results.-An MUAC measurement was easier to perform on severely malnourished adults than BMI assessment. For MUAC, the patient could be standing, sitting, or, in extreme cases, lying. For BMI, patients were required to stand. Measuring BMI requires a height board, weighing scales, and mathematical calculations; to measure MUAC, only a tape measure is required. A correlation between measurements of MUAC and BMI was demonstrated (r=0.88; 95% confidence interval, 0.82-0.92; P<.001). The proportions of the population and the actual individuals identified as malnourished by the 2 indicators were similar. Conclusions.-The MUAC measurement reflects adult nutritional status as defined by BMI. During famine, MUAC may be better suited to screening admissions to adult feeding centers than BMI. Studies to assess the capacity of MUAC cutoffs to predict mortality in severe adult malnutrition are needed.	CONCERN WORLDWIDE,DUBLIN,IRELAND; UNIV LONDON,INST CHILD HLTH,CTR INT CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of London; University College London								BAIRAGI R, 1981, AM J CLIN NUTR, V34, P2592, DOI 10.1093/ajcn/34.11.2592; BERN C, 1995, LANCET, V345, P631, DOI 10.1016/S0140-6736(95)90527-8; BOELAERT M, 1995, NUTR GUIDELINES; BRIEND A, 1987, LANCET, V2, P725; BROOM J, 1993, HUMAN NUTR DIETETICS, P456; BURGER GCE, 1945, LANCET, V1, P282; COLLINS S, 1993, LANCET, V341, P1478; COLLINS S, 1993, JAMA-J AM MED ASSOC, V270, P637; COLLINS S, 1995, NAT MED, V1, P810, DOI 10.1038/nm0895-810; de Ville de Goyet C., 1978, MANAGEMENT NUTR EMER; DEAN AG, 1990, EPI INFO VERSION 6 W; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; FRIEDMAN PJ, 1991, NUTRITION, V7, P223; GASSULL MA, 1984, HUM NUTR-CLIN NUTR, V38C, P419; HAKEWELL P, 1991, TROP DOCT S, V1, P24; HENRY CJK, 1990, EUR J CLIN NUTR, V44, P329; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; JAMES WPT, 1994, EUR J CLIN NUTR, V48, P883; LIPSCOMB FM, 1945, LANCET, V1, P313; MCCANCE RA, 1951, STUDIES UNDERNUTRITI; MCLAREN DS, 1986, LANCET, V2, P152; *MICR CORP, 1995, MICR EXC VERS 6; OHLSON M. A., 1956, HUMAN BIOL, V28, P189; Reddy R., 1991, Progress in Molecular and Subcellular Biology, V12, P1; ROSS DA, 1990, INT J EPIDEMIOL, V19, P636, DOI 10.1093/ije/19.3.636; SHAKIR A, 1975, AM J CLIN NUTR, V26, P661; VELLA V, 1994, EUR J CLIN NUTR, V48, P189; VELZEBOER MI, 1983, J TROP PEDIATRICS, V29, P135, DOI 10.1093/tropej/29.3.135; VELZEBOER MI, 1983, J TROP PEDIATRICS, V29, P159, DOI 10.1093/tropej/29.3.159; WATERLOW JC, 1986, ANNU REV NUTR, V6, P495, DOI 10.1146/annurev.nu.06.070186.002431; YOUNG H, 1992, FOOD SCARCITY FAMINE; 1992, MMWR-MORBID MORTAL W, V41, P913; [No title captured]; 1991, EUR J CLIN NUTR, V45, P31	34	48	50	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					391	395		10.1001/jama.276.5.391	http://dx.doi.org/10.1001/jama.276.5.391			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683818				2022-12-28	WOS:A1996UZ77600021
J	Silove, D; Curtis, J; Mason, C; Becker, R				Silove, D; Curtis, J; Mason, C; Becker, R			Ethical considerations in the management of asylum seekers on hunger strike	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Hunger strikes have confronted physicians with complex ethical dilemmas throughout history. Asylum seekers under threat of forced repatriation have emerged as a new category of hunger strikers, posing novel challenges for management. The management of 3 Cambodian asylum seekers on hunger strike admitted to a hospital in Sydney, New South Wales, Australia, posed important ethical dilemmas for the physicians and mental health experts involved in their care. Several factors confounded the task oi assessment and decision making, including language and cultural barriers, the patients' past exposure to persecution by authorities, and the complexities of the legal procedures being pursued. Different rules appeared to govern the actions of the hunger strikers, the medical team, and the immigration authorities, creating a ''malignant triangle'' of mounting confrontation. Recent recommendations for the management of asylum-seeking hunger strikers include the appointment of an external physician of confidence and the writing of a confidential advance directive specifying the hunger striker's wishes about resuscitation in the event of collapse. In addition, we consider the value of constituting an ad hoc ethics committee to advise the responsible physician on points of conflict in managing the hunger strike, The advantages and limitations of these proposals in relation to the particular cultural, historical, and contextual issues relevant to asylum seekers are examined herein.	PRINCE HENRY HOSP,SYDNEY,NSW,AUSTRALIA; STARTTS,SYDNEY,NSW,AUSTRALIA		Silove, D (corresponding author), UNIV NEW S WALES,LIVERPOOL HOSP,SCH PSYCHIAT,PSYCHIAT RES & TEACHING UNIT,LEVEL 4 HLTH SERV BLDG,LIVERPOOL,NSW 2170,AUSTRALIA.			Curtis, Jackie/0000-0001-6884-0098				ANNAS GJ, 1995, BRIT MED J, V311, P1114, DOI 10.1136/bmj.311.7013.1114; Becker R., 1993, PROTECTION PUNISHMEN, P81; Benatar S R, 1990, Law Med Health Care, V18, P140; BHABHA J, 1992, IMMIGRATION NATIONAL, V6, P117; Brody Baruch, 1988, LIFE DEATH DECISION; BROWN P, 1991, PSYCHIAT ETHICS, P167; GEVERS S, 1995, ASSISTANCE HUNGER ST, P23; Helton Arthur, 1993, PROTECTION PUNISHMEN, P103; *J WIER F HLTH HUM, 1995, ASS HUNG STRIK MAN P; KALK WJ, 1991, LANCET, V337, P660, DOI 10.1016/0140-6736(91)92465-E; KLEINMAN I, 1986, CAN J PSYCHIAT, V31, P313, DOI 10.1177/070674378603100405; KOS A, 1993, DRAFT GUIDELINES EVA; LOCKWOOD R, 1993, VICTORIAN BRANCH SEP, P192; MASON JK, 1987, LAW MED ETHICS, P322; MILLER R, 1991, PSYCHIAT ETHICS, P265; MILLER WP, 1987, J PRISON JAIL HLTH, V6, P40; MOORE M, 1974, LANCET, V1, P1109; MURRAY B, 1990, INT J REFUGEE LAW, V2, P620; OCONNOR A, 1988, MED SCI LAW, V28, P62, DOI 10.1177/002580248802800115; REID J, 1990, AUST NZ J PSYCHIAT, V24, P486, DOI 10.3109/00048679009062904; SILOVE D, 1993, AUST NZ J PSYCHIAT, V27, P606, DOI 10.3109/00048679309075823; SILOVE D, 1990, SOC SCI MED, V30, P417, DOI 10.1016/0277-9536(90)90344-R; SMEULERS J, 1995, ASSISTANCE HUNGER ST, P14; Strauss S A, 1991, Med Law, V10, P211; SUMMERFIELD D, 1991, LANCET, V338, P58, DOI 10.1016/0140-6736(91)90051-P; 1982, S AFR MED J, V62, P77; 1974, BRIT MED J, V2, P52	27	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					410	415						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ776	8683821				2022-12-28	WOS:A1996UZ77600024
J	Prasad, BVV; Rothnagel, R; Zeng, CQY; Jakana, J; Lawton, JA; Chiu, W; Estes, MK				Prasad, BVV; Rothnagel, R; Zeng, CQY; Jakana, J; Lawton, JA; Chiu, W; Estes, MK			Visualization of ordered genomic RNA and localization of transcriptional complexes in rotavirus	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CRYOELECTRON MICROSCOPY; FUNCTIONAL IMPLICATIONS; INSECT CELLS; VIRUS; IDENTIFICATION; PROTEIN; REPLICATION; POLYMERASE; RESOLUTION	IN double-stranded-RNA (dsRNA) viruses found in animals(1), bacteria(2) and yeast(3), the genome is transcribed within the structurally intact core of the virion with extraordinary efficiency. The structural organization of the genome and the enzymes involved in the transcription inside any of these viruses, critical for understanding this process, is not known. Here we report what we believe is the first three-dimensional characterization of the viral genome and the transcription complex in a prototypical dsRNA virus. Rotavirus is a large (diameter 1,000 Angstrom) icosahedral virus composed of three capsid protein layers and 11 dsRNA segments(4-9). It is the most important cause of gastroenteritis in children, accounting for over a million deaths annually(10). We show that viral dsRNA forms a dodecahedral structure in which the RNA double helices, interacting closely with the inner capsid layer, are packed around the enzyme complex located at the icosahedral 5-fold axes. The ordered RNA accounts for about 4,500 out of a total 18,525 base pairs in the genome, the largest amount of icosahedrally ordered RNA observed in any virus structure to date. We propose that the observed organization of the dsRNA is conducive for an orchestrated movement of the RNA relative to the enzyme complex during transcription.	BAYLOR COLL MED, WM KECK CTR COMPUTAT BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOL VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CELL & MOL BIOL PROGRAM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Prasad, BVV (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.			Prasad, B.V.Venkataram/0000-0002-1172-2071				BRINK J, 1992, ULTRAMICROSCOPY, V46, P229, DOI 10.1016/0304-3991(92)90017-E; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; COHEN J, 1977, J GEN VIROL, V36, P395, DOI 10.1099/0022-1317-36-3-395; CRAWFORD SE, 1994, J VIROL, V68, P5945, DOI 10.1128/JVI.68.9.5945-5952.1994; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ESTES MK, 1996, VIROLOGY, P1625; FIELDS BN, 1996, VIROLOGY, P1553; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GOTTLIEB P, 1990, J BACTERIOL, V172, P5774, DOI 10.1128/jb.172.10.5774-5782.1990; Kapikian A.Z., 1996, FIELDS VIROLOGY, P1657; LABBE M, 1994, J GEN VIROL, V75, P3423, DOI 10.1099/0022-1317-75-12-3423; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; Lawton JA, 1996, J STRUCT BIOL, V116, P209, DOI 10.1006/jsbi.1996.0032; LIU M, 1988, VIROLOGY, V163, P26, DOI 10.1016/0042-6822(88)90230-9; LIU M, 1992, VIROLOGY, V188, P77, DOI 10.1016/0042-6822(92)90736-9; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; PRASAD BVV, 1994, ROTAVIRUSES, P9; SHATKIN AJ, 1968, P NATL ACAD SCI USA, V59, P246, DOI 10.1073/pnas.59.1.246; SHAW AL, 1993, CELL, V74, P693, DOI 10.1016/0092-8674(93)90516-S; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VALENZUELA S, 1991, J VIROL, V65, P3964, DOI 10.1128/JVI.65.7.3964-3967.1991; WICKNER RB, 1993, J BIOL CHEM, V268, P3797; YEAGER M, 1994, EMBO J, V13, P1011, DOI 10.1002/j.1460-2075.1994.tb06349.x; ZENG CQY, 1994, VIROLOGY, V201, P55, DOI 10.1006/viro.1994.1265; Zeng CQY, 1996, J VIROL, V70, P2736, DOI 10.1128/JVI.70.5.2736-2742.1996; ZHOU ZH, 1994, J MOL BIOL, V242, P456, DOI 10.1006/jmbi.1994.1594	30	171	186	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1996	382	6590					471	473		10.1038/382471a0	http://dx.doi.org/10.1038/382471a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684490				2022-12-28	WOS:A1996VA25100063
J	Hornsveld, HK; Garssen, B; Dop, MJCF; vanSpiegel, PI; deHaes, JCJM				Hornsveld, HK; Garssen, B; Dop, MJCF; vanSpiegel, PI; deHaes, JCJM			Double-blind placebo-controlled study of the hyperventilation provocation test and the validity of the hyperventilation syndrome	LANCET			English	Article							GENERALIZED ANXIETY DISORDER; PANIC DISORDER; AGORAPHOBIA; RESPIRATION; SYMPTOM	Background Hyperventilation syndrome (HVS) describes a set of somatic and psychological symptoms thought to result from episodic or chronic hyperventilation. Recognition of symptoms during the hyperventilation provocation test (HVPT) is the most widely used criterion for diagnosis of HVS. We have investigated the validity of the HVPT and of the concept of HVS. Methods in a randomised, double blind, crossover design, the ability of 115 patients with suspected HVS to recognise symptoms during the HVPT was compared with the ability to recognise symptoms during a placebo test (isocapnic overbreathing, with carbon dioxide levels maintained by manual titration). 30 patients who had positive results on the HVPT underwent ambulatory transcutaneous monitoring of pCO(2) to ascertain whether they hyperventilated during spontaneous symptom attacks. Findings Of the 115 patients who underwent the HVPT and the placebo test, 85 (74%) reported symptom recognition during: the HVPT (positive diagnosis HVS). Of that subset, 56 were also positive on the placebo test (false-positive), and 29 were negative on the placebo test (true-positive). False-positive and true-positive patients did not differ in symptom profile or in physiological variables. During ambulatory monitoring (15 true-positive, 15 false-positive) 22 attacks were registered. Transcutaneous end-tidal pCO(2) decreased during only seven. The decreases were slight and apparently followed the onset of the attack, which suggests that hyperventilation is a consequence rather than a cause of the attack. There were no apparent differences between false-positive and true-positive patients. Interpretation The HVPT is invalid as a diagnostic lest for HVS. Hyperventilation seems a negligible factor in the experience of spontaneous symptoms. The term HVS should be avoided.	SLOTERVAART HOSP,DEPT PSYCHOL MED,AMSTERDAM,NETHERLANDS; HELEN DOWLING INST,ROTTERDAM,NETHERLANDS; SLOTERVAART HOSP,DEPT PULM DIS,AMSTERDAM,NETHERLANDS	Slotervaart Hospital; Slotervaart Hospital	Hornsveld, HK (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PSYCHOL MED,MELBERGDREEF 15,NL-1105 AZ AMSTERDAM,NETHERLANDS.							BRASHEAR RE, 1983, LUNG, V161, P257, DOI 10.1007/BF02713872; CHAMBLESS DL, 1984, J CONSULT CLIN PSYCH, V52, P1090, DOI 10.1037/0022-006X.52.6.1090; COWLEY DS, 1987, AM J MED, V83, P929, DOI 10.1016/0002-9343(87)90654-1; DERUITER C, 1989, BEHAV RES THER, V27, P447, DOI 10.1016/0005-7967(89)90015-6; DOUGLAS NJ, 1982, THORAX, V37, P840, DOI 10.1136/thx.37.11.840; GARDNER WN, 1986, LANCET, V2, P826; GARSSEN B, 1983, BEHAV RES THER, V21, P643, DOI 10.1016/0005-7967(83)90082-7; Garssen B, 1996, AM J PSYCHIAT, V153, P513; GARSSEN B, 1992, CLIN PSYCHOL REV, V12, P141, DOI 10.1016/0272-7358(92)90111-K; GARSSEN B, 1994, J PSYCHOPHYSIOL, V8, P231; GORMAN JM, 1984, AM J PSYCHIAT, V141, P857; Hardonk H., 1979, HDB CLIN NEUROLOGY, V38, P309; HIBBERT GA, 1989, BRIT J PSYCHIAT, V152, P76; HORNSVELD H, 1995, INT J BEHAV MED, V2, P135, DOI 10.1207/s15327558ijbm0202_4; HORNSVELD H, 1990, J PSYCHOSOM RES, V34, P687, DOI 10.1016/0022-3999(90)90113-I; HORNSVELD H, 1995, BIOL PSYCHOL, V40, P299, DOI 10.1016/0301-0511(95)05120-Y; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; Kerr WJ, 1937, ANN INTERN MED, V11, P961, DOI 10.7326/0003-4819-11-6-961; LEWIS RA, 1986, B EUR PHYSIOPATH RES, V22, P201; LUM LC, 1976, MODERN TRENDS PSYCHO, P196; PILOWSKY I, 1967, BRIT J PSYCHIAT, V113, P89, DOI 10.1192/bjp.113.494.89; PILSBURY D, 1987, B EUR PHYSIOPATH RES, V23, P9; RAPEE R, 1986, J ABNORM PSYCHOL, V95, P24, DOI 10.1037/0021-843X.95.1.24; RICE RL, 1950, AM J MED, V8, P691, DOI 10.1016/0002-9343(50)90093-3; ROLL M, 1990, J INTERN MED, V228, P223, DOI 10.1111/j.1365-2796.1990.tb00222.x; Soley MH, 1938, AM J MED SCI, V196, P840, DOI 10.1097/00000441-193812000-00010; Spielberger C. D., 1970, SELF EVALUATION QUES; SPINHOVEN P, 1993, J PSYCHOSOM RES, V37, P281, DOI 10.1016/0022-3999(93)90037-G; SVEBAK S, 1985, SCAND J PSYCHOL, V26, P327, DOI 10.1111/j.1467-9450.1985.tb01171.x; Weimann G, 1968, HYPERVENTILATIONSSYN; WIENTJES CJE, 1992, BIOL PSYCHOL, V34, P179, DOI 10.1016/0301-0511(92)90015-M	31	99	100	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					154	158		10.1016/S0140-6736(96)02024-7	http://dx.doi.org/10.1016/S0140-6736(96)02024-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UX789	8684155				2022-12-28	WOS:A1996UX78900010
J	Turner, G				Turner, G			Intelligence and the X chromosome	LANCET			English	Article							MAJOR INTELLECTUAL TRAITS; LINKED MENTAL-RETARDATION; 4 HYPOTHESES; LINKAGE; LEHRKES; GENES				Turner, G (corresponding author), HUNTER GENET,POB 84,NEWCASTLE,NSW 2298,AUSTRALIA.							ANASTASI A, 1972, AM J MENT DEF, V76, P620; BOUCHARD TJ, 1990, SCIENCE, V250, P223, DOI 10.1126/science.2218526; GEDEON AK, IN PRESS AM J MED GE; GLASS IA, 1991, J MED GENET, V28, P361, DOI 10.1136/jmg.28.6.361; HERBST DS, 1980, AM J MED GENET, V7, P461, DOI 10.1002/ajmg.1320070407; LEHRKE R, 1972, AM J MENT DEF, V76, P611; LEHRKE R, 1994, BIRTH DEFECTS ORIG A, V10; MORTON NE, 1992, J MED GENET, V29, P71, DOI 10.1136/jmg.29.1.71; NANCE WE, 1972, AM J MENT DEF, V76, P623; Ohno S., 1967, SEX CHROMOSOMES SEX; OPITZ JM, 1986, AM J MED GENET, V23, P1, DOI 10.1002/ajmg.1320230102; RESTA RG, 1995, AM J MED GENET, V59, P131, DOI 10.1002/ajmg.1320590202; TURNER G, 1974, J MED GENET, V11, P109, DOI 10.1136/jmg.11.2.109; TURNER G, 1991, J MED GENET, V28, P429, DOI 10.1136/jmg.28.6.429; TURNER G, IN PRESS AM J MED GE; WILSON R, 1987, ENCY NEUROSCIENCE, V1, P539	16	33	34	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1814	1815		10.1016/S0140-6736(96)91623-2	http://dx.doi.org/10.1016/S0140-6736(96)91623-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667929				2022-12-28	WOS:A1996UU46900016
J	Fraser, A; Evan, G				Fraser, A; Evan, G			A license to kill	CELL			English	Review							CELL-DEATH				Fraser, A (corresponding author), IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Fraser, Andrew/0000-0001-9939-6014				BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1995, J CELL SCI S, V19, P41; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAHASHI A, 1996, IN PRESS P NATL ACAD; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	19	602	631	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					781	784		10.1016/S0092-8674(00)81005-3	http://dx.doi.org/10.1016/S0092-8674(00)81005-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681372	Bronze			2022-12-28	WOS:A1996UR60400001
J	Danielian, PJ; Wang, J; Hall, MH				Danielian, PJ; Wang, J; Hall, MH			Long term outcome by method of delivery of fetuses in breech presentation at term: Population based follow up	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To compare the long term outcome of infants delivered in breech presentation at term by intended mode of delivery. Design-A population based comparison of outcomes up to school age. Data obtained from maternity, health visitor, and school medical records and handicap register. Setting-Grampian region 1981-90. Subjects-1645 infants delivered alive at term after breech presentation. Main outcome measures-Handicap, developmental delay, neurological deficit, psychiatric referral. Results-Elective caesarean section was performed in 590 (35.9%) cases. The remainder (1055; 64.1%) were intended vaginal deliveries, Handicap or other health problem was recorded in 269 (19.4%) of 1387 infants for whom records were available. Proportions of elective caesarean sections and intended vaginal deliveries in this group were 37.2% (100 cases) and 62.8% (169) respectively, almost the same as in the total cohort. There were no significant differences between elective caesarean section and planned vaginal delivery in terms of severe handicap or any other outcome measure. Case records were obtained for 23 of 27 infants with severe handicap. 11 (47.8%) were delivered by elective caesarean section. Of these, three had undiagnosed congenital abnormalities and seven were unexplained. Of the 12 (52.2%) planned vaginal deliveries, in only one was handicap possibly attributable to delivery and four cases were unavoidable even if elective caesarean section had been planned. Conclusion-In selected cases of breech presentation at term planned vaginal delivery with caesarean section if necessary remains as safe as elective caesarean section in terms of long term handicap. It was not possible to determine whether particular babies would have fared better had they been delivered by elective caesarean section.	UNIV ABERDEEN,SCH MED,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen	Danielian, PJ (corresponding author), ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZA,SCOTLAND.							BINGHAM P, 1987, OBSTET GYNECOL, V69, P965; BISTOLETTI P, 1981, ACTA OBSTET GYN SCAN, V60, P165; BYRNE P, 1992, BRIT MED J, V305, P1092, DOI 10.1136/bmj.305.6861.1092; CHENG M, 1993, OBSTET GYNECOL, V82, P605; COLLEA JV, 1980, AM J OBSTET GYNECOL, V137, P235, DOI 10.1016/0002-9378(80)90780-2; FABERNIJHOLT R, 1983, BRIT MED J, V286, P9, DOI 10.1136/bmj.286.6358.9; HALL MH, 1993, BRIT MED J, V306, P718, DOI 10.1136/bmj.306.6879.718-b; HALL MH, 1982, BRIT MED J, V285, P701; LYONS ER, 1978, AM J OBSTET GYNECOL, V130, P558, DOI 10.1016/0002-9378(78)90076-5; MYERS SA, 1986, AM J OBSTET GYNECOL, V155, P6; OHLSEN H, 1975, ACTA OBSTET GYNECOL, V54, P165; ROSEN MG, 1984, AM J OBSTET GYNECOL, V148, P909, DOI 10.1016/0002-9378(84)90533-7; SAVAGE W, 1992, BRIT MED J, V305, P1092, DOI 10.1136/bmj.305.6861.1092-a; SVENNINGSEN NW, 1985, J PERINAT MED, V13, P117, DOI 10.1515/jpme.1985.13.3.117; WRIGHT RC, 1959, OBSTET GYNECOL, V14, P758	15	86	88	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1451	1453		10.1136/bmj.312.7044.1451	http://dx.doi.org/10.1136/bmj.312.7044.1451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664622	Green Published			2022-12-28	WOS:A1996UQ29600024
J	Ermakov, V				Ermakov, V			Reform of the World Health Organization	LANCET			English	Article											Ermakov, V (corresponding author), RUSSIAN ACAD ADV MED STUDIES,2 BARRUCADAYA STR,MOSCOW 123836,RUSSIA.							BLANCHARD K, 1986, ONE MINUTE MANAGER; DIETRICH P, 1989, ARRAN HALL STRU 0511; NAKAJIMA H, 1995, 1995 WHO; PETERS T, 1994, T PETERS SEM CRAZ TI; *WHO, 1994, 8 WHO, V5; WILDAVSKY A, 1989, DAEDALUS, V106, P105	6	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1536	1537		10.1016/S0140-6736(96)90678-9	http://dx.doi.org/10.1016/S0140-6736(96)90678-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684109	Bronze			2022-12-28	WOS:A1996UN47300017
J	Wise, R				Wise, R			Antibiotics for the uncommon cold	LANCET			English	Editorial Material											Wise, R (corresponding author), CITY HOSP,NHS TRUST,DEPT MICROBIOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							Baquero F, 1995, MICROB DRUG RESIST, V1, P115, DOI 10.1089/mdr.1995.1.115; BARRY AL, 1994, ANTIMICROB AGENTS CH, V38, P2419, DOI 10.1128/AAC.38.10.2419; FUNG CP, 1992, J ANTIMICROB CHEMOTH, V30, P47, DOI 10.1093/jac/30.1.47; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; NEU HC, 1991, J ANTIMICROB CHEMOTH, V27, P1; PENA C, 1995, ANTIMICROB AGENTS CH, V39, P520, DOI 10.1128/AAC.39.2.520	8	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1499	1499		10.1016/S0140-6736(96)90664-9	http://dx.doi.org/10.1016/S0140-6736(96)90664-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684095				2022-12-28	WOS:A1996UN47300003
J	Axworthy, D; Brook, DJH; Bobrow, M; Marteau, TM				Axworthy, D; Brook, DJH; Bobrow, M; Marteau, TM			Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up	LANCET			English	Article							SHORT-FORM; GENE; IDENTIFICATION; HEALTH; CARE	Background The objective of this study was to show the long-term psychological effects of population-based screening for cystic fibrosis. Methods The sample comprised all carriers (n=435) and, for each carrier, two matched screen-negative individuals (n=870) detected during screening programmes for cystic fibrosis in the general population and in antenatal populations carried out a median of 3 years earlier in six UK centres. Questionnaires were sent to all eligible participants, with reminders sent to non-responders, The main endpoints were understanding of test results, degree of anxiety, perceptions of health, and reproductive intentions, and behaviour. Findings 746 (62%) of 1201 questionnaires were returned, Recall of the meaning of test results was accurate in 225 (80%) of 280 carriers but only 200 (43%) of 466 screen-negative individuals. 46 (16%) of 280 proven carriers believed that their result meant that they were only likely, rather than definitely, to be a carrier; 232 (50%) of 466 of those with a screen-negative result erroneously believed that the result meant that they were definitely not carriers. There was no significant difference between carriers and screen-negative individuals in degree of general anxiety, although 16% of carriers reported feeling worried about their test results. Carriers had a poorer perception of their current health than did non-carriers, even though they had been told that carrier status confers no disadvantages to their own health. There were no differences between carriers and screen-negative individuals in reproductive intentions or behaviour. Interpretation We have shown that in the long-term, retention of the meaning of test results from cystic fibrosis screening is poor. Further research is needed to improve the performance of test-related counselling programmes to ensure that the main objectives of these programmes, to provide information on carrier status and to allow informed reproductive decisions, are met.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND; UNIV CAMBRIDGE,DEPT MED GENET,CAMBRIDGE,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Cambridge				Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BEKKER H, 1994, J MED GENET, V31, P364, DOI 10.1136/jmg.31.5.364; Croyle R.T., 1991, MENTAL REPRESENTATIO, P85, DOI DOI 10.1007/978-1-4613-9074-9_5; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Leventhal H., 1984, HDB PSYCHOL HLTH, V4, P219; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MENNIE ME, 1993, J MED GENET, V30, P543, DOI 10.1136/jmg.30.7.543; MIEDZYBRODZKA ZH, 1995, BRIT MED J, V310, P353, DOI 10.1136/bmj.310.6976.353; MITCHELL J, 1993, J MED GENET, V30, P538, DOI 10.1136/jmg.30.7.538; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS L, 1990, SCIENCE, V247, P1296, DOI 10.1126/science.2315698; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; *ROYAL COLL PHYS, 1989, PREN DIAGN GEN SCREE; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WATSON EK, 1992, LANCET, V340, P217, DOI 10.1016/0140-6736(92)90477-K; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; ZEESMAN S, 1984, AM J MED GENET, V18, P769, DOI 10.1002/ajmg.1320180424; 1995, REPORT GENETICS RES; 1995, GENETICS COMMON DISE	24	79	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1443	1446						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM485	8676627				2022-12-28	WOS:A1996UM48500010
J	Davies, MJ				Davies, MJ			Detecting vulnerable coronary plaques	LANCET			English	Editorial Material							ATHEROSCLEROTIC PLAQUES; THROMBOSIS; STENOSIS				Davies, MJ (corresponding author), ST GEORGE HOSP, SCH MED, DEPT HISTOPATHOL, LONDON SW17 0RE, ENGLAND.							DAVIES MJ, 1993, BRIT HEART J, V69, P377; FALK E, 1983, BRIT HEART J, V50, P127; HANGARTNER JRW, 1986, BRIT HEART J, V56, P501; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; NISSEN S, 1991, CIRCULATION, V84, P436; PEDERSEN TR, 1994, LANCET, V344, P1383; PETURSSON MK, 1995, AM HEART J, V129, P515, DOI 10.1016/0002-8703(95)90279-1; ROSENSCHEIN U, 1994, AM J CARDIOL, V73, P508, DOI 10.1016/0002-9149(94)90683-1; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHIOMI M, 1995, ARTERIOSCL THROM VAS, V15, P1938, DOI 10.1161/01.ATV.15.11.1938; THOMPSON GR, 1995, BRIT HEART J, V74, P343	12	24	28	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1996	347	9013					1422	1423		10.1016/S0140-6736(96)91677-3	http://dx.doi.org/10.1016/S0140-6736(96)91677-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676621				2022-12-28	WOS:A1996UM48500004
J	Jackson, AC; LopezCorella, E				Jackson, AC; LopezCorella, E			Rabies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									INST NACL PEDIAT,MEXICO CITY 04530,DF,MEXICO		Jackson, AC (corresponding author), QUEENS UNIV,KINGSTON,ON K7L 3J7,CANADA.		Jackson, Alan C/ABD-9312-2020	Jackson, Alan C/0000-0003-0413-4236					0	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					568	568		10.1056/NEJM199608223350806	http://dx.doi.org/10.1056/NEJM199608223350806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8684409				2022-12-28	WOS:A1996VD30200006
J	Shafritz, AB; Shore, EM; Gannon, FH; Zasloff, MA; Taub, R; Muenke, M; Kaplan, FS				Shafritz, AB; Shore, EM; Gannon, FH; Zasloff, MA; Taub, R; Muenke, M; Kaplan, FS			Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TGF-BETA-SUPERFAMILY; PROTEIN-4; EXPRESSION; MOUSE; INVOLVEMENT; MESODERM; PATHWAY; FAMILY; MEMBER; BMP-4	Background Fibrodysplasia ossificans progressiva is a heritable disorder of connective tissue characterized by congenital malformation of the great toes and postnatal formation of ectopic bone, Although the disorder was first described more than 300 years ago, the genetic defect and pathophysiology remain unknown. Bone morphogenetic proteins are potent bone-inducing morphogens that participate in the developmental organization of the skeleton, and increased production of one or more of these proteins has been proposed as the cause of fibrodysplasia ossificans progressiva. Methods We studied lymphoblastoid cell lines established from peripheral-blood mononuclear cells of patients with fibrodysplasia ossificans progressiva and fibroblast-like cell lines derived from lesional and nonlesional tissue. We used Northern blot analysis and ribonuclease protection assays to measure the expression of messenger RNA (mRNA) of bone morphogenetic proteins 1 to 7 and immunohistochemical analysis to examine protein expression. Results Among the bone morphogenetic proteins and mRNAs examined, only bone morphogenetic protein 4 and its mRNA were present in increased levels in cells derived from an early fibroproliferative lesion in a patient with fibrodysplasia ossificans progressiva, Bone morphogenetic protein 4 mRNA was expressed in lymphoblastoid cell lines from 26 of 32 patients with fibrodysplasia ossificans progressiva but from only 1 of 12 normal subjects (P<0.001). Bone morphogenetic protein 4 and its mRNA were detected in the lymphoblastoid cell lines from a man with fibrodysplasia ossificans progressiva and his three affected children (two girls and a boy), but not from the children's unaffected mother. No other bone morphogenetic proteins were detected. Conclusions Overexpression of a potent bone-inducing morphogen (bone morphogenetic protein 4) in lymphocytes is associated with the disabling ectopic osteogenesis of fibrodysplasia ossificans progressiva. (C) 1996, Massachusetts Medical Society.	UNIV PENN, SCH MED, DEPT ORTHOPAED SURG, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV HUMAN GENET & MOL BIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Shore, Eileen/D-2593-2009	Muenke, Maximilian/0000-0002-7719-6545	NIAMS NIH HHS [R01-AR-41916] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041916] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, V275, P287; BURING K, 1975, CLIN ORTHOP RELAT R, V110, P293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76, DOI 10.1302/0301-620X.64B1.7068725; CONNOR JM, 1993, J MED GENET, V30, P687, DOI 10.1136/jmg.30.8.687; EINHORN TA, 1995, J BONE MINER RES, V10, P1272; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JANOFF HB, 1995, J RHEUMATOL, V22, P976; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; JONES CM, 1991, DEVELOPMENT, V111, P531; KAPLAN FS, 1990, CALCIFIED TISSUE INT, V47, P117, DOI 10.1007/BF02555995; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P1214, DOI 10.2106/00004623-199308000-00011; KAPLAN FS, IN PRESS CALIF TISSU; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1995, J CELL BIOL, V128, pU8; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LANCHONEY TF, 1995, J PEDIATR-US, V126, P762, DOI 10.1016/S0022-3476(95)70408-6; Liebowitz David, 1993, P107; NAKASE T, 1994, J BONE MINER RES, V9, P651; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; REDDI AH, 1993, J BONE MINER RES, V8, pS499; ROCKE DM, 1994, CLIN ORTHOP RELAT R, P243; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAH PB, 1994, J BONE JOINT SURG AM, V76A, P1442, DOI 10.2106/00004623-199410000-00002; SHIMIZU K, 1994, CLIN ORTHOP RELAT R, P274; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TAKAOKA K, 1994, CLIN ORTHOP RELAT R, P269; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WATT JL, 1986, HUMAN CYTOGENETICS P, P39; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZECCA M, 1995, DEVELOPMENT, V121, P2265	40	283	294	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					555	561		10.1056/NEJM199608223350804	http://dx.doi.org/10.1056/NEJM199608223350804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8678932				2022-12-28	WOS:A1996VD30200004
J	McKay, DS; Gibson, EK; ThomasKeprta, KL; Vali, H; Romanek, CS; Clemett, SJ; Chillier, XDF; Maechling, CR; Zare, RN				McKay, DS; Gibson, EK; ThomasKeprta, KL; Vali, H; Romanek, CS; Clemett, SJ; Chillier, XDF; Maechling, CR; Zare, RN			Search for past life on Mars: Possible relic biogenic activity in Martian meteorite ALH84001	SCIENCE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; RECENT LAKE-SEDIMENTS; SNC METEORITES; MAGNETOTACTIC BACTERIA; ISOTOPIC COMPOSITION; WEATHERING PRODUCTS; MURCHISON METEORITE; SINGLE-DOMAIN; CARBON; MAGNETITE	Fresh fracture surfaces of the martian meteorite ALH84001 contain abundant polycyclic aromatic hydrocarbons (PAHs). These fresh fracture surfaces also display carbonate globules. Contamination studies suggest that the PAHs are indigenous to the meteorite. High-resolution scanning and transmission electron microscopy study of surface textures and internal structures of selected carbonate globules show that the globules contain fine-grained, secondary phases of single-domain magnetite and Fe-sulfides. The carbonate globules are similar in texture and size to some terrestrial bacterially induced carbonate precipitates. Although inorganic formation is possible, formation of the globules by biogenic processes could explain many of the observed features, including the PAHs. The PAHs, the carbonate globules, and their associated secondary mineral phases and textures could thus be fossil remains of a past martian biota.	NASA,LYNDON B JOHNSON SPACE CTR,HOUSTON,TX 77058; NASA,HOUSTON,TX 77058; MCGILL UNIV,DEPT EARTH & PLANETARY SCI,MONTREAL,PQ H3A 2A7,CANADA; UNIV GEORGIA,SAVANNAH RIVER ECOL LAB,AIKEN,SC 29802; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; McGill University; United States Department of Energy (DOE); Savannah River Ecology Laboratory; University System of Georgia; University of Georgia; Stanford University	McKay, DS (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,MAIL CODE SN,HOUSTON,TX 77058, USA.		Vali, Hojatollah/F-3511-2012; Zare, Richard N./A-8410-2009	Vali, Hojatollah/0000-0003-3464-9943; Zare, Richard/0000-0001-5266-4253				[Anonymous], 1995, GEOL SOC LOND SPEC P, DOI DOI 10.1144/GSL.SP.1995.098.01.02; Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; BAZYLINSKI DA, 1993, NATURE, V366, P218, DOI 10.1038/366218a0; BECKER, 1983, EARTH PLANET SC LETT, V69, P225; BLAKEMORE RP, 1982, ANNU REV MICROBIOL, V36, P217, DOI 10.1146/annurev.mi.36.100182.001245; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; BOGARD DD, 1995, LUNAR PLANET SCI, V26, P143; BUCZYNSKI C, 1991, J SEDIMENT PETROL, V61, P226, DOI 10.1306/D42676DB-2B26-11D7-8648000102C1865D; BUTLER RF, 1975, J GEOPHYS RES, V80, P4049, DOI 10.1029/JB080i029p04049; Campbell I. B., 1987, Antarctica: soils, weathering processes and environment; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHACKO T, 1991, GEOCHIM COSMOCHIM AC, V55, P2867, DOI 10.1016/0016-7037(91)90452-B; CHANG SR, 1989, PRECAMBRIAN RES, V42, P305; CLARK ID, 1992, CHEM GEOL, V102, P217, DOI 10.1016/0009-2541(92)90157-Z; Claypool G.E., 1974, NATURAL GASES MARINE, P99, DOI DOI 10.1007/978-1-4684-2757-8_8; Clemett S. J., 1996, THESIS STANFORD U; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; CLEMETT SJ, 1996, LUNAR PLANET SCI, V26, P229; DEMITRACK A, 1985, MAGNETITE BIOMINERAL, P625; FARINA M, 1990, NATURE, V343, P256, DOI 10.1038/343256a0; FASSBINDER JWE, 1990, NATURE, V343, P161, DOI 10.1038/343161a0; FOLK RL, 1993, J SEDIMENT PETROL, V63, P990, DOI 10.1306/D4267C67-2B26-11D7-8648000102C1865D; FORTIN D, 1995, J IND MICROBIOL, V14, P178, DOI 10.1007/BF01569901; FRANKEL RB, 1991, IRON BIOMINERALIZATI; GARRELS RM, 1969, SOLUTIONS MINERALS E; Gibson E. K., 1983, Journal of Geophysical Research, V88, P912, DOI 10.1029/JB088iS02p0A912; Gladman BJ, 1996, SCIENCE, V271, P1387, DOI 10.1126/science.271.5254.1387; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HARZMETZ CP, 1992, WORKSH MARS SURF ATM, P67; HENDRY JP, 1993, SEDIMENTOLOGY, V40, P87, DOI 10.1111/j.1365-3091.1993.tb01093.x; Hudson J.D., 1977, J GEOL SOC LOND, V133, P637, DOI DOI 10.1144/GSJGS.133.6.0637; JAGOUTZ E, 1994, METEORITICS, V29, P478; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JENSEN TE, 1983, ANAL CHEM, V55, P594, DOI 10.1021/ac00255a003; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; JULL AJT, 1996, 9601 LUN PLAN I 1, P22; KAWAMURA K, 1994, NATURWISSENSCHAFTEN, V81, P502, DOI 10.1007/s001140050116; KIRSCHVINK JL, 1984, GEOLOGY, V12, P559, DOI 10.1130/0091-7613(1984)12<559:UMIDSP>2.0.CO;2; KLEIN HP, 1995, EOS, V76, P334; KOVALENKO LJ, 1992, ANAL CHEM, V64, P682, DOI 10.1021/ac00030a021; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; LAFLAMME RE, 1978, GEOCHIM COSMOCHIM AC, V42, P289, DOI 10.1016/0016-7037(78)90182-5; Lovely D R, 1987, NATURE, V330, P252; MAHER BA, 1991, IRON BIOMINERALS, P179; MANN S, 1990, NATURE, V343, P258, DOI 10.1038/343258a0; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MARTINI AM, 1995, GEOL SOC AM ABSTR, V27, pA292; MAZUR P, 1978, SPACE SCI REV, V22, P3, DOI 10.1007/BF00215812; MCBRIDE EF, 1994, J SEDIMENT RES A, V64, P535; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MEIOSH HJ, 1984, ICARUS, V59, P234; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MURATA KJ, 1969, US GEOL SURV PROF B, V614, P1; Nakai N., 1975, GEOCHEM J, V9, P7, DOI [10.2343/geochemj.9.7, DOI 10.2343/GEOCHEMJ.9.7]; NEALSON KH, 1994, ANNU REV MICROBIOL, V48, P311, DOI 10.1146/annurev.mi.48.100194.001523; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; PACQUETTE J, IN PRESS GEOCHIM COS; PAQUETTE J, IN PRESS AM MINERAL; PERING KL, 1971, SCIENCE, V173, P237, DOI 10.1126/science.173.3993.237; PETERSEN N, 1986, NATURE, V320, P611, DOI 10.1038/320611a0; ROMANEK CS, 1992, GEOCHIM COSMOCHIM AC, V56, P419, DOI 10.1016/0016-7037(92)90142-6; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SCHOPF JW, 1992, PROTEROZOICIMENT BIO; STANJEK H, 1994, EUR J SOIL SCI, V45, P97, DOI 10.1111/j.1365-2389.1994.tb00490.x; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; TAYLOR RM, 1987, CLAY MINER, V22, P411, DOI 10.1180/claymin.1987.022.4.05; THOMAS KL, 1995, GEOCHIM COSMOCHIM AC, V59, P2797, DOI 10.1016/0016-7037(95)00174-X; THOMAS KL, 1995, LUNAR PLANET SCI, V26, P1409; THOMPSON JB, 1990, GEOLOGY, V18, P995, DOI 10.1130/0091-7613(1990)018<0995:CPOGCA>2.3.CO;2; Tissot B.P., 1984, PETROLEUM FORMATION, Vsecond, DOI [10.1007/978-3-642-87813-8, DOI 10.1007/978-3-642-87813-8]; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VALI H, 1987, EARTH PLANET SC LETT, V86, P389, DOI 10.1016/0012-821X(87)90235-4; VALI H, 1989, NATURE, V339, P203, DOI 10.1038/339203a0; Vali H., 1990, IRON BIOMINERALS, P97; VELBEL MA, 1988, METEORITICS, V23, P151, DOI 10.1111/j.1945-5100.1988.tb00910.x; WAKEHAM SG, 1980, GEOCHIM COSMOCHIM AC, V44, P403, DOI 10.1016/0016-7037(80)90040-X; WAKEHAM SG, 1980, GEOCHIM COSMOCHIM AC, V44, P415, DOI 10.1016/0016-7037(80)90041-1; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WING MR, 1991, GEOCHIM COSMOCHIM AC, V55, P2937, DOI 10.1016/0016-7037(91)90458-H; WRIGHT IP, 1993, J GEOPHYS RES-PLANET, V98, P3477, DOI 10.1029/92JE02056; YOUNGBLOOD WW, 1975, GEOCHIM COSMOCHIM AC, V39, P1303, DOI 10.1016/0016-7037(75)90137-4; Zenobi R., 1991, ADV MULTIPHOTON PROC, V7, P1; [No title captured]; [No title captured]; [No title captured]	87	1253	1304	11	530	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					924	930		10.1126/science.273.5277.924	http://dx.doi.org/10.1126/science.273.5277.924			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688069				2022-12-28	WOS:A1996VC67000052
J	Prezant, DJ; Kelly, KJ; Karwa, ML; Kavanagh, K				Prezant, DJ; Kelly, KJ; Karwa, ML; Kavanagh, K			Self-assessment of tuberculin skin test reactions by New York City firefighters: Reliability and cost-effectiveness in an occupational health care setting	ANNALS OF INTERNAL MEDICINE			English	Article						tuberculin test; patient compliance; patient participation; self-examination; cost savings		Objective: To determine whether self-assessment of purified protein derivative of tuberculin (PPD) skin test reactions, done using a simple two-choice approach, is an effective screening method for tuberculosis. Design: Double-blind comparison between self-assessments and trained professional readings of PPD skin test reactions, done 72 hours after test administration. Setting: The New York City Fire Department's Bureau of Health Services Participants: 2011 New York City firefighters and fire officers were given PPD skin tests during a mandatory retraining course. Thirty-seven persons were excluded because of a history of a positive PPD skin test result or a bacille Calmette-Guerin vaccination. All others agreed to participate in testing and self-assessment done using simple written instructions, Self-assessment results were submitted lust before trained professional readings were done. Measurements: Self-assessments and trained professional readings of PPD skin test reactions. Results: 1833 participants (91%) interpreted their-test reactions as flat. Of these interpretations, 1824 (99.5%) matched the professional reading and 9 (0.5%) did nor. One hundred seventy-eight participants (9%) interpreted their test reactions as not flat; 136 of these interpretations (76.4%) matched the professional reading and 42 (23.6%) did not (k = 0.828; lower 95% confidence limit = 0.790). The predictive value of a negative self-assessment reading was 99.5%, and the specificity was 97.7%. Conclusion: In this occupational health care setting, we follow (and recommend to others with similar populations) a tuberculin screening program based on self-assessment. Repeated tests with follow-up are required for all persons who do not report their results. All persons with self-assessments of ''not flat'' should return for readings by trained professionals, counseling, and treatment.	NEW YORK CITY FIRE DEPT, BUR HLTH SERV, NEW YORK, NY 10012 USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA; STATEN ISL UNIV HOSP, STATEN ISL, NY USA	Yeshiva University; Albert Einstein College of Medicine; Northwell Health	Prezant, DJ (corresponding author), MONTEFIORE MED CTR, DIV PULM, CENTENNIAL 423, BRONX, NY 10467 USA.							ASNES RS, 1975, CHEST, V68, P459, DOI 10.1378/chest.68.3_Supplement.459; BEARMAN IE, 1985, AM REV RESPIR DIS, V132, P177; *EM MED SERV COMM, 1995, US EM MED SERV MARK, P28; HOWARD TP, 1988, ARCH INTERN MED, V148, P2457, DOI 10.1001/archinte.148.11.2457; MAQBOOL S, 1975, PEDIATRICS, V55, P388; National Aboriginal and Torres Strait Islander Health Council, 1994, 1993 NAT FIR PROT AS, P3; Navin J A, 1994, J Am Coll Health, V43, P37; RISSER NL, 1985, PUBLIC HEALTH REP, V100, P439; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; WEINBERG.HL, 1969, J PEDIATR-US, V75, P111, DOI 10.1016/S0022-3476(69)80108-3; Wiecha J M, 1994, Fam Pract Res J, V14, P51	11	12	12	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					280	+		10.7326/0003-4819-125-4-199608150-00004	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678390				2022-12-28	WOS:A1996VB68000007
J	Shen, TF; Habicht, JP; Chang, Y				Shen, TF; Habicht, JP; Chang, Y			Effect of economic reforms on child growth in urban and rural areas of China	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; CARE; PRIVATISATION	Background Beginning in 1978, China implemented economic reforms to transform the economy to a free-market system. We compared the effect of the reforms on the growth of children in urban and rural areas. Methods Using data from five large cross-sectional surveys conducted between 1975 and 1992, we examined the trends in height for age of children two to five years of age in urban and rural areas. Mean height for age was expressed as the height in centimeters adjusted to a reference value of 99.1 cm for a 42-month-old boy. Results Height increased before and during the economic reforms. In 1975, the average height of children in periurban rural areas was about 3.5 cm less than that of children in urban areas, Between 1975 and 1985, the average height of children in periurban rural areas increased by 2.0 cm, as compared with 1.3 cm in urban children. Between 1987 and 1992, the average height of both urban and rural children increased, but the net increase for rural children was only one fifth that for urban children (0.5 vs. 2.5 cm). In a 1990 survey of seven provinces, the rural mean height was 92.5 cm, as compared with the urban mean of 96.9 cm and the reference value of 99.1 cm; 38 percent of rural children had moderate stunting of growth and 15 percent had severe stunting, as compared with 10 percent and 3 percent of urban children, respectively. Differences in height between rural and urban children were greater in provinces in which the average height of children was lower. Conclusions Despite an overall improvement in child growth during the economic reforms in China, the improvement has not been equitable, as judged by increased differences in height between rural and urban children and increased disparities within rural areas. (C) 1966 Massachusetts Medical Society.	CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14850 USA; CHINESE ACAD PREVENT MED, INST NUTR & FOOD HYG, BEIJING, PEOPLES R CHINA	Cornell University; Chinese Center for Disease Control & Prevention; National Institute for Nutrition & Health, Chinese Center for Disease Control & Prevention								*ADM COMM COORD, 1992, 2 WHO ADM COMM COORD, V1; ALDIS WL, 1989, LANCET, V2, P1456; *CAP I PED, 1987, ANTHR SURV CHILDR 9; CHANG Y, 1994, B WORLD HEALTH ORGAN, V72, P105; CHEN C, 1995, FOOD CONSUMPTION NUT; CHEN C, 1994, FOOD NUTR HLTH STAT, P4; CHEN M, 1989, CHINA HLTH CARE; Dean A.G., 1994, EPI INFO VERSION 6 W; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; HILLIER S, 1990, LANCET, V335, P414, DOI 10.1016/0140-6736(90)90250-9; LIN L, 1990, ANAL ANTHR MEASUREME; Lutter Chessa K., 1992, Food and Nutrition Bulletin, V14, P36; MARKS GC, 1989, AM J EPIDEMIOL, V130, P578, DOI 10.1093/oxfordjournals.aje.a115372; Martorell R, 1986, HUMAN GROWTH COMPREH, V3, P241; PIAZZA A, 1986, FOOD CONSUMPTION NUT; PINSTRUPANDERSE.P, 1991, P INT S FOOD NUTR SO, P447; ROUJIA C, 1989, J TROP PEDIATRICS, V35, P255, DOI 10.1093/tropej/35.5.255; SCHMITT LH, 1988, ANN HUM BIOL, V15, P353, DOI 10.1080/03014468800009831; SHEN T, 1991, Food and Nutrition Bulletin, V13, P303; SHEN T, 1994, THESIS CORNELL U; SHI LY, 1993, B WORLD HEALTH ORGAN, V71, P723; Snedecor GW, 1980, STAT METHODS, V7th; *STAT STAT BUR CHI, 1993, STAT YB 1993; TANG SI, 1994, 26 IDS U SUSS I DEV; TIAN J, 1990, BEIJING REV, V2, P7; *UN CHILDR FUND, 1989, CHILDR WOM CHIN; W.H.O, 1983, MEAS CHANG NUTR STAT; *WHO, 1983, MEAS CHANG NUTR STAT, P41; *WORLD BANK, 1992, CHIN REF ROL PLAN 19; World Bank, 1992, CHINA STRATEGIES RED; XIAN Z, 1993, WORKSH 1992 NAT CHIL; YAO S, 1994, AGR REFORMS GAIN PRO; YOUNG ME, 1989, HEALTH POLICY, V11, P27, DOI 10.1016/0168-8510(89)90053-5; ZHANG X, 1988, ANN HUM BIOL, V15, P289, DOI 10.1080/03014468800009761; ZHANG X, 1977, 15 INT C PED NEW DEL, P1; ZHANG X, 1976, NATL MED J CHINA, V56, P63; ZHOU B, 1993, RES ACTIONS POVERTY	38	76	79	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					400	406		10.1056/NEJM199608083350606	http://dx.doi.org/10.1056/NEJM199608083350606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8663882				2022-12-28	WOS:A1996VA90400006
J	Petridou, E; Trichopoulos, D; Dessypris, N; Flytzani, V; Haidas, S; Kalmanti, M; Koliouskas, D; Kosmidis, H; Piperopoulou, F; Tzortzatou, F				Petridou, E; Trichopoulos, D; Dessypris, N; Flytzani, V; Haidas, S; Kalmanti, M; Koliouskas, D; Kosmidis, H; Piperopoulou, F; Tzortzatou, F			Infant leukaemia after in utero exposure to radiation from Chernobyl	NATURE			English	Article							CHILDHOOD LEUKEMIA; REACTOR ACCIDENT; ONCOGENE; FALLOUT; BRITAIN; CANCER; SWEDEN	THERE has been no documented increase in childhood leukaemia following the Chernobyl accident. However, different forms of childhood leukaemia may not be equally susceptible to radiation carcinogenesis. Infant leukaemia is a distinct form associated with a specific genetic abnormality. Outside the former Soviet Union, contamination resulting from the Chernobyl accident has been highest in Greece and Austria and high also in the Scandinavian countries(1-4). All childhood leukaemia cases diagnosed throughout Greece since 1 January 1980 have been recorded. Here we report that infants exposed in utero to ionizing radiation from the Chernobyl accident had 2.6 limes the incidence of leukaemia compared to unexposed children (95% confidence interval, 1.4 to 5.1; P approximate to 0.003), and those born to mothers residing in regions with high radioactive fallout were at higher risk of developing infant leukaemia. No significant difference in leukaemia incidence was found among children aged 12 to 47 months. Preconceptional irradiation had no demonstrable effect on leukaemia risk at any of the studied age groups.	HARVARD UNIV,CTR CANC PREVENT,BOSTON,MA 02115; AGIA SOPHIA CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL ONCOL,ATHENS 11527,GREECE; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS 11527,GREECE; UNIV HOSP,DEPT PAEDIAT HAEMATOL ONCOL,IRAKLION 71500,GREECE; HIPPOKRATEION HOSP,DEPT PAEDIAT HAEMATOL ONCOL,THESSALONIKI 54642,GREECE; AGLAIA KYRIAKOU CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL ONCOL,ATHENS 11527,GREECE; AHEPA HOSP,DEPT PAEDIAT HAEMATOL ONCOL,THESSALONIKI 54636,GREECE; UNIV ATHENS,AGIA SOPHIA CHILDRENS HOSP,DEPT PAEDIAT 1,ONCOL UNIT,ATHENS 11527,GREECE	Harvard University; The Aghia Sophia Children's Hospital; Athens Medical School; National & Kapodistrian University of Athens; University of Patras; Aristotle University of Thessaloniki; Ahepa University Hospital; National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital				PETRIDOU, ELENI/0000-0003-3695-3439				ABELIN T, 1994, SOZ PRAVENTIV MED, V39, P189, DOI 10.1007/BF01309218; AUVINEN A, 1994, BRIT MED J, V309, P151, DOI 10.1136/bmj.309.6948.151; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CIMINO G, 1993, BLOOD, V82, P544; CLEARY ML, 1993, NEW ENGL J MED, V329, P958, DOI 10.1056/NEJM199309233291311; CORTES JE, 1995, CANCER-AM CANCER SOC, V76, P2393, DOI 10.1002/1097-0142(19951215)76:12<2393::AID-CNCR2820761203>3.0.CO;2-P; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; ERICSON A, 1994, ENVIRON RES, V67, P149, DOI 10.1006/enrs.1994.1070; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HJALMARS U, 1994, BRIT MED J, V309, P154, DOI 10.1136/bmj.309.6948.154; HOSHIMOTO Y, 1988, 488 RERF; *IAEA, 1992, INT CHERN PROJ TECHN; KUCHUK AA, 1994, TOXICOL LETT, V72, P213, DOI 10.1016/0378-4274(94)90031-0; MACMAHON B, 1964, NEW ENGL J MED, V270, P1082, DOI 10.1056/NEJM196405212702102; MACMAHON B, 1992, CANCER CAUSE CONTROL, V3, P283; MOLE RH, 1990, BRIT J CANCER, V62, P152, DOI 10.1038/bjc.1990.249; Monson R.R., 1984, RAD CARCINOGENESIS E, P97; PAPASTEFANOU C, 1988, J ENVIRON RADIOACTIV, V7, P49, DOI 10.1016/0265-931X(88)90041-0; PARKIN DM, 1992, EURO J CANC, V29, pA87; PETRIDOU E, 1994, SCAND J SOC MED, V22, P127, DOI 10.1177/140349489402200208; PETRIDOU E, IN PRESS BR J CANC; PUI CH, 1995, LEUKEMIA, V9, P762; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; ROTHMAN KJ, 1979, PUBLICATION NIH; *US NAT AC SCI COM, 1990, BEIR5 US NAS COMM BI; VANCHIERI C, 1992, J NATL CANCER I, V84, P1616, DOI 10.1093/jnci/84.21.1616	28	95	97	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					352	353		10.1038/382352a0	http://dx.doi.org/10.1038/382352a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684463				2022-12-28	WOS:A1996UY95000051
J	Desager, KN; VanBever, HP; Vermeire, PA				Desager, KN; VanBever, HP; Vermeire, PA			Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler	LANCET			English	Letter									UNIV ANTWERP HOSP,DEPT RESP MED,B-2650 ANTWERP,BELGIUM	University of Antwerp	Desager, KN (corresponding author), UNIV ANTWERP HOSP,DEPT PAEDIAT,B-2650 ANTWERP,BELGIUM.							DOCKHORN R, 1995, J ALLERGY CLIN IMMUN, V96, P50, DOI 10.1016/S0091-6749(95)70032-3; LEACH CL, 1995, BR J CLIN PRACT S, V79, P10; MONTE SY, 1994, J PHARMACEUT BIOMED, V12, P1489, DOI 10.1016/0731-7085(94)00104-9; THOMPSON P, 1995, BR J CLIN PRACT S, V79, P31	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					200	201		10.1016/S0140-6736(05)66151-X	http://dx.doi.org/10.1016/S0140-6736(05)66151-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684181				2022-12-28	WOS:A1996UX78900059
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Measurement error	BRITISH MEDICAL JOURNAL			English	Article									INST HLTH SCI,IRCF MED STAT GRP,CTR STAT MED,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Altman DG, 1996, BRIT MED J, V312, P1472, DOI 10.1136/bmj.312.7044.1472; BLAND JM, 1974, B PHYSIO-PATHOL RESP, V10, P699	2	361	373	2	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1654	1654		10.1136/bmj.312.7047.1654	http://dx.doi.org/10.1136/bmj.312.7047.1654			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664723	Green Published			2022-12-28	WOS:A1996UV48900029
J	French, JK; Williams, BF; Hart, HH; Wyatt, S; Poole, JE; Ingram, C; Ellis, CJ; Williams, MG; White, HD				French, JK; Williams, BF; Hart, HH; Wyatt, S; Poole, JE; Ingram, C; Ellis, CJ; Williams, MG; White, HD			Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; CARDIOPULMONARY-RESUSCITATION; INTRAVENOUS STREPTOKINASE; RANDOMIZED TRIAL; FREQUENCY; SURVIVAL	Objective-To determine the proportion of patients presenting with acute myocardial infarction who are eligible for thrombolytic therapy. Design-Cohort follow up study. Setting-The four coronary care units in Auckland, New Zealand. Subjects-All 3014 patients presenting to the units with suspected myocardial infarction in 1993. Main outcome measures-Eligibility for reperfusion with thrombolytic therapy (presentation within 12 hours of the onset of ischaemic chest pain with ST elevation greater than or equal to 2 mm in leads V1-V3, ST elevation greater than or equal to 1 mm in any other two contiguous leads, or new left bundle branch block); proportions of (a) patients eligible for reperfusion and (b) patients with contraindications to thrombolysis; death (including causes); definite myocardial infarction. Results-948 patients had definite myocardial infarction, 124 probable myocardial infarction, and nine ST elevation but no infarction; 1274 patients had unstable angina and 659 chest pain of other causes. Of patients with definite or probable myocardial infarction, 576 (53.3%) were eligible for reperfusion, 39 had definite contraindications to thrombolysis (risk of bleeding). Hence 49.7% of patients (537/1081) were eligible for thrombolysis and 43.5% (470) received this treatment. Hospital mortality among patients eligible for reperfusion was 11.7% (55/470 cases) among those who received thrombolysis and 17.0% (18/106) among those who did not. Conclusions-On current criteria about half of patients admitted to coronary care units with definite or probable myocardial infarction are eligible for thrombolytic therapy. Few eligible patients have definite contraindications to thrombolytic therapy. Mortality for all community admissions for myocardial infarction remains high.	GREEN LANE HOSP, CORONARY CARE UNIT, AUCKLAND 3, NEW ZEALAND; N SHORE HOSP, CORONARY CARE UNIT, AUCKLAND, NEW ZEALAND; MIDDLEMORE HOSP, CORONARY CARE UNIT, AUCKLAND 6, NEW ZEALAND; AUCKLAND HOSP, CORONARY CARE UNIT, AUCKLAND, NEW ZEALAND	Auckland City Hospital								[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1993, Lancet, V342, P767; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBASH GI, 1993, J AM COLL CARDIOL, V22, P707, DOI 10.1016/0735-1097(93)90180-9; BEHAR S, 1991, AM J CARDIOL, V68, P1291, DOI 10.1016/0002-9149(91)90233-B; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1995, LANCET, V345, P669; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; Gottlieb S., 1995, European Heart Journal, V16, P9; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HAMPTON J, 1993, LANCET, V342, P759; KARNASH SL, 1995, J AM COLL CARDIOL, V26, P1651, DOI 10.1016/0735-1097(95)00386-X; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NECHES RB, 1991, CLIN CARDIOL, V14, P616, DOI 10.1002/clc.4960140715; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; Rustige J., 1995, European Heart Journal, V16, P9; SCHOLZ KH, 1992, AM J CARDIOL, V69, P724, DOI 10.1016/0002-9149(92)90494-J; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1985, LANCET, V2, P578; TENAGLIA AN, 1991, AM J CARDIOL, V68, P1015, DOI 10.1016/0002-9149(91)90488-7; THOMPSON JT, 1987, ARCH OPHTHALMOL-CHIC, V105, P191; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WARD H, 1995, BMJ-BRIT MED J, V310, P3, DOI 10.1136/bmj.310.6971.3; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301; WILCOX RG, 1988, LANCET, V2, P525; WOODS KL, 1994, LANCET, V343, P232, DOI 10.1016/S0140-6736(94)91016-2	32	84	84	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	1996	312	7047					1637	1641		10.1136/bmj.312.7047.1637	http://dx.doi.org/10.1136/bmj.312.7047.1637			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664716	Green Published			2022-12-28	WOS:A1996UV48900021
J	Grierson, I				Grierson, I			Glaucoma and nitric oxide	LANCET			English	Editorial Material							TRABECULAR MESHWORK				Grierson, I (corresponding author), UNIV LIVERPOOL,DEPT MED,UNIT OPHTHALMOL ST PAULS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							LEPPLEWIENHUES A, 1991, EXP EYE RES, V53, P33, DOI 10.1016/0014-4835(91)90141-Z; MAEPEA O, 1989, EXP EYE RES, V49, P645, DOI 10.1016/S0014-4835(89)80060-0; NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1774; NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1765; WIEDERHOLT M, 1994, INVEST OPHTH VIS SCI, V35, P1515	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1781	1782		10.1016/S0140-6736(96)91613-X	http://dx.doi.org/10.1016/S0140-6736(96)91613-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667919				2022-12-28	WOS:A1996UU46900006
J	Ho, IC; Hodge, MR; Rooney, JW; Glimcher, LH				Ho, IC; Hodge, MR; Rooney, JW; Glimcher, LH			The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4	CELL			English	Article							T-CELL ACTIVATION; GENE-EXPRESSION; CYCLOSPORINE-A; V-MAF; TRANSCRIPTION; PROTEINS; MOTIF; PROMOTER; ELEMENTS; COMPLEX	The molecular basis for the distinctive cytokine expression of CD4+ T helper 1 (Th1) and T helper 2 (Th2) subsets remains elusive. Here, we report that the proto-oncogene c-maf, a basic region/leucine zipper transcription factor, controls tissue-specific expression of IL-4. c-Maf is expressed in Th2 but not Th1 clones and is induced during normal precursor cell differentiation along a Th2 but not Th1 lineage. c-Maf binds to a c-Maf response element (MARE) in the proximal IL-4 promoter adjacent to a site footprinted by extracts from Th2 but not Th1 clones. Ectopic expression of c-Maf transactivates the IL-4 promoter in Th1 cells, B cells, and nonlymphoid cells, a function that maps to the MARE and Th2-specific footprint. Furthermore, c-Maf acts in synergy with the nuclear factor of activated T cells (NF-ATp) to initiate endogeneous IL-4 production by B cells. Manipulation of c-Maf may alter Th subset ratios in human disease.			Ho, IC (corresponding author), HARVARD UNIV,SCH MED,HARVARD SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI37650] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; BARVE SS, 1994, J IMMUNOL, V152, P1171; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HAVRAN WL, 1987, NATURE, V325, P65, DOI 10.1038/325065a0; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HODGE MR, 1995, J IMMUNOL, V154, P6397; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LANE RD, 1986, METHOD ENZYMOL, V121, P183; LEDERER JA, 1994, J IMMUNOL, V152, P77; Lederer JA, 1996, J IMMUNOL, V156, P56; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; LEWEBER M, 1993, J IMMUNOL, V151, P1371; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOUZAKI A, 1991, EMBO J, V10, P1399, DOI 10.1002/j.1460-2075.1991.tb07660.x; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SUDA T, 1995, J IMMUNOL, V154, P3806; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4228, DOI 10.1128/MCB.11.8.4228; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	52	560	571	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					973	983		10.1016/S0092-8674(00)81299-4	http://dx.doi.org/10.1016/S0092-8674(00)81299-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674125	Bronze			2022-12-28	WOS:A1996UV48400005
J	KissLaszlo, Z; Henry, Y; Bachellerie, JP; CaizerguesFerrer, M; Kiss, T				KissLaszlo, Z; Henry, Y; Bachellerie, JP; CaizerguesFerrer, M; Kiss, T			Site-specific ribose methylation of preribosomal RNA: A novel function for small nucleolar RNAs	CELL			English	Article							EXTERNAL TRANSCRIBED SPACER; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; U3 SNRNA; BOX-C; YEAST; FIBRILLARIN; GENE; EXPRESSION	Eukaryotic cells contain many fibrillarin-associated small nucleolar RNAs (snoRNAs) that possess long complementarities to mature rRNAs. Characterization of 21 novel antisense snoRNAs from human cells followed by genetic depletion and reconstitution studies on yeast U24 snoRNA provides evidence that this class of snoRNAs is required for site-specific 2'-O-methylation of preribosomal RNA (pre-rRNA). Antisense snoRNAs function through direct base-pairing interactions with pre-rRNA. The antisense element, together with the D or D' box of the snoRNA, provide the information necessary to select the target nucleotide for the methyltransfer reaction. The conclusion that snoRNAs function in covalent modification of the sugar moieties of ribonucleotides demonstrates that eukaryotic small nuclear RNAs have a more versatile cellular function than earlier anticipated.			KissLaszlo, Z (corresponding author), UNIV TOULOUSE 3, LAB BIOL MOL EUCARYOTE, CNRS, F-31062 TOULOUSE, FRANCE.			Kiss, Tamas/0000-0003-0293-3093				ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bachellerie JP, 1995, BIOCHEM CELL BIOL, V73, P835, DOI 10.1139/o95-091; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; Baserga S., 1993, RNA WORLD, P359; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; CABOCHE M, 1977, EUR J BIOCHEM, V74, P19, DOI 10.1111/j.1432-1033.1977.tb11362.x; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DAVIES B, 1993, GENOMICS, V15, P68, DOI 10.1006/geno.1993.1011; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; DWOMICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181; EICHLER DC, 1987, BIOCHEMISTRY-US, V26, P1639, DOI 10.1021/bi00380a023; EICHLER DC, 1994, BIOCHIMIE, V76, P1115, DOI 10.1016/0300-9084(94)90039-6; EICHLER DC, 1995, PROG NUCL ACID RES M, V49, P179; England T E, 1980, Methods Enzymol, V65, P65; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPHS; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; LONG TW, 1983, BIOCHIM BIOPHYS ACTA, V740, P29, DOI 10.1016/0167-4781(83)90117-3; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MADEN BEH, 1988, J MOL BIOL, V201, P289, DOI 10.1016/0022-2836(88)90139-8; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; PELLIZZONI L, 1994, NUCLEIC ACIDS RES, V22, P4607, DOI 10.1093/nar/22.22.4607; PRISLEI S, 1993, NUCLEIC ACIDS RES, V21, P5824, DOI 10.1093/nar/21.25.5824; QU LH, 1995, NUCLEIC ACIDS RES, V23, P2669, DOI 10.1093/nar/23.14.2669; QU LH, 1994, NUCLEIC ACIDS RES, V22, P4073, DOI 10.1093/nar/22.20.4073; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SEGAL DM, 1991, J BIOL CHEM, V266, P24358; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; SMITH JD, 1959, BIOCHIM BIOPHYS ACTA, V31, P573, DOI 10.1016/0006-3002(59)90045-9; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; SWANN PF, 1975, BIOCHEM J, V150, P335, DOI 10.1042/bj1500335; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P6041, DOI 10.1093/nar/16.13.6041; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; TYCOWSKI KT, 1993, GENE DEV, V6, P1120; VAUGHAN MH, 1967, P NATL ACAD SCI USA, V58, P1527, DOI 10.1073/pnas.58.4.1527; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P6935, DOI 10.1093/nar/9.24.6935; WATKINS NJ, 1996, IN PRESS ELEMENTS ES; WOLF SF, 1977, BIOCHEMISTRY-US, V16, P2783, DOI 10.1021/bi00631a031; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	72	654	681	1	39	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					1077	1088		10.1016/S0092-8674(00)81308-2	http://dx.doi.org/10.1016/S0092-8674(00)81308-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674114	Bronze			2022-12-28	WOS:A1996UV48400014
J	Tritsmans, L; Briscoe, P; Lemmens, P; VandenBussche, G				Tritsmans, L; Briscoe, P; Lemmens, P; VandenBussche, G			Pharmaceutical company trials and the integrity of medical research	LANCET			English	Letter											Tritsmans, L (corresponding author), JANSSEN RES FDN,DEPT INT CR&D,TURNHOUTSEWEG 30,B-2340 BEERSE,BELGIUM.			Moher, David/0000-0003-2434-4206				CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P149; CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25; Davis JM, 1996, PSYCHIAT ANN, V26, P78, DOI 10.3928/0048-5713-19960201-08; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; MARDER SR, 1994, AM J PSYCHIAT, V151, P825; PEUSKENS J, 1995, BRIT J PSYCHIAT, V166, P712, DOI 10.1192/bjp.166.6.712	6	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1628	1628		10.1016/S0140-6736(96)91115-0	http://dx.doi.org/10.1016/S0140-6736(96)91115-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP661	8667898				2022-12-28	WOS:A1996UP66100057
J	Anderson, JD; Sjogren, WL; Schubert, G				Anderson, JD; Sjogren, WL; Schubert, G			Galileo gravity results and the internal structure of Io	SCIENCE			English	Article							TIDAL DISSIPATION; TRACKING DATA; SATELLITES; JUPITER; MODELS; FIELD	Doppler data generated with the Galileo spacecraft's radio carrier wave were used to measure lo's external gravitational field. The resulting triaxial field is consistent with the assumption that lo is in tidal and rotational equilibrium. The inescapable conclusion is that it has a large metallic core. If the core is a eutectic mixture of iron and iron sulfide, it comprises 20.2 +/- 7.4 percent of the satellite's total mass with a radius that is about 52 percent of lo's mean radius of 1821.3 kilometers; if the core is pure iron, it comprises 10.5 +/- 3.7 percent of the total mass with a radius of about 36 percent of the mean radius.	UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							ANDERSON JD, 1992, SPACE SCI REV, V60, P591, DOI 10.1007/BF00216869; ANDERSON JD, 1974, EXPT GRAVITATION, P163; ANDERSON JD, 1976, JUPITER, P113; BURNS J, 1986, SATELLITES; CAMPBELL JK, 1985, ASTRON J, V90, P364, DOI 10.1086/113741; COHEN ER, 1987, REV MOD PHYS, V59, P1121, DOI 10.1103/RevModPhys.59.1121; Davies ME, 1992, CELEST MECH DYN ASTR, V53, P377, DOI 10.1007/BF00051818; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; HOWARD HT, 1992, SPACE SCI REV, V60, P565, DOI 10.1007/BF00216868; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; JOHNSON TV, 1992, SPACE SCI REV, V60, P3, DOI 10.1007/BF00216848; Kaula W.M., 1966, THEORY SATELLITE GEO; Kaula W.M., 1968, INTRO PLANETARY PHYS; MORRISON D, 1982, SATELLITES JUPITER; MOYER T.D., 1971, 321527 JET PROP LAB; NULL GW, 1976, ASTRON J, V81, P1153, DOI 10.1086/111999; NULL GW, 1975, SCIENCE, V188, P476, DOI 10.1126/science.188.4187.476; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; SEIDELMANN PK, 1992, ASTRONOMICAL ALMAN S; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; WIENBRUCH M, 1995, PLANET SPACE SCI, V43, P1045; WOO R, 1979, J GEOPHYS RES-SPACE, V84, P7288, DOI 10.1029/JA084iA12p07288; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	23	108	112	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					709	712		10.1126/science.272.5262.709	http://dx.doi.org/10.1126/science.272.5262.709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662566				2022-12-28	WOS:A1996UJ05100046
J	Javaheri, S; Parker, TJ; Wexler, L; Liming, JD; Lindower, P; Roselle, GA				Javaheri, S; Parker, TJ; Wexler, L; Liming, JD; Lindower, P; Roselle, GA			Effect of theophylline on sleep-disordered breathing in heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE PULMONARY-DISEASE; CHEYNE-STOKES RESPIRATION; CARDIAC-OUTPUT; APNEA SYNDROME; AMINOPHYLLINE; VENTILATION; OXYGEN	Background Theophylline has been used to treat central apnea associated with Cheyne-Stokes respiration (periodic breathing), We studied the effect of short-term oral theophylline therapy on periodic breathing associated with stable heart failure due to systolic dysfunction. Methods Fifteen men with compensated heart failure (left ventricular ejection fraction, 45 percent or less) participated in the study. Their base-line polysomnograms showed periodic breathing, with more than 10 episodes of apnea and hypopnea per hour. In a double-blind crossover study, the patients received theophylline or placebo orally twice daily for five days, with one week of washout between the two periods. Results After five days of treatment, the mean (+/-SD) plasma theophylline concentration was 11+/-2 mu g per milliliter. Theophylline therapy resulted in significant decreases in the number of episodes of apnea and hypopnea per hour (18+/-17, vs. 37+/-23 with placebo and 47+/-21 at baseline; P<0.001), the number of episodes of central apnea per hour (6+/-14, vs. 26+/-21 and 26+/-20, respectively; P<0.001), and the percentage of total sleep time during which the arterial oxyhemoglobin saturation was less than 90 percent (6+/-11 percent, vs. 23+/-32 and 14+/-14 percent, respectively; P<0.04). There were no significant differences in the characteristics of sleep, the frequency of ventricular arrhythmias, daytime arterial-blood gas values, or the left ventricular ejection fraction during the base-line, placebo, and theophylline phases of the study. Conclusions In patients with stable heart failure, oral theophylline therapy reduced the number of episodes of apnea and hypopnea acid the duration of arterial oxyhemoglobin desaturation during sleep. (C) 1996, Massachusetts Medical Society.	UNIV CINCINNATI, COLL MED, CINCINNATI, OH 45221 USA; VET AFFAIRS MED CTR, MED SERV, CINCINNATI, OH 45267 USA; VET AFFAIRS MED CTR, CARDIOL SECT, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Javaheri, S (corresponding author), VET AFFAIRS MED CTR, PULM SECT 111F, SLEEP DISORDERS LAB, 3200 VINE ST, CINCINNATI, OH 45220 USA.							[Anonymous], 1980, Ann Intern Med, V93, P391; BARATZ DM, 1992, CHEST, V102, P1397, DOI 10.1378/chest.102.5.1397; BERRY RB, 1991, AM REV RESPIR DIS, V143, P245, DOI 10.1164/ajrccm/143.2.245; BONNET MH, 1992, SLEEP, V15, P526; BRADLEY TD, 1992, AM REV RESPIR DIS, V145, P377, DOI 10.1164/ajrccm/145.2_Pt_1.377; BUCKLE P, 1992, CHEST, V102, P31, DOI 10.1378/chest.102.1.31; CHERNIACK NS, 1984, J CLIN INVEST, V73, P1501, DOI 10.1172/JCI111355; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; DOWELL AR, 1965, NEW ENGL J MED, V273, P1447, DOI 10.1056/NEJM196512302732702; ELDRIDGE FL, 1985, J APPL PHYSIOL, V59, P1428, DOI 10.1152/jappl.1985.59.5.1428; ESPINOZA H, 1987, AM REV RESPIR DIS, V136, P80, DOI 10.1164/ajrccm/136.1.80; GERHARDT T, 1978, PEDIATRICS, V62, P801; GUILLEMINAULT C, 1983, B EUR PHYSIOPATH RES, V19, P632; GUILLEMINAULT C, 1993, SLEEP, V16, P524; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; HANLY PJ, 1989, CHEST, V96, P480, DOI 10.1378/chest.96.3.480; JAVAHERI S, 1995, ANN INTERN MED, V123, P77; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1988, J APPL PHYSIOL, V64, P1837, DOI 10.1152/jappl.1988.64.5.1837; JAVAHERI S, 1989, THORAX, V44, P121, DOI 10.1136/thx.44.2.121; JAVAHERI S, 1990, THORAX, V45, P743, DOI 10.1136/thx.45.10.743; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; MATTHAY RA, 1982, AM HEART J, V104, P1022, DOI 10.1016/0002-8703(82)90435-5; OGILVIE RI, 1977, EUR J CLIN PHARMACOL, V12, P409, DOI 10.1007/BF00561059; Rall T, 1982, PHARMACOLOGIST, V24, P277; RHIND GB, 1985, BRIT MED J, V291, P1605, DOI 10.1136/bmj.291.6509.1605; SAS Institute, 1988, SAS STAT US GUID VER; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	31	232	246	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					562	567		10.1056/NEJM199608223350805	http://dx.doi.org/10.1056/NEJM199608223350805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8678934				2022-12-28	WOS:A1996VD30200005
J	Brenner, MK				Brenner, MK			Gene transfer to hematopoietic cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	Brenner, MK (corresponding author), ST JUDE CHILDRENS RES HOSP, CELL & GENE THERAPY PROGRAM, 322 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Brenner, Malcolm/Y-2509-2019					BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BRENNER MK, 1994, COLD SPRING HARB SYM, V59, P691, DOI 10.1101/SQB.1994.059.01.080; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; SORRENTINO BP, 1995, BLOOD, V86, P491, DOI 10.1182/blood.V86.2.491.bloodjournal862491	5	59	62	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					337	339		10.1056/NEJM199608013350508	http://dx.doi.org/10.1056/NEJM199608013350508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663858				2022-12-28	WOS:A1996UY98200008
J	Carter, JS; Pugh, JA; Monterrosa, A				Carter, JS; Pugh, JA; Monterrosa, A			Non-insulin-dependent diabetes mellitus in minorities in the United States	ANNALS OF INTERNAL MEDICINE			English	Review							IMPAIRED GLUCOSE-TOLERANCE; STAGE RENAL-DISEASE; NON-HISPANIC WHITES; LOWER-EXTREMITY AMPUTATIONS; CARDIOVASCULAR RISK-FACTORS; NAVAJO INDIAN COMMUNITY; MEXICAN-AMERICANS; PIMA-INDIANS; SAN-ANTONIO; RACIAL-DIFFERENCES	Purpose: To review the available information on prevalence, complications, and mortality of non-insulin-dependent diabetes mellitus and primary and secondary prevention activities in black persons, Hispanic persons, Native Americans, and Asians and Pacific Islanders in the United States. Data Source: MEDLINE search from 1976 to 1994 through the PlusNet search system. Study Selection: Use of the key words non-insulin-dependent diabetes mellitus, the names of each specific minority group, socioeconomic status, acculturation, genetics, diet, complications, mortality, treatment, and intervention (lifestyle or medication) produced 290 unduplicated articles. Additional articles cited in the original articles were also included. Data Extraction: Risk factors, incidence, prevalence, complications, and mortality of non-insulin;dependent diabetes mellitus. Data Synthesis: All minorities, except natives of Alaska, have a prevalence of non-insulin-dependent diabetes mellitus that is two to six times greater than that of white persons. Most studies show an increased prevalence of nephropathy that can be as much as six times higher than that of white persons. Retinopathy has variably higher rates in black persons, Hispanic persons, and Native Americans. Amputations are done more frequently among black persons than among white persons (9.0 per 1000 compared with 6.3 per 1000), and Pima Indians have 3.7 times more amputations than do white persons. Diabetes-related mortality is higher for minorities than for white persons, and the rate is increasing. The relative importance of genetic heritage, diet, exercise, socioeconomic status, culture, language, and access to health care in the prevalence, incidence, and mortality of diabetes is not clear. Studies of interventions in minority populations are in progress. Conclusion: Diabetes should be treated as a public health problem for minority populations.	UNIV TEXAS, AUDIE L MURPHY MEM VET HOSP, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA; VET AFFAIRS MED CTR, ALBUQUERQUE, NM 87108 USA; UNIV NEW MEXICO, SCH MED, ALBUQUERQUE, NM 87131 USA; MEXICAN AMER MED TREATMENT EFFECTIVENESS CTR, SAN ANTONIO, TX USA; TEXAS DIABET INST, SAN ANTONIO, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico			Pugh, Jacqueline/I-6199-2013	Pugh, Jacqueline/0000-0003-4933-141X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038392] Funding Source: NIH RePORTER; AHRQ HHS [U01HS07397] Funding Source: Medline; NIDDK NIH HHS [DK38392] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACTON K, 1993, DIABETES CARE, V16, P263, DOI 10.2337/diacare.16.1.263; AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; Alzaid AA, 1996, DIABETES CARE, V19, P79, DOI 10.2337/diacare.19.1.79; ARONOW WS, 1993, AM J CARDIOL, V71, P999, DOI 10.1016/0002-9149(93)90923-Z; ASPENLAND S, 1992, NUTR TODAY       MAR, P6; AUSLANDER W F, 1992, Ethnicity and Disease, V2, P176; BENJAMIN E, 1993, DIABETES CARE, V16, P1231, DOI 10.2337/diacare.16.9.1231; BENNETT PH, 1983, DIABETES 1982; BENNETT PH, 1984, DIET DIABETES ATHERO, P109; BOGARDUS C, 1992, J CELL BIOCHEM, V48, P337, DOI 10.1002/jcb.240480402; BONHAM GS, 1985, AM J CLIN NUTR, V41, P776, DOI 10.1093/ajcn/41.4.776; BRANCATI FL, 1994, DIABETES, V43, pA26; BROUSSARD BA, 1982, J NUTR EDUC, V14, P56; BROUSSARD BA, 1991, AM J CLIN NUTR, V53, pS1535, DOI 10.1093/ajcn/53.6.1535S; BROWN SA, 1995, DIABETES EDUCATOR, V21, P203, DOI 10.1177/014572179502100307; Burchfiel Cecil M., 1995, Annals of Epidemiology, V5, P33, DOI 10.1016/1047-2797(94)00038-U; Bureau of the Census, 1990, CENS POP 1990; CARTER J, 1989, PUBLIC HEALTH REP, V104, P665; CARTER JS, 1993, DIABETES CARE, V16, P306, DOI 10.2337/diacare.16.1.306; COWIE C, 1994, DIABETES, V43, pA84; COWIE CC, 1994, DIABETES CARE, V17, P681, DOI 10.2337/diacare.17.7.681; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; COX B, 1991, SPIRIT HARVEST N AM; DASMAHAPATRA A, 1994, DIABETES CARE, V17, P297, DOI 10.2337/diacare.17.4.297; Doak C.C., 1985, TEACHING PATIENTS LO; DOOLEY SL, 1991, DIABETES, V40, P25, DOI 10.2337/diab.40.2.S25; DOOLEY SL, 1991, INT J GYNECOL OBSTET, V35, P13, DOI 10.1016/0020-7292(91)90057-C; DRURY TF, 1987, NIH PUBLICATION; Eggers P W, 1984, Health Care Financ Rev, V5, P69; EVERHART JE, 1992, DIABETES, V41, P235, DOI 10.2337/diabetes.41.2.235; FARRELL MA, 1993, DIABETES CARE, V16, P253, DOI 10.2337/diacare.16.1.253; FERNANDO RE, 1976, DIABETES MELLITUS AS, P123; FLEGAL KM, 1991, DIABETES CARE, V14, P628, DOI 10.2337/diacare.14.7.628; FRATI AC, 1990, DIABETES CARE, V13, P455, DOI 10.2337/diacare.13.4.455; FRATIMUNARI AC, 1983, ARCH INVEST MED, V14, P117; FREEMAN WL, 1989, DIABETES CARE, V12, P282, DOI 10.2337/diacare.12.4.282; FUJIMOTO WY, 1994, DIABETES RES CLIN PR, V24, pS43, DOI 10.1016/0168-8227(94)90226-7; FUJIMOTO WY, 1987, DIABETES, V36, P721, DOI 10.2337/diabetes.36.6.721; FUJIMOTO WY, 1991, DIABETES RES CLIN PR, V13, P119, DOI 10.1016/0168-8227(91)90042-C; FUJIMOTO WY, 1992, DIABETES RES CLIN PR, V15, P167, DOI 10.1016/0168-8227(92)90022-J; FUJIMOTO WY, 1995, NIH PUBLICATION, P661; GARDNER LI, 1984, DIABETES, V33, P86, DOI 10.2337/diabetes.33.1.86; GAVIN JR, 1992, TYPE 2 DIABETES MINO, P8; Gohdes D, 1996, ANN INTERN MED, V124, P149, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00013; GOHDES D, 1988, DIABETES CARE, V11, P189, DOI 10.2337/diacare.11.2.189; Gohdes D., DIABETES AM, V1995, P683; GOHDES DM, 1986, DIABETES CARE, V9, P609, DOI 10.2337/diacare.9.6.609; GOLDMAN D, 1991, DIABETES MEXICAN AM, P102; GOLDSCHMID MG, 1995, DIABETES CARE, V18, P955, DOI 10.2337/diacare.18.7.955; GULLI G, 1992, DIABETES, V41, P1575, DOI 10.2337/diabetes.41.12.1575; HADDOCK L, 1991, DIABETES CARE, V14, P676, DOI 10.2337/diacare.14.7.676; HAFFNER SM, 1984, DIABETES CARE, V7, P347, DOI 10.2337/diacare.7.4.347; HAFFNER SM, 1989, DIABETES CARE, V12, P128, DOI 10.2337/diacare.12.2.128; HAFFNER SM, 1991, DIABETES CARE, V14, P102, DOI 10.2337/diacare.14.2.102; HAFFNER SM, 1989, DIABETES CARE, V12, P530, DOI 10.2337/diacare.12.8.530; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; HAFFNER SM, 1986, INT J OBESITY, V10, P493; HAFFNER SM, 1985, AM J CLIN NUTR, V42, P1266, DOI 10.1093/ajcn/42.6.1266; HAFFNER SM, 1993, HYPERTENSION, V21, P83, DOI 10.1161/01.HYP.21.1.83; HAFFNER SM, 1986, NEW ENGL J MED, V315, P220, DOI 10.1056/NEJM198607243150403; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HAFFNER SM, 1991, DIABETES CARE, V14, P665, DOI 10.2337/diacare.14.7.665; HAMMAN RF, 1989, AM J EPIDEMIOL, V129, P295, DOI 10.1093/oxfordjournals.aje.a115134; HAMMAN RF, 1991, DIABETES CARE, V14, P655, DOI 10.2337/diacare.14.7.655; HANIS CL, 1983, AM J EPIDEMIOL, V118, P659, DOI 10.1093/oxfordjournals.aje.a113677; HANIS CL, 1993, DIABETES CARE, V16, P82, DOI 10.2337/diacare.16.1.82; HANIS CL, 1991, DIABETES CARE, V14, P618, DOI 10.2337/diacare.14.7.618; HARRIS EL, 1993, DIABETES CARE, V16, P748, DOI 10.2337/diacare.16.5.748; HARRIS M, 1993, DIABETES CARE, V16, P1446, DOI 10.2337/diacare.16.11.1446; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HARRIS MI, 1991, DIABETES CARE, V14, P639, DOI 10.2337/diacare.14.7.639; HARRIS MI, 1990, DIABETES METAB REV, V6, P71, DOI 10.1002/dmr.5610060202; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HARRIS MI, 1995, NIH PUBLICATION, P591; HAZUDA HP, 1988, AM J EPIDEMIOL, V128, P1289, DOI 10.1093/oxfordjournals.aje.a115082; Hendricks R T, 1991, Nurse Pract Forum, V2, P199; HERMAN WH, 1995, DIABETES CARE, V18, P382, DOI 10.2337/diacare.18.3.382; Hesse Z., 1973, SW INDIAN RECIPE BOO; Hildebrandt R, 1990, Z Gesamte Inn Med, V45, P441; HINNEN D, 1993, NURS CLIN N AM, V28, P113; HOLLINGSWORTH DR, 1991, DIABETES CARE, V14, P695, DOI 10.2337/diacare.14.7.695; HOWARD BV, 1995, AM J EPIDEMIOL, V142, P254, DOI 10.1093/oxfordjournals.aje.a117632; HOY WE, 1987, AM J KIDNEY DIS, V9, P485, DOI 10.1016/S0272-6386(87)80075-6; Humphrey L L, 1990, Clin Geriatr Med, V6, P807; JABER LA, 1995, ANN PHARMACOTHER, V29, P573, DOI 10.1177/106002809502900603; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; JOHNSON LG, 1993, DIABETES CARE, V16, P250, DOI 10.2337/diacare.16.1.250; JOOS SK, 1984, ANN HUM BIOL, V11, P167, DOI 10.1080/03014468400007031; KAHN HA, 1974, AM J OPHTHALMOL, V78, P58, DOI 10.1016/0002-9394(74)90010-5; KAPPEL DF, 1986, AM J KIDNEY DIS, V8, P234, DOI 10.1016/S0272-6386(86)80031-2; Kawate R, 1979, Diabetes Care, V2, P161, DOI 10.2337/diacare.2.2.161; Kawate R, 1979, DIABETES 1979, P526; KIM EJ, 1976, DIABETES MELLITUS AS, P41; King H., 1993, Ethnicity and Disease, V3, pS67; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; KITAZAWA Y, 1983, Tohoku Journal of Experimental Medicine, V141, P229; KNOWLER WC, 1993, DIABETES CARE, V16, P216, DOI 10.2337/diacare.16.1.216; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KNOWLER WC, 1988, AM J HUM GENET, V43, P520; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8; KUMANYIKA SK, 1990, DIABETES CARE, V13, P1154, DOI 10.2337/diacare.13.11.1154; KUNZELMAN CL, 1989, KIDNEY INT, V35, P681, DOI 10.1038/ki.1989.39; KUZUYA T, 1992, Journal of the Japan Diabetes Society, V35, P173; LAVERY L, 1994, DIABETES, V43, pA29; Lavery LA, 1996, DIABETES CARE, V19, P48, DOI 10.2337/diacare.19.1.48; LEE ET, 1994, DIABETES, V43, P572, DOI 10.2337/diabetes.43.4.572; LEE ET, 1992, DIABETES CARE, V15, P1620, DOI 10.2337/diacare.15.11.1620; LEE ET, 1985, DIABETES CARE, V8, P107, DOI 10.2337/diacare.8.2.107; LEE ET, 1995, DIABETES CARE, V18, P599, DOI 10.2337/diacare.18.5.599; LEE ET, 1993, DIABETES CARE, V16, P300, DOI 10.2337/diacare.16.1.300; Leonard B, 1986, Public Health Rep, V101, P282; Leonetti Donna L., 1992, Ethnicity and Disease, V2, P326; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LIPTON RB, 1993, AM J EPIDEMIOL, V138, P826, DOI 10.1093/oxfordjournals.aje.a116786; LIVINGSTON RC, 1993, DIABETES CARE, V16, P318, DOI 10.2337/diacare.16.1.318; MACHELEDT JE, 1992, J CLIN EPIDEMIOL, V45, P519, DOI 10.1016/0895-4356(92)90101-R; Malone TE, 1985, OFF PRES ANT RAC TAS, V1; MARINE N, 1969, DIABETES, V18, P840, DOI 10.2337/diab.18.12.840; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; MARSHALL JA, 1993, AM J EPIDEMIOL, V137, P708, DOI 10.1093/oxfordjournals.aje.a116731; MARTINEZ CB, 1993, DIABETES CARE, V16, P260, DOI 10.2337/diacare.16.1.260; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MCKENZIE SB, 1995, CLIN LAB SCI, V8, pA147; MCLARTY DG, 1989, LANCET, V1, P871; MCNABB WL, 1993, J AM DIET ASSOC, V93, P75, DOI 10.1016/0002-8223(93)92138-N; MCPHILLIPS JB, 1990, AM J EPIDEMIOL, V131, P443, DOI 10.1093/oxfordjournals.aje.a115519; MEDINA RA, 1996, IN PRESS AM J KID DI; MEGILL DM, 1988, WESTERN J MED, V149, P178; MITCHELL BD, 1990, J CLIN EPIDEMIOL, V43, P319, DOI 10.1016/0895-4356(90)90118-9; MITCHELL BD, 1995, DIABETES, V44, P1046, DOI 10.2337/diabetes.44.9.1046; MITCHELL BD, 1993, DIABETES CARE, V16, P1262, DOI 10.2337/diacare.16.9.1262; MONTERROSA AE, 1995, DIABETES CARE, V18, P448, DOI 10.2337/diacare.18.4.448; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; MUNETA B, 1993, DIABETES CARE, V16, P1619, DOI 10.2337/diacare.16.12.1619; Murphy F G, 1993, Diabetes Educ, V19, P113, DOI 10.1177/014572179301900204; MURPHY FG, 1993, DIABETES ED, V19, P118; MURPHY NJ, 1992, DIABETES CARE, V15, P1390, DOI 10.2337/diacare.15.10.1390; NARVA AS, 1985, IHS PRIMARY CARE PRO, V10, P82; *NAT CTR HLTH STAT, 1984, DHHS PUBL; NEEL JV, 1962, AM J HUM GENET, V14, P353; NEEL JV, 1982, GENETICS DIABETES ME, P283; NELSON RG, 1990, CIRCULATION, V81, P987, DOI 10.1161/01.CIR.81.3.987; NELSON RG, 1988, DIABETES CARE, V11, P8, DOI 10.2337/diacare.11.1.8; NELSON RG, 1989, DIABETOLOGIA, V32, P870, DOI 10.1007/BF00297452; NELSON RG, 1989, TRANSPLANT P, V21, P3913; NELSON RG, 1989, DIABETES, V38, P435, DOI 10.2337/diabetes.38.4.435; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; NEWMAN JM, 1993, DIABETES CARE, V16, P297, DOI 10.2337/diacare.16.1.297; OBRIEN TR, 1989, JAMA-J AM MED ASSOC, V262, P1485, DOI 10.1001/jama.262.11.1485; PEREZSTABLE EJ, 1989, AM J PUBLIC HEALTH, V79, P770, DOI 10.2105/AJPH.79.6.770; PETTITT DJ, 1990, DIABETOLOGIA, V33, P438, DOI 10.1007/BF00404096; PETTITT DJ, 1980, DIABETES CARE, V3, P458, DOI 10.2337/diacare.3.3.458; PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502; PETTITT DJ, 1982, AM J EPIDEMIOL, V115, P359, DOI 10.1093/oxfordjournals.aje.a113313; PHILIPS JN, 1994, J HEALTH CARE POOR U, V5, P266; Phillips J N, 1994, J Health Care Poor Underserved, V5, P247; POLEDNAK AP, 1990, PUBLIC HEALTH REP, V105, P393; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; PROCHAZKA M, 1995, DIABETES, V44, pA42; PUGH JA, 1995, DIABETES, V44, P1375, DOI 10.2337/diabetes.44.12.1375; PUGH JA, 1988, AM J EPIDEMIOL, V127, P135, DOI 10.1093/oxfordjournals.aje.a114773; PUGH JA, 1994, AM J KIDNEY DIS, V23, P803; Pugh JA, 1996, J INVEST MED, V44, pA83; Pugh Jacqueline A., 1992, Journal of Diabetes and its Complications, V6, P236, DOI 10.1016/1056-8727(92)90058-S; QUIGGINS PA, 1993, DIABETES CARE, V16, P342, DOI 10.2337/diacare.16.1.342; RATE RG, 1983, DIABETES, V32, P894, DOI 10.2337/diabetes.32.10.894; RAVUSSIN E, 1994, DIABETES CARE, V17, P1067, DOI 10.2337/diacare.17.9.1067; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; REID JM, 1971, AM J CLIN NUTR, V24, P1281; RITHNAJARIAN SJ, 1992, DIABETES CARE, V15, P1386, DOI 10.2337/diacare.15.10.1386; RITHNAJARIAN SJ, 1993, DIABETES CARE, V16, P266, DOI 10.2337/diacare.16.1.266; ROSEMAN JM, 1985, NIH PUBLICATION, pVIII1; SAMET JM, 1988, AM J EPIDEMIOL, V128, P1302, DOI 10.1093/oxfordjournals.aje.a115083; SCHRAER CD, 1988, DIABETES CARE, V11, P693, DOI 10.2337/diacare.11.9.693; SEIJO R, 1991, HISPANIC J BEHAV SCI, V13, P363, DOI 10.1177/07399863910134001; SILVER K, 1995, DIABETES, V44, pA42; SLOAN NR, 1963, JAMA-J AM MED ASSOC, V183, P419, DOI 10.1001/jama.1963.03700060061008; SMITH CJ, 1991, J AM DIET ASSOC, V91, P338; STAHN RM, 1993, DIABETES CARE, V16, P244, DOI 10.2337/diacare.16.1.244; STEPHENS GW, 1990, AM J KIDNEY DIS, V15, P562, DOI 10.1016/S0272-6386(12)80527-0; STERN MP, 1992, DIABETES, V41, P484, DOI 10.2337/diabetes.41.4.484; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; STERN MP, 1990, DIABETES METAB REV, V6, P29, DOI 10.1002/dmr.5610060102; STERN MP, 1981, AM J EPIDEMIOL, V113, P556, DOI 10.1093/oxfordjournals.aje.a113132; STERN MP, 1991, DIABETES CARE, V14, P649, DOI 10.2337/diacare.14.7.649; STERN MP, 1982, AM J EPIDEMIOL, V115, P917, DOI 10.1093/oxfordjournals.aje.a113379; STERN MP, 1991, DIABETES CARE, V14, P399, DOI 10.2337/diacare.14.5.399; SUGARMAN J, 1989, AM J PUBLIC HEALTH, V79, P511, DOI 10.2105/AJPH.79.4.511; SUGARMAN JR, 1990, WESTERN J MED, V153, P140; SUGARMAN JR, 1989, WESTERN J MED, V150, P548; SZATHMARY EJE, 1983, HUM BIOL, V55, P493; TAI TY, 1987, EPIDEMIOLOGY DIABETE, P49; TAYLOR R, 1983, DIABETES EPIDEMIOLOG, P58; TEUTSCH S, 1989, AM J KIDNEY DIS, V13, P11, DOI 10.1016/S0272-6386(89)80106-4; THAI C, 1987, EPIDEMIOLOGY DIABETE, P63; THOMAS DR, 1989, J GEN INTERN MED, V4, P97, DOI 10.1007/BF02602347; TREVINO R, 1995, SAN ANTONIO EXP 0806; TULL ES, 1995, NIH PUBLICATION, P621; *U MICH, 1991, DIAB ED RES MIN LOW; UBA L, 1992, PUBLIC HEALTH REP, V107, P544; *US DEP COMM, 1994, STAT ABSTR US, P475; *US DEP HHS, 1990, DIAB SURV 1980 1987, P23; *US DEP HHS, 1994, CHRON DIS MIN POP; *US DEP HHS, 1990, DIAB SURV 1980 1987, P9; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; VALWAY S, 1993, DIABETES CARE, V16, P271, DOI 10.2337/diacare.16.1.271; VALWAY SE, 1993, DIABETES CARE, V16, P349, DOI 10.2337/diacare.16.1.349; WEATHERSPOON LJ, 1994, DIABETES CARE, V17, P1148, DOI 10.2337/diacare.17.10.1148; WENDORF M, 1991, DIABETES, V40, P161, DOI 10.2337/diabetes.40.2.161; WEST K, 1978, EPIDEMIOLOGY DIABETE, P274; WETTERHALL SF, 1992, DIABETES CARE, V15, P960, DOI 10.2337/diacare.15.8.960; WILLIAMS RC, 1985, AM J PHYS ANTHROPOL, V66, P1, DOI 10.1002/ajpa.1330660102; WINGARD DL, 1993, DIABETES CARE, V16, P1022, DOI 10.2337/diacare.16.7.1022; WIRTH RB, 1993, DIABETES CARE, V16, P354, DOI 10.2337/diacare.16.1.354; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45; 1993, AM J KIDNEY DIS S2, V22, P30; 1994, VITAL HLTH STAT, V10, P1; 1996, DIABETES CARE, V19, P55; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P119; 1995, ANN BEHAV MED, V17, pSO35; 1993, MMWR-MORBID MORTAL W, V42, P398	226	368	373	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					221	232		10.7326/0003-4819-125-3-199608010-00011	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00011			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686981				2022-12-28	WOS:A1996UZ28700009
J	Currie, PD; Ingham, PW				Currie, PD; Ingham, PW			Induction of a specific muscle cell type by a hedgehog-like protein in zebrafish	NATURE			English	Article							MOTOR-NEURON INDUCTION; SONIC-HEDGEHOG; FLOOR PLATE; POLARIZING ACTIVITY; EXPRESSION; NOTOCHORD; AUTOPROTEOLYSIS; PATTERN; SOMITES; PRODUCT	THE notochord plays a central role in vertebrate development, acting as a signalling source that patterns the neural tube and somites(1-4). In in vitro assays, the secreted protein Sonic hedgehog mimics the inducing effects of notochord on both presomitic mesoderm and neural plate explants of amniote embryos, suggesting that both patterning activities of the notochord may be mediated by this protein in vivo(5-8). In zebrafish, however, mutants with disrupted notochord development lack a specific muscle cell type, the muscle pioneers, although they retain tile ability to induce neural differentiation, raising the possibility that neural tube and somite patterning may be mediated by distinct signals(9,10). Here we describe a new member of the hedgehog family, echidna hedgehog that is expressed exclusively in the notochord and has the ability to rescue the differentiation of muscle pioneer cells in mutants with no notochord, Moreover, we show that a combination of ectopic echidna hedgehog and sonic hedgehog expression induces supernumary muscle pioneers in wild-type embryos, suggesting that both signals act sequentially to pattern the developing somites.	IMPERIAL CANC RES FUND,MOL EMBRYOL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Ingham, Philip W/G-9903-2011; Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/E-6710-2010	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958; Currie, Peter/0000-0001-8874-8862				BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FELSENFELD AL, 1991, DEV BIOL, V148, P23, DOI 10.1016/0012-1606(91)90314-S; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HATTA K, 1991, DEVELOPMENT, V112, P821; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; VANEEDEN FJM, IN PRESS DEVELOPMENT; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	26	280	303	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					452	455		10.1038/382452a0	http://dx.doi.org/10.1038/382452a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684485				2022-12-28	WOS:A1996VA25100057
J	Grisso, JA; Ness, RB				Grisso, JA; Ness, RB			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Article							EXERCISE; FRAILTY; ADULTS		UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15261 USA; UNIV PENN, MED CTR, CTR CLIN EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania								ALPERT EJ, 1995, ANN INTERN MED, V123, P774, DOI 10.7326/0003-4819-123-10-199511150-00006; Baker LC, 1996, NEW ENGL J MED, V334, P960, DOI 10.1056/NEJM199604113341506; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; CREININ MD, 1995, AM J OBSTET GYNECOL, V173, P354, DOI 10.1016/0002-9378(95)90241-4; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; DARNEY PD, 1987, FAM PLANN PERSPECT, V19, P158, DOI 10.2307/2135161; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LARSON EB, 1991, J AM GERIATR SOC, V39, P635, DOI 10.1111/j.1532-5415.1991.tb03609.x; LINDHEIM BL, 1978, FAM PLANN PERSPECT, V10, P24, DOI 10.2307/2134507; MACKAY HT, 1995, FAM PLANN PERSPECT, V27, P112, DOI 10.2307/2136108; Maine D, 1994, J Am Med Womens Assoc (1972), V49, P137; OAKLEY GP, 1995, JAMA-J AM MED ASSOC, V274, P1717, DOI 10.1001/jama.274.21.1717; RENOT F, 1993, BRIT HEART J, V70, P537; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; WAGNER EH, 1992, ANNU REV PUBL HEALTH, V13, P451; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68	17	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					213	220		10.7326/0003-4819-125-3-199608010-00010	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686980				2022-12-28	WOS:A1996UZ28700008
J	Wilde, H; Thipkong, P; Sitprija, V; Chaiyabutr, N				Wilde, H; Thipkong, P; Sitprija, V; Chaiyabutr, N			Heterologous antisera and antivenins are essential biologicals: Perspectives on a worldwide crisis	ANNALS OF INTERNAL MEDICINE			English	Article							RABIES	Active immunization against infectious disease is important. However, much of our world faces poverty, social injustice, and warfare, all of which cause universal immunization to remain a distant dream. Agents that provide passive immunity thus remain essential biologicals. The most important of these are human or equine antisera against rabies, tetanus, diphtheria, and snake antivenins. Homologous products are either unavailable or unaffordable in places where they are needed the most. Less expensive heterologous (equine) antisera can be purified and are safe to use, but these antisera are also in short supply. Monoclonal antibodies have been developed but are even less likely to be affordable in poor countries. Several traditional sources of equine antisera are becoming depleted as a result of economic disincentives; a poor reputation based on the high adverse reaction rates of the old, unpurified products; and the activities of animal rights activists who, object to the use of horses as blood donors. Purified, pepsin-digested equine antisera are preferred; but developing countries sometimes are forced to make crude products that are less safe or have no specific therapy available at all.	CHULALONGKORN UNIV, FAC MED, BANGKOK 10330, THAILAND; CHULALONGKORN UNIV, FAC VET SCI, BANGKOK 10330, THAILAND	Chulalongkorn University; Chulalongkorn University	Wilde, H (corresponding author), THAI RED CROSS SOC, QUEEN SAOVABHA MEM INST, WHO, COLLABORATING CTR RES RABIES, BANGKOK, THAILAND.							ALVAREZ L, 1994, PEDIATR INFECT DIS J, V13, P1154, DOI 10.1097/00006454-199412000-00020; BLECK TP, 1995, PRINCIPLES PRACTICE, P2173; COX MJ, 1991, SNAKES THAILAND THEI, P288; ENSSLE K, 1991, HYBRIDOMA, V10, P547, DOI 10.1089/hyb.1991.10.547; HARNISCH JP, 1989, ANN INTERN MED, V111, P71, DOI 10.7326/0003-4819-111-1-71; KHAWPLOD P, 1995, CLIN INFECT DIS, V20, P646, DOI 10.1093/clinids/20.3.646; MACKAY J, 1993, STATE HLTH ATLAS, P78; POPOVIC T, 1995, J INFECT DIS, V171, P765, DOI 10.1093/infdis/171.4.765; Rando R F, 1994, Curr Top Microbiol Immunol, V187, P195; SCHUMACHER CL, 1992, VACCINE, V10, P754, DOI 10.1016/0264-410X(92)90510-Q; SMITH JS, 1993, PROG MED VIROL, V40, P82; SOUTHERLAND SK, 1990, AUST FAM PHYSICIAN, V19, P24; VICK JA, 1994, J CLIN PHARMACOL, V34, P709, DOI 10.1002/j.1552-4604.1994.tb02028.x; *WHO, 1992, WHO TECHNICAL REPORT, V824; *WHO, 1993, WORLD SURVEY RABIES, P210; *WHO, 1981, WHO TECHNICAL REPORT, V58; Wilde, 1994, J Travel Med, V1, P51, DOI 10.1111/j.1708-8305.1994.tb00556.x; Wilde H, 1996, CLIN INFECT DIS, V22, P228, DOI 10.1093/clinids/22.2.228; WILDE H, 1990, AM J TROP MED HYG, V42, P175, DOI 10.4269/ajtmh.1990.42.175; 1986, T R SOC TROP MED HYG, V80, P423; 1994, WKLY EPIDEMIOL REC, V69, P349; 1988, LANCET, V1, P917	22	66	68	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					233	236		10.7326/0003-4819-125-3-199608010-00012	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686982				2022-12-28	WOS:A1996UZ28700010
J	Zhang, DH; Nicklas, RB				Zhang, DH; Nicklas, RB			'Anaphase' and cytokinesis in the absence of chromosomes	NATURE			English	Article							SPINDLE; CELLS; KINETOCHORE; CENTROSOMES; NUCLEAR	ANAPHASE and cytokinesis are key processes in the segregation of replicated chromosomes to the daughter cell: in anaphase, chromosomes move apart; in cytokinesis, a cleavage furrow forms midway between the separate chromosomes. Some evidence suggests that chromosomes may be involved both in controlling the timing of anaphase onset(1-3) and in dictating the position of the cleavage furrow(3). Other evidence indicates that the controlling mechanisms are intrinsic to the spindle and the cell(4-7). Here we test these possibilities in grasshopper spermatocytes by observing spindles and cells after removal of chromosomes. We found that both anaphase and cytokinesis occur independently of chromosomes: stage-specific changes occur at an appropriate time and in the correct way, despite the absence of chromosomes. This finding is particularly noteworthy because chromosomes have an important impact on spindle microtubule assembly(8,9) and the timing of anaphase onset(10) in these cells.			Zhang, DH (corresponding author), DUKE UNIV,DEPT ZOOL,DURHAM,NC 27708, USA.							COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LORCH IJ, 1952, Q J MICROSC SCI, V93, P475; LUCA FC, 1993, CURR BIOL, V3, P716, DOI 10.1016/0960-9822(93)90078-3; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1993, NATO ASI SERIES H, V72, P211; WILSON EB, 1925, CELL DEV HEREDITY, P176; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	17	96	97	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					466	468		10.1038/382466a0	http://dx.doi.org/10.1038/382466a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684488				2022-12-28	WOS:A1996VA25100061
J	DargentMolina, P; Favier, F; Grandjean, H; Baudoin, C; Schott, AM; Hausherr, E; Meunier, PJ; Breart, G				DargentMolina, P; Favier, F; Grandjean, H; Baudoin, C; Schott, AM; Hausherr, E; Meunier, PJ; Breart, G			Fall-related factors and risk of hip fracture: The EPIDOS prospective study	LANCET			English	Article							EPIDEMIOLOGY; OSTEOPOROSIS; ASSOCIATION; PREDICTION; DISABILITY; COMMUNITY; MOBILITY; WOMEN	Background Most hip fractures result from falls. However, the role of fall-related factors has seldom been examined. Comparison of the predictive value of these factors with that of bone mineral density (BMD) has important implications for the prevention of hip fractures. Methods We assessed femoral-neck BMD by dual-photon X-ray absorptiometry and potential fall-related risk factors, which included self-reported physical capacity, neuromuscular function, mobility, visual function, and use of medication in 7575 women, aged 75 years or older, with no history of hip fracture recruited at five centres in France. We followed up these women every 4 months to record incident hip fractures. During an average of 1.9 years of follow-up, 154 women suffered a first hip fracture. Findings In age-adjusted multivariate analyses, we found four independent fall-related predictors of hip fracture: slower gait speed (relative risk=1.4 for 1 SD decrease [95% CI 1.1-1.6]); difficulty in doing a tandem (heel-to-toe) walk (1.2 for 1 point on the difficulty score [1.0-1.5]); reduced visual acuity (20 for acuity less than or equal to 2/10 [1.1-3.7]); and small calf circumference (1.5 [1.0-2.2]). After adjustment for femoral-neck BMD, neuromuscular impairment-gait speed, tandem walk-and poor vision remained significantly associated with an increased risk of subsequent hip fracture. With high risk defined as the top quartile of risk, the rate of hip fracture among women classified as high risk based on both a high fall-risk status and low BMD was 29 per 1000 woman-years, compared with 11 per 1000 for women classified as high risk by either a high fall-risk status or low BMD; for women classified as low risk based on both criteria the rate was five per 1000. Interpretation We conclude that neuromuscular and visual impairments, as well as femoral-neck BMD, are significant and independent predictors of the risk of hip fracture in elderly mobile women, and that their combined assessment improves the prediction of hip fractures.	INSERM, CJF 93 06, MONTPELLIER, FRANCE; INSERM, CJF 8908, TOULOUSE, FRANCE; INSERM, U21, VILLEJUIF, FRANCE; INSERM, U403, LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	DargentMolina, P (corresponding author), INSERM, U149, 16 AVE P VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Schott, Anne-Marie/V-7580-2018; Dargent-Molina, Patricia/N-3887-2017	Schott, Anne-Marie/0000-0003-3337-4474; Dargent-Molina, Patricia/0000-0001-8596-6899				ALEXANDER NB, 1994, J AM GERIATR SOC, V42, P93, DOI 10.1111/j.1532-5415.1994.tb06081.x; Brocklehurst J C, 1978, Age Ageing, V7, P2; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1985, AM J MED, V78, P487, DOI 10.1016/0002-9343(85)90343-2; DARGENTMOLINA P, 1995, REV EPIDEMIOL SANTE, V43, P72; DARGENTMOLINA P, IN PRESS INT J EPIDE; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HITCHINGS RA, 1989, BRIT MED J, V298, P1126, DOI 10.1136/bmj.298.6681.1126; KLEIN BEK, 1995, NEW ENGL J MED, V332, P1228, DOI 10.1056/NEJM199505043321811; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MELTON LJ, 1987, BONE MINER, V2, P321; NEVITT M, 1990, 2ND 50 YEARS PROMOTI, P263; NEVITT MC, 1992, FALLS, BALANCE AND GAIT DISORDERS IN THE ELDERLY, P69; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PORTER RW, 1990, BMJ-BRIT MED J, V301, P638, DOI 10.1136/bmj.301.6753.638; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x	26	647	666	1	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	1996	348	9021					145	149		10.1016/S0140-6736(96)01440-7	http://dx.doi.org/10.1016/S0140-6736(96)01440-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UX789	8684153				2022-12-28	WOS:A1996UX78900008
J	Sano, T; Martin, IG				Sano, T; Martin, IG			Lymphadenectomy and pancreatico-splenectomy in gastric cancer surgery	LANCET			English	Letter									UNIV LEEDS,GEN INFIRM,DEPT SURG,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; NATL CANC CTR,DEPT SURG ONCOL,TOKYO,JAPAN	Leeds General Infirmary; University of Leeds; National Cancer Center - Japan								Cuschieri A, 1996, LANCET, V347, P995, DOI 10.1016/S0140-6736(96)90144-0	1	17	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					195	196		10.1016/S0140-6736(05)66140-5	http://dx.doi.org/10.1016/S0140-6736(05)66140-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684171				2022-12-28	WOS:A1996UX78900048
J	Payne, K; Taylor, RM; Stocking, C; Sachs, GA				Payne, K; Taylor, RM; Stocking, C; Sachs, GA			Physicians' attitudes about the care of patients in the persistent vegetative state: A national survey	ANNALS OF INTERNAL MEDICINE			English	Article						knowledge, attitudes, practice; persistent vegetative state; ethics, medical; attitude toward death; life support care	COMA	Objective: To study the attitudes and beliefs of physicians who have experience caring for patients in the persistent vegetative state (PVS). Design: Mailed questionnaire survey. Participants: 500 physicians, 250 from the American Academy of Neurology and 250 from the American Medical Directors Association. Measurements: Physicians' beliefs about diagnosis of the PVS, patient awareness and suffering, treatment withdrawal, appropriate use of health maintenance and life-prolonging therapies, organ donation, lethal injection, and the treatment they would want if they were in the PVS. Results: 68% of surveyed neurologists and 60% of medical directors responded. Thirteen percent of responders believe that patients in the PVS have awareness and experience hunger and thirst; 30% believe they experience pain. Fewer than 9% believe that respiratory failure, cardiogenic shock, acute renal failure, or cancer should be aggressively treated. Eighty-nine percent believe that it is ethical to withdraw artificial hydration and nutrition. Almost two thirds of responders believe that it would be ethical to use the vital organs of patients in the PVS for transplantation, and 20% believe that it would be ethical to hasten the patient's death by lethal injection. Conclusions: When evaluating the appropriateness of treatments for patients in the PVS, neurologists and medical directors largely concur. Most physicians in both groups believe that patients in the PVS would be better off dead; that it is not necessary to provide aggressive therapeutic interventions; and that all therapeutic interventions, including artificial nutrition and hydration, can be withheld in certain circumstances. The areas of consensus are remarkable and suggest that-an ethical standard that physicians believe should be followed when caring for these patients may be emerging.	UNIV CHICAGO, MED CTR, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago Medical Center			Taylor, Robert/E-4181-2011		NIA NIH HHS [AG0048] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bernat J L, 1992, J Clin Ethics, V3, P21; BOYD K, 1991, LANCET, V337, P96; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; GALLUP G, 1991, GALLUP POLL NEWS SER, V55, P1; GERVAIS KG, 1985, REDEFINING DEATH; JENNETT B, 1972, LANCET, V1, P734; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNOX RA, 1991, BOSTON SUNDAY G 1103; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Plows CW, 1996, JAMA-J AM MED ASSOC, V275, P443, DOI 10.1001/jama.275.6.443; TRESCH DD, 1991, J AM GERIATR SOC, V39, P17, DOI 10.1111/j.1532-5415.1991.tb05900.x; Veatch R M, 1992, J Clin Ethics, V3, P181; 1996, NEUROLOGY, V45, P1015; 1990, JAMA-J AM MED ASSOC, V263, P426	19	83	85	2	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					104	+		10.7326/0003-4819-125-2-199607150-00004	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV921	8678363				2022-12-28	WOS:A1996UV92100007
J	Sacks, SL; Aoki, FY; DiazMitoma, F; Sellors, J; Shafran, SD				Sacks, SL; Aoki, FY; DiazMitoma, F; Sellors, J; Shafran, SD			Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes - A randomized, double-blind multicenter trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIMPLEX VIRUS-INFECTION; ACYCLOVIR; SUPPRESSION; TYPE-2; PHARMACOKINETICS; PENCICLOVIR; ANTIBODIES; MODE	Objective.-To compare the efficacy and safety of episodic patient-initiated oral famciclovir with placebo in recurrent genital herpes. Design.-Randomized, double-blind, frequent-observation, dose-ranging study comparing twice-daily 125-mg, 250-mg, or 500-mg oral famciclovir with placebo. Patients initiated therapy after self-culturing, reported to the clinic within 12 hours, and were assessed twice daily for at least 5 days. Setting.-Fifteen Canadian university, private practice, or public outpatient clinics. Patients.-A total of 692 patients with culture-proven recurrent genital herpes were randomized; 467 patients experienced a symptomatic episode and commenced treatment. Main Outcome Measure.-Time to complete healing of all lesions. Results.-Famciclovir (all doses) was significantly more effective than placebo in reducing time to healing, time to cessation of viral shedding, and durations of lesion edema, vesicles, ulcers, and crusts. Times to cessation of all symptoms and of moderate to severe lesion tenderness, pain, and burning were also reduced. Patients who initiated famciclovir prior to viral shedding were more likely to not shed virus throughout. All doses were equally effective, safe, and well tolerated. Conclusions.-Oral famciclovir reduced the onset and duration of viral shedding, lesion persistence, and uncomfortable symptoms. Several individual symptoms and lesion stages were also reduced in duration by this episodic therapy. Additionally, our twice-daily observation trial design proved to be a helpful tool for studying recurrent disease. Episodic oral famciclovir provides a convenient and effective alternative for those patients with recurrent genital herpes whose frequency rates do not require continuous antiviral suppression.	UNIV BRITISH COLUMBIA,VANCOUVER HOSP & HLTH SCI CTR,DIV INFECT DIS,VANCOUVER,BC V5Z 1M9,CANADA; UNIV MANITOBA,WINNIPEG,MB,CANADA; HLTH SCI CTR HOSP,WINNIPEG,MB,CANADA; CHILDRENS HOSP EASTERN ONTARIO,OTTAWA,ON K1H 8L1,CANADA; MCMASTER UNIV,DEPT FAMILY MED,HAMILTON,ON L8S 4L8,CANADA; UNIV ALBERTA,DEPT MED,DIV INFECT DIS,EDMONTON,AB,CANADA	University of British Columbia; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Ottawa; Children's Hospital of Eastern Ontario; McMaster University; University of Alberta			Diaz-Mitoma, Francisco/AAA-2522-2019	Diaz-Mitoma, Francisco/0000-0003-0292-4859				BOYD MR, 1993, ANTIVIR CHEM CHEMOTH, V4, P3, DOI 10.1177/095632029300401S01; CHRISTENSON B, 1992, J INFECTION, V25, P147, DOI 10.1016/0163-4453(92)93943-K; COREY L, 1995, CLINICAL MANAGEMENT OF HERPES VIRUSES, P43; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM AL, 1993, MED J AUSTRALIA, V158, P525, DOI 10.5694/j.1326-5377.1993.tb121867.x; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; GOLD D, 1987, ANTIMICROB AGENTS CH, V31, P361, DOI 10.1128/AAC.31.3.361; GOLDBERG LH, 1993, ARCH DERMATOL, V129, P582, DOI 10.1001/archderm.129.5.582; HALSOS AM, 1985, ACTA DERM-VENEREOL, V65, P59; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; HODGE RAV, 1993, ANTIVIR CHEM CHEMOTH, V4, P67, DOI 10.1177/095632029300400201; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P223, DOI 10.1128/AAC.33.2.223; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MINDEL A, 1984, LANCET, V2, P57; NILSEN AE, 1982, LANCET, V2, P571; PUE MA, 1993, ANTIVIR CHEM CHEMOTH, V4, P47, DOI 10.1177/09563202930040S602; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; RUHNEKFORSBECK M, 1985, J ANTIMICROB CHEMOTH, V16, P621, DOI 10.1093/jac/16.5.621; SACKS SL, 1983, J VIROL METHODS, V7, P199, DOI 10.1016/0166-0934(83)90009-5; SACKS SL, 1990, J INFECT DIS, V161, P692, DOI 10.1093/infdis/161.4.692; SACKS SL, 1987, CAN MED ASSOC J, V136, P701; SACKS SL, 1988, SEX TRANSM DIS, V15, P58, DOI 10.1097/00007435-198801000-00013; SACKS SL, 1991, J INFECT DIS, V164, P665, DOI 10.1093/infdis/164.4.665; SACKS SL, 1995, CLINICAL MANAGEMENT OF HERPES VIRUSES, P55; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; STRAUS SE, 1986, ANTIVIR RES, V6, P151, DOI 10.1016/0166-3542(86)90009-4; [No title captured]; [No title captured]; [No title captured]; [No title captured]	31	129	136	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					44	49		10.1001/jama.276.1.44	http://dx.doi.org/10.1001/jama.276.1.44			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667538				2022-12-28	WOS:A1996UU43900026
J	BuckleySharp, MD; Gardner, DA				BuckleySharp, MD; Gardner, DA			Replication of results - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											BuckleySharp, MD (corresponding author), UCL HOSP, DEPT CHEM PATHOL, LONDON W1P 6DB, ENGLAND.								0	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1653	1653		10.1136/bmj.312.7047.1653	http://dx.doi.org/10.1136/bmj.312.7047.1653			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664722	Green Published			2022-12-28	WOS:A1996UV48900028
J	Leake, R				Leake, R			100 years of the endocrine battle against breast cancer	LANCET			English	Editorial Material											Leake, R (corresponding author), UNIV GLASGOW,DIV BIOCHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND.							Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beatson GW, 1896, LANCET, V2, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; HAWKINS RA, 1993, BREAST, V2, P125; HOWELL A, 1996, EUR J CANCER, V32, P57; Marsden J, 1996, ENDOCR-RELAT CANCER, V3, P81, DOI 10.1677/erc.0.0030081	5	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1780	1781		10.1016/S0140-6736(96)91612-8	http://dx.doi.org/10.1016/S0140-6736(96)91612-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667918				2022-12-28	WOS:A1996UU46900005
J	Borysiewicz, LK; Fiander, A; Nimako, M; Man, S; Wilkinson, GWG; Westmoreland, D; Evans, AS; Adams, M; Stacey, SN; Boursnell, MEG; Rutherford, E; Hickling, JK; Inglis, SC				Borysiewicz, LK; Fiander, A; Nimako, M; Man, S; Wilkinson, GWG; Westmoreland, D; Evans, AS; Adams, M; Stacey, SN; Boursnell, MEG; Rutherford, E; Hickling, JK; Inglis, SC			A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer	LANCET			English	Article							GLYCOPROTEIN; VACCINATION; EXPRESSION; CELLS; BACULOVIRUS; RESPONSES; SERA	Background Human papillomavirus (HPV) infection, especially with type 16 or 18, is associated with cervical cancer, Two HPV proteins, E6 and E7, are consistently expressed in tumour cells. The objectives of the study were to examine the clinical and environmental immunogenicity in the first clinical recombinant vaccinia virus expressing proteins of HPV 16 and 18 (TA-HPV). Methods The study was an open label phase I/II trial in eight patients with late stage cervical cancer. The patients were vaccinated with a single dose of TA-HPV and kept in strict isolation to monitor local and systemic side-effects, environmental spread, and anti-E6/E7 immune responses. Findings Vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV. Each patient mounted an antivaccinia antibody response and three of the eight patients developed an HPV-specific antibody response that could be ascribed to the vaccination. HPV-specific cytotoxic T lymphocytes, the effector mechanism most likely to be of therapeutic benefit, were detected in one of three evaluable patients. Interpretation Further studies to investigate the use of TA-HPV for immunotherapy of cervical cancer are warranted.	UNIV WALES COLL CARDIFF, COLL MED, DEPT MICROBIOL, CARDIFF CF4 4XN, S GLAM, WALES; UNIV WALES COLL CARDIFF, COLL MED, DEPT ONCOL & GYNAECOL, CARDIFF CF4 4XN, S GLAM, WALES; CHRISTIE HOSP NATL HLTH SERV TRUST, PATERSON INST CANC RES, MANCHESTER, LANCS, ENGLAND; CANTAB PHARMACEUT, CAMBRIDGE, ENGLAND	Cardiff University; Cardiff University; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Borysiewicz, LK (corresponding author), UNIV WALES COLL CARDIFF, COLL MED, DEPT MED, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.		Wilkinson, Gavin WG/J-6388-2015; Man, Stephen/D-1391-2009	Wilkinson, Gavin WG/0000-0002-5623-0126; Man, Stephen/0000-0001-9103-1686; Boursnell, Mike/0000-0002-2554-8190				AURELIAN L, 1991, REV INFECT DIS, V13, pS924; BORYSIEWICZ LK, 1988, J EXP MED, V168, P919, DOI 10.1084/jem.168.3.919; BOURSNELL MEG, IN PRESS VACCINE; CAMPO MS, 1993, J GEN VIROL, V74, P945, DOI 10.1099/0022-1317-74-6-945; CHEN L, 1992, J IMMUNOL, V148, P2617; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; CRAWFORD L, 1993, CANCER SURV, V16, P215; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; FIANDER AN, 1995, INT J GYNECOL CANCER, V5, P438, DOI 10.1046/j.1525-1438.1995.05060438.x; GRAHAM S, 1991, J GEN VIROL, V72, P1183, DOI 10.1099/0022-1317-72-5-1183; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Jezek Z, 1988, HUMAN MONKEYPOX; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; STACEY SN, 1993, J MED VIROL, V40, P14, DOI 10.1002/jmv.1890400105; STACEY SN, 1992, J GEN VIROL, V73, P2337, DOI 10.1099/0022-1317-73-9-2337; TARPEY I, 1994, IMMUNOLOGY, V81, P222; TERRY G, 1993, ARCH VIROL, V128, P123, DOI 10.1007/BF01309793; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; VOUSDEN KH, 1994, HUMAN PAPILLOMAVIRUS, P92; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	26	429	472	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1996	347	9014					1523	1527		10.1016/S0140-6736(96)90674-1	http://dx.doi.org/10.1016/S0140-6736(96)90674-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684105	Bronze			2022-12-28	WOS:A1996UN47300013
J	Atkinson, DH; Pollack, JB; Seiff, A				Atkinson, DH; Pollack, JB; Seiff, A			Galileo Doppler measurements of the deep zonal winds at Jupiter	SCIENCE			English	Article							BALLOONS; MOTION; SATURN	Changes in the speed of the Galileo probe caused by zonal winds created a small but measurable Doppler effect in the probe relay carrier frequency. Analysis of the probe relay link frequency allows direct measurements of the speed of Jupiter's zonal winds beneath the cloud tops, The deep winds were prograde and strong, reaching a sustained 190 to 200 meters per second at an altitude marked by a pressure of 24 bars. The depth and strength of the zonal winds severely constrain dynamic modeling of the deeper layers and begin to rule out many shallow weather theories.	NASA,AMES RES CTR,SAN JOSE STATE UNIV FDN,MOFFETT FIELD,CA 94035	California State University System; San Jose State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Atkinson, DH (corresponding author), UNIV IDAHO,MOSCOW,ID 83844, USA.							ATKINSON DH, 1989, THESIS WASHINGTON ST; Beebe RF, 1996, SCIENCE, V272, P841, DOI 10.1126/science.272.5263.841; BEEBE RF, 1981, J GEOPHYS RES, V86, P8733; BUSSE FH, 1976, ICARUS, V29, P255, DOI 10.1016/0019-1035(76)90053-1; Counselman CC, 1980, J GEOPHYS RES-SPACE, V85, P8026, DOI 10.1029/JA085iA13p08026; COUNSELMAN CC, 1979, SCIENCE, V203, P805, DOI 10.1126/science.203.4382.805; CRISP D, 1990, ADV SPACE RES-SERIES, V10, P109, DOI 10.1016/0273-1177(90)90172-V; ENGSTROM SB, 1995, THESIS U IDAHO; GARRIGA PC, 1980, HS3731474 IDC HUGH A; GARRIGA PC, 1982, HS3732267 IDC HUGH A; GIERASCH PJ, 1976, ICARUS, V29, P445, DOI 10.1016/0019-1035(76)90064-6; GIERASCH PJ, 1983, SCIENCE, V219, P847, DOI 10.1126/science.219.4586.847; HUNT GE, 1979, NATURE, V280, P778, DOI 10.1038/280778a0; HUNTEN DM, 1980, ICARUS, V43, P143, DOI 10.1016/0019-1035(80)90114-1; INGERSOLL AP, 1982, ICARUS, V52, P62, DOI 10.1016/0019-1035(82)90169-5; JOSHI V, 1985, HS3733732 IDC HUGH A; KERZHANOVICH VV, 1972, ICARUS, V17, P659, DOI 10.1016/0019-1035(72)90030-9; KERZHANOVICH VV, 1977, ICARUS, V30, P320, DOI 10.1016/0019-1035(77)90167-1; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; NEFF J, 1994, D1038 JPL JET PROP L; POLLACK JB, 1992, SPACE SCI REV, V60, P143, DOI 10.1007/BF00216853; PRESTON R, 1987, ADV SPACE RES, V7, P299; PRESTON RA, 1986, SCIENCE, V231, P1414, DOI 10.1126/science.231.4744.1414; SAGDEYEV RZ, 1992, ASTRON ASTROPHYS, V254, P387; SEIFF A, 1993, J GEOPHYS RES-PLANET, V98, P7461, DOI 10.1029/92JE02738; WEI Y, 1995, THESIS U IDAHO; WOO R, COMMUNICATION	28	68	68	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					842	843		10.1126/science.272.5263.842	http://dx.doi.org/10.1126/science.272.5263.842			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662573				2022-12-28	WOS:A1996UK75700047
J	Bult, CJ; White, O; Olsen, GJ; Zhou, LX; Fleischmann, RD; Sutton, GG; Blake, JA; FitzGerald, LM; Clayton, RA; Gocayne, JD; Kerlavage, AR; Dougherty, BA; Tomb, JF; Adams, MD; Reich, CI; Overbeek, R; Kirkness, EF; Weinstock, KG; Merrick, JM; Glodek, A; Scott, JL; Geoghagen, NSM; Weidman, JF; Fuhrmann, JL; Nguyen, D; Utterback, TR; Kelley, JM; Peterson, JD; Sadow, PW; Hanna, MC; Cotton, MD; Roberts, KM; Hurst, MA; Kaine, BP; Borodovsky, M; Klenk, HP; Fraser, CM; Smith, HO; Woese, CR; Venter, JC				Bult, CJ; White, O; Olsen, GJ; Zhou, LX; Fleischmann, RD; Sutton, GG; Blake, JA; FitzGerald, LM; Clayton, RA; Gocayne, JD; Kerlavage, AR; Dougherty, BA; Tomb, JF; Adams, MD; Reich, CI; Overbeek, R; Kirkness, EF; Weinstock, KG; Merrick, JM; Glodek, A; Scott, JL; Geoghagen, NSM; Weidman, JF; Fuhrmann, JL; Nguyen, D; Utterback, TR; Kelley, JM; Peterson, JD; Sadow, PW; Hanna, MC; Cotton, MD; Roberts, KM; Hurst, MA; Kaine, BP; Borodovsky, M; Klenk, HP; Fraser, CM; Smith, HO; Woese, CR; Venter, JC			Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; METHANOTHERMUS-FERVIDUS; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-PROTEINS; DNA-POLYMERASES; CELL-DIVISION; GENE	The complete 1.66-megabase pair genome sequence of an autotrophic archaeon, Methanococcus jannaschii, and its 58- and 16-kilobase pair extrachromosomal elements have been determined by whole-genome random sequencing. A total of 1738 predicted protein-coding genes were identified; however, only a minority of these (38 percent) could be assigned a putative cellular role with high confidence. Although the majority of genes related to energy production, cell division, and metabolism in M. jannaschii are most similar to those found in Bacteria, most of the genes involved in transcription, translation, and replication in M. jannaschii are more similar to those found in Eukaryotes.	INST GENOM RES,ROCKVILLE,MD 20850; UNIV ILLINOIS,DEPT MICROBIOL,CHAMPAIGN,IL 61801; ARGONNE NATL LAB,DIV MATH & COMP SCI,ARGONNE,IL 60439; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214; GEORGIA INST TECHNOL,SCH BIOL,ATLANTA,GA 30332; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	J. Craig Venter Institute; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Georgia; Georgia Institute of Technology; Johns Hopkins University			Wood, David W/B-2992-2012	Fraser, Claire/0000-0003-1462-2428; Blake, Judith/0000-0001-8522-334X; Kerlavage, Anthony/0000-0002-3954-9653	NIGMS NIH HHS [GM00783] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BELAY N, 1984, NATURE, V312, P286, DOI 10.1038/312286a0; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BLAAT M, 1994, A LEEWENHOEK, V66, P187; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEPOUPLANA R, 1996, P NATL ACAD SCI USA, V93, P166; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; FAGUY DM, 1994, CAN J MICROBIOL, V40, P67, DOI 10.1139/m94-011; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOX GE, 1977, P NATL ACAD SCI USA, V74, P4537, DOI 10.1073/pnas.74.10.4537; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAMILTON PT, 1985, MOL GEN GENET, V200, P47, DOI 10.1007/BF00383311; HARTMANN E, 1989, ARCH MICROBIOL, V151, P274, DOI 10.1007/BF00413142; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HIRATA R, 1990, J BIOL CHEM, V265, P6726; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KAINE BP, 1989, J BACTERIOL, V171, P4261, DOI 10.1128/JB.171.8.4261-4266.1989; KALMOKOFF ML, 1992, ARCH MICROBIOL, V157, P481; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KEELING P, IN PRESS SYST APPL M; KLENK HP, 1994, CURR BIOL, V4, P920, DOI 10.1016/S0960-9822(00)00206-2; KOPKE AKE, 1989, CAN J MICROBIOL, V35, P11; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LANZENDORFER M, 1994, SYST APPL MICROBIOL, V16, P656; LECHNER K, 1989, J MOL EVOL, V29, P20, DOI 10.1007/BF02106178; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LUTKENHAUS J, 1993, CURR OPIN GENET DEV, V3, P783, DOI 10.1016/S0959-437X(05)80099-1; MARTIN N, 1976, J MOL BIOL, V101, P285, DOI 10.1016/0022-2836(76)90148-0; MARTIN NC, 1977, BIOCHEMISTRY-US, V16, P4672, DOI 10.1021/bi00640a022; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MOJICA FJM, 1995, MOL MICROBIOL, V17, P85, DOI 10.1111/j.1365-2958.1995.mmi_17010085.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Rothfield LI, 1996, CELL, V84, P183, DOI 10.1016/S0092-8674(00)80971-X; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; UEMORI T, 1995, J BACTERIOL, V177, P2164, DOI 10.1128/jb.177.8.2164-2177.1995; WAGNER EA, 1995, J BACTERIOL, V177, P5179; WALLACE JC, 1992, COMPUT APPL BIOSCI, V8, P249; WHITBREAD LA, 1995, GENE, V155, P113, DOI 10.1016/0378-1119(94)00925-I; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; Williams N, 1996, SCIENCE, V272, P481, DOI 10.1126/science.272.5261.481; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; WOESE CR, 1985, BACTERIA, V8; WOOD HG, 1986, TRENDS BIOCHEM SCI, V11, P14, DOI 10.1016/0968-0004(86)90223-9; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; ZHAO HX, 1988, ARCH MICROBIOL, V150, P178, DOI 10.1007/BF00425159; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1	67	2184	4090	6	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1058	1073		10.1126/science.273.5278.1058	http://dx.doi.org/10.1126/science.273.5278.1058			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688087				2022-12-28	WOS:A1996VD42800028
J	Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Willett, WC; Rosner, B; Speizer, FE; Hennekens, CH				Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Willett, WC; Rosner, B; Speizer, FE; Hennekens, CH			Postmenopausal estrogen and progestin use and the risk of cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; MYOCARDIAL-INFARCTION; CORONARY-ARTERIES; FOLLOW-UP; WOMEN; COHORT; STROKE; REPRODUCIBILITY; LIPOPROTEINS; ACCUMULATION	Background Estrogen therapy in postmenopausal women has been associated with a decreased risk of heart disease. There is little information, however, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease. Methods We examined the relation between cardiovascular disease and postmenopausal hormone therapy during up to 16 years of follow-up in 59,337 women from the Nurses' Health Study, who were 30 to 55 years of age at base line. Information on hormone use was ascertained with biennial questionnaires. From 1976 to 1992, we documented 770 cases of myocardial infarction or death from coronary disease in this group and 572 strokes. Proportional-hazards models were used to calculate relative risks and 95 percent confidence intervals, adjusted for confounding variables. Results We observed a marked decrease in the risk of major coronary heart disease among women who took estrogen with progestin, as compared with the risk among women who did not use hormones (multivariate adjusted relative risk, 0.39; 95 percent confidence interval, 0.19 to 0.78) or estrogen alone (relative risk, 0.60; 95 percent confidence interval, 0.43 to 0.83). However, there was no significant association between stroke and use of combined hormones (multivariate adjusted relative risk, 1.09; 95 percent confidence interval, 0.66 to 1.80) or estrogen alone (relative risk, 1.27; 95 percent confidence interval, 0.95 to 1.69). Conclusions The addition of progestin does not appear to attenuate the cardioprotective effects of postmenopausal estrogen therapy. (C) 1996, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 30594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; COX DR, 1972, J R STAT SOC B, V34, P187; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GANGAR KF, 1991, LANCET, V338, P839; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PINES A, 1991, AM J OBSTET GYNECOL, V164, P806, DOI 10.1016/0002-9378(91)90520-2; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; Sarrel Philip M., 1994, P251; SARREL PM, 1992, AM J OBSTET GYNECOL, V167, P467, DOI 10.1016/S0002-9378(11)91431-8; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526; Walker AE, 1981, STROKE S1, V12, P13; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1971, IHD REG REP 5 WORK G; 1995, JAMA-J AM MED ASSOC, V273, P199	35	1090	1107	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					453	461		10.1056/NEJM199608153350701	http://dx.doi.org/10.1056/NEJM199608153350701			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672166				2022-12-28	WOS:A1996VB84900001
J	Iacopino, V; Heisler, M; Pishevar, S; Kirschner, RH				Iacopino, V; Heisler, M; Pishevar, S; Kirschner, RH			Physician complicity in misrepresentation and omission of evidence of torture in postdetention medical examinations in Turkey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Between June 1994 and October 1995, representatives of Physicians for Human Rights studied the problem of physician complicity in torture (ie. misrepresentation and omission of medical evidence in postdetention examinations of detainees) in Turkey, The research consisted of a survey of forensic documentation of torture, interviews with individual physicians who examine detainees, analyses of official medical reports of detainees, and interviews with survivors of torture. Results from the survey, interviews, and medical report analyses provide evidence that torture of political and criminal detainees continues to occur in Turkey and that Turkish physicians are coerced to ignore, misrepresent, and omit evidence of torture in their examinations of detainees to certify that there are no physical signs of torture.	PHYSICIANS HUMAN RIGHTS,INT FORENS PROGRAM,CHICAGO,IL; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV CALIF BERKELEY,BERKELEY,CA 94720	Harvard University; Harvard Medical School; University of California System; University of California Berkeley	Iacopino, V (corresponding author), PHYSICIANS HUMAN RIGHTS,WESTERN REG OFF,312 SUTTER ST,SUITE 606,SAN FRANCISCO,CA 94108, USA.		Heisler, Michele/B-5774-2015	Heisler, Michele/0000-0002-6889-2063				*AMN INT, 1989, TURK TORT UNF TRIALS; *AMN INT, 1994, ETH COD DECL REL HLT, P89; *AMN INT, 1994, ETH COD DECL REL HLT, P50; BASOGLU M, 1993, JAMA-J AM MED ASSOC, V270, P606, DOI 10.1001/jama.270.5.606; Basoglu M., 1992, TORTURE ITS CONSEQUE; *BRIT MED ASS, 1992, MED BETR PART DOCT H, P33; CILASUN U, 1991, J MED ETHICS, V17, P21, DOI 10.1136/jme.17.Suppl.21; ERTUGRUL K, 1984, SAGLIK MEVZUATI; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; *HUM RIGHTS F TURK, 1994, TURK HUM RIGHTS REP; *HUM RIGHTS F TURK, 1994, FIL TORT DEATHS DET; *HUM RIGHTS WATCH, 1992, BROK RPOM TORT KILL; *INT ASS STUD PAIN, 1994, CLASS CHRON PAIN DES, P1; Lifton R.J, 1988, NAZI DOCTORS MED KIL; Patton M., 2015, QUALITATIVE RES EVAL, V4th; *PHYS HUM RIGHTS, 1988, CAS CONFL MED CAR HU; *PHYS HUM RIGHTS, 1993, HUM RIGHTS HOLD REP; *PHYS HUM RIGHTS, 1996, MED SIEG FORM YUG 19; RANDALL GR, 1991, SERVING SURVIVORS TO; RASMUSSEN OV, 1990, DAN MED B, V1, P1; Reich, 1990, ORIGINS TERRORISM PS, P161; SOMNIER FE, 1986, BRIT J PSYCHIAT, V149, P323, DOI 10.1192/bjp.149.3.323; Staub E., 1990, PSYCHOL TORTURE, P49; TRAVER J, 1993, CRUEL INHUMAN TREATM, P1; *TURK MED ASS, 1995, REP HLTH SERV HLTH P, P39; U.S. Department of State, 2021, INT COUNTR STRAT; *UN DECL HUM RIGHT, 1994, 25 HUM RIGHTS DOC, P6; *WORLD MED ASS, 1994, ETH COD DECL REL HLT, P9; 1994, TORTURE, V4, P4; 1991, J MED ETHICS S, V17, P3; 1993, TORTURE, V3, P87; [No title captured]	32	29	30	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					396	402		10.1001/jama.276.5.396	http://dx.doi.org/10.1001/jama.276.5.396			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683819				2022-12-28	WOS:A1996UZ77600022
J	Jaffe, R; Zahger, D				Jaffe, R; Zahger, D			The domino principle	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERIES; ANAPHYLAXIS				Jaffe, R (corresponding author), HADASSAH UNIV HOSP,DEPT MED,CORONARY CARE UNIT,MT SCOPUS,POB 24035,IL-91240 JERUSALEM,ISRAEL.							ABELA GS, 1995, CIRCULATION, V91, P776, DOI 10.1161/01.CIR.91.3.776; ALLAN G, 1981, J PHARMACOL EXP THER, V217, P157; AUSTIN SM, 1984, AM J MED, V77, P729, DOI 10.1016/0002-9343(84)90374-7; CONSTANTINIDES P, 1995, CIRCULATION, V92, P1083, DOI 10.1161/01.CIR.92.5.1083; GINSBURG R, 1984, CIRCULATION, V69, P430, DOI 10.1161/01.CIR.69.2.430; KOVANEN PT, 1995, CIRCULATION, V92, P1084, DOI 10.1161/01.CIR.92.5.1084; SILVERMAN HJ, 1984, AM J MED, V77, P341, DOI 10.1016/0002-9343(84)90717-4; VIGORITO C, 1986, CIRCULATION, V73, P1175, DOI 10.1161/01.CIR.73.6.1175; WEBER S, 1982, LANCET, V2, P821	9	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					340	341		10.1056/NEJM199608013350509	http://dx.doi.org/10.1056/NEJM199608013350509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663857				2022-12-28	WOS:A1996UY98200009
J	Wagner, M				Wagner, M			Midwife-managed care	LANCET			English	Editorial Material							BIRTH-CENTER; OUTCOMES; RATES											BARUFFI G, 1990, J NURSE-MIDWIFERY, V35, P274, DOI 10.1016/0091-2182(90)90080-O; BUTLER J, 1993, AM J OBSTET GYNECOL, V168, P5; Enkin M., 1995, GUIDE EFFECTIVE CARE; FELDMAN E, 1987, BIRTH-ISS PERINAT C, V14, P18, DOI 10.1111/j.1523-536X.1987.tb01444.x; ROOKS JP, 1989, NEW ENGL J MED, V321, P1804, DOI 10.1056/NEJM198912283212606; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683; STEPHENSON P, 1992, INT DIFFERENCES USE; 1986, LANCET, V2, P436	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					208	208		10.1016/S0140-6736(05)65538-9	http://dx.doi.org/10.1016/S0140-6736(05)65538-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ286	8684192				2022-12-28	WOS:A1996UZ28600002
J	Mainen, ZF; Sejnowski, TJ				Mainen, ZF; Sejnowski, TJ			Influence of dendritic structure on firing pattern in model neocortical neurons	NATURE			English	Article							RAT VISUAL-CORTEX; PYRAMIDAL NEURONS; SODIUM-CHANNELS; MORPHOLOGY; CELLS; ELECTROPHYSIOLOGY; SPIKING; LAYER-5	NEOCORTICAL neurons display a wide range of dendritic morphologies, ranging from compact arborizations to highly elaborate branching patterns(1). In vitro electrical recordings from these neurons have revealed a correspondingly diverse range of intrinsic firing patterns, including non-adapting, adapting and bursting types(2,3). This heterogeneity of electrical responsivity has generally been attributed to variability in the types and densities of ionic channels. We show here, using compartmental models of reconstructed cortical neurons, that an entire spectrum of firing patterns can be reproduced in a set of neurons that share a common distribution of ion channels and differ only in their dendritic geometry. The essential behaviour of the model depends on partial electrical coupling of fast active conductances localized to the soma and axon and slow active currents located throughout the dendrites, and can be reproduced in a two-compartment model. The results suggest a causal relationship for the observed correlations between dendritic structure and firing properties(3-7) and emphasize the importance of active dendritic conductances in neuronal function(8-10).	SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, COMPUTAT NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego			Sejnowski, Terrence/AAV-5558-2021	Mainen, Zachary/0000-0001-7913-9109				AGMON A, 1992, J NEUROSCI, V12, P319; ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; CHAGNACAMITAL Y, 1990, J COMP NEUROL, V296, P598, DOI 10.1002/cne.902960407; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; FRANCESCHETTI S, 1995, BRAIN RES, V696, P127, DOI 10.1016/0006-8993(95)00807-3; GRANIT R, 1963, J PHYSL, V168, P100; GUTFREUND Y, 1995, J PHYSIOL-LONDON, V483, P621, DOI 10.1113/jphysiol.1995.sp020611; Hamill OP, 1991, CEREB CORTEX, V1, P48, DOI 10.1093/cercor/1.1.48; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; KASPER EM, 1994, J COMP NEUROL, V339, P475, DOI 10.1002/cne.903390403; KIM HG, 1993, J NEUROSCI, V13, P5301, DOI 10.1523/JNEUROSCI.13-12-05301.1993; LARKMAN AU, 1992, J COMP NEUROL, V323, P137, DOI 10.1002/cne.903230202; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; Peters A, 1984, CEREBRAL CORTEX, V1; Pinsky P F, 1994, J Comput Neurosci, V1, P39, DOI 10.1007/BF00962717; RAPP M, IN PRESS P NATL ACAD; REUVENI I, 1993, J NEUROSCI, V13, P4609; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; SLOPER JJ, 1979, PHILOS T R SOC B, V285, P173, DOI 10.1098/rstb.1979.0004; STORM JF, 1990, PROG BRAIN RES, V83, P161; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TURNER RW, 1994, J NEUROSCI, V14, P6453; WOLLNER DA, 1986, P NATL ACAD SCI USA, V83, P8424, DOI 10.1073/pnas.83.21.8424; Yang CR, 1996, J NEUROSCI, V16, P1904; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	30	888	899	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1996	382	6589					363	366		10.1038/382363a0	http://dx.doi.org/10.1038/382363a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684467				2022-12-28	WOS:A1996UY95000055
J	Barbour, SI; Izban, KF; Reyes, CV; McKiernan, TL; Louie, EK				Barbour, SI; Izban, KF; Reyes, CV; McKiernan, TL; Louie, EK			Serpentine thrombus traversing the foramen ovale: Paradoxical embolism shown by transesophageal echocardiography	ANNALS OF INTERNAL MEDICINE			English	Article							RIGHT VENTRICULAR INFARCTION		LOYOLA UNIV, MED CTR, DIV CARDIOL, DEPT PATHOL, MAYWOOD, IL 60153 USA	Loyola University Chicago								AMSEL BJ, 1995, CHEST, V108, P1468, DOI 10.1378/chest.108.5.1468; BRODERICK TM, 1989, AM HEART J, V118, P1044, DOI 10.1016/0002-8703(89)90242-1; De Castro S, 1995, J Am Soc Echocardiogr, V8, P217; HUST MH, 1995, AM HEART J, V129, P620, DOI 10.1016/0002-8703(95)90295-3; LANGHOLZ D, 1991, J AM COLL CARDIOL, V18, P1112, DOI 10.1016/0735-1097(91)90775-5; LOUIE EK, 1993, J AM COLL CARDIOL, V21, P1231, DOI 10.1016/0735-1097(93)90251-U; LOUIE EK, 1995, CIRCULATION, V92, P819, DOI 10.1161/01.CIR.92.4.819; LOUIE EK, 1994, SYSTEMIC CARDIAC EMB, P323; MATHEW TC, 1995, AM HEART J, V129, P826, DOI 10.1016/0002-8703(95)90337-2; UPPSTROM EL, 1988, AM HEART J, V116, P1092, DOI 10.1016/0002-8703(88)90165-2	10	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					111	113		10.7326/0003-4819-125-2-199607150-00006	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678364				2022-12-28	WOS:A1996UV92100008
J	Landick, R; Roberts, JW				Landick, R; Roberts, JW			The shrewd grasp of RNA polymerase	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; ACTIVE-CENTER; BETA-SUBUNIT; TRANSCRIPT; ELONGATION; MUTATIONS; GENE		CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	Landick, R (corresponding author), UNIV WISCONSIN,DEPT BACTERIOL,1550 LINDEN DR,MADISON,WI 53706, USA.							ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, RAV S MOL C, V3, P297; CLARGET M, 1995, J MOL BIOL, V248, P768; deJong D. H., UNPUB; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOHNSON T, 1995, CELL, V77, P217; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LANDICK R, 1996, ESCHERICHIA COLI SAL, V1, P1263; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1994, P NATL ACAD SCI USA, V91, P10660, DOI 10.1073/pnas.91.22.10660; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; RICHARDSON JP, 1996, ESCHERICHIA COLI SAL, V1, P822; Roberts Jeffrey W., 1996, P27; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	36	8	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					202	203		10.1126/science.273.5272.202	http://dx.doi.org/10.1126/science.273.5272.202			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8668996				2022-12-28	WOS:A1996UW78700030
J	Sisk, JE; Gorman, SA; Reisinger, AL; Glied, SA; DuMouchel, WH; Hynes, MM				Sisk, JE; Gorman, SA; Reisinger, AL; Glied, SA; DuMouchel, WH; Hynes, MM			Evaluation of Medicaid managed care - Satisfaction, access, and use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH	Objective.-To evaluate the effects of managed care on Medicaid beneficiaries' satisfaction with, access to, and use of medical care during early implementation of an enrollment initiative. Design.-Cross-sectional survey of a random sample of Medicaid beneficiaries in 5 managed care plans and in the conventional Medicaid program. Setting.-New York, NY. Participants.-Adults aged 18 to 64 years who received Medicaid insurance benefits through Aid to Families With Dependent Children or State Home Relief and had been enrolled in a managed care plan or receiving benefits under conventional Medicaid for at least 6 months. Of the 2500 enrollees in managed care plans and the 600 other beneficiaries in conventional Medicaid whom we surveyed, 1038 enrollees and 410 nonenrollees responded. Outcome Measures.-Beneficiaries' ratings of overall satisfaction and 13 dimensions of satisfaction related to access, interpersonal and technical quality, and cost; reports of access, including regular source (location) of care, waiting time for appointment, waiting time in office, and ability to obtain care; and reports of use, including inpatient, emergency department, and ambulatory visits. Results.-Compared with beneficiaries in conventional Medicaid, managed care enrollees in general gave higher ratings of satisfaction. The results were not consistent, however, between the proportion who were extremely satisfied and the proportion who were extremely dissatisfied. Managed care enrollees had significantly greater odds of being extremely satisfied (excellent and very good ratings), but fewer differences were statistically significant for levels of extreme dissatisfaction (fair and poor ratings). With regard to access, managed care enrollees had significantly greater odds of having a usual source of care (odds ratio [OR], 2.33) and seeing the same clinician there (OR, 2.72) and had significantly shorter appointment and office waiting times. Managed care and conventional Medicaid beneficiaries reported no significant differences in obtaining or delays in getting needed care and in inpatient or emergency department use. Conclusions.-Medicaid managed care enrollees in New York City reported better access to care and higher levels of satisfaction compared with conventional Medicaid beneficiaries. Differences between these findings and those for privately insured populations highlight the pitfalls of generalizing from other groups to Medicaid for policy purposes. Given growing reliance on consumer satisfaction surveys for clinical and public policy, future research should focus on factors that explain extreme satisfaction vs extreme dissatisfaction. New York State's initiative, which has been associated with careful state and local monitoring, merits continuing evaluation as managed care enrollment grows and may become mandatory.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, PISCATAWAY, NJ 08854 USA; COLUMBIA UNIV, DEPT ECON, NEW YORK, NY 10027 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University	Sisk, JE (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, NEW YORK, NY 10027 USA.							BEAULIEU J, 1991, EVALUATION KENPAC 3; Davies AR, 1991, GHAAS CONSUMER SATIS; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; DUMOUCHEL WH, 1983, J AM STAT ASSOC, V78, P535, DOI 10.2307/2288115; Freund D A, 1989, Health Care Financ Rev, V11, P81; GOLD M, 1994, PLAN BASED SURVEYS S, P1; IDLER EL, 1991, J GERONTOL, V46, pS55; *LEW VHI INC, 1995, STAT PAY MAN CAR MED; LUFT HS, 1981, HLTH MAINTENANCE ORG; MARK T, 1995, E9502 US PROSP PAYM; *MAYORS ADV COUNC, 1993, MED MAN CAR NEW YORK; MISHRA SI, 1993, AM J PUBLIC HEALTH, V83, P94, DOI 10.2105/AJPH.83.1.94; PATAKI GE, 1995, PARTN PLAN; ROWLAND D, 1995, MEDICAID MANAGED CAR; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; TEMKINGREENER H, 1991, HEALTH SERV RES, V26, P509; *US GEN ACC OFF, 1995, MED SECT 1115 WAIV F; *US GEN ACC OFF, 1995, GEN ACC OFF PUBL; US General Accounting Office, 1993, MED STAT TURN MAN CA; *US PHYS PAYM REV, 1992, 1992 US PHYS PAYM RE; WEISS BD, 1990, MED CARE, V28, P434, DOI 10.1097/00005650-199005000-00003; 1994, NEW ENGL J MED, V330, P1426	22	156	156	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					50	55		10.1001/jama.276.1.50	http://dx.doi.org/10.1001/jama.276.1.50			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU439	8667539				2022-12-28	WOS:A1996UU43900027
J	Anderson, RM; Schwartlander, B; McCutchan, F; Hu, D				Anderson, RM; Schwartlander, B; McCutchan, F; Hu, D			Implications of genetic variability in HIV for epidemiology and public health	LANCET			English	Editorial Material									ROBERT KOCH INST,W-1000 BERLIN,GERMANY; HENRY JACKSON FDN,BETHESDA,MD; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Robert Koch Institute; Centers for Disease Control & Prevention - USA	Anderson, RM (corresponding author), UNIV OXFORD,CTR EPIDEMIOL INFECT DIS,S PARKS RD,OXFORD OX1 3PS,ENGLAND.			Anderson, Roy/0000-0002-9528-3175				KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; MYERS G, 1995, HUMAN RETROVIRUSES A; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; SHAFFER N, 1995, 3 INT C AIDS AS PAC; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; 1995, J ACQ IMMUN DEF SYND, V8, P506	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1778	1779		10.1016/S0140-6736(96)91609-8	http://dx.doi.org/10.1016/S0140-6736(96)91609-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667915				2022-12-28	WOS:A1996UU46900002
J	Dyer, AR; Elliott, P; Marmot, M; Kesteloot, H; Stamler, R; Stamler, J				Dyer, AR; Elliott, P; Marmot, M; Kesteloot, H; Stamler, R; Stamler, J			Strength and importance of the relation of dietary salt to blood pressure - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							BODY-MASS INDEX; POPULATIONS; FATNESS; SODIUM; LEVEL		UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON W2 1PG, ENGLAND; UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON W1N 8AA, ENGLAND; ST RAPHAEL UNIV HOSP, DEPT EPIDEMIOL, LOUVAIN, BELGIUM	Imperial College London; University of London; University College London; UCL Medical School	Dyer, AR (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL 60611 USA.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		BIRMINGHAM B, 1993, J CLIN EPIDEMIOL, V46, P289, DOI 10.1016/0895-4356(93)90077-E; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; DYER AR, 1994, AM J EPIDEMIOL, V139, P927, DOI 10.1093/oxfordjournals.aje.a117099; DYER AR, 1994, HYPERTENSION, V23, P729, DOI 10.1161/01.HYP.23.6.729; DYER AR, 1994, AM J EPIDEMIOL, V139, P940, DOI 10.1093/oxfordjournals.aje.a117100; ELLIOTT P, 1988, BRIT MED J, V297, P319; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P289; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; FOLSOM AR, 1994, J CLIN EPIDEMIOL, V47, P173, DOI 10.1016/0895-4356(94)90022-1; HASHIMOTO T, 1989, J HUM HYPERTENS, V3, P315; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1982, J CHRON DIS, V35, P475, DOI 10.1016/0021-9681(82)90062-5; MARKS GC, 1989, AM J EPIDEMIOL, V130, P578, DOI 10.1093/oxfordjournals.aje.a115372; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; STALLONES L, 1982, HYPERTENSION, V4, P483, DOI 10.1161/01.HYP.4.4.483; Stamler J, 1991, Ann Epidemiol, V1, P347, DOI 10.1016/1047-2797(91)90045-E; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; [No title captured]; [No title captured]	21	16	16	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1661	1664		10.1136/bmj.312.7047.1661	http://dx.doi.org/10.1136/bmj.312.7047.1661			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664726	Green Published			2022-12-28	WOS:A1996UV48900032
J	Jeremijenko, A; Kelly, H; Sibthorpe, B; Attewell, R				Jeremijenko, A; Kelly, H; Sibthorpe, B; Attewell, R			Improving vaccine storage in general practice refrigerators	BRITISH MEDICAL JOURNAL			English	Article							COLD CHAIN		AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT 0200,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT GEN PRACTICE,CLAREMONT,WA 6010,AUSTRALIA; PUBL HLTH UNIT,ALBANY,WA 6330,AUSTRALIA	Australian National University; University of Western Australia				Jeremijenko, Andrew Martin/0000-0002-0375-2713				BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; GALAZKA A, 1989, WHO EXPANDED PROGRAM; HAWORTH EA, 1993, BRIT MED J, V307, P242, DOI 10.1136/bmj.307.6898.242; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756	4	30	32	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1651	1652		10.1136/bmj.312.7047.1651	http://dx.doi.org/10.1136/bmj.312.7047.1651			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664720	Green Published			2022-12-28	WOS:A1996UV48900026
J	Sakai, J; Duncan, EA; Rawson, RB; Hua, XX; Brown, RS; Goldstein, JL				Sakai, J; Duncan, EA; Rawson, RB; Hua, XX; Brown, RS; Goldstein, JL			Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MUTANT HAMSTER-CELLS; TRANSCRIPTION; REDUCTASE; BINDING; GENES	Sterol regulatory element binding proteins (SREBPs) are transcription factors attached to the endoplasmic reticulum. The NH2-segment, which activates transcription, is connected to membranes by a hairpin anchor formed by two transmembrane sequences and a short lumenal loop. Using H-Ras-SREBP-2 fusion proteins, we show that the NH2-segment is released from membranes by two sequential cleavages. The first, regulated by sterols, occurs in the lumenal loop. The second, not regulated by sterols, occurs within the first transmembrane domain. The liberated NH2-segment enters the nucleus and activates genes controlling cholesterol synthesis and uptake. Certain mutant Chinese hamster ovary cells are auxotrophic for cholesterol because they fail to carry out the second cleavage; the NH2-segment remains membrane-bound and transcription is not activated.			Sakai, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Sakai, Juro/0000-0003-4043-1035	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bollag D.M., 1991, PROTEIN METHODS; CHIN J, 1981, J BIOL CHEM, V256, P6304; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HUA X, 1996, IN PRESS J BIOL CHEM; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; PAI JT, 1996, IN PRESS P NATL ACAD; SATO R, 1994, J BIOL CHEM, V269, P17267; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; WANG X, 1996, J BIOL CHEM, V270, P18044; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	27	426	440	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1037	1046		10.1016/S0092-8674(00)81304-5	http://dx.doi.org/10.1016/S0092-8674(00)81304-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674110	Bronze			2022-12-28	WOS:A1996UV48400010
J	Rieseberg, LH; Sinervo, B; Linder, CR; Ungerer, MC; Arias, DM				Rieseberg, LH; Sinervo, B; Linder, CR; Ungerer, MC; Arias, DM			Role of gene interactions in hybrid speciation: Evidence from ancient and experimental hybrids	SCIENCE			English	Article							HELIANTHUS ASTERACEAE	The origin of a new diploid species by means of hybridization requires the successful merger of differentiated parental species' genomes. To study this process, the genomic composition of three experimentally synthesized hybrid lineages was compared with that of an ancient hybrid species. The genomic composition of the synthesized and ancient hybrids was concordant (r(s) = 0.68, P < 0.0001), indicating that selection to a large extent governs hybrid species formation. Further, nonrandom rates of introgression and significant associations among unlinked markers in each of the three synthesized hybrid lineages imply that interactions between coadapted parental species' genes constrain the genomic composition of hybrid species.	UNIV AUTONOMA ESTADO MORELOS,CTR INVEST AMBIENTAL & INVEST SIERRA HUAUTLA,CUERNAVACA 62210,MORELOS,MEXICO	Universidad Autonoma del Estado de Morelos	Rieseberg, LH (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.		Rieseberg, Loren H/B-3591-2013	Rieseberg, Loren H/0000-0002-2712-2417				ARNOLD ML, 1995, TRENDS ECOL EVOL, V10, P67, DOI 10.1016/S0169-5347(00)88979-X; BARTON NH, 1981, HEREDITY, V47, P367, DOI 10.1038/hdy.1981.98; CARSON HL, 1975, AM NAT, V109, P83, DOI 10.1086/282975; GRANT V, 1966, GENETICS, V54, P1189; Harrison R.G., 1990, Oxford Surveys in Evolutionary Biology, V7, P69; HEISER C B JR, 1969, Memoirs of the Torrey Botanical Club, V22, P1; HEISER CB, 1947, EVOLUTION, V1, P249, DOI 10.2307/2405326; HEISER CB, 1958, RHODORA, V60, P271; Mayr E., 1963, ANIMAL SPECIES EVOLU; MCCARTHY EM, 1995, HEREDITY, V74, P502, DOI 10.1038/hdy.1995.71; NABHAN GP, 1983, SOUTHWEST NAT, V28, P231, DOI 10.2307/3671392; Palopoli M.F., 1994, ANNU REV GENET, V27, P283, DOI 10.1146/annurev.ge.28.120194.001435; RIESEBERG LH, 1995, AM J BOT, V82, P515, DOI 10.2307/2445699; RIESEBERG LH, 1995, GENETICS, V141, P1163; RIESEBERG LH, 1993, HEREDITY, V70, P285, DOI 10.1038/hdy.1993.41; RIESEBERG LH, 1995, NATURE, V375, P313, DOI 10.1038/375313a0; RIESEBERG LH, 1991, AM J BOT, V78, P1218, DOI 10.2307/2444926; RIESEBERG LH, 1995, AM J BOT, V82, P944, DOI 10.2307/2445981; RIESEBERG LH, 1991, SYST BOT, V16, P50, DOI 10.2307/2418973; TEMPLETON AR, 1980, GENETICS, V94, P1011; YOUNG ND, 1989, THEOR APPL GENET, V77, P95, DOI 10.1007/BF00292322	21	346	365	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					741	745		10.1126/science.272.5262.741	http://dx.doi.org/10.1126/science.272.5262.741			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662570				2022-12-28	WOS:A1996UJ05100057
J	Kraus, N; McGee, TJ; Carrell, TD; Zecker, SG; Nicol, TG; Koch, DB				Kraus, N; McGee, TJ; Carrell, TD; Zecker, SG; Nicol, TG; Koch, DB			Auditory neurophysiologic responses and discrimination deficits in children with learning problems	SCIENCE			English	Article							MISMATCH NEGATIVITY; SPEECH-PERCEPTION; ACOUSTIC CHANGE; WORD DEAFNESS; REPRESENTATION; STIMULUS; MODEL; BRAIN; DISABILITIES; PERFORMANCE	Children with learning problems often cannot discriminate rapid acoustic changes that occur in speech. In this study of normal children and children with learning problems, impaired behavioral discrimination of a rapid speech change (/da/versus/ga/) was correlated with diminished magnitude of an electrophysiologic measure that is not dependent on attention or a voluntary response. The ability of children with learning problems to discriminate another rapid speech change (/ba/versus/wa/) also was reflected in the neurophysiology, These results indicate that some children's discrimination deficits originate in the auditory pathway before conscious perception and have implications for differential diagnosis and targeted therapeutic strategies for children with learning disabilities and attention disorders.	NORTHWESTERN UNIV,DEPT OTOLARYNGOL,EVANSTON,IL 60208; UNIV NEBRASKA,LINCOLN,NE 68583	Northwestern University; University of Nebraska System; University of Nebraska Lincoln	Kraus, N (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 SHERIDAN RD,EVANSTON,IL 60208, USA.				NIDCD NIH HHS [DC 01510] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001510] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALHO K, 1990, ELECTROEN CLIN NEURO, V77, P151, DOI 10.1016/0168-5597(90)90031-8; AUERBACH SH, 1982, BRAIN, V105, P271, DOI 10.1093/brain/105.2.271; BALL EW, 1991, READ RES QUART, V26, P49, DOI 10.1598/RRQ.26.1.3; Barkley R. A., 1998, ATTENTION DEFICIT HY, V2nd; BRADLEY L, 1983, NATURE, V301, P419, DOI 10.1038/301419a0; CHEOURLUHTANEN M, 1995, HEARING RES, V82, P53, DOI 10.1016/0378-5955(94)00164-L; CSEPE V, 1987, ELECTROEN CLIN NEURO, V66, P571, DOI 10.1016/0013-4694(87)90103-9; CSEPE V, 1995, EAR HEARING, V16, P90; DEPAUL G, 1990, ADHD RATING SCALE NO; ELLIOTT LL, 1988, J SPEECH HEAR DISORD, V53, P467, DOI 10.1044/jshd.5304.467; FLETCHER JM, 1995, PSYCHON B REV, V2, P508; GIARD MH, 1995, J COGNITIVE NEUROSCI, V7, P133, DOI 10.1162/jocn.1995.7.2.133; GODFREY JJ, 1981, J EXP CHILD PSYCHOL, V32, P401, DOI 10.1016/0022-0965(81)90105-3; GREEN DM, 1974, SIGNAL DETECTION THE; JAVITT DC, 1992, ELECTROEN CLIN NEURO, V83, P87, DOI 10.1016/0013-4694(92)90137-7; KING C, 1995, HEARING RES, V85, P45, DOI 10.1016/0378-5955(95)00028-3; KLATT DH, 1980, J ACOUST SOC AM, V67, P971, DOI 10.1121/1.383940; KRAUS N, 1993, ELECTROEN CLIN NEURO, V88, P123, DOI 10.1016/0168-5597(93)90063-U; KRAUS N, 1994, J ACOUST SOC AM, V96, P2758, DOI 10.1121/1.411282; KRAUS N, 1994, J NEUROPHYSIOL, V72, P1270, DOI 10.1152/jn.1994.72.3.1270; KRAUS N, 1995, J COGNITIVE NEUROSCI, V7, P27; KRAUS N, 1995, EAR HEAR, V16; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; McGee T, 1996, J ACOUST SOC AM, V99, P3606, DOI 10.1121/1.414958; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1993, NEUROREPORT, V4, P503; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R., 1992, ATTENTION BRAIN FUNC, P136, DOI DOI 10.1037/E516062012-002; PAAVILAINEN P, 1991, ELECTROEN CLIN NEURO, V78, P466, DOI 10.1016/0013-4694(91)90064-B; PHILLIPS DP, 1990, BEHAV BRAIN RES, V40, P85, DOI 10.1016/0166-4328(90)90001-U; PISONI DB, 1982, J EXP PSYCHOL HUMAN, V8, P297, DOI 10.1037/0096-1523.8.2.297; REED MA, 1989, J EXP CHILD PSYCHOL, V48, P270, DOI 10.1016/0022-0965(89)90006-4; SCHERG M, 1990, PSYCHOPHYSIOLOGICAL, V1, P94; SHARE DL, 1984, J EDUC PSYCHOL, V76, P1309, DOI 10.1037/0022-0663.76.6.1309; STANOVICH KE, 1994, J EDUC PSYCHOL, V86, P24, DOI 10.1037/0022-0663.86.1.24; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TALLAL P, 1981, INT J PEDIATR OTORHI, V3, P1, DOI 10.1016/0165-5876(81)90014-8; TAYLOR MM, 1967, J ACOUST SOC AM, V41, P782, DOI 10.1121/1.1910407; TEES RC, 1987, CAN J PSYCHOL, V41, pB4; TREMBLAY K, 1995, ASS RES OT ABSTR, V18, P183; WEIRDT W, 1988, APPL PSYCHOPHYS, V9, P163; Wilkinson GS., 2006, WRAT 4 WIDE RANGE AC; WONG BYL, 1991, LEARNING LEARNING DI; Woodcock R.W., 1977, WOODCOCK JOHNSON PSY; Woodcock R.W., 1989, WOODCOCK JOHNSON PSY	46	383	393	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					971	973		10.1126/science.273.5277.971	http://dx.doi.org/10.1126/science.273.5277.971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688085				2022-12-28	WOS:A1996VC67000068
J	vanderBom, JG; Bots, ML; Haverkate, F; Slagboom, PE; Meijer, P; deJong, PTVM; Hofman, A; Grobbee, DE; Kluft, C				vanderBom, JG; Bots, ML; Haverkate, F; Slagboom, PE; Meijer, P; deJong, PTVM; Hofman, A; Grobbee, DE; Kluft, C			Reduced response to activated protein C is associated with increased risk for cerebrovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; protein C; blood coagulation disorders; factor V; thrombophlebitis	COAGULATION-FACTOR-V; POOR ANTICOAGULANT RESPONSE; TRANSIENT ISCHEMIC ATTACKS; VENOUS THROMBOSIS; MYOCARDIAL-INFARCTION; RESISTANCE; MUTATION; STROKE; ROTTERDAM; LEIDEN	Background: Resistance to activated protein C (APC), which results from various factors, including a mutation in the gene for coagulant factor V, has been associated with increased risk for venous thrombosis. However, its relation to arterial disease is sti II not well defined. Objective: To investigate the association of both response to APC and the factor V Leiden mutation with arterial disease. Design: Population-based case-control study. Setting: A district of Rotterdam, the Netherlands. Participants: 115 patients with a history of myocardial infarction; 112 patients with a history of stroke, transient ischemic attack, or both; and 222 age-matched controls without arterial disease chosen from among 7983 persons in the Rotterdam Study cohort. Patients using anticoagulant drugs were excluded. Measurements: Response to APC was determined in double-centrifuged platelet-poor plasma. Patients were genotyped for the Arg 506 to Gln mutation in the gene for coagulant factor V. Results: The prevalence of cerebrovascular disease increased gradually and corresponded to a decreasing response to APC (odds ratio per 1-unit decrease of response to APC 1.43 [95% CI, 1.12 to 1.81], adjusted for age and sex). Adjustment for the factor V mutation did not change the findings. We found no association between response to APC and myocardial infarction or between factor V mutation and cerebrovascular disease or myocardial infarction. Conclusions: Low response to APC is associated with an increased risk for cerebrovascular disease but not with an increased risk for myocardial infarction, independent of the factor V Leiden mutation. The association between the factor V Leiden mutation and cerebrovascular disease or myocardial infarction remains to be determined.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS; NETHERLANDS OPHTHALM RES INST, NL-1100 AC AMSTERDAM, NETHERLANDS; TNO, GAUBIUS INST CARDIOVASC RES, LEIDEN, NETHERLANDS	Erasmus University Rotterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Netherlands Organization Applied Science Research			Grobbee, Diederick/C-7651-2014; Slagboom, P. Eline/R-4790-2016; van der Bom, Johanna G./G-1965-2018	Grobbee, Diederick/0000-0003-4472-4468; Slagboom, P. Eline/0000-0002-2875-4723; van der Bom, Johanna G./0000-0001-9095-2475				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; CATTO A, 1995, ARTERIOSCL THROM VAS, V15, P783, DOI 10.1161/01.ATV.15.6.783; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FON EA, 1994, STROKE, V25, P282, DOI 10.1161/01.STR.25.2.282; FUJIMURA H, 1995, THROMB HAEMOSTASIS, V74, P1381; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HORVAT R, 1993, EUR J CELL BIOL, V61, P299; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KONTULA K, 1995, THROMB HAEMOSTASIS, V73, P558; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOUDSTAAL PJ, 1994, CEREBROVASC DIS, V4, P40, DOI 10.1159/000108560; MARZ W, 1995, LANCET, V345, P526, DOI 10.1016/S0140-6736(95)90626-6; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P231; Qizilbash N, 1995, LANCET, V346, P1647; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SAMANI NJ, 1994, LANCET, V344, P1709, DOI 10.1016/S0140-6736(94)90495-2; SIDELMANN J, 1995, THROMB HAEMOSTASIS, V74, P993; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346; VANDERBOM JG, 1994, FIBRINOLYSIS, V8, P157, DOI 10.1016/0268-9499(94)90283-6; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503	28	114	115	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					265	+		10.7326/0003-4819-125-4-199608150-00002	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678388				2022-12-28	WOS:A1996VB68000005
J	Walsh, TN; Noonan, N; Hollywood, D; Kelly, A; Keeling, N; Hennessy, TPJ				Walsh, TN; Noonan, N; Hollywood, D; Kelly, A; Keeling, N; Hennessy, TPJ			A comparison of multimodal therapy and surgery for esophageal adenocarcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL JUNCTION; PREOPERATIVE CHEMOTHERAPY; RADIATION-THERAPY; RESECTABLE ADENOCARCINOMA; NEOADJUVANT THERAPY; AUTOPSY FINDINGS; GASTRIC CARDIA; RESECTION; SURVIVAL	Background Uncontrolled studies suggest that a combination of chemotherapy and radiotherapy improves the survival of patients with esophageal adenocarcinoma. We conducted a prospective, randomized trial comparing surgery alone with combined chemotherapy, radiotherapy, and surgery. Methods Patients assigned to multimodal therapy received two courses of chemotherapy in weeks 1 and 6 (fluorouracil, 15 mg per kilogram of body weight daily for five days, and cisplatin, 75 mg per square meter of body-surface area on day 7) and a course of radiotherapy (40 Gy, administered in 15 fractions over a three-week period, beginning concurrently with the first course of chemotherapy), followed by surgery. The patients assigned to surgery had no preoperative therapy. Results Of the 58 patients assigned to multimodal therapy and the 55 assigned to surgery, 10 and 1, respectively, were withdrawn for protocol violations. At the time of surgery, 23 of 55 patients (42 percent) treated with preoperative multimodal therapy who could be evaluated had positive nodes or metastases, as compared with 45 of the 55 patients (82 percent) who underwent surgery alone (P<0.001). Thirteen of the 52 patients (25 percent) who underwent surgery after multimodal therapy had complete responses, as determined pathologically. The median survival of patients assigned to multimodal therapy was 16 months, as compared with 11 months for those assigned to surgery alone (P=0.01). At one, two, and three years, 52, 37, and 32 percent, respectively, of patients assigned to multimodal therapy were alive, as compared with 44, 26, and 6 percent of those assigned to surgery, with the survival advantage favoring multimodal therapy reaching significance at three years (P=0.01). Conclusions Multimodal treatment is superior to surgery alone for patients with resectable adenocarcinoma of the esophagus. (C) 1996, Massachusetts Medical Society.	ST JAMES HOSP,DEPT SURG,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; ST LUKES HOSP,DEPT RADIOTHERAPY,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT COMMUNITY HLTH,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT STAT,DUBLIN,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Walsh, Thomas N/E-9349-2013					ADELSTEIN DJ, 1994, AM J CLIN ONCOL-CANC, V17, P14, DOI 10.1097/00000421-199402000-00004; AJANI JA, 1993, J CLIN ONCOL, V11, P22, DOI 10.1200/JCO.1993.11.1.22; AJANI JA, 1990, J CLIN ONCOL, V8, P1231, DOI 10.1200/JCO.1990.8.7.1231; ANDERSON LL, 1982, CANCER, V50, P1587, DOI 10.1002/1097-0142(19821015)50:8<1587::AID-CNCR2820500820>3.0.CO;2-S; BEAHRS OH, 1988, MANUAL STAGING CANC, P63; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BOSCH A, 1979, ACTA RADIOL ONCOL, V18, P103, DOI 10.3109/02841867909128196; CAREY RW, 1991, CANCER, V68, P489, DOI 10.1002/1097-0142(19910801)68:3<489::AID-CNCR2820680307>3.0.CO;2-M; COIA LR, 1988, CANCER, V61, P643, DOI 10.1002/1097-0142(19880215)61:4<643::AID-CNCR2820610404>3.0.CO;2-4; DUHAYLONGSOD FG, 1995, ANN SURG, V221, P677, DOI 10.1097/00000658-199506000-00007; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GILL PG, 1990, BRIT J SURG, V77, P1020, DOI 10.1002/bjs.1800770922; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; HESKETH PJ, 1989, CANCER, V64, P526, DOI 10.1002/1097-0142(19890715)64:2<526::AID-CNCR2820640228>3.0.CO;2-B; HICKEY K, 1994, CANCER, V74, P1693, DOI 10.1002/1097-0142(19940915)74:6<1693::AID-CNCR2820740609>3.0.CO;2-#; HOFF SJ, 1993, ANN THORAC SURG, V56, P282, DOI 10.1016/0003-4975(93)91161-F; HUSEMANN B, 1989, BRIT J SURG, V76, P136, DOI 10.1002/bjs.1800760210; LEICHMAN L, 1984, J CLIN ONCOL, V2, P75, DOI 10.1200/JCO.1984.2.2.75; LUND O, 1989, BRIT J SURG, V76, P1301, DOI 10.1002/bjs.1800761227; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; PAPACHRISTOU DN, 1980, ANN SURG, V192, P58, DOI 10.1097/00000658-198007000-00010; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; ROSCH T, 1992, GASTROENTEROLOGIC EN, P45; STEWART JR, 1993, ANN SURG, V218, P571, DOI 10.1097/00000658-199310000-00017; URBA S, 1995, P AN M AM SOC CLIN, V14, P199; URBA SG, 1992, CANCER, V69, P285, DOI 10.1002/1097-0142(19920115)69:2<285::AID-CNCR2820690203>3.0.CO;2-E; WHITTINGTON R, 1990, INT J RADIAT ONCOL, V19, P593, DOI 10.1016/0360-3016(90)90485-3; WOLFE WG, 1993, J THORAC CARDIOV SUR, V105, P749	28	1553	1599	3	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					462	467		10.1056/NEJM199608153350702	http://dx.doi.org/10.1056/NEJM199608153350702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672151	Green Published			2022-12-28	WOS:A1996VB84900002
J	Schacht, S; Huo, Q; VoigtMartin, IG; Stucky, GD; Schuth, F				Schacht, S; Huo, Q; VoigtMartin, IG; Stucky, GD; Schuth, F			Oil-water interface templating of mesoporous macroscale structures	SCIENCE			English	Article							SURFACTANT	Ordered mesostructured porous silicas that are also macroscopically structured were created by control of the interface on two different length scales simultaneously. Micellar arrays controlled the nanometer-scale assembly, and at the static boundary between an aqueous phase and an organic phase, control was achieved on the micrometer to centimeter scale. Acid-prepared mesostructures of silica were made with the p6, Pm3n, and the P6(3)/mmc structures in the form of porous fibers 50 to 1000 micrometers in length, hollow spheres with diameters of 1 to 100 micrometers, and thin sheets up to 10 centimeters in diameter and about 10 to 500 micrometers in thickness, These results might have implications for technical applications, such as slow drug-release systems or membranes, and in biomineralization, where many processes are also interface-controlled.	UNIV FRANKFURT,INST ANORGAN CHEM,D-60439 FRANKFURT,GERMANY; UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106; UNIV MAINZ,INST PHYS CHEM,D-55099 MAINZ,GERMANY	Goethe University Frankfurt; University of California System; University of California Santa Barbara; Johannes Gutenberg University of Mainz								ANTONELLI DM, 1995, ANGEW CHEM INT EDIT, V34, P2014, DOI 10.1002/anie.199520141; ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BRINKER CJ, 1985, J NON-CRYST SOLIDS, V70, P301, DOI 10.1016/0022-3093(85)90103-6; CIESLA U, 1994, J CHEM SOC CHEM COMM, P1387, DOI 10.1039/c39940001387; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; HUO Q, 1996, M MAT RES SOC SAN FR; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1995, SCIENCE, V268, P1324, DOI 10.1126/science.268.5215.1324; HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016; Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h; ISRAELACHVILI J, 1994, COLLOID SURFACE A, V91, P1, DOI 10.1016/0927-7757(94)02743-9; KARGER J, COMMUNICATION; KARGER J, UNPUB; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; OZIN G, 1996, NATO C SUPR CHEM MON; SCHACHT S, 1995, THESIS U MAINZ; WALSH D, 1994, SCIENCE, V264, P1576, DOI 10.1126/science.264.5165.1576; Yang H, 1996, NATURE, V379, P703, DOI 10.1038/379703a0; Zaremba CM, 1996, CHEM MATER, V8, P679, DOI 10.1021/cm9503285	22	748	787	6	305	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					768	771		10.1126/science.273.5276.768	http://dx.doi.org/10.1126/science.273.5276.768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670410				2022-12-28	WOS:A1996VB42900033
J	Ronemus, MJ; Galbiati, M; Ticknor, C; Chen, JC; Dellaporta, SL				Ronemus, MJ; Galbiati, M; Ticknor, C; Chen, JC; Dellaporta, SL			Demethylation-induced developmental pleiotropy in Arabidopsis	SCIENCE			English	Article							DNA METHYLTRANSFERASE; GENE; THALIANA; METHYLATION; SEQUENCE; MUTANT; PLANTS; INACTIVATION; DOMAIN; MAIZE	The function of DNA methylation in higher plants was investigated by expression of a complementary DNA encoding a cytosine methyltransferase (MET1) from Arabidopsis thaliana as an antisense RNA in transgenic plants. This expression resulted in a 34 to 71 percent reduction in total genomic cytosine methylation. Loss of methylation was observed in both repetitive DNA and single-copy gene sequences. Developmental effects included altered heterochrony, changes in meristem identity and organ number, and female sterility. Cytosine demethylation prolonged both vegetative and reproductive phases of development. These findings implicate DNA methylation in establishing or maintaining epigenetic developmental states in the meristem.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Yale University			Galbiati, Massimo/AAV-7051-2020	Galbiati, Massimo/0000-0002-9827-4506	NIGMS NIH HHS [GM38148] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038148] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENDER J, 1995, CELL, V83, P725, DOI 10.1016/0092-8674(95)90185-X; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BRUTNELL TP, 1994, GENETICS, V138, P213; BURN JE, 1993, P NATL ACAD SCI USA, V90, P287, DOI 10.1073/pnas.90.1.287; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; Chen J., 1994, MAIZE HDB, P526, DOI [10.1007/978-1-4612-2694-9_85, DOI 10.1007/978-1-4612-2694-9_85]; CHOMET PS, 1987, EMBO J, V6, P295, DOI 10.1002/j.1460-2075.1987.tb04753.x; Dellaporta Stephen L., 1994, P569; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; GEHRKE CW, 1984, J CHROMATOGR, V301, P199, DOI 10.1016/S0021-9673(01)89189-5; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIENSSEN R, 1990, GENE DEV, V4, P331, DOI 10.1101/gad.4.3.331; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; POETHIG RS, 1990, SCIENCE, V250, P923, DOI 10.1126/science.250.4983.923; RODRIGUEZRODRIG.H, UNPUB; ROSE AB, 1992, PLANT PHYSIOL, V100, P582, DOI 10.1104/pp.100.2.582; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	33	382	410	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					654	657		10.1126/science.273.5275.654	http://dx.doi.org/10.1126/science.273.5275.654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662558				2022-12-28	WOS:A1996VA24900050
J	Antonios, TFT; MacGregor, GA				Antonios, TFT; MacGregor, GA			Salt - More adverse effects	LANCET			English	Article							SODIUM-INTAKE; HYPERTENSION; MORTALITY; STROKE; BONE		ST GEORGE HOSP,SCH MED,DEPT MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London				Antonios, Tarek/0000-0002-7204-9335				BENSTEIN JA, 1990, AM J PHYSIOL, V258, pF1675, DOI 10.1152/ajprenal.1990.258.6.F1675; BRAHIMI M, 1985, 7 EUR M HYP MIL, P26; BURNEY P, 1987, CHEST, V91, pS143, DOI 10.1378/chest.91.6.143S; CAREY OJ, 1993, THORAX, V48, P714, DOI 10.1136/thx.48.7.714; *DEP HLTH, 1991, DIET REF VAL FOOD EN, P152; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; ELLIOTT P, 1996, BRIT MED J, V312, P1246; GARRAWAY WM, 1979, NEW ENGL J MED, V300, P449, DOI 10.1056/NEJM197903013000901; Hanneman RL, 1996, BRIT MED J, V312, P1283, DOI 10.1136/bmj.312.7041.1283; IZAWA Y, 1985, CALCIFIED TISSUE INT, V37, P605, DOI 10.1007/BF02554916; JAMES WPT, 1987, LANCET, V1, P426; JOOSSENS JV, 1980, EPIDEMIOLOGY ARTERIA, P489; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LIEBSON P, 1992, CIRCULATION, V86, P599; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; MACGREGOR GA, 1993, J HYPERTENS, V11, P781, DOI 10.1097/00004872-199308000-00003; MATKOVIC V, 1995, AM J CLIN NUTR, V62, P417, DOI 10.1093/ajcn/62.2.417; MCCARRON DA, 1981, AM J NEPHROL, V1, P84, DOI 10.1159/000166496; MCPARLAND BE, 1989, BMJ-BRIT MED J, V299, P834, DOI 10.1136/bmj.299.6703.834-a; PAK CYC, 1984, J UROLOGY, V131, P850, DOI 10.1016/S0022-5347(17)50678-3; PERRY IJ, 1992, J HUM HYPERTENS, V6, P23; Reid R, 1983, J Hypertens, V1, P303, DOI 10.1097/00004872-198310000-00016; Sato T., 1959, B I PUBL HLTH, V8, P187; Schmieder Roland E., 1995, P1327; SILVER J, 1983, LANCET, V2, P484; TOBIAN L, 1990, HYPERTENSION, V15, P900, DOI 10.1161/01.HYP.15.6.900; XIE JX, 1992, J HUM HYPERTENS, V6, P17	27	74	77	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					250	251		10.1016/S0140-6736(96)01463-8	http://dx.doi.org/10.1016/S0140-6736(96)01463-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684205				2022-12-28	WOS:A1996UZ28600016
J	PascualLeone, A; Rubio, B; Pallardo, F; Catala, MD				PascualLeone, A; Rubio, B; Pallardo, F; Catala, MD			Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression	LANCET			English	Article								Background Lesion and neuroimaging studies suggest that left prefrontal lobe dysfunction is pathophysiologically linked to depression. Rapid-rate transcranial magnetic stimulation (rTMS) to prefrontal lateralised effect on mood In normal several preliminary studies suggest a beneficial effect of rTMS on depression. However, adequately controlled studies have not been conducted. Methods We have studied the effects of focal rTMS on the depressive symptoms in 17 patients with medication-resistant depression of psychotic subtype. The study was designed as a multiple cross-over, randomised placebo-controlled trial. Sham rTMS and stimulation of different cortical areas were used as controls. Findings Left dorsolateral prefrontal cortex rTMS resulted in a significant decrease in scores on the Hamilton depression rating scale HDRS (from 25.2 to 13.8) and the self-rated Beck questionnaire BQ (from 47.9 to 25.7). 11 of the 17 patients showed pronounced improvement that lasted for about 2 weeks after 5 days of daily rTMS sessions. No patient experienced any significant undesirable side-effects. Interpretation Our findings emphasise the role of the left dorsolateral prefrontal cortex in depression, and suggest that rTMS of the left dorsolateral prefrontal cortex might become a safe, non-convulsive alternative to electroconvulsive treatment in depression.	CSIC,INST RAMON Y CAJAL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)	PascualLeone, A (corresponding author), UNIV VALENCIA,DEPT FISIOL,UNIDAD NEUROBIOL,AVE BLASCO IBANEZ 17,E-46010 VALENCIA,SPAIN.		Pascual-Leone, Alvaro/AAC-5101-2019; Pallardo, Federico V./T-1156-2017	Pascual-Leone, Alvaro/0000-0001-8975-0382; Pallardo, Federico V./0000-0003-3715-1980; Rubio, Belen/0000-0003-0858-1842				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; GEORGE MS, 1994, CONVULSIVE THER, V10, P251; George MS, 1994, DEPRESSION, V2, P59, DOI [DOI 10.1002/DEPR.3050020202, 10.1002/depr.3050020202]; GRISARU N, 1994, EUR NEUROPSYCHOPHARM, V4, P287; HAMILTON M, 1961, BR J SOC CLIN PSYCHO, V4, P561; HOFLICH G, 1993, HUM PSYCHOPHARM CLIN, V8, P361, DOI 10.1002/hup.470080510; KOLBINGER HM, 1995, HUM PSYCHOPHARM CLIN, V10, P305, DOI 10.1002/hup.470100408; PascualLeone A, 1996, NEUROLOGY, V46, P499, DOI 10.1212/WNL.46.2.499; PASCUALLEONE A, 1994, NEUROREPORT, V5, P2517, DOI 10.1097/00001756-199412000-00028; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; PASCUALLEONE A, IN PRESS HDB NEUROPS, V10; PAZZAGLIA PJ, 1993, PSYCHIAT RES, V49, P257, DOI 10.1016/0165-1781(93)90066-P; ROTH BJ, 1991, ELECTROEN CLIN NEURO, V81, P47, DOI 10.1016/0168-5597(91)90103-5; SACKEIM HA, 1994, CONVULSIVE THER, V10, P255; TOFTS PS, 1990, PHYS MED BIOL, V35, P1119, DOI 10.1088/0031-9155/35/8/008; Wassermann EM, 1996, NEUROIMAGE, V3, P1, DOI 10.1006/nimg.1996.0001; WILLIAMS WA, 1995, NEUROLOGY S4, V5, pA168; 1985, JAMA-J AM MED ASSOC, V254, P2103	21	883	926	3	199	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					233	237		10.1016/S0140-6736(96)01219-6	http://dx.doi.org/10.1016/S0140-6736(96)01219-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684201				2022-12-28	WOS:A1996UZ28600012
J	Shibasaki, F; Price, ER; Milan, D; McKeon, F				Shibasaki, F; Price, ER; Milan, D; McKeon, F			Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4	NATURE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CYCLOSPORINE-A; ACTIVATION; PROTEIN; DOMAIN; IDENTIFICATION; COMPLEXES; FAR1	A NEW facet of calcium signallin involves the nuclear import of the NF-AT transcription factors from their dormant position in the cytoplasm(1-3). The protein phosphatase calcineurin appears to play an essential role in activating NF-AT nuclear import, as the calcineurin inhibitors cyclosporin A and FK506 block dephosphorylation and nuclear import of NF-AT (refs 4-7). Here we show that calcium signalling induces an association between NF-AT4 and calcineurin, and that these molecules are transported, as a complex, to the nucleus, where calcineurin continues to dephosphorylate NF-AT4. We propose that a nuclear complex of NF-AT4 and calcineurin maintains calcium signalling by counteracting a vigorous nuclear NF-AT kinase.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274	26	436	451	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					370	373		10.1038/382370a0	http://dx.doi.org/10.1038/382370a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684469				2022-12-28	WOS:A1996UY95000057
J	Dudley, J; Chambers, T				Dudley, J; Chambers, T			Why the resistance to diagnostic imaging in childhood urinary tract infections	LANCET			English	Editorial Material							VESICOURETERAL REFLUX; CHILDREN				Dudley, J (corresponding author), SOUTHMEAD GEN HOSP,DEPT PAEDIAT,BRISTOL BS10 5NB,AVON,ENGLAND.							ARANT BS, 1991, AM J KIDNEY DIS, V17, P491, DOI 10.1016/S0272-6386(12)80490-2; *CAN ORG REPL REG, 1994, 1992 CAN I HLTH INF; Dick PT, 1996, J PEDIATR-US, V128, P15, DOI 10.1016/S0022-3476(96)70422-5; ESBJORNER E, 1990, PEDIATR NEPHROL, V4, P249, DOI 10.1007/BF00857667; GORDON I, 1990, PEDIATR NEPHROL, V4, P604, DOI 10.1007/BF00858633; JODAL U, 1987, PEDIATR NEPHROL, V1, P647, DOI 10.1007/BF00853603; MARRA G, 1994, ARCH DIS CHILD-FETAL, V70, pF147, DOI 10.1136/fn.70.2.F147; Matsumoto T, 1996, LANCET, V347, P757, DOI 10.1016/S0140-6736(96)90106-3; ROLLESTON GL, 1971, RENAL FUNCTION RENAL, P246; 1991, J R COLL PHYSICIANS, V25, P36	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					71	72		10.1016/S0140-6736(05)64600-4	http://dx.doi.org/10.1016/S0140-6736(05)64600-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676716				2022-12-28	WOS:A1996UW67300004
J	Cook, GC				Cook, GC			Familial Mediterranean fever: Underlying defect clearer, but diagnostic problems persist	LANCET			English	Editorial Material							GENE				Cook, GC (corresponding author), HOSP TROP DIS,LONDON NW1 0PE,ENGLAND.							BRENNERULLMAN A, 1994, AM J MED GENET, V53, P172, DOI 10.1002/ajmg.1320530210; FISCHELGHODSIAN N, 1993, AM J MED GENET, V46, P689, DOI 10.1002/ajmg.1320460619; HAVENAAR EC, 1995, CLIN IMMUNOL IMMUNOP, V76, P279, DOI 10.1006/clin.1995.1126; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; REISSMAN P, 1994, WORLD J SURG, V18, P139, DOI 10.1007/BF00348205; RIVAS AL, 1992, CLIN IMMUNOL IMMUNOP, V64, P36, DOI 10.1016/0090-1229(92)90057-U; SCHATTNER A, 1991, AM J MED, V90, P434; Schattner A, 1996, QJM-MON J ASSOC PHYS, V89, P205; SHOHAT M, 1992, AM J MED GENET, V44, P179, DOI 10.1002/ajmg.1320440212; SHOHAT M, 1992, AM J HUM GENET, V51, P1349; SUNGUR C, 1993, KIDNEY INT, V44, P834, DOI 10.1038/ki.1993.318; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1779	1780		10.1016/S0140-6736(96)91611-6	http://dx.doi.org/10.1016/S0140-6736(96)91611-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667917				2022-12-28	WOS:A1996UU46900004
J	Crooks, SW; Colman, SB; Campbell, IA				Crooks, SW; Colman, SB; Campbell, IA			Costs and getting ethical approval deter doctors from participating in multicentre trials	BRITISH MEDICAL JOURNAL			English	Letter									UNIV WALES COLL CARDIFF,COLL MED,LLANDOUGH HOSP,DEPT THERAPEUT & CLIN PHARMACOL,CARDIFF CF64 2XX,S GLAM,WALES	Cardiff University	Crooks, SW (corresponding author), QUEEN ELIZABETH HOSP,MED CTR,DEPT RESP MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; CAMPBELL IA, 1991, EUROPEAN RESP REV, V1, P426; DRURY M, 1992, BRIT MED J, V304, P1696, DOI 10.1136/bmj.304.6843.1696-b; NICHOLSON RH, 1991, BRIT MED J, V303, P995, DOI 10.1136/bmj.303.6808.995-b; SMYTH JF, 1994, BRIT MED J, V309, P457, DOI 10.1136/bmj.309.6952.457	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1669	1669		10.1136/bmj.312.7047.1669a	http://dx.doi.org/10.1136/bmj.312.7047.1669a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664734	Green Published			2022-12-28	WOS:A1996UV48900045
J	Edelmann, W; Cohen, PE; Kane, M; Lau, K; Morrow, B; Bennett, S; Umar, A; Kunkel, T; Cattoretti, G; Chaganti, R; Pollard, JW; Kolodner, RD; Kucherlapati, R				Edelmann, W; Cohen, PE; Kane, M; Lau, K; Morrow, B; Bennett, S; Umar, A; Kunkel, T; Cattoretti, G; Chaganti, R; Pollard, JW; Kolodner, RD; Kucherlapati, R			Meiotic pachytene arrest in MLH1-deficient mice	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; MISMATCH REPAIR; SYNAPTONEMAL COMPLEX; COLON-CANCER; GENES; MUTATIONS; LOCUS; IDENTIFICATION; HOMOLOG	Germ line mutations in DNA mismatch repair genes including MLH1 cause hereditary nonpolyposis colon cancer. To understand the role of MLH1 in normal growth and development, we generated mice that have a null mutation of this gene. Mice homozygous for this mutation show a replication error phenotype, and extracts of these cells are deficient in mismatch repair activity. Homozygous mutant males show normal mating behavior but have no detectable mature sperm. Examination of meiosis in these males reveals that the cells enter meiotic prophase and arrest at pachytene. Homozygous mutant females have normal estrous cycles and reproductive and mating behavior but are infertile. The phenotypes of the mlh1 mutant mice are distinct from those deficient in msh2 and pms2. The different phenotypes of the three types of mutant mice suggest that these three genes may have independent functions in mammalian meiosis.	ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,BRONX,NY 10467; DANA FARBER CANC INST,BOSTON,MA 02115; NIEHS,RES TRIANGLE PK,NC 27709; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY; MEM SLOAN KETTERING CANC CTR,DEPT GENET,NEW YORK,NY 10021	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Columbia University; Memorial Sloan Kettering Cancer Center	Edelmann, W (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY 10467, USA.		Kucherlapati, Raju/ABC-8807-2021	Morrow, Bernice/0000-0002-8076-4726; Cattoretti, Giorgio/0000-0003-3799-3221	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA067944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67944] Funding Source: Medline; NICHD NIH HHS [HD/AI 30280] Funding Source: Medline; NIGMS NIH HHS [GM 50006] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOYER JC, 1995, CANCER RES, V55, P6062; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHAGANTI RSK, 1980, AM J HUM GENET, V32, P833; COHEN PE, 1996, IN PRESS BIOL REPROD, V55; COUNCE SJ, 1973, CHROMOSOMA, V44, P231, DOI 10.1007/BF00329119; Datta A, 1996, MOL CELL BIOL, V16, P1085; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRASER LR, 1983, J REPROD FERTIL, V69, P419, DOI 10.1530/jrf.0.0690419; GOODPASTURE C, 1975, CHROMOSOMA, V53, P37, DOI 10.1007/BF00329389; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAWN MT, 1995, CANCER RES, V55, P3721; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, COLD SPRING HARB SYM, V59, P331, DOI 10.1101/SQB.1994.059.01.037; KOLODNER RD, 1995, CANCER RES, V55, P242; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PROLLA TA, 1994, THESIS YALE U NEW HA; PSYCHOYOS A, 1961, CR HEBD ACAD SCI, V252, P1515; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; WILLIAMSON MS, 1985, GENETICS, V110, P609	58	467	494	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1125	1134		10.1016/S0092-8674(00)81312-4	http://dx.doi.org/10.1016/S0092-8674(00)81312-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674118	hybrid			2022-12-28	WOS:A1996UV48400018
J	Corral, J; Lavenir, I; Impey, H; Warren, AJ; Forster, A; Larson, TA; Bell, S; McKenzie, ANJ; King, G; Rabbitts, TH				Corral, J; Lavenir, I; Impey, H; Warren, AJ; Forster, A; Larson, TA; Bell, S; McKenzie, ANJ; King, G; Rabbitts, TH			An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes	CELL			English	Article							11Q23 CHROMOSOMAL TRANSLOCATIONS; PROLINE-RICH PROTEIN; DROSOPHILA-TRITHORAX; ALL-1 GENE; STEM-CELLS; MLL GENE; BREAKPOINT; PRODUCT; INT-2	Homologous recombination in embryonal stem cells has been used to produce a fusion oncogene, thereby mimicking chromosomal translocations that frequently result in formation of tumor-specific fusion oncogenes in human malignancies. AF9 sequences were fused into the mouse MII gene so that expression of the MII-AF9 fusion gene occurred from endogenous MII transcription control elements, as in t(9;11) found in human leukemias. Chimeric mice carrying the fusion gene developed tumors, which were restricted to acute myeloid leukemias despite the widespread activity of the MII promoter. Onset of perceptible disease was preceded by expansion of ES cell derivatives in peripheral blood. This novel use of homologous recombination formally proves that chromosomal translocations contribute to malignancy and provides a general strategy to create fusion oncogenes for studying their role in tumorigenesis.			Corral, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		; Rabbitts, Terence/D-6262-2016	Corral, Javier/0000-0003-0288-1107; Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; IIDA S, 1993, ONCOGENE, V8, P3085; LOCOCO F, 1993, CANCER RES, V53, P3800; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Papaioannou V., 1993, Gene targeting: a practical approach., P107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	27	425	436	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					853	861		10.1016/S0092-8674(00)81269-6	http://dx.doi.org/10.1016/S0092-8674(00)81269-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681380	Bronze			2022-12-28	WOS:A1996UR60400009
J	Herbst, R; Carroll, PM; Allard, JD; Schilling, J; Raabe, T; Simon, MA				Herbst, R; Carroll, PM; Allard, JD; Schilling, J; Raabe, T; Simon, MA			Daughter of sevenless is a substrate of the phosphotyrosine phosphatase corkscrew and functions during sevenless signaling	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTOR; GENE-PRODUCT; PROTEIN; ACTIVATION; DROSOPHILA; PHOSPHORYLATION; RAS1; TRANSDUCTION	The SH2 domain-containing phosphotyrosine phosphatase Corkscrew (CSW) is an essential component of the signaling pathway initiated by the activation of the sevenless receptor. tyrosine kinase (SEV) during Drosophila eye development We have used genetic and biochemical approaches to identify a substrate for CSW. Expression of a catalytically inactive CSW was used to trap CSW in a complex with a 115 kDa tyrosine-phosphorylated substrate. This substrate was purified and identified as the product of the daughter of sevenless (dos) gene. Mutations of dos were identified in a screen for dominant mutations which enhance the phenotype caused by overexpression of inactive CSW during photoreceptor development. Analysis of dos mutations indicates that DOS is a positive component of the SEV signaling pathway and suggests that DOS dephosphorylation by CSW may be a key event during signaling by SEV.	SUGEN INC,REDWOOD CITY,CA 94063; UNIV WURZBURG,THEODOR BOVERI INST BIOWISSENSCH,LEHRSTUHL GENET,D-97074 WURZBURG,GERMANY	University of Wurzburg	Herbst, R (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL EYE INSTITUTE [R01EY009845] Funding Source: NIH RePORTER; NEI NIH HHS [1RO1EY9845] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLARD JD, 1996, DEVELOPMENT, V122, P1125; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HERBST R, 1995, ONCOGENE, V10, P369; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	44	194	196	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					899	909		10.1016/S0092-8674(00)81273-8	http://dx.doi.org/10.1016/S0092-8674(00)81273-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681384	Bronze			2022-12-28	WOS:A1996UR60400013
J	Brook, EJ; Sowers, T; Orchardo, J				Brook, EJ; Sowers, T; Orchardo, J			Rapid variations in atmospheric methane concentration during the past 110,000 years	SCIENCE			English	Article							CONTINUOUS POLLEN RECORD; LAST GLACIAL MAXIMUM; ICE-CORE RECORD; GREENLAND ICE; CLIMATE RECORDS; CH4 INCREASE; POLAR ICE; ACCUMULATION; PERIOD; TRENDS	A methane record from the GISP2 ice core reveals that millennial-scale variations in atmospheric methane concentration characterized much of the past 110,00 years, As previously observed in a shorter record from central Greenland, abrupt concentration shifts of about 50 to 300 parts per billion by volume were coeval with most of the interstadial warming events (better known as Dansgaard-Oeschger events) recorded in the GISP2 ice core throughout the last glacial period. The magnitude of the rapid concentration shifts varied on a longer time scale in a manner consistent with variations in Northern Hemisphere summer insolation, which suggests that insolation may have modulated the effects of interstadial climate change on the terrestrial biosphere.	PENN STATE UNIV,DEPT GEOSCI,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Brook, EJ (corresponding author), UNIV RHODE ISL,GRAD SCH OCEANOG,NARRAGANSETT,RI 02882, USA.		Brook, Edward/AAB-7807-2021					ADAM DP, 1981, GEOLOGY, V9, P373, DOI 10.1130/0091-7613(1981)9<373:YCPRFC>2.0.CO;2; ALLEY RB, 1995, NATURE, V373, P393, DOI 10.1038/373393b0; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; BARTLETT K, 1993, CHEMOSPHERE, V26, P26; BENDER M, 1993, EOS, V74, P78; BENDER M, 1995, NATURE, V373, P663; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BLUNIER T, 1993, GEOPHYS RES LETT, V20, P2219, DOI 10.1029/93GL02414; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; BOND G, 1992, NATURE, V360, P245, DOI 10.1038/360245a0; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BROOK E, 1994, EOS, V74, P381; CHAPPELIAZ J, UNPUB; CHAPPELLAZ J, 1990, NATURE, V345, P127, DOI 10.1038/345127a0; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CHAPPELLAZ JA, 1993, TELLUS B, V45, P228, DOI 10.1034/j.1600-0889.1993.t01-2-00002.x; CRAIG H, 1982, GEOPHYS RES LETT, V9, P1221, DOI 10.1029/GL009i011p01221; CROWLEY TJ, 1991, NATURE, V353, P122, DOI 10.1038/353122b0; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; EHHALT DH, 1974, TELLUS, V26, P58, DOI 10.1111/j.2153-3490.1974.tb01952.x; ETHERIDGE DM, 1992, TELLUS B, V44, P282, DOI 10.1034/j.1600-0889.1992.t01-3-00006.x; FUNG I, 1991, J GEOPHYS RES-ATMOS, V96, P13033, DOI 10.1029/91JD01247; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; KEIGWIN LD, 1994, NATURE, V371, P323, DOI 10.1038/371323a0; MARTINERIE P, 1995, J GEOPHYS RES-ATMOS, V100, P14291, DOI 10.1029/95JD00826; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Matthews E, 1993, ATMOSPHERIC METHANE, P314; MEESE DA, 1994, 941 COLD REG RES ENG; Mix A, 1992, GEOLOGICAL SOC AM SP, V270, P19; PETITMAIRE N, 1991, PALAEOGEOGR PALAEOCL, V86, P197, DOI 10.1016/0031-0182(91)90009-G; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; PRINN R, 1987, SCIENCE, V238, P945, DOI 10.1126/science.238.4829.945; PRINN RG, 1995, SCIENCE, V269, P187, DOI 10.1126/science.269.5221.187; RASMUSSEN RA, 1984, J GEOPHYS RES-ATMOS, V89, P1599, DOI 10.1029/JD089iD07p11599; RAYNAUD D, 1988, NATURE, V333, P655, DOI 10.1038/333655a0; SEVERINGHAUS J, 1995, EOS, V76, pF291; Severinghaus J. P., 1996, EOS, V77, pS157; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; SOWERS T, 1992, J GEOPHYS RES-ATMOS, V97, P15683, DOI 10.1029/92JD01297; Stuiver M, 1995, QUATERNARY RES, V44, P341, DOI 10.1006/qres.1995.1079; THOMPSON AM, 1992, SCIENCE, V256, P1157, DOI 10.1126/science.256.5060.1157; THOMPSON AM, 1993, TELLUS B, V45, P242, DOI 10.1034/j.1600-0889.1993.t01-2-00003.x; TZEDAKIS PC, 1993, NATURE, V364, P437, DOI 10.1038/364437a0; WOILLARD GM, 1978, QUATERNARY RES, V9, P1, DOI 10.1016/0033-5894(78)90079-0	47	238	257	0	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1087	1091		10.1126/science.273.5278.1087	http://dx.doi.org/10.1126/science.273.5278.1087			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688091				2022-12-28	WOS:A1996VD42800032
J	Evans, E; Bowman, H; Leung, A; Needham, D; Tirrell, D				Evans, E; Bowman, H; Leung, A; Needham, D; Tirrell, D			Biomembrane templates for nanoscale conduits and networks	SCIENCE			English	Article							FILLING CARBON NANOTUBES; MEMBRANE; TUBULES; TETHER; GIANT	Long nanotubes of fluid-lipid bilayers can be used to create templates for photochemical polymerization into solid-phase conduits and networks. Each nanotube is pulled from a micropipette-held feeder vesicle by mechanical retraction of the vesicle after molecular bonding to a rigid substrate. The caliber of the tube is controlled precisely in a range from 20 to 200 nanometers merely by setting the suction pressure in the micropipette. Branched conduits can be formed by coalescing separate nanotubes drawn serially from the feeder vesicle surface. Single nanotubes and nanotube junctions can be linked together between bonding sites on a surface to create a functionalized network. After assembly, the templates can be stabilized by photoinitiated radical cross-linking of macromonomers contained in the aqueous solution confined by the lipid bilayer boundary.	UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER,BC V6T 1W5,CANADA; UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; DUKE UNIV,DEPT MECH ENGN & MAT SCI,DURHAM,NC 27708	University of British Columbia; University of Massachusetts System; University of Massachusetts Amherst; Duke University	Evans, E (corresponding author), UNIV BRITISH COLUMBIA,DEPT PHYS,6224 AGR RD,VANCOUVER,BC V6T 1W5,CANADA.			Needham, David/0000-0002-0082-9148				ANSETH KS, 1995, MACROMOLECULES, V28, P2491, DOI 10.1021/ma00111a050; ARCHIBALD DD, 1993, NATURE, V364, P430, DOI 10.1038/364430a0; BARAL S, 1993, CHEM MATER, V5, P145, DOI 10.1021/cm00026a001; BO L, 1989, BIOPHYS J, V55, P509, DOI 10.1016/S0006-3495(89)82844-9; CHOPRA NG, 1995, SCIENCE, V269, P966, DOI 10.1126/science.269.5226.966; Eaton DF, 1986, ADV PHOTOCHEM, V13, P427; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1994, CHEM PHYS LIPIDS, V73, P39, DOI 10.1016/0009-3084(94)90173-2; HEATH JR, 1993, CHEM PHYS LETT, V208, P263, DOI 10.1016/0009-2614(93)89073-Q; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HOCHMUTH RM, 1982, BIOPHYS J, V39, P71, DOI 10.1016/S0006-3495(82)84492-5; HOCHMUTH RM, 1983, SCIENCE, V220, P101, DOI 10.1126/science.6828875; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; LAGO RM, 1995, J CHEM SOC CHEM COMM, P1355, DOI 10.1039/c39950001355; NEEDHAM D, 1988, BIOCHEMISTRY-US, V27, P8261, DOI 10.1021/bi00421a041; NEEDHAM D, 1993, METHOD ENZYMOL, V220, P111, DOI 10.1016/0076-6879(93)20078-H; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; TSANG SC, 1994, NATURE, V372, P159, DOI 10.1038/372159a0; WHITESIDES GM, 1995, SCI AM, V273, P146; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Yeung A. K. C., 1994, THESIS U BRIT COLUMB; ZAKRZEWSKI A, 1987, TETRAHEDRON, V43, P4507, DOI 10.1016/S0040-4020(01)86891-5	22	195	198	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					933	935		10.1126/science.273.5277.933	http://dx.doi.org/10.1126/science.273.5277.933			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688071				2022-12-28	WOS:A1996VC67000054
J	Farinella, P; Davis, DR				Farinella, P; Davis, DR			Short-period comets: Primordial bodies or collisional fragments?	SCIENCE			English	Article							SOLAR-SYSTEM; IMPACT EXPERIMENTS; ASTEROIDS; BELT; ORIGIN; DISCOVERY; NEPTUNE; NUCLEI	Modeling results show that collisions among Edgeworth-Kuiper Belt Objects (EKOs), a vast swarm of small bodies orbiting beyond Neptune, have been a major process affecting this population and its progeny, the short-period comets. Most EKOs larger than about 100 kilometers in diameter survive over the age of the solar system, but at smaller sizes collisional breakup is frequent, producing a cascade of fragments having a power law size-frequency distribution. Collisions are also a plausible mechanism for injecting EKOs 1 to 10 kilometers in diameter into dynamical resonances, where they can be transported into the inner solar system to become short-period comets. The fragmental nature of these comets may explain their physical properties, such as shape, color, and strength.	PLANETARY SCI INST,TUCSON,AZ 85705		Farinella, P (corresponding author), UNIV PISA,DIPARTIMENTO MATEMAT,VIA BUONARROTI 2,I-56127 PISA,ITALY.							ARAKAWA M, 1996, ICARUS, V118, P341; BOTTKE WF, 1994, ICARUS, V107, P255, DOI 10.1006/icar.1994.1021; CATULLO V, 1984, ASTRON ASTROPHYS, V138, P464; CINTALA MJ, 1985, LUNAR PLANET SCI C, V16, P1298; COCHRAN AL, 1995, ASTROPHYS J, V455, P342, DOI 10.1086/176581; DAVIS DR, IN PRESS ICARUS; DAVIS DR, 1989, ASTEROIDS, V2, P805; DOHNANYI JS, 1969, J GEOPHYS RES, V74, P2531, DOI 10.1029/JB074i010p02531; DUNCAN M, 1987, ASTRON J, V94, P1330, DOI 10.1086/114571; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; Duncan MJ, 1995, ASTRON J, V110, P3073, DOI 10.1086/117748; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; FARINELLA P, 1982, ICARUS, V52, P409, DOI 10.1016/0019-1035(82)90003-3; FARINELLA P, 1992, ICARUS, V97, P111, DOI 10.1016/0019-1035(92)90060-K; FERNANDEZ JA, 1980, MON NOT R ASTRON SOC, V192, P481, DOI 10.1093/mnras/192.3.481; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; JEWITT D, 1993, NATURE, V362, P730, DOI 10.1038/362730a0; JEWITT DC, 1995, ASTRON J, V109, P1867, DOI 10.1086/117413; JEWITT DC, 1988, ASTROPHYS J, V328, P974, DOI 10.1086/166351; KAWAKAMI SI, 1983, J GEOPHYS RES, V88, P5806, DOI 10.1029/JB088iB07p05806; KNEZEVIC Z, 1991, ICARUS, V93, P316, DOI 10.1016/0019-1035(91)90215-F; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; LANGE A, 1981, LUNAR PLANET SCI C, V12, P1667; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; Luu JX, 1996, ASTRON J, V111, P499, DOI 10.1086/117801; MORBIDELLI A, 1996, ICARUS, V118, P322; Oort J. H., 1950, B ASTRON I NETH, V11, P91; QUINN T, 1990, ASTROPHYS J, V355, P667, DOI 10.1086/168800; RICKMAN H, 1994, IAU SYMP, P297; RYAN EV, 1991, ICARUS, V94, P283, DOI 10.1016/0019-1035(91)90228-L; Safronov V S., 1969, EVOLUTION PROTOPLANE; SCHLEICHER DG, 1994, IAU SYMP, P415; STERN SA, 1995, ASTRON J, V110, P856, DOI 10.1086/117568; WEIDENSCHILLING SJ, 1994, NATURE, V368, P721, DOI 10.1038/368721a0; WETHERILL GW, 1967, J GEOPHYS RES, V72, P2429, DOI 10.1029/JZ072i009p02429; WILLIAMS DR, 1994, ICARUS, V107, P117, DOI 10.1006/icar.1994.1010	36	107	108	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					938	941		10.1126/science.273.5277.938	http://dx.doi.org/10.1126/science.273.5277.938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688073				2022-12-28	WOS:A1996VC67000056
J	Rowe, T				Rowe, T			Coevolution of the mammalian middle ear and neocortex	SCIENCE			English	Article							EVOLUTION; PHYLOGENY; DIDELPHIDAE; MECHANISMS; ONTOGENY	Phylogenetic analysis with x-ray computed tomography of fossilized and recent crania implicates differential growth of the neocortex in the evolution and development of the mammalian middle ear, In premammalian tetrapods, the middle ear evolved as a chain of bones attached to the mandible and cranium, but in adult mammals the chain is detached from the mandible and lies behind it, The neocortex evolved concurrently with detachment of the chain. In mammalian development the auditory chain arises connected to the mandible but later detaches, recapitulating the phylogenetic transformation. In modern didelphid development, the auditory chain reaches mature size by the third week after birth and is then separated from the jaw and displaced caudally as the neocortex grows for another 9 weeks.	UNIV TEXAS,VERTEBRATE PALEONTOL LAB,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	Rowe, T (corresponding author), UNIV TEXAS,DEPT GEOL SCI,AUSTIN,TX 78712, USA.							ALBERCH P, 1979, PALEOBIOLOGY, V5, P296, DOI 10.1017/S0094837300006588; Allin E.F., 1986, P283; ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; Allman J., 1990, Seminars in the Neurosciences, V2, P257; Bottorff W., 1995, THRINAXODON DIGITAL; BRAMBLE DM, 1978, PALEOBIOLOGY, V4, P271, DOI 10.1017/S009483730000600X; BUTLER AB, 1994, BRAIN RES REV, V19, P66, DOI 10.1016/0165-0173(94)90004-3; CARTER DR, 1987, J BIOMECH, V20, P1095, DOI 10.1016/0021-9290(87)90027-3; CLARK CT, 1993, J MORPHOL, V215, P119, DOI 10.1002/jmor.1052150203; Crompton A.W., 1986, P263; CROMPTON AW, 1978, AM SCI, V66, P192; de Beer G., 1937, DEV VERTEBRATE SKULL; de Beer G., 1958, EMBRYOS ANCESTORS; DESMOND ME, 1977, DEV BIOL, V57, P188, DOI 10.1016/0012-1606(77)90364-5; FILAN SL, 1991, J ZOOL, V225, P577, DOI 10.1111/j.1469-7998.1991.tb04326.x; FINK WL, 1982, PALEOBIOLOGY, V8, P254, DOI 10.1017/S0094837300006977; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; GOODRICH ES, 1930, STUDIES STRUCTURE DE; Gould S. J., 1977, ONTOGENY PHYLOGENY; Hall B. K., 1999, EVOLUTIONARY DEV BIO; Hanken J., 1993, SKULL, V1; Hanken J., 1993, SKULL, V2; Hanken J., 1993, SKULL; HERRING SW, 1993, AM ZOOL, V33, P472; Hopson J.A., 1979, P39; Hoyte D. A. N., 1966, International Review of General and Experimental Zoology, V2, P345; JELINEK R, 1970, FOLIA MORPHOL, V17, P184; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JERISON HJ, 1990, NEOCORTEX, P5; Kluge A.G., 1988, P57; Langworthy OR, 1928, J COMP NEUROL, V46, P201, DOI 10.1002/cne.900460107; Larsell O, 1935, J COMP NEUROL, V63, P95, DOI 10.1002/cne.900630107; LENDE RA, 1963, SCIENCE, V141, P730, DOI 10.1126/science.141.3582.730; Maier W., 1987, Gegenbaurs Morphologisches Jahrbuch, V133, P123; McCLAIN JOHN A., 1939, JOUR MORPH, V64, P211, DOI 10.1002/jmor.1050640204; McCrady E, 1937, J EXP ZOOL, V75, P503, DOI 10.1002/jez.1400750306; MCCRADY E, 1938, AM ANAT MEM, V16; NANAGAS IC, 1925, J PHILIPP ISL MED AS, V5, P251; NEWMAN SA, 1990, DEVELOPMENT, V110, P1; NORTHCUTT RG, 1984, AM ZOOL, V24, P710; OLSON EC, 1959, EVOLUTION, V13, P344, DOI 10.2307/2406111; ROSE T, NEW PERSPECTIVES HIS; ROWE T, 1992, SYST BIOL, V41, P372, DOI 10.2307/2992573; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; ROWE T, 1993, MAMMAL PHYLOGENY, P129; SIMPSON GG, 1959, EVOLUTION, V13, P405, DOI 10.2307/2406116; SIMPSON GG, 1927, AM J SCI, V214, P259; THATCH WT, 1992, ANNU REV NEUROSCI, V15, P403; Ulinski P.S., 1986, P149; ULINSKI PS, 1971, J COMP NEUROL, V142, P33, DOI 10.1002/cne.901420104; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WEED LH, 1920, CONTRIB EMBRYOL, V9, P425; Wible J.R., 1991, Journal of Vertebrate Paleontology, V11, P1	54	124	128	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					651	654		10.1126/science.273.5275.651	http://dx.doi.org/10.1126/science.273.5275.651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662557				2022-12-28	WOS:A1996VA24900049
J	Garnick, MB; Fair, WR				Garnick, MB; Fair, WR			Prostate cancer: Emerging concepts .2.	ANNALS OF INTERNAL MEDICINE			English	Article							CONFORMAL RADIATION-THERAPY; RADICAL PROSTATECTOMY; WITHDRAWAL SYNDROME; MEMBRANE ANTIGEN; DOSE-ESCALATION; TUMOR-CELLS; CARCINOMA	Objective: To review important topics related to prostate cancer that have arisen since this subject was last covered in Annals in 1993. The review consists of two parts. Part II describes neoadjuvant hormonal therapy, new local treatment options (including three-dimensional conformal radiation therapy, brachytherapy, and cryosurgery), antiandrogen therapy management of erectile dysfunction, funding and legislation for research, and areas for future research, especially in genetics investigations. Study Selection: Randomized studies identified through a MEDLINE search (1992 to 1996); large, single-institutional conferences and consortiums; and studies presented at regional, national, and international symposia. Data Synthesis: Qualitative and quantitative data are reported. Part II describes results of completed randomized trials that used neoadjuvant hormonal therapy. Studies have shown that nearly 50% more patients with cT2 disease will have pathologically confined (pT2) prostate cancer as a result of preoperative neoadjuvant hormonal therapy. Time to development of progressive disease and disease-free survival are improved in patients receiving neoadjuvant hormonal therapy before radiation therapy, but the long-term overall effects on survival of neoadjuvant therapy before surgery or radiation are unknown. Other methods for treating localized prostate cancer (three-dimensional conformal radiation therapy, brachytherapy, and cryotherapy) are gaining popularity, despite the lack of long-term efficacy results. Advances in the understanding of the optimal use of antiandrogens and managing treatment-induced erectile dysfunction continue to benefit patients with prostate cancer. Conclusions: Prostate cancer is being detected with increasing frequency, and many patients are receiving such treatments as radical prostatectomy and radiation therapy. Although refinements in prostate-specific antigen (PSA)based testing have contributed substantially to the increased rate of detection of prostate cancer, the incidence of disease was increasing dramatically even before PSA detection was possible. Despite earlier detection, the optimal therapy for the early form of the disease is still enigmatic. Further studies and longer follow-up of patients who participated in completed studies are needed to better define the outcomes and importance of prostate cancer therapies. More research is needed to help elucidate the reasons for the increased incidence of the disease; such efforts should help define strategies to ultimately prevent prostate cancer.	MEM SLOAN KETTERING CANC CTR, DEPT SURG, UROL SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Garnick, MB (corresponding author), BETH ISRAEL HOSP, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							APRIKIAN AG, 1994, BRIT J UROL, V74, P630, DOI 10.1111/j.1464-410X.1994.tb09196.x; BABAIAN RJ, 1995, CANCER, V75, P2153, DOI 10.1002/1097-0142(19950415)75:8<2153::AID-CNCR2820750819>3.0.CO;2-G; BIJHOLD J, 1992, RADIOTHER ONCOL, V24, P261, DOI 10.1016/0167-8140(92)90233-K; BISSADA NK, 1995, J UROLOGY, V153, P1944, DOI 10.1016/S0022-5347(01)67364-6; CARTER BS, 1990, PROSTATE, V16, P187, DOI 10.1002/pros.2990160302; COX RL, 1995, UROLOGY, V45, P932; CROOK JM, 1995, UROLOGY, V45, P624, DOI 10.1016/S0090-4295(99)80054-5; DALESIO O, 1995, LANCET, V346, P265; DAMICO AV, 1995, J UROLOGY, V154, P131, DOI 10.1016/S0022-5347(01)67248-3; DAmico AV, 1996, J CLIN ONCOL, V14, P304, DOI 10.1200/JCO.1996.14.1.304; DAMICO AV, 1996, IN PRESS UROLOGY; DAWSON NA, 1995, J UROLOGY, V153, P1946, DOI 10.1016/S0022-5347(01)67365-8; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; Epstein, 1993, Semin Radiat Oncol, V3, P179, DOI 10.1016/S1053-4296(05)80114-6; ESCHWEGE P, 1995, LANCET, V346, P1528, DOI 10.1016/S0140-6736(95)92054-4; Fair William R., 1995, Journal of Urology, V153, p391A; FAIR WR, 1993, CLIN INVEST MED, V16, P516; FAIR WR, 1996, IN PRESS UROLOGY; FLANDERS WD, 1984, PROSTATE, V5, P621, DOI 10.1002/pros.2990050608; FORMAN JD, 1995, CANCER INVEST, V13, P8, DOI 10.3109/07357909509024889; GAGE AA, 1992, SURG GYNECOL OBSTET, V174, P73; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; Garnick MB, 1996, ANN INTERN MED, V125, P118, DOI 10.7326/0003-4819-125-2-199607150-00008; GAZIANO JM, 1995, J NATL CANCER I, V87, P1427, DOI 10.1093/jnci/87.19.1427; Gleave ME, 1996, J UROLOGY, V155, P213, DOI 10.1016/S0022-5347(01)66598-4; ILLER RJ, 1994, UROLOGY, V44, P170; ISRAELI RS, 1993, CANCER RES, V53, P227; ISRAELI RS, 1994, CANCER RES, V54, P6306; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; LABRIE F, 1994, UROLOGY, V44, P29, DOI 10.1016/S0090-4295(94)80241-6; LANGE PH, 1990, J UROLOGY, V144, P927, DOI 10.1016/S0022-5347(17)39624-6; LEE WR, 1995, J CLIN ONCOL, V13, P464, DOI 10.1200/JCO.1995.13.2.464; LEIBEL SA, 1994, J UROLOGY, V152, P1792, DOI 10.1016/S0022-5347(17)32387-X; LEIBEL SA, 1994, INT J RADIAT ONCOL, V28, P55, DOI 10.1016/0360-3016(94)90141-4; MORENO JG, 1992, CANCER RES, V52, P6110; OLIVER RTD, 1995, LANCET, V346, P1506, DOI 10.1016/S0140-6736(95)92046-3; ONIK GM, 1993, CANCER, V72, P1291, DOI 10.1002/1097-0142(19930815)72:4<1291::AID-CNCR2820720423>3.0.CO;2-I; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; ROACH M, 1994, INT J RADIAT ONCOL, V28, P267, DOI 10.1016/0360-3016(94)90167-8; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SANDLER HM, 1992, INT J RADIAT ONCOL, V22, P361, DOI 10.1016/0360-3016(92)90055-M; SCHELLHAMMER P, 1995, UROLOGY, V45, P745, DOI 10.1016/S0090-4295(99)80077-6; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; SEIDEN MV, 1994, J CLIN ONCOL, V12, P2634, DOI 10.1200/JCO.1994.12.12.2634; SMALL EJ, 1994, UROLOGY, V43, P408, DOI 10.1016/0090-4295(94)90092-2; SOLOWAY MS, 1995, J UROLOGY, V154, P424, DOI 10.1016/S0022-5347(01)67067-8; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; Sullivan Lorne, 1994, Journal of Urology, V151, p435A; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THOMPSON IM, 1995, 74 ANN M S CENT SECT, P138; VIJAYAKUMAR S, 1993, INT J RADIAT ONCOL, V25, P359, DOI 10.1016/0360-3016(93)90361-X; WALLNER K, 1994, INT J RADIAT ONCOL, V30, P405, DOI 10.1016/0360-3016(94)90021-3; WANG Y, 1995, J NATL CANCER I, V87, P1456, DOI 10.1093/jnci/87.19.1456; WAXMAN J, 1995, LANCET, V346, P1030; Wynder EL, 1996, J UROLOGY, V156, P1364, DOI 10.1016/S0022-5347(01)65587-3; ZAGARS GK, 1995, INT J RADIAT ONCOL, V32, P293, DOI 10.1016/0360-3016(95)00077-C; Zelefsky M J, 1995, Cancer J Sci Am, V1, P142; ZELEFSKY MJ, 1995, J CLIN ONCOL, V13, P459, DOI 10.1200/JCO.1995.13.2.459; ZIETMAN AL, 1995, INT J RADIAT ONCOL, V32, P287, DOI 10.1016/0360-3016(95)00123-G	60	15	16	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					205	212		10.7326/0003-4819-125-3-199608010-00009	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686979				2022-12-28	WOS:A1996UZ28700007
J	Cowing, D; Kenyon, C				Cowing, D; Kenyon, C			Correct Hox gene expression established independently of position in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; HOMEOBOX GENES; BODY REGION; CELL FATES; EMBRYO; POLARITY; GLP-1	THE Hox genes are expressed in a conserved sequence of spatial domains along the anteroposterior (A/P) body axes of many organisms(1). In Drosophila, position-specific signals located along the A/P axis establish the pattern of Hox gene expression(2-4). In the nematode Caenorhabditis elegans, it is not known how the pattern of Hox gene expression is established, C. elegans uses lineal control mechanisms and local cell interactions to specify early blastomere identities(5,6). However, many cells expressing the same Hox gene are unrelated by lineage, suggesting that, as in Drosophila, domains of Hox gene expression may be defined by cell-extrinsic A/P positional signals. To test this, we have investigated whether posterior mesodermal and ectodermal cells will express their normal posterior Hox gene when they are mispositioned in the anterior. Surprisingly, we find that correct Hox gene expression does not depend on cell position, but is highly correlated with cell lineage, Thus, although the most striking feature of Hox gene expression is its positional specificity, in C. elegans the pattern is achieved, at least in part, by a lineage-specific control system that operates without regard to A/P position.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								CHALFIE M, 1994, SCIENCE, V263; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; COWING DW, 1992, DEVELOPMENT, V116, P481; Dustin P., 1984, MICROTUBULES; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGinnis W, 1990, Adv Genet, V27, P363; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; NARDELLIHAEFLIGER D, 1994, DEVELOPMENT, V120, P1839; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIESS JR, 1994, CURR OPIN GENET DEV, V4, P563, DOI 10.1016/0959-437X(94)90073-C; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1	23	37	38	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					353	356		10.1038/382353a0	http://dx.doi.org/10.1038/382353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684464				2022-12-28	WOS:A1996UY95000052
J	Jefferson, T				Jefferson, T			Economic evaluations to aid decision to conduct a trial	LANCET			English	Editorial Material											Jefferson, T (corresponding author), MINIST DEF,ARMY MED DIRECTORATE,ASH VALE GU12 5RR,HANTS,ENGLAND.							MASON JM, 1993, J PUBLIC HEALTH MED, V15, P154; SCULPHER M, 1995, 12 HERG	2	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					141	141		10.1016/S0140-6736(05)66104-1	http://dx.doi.org/10.1016/S0140-6736(05)66104-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UX789	8684148				2022-12-28	WOS:A1996UX78900003
J	Mossad, SB; Macknin, ML; Medendorp, SV; Mason, P				Mossad, SB; Macknin, ML; Medendorp, SV; Mason, P			Zinc gluconate lozenges for treating the common cold - A randomized, double-blind, placebo-controlled study	ANNALS OF INTERNAL MEDICINE			English	Article						common cold; zinc compounds; cough; headache; rhinitis	RESPIRATORY-TRACT INFECTIONS; CONTROLLED TRIALS; ZN-2+; FAILURE	Background: The common cold is one of the most frequent human illnesses and is responsible for substantial morbidity and economic loss. No consistently effective therapy for the common cold has been well documented, but evidence suggests that several possible mechanisms may make zinc an effective treatment. Objective: To test the efficacy of zinc gluconate lozenges in reducing the duration of symptoms caused by the common cold. Design: Randomized, double-blind, placebo-controlled study. Setting: Outpatient department of a large tertiary care center. Patients: 100 employees of the Cleveland Clinic who developed symptoms of the common cold within 24 hours before enrollment. Intervention: Patients in the zinc group (n = 50) received lozenges (one lozenge every 2 hours while awake) containing 13.3 mg of zinc from zinc gluconate as long as they had cold symptoms. Patients in the placebo group (n = 50) received similarly administered lozenges that contained 5% calcium lactate pentahydrate instead of zinc gluconate. Main Outcome Measures: Subjective daily symptom scores for cough, headache, hoarseness, musele ache, nasal drainage, nasal congestion, scratchy throat, sore throat, sneezing, and fever (assessed by oral temperature). Results: The time to complete resolution of symptoms was significantly shorter in the zinc group than in the placebo group (median, 4.4 days compared with 7.6 days; P < 0.001). The zinc group had significantly fewer days with coughing (median, 2.0 days compared with 4.5 days; P = 0.04), headache (2.0 days and 3.0 days; P = 0.02), hoarseness (2.0 days and 3.0 days; P = 0.02), nasal congestion (4.0 days and 6.0 days; P = 0.002), nasal drainage (4.0 days and 7.0 days; P < 0.001), and sore throat (1.0 day and 3.0 days; P < 0.001). The groups did not differ significantly in the resolution of fever, muscle ache, scratchy throat, or sneezing. More patients in the zinc group than in the placebo group had side effects (90% compared with 62%; P < 0.001), nausea (20% compared with 4%; P = 0.02), and bad-taste reactions (80% compared with 30%; P < 0.001). Conclusion: Zinc gluconate in the form and dosage studied significantly reduced the duration of symptoms of the common cold. The mechanism of action of this substance in treating the common cold remains unknown. Individual patients must decide whether the possible beneficial effects of zinc gluconate on cold symptoms outweigh the possible adverse effects.	CLEVELAND CLIN FDN, DEPT PEDIAT & ADOLESCENT MED, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation								ALNAKIB W, 1987, J ANTIMICROB CHEMOTH, V20, P893, DOI 10.1093/jac/20.6.893; ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044; CHANDRA RK, 1984, JAMA-J AM MED ASSOC, V252, P1443, DOI 10.1001/jama.252.11.1443; COUCH RB, 1984, J INFECT DIS, V150, P167, DOI 10.1093/infdis/150.2.167; DINGLE JH, 1964, ILLNES HOME STUDY 25; DOUGLAS RM, 1987, ANTIMICROB AGENTS CH, V31, P1263, DOI 10.1128/AAC.31.8.1263; EBY GA, 1984, ANTIMICROB AGENTS CH, V25, P20, DOI 10.1128/AAC.25.1.20; EBY GA, 1988, ANTIMICROB AGENTS CH, V32, P606, DOI 10.1128/AAC.32.4.606; FARR BM, 1987, ANTIMICROB AGENTS CH, V31, P1183, DOI 10.1128/AAC.31.8.1183; FARR BM, 1988, ANTIMICROB AGENTS CH, V32, P606; FIRPO EJ, 1979, ARCH VIROL, V61, P175, DOI 10.1007/BF01320603; FORSTALL GJ, 1994, JAMA-J AM MED ASSOC, V271, P1109, DOI 10.1001/jama.271.14.1109; GEIST FC, 1987, ANTIMICROB AGENTS CH, V31, P622, DOI 10.1128/AAC.31.4.622; GODFREY JC, 1992, J INT MED RES, V20, P234, DOI 10.1177/030006059202000305; GODFREY JC, 1988, ANTIMICROB AGENTS CH, V32, P605, DOI 10.1128/AAC.32.4.605; GORDON YJ, 1975, ANTIMICROB AGENTS CH, V8, P377, DOI 10.1128/AAC.8.3.377; GRANT A, 1989, BRIT J OBSTET GYNAEC, V96, P397, DOI 10.1111/j.1471-0528.1989.tb02412.x; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; HARISCH G, 1987, RES COMMUN CHEM PATH, V55, P39; KAPLAN EL, 1937, J AM STAT ASSOC, V32, P675; KELLY RW, 1983, BIOL REPROD, V28, P883, DOI 10.1095/biolreprod28.4.883; KORANT BD, 1976, J VIROL, V18, P298, DOI 10.1128/JVI.18.1.298-306.1976; Lee E.T., 1992, STAT METHODS SURVIVA, P77, DOI [10.1002/bimj.4710360103, DOI 10.1002/BIMJ.4710360103]; MACKNIN ML, 1990, JAMA-J AM MED ASSOC, V264, P989; MARONE G, 1979, J ALLERGY CLIN IMMUN, V63, P217; MOFFAT AS, 1993, SCIENCE, V260, P910, DOI 10.1126/science.8493525; Novick SG, 1996, MED HYPOTHESES, V46, P295, DOI 10.1016/S0306-9877(96)90259-5; PASTERNAK CA, 1987, BIOSCIENCE REP, V7, P81, DOI 10.1007/BF01121871; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PFEIFFER CC, 1980, ORTHOMOL PSYCHIAT, V9, P79; RATKA M, 1989, J VIROL, V63, P3954, DOI 10.1128/JVI.63.9.3954-3960.1989; SALAS M, 1987, CLIN IMMUNOL IMMUNOP, V45, P139, DOI 10.1016/0090-1229(87)90120-6; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SIMON G, 1995, J CLIN EPIDEMIOL, V48, P363, DOI 10.1016/0895-4356(94)00141-C; SMITH DS, 1989, ANTIMICROB AGENTS CH, V33, P646, DOI 10.1128/AAC.33.5.646; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; WEISMANN K, 1990, DAN MED BULL, V37, P279; ZAREMBO JE, 1992, J PHARM SCI, V81, P128, DOI 10.1002/jps.2600810205	41	159	163	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					81	+		10.7326/0003-4819-125-2-199607150-00001	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678384				2022-12-28	WOS:A1996UV92100004
J	Brennan, P; Ollier, B; Worthington, J; Hajeer, A; Silman, A				Brennan, P; Ollier, B; Worthington, J; Hajeer, A; Silman, A			Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin?	LANCET			English	Article							SHARED-EPITOPE HYPOTHESIS; PREGNANCY; ONSET; RFLP	The risk of rheumatoid arthritis (RA) seems to be associated with reduced fecundity and with breastfeeding; these apparently contradictory risk factors can be explained by their association with high prolactin concentrations. The only consistent genetic association with RA is for genes encoded in the HLA complex, particularly HLA DR4. We have identified some data indicating that the effects of breastfeeding and nulliparity are modified by HLA DR4 status, suggesting an interaction between genetic and reproductive risk factors in the aetiology of RA. The prolactin gene is in close proximity to the HLA region on the short arm of chromosome six. We therefore propose the hypothesis that the associations between DR4 and reproductive risk factors in RA are due to linkage disequilibrium between DR4 and an abnormally regulated prolactin gene polymorphism.			Brennan, P (corresponding author), UNIV MANCHESTER, SCH MED, ARTHRIT & RHEUMATISM COUNCIL, EPIDEMIOL RES UNIT, MANCHESTER M13 9PT, LANCS, ENGLAND.		Hajeer, Ali/L-4189-2019; Worthington, Jane/M-9770-2014	Hajeer, Ali/0000-0003-2727-9964; Worthington, Jane/0000-0003-0544-042X				BRENNAN P, 1994, ARTHRITIS RHEUM, V37, P808, DOI 10.1002/art.1780370605; BRENNAN P, 1994, AM J EPIDEMIOL, V140, P453, DOI 10.1093/oxfordjournals.aje.a117267; BRENNAN P, 1995, ANN RHEUM DIS, V54, P694, DOI 10.1136/ard.54.9.694; BUSKILA D, 1991, AM J REPROD IMMUNOL, V26, P118, DOI 10.1111/j.1600-0897.1991.tb00708.x; CHIKANZA I C, 1990, British Journal of Rheumatology, V29, P22; CHIKANZA IC, 1993, BRIT J RHEUMATOL, V32, P445; CHIKANZA IC, 1988, BRIT J RHEUMATOL, V27, P324; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; DAVIS JRE, 1990, BAILLIERE CLIN ENDOC, V4, P273, DOI 10.1016/S0950-351X(05)80051-5; Del Junco D J, 1989, Br J Rheumatol, V28 Suppl 1, P42; DIZIER MH, 1993, AM J HUM GENET, V53, P715; EVANS A M, 1988, American Journal of Human Genetics, V43, pA143; FARID NR, 1980, TISSUE ANTIGENS, V15, P333; GAGNERAULT MC, 1993, J IMMUNOL, V150, P5673; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Hajeer A. H., 1995, Arthritis and Rheumatism, V38, pS374; HAZES JMW, 1991, ANN RHEUM DIS, V50, P72, DOI 10.1136/ard.50.2.72; Holmdahl R, 1989, Br J Rheumatol, V28 Suppl 1, P54; JARA LJ, 1991, SEMIN ARTHRITIS RHEU, V20, P273, DOI 10.1016/0049-0172(91)90028-X; JAWAHEER D, 1993, EUR J IMMUNOGENET, V20, P175, DOI 10.1111/j.1744-313X.1993.tb00108.x; Jorgensen C, 1996, ANN RHEUM DIS, V55, P94, DOI 10.1136/ard.55.2.94; MACGREGOR A, 1995, J RHEUMATOL, V22, P1032; MAEDA H, 1981, ANN RHEUM DIS, V40, P299, DOI 10.1136/ard.40.3.299; MASI AT, 1995, SEMIN ARTHRITIS RHEU, V25, P1, DOI 10.1016/S0049-0172(95)80014-X; Mateo L., 1994, Arthritis and Rheumatism, V37, pS223; Matt K. S., 1994, Arthritis and Rheumatism, V37, pS246; MCMURRAY RW, 1995, J RHEUMATOL, V22, P1577; MCMURRAY RW, 1994, J RHEUMATOL, V21, P843; MYAL Y, 1991, NUCLEIC ACIDS RES, V19, P1167, DOI 10.1093/nar/19.5.1167-a; NAGY E, 1991, J RHEUMATOL, V18, P1662; Nelson J. Lee, 1995, Arthritis and Rheumatism, V38, pS232; NELSON JL, 1993, ARTHRITIS RHEUM, V36, P7; Nelson JL, 1987, HORMONES IMMUNITY, P93; NOEL GL, 1974, J CLIN ENDOCR METAB, V38, P413, DOI 10.1210/jcem-38-3-413; OLLIER W, 1992, RHEUM DIS CLIN N AM, V18, P741; SILMAN A, 1992, ARTHRITIS RHEUM, V35, P152, DOI 10.1002/art.1780350205; SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735; THOMSON W, 1992, EUR J IMMUNOGENET, V19, P169, DOI 10.1111/j.1744-313X.1992.tb00056.x; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; WEBER G, 1987, J AM ACAD DERMATOL, V16, P388, DOI 10.1016/S0190-9622(87)80135-4	40	45	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	1996	348	9020					106	109		10.1016/S0140-6736(96)02037-5	http://dx.doi.org/10.1016/S0140-6736(96)02037-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676677				2022-12-28	WOS:A1996UW67300015
J	Steptoe, A; Butler, N				Steptoe, A; Butler, N			Sports participation and emotional wellbeing in adolescents	LANCET			English	Article							PHYSICAL-ACTIVITY; HEALTH	Background Regular physical activity may have psychological benefits. Our study assessed the association between extent of participation in regular sport or vigorous recreational activity and emotional wellbeing in adolescents aged 16 years. Methods Data were collected from a cohort of adolescents, born between April 5 and April 11, 1970, in England, Scotland, and Wales, who took part in the follow-up assessment at age 16 years. Emotional wellbeing was assessed by the general health questionnaire (GHQ) and the malaise inventory (divided into psychological and somatic subscales). Information was obtained about participation in ten team and 25 individual sports and vigorous recreational activities during the previous year. Non-vigorous recreations, such as darts and snooker, were assessed separately. Social class and health status (recent illness and use of hospital services) were included in our analyses as possible confounding factors. 2223 boys and 2838 girls with a mean age of 16.3 years (SD 0.38) were included in our analysis. Statistical analysis was by multiple linear and logistic regression. Findings The sport and vigorous recreational activity index was positively associated with emotional wellbeing independently of sex, social class, health status, and use of hospital services. These associations were significant for the psychological symptom subscale of the malaise inventory (regression coefficient -0.024, 95% CI -0.036 to -0.011, p<0.001) and the GHQ (odds ratio of emotional unit increase in vigorous physical activity CI 0.985-0.998, p<0.01). By contrast, participation in non-vigorous activities was associated with high psychological and somatic symptoms on the malaise inventory. Interpretation We conclude that emotional wellbeing is positively associated with extent of participation in sport and vigorous recreational activity among adolescents. Although causal associations cannot be assumed in this cross-sectional analysis, our results are consistent with experimental evidence that vigorous exercise has favourable effects on emotional state.	CITY UNIV LONDON,SOCIAL STAT RES UNIT,INT CTR CHILD STUDIES,LONDON,ENGLAND	City University London; University of London; University College London	Steptoe, A (corresponding author), UNIV LONDON,ST GEORGE HOSP,SCH MED,DEPT PSYCHOL,LONDON SW17 0RE,ENGLAND.		Steptoe, Andrew/Y-2440-2019	Steptoe, Andrew/0000-0001-7808-4943				ARMSTRONG N, 1990, BRIT MED J, V301, P203, DOI 10.1136/bmj.301.6745.203; Armstrong N., 1994, British Journal of Physical Education, V25, P20; BALDING Y, 1989, YOUNG PEOPLE 1988; BANKS MH, 1983, PSYCHOL MED, V13, P349, DOI 10.1017/S0033291700050972; Butler N. R., 1985, BIRTH 5 STUDY HLTH B; CALFAS KJ, 1994, PEDIATR EXERC SCI, V6, P406, DOI 10.1123/pes.6.4.406; CAMACHO TC, 1991, AM J EPIDEMIOL, V134, P220, DOI 10.1093/oxfordjournals.aje.a116074; Dearing R., 1993, NATL CURRICULUM ITS; FARMER ME, 1988, AM J EPIDEMIOL, V128, P1340, DOI 10.1093/oxfordjournals.aje.a115087; Furlong A., 1993, SCH JOBS; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; GRANT G, 1990, SOC PSYCH PSYCH EPID, V25, P170; Hendry L., 1993, YOUNG PEOPLES LEISUR; MIROWSKY J, 1995, AM SOCIOL REV, V60, P449, DOI 10.2307/2096424; RUTTER M, 1970, ED HLTH BEHAVIOR; STEPHENS T, 1988, PREV MED, V17, P35, DOI 10.1016/0091-7435(88)90070-9; STEPTOE A, 1992, PHYSICAL ACTIVITY HL, P207	17	240	243	1	70	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1789	1792		10.1016/S0140-6736(96)91616-5	http://dx.doi.org/10.1016/S0140-6736(96)91616-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU469	8667922				2022-12-28	WOS:A1996UU46900009
J	Hatanaka, H; Ogura, K; Moriyama, K; Ichikawa, S; Yahara, I; Inagaki, F				Hatanaka, H; Ogura, K; Moriyama, K; Ichikawa, S; Yahara, I; Inagaki, F			Tertiary structure of destrin and structural similarity between two actin-regulating protein families	CELL			English	Article							ISOTOPICALLY ENRICHED PROTEINS; LABEL FINGERPRINTINGS SHOW; SIDE-CHAIN H-1; DEPOLYMERIZING PROTEIN; BINDING PROTEIN; HEAT-SHOCK; F-ACTIN; NMR-SPECTROSCOPY; C-13/N-15-ENRICHED PROTEINS; BACKBONE AMIDE	Destrin is an isoprotein of cofilin that regulates actin cytoskeleton in various eukaryotes. We determined the tertiary structure of destrin by triple-resonance multidimensional nuclear magnetic resonance. In spite of there being no significant amino acid sequence homology, we found that the folding of destrin was strikingly similar to that of repeated segments in the gelsolin family, which resulted in a new protein fold group. Sequential dissimilarity of the actin-binding helix of destrin to that of gelsolin explains the Ca2+-independent actin-binding of destrin. Possible mechanisms of phosphorylation-sensitive phosphoinositide-competitive actin binding, of pH-dependent filament severing, and of nuclear translocation with actin in response to stresses, are discussed on the basis of the tertiary structure.			Hatanaka, H (corresponding author), TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.							ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; COOPER JA, 1986, J BIOL CHEM, V261, P477; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; IIDA K, 1993, GENE, V124, P115; IIDA K, 1986, EXP CELL RES, V165, P207, DOI 10.1016/0014-4827(86)90545-8; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MARKUS MA, 1994, PROTEIN SCI, V3, P70; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MCLAUGHLIN PJ, 1995, ANNU REV BIOPH BIOM, V24, P643, DOI 10.1146/annurev.bb.24.060195.003235; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OHTA Y, 1989, J BIOL CHEM, V264, P16143; PALMER AG, 1992, J MAGN RESON, V96, P416, DOI 10.1016/0022-2364(92)90097-Q; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; SCHNUCHEL A, 1995, J MOL BIOL, V247, P21, DOI 10.1006/jmbi.1994.0118; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SEIP S, 1992, J MAGN RESON, V100, P406, DOI 10.1016/0022-2364(92)90274-B; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P6186, DOI 10.1021/bi00368a053; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	71	125	128	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1047	1055		10.1016/S0092-8674(00)81305-7	http://dx.doi.org/10.1016/S0092-8674(00)81305-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674111	Bronze			2022-12-28	WOS:A1996UV48400011
J	vanderHoeven, F; Zakany, J; Duboule, D				vanderHoeven, F; Zakany, J; Duboule, D			Gene transpositions in the HoxD complex reveal a hierarchy of regulatory controls	CELL			English	Article							EXPRESSION PATTERNS; BITHORAX COMPLEX; HOMEOBOX GENES; MOUSE EMBRYOS; RETINOIC ACID; DROSOPHILA; MURINE; ELEMENTS; BODY; ORGANIZATION	Vertebrate Hox genes are activated following a temporal sequence that reflects their linear order in the clusters. We introduced two Herd transcription units, labeled with lacZ, to an ectopic 5' position in the HoxD complex. Early expression of the relocated genes was delayed and resembled that of the neighboring Hoxd-13. At later stages, locus-dependent expression in distal limbs and the genital eminence was observed, indicating that common regulatory mechanisms are used for several genes. These experiments also illustrated that neighboring genes can share the same cis-acting sequence and that moving genes around in the complex induces novel regulatory interferences. These results suggest that high order regulation controls the activation of Hox genes and highlight three important constraints responsible for the conservation of Hox gene clustering.			vanderHoeven, F (corresponding author), UNIV GENEVA, DEPT ZOOL & ANIM BIOL, QUAI ERNEST ANSERMET 30, CH-1211 GENEVA 4, SWITZERLAND.			duboule, denis/0000-0001-9961-2960				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DEKKER EJ, 1993, MECH DEVELOP, V40, P3, DOI 10.1016/0925-4773(93)90083-A; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1994, DEVELOPMENT, P135; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1994, DEV DYNAM, V199, P229, DOI 10.1002/aja.1001990307; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1990, TRENDS GENET, V6, P208; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRAPINBOTTON A, 1995, DEVELOPMENT, V121, P2707; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; INOUYE M, 1976, Congenital Anomalies, V16, P171; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; Joyner AL, 1993, GENE TARGETING PRACT; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER J, 1995, DEVELOPMENT, V121, P2847; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RENUCCI A, 1992, EMBO J, V11, P1459, DOI 10.1002/j.1460-2075.1992.tb05190.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; STEWART A, 1995, TRENDS GENET, V11, P35; vanderHoeven F, 1996, MECH DEVELOP, V54, P9, DOI 10.1016/0925-4773(95)00455-6; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	51	193	193	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					1025	1035		10.1016/S0092-8674(00)81303-3	http://dx.doi.org/10.1016/S0092-8674(00)81303-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674109	Bronze			2022-12-28	WOS:A1996UV48400009
J	Raabe, T; RiesgoEscovar, J; Liu, XD; Bausenwein, BS; Deak, P; Maroy, P; Hafen, E				Raabe, T; RiesgoEscovar, J; Liu, XD; Bausenwein, BS; Deak, P; Maroy, P; Hafen, E			DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and RAS1 in Drosophila	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOTYROSINE PHOSPHATASE; 2ND CHROMOSOME; EYE; ACTIVATION; MELANOGASTER; LIGAND; TORSO; PHOSPHORYLATION	The specification of the R7 photoreceptor cell in the developing eye of Drosophila is dependent upon activation of the Sevenless (SEV) receptor tyrosine kinase. By screening for mutations that suppress signaling via a constitutively activated SEV protein, we have identified a novel gene, daughter of sevenless (dos). DOS is required not only for signal transduction via SEV but also in other receptor tyrosine kinase signaling pathways throughout development. The presence of an amino-terminally located pleckstrin homology domain and many potential tyrosine phosphorylation sites suggests that DOS functions as an adaptor protein able to interact with multiple signaling molecules. Our genetic analysis demonstrates that DOS functions upstream of Ras1 and defines a signaling pathway that is independent of direct binding of the DRK SH2/SH3 adaptor protein to the SEV receptor tyrosine kinase.	UNIV WURZBURG, THEODOR BOVERI INST BIOWISSENSCH, LEHRSTUHL GENET, D-97074 WURZBURG, GERMANY; ATTILA JOZSEF UNIV, DEPT GENET, H-6701 SZEGED, HUNGARY	University of Wurzburg; Szeged University	Raabe, T (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Deák, Péter/M-5674-2018; Deak, Peter/F-7751-2012	Deak, Peter/0000-0002-8849-0352				Allard JD, 1996, DEVELOPMENT, V122, P1137; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1993, DEVELOPMENT, P41; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SIMON MA, 1994, DEV BIOL, V166, P431, DOI 10.1006/dbio.1994.1327; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STERN MJ, 1994, DEV BIOL, V166, P443, DOI 10.1006/dbio.1994.1328; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SZABAD J, 1989, GENETICS, V122, P823; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TOROK T, 1993, GENETICS, V135, P71; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	55	179	181	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					911	920		10.1016/S0092-8674(00)81274-X	http://dx.doi.org/10.1016/S0092-8674(00)81274-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681385	Bronze, Green Accepted			2022-12-28	WOS:A1996UR60400014
J	Freemantle, N; Bloor, K				Freemantle, N; Bloor, K			Lessons from international experience in controlling pharmaceutical expenditure .1. Influencing patients	BRITISH MEDICAL JOURNAL			English	Article							PAYMENT; THERAPY; DRUGS	This is the first of three papers to review international policies to control spending on drugs and improve the efficiency of drug use. Policies can target three main groups: patients, prescribing doctors, and the drugs industry, In this paper we examine policies aimed at patients, particularly restrictions on reimbursement (such as prescription charges), Rigorous experimental and quasi-experimental studies suggest that policies to limit the level of reimbursement of drugs reduce the use of essential as well as non-essential drugs and may do more harm than good.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK				Bloor, Karen/0000-0003-4852-9854; Freemantle, Nick/0000-0001-5807-5740				BARER M, 1979, CONTROLLING HLTH CAR; *COCHR COLL EFF PR, 1995, COCHR DAT SYST REV; Cook T.C., 1979, QUASIEXPERIMENTATION; Department of Health, 1994, HLTH PERS SOC SERV S; HARRIS BL, 1990, MED CARE, V28, P901; HINCHCLIFFE H, 1959, FINAL REPORT COMMITT; LAVERS RJ, 1989, APPL ECON, V21, P1043; OBRIEN B, 1982, TIMES HLTH S    0119, P1; *OFF HLTH EC, 1995, OHE COMP HLTH STAT; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; RYAN M, 1991, SOC SCI MED, V33, P681, DOI 10.1016/0277-9536(91)90022-5; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STODDART GL, 1994, USER CHARGES SNARES; 1994, SCRIP           0315, P6; 1995, PHARM PRICING REV, P1	18	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1469	1471		10.1136/bmj.312.7044.1469	http://dx.doi.org/10.1136/bmj.312.7044.1469			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664631	Green Published			2022-12-28	WOS:A1996UQ29600035
J	Humphreys, M; Ryman, A				Humphreys, M; Ryman, A			Knowledge of emergency compulsory detention procedures among general practitioners in Edinburgh: Sample survey	BRITISH MEDICAL JOURNAL			English	Article											Humphreys, M (corresponding author), UNIV EDINBURGH,ROYAL EDINBURGH HOSP,DEPT PSYCHIAT,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND.							AFFLECK GG, 1978, AM J PSYCHIAT, V135, P205; EASTMAN N, 1994, BRIT MED J, V308, P43, DOI 10.1136/bmj.308.6920.43; HUMPHREYS M, 1994, INT J LAW PSYCHIAT, V17, P421, DOI 10.1016/0160-2527(94)90017-5; PESKE MA, 1974, AM J PSYCHIAT, V131, P36; SEGAL SP, 1989, AM J PSYCHIAT, V146, P187	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1462	1463		10.1136/bmj.312.7044.1462	http://dx.doi.org/10.1136/bmj.312.7044.1462			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UQ296	8664628	Green Published			2022-12-28	WOS:A1996UQ29600031
J	Galloway, DA				Galloway, DA			Papillomavirus oncoproteins as vaccine candidates	LANCET			English	Editorial Material							TYPE-16; CANCER				Galloway, DA (corresponding author), FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA.							BERAL V, 1994, TRENDS CANC INCIDENC, P265; BEVERLEY PCL, 1994, CIBA F SYMP, V187, P78; BREITBURD F, 1995, J VIROL, V69, P3959, DOI 10.1128/JVI.69.6.3959-3963.1995; CHEN L, 1992, J IMMUNOL, V148, P2617; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; DEVESA SS, 1989, CANCER, V64, P2184, DOI 10.1002/1097-0142(19891115)64:10<2184::AID-CNCR2820641034>3.0.CO;2-8; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; SUZICH JA, 1995, P NATL ACAD SCI USA, V92, P11553, DOI 10.1073/pnas.92.25.11553; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WIGGINS CL, 1993, CANC W WASHINGTON ST, P37	11	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1996	347	9014					1498	1499		10.1016/S0140-6736(96)90663-7	http://dx.doi.org/10.1016/S0140-6736(96)90663-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684094				2022-12-28	WOS:A1996UN47300002
J	Joffe, M				Joffe, M			Decreased fertility in Britain compared with Finland	LANCET			English	Article							TIME-TO-PREGNANCY; PRENATAL EXPOSURE; FUTURE FERTILITY; FECUNDABILITY; SMOKING; QUESTIONNAIRE; QUALITY; SEMEN	Background There has been much interest in the apparent decrese in semen quality. Because the evidence for such a decrease is open to criticism, a different type of evidence is needed. Finland seems to have escaped this decrease, as well as other disorders of the male reproductive tract, notably testicular cancer. If there has been a true decrease, the implications for fertility are unknown. Methods The most sensitive functional measure of fertility is time to pregnancy (TTP); this can be studied retrospectively at group level with a high degree of validity. To test the hypothesis that Finnish men are more fertile than British men, TTP distributions from published Finnish studies and data from Britain were compared. Two comparisons were made: a pair of antenatal studies, and a pair of cross-sectional studies. Findings In both comparisons, fertility was statistically significantly greater in Finland than in Britain. The findings did not seem to be due to methodological problems; in particular, the results could not be attributed to differences in frequency of intercourse, since this would have had the opposite effect on sperm concentration and on TTP. Interpretation The previously reported difference in sperm counts between Finland and elsewhere in northwest Europe (including Britain) is probably not artefactual, suggesting that the reported world-wide decline in semen quality is also real. Reasons for the ''Finnish exception'' may include maternal smoking, which used to be lower in Finnish women than elsewhere, and which might affect developing male offspring.			Joffe, M (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON W2 1PG,ENGLAND.							ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BAIRD DD, 1991, AM J EPIDEMIOL, V133, P1282, DOI 10.1093/oxfordjournals.aje.a115840; BAIRD DD, 1986, FERTIL STERIL, V46, P368; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; Bujan L, 1996, BRIT MED J, V312, P471, DOI 10.1136/bmj.312.7029.471; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; JOFFE M, 1985, INT J EPIDEMIOL, V14, P118, DOI 10.1093/ije/14.1.118; JOFFE M, 1994, AM J EPIDEMIOL, V140, P921, DOI 10.1093/oxfordjournals.aje.a117180; JOFFE M, 1989, J EPIDEMIOL COMMUN H, V43, P268, DOI 10.1136/jech.43.3.268; JOFFE M, 1993, FERTIL STERIL, V60, P99; JOFFE M, 1995, J EPIDEMIOL COMMUN H, V49, P314, DOI 10.1136/jech.49.3.314; JOFFE M, 1994, FERTIL STERIL, V62, P71; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; OLSEN J, 1994, SCAND J WORK ENV HEA, V20, P72; PORKKA KVK, 1994, AM J EPIDEMIOL, V140, P1096, DOI 10.1093/oxfordjournals.aje.a117210; RAHNONEN O, 1992, BR J ADDICTION, V87, P103; RATCLIFFE JM, 1992, REPROD TOXICOL, V6, P297, DOI 10.1016/0890-6238(92)90192-V; SALLMEN M, 1995, AM J IND MED, V27, P699, DOI 10.1002/ajim.4700270506; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SOUMINEN J, 1993, BRIT MED J, V306, P1579; SUONIO S, 1990, EUR J OBSTET GYN R B, V34, P89, DOI 10.1016/0028-2243(90)90011-O; Van Waeleghem K, 1994, HUM REPROD S4, V9, P73; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VESSEY MP, 1978, BRIT MED J, V1, P265, DOI 10.1136/bmj.1.6108.265; WEINBERG CR, 1989, AM J EPIDEMIOL, V129, P1072, DOI 10.1093/oxfordjournals.aje.a115211; Wittmaack F M, 1992, Wis Med J, V91, P477; ZIELHUIS GA, 1992, INT J EPIDEMIOL, V21, P1151, DOI 10.1093/ije/21.6.1151	30	63	63	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1519	1522		10.1016/S0140-6736(96)90673-X	http://dx.doi.org/10.1016/S0140-6736(96)90673-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684104				2022-12-28	WOS:A1996UN47300012
J	Keystone, JS				Keystone, JS			Of bites and body odour	LANCET			English	Editorial Material							HOST				Keystone, JS (corresponding author), UNIV TORONTO, TROP DIS UNIT, 100 COLL ST, TORONTO, ON, CANADA.							ACREE F, 1968, SCIENCE, V161, P1346, DOI 10.1126/science.161.3848.1346; DAVIS EE, 1976, J COMP PHYSIOL, V105, P43, DOI 10.1007/BF01380052; GILBERT IH, 1996, FLORIDA ENTOMOL, V49, P53; Knols BGJ, 1995, T ROY SOC TROP MED H, V89, P604, DOI 10.1016/0035-9203(95)90406-9; KNOLS BGJ, 1994, MED VET ENTOMOL, V8, P386, DOI 10.1111/j.1365-2915.1994.tb00104.x; KNOLS BGJ, 1995, PROCEEDINGS OF THE SECTION EXPERIMENTAL AND APPLIED ENTOMOLOGY OF THE NETHERLANDS ENTOMOLOGICAL SOCIETY (N.E.V.), VOL 6, 1995, P201; PORT GR, 1980, B ENTOMOL RES, V70, P133, DOI 10.1017/S0007485300009834; SCHRECK CE, 1981, J CHEM ECOL, V8, P429; SUTCLIFFE JF, 1986, CAN J ZOOL, V64, P1041, DOI 10.1139/z86-156; THOMPSON BH, 1976, TROPENMED PARASITOL, V27, P83	10	10	11	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1996	347	9013					1423	1423		10.1016/S0140-6736(96)91678-5	http://dx.doi.org/10.1016/S0140-6736(96)91678-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676622				2022-12-28	WOS:A1996UM48500005
J	Bagneres, AG; Lorenzi, MC; Dusticier, G; Turillazzi, S; Clement, JL				Bagneres, AG; Lorenzi, MC; Dusticier, G; Turillazzi, S; Clement, JL			Chemical usurpation of a nest by paper wasp parasites	SCIENCE			English	Article							POLISTES-BIGLUMIS-BIMACULATUS; ANT CAMPONOTUS-VAGUS; CUTICULAR HYDROCARBONS; SOCIAL WASPS; FIRE ANTS; HYMENOPTERA; RECOGNITION; MIMICRY; FORMICIDAE; VESPIDAE	The paper wasp Polistes atrimandibularis is an obligatory social parasite of another Polistes species, P. biglumis bimaculatus. To control the host nest, the parasite sequentially changes the composition of its chemical signature, the cuticular hydrocarbons, during the colonial cycle. Gas chromatography-mass spectrometry of the cuticular hydrocarbons at every stage of the cycle showed that the parasite can switch on and off an entire chemical family, namely, the unsaturated hydrocarbons. In this way the parasite can match the host signature at a critical moment of the colonial cycle.	UNIV TURIN,DIPARTIMENTO MORFOFISIOL VET,I-10125 TURIN,ITALY; UNIV FLORENCE,DIPARTIMENTO BIOL ANIM & GENET,I-50125 FLORENCE,ITALY	University of Turin; University of Florence	Bagneres, AG (corresponding author), LAB NEUROBIOL COMMUN CHIM,CNRS,UPR 9024,31 CHEM JOSEPH AIGUIER,F-13402 MARSEILLE 09,FRANCE.		Bagneres, Anne-Genevieve/P-9764-2019; Lorenzi, Maria Cristina/D-5193-2013; Bagneres, Anne-Genevieve/A-6075-2009	Bagneres, Anne-Genevieve/0000-0002-1729-379X; Lorenzi, Maria Cristina/0000-0002-7364-729X; Bagneres, Anne-Genevieve/0000-0002-1729-379X				ADAMS TS, 1995, J INSECT PHYSIOL, V41, P609, DOI 10.1016/0022-1910(95)00003-D; BAGNERES AG, 1991, J CHEM ECOL, V17, P2397, DOI 10.1007/BF00994590; BAGNERES AG, 1991, J CHEM ECOL, V17, P1641, DOI 10.1007/BF00984695; BAGNERES AG, 1989, THESIS U PARIS 6; BLOMQUIST GJ, 1993, INSECT LIPIDS: CHEMISTRY, BIOCHEMISTRY AND BIOLOGY, P317; BONAVITACOUGOUR.A, IN PRESS COMP BIOC B; BONAVITACOUGOURDAN A, 1991, COMP BIOCHEM PHYS B, V100, P667, DOI 10.1016/0305-0491(91)90272-F; BONAVITACOUGOURDAN A, 1989, SOCIOBIOLOGY, V16, P49; BONAVITACOUGOURDAN A, 1987, J ENTOMOL SCI, V22, P1; CARPENTER JM, 1993, CLADISTICS, V9, P129, DOI 10.1111/j.1096-0031.1993.tb00214.x; CERVO R, 1990, INSECT SOC, V37, P333, DOI 10.1007/BF02225996; CHASE J, 1992, P NATL ACAD SCI USA, V89, P6050, DOI 10.1073/pnas.89.13.6050; DETTNER K, 1994, ANNU REV ENTOMOL, V39, P129, DOI 10.1146/annurev.en.39.010194.001021; ESPELIE KE, 1990, J CHEM ECOL, V16, P2229, DOI 10.1007/BF01026933; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; FERVEUR JF, 1993, GENETICS, V133, P561; FRANKS N, 1990, J CHEM ECOL, V16, P1431, DOI 10.1007/BF01014079; GAMBOA GJ, 1986, ANIM BEHAV, V34, P685, DOI 10.1016/S0003-3472(86)80053-7; GAMBOA GJ, 1996, NATURAL HIST EVOLUTI, pCH9; GU X, 1995, J INSECT PHYSIOL, V41, P257, DOI 10.1016/0022-1910(94)00100-U; HABERSETZER C, 1993, PHYSIOL ENTOMOL, V18, P160, DOI 10.1111/j.1365-3032.1993.tb00463.x; Howard R.W., 1982, Psyche (Cambridge), V89, P157, DOI 10.1155/1982/91358; HOWARD RW, 1980, SCIENCE, V210, P431, DOI 10.1126/science.210.4468.431; HOWARD RW, 1993, INSECT LIPIDS: CHEMISTRY, BIOCHEMISTRY AND BIOLOGY, P179; HOWARD RW, 1990, ANN ENTOMOL SOC AM, V83, P607, DOI 10.1093/aesa/83.3.607; LIEPERT C, 1993, J CHEM ECOL, V19, P2143, DOI 10.1007/BF00979653; LORENZI MC, 1986, ECOL ENTOMOL, V11, P199, DOI 10.1111/j.1365-2311.1986.tb00295.x; LORENZI MC, UNPUB INSECTES SOC; LORENZI MC, 1996, NATURAL HIST EVOLUTI, pCH10; LORENZI MC, 1991, ETHOL ECOL EVOL, V1, P45; NELSON DR, 1993, INSECT LIPIDS: CHEMISTRY, BIOCHEMISTRY AND BIOLOGY, P271; PFENNIG DW, 1983, BEHAV ECOL SOCIOBIOL, V13, P299, DOI 10.1007/BF00299677; PROVOST E, 1993, INSECT BIOCHEM MOLEC, V23, P945, DOI 10.1016/0965-1748(93)90112-6; ROSS KG, 1987, EVOLUTION, V41, P280, DOI 10.1111/j.1558-5646.1987.tb05797.x; SINGER TL, 1992, ANIM BEHAV, V44, P63, DOI 10.1016/S0003-3472(05)80755-9; VANDERMEER RK, 1982, SCIENCE, V218, P806, DOI 10.1126/science.218.4574.806; VANDERMEER RK, 1989, J CHEM ECOL, V15, P2247, DOI 10.1007/BF01014113; Vauchot B, 1996, J INSECT PHYSIOL, V42, P309, DOI 10.1016/0022-1910(95)00102-6; WICKER C, 1995, EUR J ENTOMOL, V92, P197; WICKER C, 1995, J INSECT PHYSIOL, V41, P65, DOI 10.1016/0022-1910(94)00074-Q	41	94	95	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					889	892		10.1126/science.272.5263.889	http://dx.doi.org/10.1126/science.272.5263.889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662579				2022-12-28	WOS:A1996UK75700064
J	Aksay, IA; Trau, M; Manne, S; Honma, I; Yao, N; Zhou, L; Fenter, P; Eisenberger, PM; Gruner, SM				Aksay, IA; Trau, M; Manne, S; Honma, I; Yao, N; Zhou, L; Fenter, P; Eisenberger, PM; Gruner, SM			Biomimetic pathways for assembling inorganic thin films	SCIENCE			English	Article							ELECTRICAL DOUBLE-LAYER; GEL WATER INTERFACE; MOLLUSK SHELLS; FORCE MICROSCOPY; MONOLAYERS; BIOMINERALIZATION; MACROMOLECULES; ORGANIZATION; DIFFRACTION; SURFACTANTS	Living organisms construct various forms of laminated nanocomposites through directed nucleation and growth of inorganics at self-assembled organic templates at temperatures below 100 degrees C and in aqueous solutions. Recent research has focused on the use of functionalized organic surfaces to form continuous thin films of single-phase ceramics. Continuous thin films of mesostructured silicates have also been formed on hydrophobic and hydrophilic surfaces through a two-step mechanism. First, under acidic conditions, surfactant micellar structures are self-assembled at the solid/liquid interface, and second, inorganic precursors condense to form an inorganic-organic nanocomposite. Epitaxial coordination of adsorbed surfactant tubules is observed on mica and graphite substrates, whereas a random arrangement is observed on amorphous silica. The ability to process ceramic-organic nanocomposite films by these methods provides new technological opportunities.	PRINCETON UNIV,PRINCETON MAT INST,PRINCETON,NJ 08544	Princeton University	Aksay, IA (corresponding author), PRINCETON UNIV,DEPT CHEM ENGN,PRINCETON,NJ 08544, USA.		Aksay, Ilhan A/B-9281-2008; Gruner, Sol/G-2924-2010; , Paul/AFZ-1599-2022; Honma, Itaru/S-1983-2019; Fenter, Paul/ABE-6009-2020; Trau, Matt/E-3944-2015; Yao, Nan/H-2423-2011; Honma, Itaru/L-7108-2015	Gruner, Sol/0000-0002-1171-4426; , Paul/0000-0002-6672-9748; Honma, Itaru/0000-0002-6536-576X; Fenter, Paul/0000-0002-6672-9748; Trau, Matt/0000-0001-5516-1280; Honma, Itaru/0000-0002-6536-576X; Yao, Nan/0000-0002-4081-1495				ABRAHAM FF, 1974, HOMOGENEOUS NUCLEATI, pCH5; ADAMSON AW, 1990, PHYSICAL CHEM SURFAC; AKSAY IA, 1992, MRS P, V255; ANTONELLI DM, 1995, ANGEW CHEM INT EDIT, V34, P2014, DOI 10.1002/anie.199520141; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; Becker R, 1935, ANN PHYS-BERLIN, V24, P719; Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; Braun PV, 1996, NATURE, V380, P325, DOI 10.1038/380325a0; BUNKER BC, 1994, SCIENCE, V264, P48, DOI 10.1126/science.264.5155.48; CARIOLOU MA, 1988, J COMP PHYSIOL B, V157, P717, DOI 10.1007/BF00691002; CHEN CY, 1993, MICROPOROUS MATER, V2, P27, DOI 10.1016/0927-6513(93)80059-4; COLLINS RE, UNPUB; CURREY JD, 1977, PROC R SOC SER B-BIO, V196, P443, DOI 10.1098/rspb.1977.0050; DEGUIRE MR, IN PRESS SPIE P; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; GAO YY, 1987, J CHEM SOC FARAD T 1, V83, P2671, DOI 10.1039/f19878302671; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; GU T, 1989, COLLOID SURFACE, V40, P71, DOI 10.1016/0166-6622(89)80007-1; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HEYWOOD BR, 1992, LANGMUIR, V8, P1492, DOI 10.1021/la00041a041; HEYWOOD BR, 1996, BIOMIMETIC MAT CHEM, P143; HUMBERT R, 1994, MATER RES SOC SYMP P, V330, P89; KEITH J, 1993, COMP BIOCHEM PHYS B, V105, P487, DOI 10.1016/0305-0491(93)90078-J; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; LEIMBACH J, 1995, COLLOID SURFACE A, V94, P1, DOI 10.1016/0927-7757(94)02946-P; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1993, J CHEM SOC DALTON, P1, DOI 10.1039/dt9930000001; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MANN S, 1996, BIOMIMETIC MAT CHEM, P1; Mann S., 1989, BIOMINERALIZATION CH; MANNE S, 1994, LANGMUIR, V10, P4409, DOI 10.1021/la00024a003; MANNE S, 1995, SCIENCE, V270, P1480, DOI 10.1126/science.270.5241.1480; Meldrum F.C., 1996, BIOMIMETIC MAT CHEM, P175; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; NAKAGAWA N, UNPUB; Nakahara H., 1980, JPN J MALACOL, V39, P167; NAKAHARA H, 1983, B JOSAI DENT U, V12, P1; RAND RP, 1990, BIOCHEMISTRY-US, V29, P76, DOI 10.1021/bi00453a010; RIEKE PC, 1994, LANGMUIR, V10, P619, DOI 10.1021/la00015a003; Sarikaya M, 1995, BIOMIMETICS DESIGN P, P35; Sarikaya M., 1992, STRUCT CELL SYNTH AS, P1; SENDEN TJ, 1994, LANGMUIR, V10, P358, DOI 10.1021/la00014a004; SHIN H, 1995, J MATER RES, V10, P692, DOI 10.1557/JMR.1995.0692; Slamovich EB, 1996, J AM CERAM SOC, V79, P239, DOI 10.1111/j.1151-2916.1996.tb07904.x; Tarasevich BJ, 1996, CHEM MATER, V8, P292, DOI 10.1021/cm940391e; WAINWRIGHT SA, 1982, MECHANICAL DESIGN OR; WEINER S, 1983, INT J BIOL MACROMOL, V5, P325, DOI 10.1016/0141-8130(83)90055-7; WEINER S, 1980, FEBS LETT, V111, P311, DOI 10.1016/0014-5793(80)80817-9; WEINER S, 1984, PHIL T R SOC LOND B, V304, P421; Yang H, 1996, NATURE, V381, P589, DOI 10.1038/381589a0; Yang H, 1996, NATURE, V379, P703, DOI 10.1038/379703a0; ZHU BY, 1989, J CHEM SOC FARAD T 1, V85, P3813, DOI 10.1039/f19898503813; 1994, HIERARCHICAL STRUCTU	58	734	773	5	262	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					892	898		10.1126/science.273.5277.892	http://dx.doi.org/10.1126/science.273.5277.892			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688064				2022-12-28	WOS:A1996VC67000036
J	Hooton, TM; Scholes, D; Hughes, JP; Winter, C; Roberts, PL; Stapleton, AE; Stergachis, A; Stamm, WE				Hooton, TM; Scholes, D; Hughes, JP; Winter, C; Roberts, PL; Stapleton, AE; Stergachis, A; Stamm, WE			A prospective study of risk factors for symptomatic urinary tract infection in young women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VAGINAL EPITHELIAL-CELLS; SEXUAL INTERCOURSE; DIAPHRAGM USE; BLOOD-GROUP; EPIDEMIOLOGY; ASSOCIATION; BACTERIURIA; BEHAVIOR	Background Although acute urinary tract infections are common in young women, the associated risk factors have not been defined prospectively. Methods We recruited sexually active young women who were starting a new method of contraception at a university health center or a health maintenance organization (HMO) and monitored them for six months for symptomatic urinary tract infections. Daily diaries and serial interviews were used to collect data on potential risk factors. Results Among 796 women, the incidence of urinary tract infections per person-year was 0.7 in the university cohort (mean age, 23 years; n=348) and 0.5 in the HMO cohort (mean age, 29; n=448). In both cohorts, there were strong dose-response relations between the risk of infection and both recent use of a diaphragm with spermicide (respective relative risks for one, three, and five days of use in the past week, 1.42, 2.83, and 5.68 in the university cohort, P<0.001; and 1.29, 2.14, and 3.54 in the HMO cohort, P=0.04) and recent sexual intercourse (respective relative risks for one, three, and five days with intercourse in the past week, 1.37, 2.56, and 4.81 in-the university cohort, P<0.001; and 1.24, 1.91, and 2.96 in the HMO cohort, P=0.002). The risk of acute infection was also associated with a history of recurrent infection (relative risk, 5.58 in the university cohort and 2.10 in the HMO cohort) but not with cervical-cap use, ABO-blood-group nonsecretor phenotype, or delayed postcoital voiding. Conclusions Among sexually active young women the incidence of symptomatic urinary tract infection is high, and the risk is strongly and independently associated with recent sexual intercourse, recent use of a diaphragm with spermicide, and a history of recurrent urinary tract infections. (C) 1996, Massachusetts Medical Society.	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PHARM,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative			Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047549, R01DK040045] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47549, DK 40045] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADATTO K, 1979, JAMA-J AM MED ASSOC, V241, P2525, DOI 10.1001/jama.241.23.2525; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; COUNTS GW, 1982, REV INFECT DIS, V4, P484; COX DR, 1972, J R STAT SOC B, V34, P187; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOXMAN B, 1990, J CLIN EPIDEMIOL, V43, P329, DOI 10.1016/0895-4356(90)90119-A; FOXMAN B, 1995, EPIDEMIOLOGY, V6, P162, DOI 10.1097/00001648-199503000-00013; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1314, DOI 10.2105/AJPH.75.11.1314; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; HOOTEN TM, 1994, CLIN INFECT DIS, V19, P274, DOI 10.1093/clinids/19.2.274; Hooton Thomas M., 1996, P67; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; HOOTON TM, 1991, J INFECT DIS, V164, P1216, DOI 10.1093/infdis/164.6.1216; HOPKINS WJ, 1995, J INFECT DIS, V172, P1612, DOI 10.1093/infdis/172.6.1612; Johnson J R, 1987, Infect Dis Clin North Am, V1, P773; JOHNSON JR, 1990, INFECT DIS CLIN N AM, V4, pRA7; KINANE DF, 1982, BRIT MED J, V285, P7, DOI 10.1136/bmj.285.6334.7; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; NICOLLE LE, 1982, J INFECT DIS, V146, P579, DOI 10.1093/infdis/146.5.579; PEARSON DC, 1987, PREV MED, V16, P783, DOI 10.1016/0091-7435(87)90018-1; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; SCHAPPERT SM, 1994, ADV DATA VITAL HLTH, V253; SHEINFELD J, 1989, NEW ENGL J MED, V320, P773, DOI 10.1056/NEJM198903233201205; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; *US BUR CENS, 1995, 1995 STAT ABSTR US, P82; WALKER RH, 1990, TECHNICAL MANUAL	31	420	452	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					468	474		10.1056/NEJM199608153350703	http://dx.doi.org/10.1056/NEJM199608153350703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672152				2022-12-28	WOS:A1996VB84900003
J	Golden, JH; DiSalvo, FJ; Frechet, JMJ; Silcox, J; Thomas, M; Elman, J				Golden, JH; DiSalvo, FJ; Frechet, JMJ; Silcox, J; Thomas, M; Elman, J			Subnanometer-diameter wires isolated in a polymer matrix by fast polymerization	SCIENCE			English	Article							CLUSTERS; ARRAYS	The preparation and analysis of inorganic-organic polymer nanocomposites consisting of inorganic nanowires and multiwire ''cables'' in a random-coil organic polymer host is reported. Dissolution of inorganic (LiMo3Se3)(n) wires in a strongly coordinating monomer, vinylene carbonate, and the use of a rapid polymerization in the presence of a crosslinking agent produce nanocomposites without phase separation. Polymerization of dilute solutions yields a material containing mostly (Mo3Se3-)n mono- and biwires, 6 to 20 angstroms in diameter and 50 to 100 nanometers long. Polymerization of more concentrated liquid crystalline solutions yields a nanocomposite containing oriented multiwire cables, 20 to 40 angstroms in diameter and up to 1500 nanometers long, that display optical anisotropy and electrical conductivity.	CORNELL UNIV,CTR MAT SCI,ITHACA,NY 14853; CORNELL UNIV,BAKER LAB,DEPT CHEM,ITHACA,NY 14853; EASTMAN KODAK CO,ROCHESTER,NY 14650	Cornell University; Cornell University; Eastman Kodak			FRECHET, Jean M/P-1497-2016	Frechet, Jean/0000-0001-6419-0163				AJAYAN PM, 1994, SCIENCE, V265, P1212, DOI 10.1126/science.265.5176.1212; Ashcroft N., 1976, SOLID STATE PHYS; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; CARTER FL, 1982, MOL ELECTRONIC DEVIC; CHEVREL R, 1971, J SOLID STATE CHEM, V3, P515, DOI 10.1016/0022-4596(71)90095-8; FLORY PJ, 1978, MACROMOLECULES, V11, P1138, DOI 10.1021/ma60066a015; GOLDEN JH, 1995, SCIENCE, V268, P1463, DOI 10.1126/science.268.5216.1463; GOLDEN JH, 1995, CHEM MATER, V7, P232, DOI 10.1021/cm00049a036; HERRING C, 1952, PHYS REV, V85, P1060, DOI 10.1103/PhysRev.85.1060.2; HOSHINO H, 1992, POLYM BULL, V29, P453, DOI 10.1007/BF00944844; HUBER CA, 1994, SCIENCE, V263, P800, DOI 10.1126/science.263.5148.800; KAPLAN ML, 1987, SOLID STATE IONICS, V25, P37, DOI 10.1016/0167-2738(87)90175-5; Landau L. D., 1970, THEORY ELASTICITY, P75; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; PENNYCOOK SJ, 1988, NATURE, V336, P565, DOI 10.1038/336565a0; POTEL M, 1980, J SOLID STATE CHEM, V35, P286, DOI 10.1016/0022-4596(80)90505-8; TARASCON JM, 1985, J SOLID STATE CHEM, V58, P290, DOI 10.1016/0022-4596(85)90211-7; VANNOSTRUM CF, 1994, ANGEW CHEM INT EDIT, V33, P2173, DOI 10.1002/anie.199421731; WAGNER RW, 1994, J AM CHEM SOC, V116, P9759, DOI 10.1021/ja00100a055; WEGNER G, 1994, MATER RES SOC SYMP P, V328, P15; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Wu JH, 1996, ADV MATER, V8, P151, DOI 10.1002/adma.19960080211	23	91	94	4	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					782	784		10.1126/science.273.5276.782	http://dx.doi.org/10.1126/science.273.5276.782			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670415				2022-12-28	WOS:A1996VB42900038
J	Epstein, N				Epstein, N			The examination	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					250	251		10.7326/0003-4819-125-3-199608010-00016	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686986				2022-12-28	WOS:A1996UZ28700014
J	Bosboom, WMJ; Frijns, CJM; vanGijn, J				Bosboom, WMJ; Frijns, CJM; vanGijn, J			Yelling attacks and wasted hands	LANCET			English	Article							INSULINOMAS				Bosboom, WMJ (corresponding author), UNIV UTRECHT HOSP,DEPT NEUROL,NL-3584 CX UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					DAGGETT P, 1984, POSTGRAD MED J, V60, P577, DOI 10.1136/pgmj.60.707.577; JASPAN JB, 1982, MEDICINE, V61, P33, DOI 10.1097/00005792-198201000-00004; LISHMAN WA, 1987, ORGANIC PSYCHIAT PSY, P457; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; SERVICE FJ, 1976, MAYO CLIN PROC, V51, P417	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					238	238		10.1016/S0140-6736(96)04188-8	http://dx.doi.org/10.1016/S0140-6736(96)04188-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684202				2022-12-28	WOS:A1996UZ28600013
J	Young, W				Young, W			Spinal cord regeneration	SCIENCE			English	Editorial Material							FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; RAT; CELLS				Young, W (corresponding author), NYU,MED CTR,DEPT NEUROSURG,NEW YORK,NY 10016, USA.							AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025; BAFFOUR R, 1995, J NEUROSURG, V83, P105, DOI 10.3171/jns.1995.83.1.0105; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BASSO DM, 1995, J NEUROTRAUM, V12, P110; BASSO M, 1996, J NEUROTRAUM, V13, P343; BEATTIE MS, 1989, C P CRITERIA ASSESSI, P16; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CHENG C, 1996, SCIENCE, V273, P510; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GUTH L, 1980, J NEUROSURG, V52, P73, DOI 10.3171/jns.1980.52.1.0073; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; WALTER MA, 1993, LYMPHOKINE CYTOK RES, V12, P135; WINDLE WF, 1958, NEUROLOGY, V8, P518, DOI 10.1212/WNL.8.7.518	18	46	55	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					451	451		10.1126/science.273.5274.451	http://dx.doi.org/10.1126/science.273.5274.451			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8677439				2022-12-28	WOS:A1996UY98300029
J	Malkovsky, M				Malkovsky, M			HLA and natural history of HIV infection	LANCET			English	Editorial Material											Malkovsky, M (corresponding author), UNIV WISCONSIN,SCH MED,DEPT MED MICROBIOL & IMMUNOL,MADISON,WI 53706, USA.			Malkovsky, Miroslav/0000-0002-5056-5224				BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; HEENEY JL, 1995, IMMUNOL TODAY, V16, P515, DOI 10.1016/0167-5699(95)80043-3; Hill AVS, 1996, NAT MED, V2, P395, DOI 10.1038/nm0496-395; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEELAYUWAT C, 1993, HUM IMMUNOL, V38, P30, DOI 10.1016/0198-8859(93)90517-5; MALKOVSKY M, 1996, INT ANTIVIRAL NEWS, V4, P7; McNeil AJ, 1996, QJM-INT J MED, V89, P177; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; RICE WG, 1996, INT ANTIVIRAL NEWS, V4, P3	12	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					142	143						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684150				2022-12-28	WOS:A1996UX78900005
J	LopezJaramillo, P; Teran, E; Molina, G; Rivera, J; Lozano, A				LopezJaramillo, P; Teran, E; Molina, G; Rivera, J; Lozano, A			Oestrogens and depression	LANCET			English	Letter											LopezJaramillo, P (corresponding author), CENT UNIV ECUADOR,FAC MED,MINERAL METAB UNIT,POB 17-21-1060,QUITO,ECUADOR.		Terán, Enrique/L-6000-2016; Lozano, Andres M/A-5058-2012	Terán, Enrique/0000-0001-6979-5655; 				Gregoire AJP, 1996, LANCET, V347, P930, DOI 10.1016/S0140-6736(96)91414-2; LopezJaramillo P, 1996, BRIT J OBSTET GYNAEC, V103, P33, DOI 10.1111/j.1471-0528.1996.tb09512.x; LOZANO A, 1993, REV MED COL MED IMBA, V2, P20; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; ROSELLI M, 1995, HYPERTENSION, V25, P845	5	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					135	136		10.1016/S0140-6736(05)64656-9	http://dx.doi.org/10.1016/S0140-6736(05)64656-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676707				2022-12-28	WOS:A1996UW67300065
J	Richard, D; Marty, B; Chaussidon, M; Arndt, N				Richard, D; Marty, B; Chaussidon, M; Arndt, N			Helium isotopic evidence for a lower mantle component in depleted Archean komatiite	SCIENCE			English	Article							GORGONA-ISLAND; LOIHI SEAMOUNT; HE-3; GEOCHEMISTRY; COLOMBIA; DIAMONDS; BASALTS; FIELD; ROCKS	Archean magnesium-rich komatiites require hot and presumably deep mantle sources, but their trace-element composition and radiogenic isotope composition are similar to those of modern mid-ocean ridge basalts, which originate in the upper mantle. The isotopic composition of helium extracted by sequential crushing of fresh olivines separated from two Archean and one mid-Proterozoic komatiites varies over three orders of magnitude, between a radiogenic end-member rich in helium-4 and a component rich in helium-3, Such helium-3 enrichment suggests the presence of a lower mantle component in Archean komatiites.	CNRS,CTR RECH PETROG & GEOCHIM,F-54501 VANDOEUVRE NANCY,FRANCE; ECOLE NATL SUPER GEOL,F-54001 NANCY,FRANCE; UNIV RENNES,CNRS,UPR 4661,F-35042 RENNES,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes			Chaussidon, Marc/E-7067-2017					AITKEN BG, 1984, CONTRIB MINERAL PETR, V86, P94, DOI 10.1007/BF00373714; ANTHONY EY, 1992, GEOCHIM COSMOCHIM AC, V56, P4105, DOI 10.1016/0016-7037(92)90022-B; Arndt N.T., 1994, ARCHEAN CRUSTAL EVOL, P11, DOI [10.1016/ S0166- 2635(08)70219-6, DOI 10.1016/S0166-2635(08)70219-6]; ARNDT NT, 1986, J PETROL, V27, P279, DOI 10.1093/petrology/27.2.279; ARNDT NT, 1994, CHEM GEOL, V118, P9, DOI 10.1016/0009-2541(94)90167-8; ARNDT NT, 1982, GEOL SURV CAN PAP A, V831, P137; BASU AR, 1995, SCIENCE, V269, P822, DOI 10.1126/science.269.5225.822; BICKLE MJ, 1993, GEOLOGY BELINGWE GRE, P175; CAMPBELL IH, 1989, NATURE, V339, P697, DOI 10.1038/339697a0; CHAUVEL C, 1993, GEOLOGY BELINGWE GRE, P167; DUPRE B, 1990, CHEM GEOL, V85, P35, DOI 10.1016/0009-2541(90)90122-N; ECHEVERRIA LM, 1980, CONTRIB MINERAL PETR, V73, P253, DOI 10.1007/BF00381444; JARVIS GT, 1983, GEOPHYS RES LETT, V10, P1133, DOI 10.1029/GL010i012p01133; JOCHUM KP, 1983, NATURE, V306, P431, DOI 10.1038/306431a0; KELLOGG LH, 1990, EARTH PLANET SC LETT, V99, P276, DOI 10.1016/0012-821X(90)90116-F; KERR AC, 1995, GEOLOGY, V23, P843, DOI 10.1130/0091-7613(1995)023<0843:DMPGSN>2.3.CO;2; KURZ MD, 1982, NATURE, V297, P43, DOI 10.1038/297043a0; KURZ MD, 1986, NATURE, V320, P435, DOI 10.1038/320435a0; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; KURZ MD, 1987, EARTH PLANET SC LETT, V86, P57, DOI 10.1016/0012-821X(87)90188-9; LAHAYE Y, 1995, CHEM GEOL, V126, P43, DOI 10.1016/0009-2541(95)00102-1; LAL D, 1987, CHEM GEOL, V66, P89, DOI 10.1016/0168-9622(87)90031-5; MCDONOUGH WF, 1993, NATURE, V365, P432, DOI 10.1038/365432a0; Morgan W.J., 1981, SEA VOLUME 7 OCEANIC, V7, P443; NESBITT RW, 1982, J VOLCANOL GEOTH RES, V14, P31, DOI 10.1016/0377-0273(82)90041-5; NISBET EG, 1993, LITHOS, V30, P291, DOI 10.1016/0024-4937(93)90042-B; NISBET EG, 1987, GEOLOGY, V15, P1147, DOI 10.1130/0091-7613(1987)15<1147:UFGKFT>2.0.CO;2; ONIONS RK, 1994, EARTH PLANET SC LETT, V124, P131, DOI 10.1016/0012-821X(94)00070-0; OZIMA M, 1989, ANNU REV EARTH PL SC, V17, P361, DOI 10.1146/annurev.earth.17.1.361; RISON W, 1983, EARTH PLANET SC LETT, V66, P407, DOI 10.1016/0012-821X(83)90155-3; SCHILLING JG, 1974, EARTH PLANET SC LETT, V24, P1, DOI 10.1016/0012-821X(74)90002-8; STOREY M, 1991, GEOLOGY, V19, P376, DOI 10.1130/0091-7613(1991)019<0376:AOPSOK>2.3.CO;2; SUN SS, 1978, CONTRIB MINERAL PETR, V65, P301, DOI 10.1007/BF00375516; TRULL TW, 1993, GEOCHIM COSMOCHIM AC, V57, P1313, DOI 10.1016/0016-7037(93)90068-8; Veillette J.J, 1988, GEOGR PHYS QUATERN, V42, P7, DOI DOI 10.7202/032706AR; WHITE WM, 1985, GEOLOGY, V13, P115, DOI 10.1130/0091-7613(1985)13<115:SOOBRI>2.0.CO;2; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	37	36	38	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					93	95		10.1126/science.273.5271.93	http://dx.doi.org/10.1126/science.273.5271.93			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688058				2022-12-28	WOS:A1996UV47800045
J	Nightingale, SL				Nightingale, SL			Dexfenfluramine approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKLAND,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					14	14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667525				2022-12-28	WOS:A1996UU43900006
J	Lenaghan, J; New, B; Mitchell, E				Lenaghan, J; New, B; Mitchell, E			Setting priorities: Is there a role for citizens' juries?	BRITISH MEDICAL JOURNAL			English	Article								Citizens' juries are an attempt to meaningfully involve members of the public in decisions which affect them in their own communities. The Institute for Public Policy Research and Cambridge and Huntingdon Health Authority have recently piloted the first jury in the United Kingdom. Sixteen jurors sat for four days, hearing evidence from a number of expert witnesses. The jurors were asked to consider how priorities for health care should be set, according to what criteria, and to what extent the public should be involved in this process. This pilot was also an attempt to assess the process itself, and our initial evaluation indicates that, given enough time and information, the public is willing and able to contribute to the debate about priority setting in health care.	KINGS FUND POLICY INST,LONDON W1M 0AN,ENGLAND; FULBOURNE HOSP,CAMBRIDGE & HUNTINGDON HLTH AUTHOR,CAMBRIDGE CB1 5EF,ENGLAND		Lenaghan, J (corresponding author), INST PUBL POLICY RES,LONDON WC2E 7RA,ENGLAND.							Bowling A, 1996, BRIT MED J, V312, P670; COOPER L, 1995, TACKLING DEMOCRATIC; COOTE AL, 1994, CITIZENS JURIES; REDMAYNE S, 1995, RESHAPING NHS STRATE; 1995, J COLL PHYSICIANS LO, V29, P379	5	71	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1591	1593		10.1136/bmj.312.7046.1591	http://dx.doi.org/10.1136/bmj.312.7046.1591			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664672	Green Published			2022-12-28	WOS:A1996UU80600025
J	Meade, TW; Cooper, JA; Chakrabarti, R; Miller, GJ; Stirling, Y; Howarth, DJ				Meade, TW; Cooper, JA; Chakrabarti, R; Miller, GJ; Stirling, Y; Howarth, DJ			Fibrinolytic activity and clotting factors in ischaemic heart disease in women	BRITISH MEDICAL JOURNAL			English	Article											Meade, TW (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON HOSP,SCH MED & DENT,MRC EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1994, BRIT J HAEMATOL, V88, P601, DOI 10.1111/j.1365-2141.1994.tb05079.x; MEADE TW, 1994, LANCET, V343, P1442, DOI 10.1016/S0140-6736(94)92572-0	5	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1581	1581						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664669				2022-12-28	WOS:A1996UU80600021
J	Sintchak, MD; Fleming, MA; Futer, O; Raybuck, SA; Chambers, SP; Caron, PR; Murcko, MA; Wilson, KP				Sintchak, MD; Fleming, MA; Futer, O; Raybuck, SA; Chambers, SP; Caron, PR; Murcko, MA; Wilson, KP			Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid	CELL			English	Article							HUMAN IMP DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; GMP REDUCTASE; 5'-MONOPHOSPHATE DEHYDROGENASE; CELL LINES; EXPRESSION; INHIBITORS; GENE; PROLIFERATION; SEQUENCE	The structure of inosine-5'-monophosphate dehydrogenase (IMPDH) in complex with IMP and mycophenolic acid (MPA) has been determined by X-ray diffraction. IMPDH plays a central role in B and T lymphocyte replication. MPA is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug recently approved for the treatment of allograft rejection. IMPDH comprises two domains: a core domain, which is an alpha/beta barrel and contains the active site, and a flanking domain. The complex, in combination with mutagenesis and kinetic data, provides a structural basis for understanding the mechanism of IMPDH activity and indicates that MPA inhibits IMPDH by acting as a replacement for the nicotinamide portion of the nicotinamide adenine dinucleotide cofactor and a catalytic water molecule.			Sintchak, MD (corresponding author), VERTEX PHARMACEUT INC, 40 ALLSTON ST, CAMBRIDGE, MA 02139 USA.							Allison A C, 1977, Ciba Found Symp, P207; ALLISON AC, 1975, LANCET, V2, P1179; ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; ANDREWS SC, 1988, BIOCHEM J, V255, P35, DOI 10.1042/bj2550035; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; ARTIS DR, 1995, Patent No. 22538; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BORK P, 1995, PROTEIN SCI, V4, P268; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CARR SF, 1993, J BIOL CHEM, V268, P27286; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; COONEY D, 1987, BIOCHIM BIOPHYS ACTA, V916, P89, DOI 10.1016/0167-4838(87)90214-7; CRABTREE GW, 1971, CANCER RES, V31, P985; DAYTON JS, 1994, J IMMUNOL, V152, P984; FLEMING MA, 1996, IN PRESS BIOCHEMISTR; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; FUREY W, 1996, IN PRESS MACROMOLECU; GIBLETT ER, 1972, LANCET, V2, P1067; Gosio B., 1896, RIV DIGIENE SANITA P, V7, P825; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HARRISON W, 1972, J CHEM SOC PERK T 2, P1542, DOI 10.1039/p29720001542; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HODGES SD, 1989, J BIOL CHEM, V264, P18137; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUETEPEREZ JA, 1995, BIOCHEMISTRY-US, V34, P13889, DOI 10.1021/bi00042a021; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KONNO Y, 1991, J BIOL CHEM, V266, P506; LEE HJ, 1985, CANCER RES, V45, P5512; LIGHTFOOT T, 1994, BBA-GENE STRUCT EXPR, V1217, P156, DOI 10.1016/0167-4781(94)90029-9; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; Makara GM, 1996, J MED CHEM, V39, P1236, DOI 10.1021/jm950600m; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NAKAMURA H, 1992, LEUKEMIA RES, V16, P561, DOI 10.1016/0145-2126(92)90002-O; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; NATSUMEDA Y, 1993, ANN NY ACAD SCI, V696, P88; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; Rashtchian A, 1992, PCR Methods Appl, V2, P124; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; SJOGEN EB, 1995, Patent No. 22535; SNYDER FF, 1972, BIOCHEM PHARMACOL, V21, P2351, DOI 10.1016/0006-2952(72)90386-3; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SPECTOR T, 1979, J BIOL CHEM, V254, P2308; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WEBER G, 1983, CANCER RES, V43, P3466; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004; WU YD, 1995, J AM CHEM SOC, V117, P4100, DOI 10.1021/ja00119a026; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435	58	368	390	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					921	930		10.1016/S0092-8674(00)81275-1	http://dx.doi.org/10.1016/S0092-8674(00)81275-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681386	Bronze			2022-12-28	WOS:A1996UR60400015
J	Hannah, M; Hannah, W				Hannah, M; Hannah, W			Caesarean section or vaginal birth for breech presentation at term - We need better evidence as to which is better	BRITISH MEDICAL JOURNAL			English	Editorial Material							RANDOMIZED MANAGEMENT				Hannah, M (corresponding author), CTR RES WOMENS HLTH,MATERNAL INFANT & REPROD HLTH RES UNIT,TORONTO,ON M5G 1N8,CANADA.							CHENG M, 1993, OBSTET GYNECOL, V82, P605; COLLEA JV, 1980, AM J OBSTET GYNECOL, V137, P235, DOI 10.1016/0002-9378(80)90780-2; Danielian PJ, 1996, BRIT MED J, V312, P1451, DOI 10.1136/bmj.312.7044.1451; GIMOVSKY ML, 1983, AM J OBSTET GYNECOL, V146, P34, DOI 10.1016/0002-9378(83)90923-7; Hofmeyr GJ, 1995, COCHRANE DATABASE SY; Penkin P, 1996, J SOGC, V18, P233	6	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1433	1434		10.1136/bmj.312.7044.1433	http://dx.doi.org/10.1136/bmj.312.7044.1433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664609	Green Published			2022-12-28	WOS:A1996UQ29600003
J	Kreiss, C; Buclin, T; Cosma, M; CorthesyTheulaz, I; Michetti, P				Kreiss, C; Buclin, T; Cosma, M; CorthesyTheulaz, I; Michetti, P			Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection	LANCET			English	Letter									UNIV HOSP,DIV GASTROENTEROL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Kreiss, C (corresponding author), UNIV HOSP,DIV CLIN PHARMACOL,CH-1011 LAUSANNE,SWITZERLAND.		Buclin, Thierry/P-1640-2014	Buclin, Thierry/0000-0003-0639-5536				CORTHESYTHEULAZ I, 1995, GASTROENTEROLOGY, V109, P115, DOI 10.1016/0016-5085(95)90275-9; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; FERRERO RL, 1993, MOL MICROBIOL, V9, P323, DOI 10.1111/j.1365-2958.1993.tb01693.x; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x	5	68	71	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1630	1631		10.1016/S0140-6736(96)91119-8	http://dx.doi.org/10.1016/S0140-6736(96)91119-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667902				2022-12-28	WOS:A1996UP66100064
J	Mollnes, TE; Harboe, M				Mollnes, TE; Harboe, M			Clinical immunology	BRITISH MEDICAL JOURNAL			English	Article									UNIV OSLO,RIKSHOSP,INST IMMUNOL & RHEUMATOL,N-0027 OSLO,NORWAY	University of Oslo; National Hospital Norway	Mollnes, TE (corresponding author), UNIV TROMSO,NORDLAND CENT HOSP,DEPT IMMUNOL & TRANSFUS MED,N-8017 BODO,NORWAY.		Mollnes, Tom/ABI-5183-2020					AABERGE IS, 1995, J CELL BIOCH A S, V19, P242; BEGUE RE, 1995, VACCINE, V13, P691, DOI 10.1016/0264-410X(94)00056-S; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; Brandtzaeg P, 1995, IMMUNOLOGIST, V3, P89; COUSER WG, 1995, J AM SOC NEPHROL, V5, P1888; CRYZ SJ, 1995, DEV BIOL STAND, V84, P237; DALAKAS MC, 1995, J CLIN IMMUNOL, V15, P870; DESOUZA VR, 1995, EUR J IMMUNOL, V25, P1267, DOI 10.1002/eji.1830250521; Edwards KM, 1996, NEW ENGL J MED, V334, P391, DOI 10.1056/NEJM199602083340609; FISHER A, 1995, IMMUNOLOGIST, V3, P237; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; GAUTREAU C, 1995, TRANSPLANTATION, V60, P903, DOI 10.1097/00007890-199511150-00004; GLOTZ D, 1995, XENOBIOTICA, V3, P30; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HARBOE M, 1996, IN PRESS VACCINE; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; JENKINS PG, 1995, J DRUG TARGET, V3, P79, DOI 10.3109/10611869509015939; KILGORE KS, 1995, J IMMUNOL, V155, P1434; Kniskern P J, 1995, Pharm Biotechnol, V6, P673; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; KRAUSE I, 1995, J RHEUMATOL, V6, P1068; LAVECCHIO JA, 1995, TRANSPLANTATION, V60, P841, DOI 10.1097/00007890-199510270-00014; MAGEE JC, 1995, J CLIN INVEST, V96, P2404, DOI 10.1172/JCI118297; MCCOY R, 1995, J EXP MED, V182, P207, DOI 10.1084/jem.182.1.207; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868; Miletic VD, 1996, J IMMUNOL, V156, P749; MOBINI N, 1995, ANN ALLERG ASTHMA IM, V74, P119; MOLLNES TE, 1995, SCAND J IMMUNOL, V41, P449, DOI 10.1111/j.1365-3083.1995.tb03591.x; QI M, 1995, ARTHRITIS RHEUM, V38, P146, DOI 10.1002/art.1780380123; QUIGG RJ, 1995, J IMMUNOL, V154, P3437; QUINTI I, 1995, CLIN EXP IMMUNOL, V102, P11; RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; ROSS C, 1995, J CLIN INVEST, V95, P1974, DOI 10.1172/JCI117881; SAADI S, 1995, J EXP MED, V181, P21, DOI 10.1084/jem.181.1.21; SAADI S, 1995, J EXP MED, V182, P1807, DOI 10.1084/jem.182.6.1807; SAIKI O, 1995, J CLIN INVEST, V95, P510, DOI 10.1172/JCI117692; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; SMILEY JD, 1995, AM J MED SCI, V309, P295; TOUNGOUZ M, 1995, BRIT J HAEMATOL, V89, P698; VASSILEV TL, 1995, J AUTOIMMUN, V8, P405, DOI 10.1006/jaut.1995.0032; WIGZELL H, 1995, IMMUNOLOGIST, V3, P234	46	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1465	1469		10.1136/bmj.312.7044.1465	http://dx.doi.org/10.1136/bmj.312.7044.1465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664630	Green Published			2022-12-28	WOS:A1996UQ29600034
J	Astrow, AB				Astrow, AB			Fludarabine in chronic leukaemia	LANCET			English	Editorial Material							CHRONIC LYMPHOCYTIC-LEUKEMIA; AGENT		ST VINCENTS HOSP & MED CTR,SECT ONCOL,NEW YORK,NY 10011	Saint Vincents Hospital Manhattan	Astrow, AB (corresponding author), ST VINCENTS HOSP & MED CTR,DEPT MED,SECT HEMATOL,NEW YORK,NY 10011, USA.							CHESON BD, 1995, J CLIN ONCOL, V13, P2431, DOI 10.1200/JCO.1995.13.9.2431; CHUN HG, 1991, J CLIN ONCOL, V9, P175, DOI 10.1200/JCO.1991.9.1.175; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; KEATING MJ, 1991, J CLIN ONCOL, V9, P44, DOI 10.1200/JCO.1991.9.1.44; KEATING MJ, 1989, BLOOD, V74, P19; OBRIEN S, 1993, BLOOD, V82, P1695; OBRIEN S, 1995, BLOOD, V85, P307; Rai K. R., 1995, Blood, V86, p607A; ROZMAN R, 1995, NEW ENGL J MED, V333, P1052; TALLMAN MS, 1995, BLOOD, V86, P2463	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1420	1421		10.1016/S0140-6736(96)91675-X	http://dx.doi.org/10.1016/S0140-6736(96)91675-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676619				2022-12-28	WOS:A1996UM48500002
J	Fischer, HM; Pehlke, E; Wibberenz, G; Lanzerotti, LJ; Mihalov, JD				Fischer, HM; Pehlke, E; Wibberenz, G; Lanzerotti, LJ; Mihalov, JD			High-energy charged particles in the innermost jovian magnetosphere	SCIENCE			English	Article								The energetic particles investigation carried by the Galileo probe measured the energy and angular distributions of the high-energy particles from near the orbit of lo to probe entry into the jovian atmosphere. Jupiter's inner radiation region had extremely large fluxes of energetic electrons and protons; intensities peaked at similar to 2.2R(J) (where R(J) is the radius of Jupiter). Absorption of the measured particles was found near the outer edge of the bright dust ring. The instrument measured intense fluxes of high-energy helium ions (similar to 62 megaelectron volts per nucleon) that peaked at similar to 1.5R(J) inside the bright dust ring. The abundances of all particle species decreased sharply at similar to 1.35R(J); this decrease defines the innermost edge of the equatorial jovian radiation.	AT&T BELL LABS, LUCENT TECHNOL, MURRAY HILL, NJ 07974 USA; NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Fischer, HM (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL, INST KERNPHYS, GUTENBERGSTR 76-78, D-24118 KIEL, GERMANY.							BURKE BF, 1955, J GEOPHYS RES, V60, P213, DOI 10.1029/JZ060i002p00213; DEPATER I, 1990, J GEOPHYS RES-SPACE, V95, P39, DOI 10.1029/JA095iA01p00039; FILLIUS RW, 1975, SCIENCE, V188, P465, DOI 10.1126/science.188.4187.465; FISCHER HM, 1992, SPACE SCI REV, V60, P79, DOI 10.1007/BF00216850; JEWITT DC, 1981, J GEOPHYS RES-SPACE, V86, P8691, DOI 10.1029/JA086iA10p08691; Lanzerotti LJ, 1996, SCIENCE, V272, P858, DOI 10.1126/science.272.5263.858; MCDONALD FB, 1976, JUPITER, P961; MCKIBBEN RB, 1983, J GEOPHYS RES-SPACE, V88, P36, DOI 10.1029/JA088iA01p00036; PEHLKE E, 1988, THESIS U KIEL GERMAN; PYLE KR, 1983, J GEOPHYS RES-SPACE, V88, P45, DOI 10.1029/JA088iA01p00045; Simpson J. A., 1976, JUPITER, P738; TRAINOR JH, 1975, SCIENCE, V188, P462, DOI 10.1126/science.188.4187.462; VANALLEN JA, 1975, SCIENCE, V188, P459, DOI 10.1126/science.188.4187.459; 1974, SCIENCE, V183; 1974, J GEOPHYS RES, V79	15	43	43	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1996	272	5263					856	858		10.1126/science.272.5263.856	http://dx.doi.org/10.1126/science.272.5263.856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662575				2022-12-28	WOS:A1996UK75700053
J	Lin, HP; Mou, CY				Lin, HP; Mou, CY			''Tubules-within-a-tubule'' hierarchical order of mesoporous molecular sieves in MCM-41	SCIENCE			English	Article							SURFACTANT; ORGANIZATION; TRANSITION	The recently discovered mesoporous aluminosilicate MCM-41 consists of hexagonal arrays of nanometer-sized cylindrical pores. It is shown that this material can be synthesized by cooperative condensation of silicate and cylindrical cation ic micelles. Careful control of the surfactant-water content and the rate of condensation of silica at high alkalinity resulted in hollow tubules 0.3 to 3 micrometers in diameter. The wall of the tubules consisted of coaxial cylindrical pores, nanometers in size, that are characteristic of those of MCM-41. The formation of this higher order structure may take place through a liquid crystal phase transformation mechanism involving an anisotropic membrane-to-tubule phase change. The hierarchical organization of this ''tubules-within-a-tubule'' particle texture is similar to that of the frustules of marine diatoms.	NATL TAIWAN UNIV,DEPT CHEM,TAIPEI 10764,TAIWAN	National Taiwan University				MOU, CHUNG-YUAN/0000-0001-7060-9899				BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BLACKMORE ES, 1988, J CHEM SOC FARAD T 2, V84, P1115, DOI 10.1039/f29888401115; BROWN RE, 1995, BIOPHYS J, V68, P1396, DOI 10.1016/S0006-3495(95)80312-7; BUREKLE LH, 1978, INTRO MARINE MICROPA, P245; CHENITE A, 1995, CHEM MATER, V7, P1015, DOI 10.1021/cm00053a031; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; FYFE CA, 1995, J AM CHEM SOC, V117, P9709, DOI 10.1021/ja00143a014; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lin H, UNPUB; LUAN ZH, 1995, J CHEM SOC FARADAY T, V91, P2955, DOI 10.1039/ft9959102955; MANN S, 1995, J MATER CHEM, V5, P935, DOI 10.1039/jm9950500935; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Radzihovsky L, 1995, PHYS REV LETT, V75, P4752, DOI 10.1103/PhysRevLett.75.4752; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; SEIN A, 1995, LANGMUIR, V11, P455, DOI 10.1021/la00002a015; Tanev PT, 1996, SCIENCE, V271, P1267, DOI 10.1126/science.271.5253.1267; THOMAS BN, 1995, SCIENCE, V267, P1635, DOI 10.1126/science.267.5204.1635; VARTULI JC, 1994, CHEM MATER, V6, P2317, DOI 10.1021/cm00048a018; WACK DC, 1988, PHYS REV LETT, V61, P1210, DOI 10.1103/PhysRevLett.61.1210; ZASADZINSKI JAN, 1988, SCIENCE, V239, P1013, DOI 10.1126/science.3344420	23	323	341	3	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					765	768		10.1126/science.273.5276.765	http://dx.doi.org/10.1126/science.273.5276.765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670409				2022-12-28	WOS:A1996VB42900032
J	Lanske, B; Karaplis, AC; Lee, K; Luz, A; Vortkamp, A; Pirro, A; Karperien, M; Defize, LHK; Ho, C; Mulligan, RC; AbouSamra, AB; Juppner, H; Segre, GV; Kronenberg, HM				Lanske, B; Karaplis, AC; Lee, K; Luz, A; Vortkamp, A; Pirro, A; Karperien, M; Defize, LHK; Ho, C; Mulligan, RC; AbouSamra, AB; Juppner, H; Segre, GV; Kronenberg, HM			PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth	SCIENCE			English	Article							HORMONE-RELATED PEPTIDE; PARATHYROID-HORMONE; MESSENGER-RNA; EXPRESSION; PROTEIN; TISSUES; MOUSE; RAT; CARTILAGE; CELLS	The PTH/PTHrP receptor binds to two ligands with distinct functions: the calcium-regulating hormone, parathyroid hormone (PTH), and the paracrine factor, PTH-related protein (PTHrP). Each ligand, in turn, is likely to activate more than one receptor. The functions of the PTH/PTHrP receptor were investigated by deletion of the murine gene by homologous recombination. Most PTH/PTHrP receptor (-/-) mutant mice died in mid-gestation, a phenotype not observed in PTHrP (-/-) mice, perhaps because of the effects of maternal PTHrP. Mice that survived exhibited accelerated differentiation of chondrocytes in bone, and their bones, grown in explant culture, were resistant to the effects of PTHrP and Sonic hedgehog. These results suggest that the PTH/PTHrP receptor mediates the effects of Indian Hedgehog and PTHrP on chondrocyte differentiation.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; MCGILL UNIV,SIR MORTIMER B DAVIS JEWISH GEN HOSP,MONTREAL,PQ H3T 1E2,CANADA; GSF MUNCHEN,INST PATHOL,D-85758 MUNICH,GERMANY; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,CAMBRIDGE,MA 02139	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; McGill University; Harvard University; Harvard Medical School; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Abou-Samra, Abdul/ABE-8723-2020; Karperien, Marcel/R-3270-2018	Abou-Samra, Abdul/0000-0001-8735-1142; Lanske, Beate/0000-0003-4638-804X; Karperien, Marcel/0000-0003-0751-0604	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047237, R01DK047038] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47038, DK 47237] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BECK F, 1993, J REPROD FERTIL, V99, P343; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Broadus Arthur E., 1994, P259; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; INOMATA N, 1995, ENDOCRINOLOGY, V136, P4732, DOI 10.1210/en.136.11.4732; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KARPERIEN M, 1994, MECH DEVELOP, V47, P29, DOI 10.1016/0925-4773(94)90093-0; KARPERIEN M, IN PRESS INT J DEV B; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; POTTS JT, 1995, ENDOCRINOLOGY, V2, P920; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; VANDESTOLPE A, 1993, J CELL BIOL, V120, P235, DOI 10.1083/jcb.120.1.235; VORTKAMP A, 1996, SCIENCE, V273, pR30	23	1013	1047	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					663	666		10.1126/science.273.5275.663	http://dx.doi.org/10.1126/science.273.5275.663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662561				2022-12-28	WOS:A1996VA24900053
J	Maldonado, R; Blendy, JA; Tzavara, E; Gass, P; Roques, BP; Hanoune, J; Schutz, G				Maldonado, R; Blendy, JA; Tzavara, E; Gass, P; Roques, BP; Hanoune, J; Schutz, G			Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB	SCIENCE			English	Article							ELEMENT-BINDING PROTEIN; NERVE GROWTH-FACTOR; OPIATE WITHDRAWAL; TARGETED MUTATION; ADENYLATE-CYCLASE; LOCUS-CERULEUS; RAT-BRAIN; C-FOS; TRANSCRIPTION	Chronic morphine administration induces an up-regulation of several components of the cyclic adenosine 5'-monophosphate (cAMP) signal transduction cascade. The behavioral and biochemical consequences of opiate withdrawal were investigated in mice with a genetic disruption of the alpha and Delta isoforms of the cAMP-responsive element-binding protein (CREB). In CREB alpha Delta mutant mice the main symptoms of morphine withdrawal were strongly attenuated. No change in opioid binding sites or in morphine-induced analgesia was observed in these mutant mice, and the increase of adenylyl cyclase activity and immediate early gene expression after morphine withdrawal was normal. Thus, CREB-dependent gene transcription is a factor in the onset of behavioral manifestations of opiate dependence.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY; HOP HENRI MONDOR,INSERM,U99,UNITE REGULAT GENES & SIGNALISAT CELLULAIRE,F-94010 CRETEIL,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Maldonado, R (corresponding author), UNIV PARIS 05,FAC PHARM,DEPT PHARMOCOCHIM MOL & STRUCT,INSERM,U266,CNRS,F-75270 PARIS 06,FRANCE.		Maldonado, Rafael/F-5657-2014	Maldonado, Rafael/0000-0002-4359-8773				Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DELAYGOYET P, 1987, LIFE SCI, V41, P723, DOI 10.1016/0024-3205(87)90452-8; DUMAN RS, 1988, J PHARMACOL EXP THER, V246, P1033; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x; HANOUNE J, 1977, J BIOL CHEM, V252, P2039; HAYWARD MD, 1990, BRAIN RES, V525, P256, DOI 10.1016/0006-8993(90)90872-9; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; SCHMIDT C, 1991, EUR J PHARMACOL, V192, P253, DOI 10.1016/0014-2999(91)90050-Z; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D	17	252	264	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					657	659		10.1126/science.273.5275.657	http://dx.doi.org/10.1126/science.273.5275.657			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662559				2022-12-28	WOS:A1996VA24900051
J	Morgan, TO; Jacobsen, SJ; McCarthy, WF; Jacobson, DJ; McLeod, DG; Moul, JW				Morgan, TO; Jacobsen, SJ; McCarthy, WF; Jacobson, DJ; McLeod, DG; Moul, JW			Age-specific reference ranges for serum prostate-specific antigen in black men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER; ADENOCARCINOMA; CARCINOMA	Background The detection of prostate cancer by screening for prostate-specific antigen (PSA) in serum is improved when age-specific reference ranges are used, but these ranges have been derived from white populations. We determined the distribution of PSA and age-specific reference ranges in black men both with and without prostate cancer. Methods From January 1991 through May 1995, we measured serum PSA in 3475 men with no clinical evidence of prostate cancer (1802 white and 1673 black) and 1783 men with prostate cancer (1372 white and 411 black). We studied the data asa function of age and race to determine the usefulness of measuring PSA in diagnosing prostate cancer. Results Serum PSA concentrations in black men (geometric mean in controls, 1.48 ng per milliliter; in patients, 7.46) were significantly higher than those in white men (geometric mean in controls, 1.33 ng per milliliter; in patients, 6.28). The values in the controls correlated directly with age. The area under the receiver-operating-characteristic curve was 0.91 for blacks and 0.94 for whites. If traditional age-specific reference ranges were used in screening black men, with the test specificity kept at 95 percent, 41 percent of cases of prostate cancer would be missed. For the test to have 95 percent sensitivity among black men, the following normal reference ranges should be used: for men in their 40s, 0 to 2.0 ng of PSA per milliliter (test specificity, 93 percent); for men in their 50s, 0 to 4.0 ng per milliliter (specificity, 88 percent); for men in their 60s, 0 to 4.5 ng per milliliter (specificity, 81 percent); and for men in their 70s, 0 to 5.5 ng per milliliter (specificity, 78 percent). Conclusions Serum PSA concentrations can be used to discriminate between men with prostate cancer and those without it among both blacks and whites. Over 40 percent of cases of prostate cancer in black men would not be detected by tests using traditional age-specific reference ranges, which maintain specificity at 95 percent. In this high-risk population, the alternative approach - maintaining sensitivity at 95 percent - may be used with acceptable decrements in specificity. (C) 1996, Massachusetts Medical Society.	UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814; WALTER REED ARMY MED CTR,DEPT SURG,UROL SERV,WASHINGTON,DC 20307; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,BIOSTAT SECT,ROCHESTER,MN 55905; UNIFORMED SERV UNIV HLTH SCI,CTR PROSTATE DIS RES,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Mayo Clinic; Mayo Clinic; Uniformed Services University of the Health Sciences - USA				Jacobsen, Steven/0000-0002-8174-8533				*AM UR ASS, 1992, AM UR ASS 1992 POL S, V4, P20; ANDERSON JR, 1995, UROLOGY, V46, P54, DOI 10.1016/S0090-4295(99)80158-7; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; DALKIN BL, 1993, J UROLOGY, V150, P1837, DOI 10.1016/S0022-5347(17)35910-4; DEANTONI EP, 1995, CANCER, V75, P1874, DOI 10.1002/1097-0142(19950401)75:7+<1874::AID-CNCR2820751618>3.0.CO;2-I; ELGALLEY RES, 1995, UROLOGY, V46, P200, DOI 10.1016/S0090-4295(99)80194-0; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KEETCH DW, 1994, J UROLOGY, V151, P1571, DOI 10.1016/S0022-5347(17)35304-1; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MORTON RA, 1994, UROLOGY, V44, P637, DOI 10.1016/S0090-4295(94)80196-7; MOUL JW, 1995, JAMA-J AM MED ASSOC, V274, P1277, DOI 10.1001/jama.274.16.1277; OESTERLING JE, 1995, BRIT J UROL, V75, P347, DOI 10.1111/j.1464-410X.1995.tb07347.x; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PIENTA KJ, 1995, UROLOGY, V45, P93, DOI 10.1016/S0090-4295(95)96996-9; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015	21	330	341	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					304	310		10.1056/NEJM199608013350502	http://dx.doi.org/10.1056/NEJM199608013350502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663870				2022-12-28	WOS:A1996UY98200002
J	Guy, E				Guy, E			Epidemiological surveillance for detecting typical Lyme disease	LANCET			English	Editorial Material							SP-NOV; BORRELIOSIS				Guy, E (corresponding author), SINGLETON HOSP,SWANSEA PUBL HLTH LAB,SWANSEA SA2 8QA,W GLAM,WALES.							Afzelius A., 1910, ARCH DERM SYPH-BERL, P405; ANDA P, 1993, CLIN INFECT DIS, V16, P310, DOI 10.1093/clind/16.2.310; BALMELLI T, 1996, J SYST BACTERIOL, V46, P167; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CANICA MM, 1993, SCAND J INFECT DIS, V25, P441, DOI 10.3109/00365549309008525; MONCO JCG, 1991, MED CLIN-BARCELONA, V98, P89; STANEK G, IN PRESS WIEN KLIN W; 1990, MMWR-MORBID MORTAL W, V39, P19	9	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					141	142		10.1016/S0140-6736(05)66105-3	http://dx.doi.org/10.1016/S0140-6736(05)66105-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684149				2022-12-28	WOS:A1996UX78900004
J	Rahhal, FM; Arevalo, JF; delaPaz, EC; Munguia, D; Azen, SP; Freeman, WR				Rahhal, FM; Arevalo, JF; delaPaz, EC; Munguia, D; Azen, SP; Freeman, WR			Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS - A preliminary report	ANNALS OF INTERNAL MEDICINE			English	Article						cytomegalovirus retinitis; acquired immunodeficiency syndrome; cidofovir; injections, intravitreous	RHEGMATOGENOUS RETINAL-DETACHMENT; GANCICLOVIR; FOSCARNET; (S)-1-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)CYTOSINE; THERAPY	Background: Cytomegalovirus retinitis remains a major cause of illness in patients with the acquired immunodeficiency syndrome (AIDS), and existing therapies for this condition are relatively ineffective and toxic. Objective: To evaluate the efficacy of intravitreous cidofovir injections alone for initial and maintenance therapy for cytomegalovirus retinitis. Design: Prospective, nonrandomized, consecutive case series. Setting: University ophthalmology referral clinic. Patients: 22 patients with AIDS and cytomegalovirus retinitis. In 15 of 32 affected eyes, intravitreous cidofovir was administered as the initial treatment for cytomegalovirus retinitis (group A); 17 eyes had previously been treated with intravenous therapy (group B). Intervention: All eyes were intravitreously injected with 20 mu g of cidofovir at 5- to 6-week intervals. No patient in either group received systemic anticytomegalovirus therapy at-any time during the study period. Measurements: Healing of retinitis was defined as resolution of retinal opacification and cessation of border progression. Progression, the primary end point, was defined as 750 microns of border progression or development of a new lesion. Results: The mean duration of follow-up was 15.3 weeks (range, 5 to 44 weeks). Of the eyes with active retinitis, 100% (95% CI, 87% to 100%) healed in response to the initial injection. In two eyes (6%; CI, 0% to 15%), two episodes of retinitis progression occurred (one in each eye). Both of these eyes were in a patient with clinically resistant retinitis. In 3% of eyes (CI, 0% to 9%). the retina became detached. Mild iritis developed after 14% of the injections that had been preceded by prophylaxis with oral probenecid. Irreversible, visually significant hypotonia developed in one eye. Conclusion: Treatment and subsequent maintenance of cytomegalovirus retinitis with 20 mu g of intravitreously injected cidofovir, given at 5- to 6-week intervals, is safe and highly effective.	UNIV SO CALIF, SCH MED, DEPT PREVENT MED, DIV BIOMETRY, LOS ANGELES, CA 90033 USA; UNIV CALIF SAN DIEGO, SCH MED, SAN DIEGO, CA 92103 USA	University of Southern California; University of California System; University of California San Diego				Arevalo Suarez, Fernando Antonio/0000-0002-4114-5949	PHS HHS [E707366] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; DIAZLLOPIS M, 1994, BRIT J OPHTHALMOL, V78, P120, DOI 10.1136/bjo.78.2.120; FANNING MM, 1990, J ACQ IMMUN DEF SYND, V3, P472; FLORESAGUILAR M, 1993, OPHTHALMOLOGY, V100, P1022; FREEMAN WR, 1993, AM J OPHTHALMOL, V116, P713, DOI 10.1016/S0002-9394(14)73471-3; FREEMAN WR, 1992, OPHTHALMOLOGY, V99, P466; HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025; HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JABS DA, 1994, OPHTHALMOLOGY, V101, P1250; KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2; KIRSH LS, 1995, AM J OPHTHALMOL, V119, P466, DOI 10.1016/S0002-9394(14)71233-4; KORETZ SH, 1986, NEW ENGL J MED, V314, P801, DOI 10.1056/NEJM198603273141301; KUPPERMANN BD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1359, DOI 10.1001/archopht.1993.01090100067029; LESAR TS, 1985, DRUG INTEL CLIN PHAR, V19, P642, DOI 10.1177/106002808501900905; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; NEYTS J, 1990, VIROLOGY, V179, P41, DOI 10.1016/0042-6822(90)90271-R; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; SNOECK R, 1988, ANTIMICROB AGENTS CH, V32, P1839, DOI 10.1128/AAC.32.12.1839; *STUD OC COMPL AID, 1995, HPMPC PER CMV RET TR; 1992, CONTROLLED CLIN TRIA, V13, P22	25	53	54	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					98	+		10.7326/0003-4819-125-2-199607150-00003	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678386				2022-12-28	WOS:A1996UV92100006
J	Bussey, H				Bussey, H			Update - Rho returns: Its targets in focal adhesions	SCIENCE			English	Editorial Material											Bussey, H (corresponding author), MCGILL UNIV,DEPT BIOL,1205 AVE DOCTEUR PENFIELD,MONTREAL,PQ H3A 1B1,CANADA.							BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	7	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					203	203		10.1126/science.273.5272.203	http://dx.doi.org/10.1126/science.273.5272.203			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8668997				2022-12-28	WOS:A1996UW78700031
J	Grant, D				Grant, D			Current results of intestinal transplantation	LANCET			English	Article								Background Intestinal transplantation is an alternative to total parenteral nutrition (TPN) for the treatment of chronic intestinal failure. To determine the current status of small-bowel transplantation, we have reviewed the world experience since 1985. Methods We built up an international registry by asking twenty-five intestinal transplantation programmes to submit standard data on their cases operated on between 1985 and June, 1995. Findings One centre (two transplantations) did not use our report form, and these cases were excluded. The remaining twenty-four programmes did 180 transplantations in 170 patients. Two-thirds of the recipients were children. The main indication (64%) was short-gut syndrome; another 13% had a tumour. Of the grafts, 38% were small-bowel with or without colon, 46% were intestine plus liver, and 16% were multivisceral. Graft/patients' survival (%) at 1 and 3 years under cyclosporin immunosuppression was, respectively: 17/57 and 11/50 for small bower only; 44/44 and 28/28 for intestine plus liver; and 41/41 and 41/41 for multiviscera. The corresponding figures under tacrolimus were: 65/83 and 29/47; 64/66 and 38/40; and 51/59 and 37/43. 78% of the 86 survivors had stopped TPN and resumed oral nutrition. Interpretation Our approach cannot give data on long-term outcome. The short-term results of intestinal transplantation are similar to those of lung grafting. We conclude that small-bowel transplantation has become a life-saving option for patients who cannot be maintained on TPN and for those who require massive abdominal evisceration for locally aggressive tumours.			Grant, D (corresponding author), LONDON HLTH SCI CTR,4-TU36,UNIV CAMPUS,LONDON,ON N6A 5A5,CANADA.							ASFAR S, 1994, SURG CLIN N AM, V74, P1197, DOI 10.1016/S0039-6109(16)46441-8; CANIANO DA, 1988, NEW ENGL J MED, V318, P703, DOI 10.1056/NEJM198803173181111; GRUESSNER RWG, 1995, TRANSPLANTATION, V59, P164, DOI 10.1097/00007890-199501270-00002; HOFFMAN AL, 1990, TRANSPLANTATION, V49, P483, DOI 10.1097/00007890-199003000-00001; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; THOMPSON JS, 1995, ANN SURG, V222, P600; TODO S, 1995, ANN SURG, V222, P270, DOI 10.1097/00000658-199509000-00006	7	177	181	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1801	1803		10.1016/S0140-6736(96)91619-0	http://dx.doi.org/10.1016/S0140-6736(96)91619-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667925				2022-12-28	WOS:A1996UU46900012
J	Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A				Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A			Measles and atopy in Guinea-Bissau	LANCET			English	Article							SKIN-TEST REACTIVITY; RESPIRATORY-INFECTIONS; CHILD-MORTALITY; VACCINATION; PREVALENCE; POPULATION; NUTRITION; COMMUNITY; ASTHMA; HEALTH	Background Epidemiological studies have led to speculation that infections in early childhood may prevent allergic sensitisation but evidence to support this hypothesis is lacking. We investigated whether measles infection protects against the development of atopy in children of Guinea-Bissau, West Africa. Methods We conducted a historical cohort study in Bandim, a semi-rural district of Bissau, the capital of Guinea-Bissau. 395 young adults, first surveyed in 1978-80 aged 0-6 years, were followed up in 1994. Our analyses were restricted to 262 individuals still living in Bandim for whom a measles history, documented in childhood, was judged to be reliable. We defined atopy as skin-prick test positivity (greater than or equal to 3 mm weal) to one OF more of seven allergens. Findings 17 (12.8%) of 133 participants who had had measles infection were atopic compared with 33 (25.6%) of 129 of those who had been vaccinated and not had measles (odds ratio, adjusted for potential confounding variables 0.36 [95% CI 0.17-0.78], p=0.01). Participants who had been breastfed for more than a year were less likely to have a positive skin test to housedust mite. After adjustment for breastfeeding and other variables, measles infection was associated with a large reduction in the risk of shin-prick test positivity to housedust mite (odds ratio for Dermatophagoides pteronyssinus 0.20 [0.05-0.81], p=0.02; D farinae 0.20 [0.06-0.71], p=0.01). Interpretation Measles infection may prevent the development of atopy in African children.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,HANTS,ENGLAND; STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN,DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND; MINIST PUBL HLTH,BISSAU,GUINEA BISSAU	University of Southampton; Aarhus University; Statens Serum Institut; University of London; London School of Hygiene & Tropical Medicine				Aaby, Peter/0000-0001-8331-1389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1983, J INFECT DIS, V147, P693, DOI 10.1093/infdis/147.4.693; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; AABY P, 1995, CROWDING HLTH LOW IN; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; Burnet M., 1972, NATURAL HIST INFECT; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; Gardner M. J., 1989, STAT CONFIDENCE; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P295; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209, DOI 10.1159/000236521; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MAGGI E, 1992, J IMMUNOL, V148, P2142; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Pepys J., 1975, BRIT J HOSP MED, V14, P412; Peters T J, 1987, Paediatr Perinat Epidemiol, V1, P80, DOI 10.1111/j.1365-3016.1987.tb00092.x; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; SIGURS N, 1995, PEDIATRICS, V95, P500; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573	34	461	472	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1792	1796		10.1016/S0140-6736(96)91617-7	http://dx.doi.org/10.1016/S0140-6736(96)91617-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667923				2022-12-28	WOS:A1996UU46900010
J	New, B				New, B			The rationing agenda in the NHS	BRITISH MEDICAL JOURNAL			English	Article											New, B (corresponding author), KINGS FUND POLICY INST,LONDON W1M 0AN,ENGLAND.							Doyal L, 1995, Qual Health Care, V4, P273, DOI 10.1136/qshc.4.4.273; Harrison Stephan, 1994, RATIONING HLTH CARE; Maxwell R., 1995, RATIONING HLTH CARE; PETERS BG, 1989, POLITICS BUREAUCRACY; REDMAYNE S, 1993, BRIT MED J, V306, P1521, DOI 10.1136/bmj.306.6891.1521; WALLEY T, 1995, BRIT MED J, V311, P796, DOI 10.1136/bmj.311.7008.796	6	61	62	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1593	1601		10.1136/bmj.312.7046.1593	http://dx.doi.org/10.1136/bmj.312.7046.1593			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664673	Green Published			2022-12-28	WOS:A1996UU80600026
J	Bostrom, H; Willetts, K; Pekny, M; Leveen, P; Lindahl, P; Hedstrand, H; Pekna, M; Hellstrom, M; GebreMedhin, S; Schalling, M; Nilsson, M; Kurland, S; Tornell, J; Heath, JK; Betsholtz, C				Bostrom, H; Willetts, K; Pekny, M; Leveen, P; Lindahl, P; Hedstrand, H; Pekna, M; Hellstrom, M; GebreMedhin, S; Schalling, M; Nilsson, M; Kurland, S; Tornell, J; Heath, JK; Betsholtz, C			PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis	CELL			English	Article							GROWTH-FACTOR-A; ALPHA-RECEPTOR; MOUSE EMBRYOS; EXPRESSION; CELLS; CHAIN; PREIMPLANTATION; EMBRYOGENESIS; LOCALIZATION; MUTATION	A mouse platelet-derived growth factor A chain (PDGF-A) null allele is shown to be homozygous lethal, with two distinct restriction points, one prenatally before E10 and one postnatally. Postnatally surviving PDGF-A-deficient mice develop lung emphysema secondary to the failure of alveolar septation. This is apparently caused by the loss of alveolar myofibroblasts and associated elastin fiber deposits. PDGF alpha receptor-positive cells in the lung having the location of putative alveolar myofibroblast progenitors were specifically absent in PDGF-A null mutants. We conclude that PDGF-A is crucial for alveolar myofibroblast ontogeny. We have previously shown that PDGF-B is required in the ontogeny of kidney mesangial cells. The PDGFs therefore appear to regulate the generation of specific populations of myofibroblasts during mammalian development. The two PDGF null phenotypes also reveal analogous morphogenetic functions for myofibroblast-type cells in lung and kidney organogenesis.	GOTHENBURG UNIV,DEPT PHYSIOL,S-41390 GOTHENBURG,SWEDEN; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; KAROLINSKA HOSP,DEPT MOLEC MED,NEUROGENET UNIT,S-17176 STOCKHOLM,SWEDEN	University of Gothenburg; University of Birmingham; University of Oxford; Karolinska Institutet; Karolinska University Hospital	Bostrom, H (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN.		Pekna, Marcela/AAM-3261-2021; Schalling, Martin/F-1518-2015; Ehrencrona, Hans/M-5619-2014; Pekna, Marcela/AAM-3249-2021; Ehrencrona, Hans/Q-4621-2019	Pekna, Marcela/0000-0003-2734-8237; Schalling, Martin/0000-0001-5011-2922; Ehrencrona, Hans/0000-0002-5589-3622; Pekna, Marcela/0000-0003-2734-8237; Ehrencrona, Hans/0000-0002-5589-3622; Hellstrom, Mats/0000-0002-7088-9533				ADAMSON IYR, 1985, EXP LUNG RES, V8, P261, DOI 10.3109/01902148509087808; ADLER KB, 1989, LAB INVEST, V60, P473; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; Betsholtz C, 1995, INT J DEV BIOL, V39, P817; BRODY AR, 1991, CHEST, V99, pS50, DOI 10.1378/chest.99.3_Supplement.50S; DAMIANO VV, 1979, AM J PATHOL, V96, P439; DUTTLINGER R, 1995, P NATL ACAD SCI USA, V92, P3754, DOI 10.1073/pnas.92.9.3754; EMERY JL, 1970, RESPIRATION, V27, P41, DOI 10.1159/000192718; FUKUDA Y, 1983, AM J ANAT, V167, P405, DOI 10.1002/aja.1001670402; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1993, GROWTH FACTORS, V8, P245, DOI 10.3109/08977199308991570; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KAPANCI Y, 1974, J CELL BIOL, V60, P375, DOI 10.1083/jcb.60.2.375; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LESLIE KO, 1990, DIFFERENTIATION, V44, P143, DOI 10.1111/j.1432-0436.1990.tb00547.x; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; NOGUCHI A, 1989, EXP LUNG RES, V4, P537; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAMACHANDRAN RK, 1995, DEV DYNAM, V204, P77, DOI 10.1002/aja.1002040110; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; Rorsman F, 1992, GROWTH FACTORS, V6, P303, DOI 10.3109/08977199209021542; Rubin E, 1988, PATHOLOGY, P1444; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHURCH W, 1992, HISTOLOGY PATHOLOGIS, P109; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SMITH A, 1978, WOLFE MED ATLASES, V18; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; [No title captured]	41	624	635	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					863	873		10.1016/S0092-8674(00)81270-2	http://dx.doi.org/10.1016/S0092-8674(00)81270-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681381	Bronze			2022-12-28	WOS:A1996UR60400010
J	Denton, CP; Black, CM; Korn, JH; deCrombrugghe, B				Denton, CP; Black, CM; Korn, JH; deCrombrugghe, B			Systemic sclerosis: Current pathogenetic concepts and future prospects for targeted therapy	LANCET			English	Editorial Material							I COLLAGEN GENES; SCLERODERMA FIBROBLASTS; TRANSGENIC MICE; EXPRESSION; PROMOTER; ACTIVATION; DISEASE; CELLS	Although there is no cure for systemic sclerosis, the disease is certainly treatable. And the more that is understood of its pathogenesis, the better the prospects for treatment. Excessive collagen deposition in the skin and viscera is responsible for the morbidity and mortality. The immune system plays a critical role in setting up the fibrotic process, but impaired regulation of collagen gene expression probably underlies the persistence of fibrosis. The development of effective antifibrotic drugs, in particular agents that inhibit transcription factors involved in the activation of type I collagen genes, is likely to be the way forward for treatment of the later stages of diffuse systemic sclerosis, with immunomodulatory therapy for the earlier stages.	ROYAL FREE HOSP,SCH MED,DEPT MED,DIV RHEUMATOL,LONDON NW3 2QG,ENGLAND; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Texas System; UTMD Anderson Cancer Center; Boston University; Boston University								ABRAHAM D, 1991, ARTHRITIS RHEUM, V34, P1164, DOI 10.1002/art.1780340913; BLACK CM, 1993, J INTERN MED, V234, P3, DOI 10.1111/j.1365-2796.1993.tb00697.x; BLACK CM, 1995, BRIT J RHEUMATOL, V34, P3; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BOTSTEIN GR, 1982, ARTHRITIS RHEUM, V25, P189, DOI 10.1002/art.1780250212; BOUGHARIOS G, 1996, IN PRESS J CELL BIOL; BRIGGS D, 1990, RHEUM DIS CLIN N AM, V16, P31; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HIRAKATA M, 1993, J CLIN INVEST, V91, P2665, DOI 10.1172/JCI116505; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JAFFEE BD, 1983, CELL IMMUNOL, V77, P1, DOI 10.1016/0008-8749(83)90001-1; JIMENEZ SA, 1986, BIOCHEM J, V237, P837, DOI 10.1042/bj2370837; KAHARI VM, 1987, FEBS LETT, V215, P331, DOI 10.1016/0014-5793(87)80172-2; KAHARI VM, 1993, ANN MED, V25, P511; LEROY EC, 1988, J RHEUMATOL, V15, P202; Leroy Edward Carwile, 1994, Journal of Dermatology (Tokyo), V21, P1; LISKA DJ, 1992, J CELL BIOL, V119, P1361; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; OBRIEN BM, 1992, J HAND SURG-BRIT EUR, V17B, P447, DOI 10.1016/S0266-7681(05)80272-4; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; Postlethwaite Arnold E., 1993, Current Opinion in Rheumatology, V5, P766; PRESCOTT RJ, 1992, J PATHOL, V166, P255, DOI 10.1002/path.1711660307; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SILMAN AJ, 1991, ANN RHEUM DIS, V50, P267, DOI 10.1136/ard.50.4.267; SILVER RM, 1993, J RHEUMATOL, V20, P838; SJOGREN RW, 1994, ARTHRITIS RHEUM-US, V37, P1265, DOI 10.1002/art.1780370902; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; STEEN VD, 1990, ANN INTERN MED, V113, P352, DOI 10.7326/0003-4819-113-5-352; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORIO T, 1985, J CELL BIOCHEM, V28, P105, DOI 10.1002/jcb.240280204; WELLS AU, 1992, THORAX, V47, P738, DOI 10.1136/thx.47.9.738	33	72	73	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1453	1458		10.1016/S0140-6736(96)91687-6	http://dx.doi.org/10.1016/S0140-6736(96)91687-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676631				2022-12-28	WOS:A1996UM48500014
J	Knox, TA; Olans, LB				Knox, TA; Olans, LB			Current concepts - Liver disease in pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE FATTY LIVER; LOW PLATELETS HELLP; SEVERE PREECLAMPSIA-ECLAMPSIA; BUDD-CHIARI SYNDROME; OBSTETRIC CHOLESTASIS; HYPEREMESIS GRAVIDARUM; INTRAHEPATIC CHOLESTASIS; SYNDROME HEMOLYSIS; ENZYMES; MANAGEMENT				Knox, TA (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV GASTROENTEROL, BOX 103, 750 WASHINGTON ST, BOSTON, MA 02111 USA.							ADAMS RH, 1968, OBSTET GYNECOL, V31, P659, DOI 10.1097/00006250-196805000-00011; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; ANTIA FP, 1958, LANCET, V2, P776; Bacq Y, 1993, Gastroenterologist, V1, P257; BARRON WM, 1992, GASTROENTEROL CLIN N, V21, P851; BARTON JR, 1992, GASTROENTEROL CLIN N, V21, P937; BARTON JR, 1992, AM J OBSTET GYNECOL, V167, P1538, DOI 10.1016/0002-9378(92)91735-S; BEAN WB, 1949, SURG GYNECOL OBSTET, V88, P739; CAMPILLO B, 1986, ANN INTERN MED, V105, P383, DOI 10.7326/0003-4819-105-3-383; COHEN L, 1972, GASTROENTEROLOGY, V62, P1182; ELLIOTT JR, 1971, CLIN CHEM, V17, P156; FISK NM, 1988, BRIT J OBSTET GYNAEC, V95, P1137, DOI 10.1111/j.1471-0528.1988.tb06791.x; FISK NM, 1988, AUST NZ J OBSTET GYN, V28, P172, DOI 10.1111/j.1479-828X.1988.tb01657.x; GOODLIN RC, 1985, J REPROD MED, V30, P368; GROSS S, 1989, AM J OBSTET GYNECOL, V160, P906, DOI 10.1016/0002-9378(89)90307-4; HIBBARD LT, 1976, AM J OBSTET GYNECOL, V126, P334, DOI 10.1016/0002-9378(76)90545-7; HIRVIOJA ML, 1992, BRIT J OBSTET GYNAEC, V99, P109, DOI 10.1111/j.1471-0528.1992.tb14465.x; JAMIDAR PA, 1995, AM J GASTROENTEROL, V90, P1263; JOHNSTON WG, 1979, AM J OBSTET GYNECOL, V133, P299, DOI 10.1016/0002-9378(79)90683-5; KAPLAN MM, 1985, NEW ENGL J MED, V313, P367, DOI 10.1056/NEJM198508083130606; KHUROO MS, 1980, AM J MED, V68, P113, DOI 10.1016/0002-9343(80)90180-1; KLEIN NA, 1991, GASTROENTEROLOGY, V100, P239, DOI 10.1016/0016-5085(91)90607-M; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LAATIKAINEN T, 1977, OBSTET GYNECOL, V50, P313; LARREY D, 1984, GUT, V25, P1414, DOI 10.1136/gut.25.12.1414; LONG RG, 1977, J CLIN PATHOL, V30, P212, DOI 10.1136/jcp.30.3.212; LUNZER M, 1986, GASTROENTEROLOGY, V91, P825, DOI 10.1016/0016-5085(86)90682-7; MAGANN EF, 1994, AM J OBSTET GYNECOL, V171, P1154, DOI 10.1016/0002-9378(94)90055-8; MAGANN EF, 1994, AM J OBSTET GYNECOL, V171, P1148, DOI 10.1016/0002-9378(94)90054-X; MANAS KJ, 1985, NEW ENGL J MED, V312, P424, DOI 10.1056/NEJM198502143120707; MARTIN JN, 1990, AM J OBSTET GYNECOL, V162, P126, DOI 10.1016/0002-9378(90)90835-U; MARTIN JN, 1991, AM J OBSTET GYNECOL, V164, P1500, DOI 10.1016/0002-9378(91)91429-Z; MINAKAMI H, 1988, AM J OBSTET GYNECOL, V159, P1043, DOI 10.1016/0002-9378(88)90407-3; MINAKAMI H, 1991, AM J OBSTET GYNECOL, V164, P1690, DOI 10.1016/0002-9378(91)91465-9; MITCHELL MC, 1982, MEDICINE, V61, P199, DOI 10.1097/00005792-198207000-00001; OCKNER SA, 1990, HEPATOLOGY, V11, P59, DOI 10.1002/hep.1840110112; PALMA J, 1992, HEPATOLOGY, V15, P1043, DOI 10.1002/hep.1840150612; POCKROS PJ, 1984, MEDICINE, V63, P1; REID R, 1976, BRIT MED J, V1, P870, DOI 10.1136/bmj.1.6014.870; REYES H, 1992, GASTROENTEROL CLIN N, V21, P905; RIELY CA, 1987, SEMIN LIVER DIS, V7, P47, DOI 10.1055/s-2008-1040563; RIELY CA, 1987, ANN INTERN MED, V106, P703, DOI 10.7326/0003-4819-106-5-703; ROLFES DB, 1986, AM J GASTROENTEROL, V81, P1138; ROLFES DB, 1985, HEPATOLOGY, V5, P1149, DOI 10.1002/hep.1840050615; RUSTGI VK, 1987, SEMIN LIVER DIS, V7, P40, DOI 10.1055/s-2008-1040562; SELIGMAN SP, 1994, AM J OBSTET GYNECOL, V171, P944, DOI 10.1016/S0002-9378(94)70064-8; SIBAI BM, 1995, AM J OBSTET GYNECOL, V172, P125, DOI 10.1016/0002-9378(95)90099-3; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P501, DOI 10.1016/0002-9378(86)90266-8; SIBAI BM, 1984, OBSTET GYNECOL, V64, P319; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P311, DOI 10.1016/0002-9378(90)90376-I; SIBAI BM, 1982, OBSTET GYNECOL, V59, P153; SIBAI BM, 1993, AM J OBSTET GYNECOL, V169, P1000, DOI 10.1016/0002-9378(93)90043-I; STEVEN MM, 1981, GUT, V22, P592, DOI 10.1136/gut.22.7.592; SULLIVAN CA, 1994, AM J OBSTET GYNECOL, V171, P940, DOI 10.1016/S0002-9378(94)70063-X; THIAGARAJAH S, 1984, AM J OBSTET GYNECOL, V150, P1; USTA IM, 1994, AM J OBSTET GYNECOL, V171, P1342, DOI 10.1016/0002-9378(94)90158-9; VANDAM PA, 1989, OBSTET GYNECOL, V73, P97; WALLSTEDT A, 1990, CLIN RES, V38, pA970; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; ZUCKERMAN H, 1965, OBSTET GYNECOL, V25, P819	60	161	165	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					569	576		10.1056/NEJM199608223350807	http://dx.doi.org/10.1056/NEJM199608223350807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8678935				2022-12-28	WOS:A1996VD30200007
J	Lowndes, DH; Geohegan, DB; Puretzky, AA; Norton, DP; Rouleau, CM				Lowndes, DH; Geohegan, DB; Puretzky, AA; Norton, DP; Rouleau, CM			Synthesis of novel thin-film materials by pulsed laser deposition	SCIENCE			English	Article							AMORPHIC DIAMOND FILMS; CARBON-FILMS; YBA2CU3O7-X/PRBA2CU3O7-X SUPERLATTICES; EXCIMER-LASER; ABLATION; EVAPORATION; GROWTH; SUPERCONDUCTIVITY; MAGNETORESISTANCE; SPECTROSCOPY	Pulsed laser deposition (PLD) is a conceptually and experimentally simple yet highly versatile tool for thin-film and multilayer research. Its advantages for the film growth of oxides and other chemically complex materials include stoichiometric transfer, growth from an energetic beam, reactive deposition, and inherent simplicity for the growth of multilayered structures. With the use of PLD, artificially layered materials and metastable phases have been created and their properties varied by control of the layer thicknesses. In situ monitoring techniques have provided information about the role of energetic species in the formation of ultrahard phases and in the doping of semiconductors. Cluster-assembled nanocrystalline and composite films offer opportunities to control and produce new combinations of properties with PLD.	RUSSIAN ACAD SCI, INST SPECT, TROITSK 142092, RUSSIA	Russian Academy of Sciences; Institute of Spectroscopy	Lowndes, DH (corresponding author), OAK RIDGE NATL LAB, DIV SOLID STATE, POB 2008, OAK RIDGE, TN 37831 USA.		Puretzky, Alexander/B-5567-2016; Geohegan, David B/D-3599-2013; Rouleau, Christopher M/Q-2737-2015	Puretzky, Alexander/0000-0002-9996-4429; Geohegan, David B/0000-0003-0273-3139; Rouleau, Christopher M/0000-0002-5488-3537				BERGER SD, 1988, PHIL MAG LETT, V57, P285, DOI 10.1080/09500838808214715; CANHAM L, 1993, MRS BULL, V18, P22, DOI 10.1557/S0883769400037490; CHEN LC, 1994, PULSED LASER DEPOSIT, P167; CHERN MY, 1993, J VAC SCI TECHNOL A, V11, P637, DOI 10.1116/1.578784; CHIU LA, 1994, J ELECTRON MATER, V23, P347, DOI 10.1007/BF03296063; Chrisey D.B., 1994, PULSED LASER DEPOSIT; Christen HM, 1996, APPL PHYS LETT, V68, P1488, DOI 10.1063/1.116263; COLLINS CB, 1993, J VAC SCI TECHNOL B, V11, P1936, DOI 10.1116/1.586525; COLLINS CB, 1991, J APPL PHYS, V69, P7862, DOI 10.1063/1.347519; CUOMO JJ, 1991, J APPL PHYS, V70, P1706, DOI 10.1063/1.349540; DAVANLOO F, 1992, J APPL PHYS, V71, P1446, DOI 10.1063/1.351267; DAVANLOO F, 1990, J APPL PHYS, V67, P2081, DOI 10.1063/1.345566; DIJKKAMP D, 1987, APPL PHYS LETT, V51, P619, DOI 10.1063/1.98366; FEILER D, IN PRESS J CRYST GRO; FULLERTON EE, 1993, APPL PHYS LETT, V63, P1699, DOI 10.1063/1.110689; Geohegan DB, 1996, APPL SURF SCI, V96-8, P131, DOI 10.1016/0169-4332(95)00421-1; GEOHEGAN DB, 1995, APPL PHYS LETT, V67, P197, DOI 10.1063/1.114665; GEOHEGAN DB, IN PRESS MATER RES S; GREER JA, 1995, J VAC SCI TECHNOL A, V13, P1175, DOI 10.1116/1.579857; Jaskie JE, 1996, MRS BULL, V21, P59, DOI 10.1557/S0883769400036149; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; JIN S, 1995, APPL PHYS LETT, V67, P557, DOI 10.1063/1.115168; KAWAI T, 1991, NATURE, V348, P2000; KOINUMA H, 1991, APPL PHYS LETT, V58, P2027, DOI 10.1063/1.105002; KOINUMA H, IN PRESS MATER RES S; LEE LP, 1991, APPL PHYS LETT, V59, P3051, DOI 10.1063/1.105790; LI Q, 1990, PHYS REV LETT, V64, P3086, DOI 10.1103/PhysRevLett.64.3086; LI XM, 1994, JPN J APPL PHYS 2, V33, pL18, DOI 10.1143/JJAP.33.L18; LOWNDES DH, 1990, PHYS REV LETT, V65, P1160, DOI 10.1103/PhysRevLett.65.1160; LOWNDES DH, IN PRESS MATER RES S; Marks NA, 1996, PHYS REV LETT, V76, P768, DOI 10.1103/PhysRevLett.76.768; MCKENZIE DR, 1991, PHYS REV LETT, V67, P773, DOI 10.1103/PhysRevLett.67.773; NORTON DP, 1994, SCIENCE, V265, P2074, DOI 10.1126/science.265.5181.2074; PAPPAS DL, 1992, J APPL PHYS, V72, P3966, DOI 10.1063/1.352249; PAPPAS DL, 1992, J APPL PHYS, V71, P5675, DOI 10.1063/1.350501; POWERS DE, 1982, J PHYS CHEM-US, V86, P2556, DOI 10.1021/j100211a002; Puretzky AA, 1996, APPL SURF SCI, V96-8, P859, DOI 10.1016/0169-4332(95)00567-6; PURETZKY AA, 1995, FILM SYNTHESIS GROWT, V388, P145; Ramesh R., 1995, Science and Technology of Electroceramic Thin Films. Proceedings of the NATO Advanced Research Workshop, P1; RAMESH R, 1994, MATER RES SOC SYMP P, V343, P431, DOI 10.1557/PROC-343-431; RINNEN KD, 1992, J CHEM PHYS, V96, P4088, DOI 10.1063/1.461864; ROULEAU CM, 1995, APPL PHYS LETT, V67, P2545, DOI 10.1063/1.114453; ROULEAU CM, IN PRESS MATER RES S; SANKUR H, 1988, APPL PHYS A-MATER, V47, P271, DOI 10.1007/BF00615933; SHAW TM, 1994, J MATER RES, V9, P2566, DOI 10.1557/JMR.1994.2566; SMITH HM, 1965, APPL OPTICS, V4, P147, DOI 10.1364/AO.4.000147; TABATA H, 1994, APPL PHYS LETT, V65, P1970, DOI 10.1063/1.112837; TRISCONE JM, 1990, PHYS REV LETT, V64, P804, DOI 10.1103/PhysRevLett.64.804; VENKATESAN T, 1988, APPL PHYS LETT, V52, P1193, DOI 10.1063/1.99673; WIJEKOON WMKP, 1995, APPL PHYS LETT, V67, P1698, DOI 10.1063/1.115061; WITANACHCHI S, 1995, APPL PHYS LETT, V66, P1469, DOI 10.1063/1.113657; WITANACHCHI S, 1995, J VAC SCI TECHNOL A, V13, P1171, DOI 10.1116/1.579856; WU XD, 1987, APPL PHYS LETT, V51, P861, DOI 10.1063/1.98837; XIONG FL, 1993, PHYS REV B, V48, P8016, DOI 10.1103/PhysRevB.48.8016; XIONG FL, 1993, J MATER RES, V8, P2265, DOI 10.1557/JMR.1993.2265; Yoshida T, 1996, APPL PHYS LETT, V68, P1772, DOI 10.1063/1.116662	56	514	524	8	307	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					898	903		10.1126/science.273.5277.898	http://dx.doi.org/10.1126/science.273.5277.898			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688065				2022-12-28	WOS:A1996VC67000037
J	Urbina, JA; Payares, G; Molina, J; Sanoja, C; Liendo, A; Lazardi, K; Piras, MM; Piras, R; Perez, N; Wincker, P; Ryley, JF				Urbina, JA; Payares, G; Molina, J; Sanoja, C; Liendo, A; Lazardi, K; Piras, MM; Piras, R; Perez, N; Wincker, P; Ryley, JF			Cure of short- and long-term experimental Chagas' disease using D0870	SCIENCE			English	Article							TRYPANOSOMA SCHIZOTRYPANUM CRUZI; TRIAZOLE D0870; BLOOD-SAMPLES; IN-VITRO; KETOCONAZOLE; EPIMASTIGOTES; INVITRO; TRYPANOSOMA-(SCHIZOTRYPANUM)-CRUZI; CHEMOTHERAPY; COMBINATIONS	Chagas' disease, a protozoan infection by the kinetoplastid Trypanosoma cruzi, constitutes a major public health problem in Latin America. With the use of mouse models of both short- and long-term forms of the disease, the efficacy of D0870, a bis-triazole derivative, was tested. D0870 was able to prevent death and induced parasitological cure in 70 to 90 percent of animals, in both the short- and long-term disease. In contrast, currently used drugs such as nifurtimox or ketoconazole prolonged survival but did not induce significant curing effects. D0870 may be useful in the treatment of human long-term Chagas' disease, a condition that is currently incurable.	CENT UNIV VENEZUELA,FAC CIENCIAS,DEPT PARASITOL,INST ZOOL TROP,CARACAS 1040,VENEZUELA; CTR MED DOCENTE LA TRINIDAD,UNIDAD INVEST,CARACAS 1080,VENEZUELA; UNIV MONTPELLIER,FAC MED,LAB GENOME PARASITES,F-34000 MONTPELLIER,FRANCE	University of Central Venezuela; Universite de Montpellier	Urbina, JA (corresponding author), INST VENEZOLANO INVEST CIENT,LAB QUIM BIOL,CTR BIOQUIM & BIOFIS,APARTADO 21827,CARACAS 1020A,VENEZUELA.							ATKINSON BA, 1994, ANTIMICROB AGENTS CH, V38, P1604, DOI 10.1128/AAC.38.7.1604; BRENER Z, 1993, MEM I OSWALDO CRUZ, V88, P149, DOI 10.1590/S0074-02761993000100023; BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030; CLEMONS KV, 1994, J MED VET MYCOL, V32, P323; CLEMONS KV, 1995, ANTIMICROB AGENTS CH, V39, P778, DOI 10.1128/AAC.39.3.778; de Maio A., 1984, Acta Cientifica Venezolana, V35, P136; DECASTRO SL, 1993, ACTA TROP, V53, P83, DOI 10.1016/0001-706X(93)90021-3; DEWIT S, 1995, ICAAC ABSTR, V35, pF97; GOAD LJ, 1989, MOL BIOCHEM PARASIT, V32, P179, DOI 10.1016/0166-6851(89)90069-8; KARYOTAKIS NC, 1995, ANTIMICROB AGENTS CH, V39, P571, DOI 10.1128/AAC.39.2.571; LARRALDE G, 1988, ACTA CIENT VENEZ, V39, P140; LAZARDI K, 1991, ANTIMICROB AGENTS CH, V35, P736, DOI 10.1128/AAC.35.4.736; MALDONADO RA, 1993, ANTIMICROB AGENTS CH, V37, P1353, DOI 10.1128/AAC.37.6.1353; MCCABE R, 1988, J INFECT DIS, V158, P1408, DOI 10.1093/infdis/158.6.1408; MOREIRA AAB, 1992, REV I MED TROP, V34, P177, DOI 10.1590/S0036-46651992000200015; Rassi A, 1992, CHAGAS DIS AM TYP IT, P237; RILEY JF, 1988, ANN NY ACAD SCI, V544, P310; URBINA JA, 1991, ANTIMICROB AGENTS CH, V35, P730, DOI 10.1128/AAC.35.4.730; Urbina JA, 1996, CHEMOTHERAPY, V42, P294, DOI 10.1159/000239458; URBINA JA, 1993, ANTIMICROB AGENTS CH, V37, P580, DOI 10.1128/AAC.37.3.580; URBINA JA, 1995, MOL BIOCHEM PARASIT, V73, P199, DOI 10.1016/0166-6851(95)00117-J; URBINA JA, 1988, ANTIMICROB AGENTS CH, V32, P1237, DOI 10.1128/AAC.32.8.1237; VANDENBOSSCHE H, 1992, RECENT PROGRESS IN ANTIFUNGAL CHEMOTHERAPY, P25; VANDENBOSSCHE H, 1995, MODERN SELECTIVE FUN, P431; WARDLE HM, 1995, ANTIMICROB AGENTS CH, V39, P868, DOI 10.1128/AAC.39.4.868; WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771; *WORLD BANK, 1993, 1993 WORLD BANK WORL; YAMADA H, 1993, ANTIMICROB AGENTS CH, V37, P2412, DOI 10.1128/AAC.37.11.2412	28	161	164	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					969	971		10.1126/science.273.5277.969	http://dx.doi.org/10.1126/science.273.5277.969			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688084				2022-12-28	WOS:A1996VC67000067
J	Terada, S; Nakata, T; Peterson, AC; Hirokawa, N				Terada, S; Nakata, T; Peterson, AC; Hirokawa, N			Visualization of slow axonal transport in vivo	SCIENCE			English	Article							RECOMBINANT ADENOVIRUSES IMPROVES; NEURONAL INTERMEDIATE FILAMENTS; INVIVO GENE-TRANSFER; NF-M; NEUROFILAMENT PROTEIN; CYSTIC-FIBROSIS; MODEL SYSTEM; CYTOSKELETON; SEQUENCE; VECTOR	In axons, cytoskeletal constituents move by slow transport, However, it remains controversial whether axonal neurofilaments are dynamic structures in which only subunits are transported or whether filaments assemble in the proximal axon and are transported intact as polymers to the axon terminus. To investigate the form neurofilament proteins rake during transport, neurons of transgenic mice lacking axonal neurofilaments were infected with a recombinant adenoviral vector encoding epitope-tagged neurofilament M. Confocal and electron microscopy revealed that the vitally encoded neurofilament M was transported in unpolymerized form along axonal microtubules. Thus, neurofilament proteins are probably transported as subunits or small oligomers along microtubules, which are major routes for slow axonal transport.	UNIV TOKYO, BRAIN RES INST, FAC MED, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN; MCGILL UNIV, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA	University of Tokyo; University of Tokyo; McGill University				Terada, Sumio/0000-0001-5689-0186				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BLUM JJ, 1989, CELL MOTIL CYTOSKEL, V12, P53, DOI 10.1002/cm.970120107; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CLEVELAND DW, 1991, CELL, V67, P453, DOI 10.1016/0092-8674(91)90518-4; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; GEISLER N, 1984, EMBO J, V3, P2701, DOI 10.1002/j.1460-2075.1984.tb02196.x; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; Hayat MA, 1989, PRINCIPLES TECHNIQUE; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HIROKAWA N, 1985, J CELL BIOL, V101, P227, DOI 10.1083/jcb.101.1.227; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1990, NATURE, V343, P408, DOI 10.1038/343408a0; JOSHI HC, 1993, J CELL BIOL, V121, P1191, DOI 10.1083/jcb.121.6.1191; JULIEN JP, UNPUB; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KOMIYA Y, 1986, BIOMED RES-TOKYO, V7, P359; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LASEK RJ, 1982, PHILOS T ROY SOC B, V299, P313, DOI 10.1098/rstb.1982.0135; LASEK RJ, 1986, J CELL SCI, P161; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1986, J CELL BIOL, V102, P647, DOI 10.1083/jcb.102.2.647; NIXON RA, 1991, NEURONAL CYTOSKELETO; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; TAKEDA S, 1994, J CELL BIOL, V127, P173, DOI 10.1083/jcb.127.1.173; TASHIRO T, 1989, J NEUROSCI, V9, P760; YAMASAKI H, 1992, LAB INVEST, V66, P734; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	45	82	82	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					784	788		10.1126/science.273.5276.784	http://dx.doi.org/10.1126/science.273.5276.784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670416				2022-12-28	WOS:A1996VB42900039
J	Khalak, R; Roberts, JK				Khalak, R; Roberts, JK			Cauliflower ear	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Khalak, R (corresponding author), UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14621, USA.								0	2	2	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					399	399		10.1056/NEJM199608083350605	http://dx.doi.org/10.1056/NEJM199608083350605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8676933				2022-12-28	WOS:A1996VA90400005
J	Hanoch, J; Feigin, E; Pikarsky, A; Kugel, C; Rivkind, A				Hanoch, J; Feigin, E; Pikarsky, A; Kugel, C; Rivkind, A			Stab wounds associated with terrorist activities in Israel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELECTIVE MANAGEMENT; INJURY; EXPERIENCE; VICTIMS; CHEST	Objective.-To describe injuries resulting from terrorist-associated knife stabbings. Design.-Retrospective case series. Setting.-Israel (population 5.5 million). Subjects.-Israeli victims (N=154) of knife stabbings on nationalistic basis (the intifada) between July 1987 and April 1994. Results.-A total of 125 men and 29 women sustained stab wounds associated with terrorist activities. The median age was 28 years (range, 12-92 years), and 99 victims were aged 18 to 35 years. Seventy percent (108 patients) of the stabbing events occurred between 7 AM and 11 AM. The 154 victims sustained a total of 327 stab wounds, the median number of injuries was 2 per person (range, 1-28), and 68 individuals (44%) sustained more than 1 stab wound. The chest was the most commonly involved site (146 wounds), with the right posterior chest stabbed in 71 patients. The knife penetrated the heart in 20 patients and penetrated the peritoneal cavity in 29 patients. Overall, 29 patients (19%) had superficial injuries, 86 (56%) had internal organ injuries that mandated operative interventions, and 39 died (overall mortality, 25.3%). Conclusions.-Unlike other civilian stabbings, wounds resulting from terrorist-associated stabbings represent severe and highly lethal injuries.	HADASSAH UNIV HOSP,TRAUMA UNIT,DEPT SURG,IL-91120 JERUSALEM,ISRAEL; TEL AVIV UNIV,INST FORENS MED,IL-69978 TEL AVIV,ISRAEL	Hebrew University of Jerusalem; Tel Aviv University								*AM COLL SURG COMM, 1988, ADV TRAUM LIF SUPP, P3; DONCHIN Y, 1994, J TRAUMA, V37, P552, DOI 10.1097/00005373-199410000-00006; FLETCHER TB, 1989, RADIOLOGY, V173, P621, DOI 10.1148/radiology.173.3.2813764; FULLUM TM, 1990, J NATL MED ASSOC, V82, P109; GOODMAN RA, 1986, AM J PUBLIC HEALTH, V76, P144, DOI 10.2105/AJPH.76.2.144; ITANI KMF, 1992, J TRAUMA, V32, P302, DOI 10.1097/00005373-199203000-00007; KRESSEL GM, 1981, MURDER NAME FAMILY H; LAMBRIANIDES AL, 1984, INJURY, V15, P300, DOI 10.1016/0020-1383(84)90050-0; LEE WC, 1984, ANN SURG, V199, P549, DOI 10.1097/00000658-198405000-00009; MARIADASON JG, 1988, ANN SURG, V207, P335, DOI 10.1097/00000658-198803000-00019; PAPPE I, 1993, PROFILE STABBER DEPR; ROBIN AP, 1989, J TRAUMA, V29, P1684, DOI 10.1097/00005373-198912000-00018; SHAFTAN GW, 1960, AM J SURG, V99, P657, DOI 10.1016/0002-9610(60)90010-6; SHORR RM, 1988, ARCH SURG-CHICAGO, V123, P1141; SIEGEL JH, 1987, TRAUMA EMERGENCY SUR, P1; SIRINEK KR, 1990, ARCH SURG-CHICAGO, V125, P844; STEBBINGS WSL, 1987, POSTGRAD MED J, V63, P81, DOI 10.1136/pgmj.63.736.81; SWANN IJ, 1985, ARCH EMERG MED, V2, P31; THORESEN SO, 1986, FORENSIC SCI INT, V31, P181, DOI 10.1016/0379-0738(86)90186-6; WALTON CB, 1989, J TRAUMA, V29, P99, DOI 10.1097/00005373-198901000-00021	20	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					388	390		10.1001/jama.276.5.388	http://dx.doi.org/10.1001/jama.276.5.388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683817				2022-12-28	WOS:A1996UZ77600020
J	Ohta, K; Yamada, T; Nakanishi, K; Kohno, K; Akiyama, M; Kawabe, R				Ohta, K; Yamada, T; Nakanishi, K; Kohno, K; Akiyama, M; Kawabe, R			Detection of molecular gas in the quasar BR1202-0725 at redshift z=4.69	NATURE			English	Article							LYMAN-ALPHA SYSTEM; CO EMISSION; IRAS F10214+4724; GALAXY; SEARCH	ALTHOUGH great efforts(1-8) have been made to locate molecular gas-the material out of which stars form-in the early Universe, there have been only two firm detections at high redshift. Both are gravitationally lensed objects at redshift z approximate to 2.5 (refs 9-14). Here we report the detection of CO emission from the radio-quite quasar BR1202 - 0725, which is at redshift z approximate to 4.69. From the observed CO luminosity, we estimate that almost 10(11) solar masses of molecular hydrogen are associated with the quasar; this is comparable to the stellar mass of a present-day luminous galaxy. Our results suggest that BR1202 - 0725 is a massive galaxy, in which the gas is largely concentrated in the central region, and that it is currently undergoing a large burst of star formation.	UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822; INST PHYS & CHEM RES,COSM RADIAT LAB,WAKO,SAITAMA 35101,JAPAN; NATL ASTRON OBSERV,NOBEYAMA RADIO OBSERV,MINAMISA KU,NAGANO 38413,JAPAN; UNIV TOKYO,DEPT ASTRON,TOKYO 113,JAPAN	University of Hawaii System; RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); University of Tokyo	Ohta, K (corresponding author), KYOTO UNIV,DEPT ASTRON,KYOTO 60601,JAPAN.			Nakanishi, Kouichiro/0000-0002-6939-0372				Arimoto N, 1996, PUBL ASTRON SOC JPN, V48, P275, DOI 10.1093/pasj/48.2.275; ATHANASSOULA E, 1987, ASTRON ASTROPHYS, V179, P23; BARVAINIS R, 1994, NATURE, V371, P586, DOI 10.1038/371586a0; BARVAINIS R, IN PRESS INT ASTR UN, V170; BROADHURST T, 1995, ASTROPHYS J, V450, pL41, DOI 10.1086/316774; BROWN RL, 1993, ASTROPHYS J, V412, pL21, DOI 10.1086/186930; BROWN RL, 1992, ASTROPHYS J, V397, pL19, DOI 10.1086/186534; BROWN RL, 1991, ASTRON J, V102, P1956, DOI 10.1086/116017; Evans AS, 1996, ASTROPHYS J, V457, P658, DOI 10.1086/176761; FRAYER DT, 1994, ASTROPHYS J, V433, pL5, DOI 10.1086/187534; HU CM, 1996, ASTROPHYS J, V459, pL53; IRWIN M, 1991, ASTR SOC P, V21, P117; ISAAK KG, 1994, MON NOT R ASTRON SOC, V269, pL28, DOI 10.1093/mnras/269.1.L28; KAWABE R, 1992, ASTROPHYS J, V397, pL23, DOI 10.1086/186535; KORMENDY J, 1992, ASTROPHYS J, V390, pL53, DOI 10.1086/186370; MCMAHON RG, 1994, MON NOT R ASTRON SOC, V267, pL9, DOI 10.1093/mnras/267.1.L9; Ohta K, 1995, PUBL ASTRON SOC JPN, V47, P739; OHTA K, 1994, PUBL ASTRON SOC JPN, V46, pL163; Petitjean P, 1996, NATURE, V380, P411, DOI 10.1038/380411a0; SILK J, 1983, NATURE, V301, P574, DOI 10.1038/301574a0; SOLOMON PM, 1992, NATURE, V356, P318, DOI 10.1038/356318a0; SOLOMON PM, 1992, ASTROPHYS J, V398, pL29, DOI 10.1086/186569; STORRIELOMBARDI LJ, IN PRESS ASTROPHYS J; TSUBOI M, 1994, PUBL ASTRON SOC JPN, V46, pL179; WIKLIND T, 1994, ASTRON ASTROPHYS, V288, pL41; WRIGHT EL, 1991, ASTROPHYS J, V381, P200, DOI 10.1086/170641; YAMADA T, 1995, ASTRON J, V110, P1564, DOI 10.1086/117629; YAMADA T, 1995, ASTROPHYS J, V438, pL5, DOI 10.1086/187701; YAMADA T, 1995, ASTRON J, V110, P1572	29	151	151	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					426	428		10.1038/382426a0	http://dx.doi.org/10.1038/382426a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684482				2022-12-28	WOS:A1996VA25100048
J	Parsonnet, J; Harris, RA; Hack, HM; Owens, DK				Parsonnet, J; Harris, RA; Hack, HM; Owens, DK			Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials	LANCET			English	Article							INFECTION; POPULATION; EPIDEMIOLOGY; ERADICATION; EFFICACY; RISK; AGE	Background It is unknown whether eradication of Helicobacter pyiori infection prevents development of gastric adenocarcinoma. To determine whether screening and treatment trials are warranted, we conducted a cost-effectiveness analysis to estimate the costs and benefits associated with screening for H pylori at age 50 and treating those individuals infected with antibiotics. Methods We compared two interventions: (1) screen for H pylori and treat those with a positive rest, and (2) do not screen and do not treat. Estimates of risks and costs were obtained by review of published reports. Since the efficacy of H pyiori therapy in cancer prevention is unknown, we did sensitivity analyses, varying this estimate widely. In our base-case analysis, we assumed that H pylori treatment prevented 30% of attributable gastric cancers. Findings In the base-case analysis, 11 646 000 persons in the US would be screened and 4 658 400 treated, at a cost of $996 million. Cost-effectiveness was $25 000 per year of life saved, Cost-effectiveness was sensitive to the efficacy of the cancer prevention strategy. At low efficacy rates (<10%), the screening programme was more expensive (>$75 000 per year of life saved), In a high-risk group such as Japanese-Americans, however, screening and treatment required less than $50 000 per year of life saved, even at 5% treatment efficacy. Interpretation Screening and treatment for H pyiori infection is potentially cost-effective in the prevention of gastric cancer, particularly in high-risk populations. Cancer prevention trials are strongly recommended.	STANFORD UNIV,SCH MED,DEPT HLTH RES & POLICY,STANFORD,CA 94305; VET ADM PALO ALTO HLTH CARE SYST,SECT GEN MED,PALO ALTO,CA	Stanford University	Parsonnet, J (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,HRP BLDG,ROOM T225,STANFORD,CA 94305, USA.			Parsonnet, Julie/0000-0001-7342-5366				ASAKA M, 1992, GASTROENTEROLOGY, V102, P760, DOI 10.1016/0016-5085(92)90156-S; BAKER MS, 1989, CANCER CARE AND COST, P127; BELL GD, 1993, Q J MED, V86, P743; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FELDMAN RA, 1995, ALIMENT PHARM THER, V9, P21; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Hahn B., 1992, ANN EXPENSES SOURCES; HAHN RA, 1995, EPIDEMIOLOGY, V6, P350, DOI 10.1097/00001648-199507000-00004; *HLTH CAR CONS AM, 1995, PHYS FEE COD GUID; HORNBERGER JC, 1995, STAT MED, V14, P2249, DOI 10.1002/sim.4780142008; *IARC WORK GROUP E, 1994, SCHIST LIV FLUK HEL, P177; Labenz J., 1995, Gut, V37, pA41; *MED EC CO INC, 1995, REDB UPD; MITCHELL HM, 1993, J PEDIATR GASTR NUTR, V16, P120, DOI 10.1097/00005176-199302000-00004; PARSONNET J, 1993, GASTROENTEROL CLIN N, V22, P89; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Perkins C, 1993, CANC INCIDENCE MORTA; Replogle ML, 1996, INT J EPIDEMIOL, V25, P210, DOI 10.1093/ije/25.1.210; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SIPPONEN P, 1991, J GASTROEN HEPATOL, V6, P244, DOI 10.1111/j.1440-1746.1991.tb01472.x; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; *US BUR CENS, 1993, STAT ABSTR US, P86; VILLAKO K, 1981, ANN CLIN RES, V13, P114; YOUSFI MM, 1995, ALIMENT PHARM THERAP, V9, P209; ZHENG TZ, 1993, CANCER, V72, P330, DOI 10.1002/1097-0142(19930715)72:2<330::AID-CNCR2820720205>3.0.CO;2-L; 1994, JAMA-J AM MED ASSOC, V272, P65	30	272	282	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					150	154		10.1016/S0140-6736(96)01501-2	http://dx.doi.org/10.1016/S0140-6736(96)01501-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684154				2022-12-28	WOS:A1996UX78900009
J	Masters, PW; Lawson, N; Marenah, CB; Maile, LJ				Masters, PW; Lawson, N; Marenah, CB; Maile, LJ			High ambient temperature: A spurious cause of hypokalaemia	BRITISH MEDICAL JOURNAL			English	Article							SERUM POTASSIUM		THE SURGERY,CALVERTON NG14 4FP,ENGLAND		Masters, PW (corresponding author), CITY HOSP NOTTINGHAM,DEPT CLIN CHEM,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.		Masters, Paul/AAL-9303-2021					GOODMAN JR, 1954, AM J CLIN PATHOL, V24, P111, DOI 10.1093/ajcp/24.1_ts.111; KALSHEKER N, 1984, CLIN CHEM, V30, P1581; MOORE D, 1989, PRACTITIONER, V233, P395; Tietz N., 1986, TXB CLIN CHEM, P1176; VERRESEN L, 1986, CLIN CHEM, V32, P698	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1652	1653		10.1136/bmj.312.7047.1652	http://dx.doi.org/10.1136/bmj.312.7047.1652			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664721	Green Published			2022-12-28	WOS:A1996UV48900027
J	Choe, H; Farzan, M; Sun, Y; Sullivan, N; Rollins, B; Ponath, PD; Wu, LJ; Mackay, CR; LaRosa, G; Newman, W; Gerard, N; Gerard, C; Sodroski, J				Choe, H; Farzan, M; Sun, Y; Sullivan, N; Rollins, B; Ponath, PD; Wu, LJ; Mackay, CR; LaRosa, G; Newman, W; Gerard, N; Gerard, C; Sodroski, J			The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates	CELL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HAMSTER OVARY CELLS; ENVELOPE GLYCOPROTEIN; T-CELL; HTLV-III/LAV; MONONUCLEAR PHAGOCYTES; CD4-MEDIATED FUSION; MACROPHAGE TROPISM; MOLECULAR-CLONING; MEMBRANE-FUSION	We examined the ability of chemokine receptors and related G protein-coupled receptors to facilitate infection by primary, clinical HIV-1 isolates. CCR5, when expressed along with CD4, the HIV-1 receptor, allowed cell lines resistant to most primary HIV-1 isolates to be infected. CCR3 facilitated infection by a more restricted subset of primary viruses, and binding of the CCR3 ligand, eotaxin, inhibited infection by these isolates. Utilization of CCR3 and CCR5 on the target cell depended upon the sequence of the third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein. The ability of various members of the chemokine receptor family to support the early stages of HIV-1 infection helps to explain viral tropism and beta-chemokine inhibition of primary HIV-1 isolates.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; LEUKOSITE INC,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,PERLMUTTER LAB,DEPT PEDIAT,DEPT MED,CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital; Harvard Medical School	Choe, H (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,44 BINNEY ST,BOSTON,MA 02115, USA.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340; Farzan, Michael/0000-0002-2990-5319	NCI NIH HHS [CA06516] Funding Source: Medline; NIAID NIH HHS [AI24755, AI28691] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024755, P30AI028691, R37AI024755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; ASJO B, 1986, LANCET, V2, P660; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERGERON L, 1992, J VIROL, V66, P2389, DOI 10.1128/JVI.66.4.2389-2397.1992; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; BRAND D, 1995, J VIROL, V69, P166, DOI 10.1128/JVI.69.1.166-171.1995; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; CARRILLO A, 1993, VIROLOGY, V197, P817, DOI 10.1006/viro.1993.1664; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CULLEN BR, 1989, METHOD ENZYMOL, V152, P64; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FENYO EM, 1988, J VIROL, V62, P4414; FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; FREEDMAN AR, 1991, J EXP MED, V174, P1661, DOI 10.1084/jem.174.6.1661; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; IVANOFF LA, 1991, AIDS RES HUM RETROV, V7, P595, DOI 10.1089/aid.1991.7.595; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KARLSSON G, IN PRESS J VIROL; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MONTEFIORI DC, 1991, VIROLOGY, V182, P635, DOI 10.1016/0042-6822(91)90604-A; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MYERS G, 1994, HUMAN RETROVIRUSES A; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALERMO DP, 1991, J BIOTECHNOL, V19, P35, DOI 10.1016/0168-1656(91)90073-5; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; PONATH P, 1996, J EXP MED, V183, P1; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; RAPORT C, 1996, IN PRESS J BIOL CHEM; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SOZZANI S, 1995, J IMMUNOL, V155, P3292; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TRAVIS BM, 1992, VIROLOGY, V186, P313, DOI 10.1016/0042-6822(92)90088-7; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826; WELLER P, 1995, AM J RESPIR CELL MOL, V10, P610; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WILLEY RL, 1994, J VIROL, V68, P4409, DOI 10.1128/JVI.68.7.4409-4419.1994; WRIN T, 1995, J VIROL, V69, P39, DOI 10.1128/JVI.69.1.39-48.1995	108	2063	2167	2	129	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1135	1148		10.1016/S0092-8674(00)81313-6	http://dx.doi.org/10.1016/S0092-8674(00)81313-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674119	Bronze			2022-12-28	WOS:A1996UV48400019
J	Doranz, BJ; Rucker, J; Yi, YJ; Smyth, RJ; Samson, M; Peiper, SC; Parmentier, M; Collman, RG; Doms, RW				Doranz, BJ; Rucker, J; Yi, YJ; Smyth, RJ; Samson, M; Peiper, SC; Parmentier, M; Collman, RG; Doms, RW			A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; MOLECULAR-CLONING; CELL-LINE; CD4-MEDIATED FUSION; HUMAN HOMOLOG; NPY BINDING; INFECTION; MACROPHAGE; VARIANTS	Here, we show that the beta-chemokine receptor CKR-5 serves as a cofactor for M-tropic HIV viruses. Expression of CKR-5 with CD4 enables nonpermissive cells to form syncytia with cells expressing M-tropic, but not T-tropic, HIV-1 env proteins. Expression of CKR-5 and CD4 enables entry of a M-tropic, but not a T-tropic, virus strain. A dual-tropic primary HIV-1 isolate (89.6) utilizes both Fusin and CKR-5 as entry cofactors. Cells expressing the 89.6 env protein form syncytia with QT6 cells expressing CD4 and either Fusin or CKR-5. The beta-chemokine receptors CKR-3 and CKR-2b support HIV-1 89.6 env-mediated syncytia formation but do not support fusion by any of the T-tropic or M-tropic strains tested. Our results suggest that the T-tropic viruses characteristic of disease progression may evolve from purely M-tropic viruses prevalent early in virus infection through changes in the env protein that enable the virus to use multiple entry cofactors.	UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; FREE UNIV BRUSSELS,IRIBHN,B-1070 BRUSSELS,BELGIUM; UNIV LOUISVILLE,JAMES GRAHAM BROWN CANC CTR,DEPT PATHOL,LOUISVILLE,KY 40202	University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Louisville	Doranz, BJ (corresponding author), UNIV PENN,DEPT MED,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19104, USA.		Samson, Michel/F-8356-2013	Parmentier, Marc/0000-0001-8081-4685	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035383, R01AI038225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027405] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35383, AI-38225] Funding Source: Medline; NINDS NIH HHS [NS27405] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BERSON JF, 1996, IN PRESS J VIROL; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHENGMAYER C, 1991, J VIROL, V65, P6931, DOI 10.1128/JVI.65.12.6931-6941.1991; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KIM FM, 1995, J VIROL, V69, P1755, DOI 10.1128/JVI.69.3.1755-1761.1995; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LIU ZQ, 1990, J VIROL, V64, P6148, DOI 10.1128/JVI.64.12.6148-6153.1990; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Puri A, 1996, VIROLOGY, V219, P262, DOI 10.1006/viro.1996.0244; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; ZHO T, 1993, SCIENCE, V261, P1179	53	1705	1806	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1149	1158		10.1016/S0092-8674(00)81314-8	http://dx.doi.org/10.1016/S0092-8674(00)81314-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674120	hybrid			2022-12-28	WOS:A1996UV48400020
J	Dennehy, JA; Appleby, L; Thomas, CS; Faragher, EB				Dennehy, JA; Appleby, L; Thomas, CS; Faragher, EB			Case-control study of suicide by discharged psychiatric patients	BRITISH MEDICAL JOURNAL			English	Article							RISK		UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV S MANCHESTER HOSP,MANCHESTER,LANCS,ENGLAND	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; *DEP HLTH, 1992, HLTH NAT; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; WILLIAMS P, 1986, SOC PSYCH PSYCH EPID, V21, P89, DOI 10.1007/BF00578748	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1580	1580		10.1136/bmj.312.7046.1580	http://dx.doi.org/10.1136/bmj.312.7046.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU806	8664668	Green Published			2022-12-28	WOS:A1996UU80600020
J	McMahon, AJ; ODwyer, PJ; Baxter, JN				McMahon, AJ; ODwyer, PJ; Baxter, JN			Randomised trial of laparoscopic versus small-incision cholecystectomy	LANCET			English	Letter									UNIV GLASGOW,WESTERN INFIRM,GLASGOW G11 6NT,LANARK,SCOTLAND; MORRISTON HOSP,SWANSEA,W GLAM,WALES	University of Glasgow; Morriston Hospital	McMahon, AJ (corresponding author), STOBHILL GEN HOSP,GLASGOW G21 3UW,LANARK,SCOTLAND.							Antia NH, 1996, LANCET, V347, P985, DOI 10.1016/S0140-6736(96)90138-5; MCMAHON AJ, 1994, SURGERY, V115, P533; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; MCMAHON AJ, IN PRESS P ASS SURG	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1622	1622						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667887				2022-12-28	WOS:A1996UP66100045
J	Radloff, PD; Philipps, J; Nkeyi, M; Hutchinson, D; Kremsner, PG				Radloff, PD; Philipps, J; Nkeyi, M; Hutchinson, D; Kremsner, PG			Atovaquone and proguanil for Plasmodium falciparum malaria	LANCET			English	Article							PYRIMETHAMINE-SULFADOXINE FANSIDAR; RESISTANT MALARIA; DRUG-RESISTANCE; PROPHYLAXIS; CHLOROQUINE; INVITRO; 566C80	Background The increasing spread of multidrug-resistant Plasmodium falciparum malaria emphasises the urgent need for alternative treatment regimens. The objective of the study was to establish the efficacy of a novel drug combination. We compared a combination of atovaquone and proguanil with amodiaquine in the treatment of acute uncomplicated P falciparum malaria in Lambarene Gabon. Methods 142 adults were randomly allocated either a combination treatment of atovaquone 1000 mg daily and proguanil 400 mg daily for 3 days or treatment with amodiaquine 600 mg on admission, 600 mg 24 h later, and 300 mg after a further 24 h. Symptoms and clinical signs were recorded and giemsa-stained thick blood smears were done every 12 h until patients had been symptom-free and aparasitaemic for 24 h. 126 patients were followed up for 28 days or until recrudescence. Findings In the atovaquone plus proguanil group 62 (87%) of 71 patients were cured and only one had recrudescent infection, By contrast, the cure rate was significantly lower (p=0 . 022) with amodiaquine (51 [72%] of 71; there were 12 recrudescences in the amodiaquine group), Eight patients in each group were lost to follow-up. Patients treated with atovaquone plus proguanil complained of nausea (33%) and vomiting (29%), and the most commonly reported adverse effects of amodiaquine were pruritus (43%) and insomnia (27%). Interpretation Atovaquone and proguanil was a highly effective and safe drug combination in patients with acute uncomplicated P falciparum malaria in Gabon.	UNIV TUBINGEN,INST TROP MED,SEKT HUMANPARASITOL,D-72074 TUBINGEN,GERMANY; UNIV VIENNA,DEPT INFECT DIS,VIENNA,AUSTRIA; ALBERT SCHWEITZER HOSP,INT RES LAB,LAMBARENE,GABON	Eberhard Karls University of Tubingen; University of Vienna			Philipps, Joerg/AAM-2431-2020	Philipps, Joerg/0000-0003-3327-3550				BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BLANCHARD TJ, 1994, T ROY SOC TROP MED H, V88, P693, DOI 10.1016/0035-9203(94)90233-X; BRASSEU P, 1993, LANCET, V341, P901, DOI 10.1016/0140-6736(93)93115-H; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P8, DOI 10.4269/ajtmh.1992.46.8; CANFIELD CJ, 1995, EXP PARASITOL, V80, P373, DOI 10.1006/expr.1995.1049; CARME B, 1991, B SOC PATHOL EXOT, V84, P77; FAIRLEY NH, 1946, T ROY SOC TROP MED H, V40, P105, DOI 10.1016/0035-9203(46)90052-1; FAWAZ G, 1951, AM J TROP MED, V31, P569; HAMMOND DJ, 1985, MOL BIOCHEM PARASIT, V14, P97, DOI 10.1016/0166-6851(85)90109-4; HATTON CSR, 1986, LANCET, V1, P411; HUDSON AT, 1991, DRUG EXP CLIN RES, V17, P427; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; HUGHES WT, 1991, J INFECT DIS, V163, P843, DOI 10.1093/infdis/163.4.843; KREMSNER PG, 1995, ANTIMICROB AGENTS CH, V39, P1603, DOI 10.1128/AAC.39.7.1603; KREMSNER PG, 1994, J INFECT DIS, V169, P467, DOI 10.1093/infdis/169.2.467; KREMSNER PG, 1993, AM J TROP MED HYG, V49, P650, DOI 10.4269/ajtmh.1993.49.650; LOOAREESUWAN S, IN PRESS AM J TROP M; METZGER W, 1995, ANTIMICROB AGENTS CH, V39, P245, DOI 10.1128/AAC.39.1.245; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M; PANISKO DM, 1990, DRUGS, V39, P160, DOI 10.2165/00003495-199039020-00002; REACHER M, 1981, LANCET, V2, P1066, DOI 10.1016/S0140-6736(81)91274-5; WERNSDORFER WH, 1991, PHARMACOL THERAPEUT, V50, P95, DOI 10.1016/0163-7258(91)90074-V; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; *WHO, 1993, 911063 WHOMAL; WILDLING E, 1995, TROP MED PARASITOL, V46, P77; WINKLER S, 1994, TROP MED PARASITOL, V45, P214; 1994, WEEKLY EPIDEMIOL REC, V69, P309	29	149	150	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1511	1514		10.1016/S0140-6736(96)90671-6	http://dx.doi.org/10.1016/S0140-6736(96)90671-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684102				2022-12-28	WOS:A1996UN47300010
J	Hanan, BB; Graham, DW				Hanan, BB; Graham, DW			Lead and helium isotope evidence from oceanic basalts for a common deep source of mantle plumes	SCIENCE			English	Article							SPREADING CENTER SYSTEM; MID-ATLANTIC RIDGE; SOUTH-ATLANTIC; VOLCANIC-ROCKS; LOIHI SEAMOUNT; EARTHS MANTLE; EVOLUTION; PB; ISLAND; ORIGIN	Linear arrays in lead isotope space for mid-ocean ridge basalts (MORBs) converge on a single end-member component that has intermediate lead, strontium, and neodymium isotope ratios compared with the total database for oceanic island basalts (OIBs) and MORBs. The MORE data are consistent With the presence of a common mantle source region for OIBs that is sampled by mantle plumes. He-3/He-4 ratios for MORBs show both positive and negative correlation with the Pb-206/Pb-204 ratios, depending on the MORE suite. These data suggest that the common mantle source is located in the transition zone region. This region contains recycled, oceanic crustal protoliths that incorporated some continental lead before their subduction during the past 300 to 2000 million years.	OREGON STATE UNIV,COLL OCEAN & ATMOSPHER SCI,CORVALLIS,OR 97331	Oregon State University	Hanan, BB (corresponding author), SAN DIEGO STATE UNIV,DEPT GEOL SCI,SAN DIEGO,CA 92182, USA.		Graham, David/C-3612-2014	Graham, David/0000-0002-7411-1905; Hanan, Barry/0000-0002-8240-2200				ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; ALLEGRE CJ, 1988, CHEM GEOL, V70, P211, DOI 10.1016/0009-2541(88)90094-0; ALLEGRE CJ, 1985, GEOPHYS RES LETT, V12, P207, DOI 10.1029/GL012i004p00207; ALLEGRE CJ, 1986, EARTH PLANET SC LETT, V81, P319; ANDERSON DL, 1995, REV GEOPHYS, V33, P125, DOI 10.1029/94RG02785; BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; CHASE CG, 1981, EARTH PLANET SC LETT, V52, P277, DOI 10.1016/0012-821X(81)90182-5; CHEN CY, 1983, NATURE, V302, P785, DOI 10.1038/302785a0; DEPAOLO DJ, 1976, GEOPHYS RES LETT, V3, P249, DOI 10.1029/GL003i005p00249; DOSSO L, 1991, EARTH PLANET SC LETT, V106, P29, DOI 10.1016/0012-821X(91)90061-L; FARLEY KA, 1992, EARTH PLANET SC LETT, V111, P183, DOI 10.1016/0012-821X(92)90178-X; FEIGENSON MD, 1986, J GEOPHYS RES-SOLID, V91, P9383, DOI 10.1029/JB091iB09p09383; GALER SJG, 1979, EARTH PLANET SC LETT, V44, P91; GARCIA MO, 1989, J GEOPHYS RES-SOLID, V94, P10525, DOI 10.1029/JB094iB08p10525; GRAHAM DW, 1993, SCIENCE, V262, P2023, DOI 10.1126/science.262.5142.2023; GRAHAM DW, 1992, EARTH PLANET SC LETT, V110, P133, DOI 10.1016/0012-821X(92)90044-V; HANAN BB, 1989, J GEOPHYS RES-SOLID, V94, P7432, DOI 10.1029/JB094iB06p07432; HANAN BB, 1986, NATURE, V322, P137, DOI 10.1038/322137a0; HANAN BB, 1991, GEOL SOC AUST ABSTR, V27, P43; HANAN BB, 1992, EOS, V73, P582; HANAN BB, 1994, MIN MAG A, V58, P370; HANAN BB, 1994, EOS, V75, P67; HANAN BB, 1991, MANTL PLUM S; HANAN BB, 1995, 21 GEN ASS IUGG BOUL, pB418; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; HAURI EH, 1994, J GEOPHYS RES-SOL EA, V99, P24275, DOI 10.1029/94JB01257; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; KELLOGG LH, 1990, EARTH PLANET SC LETT, V99, P276, DOI 10.1016/0012-821X(90)90116-F; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; KURZ MD, 1987, GEOCHIM COSMOCHIM AC, V51, P2905, DOI 10.1016/0016-7037(87)90366-8; LANGMUIR CH, 1978, EARTH PLANET SC LETT, V37, P380, DOI 10.1016/0012-821X(78)90053-5; MAHONEY JJ, 1994, EARTH PLANET SC LETT, V121, P173, DOI 10.1016/0012-821X(94)90039-6; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; MCKENZIE D, 1983, NATURE, V301, P229, DOI 10.1038/301229a0; MILLER DM, 1994, NATURE, V368, P514, DOI 10.1038/368514a0; ONIONS RK, 1983, NATURE, V306, P429, DOI 10.1038/306429a0; PATTERSON C, 1964, GEOCHIM COSMOCHIM AC, V28, P1, DOI 10.1016/0016-7037(64)90052-3; PATTERSON C, 1956, GEOCHIM COSMOCHIM AC, V10, P230, DOI 10.1016/0016-7037(56)90036-9; PEUCKEREHRENBRINK B, 1994, EARTH PLANET SC LETT, V125, P129, DOI 10.1016/0012-821X(94)90211-9; POREDA RJ, 1993, EARTH PLANET SC LETT, V119, P319, DOI 10.1016/0012-821X(93)90141-U; RINGWOOD AE, 1982, J GEOL, V90, P611, DOI 10.1086/628721; RINGWOOD AE, 1992, EARTH PLANET SC LETT, V113, P521, DOI 10.1016/0012-821X(92)90129-J; RUDNICK RL, 1990, EARTH PLANET SC LETT, V98, P192, DOI 10.1016/0012-821X(90)90059-7; SCHILLING JG, 1994, J GEOPHYS RES-SOL EA, V99, P12005, DOI 10.1029/94JB00337; STACEY JS, 1975, EARTH PLANET SC LETT, V26, P207, DOI 10.1016/0012-821X(75)90088-6; STAUDACHER T, 1989, EARTH PLANET SC LETT, V96, P119, DOI 10.1016/0012-821X(89)90127-1; STAUDIGEL H, 1984, EARTH PLANET SC LETT, V69, P13, DOI 10.1016/0012-821X(84)90071-2; STEIN M, 1994, NATURE, V372, P63, DOI 10.1038/372063a0; SUN SS, 1980, PHILOS T R SOC A, V297, P409, DOI 10.1098/rsta.1980.0224; SUN SS, 1975, SCIENCE, V190, P143, DOI 10.1126/science.190.4210.143; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; TATSUMOTO M, 1978, EARTH PLANET SC LETT, V38, P63, DOI 10.1016/0012-821X(78)90126-7; Tatsumoto M., 1987, 1350 US GEOL SURV, P723; VERMA SP, 1982, J GEOPHYS RES, V87, P838, DOI 10.1029/JB087iB13p10838; VERMA SP, 1983, NATURE, V306, P654, DOI 10.1038/306654a0; WHITE WM, 1985, GEOLOGY, V13, P115, DOI 10.1130/0091-7613(1985)13<115:SOOBRI>2.0.CO;2; WHITE WM, 1993, EARTH PLANET SC LETT, V115, P211, DOI 10.1016/0012-821X(93)90223-V; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	60	378	392	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					991	995		10.1126/science.272.5264.991	http://dx.doi.org/10.1126/science.272.5264.991			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662585				2022-12-28	WOS:A1996UL61900039
J	Uckun, FM; Waddick, KG; Mahajan, S; Jun, X; Takata, M; Bolen, J; Kurosaki, T				Uckun, FM; Waddick, KG; Mahajan, S; Jun, X; Takata, M; Bolen, J; Kurosaki, T			BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells	SCIENCE			English	Article							PROTEIN-TYROSINE KINASES; X-LINKED AGAMMAGLOBULINEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PRIMARY CLONOGENIC BLASTS; LYN-DEFICIENT MICE; SRC-FAMILY; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-2; HEMATOPOIETIC-CELLS	Bruton's tyrosine kinase (BTK) is a member of the SRC-related TEC family of protein tyrosine kinases (PTKs). DT-40 lymphoma B cells, rendered BTK-deficient through targeted disruption of the btk gene by homologous recombination knockout, did not undergo radiation-induced apoptosis, but cells with disrupted lyn or syk genes did. Introduction of the wild-type, or a SRC homology 2 domain or a plecstrin homology domain mutant (but not a kinase domain mutant), human btk gene into BTK-deficient cells restored the apoptotic response to radiation. Thus, BTK is the PTK responsible for triggering radiation-induced apoptosis of lymphoma B cells, and its kinase domain is indispensable for the apoptotic response.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	Yale University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Uckun, FM (corresponding author), UNIV MINNESOTA,MOL SIGNAL TRANSDUCT LAB,BIOTHERAPY INST,ROSEVILLE,MN 55113, USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Uckun, Fatih M./0000-0001-9334-183X; Takata, Minoru/0000-0002-4926-3675	NATIONAL CANCER INSTITUTE [R01CA042633, R01CA042111] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-42633, R01-CA-42111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CONLEY ME, 1994, CURR OPIN GENET DEV, V4, P401, DOI 10.1016/0959-437X(94)90028-0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DELBUONO BJ, 1989, J CELL PHYSIOL, V138, P61, DOI 10.1002/jcp.1041380110; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; FADOK VA, 1992, J IMMUNOL, V148, P2207; GIBSON S, 1993, BLOOD, V82, P1561; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; JI L, 1995, BIOCHEM BIOPH RES CO, V212, P640, DOI 10.1006/bbrc.1995.2017; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW DA, 1993, CURR BIOL, V3, P654; LEE E, 1994, BIOCHEM BIOPH RES CO, V202, P128, DOI 10.1006/bbrc.1994.1902; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MESSINGER Y, IN PRESS CLIN CANC R; MIGITA K, 1994, J IMMUNOL, V153, P3457; MOWER DA, 1994, J IMMUNOL, V152, P4832; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P1; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKATA M, IN PRESS J EXP MED; TAKATA M, UNPUB; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; UCKUN FM, 1993, J CLIN INVEST, V91, P1044, DOI 10.1172/JCI116261; UCKUN FM, 1993, CANCER RES, V53, P1431; UCKUN FM, 1995, BLOOD, V85, P2817, DOI 10.1182/blood.V85.10.2817.bloodjournal85102817; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UCKUN FM, UNPUB; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WAADDICK KG, 1995, BLOOD, V86, P4228; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461	78	161	212	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1096	1100		10.1126/science.273.5278.1096	http://dx.doi.org/10.1126/science.273.5278.1096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688094				2022-12-28	WOS:A1996VD42800035
J	Wang, SX; Mure, M; Medzihradszky, KF; Burlingame, AL; Brown, DE; Dooley, DM; Smith, AJ; Kagan, HM; Klinman, JP				Wang, SX; Mure, M; Medzihradszky, KF; Burlingame, AL; Brown, DE; Dooley, DM; Smith, AJ; Kagan, HM; Klinman, JP			A crosslinked cofactor in lysyl oxidase: Redox function for amino acid side chains	SCIENCE			English	Article							RESONANCE RAMAN-SPECTROSCOPY; TOPA QUINONE COFACTOR; PYRROLOQUINOLINE QUINONE; PYRIDOXAL-PHOSPHATE; PROSTHETIC GROUP; MENKES SYNDROME; CROSS-LINKING; ACTIVE-SITE; ENZYME; MECHANISM	A previously unknown redox cofactor has been identified in the active site of lysyl oxidase from the bovine aorta. Edman sequencing, mass spectrometry, ultraviolet-visible spectra, and resonance Raman studies showed that this cofactor is a quinone. Its structure is derived from the crosslinking of the epsilon-amino group of a peptidyl lysine with the modified side chain of a tyrosyl residue, and it has been designated lysine tyrosylquinone. This quinone appears to be the only example of a mammalian cofactor formed from the crosslinking of two amino acid side chains, This discovery expands the range of known quino-cofactor structures and has implications for the mechanism of their biogenesis.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; MONTANA STATE UNIV,DEPT CHEM & BIOCHEM,BOZEMAN,MT 59717; STANFORD UNIV,MED CTR,BECKMAN CTR,STANFORD,CA 94305; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Montana State University System; Montana State University Bozeman; Stanford University; Boston University					NCRR NIH HHS [P41 RR01614] Funding Source: Medline; NIGMS NIH HHS [GM39296, GM27659] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296, R01GM027659] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN G, 1989, SEQUENCING PROTEINS, P58; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BIRD TA, 1982, BIOCHEM BIOPH RES CO, V108, P1172, DOI 10.1016/0006-291X(82)92124-6; BUFFONI F, 1981, ITAL J BIOCHEM, V30, P179; BUFFONI F, 1966, PHARMACOL REV, V18, P1163; BURBELO PD, 1986, COLLAGEN REL RES, V6, P153; BYERS PH, 1980, NEW ENGL J MED, V303, P61, DOI 10.1056/NEJM198007103030201; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; Carr S. A, 1996, MASS SPECTROMETRY BI, P546; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; GACHERU SN, 1989, J BIOL CHEM, V264, P12963; HAMILTON GA, 1981, COPPER PROTEINS; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1995, J CELL BIOCHEM, V59, P329, DOI 10.1002/jcb.240590305; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1993, PRINCIPLES APPLICATI, P173; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; KIVIRIKKO KI, 1987, CONNECTIVE TISSUE DI; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1987, BIOCHEM J, V241, P603, DOI 10.1042/bj2410603; KNOWLES PF, 1984, COPPER PROTEINS COPP, V2, P103; KUIVANIEMI H, 1985, AM J HUM GENET, V37, P798; KUIVANIEMI H, 1982, J CLIN INVEST, V69, P730, DOI 10.1172/JCI110503; KUIVANIEMI H, 1984, J BIOL CHEM, V259, P6996; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MOOG RS, 1986, P NATL ACAD SCI USA, V83, P8435, DOI 10.1073/pnas.83.22.8435; MU D, 1992, J BIOL CHEM, V267, P7979; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; PAZ MA, 1991, J BIOL CHEM, V266, P689; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; ROWE DW, 1977, J BIOL CHEM, V252, P939; ROYCE PM, 1980, BIOCHEM J, V192, P579, DOI 10.1042/bj1920579; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; SUVA RH, 1978, BIOCHEMISTRY-US, V17, P3538, DOI 10.1021/bi00610a018; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; VANDERMEER RA, 1986, BIOCHEM J, V239, P789, DOI 10.1042/bj2390789; VANDERMEER RA, 1989, FEBS LETT, V254, P99, DOI 10.1016/0014-5793(89)81017-8; WANG SG, UNPUB; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P6302; YASUNOBU KT, 1976, MOL CELL BIOCHEM, V13, P3, DOI 10.1007/BF01732392	55	301	328	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1078	1084		10.1126/science.273.5278.1078	http://dx.doi.org/10.1126/science.273.5278.1078			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688089				2022-12-28	WOS:A1996VD42800030
J	Zhang, KK; Schubert, G				Zhang, KK; Schubert, G			Penetrative convection and zonal flow on Jupiter	SCIENCE			English	Article							GIANT PLANETS; THERMAL-CONVECTION; MODEL; SHELL	Measurements by the Galileo probe support the possibility that the zonal winds in Jupiter's atmosphere originate from convection that takes place in the deep hydrogen-helium interior. However, according to models based on recent opacity data and the probe's temperature measurements, there may be radiative and nonconvective layers in the outer part of the jovian interior, raising the question of how deep convection could extend to the surface. A theoretical model is presented to demonstrate that, because of predominant rotational effects and spherical geometry, thermal convection in the deep jovian interior can penetrate into any outer nonconvective layer. These penetrative convection rolls interact nonlinearly and efficiently in the model to generate and sustain a mean zonal wind with a larger amplitude than that of the nonaxisymmetric penetrative convective motions, a characteristic of the wind field observed at the cloud level on Jupiter.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095; UNIV EXETER,DEPT MATH,EXETER EX4 4QJ,DEVON,ENGLAND	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Exeter								Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; BUSSE FH, 1976, ICARUS, V29, P255, DOI 10.1016/0019-1035(76)90053-1; BUSSE FH, 1970, J FLUID MECH, V44, P441, DOI 10.1017/S0022112070001921; BUSSE FH, 1970, ASTROPHYS J, V159, P620; BUSSE FH, 1981, GEOPHYS ASTROPHYS FL, V21, P59; DELGENIO AD, 1990, ICARUS, V84, P29, DOI 10.1016/0019-1035(90)90156-4; GIERASCH PJ, 1993, J GEOPHYS RES-PLANET, V98, P5459, DOI 10.1029/92JE01897; GLATZMAIER GA, 1993, GEOPHYS ASTRO FLUID, V70, P113, DOI 10.1080/03091929308203589; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; Jacobs J. A., 1975, EARTHS CORE; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; MANNEVILLE JB, IN PRESS ICARUS; MATTHEWS PC, 1988, J FLUID MECH, V188, P571, DOI 10.1017/S0022112088000850; Moffatt H. K., 1978, MAGNETIC FIELD GENER; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; Straughan B., 1993, MATH ASPECTS PENETRA; SUN ZP, 1995, PHYS FLUIDS, V7, P2686, DOI 10.1063/1.868716; SUN ZP, 1993, SCIENCE, V260, P661, DOI 10.1126/science.260.5108.661; VERONIS G, 1963, ASTROPHYS J, V137, P641, DOI 10.1086/147538; ZAHN JP, 1990, LECT NOTE PHYS, V388, P225; ZHANG K, 1992, J FLUID MECH, V236, P535, DOI 10.1017/S0022112092001526	25	33	35	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					941	943		10.1126/science.273.5277.941	http://dx.doi.org/10.1126/science.273.5277.941			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688074				2022-12-28	WOS:A1996VC67000057
J	Link, RE; Desai, K; Hein, L; Stevens, ME; Chruscinski, A; Bernstein, D; Barsh, GS; Kobilka, BK				Link, RE; Desai, K; Hein, L; Stevens, ME; Chruscinski, A; Bernstein, D; Barsh, GS; Kobilka, BK			Cardiovascular regulation in mice lacking alpha(2)-adrenergic receptor subtypes b and c	SCIENCE			English	Article							POSTSYNAPTIC ALPHA-ADRENOCEPTOR; 2 DISTINCT TYPES; ADRENERGIC-RECEPTOR; MESSENGER-RNAS; ALPHA-2-ADRENOCEPTOR SUBTYPES; IMIDAZOLINE RECEPTORS; BLOOD-PRESSURE; RAT-KIDNEY; EXPRESSION; DEXMEDETOMIDINE	alpha(2)-Adrenergic receptors (alpha(2)ARs) are essential components of the neural circuitry regulating cardiovascular function. The role of specific alpha(2)AR subtypes alpha(2a), alpha(2b), and alpha(2c) was characterized with hemodynamic measurements obtained from strains of genetically engineered mice deficient in either alpha(2b) or alpha(2c) receptors. Stimulation of alpha(2b) receptors in vascular smooth muscle produced hypertension and counteracted the clinically beneficial hypotensive effect of stimulating alpha(2a) receptors in the central nervous system. There were no hemodynamic effects produced by disruption of the alpha(2c) subtype. These results provide evidence for the clinical efficacy of more subtype-selective alpha(2)AR drugs.	STANFORD UNIV, HOWARD HUGHES MED INST, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA; STANFORD UNIV, DIV CARDIOVASC MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University				Bernstein, Daniel/0000-0001-7761-5853; Kobilka, Brian/0000-0001-5958-3990	NHLBI NIH HHS [HL48638] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL I, 1992, J PHARMACOL EXP THER, V263, P1327; BENTLEY SM, 1977, BRIT J PHARMACOL, V61, pP116; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; BLOOR BC, 1992, J PHARMACOL EXP THER, V263, P690; BOUSQUET P, 1992, AM J HYPERTENS, V5, pS47, DOI 10.1093/ajh/5.4.47S; CHEN DG, 1988, AM J PHYSIOL, V254, pH984, DOI 10.1152/ajpheart.1988.254.5.H984; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; COFFMAN JD, 1988, EUR J CLIN INVEST, V18, P309, DOI 10.1111/j.1365-2362.1988.tb01264.x; DOCHERTY JR, 1979, BRIT J PHARMACOL, V67, pP421; DREW GM, 1979, BRIT J PHARMACOL, V67, P207, DOI 10.1111/j.1476-5381.1979.tb08668.x; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; Flacke W E, 1993, J Cardiothorac Vasc Anesth, V7, P41, DOI 10.1016/1053-0770(93)90117-4; HAMILTON CA, 1992, PHARMACOL THERAPEUT, V54, P231, DOI 10.1016/0163-7258(92)90001-G; HANDY DE, 1993, HYPERTENSION, V21, P861, DOI 10.1161/01.HYP.21.6.861; KALLIO A, 1989, CLIN PHARMACOL THER, V46, P33, DOI 10.1038/clpt.1989.103; LINK R, 1992, MOL PHARMACOL, V42, P16; LINK RE, 1995, MOL PHARMACOL, V48, P48; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MEISTER B, 1994, J PHARMACOL EXP THER, V268, P1605; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NICHOLAS AP, 1993, J COMP NEUROL, V328, P575, DOI 10.1002/cne.903280409; OHGUSHI M, 1993, CARDIOVASC RES, V27, P779, DOI 10.1093/cvr/27.5.779; PERALA M, 1992, MOL BRAIN RES, V16, P57, DOI 10.1016/0169-328X(92)90193-F; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; SAVOLA JM, 1989, ACTA VET SCAND, P39; SCHEININ H, 1989, PROG NEURO-PSYCHOPH, V13, P635, DOI 10.1016/0278-5846(89)90051-1; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SUN L, 1992, EUR J PHARM-MOLEC PH, V226, P367, DOI 10.1016/0922-4106(92)90055-Z; TIMMERMANS PBMWM, 1983, J CARDIOVASC PHARM, V5, P1, DOI 10.1097/00005344-198301000-00001; TIMMERMANS PBMWM, 1979, N-S ARCH PHARMACOL, V310, P189, DOI 10.1007/BF00500284; UHLEN S, 1991, BRIT J PHARMACOL, V104, P657, DOI 10.1111/j.1476-5381.1991.tb12485.x; VANMEEL JCA, 1982, J AUTON PHARMACOL, V2, P13, DOI 10.1111/j.1474-8673.1982.tb00465.x; VIRTANEN R, 1989, ACTA VET SCAND, P29; VIRTANEN R, 1989, ARCH INT PHARMACOD T, V297, P190; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YAMAGUCHI I, 1980, J PHARMACOL EXP THER, V214, P275; ZENG DW, 1991, MOL BRAIN RES, V10, P219, DOI 10.1016/0169-328X(91)90064-5	38	392	409	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					803	805		10.1126/science.273.5276.803	http://dx.doi.org/10.1126/science.273.5276.803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670422				2022-12-28	WOS:A1996VB42900045
J	Xu, XA; Sun, YL; Hoey, T				Xu, XA; Sun, YL; Hoey, T			Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; GENE; TRANSCRIPTION; PROTEIN; INTERLEUKIN-12; EXPRESSION; LYMPHOCYTES; ACTIVATION; CYTOKINE; MEMBERS	STAT proteins (signal transducers and activators of transcription) activate distinct target genes despite having similar DNA binding preferences. The transcriptional specificity of STAT proteins was investigated on natural STAT binding sites near the interferon-gamma gene. These sites are arranged in multiple copies and required cooperative interactions for STAT binding. The conserved amino-terminal domain of STAT proteins was required for cooperative DNA binding, although this domain was not essential for dimerization or binding to a single site. Cooperative binding interactions enabled the STAT proteins to recognize Variations of the consensus site. These sites can be specific for the different STAT proteins and may function to direct selective transcriptional activation.	TULARIK,S SAN FRANCISCO,CA 94080									BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHAN SH, 1992, J IMMUNOL, V148, P92; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; HARDY KJ, 1989, J EXP MED, V170, P1021, DOI 10.1084/jem.170.3.1021; HELM MH, 1995, SCIENCE, V267, P1347; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOEY T, UNPUB; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KAPLAN MH, 1996, NATURE, V382, P162; MIKITA T, UNPUB; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHINDLER U, UNPUB; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WEN Z, 1995, CELL, V82, P24; Xu X.Y, UNPUB; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YOUNG HA, 1989, J IMMUNOL, V143, P2389; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	28	395	402	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					794	797		10.1126/science.273.5276.794	http://dx.doi.org/10.1126/science.273.5276.794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670419				2022-12-28	WOS:A1996VB42900042
J	Walters, MC; Patience, M; Leisenring, W; Eckman, JR; Scott, JP; Mentzer, WC; Davies, SC; OheneFrempong, K; Bernaudin, F; Matthews, DC; Storb, R; Sullivan, KM				Walters, MC; Patience, M; Leisenring, W; Eckman, JR; Scott, JP; Mentzer, WC; Davies, SC; OheneFrempong, K; Bernaudin, F; Matthews, DC; Storb, R; Sullivan, KM			Bone marrow transplantation for sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APLASTIC-ANEMIA; MIXED CHIMERISM; HOST-DISEASE; ACUTE GRAFT; THALASSEMIA; EXPERIENCE; PATHOGENESIS; METHOTREXATE; CYCLOSPORINE; PROPHYLAXIS	Background We investigated the risks and benefits of allogeneic bone marrow transplantation in children with complications of sickle cell disease. Methods Twenty-two children less than 16 years of age who had symptomatic sickle cell disease received marrow allografts from HLA-identical siblings between September 1991 and April 1995. The indications for transplantation included a history of stroke (n = 12), recurrent acute chest syndrome (n = 5), and recurrent painful crises (n = 5). Patients were prepared for transplantation with busulfan, cyclophosphamide, and antithymocyte globulin. Results Twenty of the 22 patients survived, with a median follow-up of 23.9 months (range, 10.1 to 51.0), and 16 patients had stable engraftment of donor hematopoietic cells. In three patients the graft was rejected and sickle cell disease recurred; in a fourth patient graft rejection was accompanied by marrow aplasia. In 1 of the 16 patients with engraft ment, there was stable mixed chimerism. Two patients died of central nervous system hemorrhage dor graft-versus-host disease. Kaplan-Meier estimates of survival and event-free survival at four years were 91 percent and 73 percent, respectively. Among patients with a history of acute chest syndrome, lung function stabilized; among patients with prior central nervous system vasculopathy who had engraftment, stabilization of cerebrovascular disease was documented by magnetic resonance imaging. Conclusions Allogeneic stem-cell transplantation can be curative in young patients with symptomatic sickle cell disease. (C) 1996, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; EMORY UNIV, ATLANTA, GA 30322 USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; CENT MIDDLESEX HOSP NATL HLTH SERV TRUST, LONDON, ENGLAND; UNIV PENN, PHILADELPHIA, PA 19104 USA; HOP HENRI MONDOR, F-94010 CRETEIL, FRANCE	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Emory University; Medical College of Wisconsin; University of California System; University of California San Francisco; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP					NCI NIH HHS [CA15704, CA18221] Funding Source: Medline; NHLBI NIH HHS [HL36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018221, P30CA015704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANASETTI C, 1986, ANN INTERN MED, V104, P461, DOI 10.7326/0003-4819-104-4-461; ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; Andreani M, 1996, BLOOD, V87, P3494, DOI 10.1182/blood.V87.8.3494.bloodjournal8783494; Andreani M, 1991, Bone Marrow Transplant, V7 Suppl 2, P75; BERNAUDIN F, 1993, BONE MARROW TRANSPL, V12, P118; BEUTLER E, 1994, BONE MARROW TRANSPL, P840; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; CAMITTA BM, 1982, NEW ENGL J MED, V306, P645, DOI 10.1056/NEJM198203183061105; CAMITTA BM, 1982, NEW ENGL J MED, V306, P712, DOI 10.1056/NEJM198203253061204; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; DYER MJS, 1989, BLOOD, V73, P1431; FERSTER A, 1992, BRIT J HAEMATOL, V80, P102, DOI 10.1111/j.1365-2141.1992.tb06407.x; FERSTER A, 1995, SICKLE CELL DIS THAL, P579; FISHER LD, 1993, BIOSTATISTICS METHOD, P185; GIARDINI C, 1991, BONE MARROW TRANS S2, V7, P122; HOPKINS KA, 1990, ASHI LABORATORY MANU, P195; JOHNSON FL, 1984, NEW ENGL J MED, V311, P780, DOI 10.1056/NEJM198409203111207; JOHNSON FL, 1994, AM J PEDIAT HEMATOL, V16, P22; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, V79, P168; KAPELUSHNIK J, 1995, BLOOD, V86, P3241, DOI 10.1182/blood.V86.8.3241.bloodjournal8683241; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; NESCI S, 1992, BONE MARROW TRANSPL, V10, P143; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; PIOMELLI S, 1991, SEMIN HEMATOL, V28, P227; Platt OS, 1995, BLOOD PRINCIPLES PRA, P1645; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; POWARS DR, 1991, ANN INTERN MED, V115, P614, DOI 10.7326/0003-4819-115-8-614; SCHUENING F, 1993, BONE MARROW TRANSPL, V12, pS48; SLATTERY JT, 1995, BONE MARROW TRANSPL, V16, P31; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STYLES LA, 1994, J PEDIATR-US, V125, P909, DOI 10.1016/S0022-3476(05)82006-2; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P177; VANDENBOS C, 1993, BONE MARROW TRANSPL, V12, P9; VERMYLEN C, 1988, LANCET, V1, P1427; VERMYLEN C, 1994, AM J PEDIAT HEMATOL, V16, P18; WALTERS MC, 1995, BLOOD, V85, P879, DOI 10.1182/blood.V85.4.879.bloodjournal854879; WALTERS MC, IN PRESS BIOL BLOOD	40	418	421	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					369	376		10.1056/NEJM199608083350601	http://dx.doi.org/10.1056/NEJM199608083350601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8663884				2022-12-28	WOS:A1996VA90400001
J	Begovic, M; Pretto, EA				Begovic, M; Pretto, EA			The way to Jerusalem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Pretto, Ernesto A/I-4679-2015	Pretto, Ernesto A/0000-0003-4732-534X					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					426	426						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683825				2022-12-28	WOS:A1996UZ77600028
J	Duke, C; Kovar, IZ				Duke, C; Kovar, IZ			HIV and the paediatrician as the child's advocate	LANCET			English	Article							TRANSMISSION; INFECTION; DELIVERY		CHELSEA & WESTMINSTER HOSP,LONDON SW10 9NH,ENGLAND	Imperial College London								BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *GEN MED COUNC, 1995, DUT DOCT HIV AIDS CL; Kennedy I, 1994, MED LAW TEXT MAT; NEWELL ML, 1994, LANCET, V343, P1464; RHODEN NK, 1986, CALIF LAW REV, V74, P1951, DOI 10.2307/3480420; 1995, COMM DIS REP CDR WKL, V5, P111; 1991, MMWR-MORBID MORTAL W, V40, P1; 1994, MMWR-MORBID MORTAL W, V43, P285	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					247	249		10.1016/S0140-6736(96)00428-X	http://dx.doi.org/10.1016/S0140-6736(96)00428-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684204				2022-12-28	WOS:A1996UZ28600015
J	Maron, BJ; Shirani, J; Poliac, LC; Mathenge, R; Roberts, WC; Mueller, FO				Maron, BJ; Shirani, J; Poliac, LC; Mathenge, R; Roberts, WC; Mueller, FO			Sudden death in young competitive athletes - Clinical, demographic, and pathological profiles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; RIGHT CORONARY-ARTERY; LONG-QT SYNDROME; CARDIAC DEATH; MITRAL-VALVE; CARDIOVASCULAR-DISEASE; PATHO-PHYSIOLOGY; LEFT MAIN; CARDIOMYOPATHY; SINUS	Objective.-To develop clinical, demographic, and pathological profiles of young competitive athletes who died suddenly, Design.-Systematic evaluation of clinical information and circumstances associated with sudden deaths; interviews with family members, witnesses, and coaches; and analyses of postmortem anatomic, microscopic, and toxicologic data. Participants and Setting.-A total of 158 sudden deaths that occurred in trained athletes throughout the United States from 1985 through 1995 were analyzed. Main Outcome Measures.-Characteristics and probable cause of death, Results.-Of 158 sudden deaths among athletes, 24 (15%) were explained by noncardiovascular causes, Among the 134 athletes who had cardiovascular causes of sudden death, the median age was 17 years (range, 12-40 years), 120 (90%) were male, 70 (52%) were white, and 59 (44%) were black. The most common competitive sports involved were basketball (47 cases) and football (45 cases), together accounting for 68% of sudden deaths, A total of 121 athletes (90%) collapsed during or immediately after a training session (78 cases) or a formal athletic contest (43 cases), with 80 deaths (63%) occurring between 3 PM and 9 PM, The most common structural cardiovascular diseases identified at autopsy as the primary cause of death were hypertrophic cardiomyopathy (48 athletes [36%]), which was disproportionately prevalent in black athletes compared with white athletes (48% vs 26% of deaths; P=.01), and malformations involving anomalous coronary artery origin (17 athletes [13%]), Of 115 athletes who had a standard preparticipation medical evaluation, only 4 (3%) were suspected of having cardiovascular disease, and the cardiovascular abnormality responsible for sudden death was correctly identified in only 1 athlete (0.9%). Conclusions.-Sudden death in young competitive athletes usually is precipitated by physical activity and may be due to a heterogeneous spectrum of cardiovascular disease, most commonly hypertrophic cardiomyopathy. Preparticipation screening appeared to be of limited value in identification of underlying cardiovascular abnormalities.	MINNEAPOLIS HEART INST FDN, DIV CARDIOVASC RES, 920 E 28TH ST, SUITE 40, MINNEAPOLIS, MN 55407 USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; NATL CTR CATASTROPH SPORTS INJURY RES, CHAPEL HILL, NC USA; BAYLOR UNIV, MED CTR, DALLAS, TX USA	Minneapolis Heart Institute Foundation; Yeshiva University; Albert Einstein College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Baylor University; Baylor University Medical Center								Aretz T., 1986, AM J CARDIOVASC PATH, V1, P3; BARTH CW, 1986, J AM COLL CARDIOL, V7, P366, DOI 10.1016/S0735-1097(86)80507-1; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; BURKE AP, 1993, J AM COLL CARDIOL, V21, P117, DOI 10.1016/0735-1097(93)90725-G; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; CHESLER E, 1983, CIRCULATION, V67, P632, DOI 10.1161/01.CIR.67.3.632; CORRADO D, 1992, BRIT HEART J, V68, P601; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; DALIENTO L, 1995, J AM COLL CARDIOL, V25, P655, DOI 10.1016/0735-1097(94)00433-Q; DOLLAR AL, 1991, J AM COLL CARDIOL, V17, P921, DOI 10.1016/0735-1097(91)90875-A; DRORY Y, 1991, AM J CARDIOL, V68, P1388, DOI 10.1016/0002-9149(91)90251-F; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; GOODIN JC, 1991, MODERN PATHOL, V4, P702; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; KARK JA, 1987, NEW ENGL J MED, V317, P781, DOI 10.1056/NEJM198709243171301; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; KLUES HG, 1992, CIRCULATION, V85, P1651, DOI 10.1161/01.CIR.85.5.1651; LECOMTE D, 1993, J FORENSIC SCI, V38, P617; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; MARON BJ, 1990, BRIT HEART J, V63, P308; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1994, J AM COLL CARDIOL, V24, P848, DOI 10.1016/0735-1097(94)90837-0; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1979, AM J CARDIOL, V43, P1242, DOI 10.1016/0002-9149(79)90160-7; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MARON BJ, 1994, J AM COLL CARDIOL, V23, P1405, DOI 10.1016/0735-1097(94)90384-0; MARON BJ, 1981, CIRCULATION, V63, P882, DOI 10.1161/01.CIR.63.4.882; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; MCKENNA WJ, 1990, BRIT HEART J, V63, P287; MENKE DM, 1985, CHEST, V88, P299, DOI 10.1378/chest.88.2.299; MORALES AR, 1980, CIRCULATION, V62, P230, DOI 10.1161/01.CIR.62.2.230; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; OLSEN EGJ, 1983, EUR HEART J, V4, P1; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; RAMPAZZO A, 1994, HUM MOL GENET, V3, P959, DOI 10.1093/hmg/3.6.959; ROBERTS CS, 1989, PROGR CARDIOLOGY, V2, P3; ROBERTS WC, 1986, AM J CARDIOL, V57, P179, DOI 10.1016/0002-9149(86)90977-X; ROBERTS WC, 1992, AM J CARDIOL, V70, P121, DOI 10.1016/0002-9149(92)91407-U; ROBERTS WC, 1982, AM HEART J, V104, P303, DOI 10.1016/0002-8703(82)90206-X; ROBERTS WC, 1982, AM J CARDIOL, V49, P863, DOI 10.1016/0002-9149(82)91970-1; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R; TAMBURRO P, 1992, AM HEART J, V124, P1035, DOI 10.1016/0002-8703(92)90989-9; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; VIRMANI R, 1984, J AM COLL CARDIOL, V3, P766, DOI 10.1016/S0735-1097(84)80253-3; VIRMANI R, 1988, AM HEART J, V115, P1068, DOI 10.1016/0002-8703(88)90078-6; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; ZIPES DP, 1994, J AM COLL CARDIOL, V24, P892, DOI 10.1016/0735-1097(94)90847-8	62	1203	1242	6	110	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					199	204		10.1001/jama.276.3.199	http://dx.doi.org/10.1001/jama.276.3.199			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667563	Green Published			2022-12-28	WOS:A1996UW46900030
J	Anderson, JC				Anderson, JC			Is childhood hyperactivity the product of western culture?	LANCET			English	Editorial Material							ATTENTION-DEFICIT; DSM-III; DISORDER				Anderson, JC (corresponding author), PUKETIRO CTR,CHILD ADOLESCENT & FAMILY SERV,POB 50-047,PORIRUA,NEW ZEALAND.							ANDERSON J, 1994, EPIDEMIOLOGY CHILDHO, P304; BIEDERMAN J, 1990, J AM ACAD CHILD PSY, V29, P526, DOI 10.1097/00004583-199007000-00004; Bird HR, 1996, J CHILD PSYCHOL PSYC, V37, P35, DOI 10.1111/j.1469-7610.1996.tb01379.x; FERGUSSON DM, 1991, J CHILD PSYCHOL PSYC, V32, P257, DOI 10.1111/j.1469-7610.1991.tb00305.x; LEUNG PWL, 1996, BRIT J PSYCHIAT, V168, P468; MCGEE R, 1985, J CONSULT CLIN PSYCH, V53, P480, DOI 10.1037/0022-006X.53.4.480; PRENDERGAST M, 1988, J CHILD PSYCHOL PSYC, V29, P289, DOI 10.1111/j.1469-7610.1988.tb00717.x	7	37	39	2	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					73	74		10.1016/S0140-6736(05)64598-9	http://dx.doi.org/10.1016/S0140-6736(05)64598-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UW673	8676718				2022-12-28	WOS:A1996UW67300006
J	Cobbe, SM; Dalziel, K; Ford, I; Marsden, AK				Cobbe, SM; Dalziel, K; Ford, I; Marsden, AK			Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest	BRITISH MEDICAL JOURNAL			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; HEARTSTART-SCOTLAND PROJECT; LONG-TERM SURVIVAL; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; EXPERIENCE; MORTALITY; DISEASE	Objectives-To determine the short and long term outcome of patients admitted to hospital after initially successful resuscitation from cardiac arrest out of hospital. Design-Review of ambulance and hospital records. Follow up of mortality by ''flagging'' with the registrar general. Cox proportional hazards analysis of predictors of mortality in patients discharged alive fi om hospital. Setting-Scottish Ambulance Service and acute hospitals throughout Scotland. Subjects-1476 patients admitted to a hospital ward, of whom 680 (46%) were discharged alive. Main outcome measures-Survival to hospital discharge, neurological status at discharge, time to death, and cause of death after discharge. Results-The median duration of hospital stay was 10 days (interquartile range 8-15) in patients discharged alive and 1 (1-4) day in those dying in hospital. Neurological status at discharge in survivors was normal or mildly impaired in 605 (89%), moderately impaired in 58 (8.5%), and severely impaired in 13 (2%); one patient was comatose. Direct discharge to home occurred in 622 (91%) cases. The 680 discharged survivors were followed up for a median of 25 (range 0-68) months. There were 176 deaths, of which 81 were sudden cardiac deaths, 55 were non-sudden cardiac deaths, and 40 were due to other causes. The product limit estimate of 4 year survival after discharge was 68%. The independent predictors of mortality on follow up were increased age, treatment for heart failure, and cardiac arrest not due to definite myocardial infarction. Conclusion-About 40% of initial survivors of resuscitation out of hospital are discharged home without major neurological disability. Patients at high risk of subsequent cardiac death can be identified and may benefit from further cardiological evaluation.	UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW G12 8QQ,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND; SCOTTISH AMBULANCE SERV,EDINBURGH EH10 5UU,MIDLOTHIAN,SCOTLAND	University of Glasgow; University of Glasgow			Ford, Ian/ABE-6145-2020					COBB LA, 1975, CIRCULATION, V52, P223; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; Connolly SJ, 1993, AM J CARDIOL, V72, P103; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; EVERY NR, 1992, J AM COLL CARDIOL, V19, P1435, DOI 10.1016/0735-1097(92)90599-I; GEDDES JS, 1967, LANCET, V2, P273; GOLDSTEIN S, 1985, CIRCULATION, V71, P873, DOI 10.1161/01.CIR.71.5.873; GOLDSTEIN S, 1981, CIRCULATION, V64, P977, DOI 10.1161/01.CIR.64.5.977; *GOV ACT DEP, 1992, SCOTT POP MAL FEM IN; HALLSTROM AP, 1991, AM J CARDIOL, V68, P1021; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; LEHMANN MH, 1991, PACE, V14, P969, DOI 10.1111/j.1540-8159.1991.tb04143.x; MACKINTOSH AF, 1978, BRIT MED J, V1, P1115, DOI 10.1136/bmj.1.6120.1115; MOOSVI AR, 1990, AM J CARDIOL, V65, P1192, DOI 10.1016/0002-9149(90)90972-4; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; SHARMA B, 1987, AM J CARDIOL, V59, P740, DOI 10.1016/0002-9149(87)91084-8; SIEBELS J, 1993, PACE, V16, P552, DOI 10.1111/j.1540-8159.1993.tb01624.x; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, AM J CARDIOL, V72, P280	30	88	88	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1633	1637		10.1136/bmj.312.7047.1633	http://dx.doi.org/10.1136/bmj.312.7047.1633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664715	Green Published			2022-12-28	WOS:A1996UV48900020
J	Forster, A; Young, J				Forster, A; Young, J			Specialist nurse support for patients with stroke in the community: A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL SUPPORT; RECOVERY	Objective-To evaluate whether specialist nurse visits enhance the social integration and perceived health of patients with stroke or alleviate stress in carers in longer term stroke care, Design-Stratified randomised controlled trial; both groups assessed at time of recruitment and at 3, 6, and 12 months. Setting-Patients with disability related to new stroke who lived in their own homes in the Bradford Metropolitan District. Subjects-240 patients aged 60 years or over, randomly allocated to control group (n = 120) or intervention group (n = 120). Intervention-Visits by specialist outreach nurses over 12 months to provide information, advice, and support; minimum of six visits during the first six months. The control group received no visits. Main outcome measures-The Barthel index (functional ability), the Frenchay activities index (social activity), the Nottingham health profile (perceived health status). Stress among carers was indicated by the general health questionnaire-28 (28 items). The nurses recorded their interventions in trial diaries. Results-There were no significant differences in perceived health, social activities, or stress among carers between the treatment and control groups at any of the assessments points. A subgroup of mildly disabled patients with stroke (Barthel index 15-19) had an improved social outcome at six months (Frenchay activities index, median difference 3 (95% confidence interval 0 to 6; P = 0.03)) and for the full 12 months of follow up (analysis of covariance P = 0.01) compared with the control group. Conclusions-The specialist nurse intervention resulted in a small improvement in social activities only for the mildly disabled patients. No proved strategy yet exists that can be recommended to address the psychosocial difficulties of patients with stroke and their families.			Forster, A (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			Forster, Anne/0000-0001-7466-4414; young, john/0000-0003-4085-9306				Altman DG., 1982, STATISTICS PRACTICE, P6; Anderson R, 1988, Int Disabil Stud, V10, P107; COLIN C, 1988, INT DISABIL STUD, V10, P61; Department of Health, 1992, HLTH NAT STRAT HLTH; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; EBRAHIM S, 1986, J EPIDEMIOL COMMUN H, V40, P166, DOI 10.1136/jech.40.2.166; Ebrahim S, 1987, Int Disabil Stud, V9, P103; Enderby P M, 1987, Int Rehabil Med, V8, P166; EVANS RL, 1987, ARCH PHYS MED REHAB, V68, P513; FORSTER A, 1992, BRIT MED J, V305, P1446, DOI 10.1136/bmj.305.6867.1446; FRIEDLAND JF, 1992, ARCH PHYS MED REHAB, V73, P573; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; GEDDES JML, 1989, CLIN REHABIL, V3, P189; GLADMAN J, 1995, AGE AGEING, V24, P49, DOI 10.1093/ageing/24.1.49; GLASS TA, 1992, SOC SCI MED, V34, P1249, DOI 10.1016/0277-9536(92)90317-J; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GORE SM, 1982, STATISTICS PRACTICE, P44; Greveson G, 1991, Health Trends, V23, P161; HANGER HC, 1993, STROKE, V24, P536, DOI 10.1161/01.STR.24.4.536; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HOLBROOK M, 1982, J ROY COLL PHYS LOND, V16, P100; Hunt SM, 1986, MEASURING HLTH STATU; KETTLE M, 1989, CLIN REHABIL, V3, P131; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Norusis MJ, 1990, SPSS ADV STAT USERS, P121; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; THORNGREN M, 1990, STROKE, V21, P236, DOI 10.1161/01.STR.21.2.236; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	32	142	145	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1642	1646		10.1136/bmj.312.7047.1642	http://dx.doi.org/10.1136/bmj.312.7047.1642			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664717	Green Published			2022-12-28	WOS:A1996UV48900022
J	Logie, S				Logie, S			''Coming out'' - A personal dilemma	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1679	1679		10.1136/bmj.312.7047.1679	http://dx.doi.org/10.1136/bmj.312.7047.1679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664756	Green Published			2022-12-28	WOS:A1996UV48900074
J	Massague, J				Massague, J			TGF beta signaling: Receptors, transducers, and mad proteins	CELL			English	Review									MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Massague, Joan/0000-0001-9324-8408				ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BAKER J, 1996, IN PRESS GENES DEV; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; LECHLEIDER RJ, 1996, IN PRESS J BIOL CHEM; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MASSAGUE J, 1996, CANC SURVEYS, V381, P620; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; NEWFELD SJ, 1996, IN PRESS DEVELOPMENT; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; THOMSEN GH, 1996, IN PRESS DEVELOPMENT; WIERSDORFF V, 1996, IN PRESS DEVELOPMENT; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YINGLING JM, 1996, IN PRESS P NATL ACAD	22	794	828	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					947	950		10.1016/S0092-8674(00)81296-9	http://dx.doi.org/10.1016/S0092-8674(00)81296-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674122	Bronze			2022-12-28	WOS:A1996UV48400002
J	Kipreos, ET; Lander, LE; Wing, JP; He, WW; Hedgecock, EM				Kipreos, ET; Lander, LE; Wing, JP; He, WW; Hedgecock, EM			cul-1 is required for cell cycle exit in C-elegans and identifies a novel gene family	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SACCHAROMYCES-CEREVISIAE; SEQUENCE; GENOME; FIBROBLASTS; LINEAGES; PROJECT; PHASE; G(1)	The gene cul-1 (formerly lin-19) is a negative regulator of the cell cycle in C. elegans. Null mutations cause hyperplasia of all tissues. cul-1 is required for developmentally programmed transitions from the G1 phase of the cell cycle to the G0 phase or the apoptotic pathway. Moreover, the mutant phenotype suggests that G1-to-S phase progression is accelerated, overriding mechanisms for mitotic arrest and producing abnormally small cells. Significantly, diverse aspects of cell fate and differentiation are unaffected in cul-1 mutants. cul-1 represents a conserved family of genes, designated cullins, with at least five members in nematodes, six in humans, and three in budding yeast.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	Johns Hopkins University; GlaxoSmithKline; Human Genome Sciences Inc					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; BURNATOWSKAHLEDIN MA, 1995, AM J PHYSIOL-RENAL, V268, pF1198, DOI 10.1152/ajprenal.1995.268.6.F1198; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Mello C, 1995, METHOD CELL BIOL, P452; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J, 1989, MOL CLONING; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J., 1988, NEMATODE CAENORHABDI, P415; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Swofford D., 1998, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	47	387	411	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					829	839		10.1016/S0092-8674(00)81267-2	http://dx.doi.org/10.1016/S0092-8674(00)81267-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681378	hybrid			2022-12-28	WOS:A1996UR60400007
J	Hennessy, S; Liu, ZL; Tsai, TF; Strom, BL; Wan, CM; Liu, HL; Wu, TX; Yu, HJ; Liu, QM; Karabatsos, N; Bilker, WB; Halstead, SB				Hennessy, S; Liu, ZL; Tsai, TF; Strom, BL; Wan, CM; Liu, HL; Wu, TX; Yu, HJ; Liu, QM; Karabatsos, N; Bilker, WB; Halstead, SB			Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study	LANCET			English	Article								Background Japanese encephalitis is a major cause of death and disability throughout Asia, including the Indian subcontinent. Although an effective vaccine for Japanese encephalitis is available, hundreds of millions of susceptible individuals remain unimmunised because of the vaccine's cost. In 1988, an inexpensive live-attenuated vaccine (SA14-14-2) was licensed in China. We have measured the effectiveness of this vaccine, Methods In a case-control study in rural Sichuan Province, to China, the 56 cases consisted of children admitted to hospital with acute Japanese encephalitis, and were confirmed serologically. 1299 village-matched and age-matched controls were identified, and vaccination histories obtained from pre-existing written records. Findings The effectiveness of one dose was 80% (95% CI 44 to 93%); that of two doses was 97.5% (86 to 99.6%). Controlling for multiple potential confounders did not alter these results. Interpretation We conclude that a regimen of two doses of live-attenuated Japanese encephalitis vaccine, administered 1 year apart, is effective in the prevention of clinically important disease, Subsequent study is needed to assure the safety of this vaccine.	UNIV PENN, SCH MED, DEPT BIOSTAT & EPIDEMIOL, PHILADELPHIA, PA 19104 USA; W CHINA UNIV MED SCI, CLIN EPIDEMIOL UNIT, CHENGDU 610041, SICHUAN, PEOPLES R CHINA; CTR DIS CONTROL & PREVENT, FT COLLINS, CO 80522 USA; UNIV PENN, SCH MED, DEPT MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; ROCKEFELLER FDN, NEW YORK, NY USA	University of Pennsylvania; Sichuan University; Centers for Disease Control & Prevention - USA; University of Pennsylvania	Hennessy, S (corresponding author), UNIV PENN, SCH MED, CTR CLIN EPIDEMIOL & BIOSTAT, ROOM 832, BLOCKLEY HALL, PHILADELPHIA, PA 19104 USA.		Bilker, Warren/AAS-3515-2021					Burke DS, 1988, ARBOVIRUSES EPIDEMIO, V3, P63; FLANDERS WD, 1986, AM J EPIDEMIOL, V124, P684, DOI 10.1093/oxfordjournals.aje.a114442; HALSTEAD SB, 1992, TXB PEDIAT INFECT DI, P1468; HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004; LUO D, 1994, SE ASIAN J TROP MED, V24, P643; *MED EC CO INC, 1995, DRUG TOP RED BOOK, P292; OLIN BR, 1995, DRUG FACTS COMP, pG465; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; POLAND JD, 1990, J INFECT DIS, V161, P878, DOI 10.1093/infdis/161.5.878; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P64; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P297; TSAI TF, 1995, VACCINES, P671; TSAI TF, 1992, AM SOC MICROBIOL, P606; XIN YY, 1988, AM J TROP MED HYG, V319, P214	14	167	182	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1996	347	9015					1583	1586		10.1016/S0140-6736(96)91075-2	http://dx.doi.org/10.1016/S0140-6736(96)91075-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667866	hybrid			2022-12-28	WOS:A1996UP66100009
J	Carolei, A; Marini, C; DeMatteis, G; Fieschi, C; Frontoni, M; Zanette, E; Inzitari, D; Nencini, P; Gandolfo, C; Finocchi, C; Prencipe, M; Totaro, R; Landi, G; Motto, C; DeZanche, L; Parma, M; Scoditti, U				Carolei, A; Marini, C; DeMatteis, G; Fieschi, C; Frontoni, M; Zanette, E; Inzitari, D; Nencini, P; Gandolfo, C; Finocchi, C; Prencipe, M; Totaro, R; Landi, G; Motto, C; DeZanche, L; Parma, M; Scoditti, U			History of migraine and risk of cerebral ischaemia in young adults	LANCET			English	Article							ISCHEMIC STROKE; HEADACHE	Background A history of migraine has been proposed as a risk factor for cerebral ischaemia in women under 45. Methods To investigate the association between history of migraine and cerebral ischaemia, we performed a case-control study of 308 patients aged 15-44, with either transient ischaemic attach (TIA) or stroke, and of 591 age-and sex-matched controls prospectively recruited in seven university hospitals. Crude and adjusted odds ratios were calculated using logistic regression analysis. Findings A history of migraine was more frequent in patients than in controls (14.9% vs 9.1%; adjusted odds ratio 1.9, 95% confidence interval 1.1-3.1). In the prospectively designed subgroup analyses, a history of migraine reached the highest odds ratio (3.7, 95% Cl 1.5-9) and was the only significant risk factor in women below age 35 (p=0.003); atherogenic risk factors were more relevant in men and in patients older than 35; previous migraine attacks with aura were more frequent in stroke patients (odds ratio 8.6, 95% CI 1-75). Interpretation Our findings indicated that the rare association between migraine and cerebral ischaemia is limited to women below age 35, and suggest a need for careful clinical evaluation of comorbidity in the presence of migraine with aura.	UNIV ROMA LA SAPIENZA, DEPT NEUROL, ROME, ITALY; UNIV HOSP, DEPT NEUROL, FLORENCE, ITALY; UNIV HOSP, DEPT NEUROL, GENOA, ITALY; UNIV HOSP, DEPT NEUROL, LAQUILA, ITALY; OSPED MAGGIORE, DEPT NEUROL, MILAN, ITALY; UNIV HOSP, DEPT NEUROL, PADUA, ITALY; UNIV HOSP, DEPT NEUROL, PARMA, ITALY	Sapienza University Rome; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Genoa; IRCCS AOU San Martino IST; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Parma; University Hospital of Parma	Carolei, A (corresponding author), UNIV LAQUILA, DIPARTIMENTO MED INTERNA & SANITA PUBBL, NEUROL CLIN, NEUROL INST, I-67100 LAQUILA, ITALY.		Finocchi, Cinzia/AAA-7409-2020; Inzitari, Domenico/AAH-8722-2020	Finocchi, Cinzia/0000-0003-4385-1203; 				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; BLAU JN, 1994, LANCET, V344, P1623, DOI 10.1016/S0140-6736(94)90413-8; BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012; CAROLEI A, 1995, BRIT MED J, V310, P1363, DOI 10.1136/bmj.310.6991.1363; DANDREA G, 1994, J NEUROL NEUROSUR PS, V57, P557, DOI 10.1136/jnnp.57.5.557; EASTON JD, 1993, CEREBROVASC DIS, V3, P244; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; HARRIS M, 1979, DIABETES, V28, P1039; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; HONKASALO ML, 1993, HEADACHE, V33, P403, DOI 10.1111/j.1526-4610.1993.hed3308403.x; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; LEVINE SR, 1987, CEPHALALGIA, V7, P93, DOI 10.1046/j.1468-2982.1987.0702093.x; LIDEGAARD O, 1986, STROKE, V17, P670, DOI 10.1161/01.STR.17.4.670; Lipton R B, 1993, Neurology, V43, pS6; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; MILLIKAN CH, 1975, STROKE, V6, P565; MOSKOWITZ MA, 1993, CEREBROVAS BRAIN MET, V5, P159; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TZOURIO C, 1993, BMJ-BRIT MED J, V307, P289, DOI 10.1136/bmj.307.6899.289; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; WELCH KMA, 1994, NEUROLOGY, V44, P33; WELCH KMA, 1990, ARCH NEUROL-CHICAGO, V47, P458, DOI 10.1001/archneur.1990.00530040114027; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505; 1973, NEW ENGL J MED, V288, P871	24	247	253	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1996	347	9014					1503	1506		10.1016/S0140-6736(96)90669-8	http://dx.doi.org/10.1016/S0140-6736(96)90669-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684100				2022-12-28	WOS:A1996UN47300008
J	Casscells, W; Hathorn, B; David, M; Krabach, T; Vaughn, WK; McAllister, HA; Bearman, G; Willerson, JT				Casscells, W; Hathorn, B; David, M; Krabach, T; Vaughn, WK; McAllister, HA; Bearman, G; Willerson, JT			Thermal detection of cellular infiltrates in living atherosclerotic plaques: Possible implications for plaque rupture and thrombosis	LANCET			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION	Background Atherosclerotic lesions are heterogeneous and prognosis cannot easily be predicted, intracoronary ultrasound and angioscopy, angiographic and necropsy studies suggest that the risk of plaque rupture correlates only weakly with the degree of stenosis. Most ruptured plaques are characterised by a large pool of cholesterol or necrotic debris and a thin fibrous cap with a dense infiltration of macrophages. The release of matrix-digesting enzymes by these cells is thought to contribute to plaque rupture. Other thromboses are found on non-ruptured but inflamed plaque surfaces, We postulated that both types of thrombotic events may be predicted by heat released by activated macrophages either on the plaque surface or under a thin cap. Methods To test the hypothesis, we measured the intimal surface temperatures at 20 sites in each of 50 samples of carotid artery taken at endarterectomy from 48 patients. The living samples were probed with a thermistor (24-gauge needle-tip; accuracy 0.1 degrees C; time contrast 0.15 s), The tissues were then fixed and stained. Findings Plaques showed several regions in which the surface temperatures varied reproducibly by 0.2-0.3 degrees C, but 37% of plaques had substantially warmer regions (0.4-2.2 degrees C). Points with substantially different temperatures could not be distinguished from one another by the naked eye; such points could also be very close to one another (<1 mm apart). Temperature correlated positively with cell density (r=0.68, p=0.0001) and inversely with the distance of the cell clusters from the luminal surface (r=-0.38, p=0.0006), Most cells were macrophages, Infrared thermographic images also revealed heterogeneity in temperature among the plaques. Interpretation Living atherosclerotic plaques show thermal heterogeneity, which raises the possibility that an infrared catheter or other techniques that can localise heat or metabolic activity might be able to identify plaques at high risk of rupture or thrombosis.	ST LUKES EPISCOPAL HOSP,TEXAS HEART INST,HOUSTON,TX; HERMANN HOSP,HOUSTON,TX; CALTECH,JET PROP LAB,PASADENA,CA	Saint Lukes Episcopal Hospital; Texas Heart Institute; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Casscells, W (corresponding author), UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV CARDIOL,6431 FANNIN,POB 20708,HOUSTON,TX 77225, USA.				NHLBI NIH HHS [91HL07] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN EL, 1993, J AM COLL CARDIOL, V22, P1141, DOI 10.1016/0735-1097(93)90429-5; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; BENARON DA, 1995, J CLIN MONITOR, V11, P109, DOI 10.1007/BF01617732; BUJA LM, 1994, CIRCULATION, V89, P503, DOI 10.1161/01.CIR.89.1.503; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEFEYTER PJ, 1995, CIRCULATION, V92, P1408, DOI 10.1161/01.CIR.92.6.1408; FALK E, 1995, CIRCULATION, V92, P2033, DOI 10.1161/01.CIR.92.8.2033; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; GERTZ SD, 1995, CIRCULATION S1, V92, P293; Kannel W B, 1994, J Cardiovasc Risk, V1, P333, DOI 10.1097/00043798-199412000-00009; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MACFALL J, 1995, INT J HYPERTHER, V11, P73, DOI 10.3109/02656739509004949; MORENO PR, 1995, CIRCULATION, V92, P161; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Shah Prediman K., 1996, Cardiology Clinics, V14, P17; SKINNER MP, 1995, NAT MED, V1, P69, DOI 10.1038/nm0195-69; TOUSSAINT JF, 1995, ARTERIOSCL THROM VAS, V15, P1533; VANDAMME H, 1994, CARDIOVASC PATHOL, V3, P9, DOI 10.1016/1054-8807(94)90003-5; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36	19	268	301	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1447	1449		10.1016/S0140-6736(96)91684-0	http://dx.doi.org/10.1016/S0140-6736(96)91684-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676628				2022-12-28	WOS:A1996UM48500011
J	Ellis, TM; Atkinson, MA				Ellis, TM; Atkinson, MA			Early infant diets and insulin-dependent diabetes	LANCET			English	Editorial Material							MELLITUS; MILK; ALBUMIN; TRIGGER; IDDM		UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT PATHOL,COLL MED,GAINESVILLE,FL 32610	State University System of Florida; University of Florida								AKERBLOM HK, 1993, DIABETES METAB REV, V9, P269, DOI 10.1002/dmr.5610090407; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; ATKINSON MA, 1993, NEW ENGL J MED, V329, P1853, DOI 10.1056/NEJM199312163292505; BODINGTON MJ, 1994, DIABETIC MED, V11, P663, DOI 10.1111/j.1464-5491.1994.tb00329.x; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; CHEUNG R, 1994, SCAND J IMMUNOL, V40, P623, DOI 10.1111/j.1365-3083.1994.tb03514.x; DAHLJORGENSEN K, 1991, DIABETES CARE, V14, P1081, DOI 10.2337/diacare.14.11.1081; DOSCH HM, 1993, CLIN BIOCHEM, V26, P307, DOI 10.1016/0009-9120(93)90131-O; DRASH AL, 1994, PEDIATRICS, V94, P752; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; FAVA D, 1994, DIABETES CARE, V17, P1488, DOI 10.2337/diacare.17.12.1488; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KOSTRABA JN, 1994, DIABETES CARE, V17, P87, DOI 10.2337/diacare.17.1.87; MACLAREN N, 1992, NEW ENGL J MED, V327, P348, DOI 10.1056/NEJM199207303270509; MARTIN JM, 1991, ANN MED, V23, P447, DOI 10.3109/07853899109148088; PATTERSON CC, 1994, DIABETES CARE, V17, P376, DOI 10.2337/diacare.17.5.376; PETERSEN JS, 1994, DIABETES, V43, P1478, DOI 10.2337/diabetes.43.12.1478; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; SCOTT FW, 1991, CAN J PHYSIOL PHARM, V69, P311, DOI 10.1139/y91-048	20	42	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1464	1465		10.1016/S0140-6736(96)91690-6	http://dx.doi.org/10.1016/S0140-6736(96)91690-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676633				2022-12-28	WOS:A1996UM48500017
J	Farci, P; Alter, HJ; Shimoda, A; Govindarajan, S; Cheung, LC; Melpolder, JC; Sacher, RA; Shih, JW; Purcell, RH				Farci, P; Alter, HJ; Shimoda, A; Govindarajan, S; Cheung, LC; Melpolder, JC; Sacher, RA; Shih, JW; Purcell, RH			Hepatitis C virus-associated fulminant hepatic failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NON-B HEPATITIS; NON-A; VIRAL-HEPATITIS; LIVER-FAILURE; RNA; DNA	FULMINANT hepatic failure is a dramatic clinical syndrome characterized by massive necrosis of liver cells.(1) It is most often caused by hepatitis A virus and hepatitis B virus (HBV)(2); whether hepatitis C virus (HCV) can cause it is still controversial.(3,4) Among patients with non-A, non-B fulminant hepatitis, antibodies against HCV (anti-HCV) or serum HCV RNA were found in 40 to 60 percent in Japan(5,6) and Taiwan,(7) but in only 2 percent (range, 0 to 12 percent) in Western countries,(8-13) with one exception: a recent study conducted in California reported a prevalence of 60 percent associated with low socioeconomic status and Hispanic ethnicity.(14) Whether these discrepancies reflect geographic differences in the epidemiology of HCV infection or the pathogenicity of the prevalent viral strains is not known. Furthermore, because of the dramatic course of fulminant hepatic failure, in most patients only a single serum sample, often obtained late in the course of the disease, was studied. In this report, we describe a patient with HCV-associated fulminant hepatitis in whom serial studies were done that provided a unique opportunity to establish a temporal association between the acquisition of HCV infection and the development of fulminant hepatitis and to define the clinical, virologic, and histologic profile of fulminant hepatitis C.	NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892; NIH,DEPT TRANSFUS MED,WARREN G MAGNUSON CLIN CTR,BETHESDA,MD 20892; UNIV SO CALIF,RANCHO LOS AMIGOS MED CTR,DEPT PATHOL,DOWNEY,CA 90242; GEORGETOWN UNIV,MED CTR,DIV CLIN & LAB SERV,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; University of Southern California; Georgetown University								ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHU CM, 1994, GASTROENTEROLOGY, V107, P189, DOI 10.1016/0016-5085(94)90076-0; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUWADA SK, 1994, AM J GASTROENTEROL, V89, P57; LEE WM, 1994, NEW ENGL J MED, V330, P584; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LIANG TJ, 1993, GASTROENTEROLOGY, V104, P556, DOI 10.1016/0016-5085(93)90426-D; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MUTO Y, 1990, Gastroenterologia Japonica, V25, P32; SACHER RA, 1991, ANN INTERN MED, V115, P984; SALLIE R, 1994, J HEPATOL, V20, P580, DOI 10.1016/S0168-8278(05)80343-5; SHERLOCK S, 1993, ADV INTERNAL MED, V38, P245; SHIH JWK, 1991, J CLIN MICROBIOL, V29, P1640, DOI 10.1128/JCM.29.8.1640-1644.1991; THEILMANN L, 1992, EUR J CLIN INVEST, V22, P569, DOI 10.1111/j.1365-2362.1992.tb01507.x; Trey C, 1970, Prog Liver Dis, V3, P282; VILLAMIL FG, 1995, HEPATOLOGY, V22, P1379; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111; WRIGHT TL, 1993, GASTROENTEROLOGY, V104, P640, DOI 10.1016/0016-5085(93)90437-H; YANAGI M, 1991, NEW ENGL J MED, V324, P1895, DOI 10.1056/NEJM199106273242615	28	116	119	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					631	634		10.1056/NEJM199608293350904	http://dx.doi.org/10.1056/NEJM199608293350904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8687517				2022-12-28	WOS:A1996VD42500004
J	Blackwood, KM				Blackwood, KM			Device applications of side-chain ferroelectric liquid crystalline polymer films	SCIENCE			English	Article								Side-chain ferroelectric liquid crystalline polymers are currently used in a number of applications, including displays and electrical sensors. Comparisons with existing technologies and materials indicate that relative to ceramics, such polymers have lower figures of merit but offer greater durability in sensor applications.			Blackwood, KM (corresponding author), DEF RES AGCY,ST ANDREWS RD,MALVERN WR14 3PS,WORCS,ENGLAND.								0	28	28	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					909	912		10.1126/science.273.5277.909	http://dx.doi.org/10.1126/science.273.5277.909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688067				2022-12-28	WOS:A1996VC67000039
J	Howard, AD; Feighner, SD; Cully, DF; Arena, JP; Liberator, PA; Rosenblum, CI; Hamelin, M; Hreniuk, DL; Palyha, OC; Anderson, J; Paress, PS; Diaz, C; Chou, M; Liu, KK; McKee, KK; Pong, SS; Chaung, LY; Elbrecht, A; Dashkevicz, M; Heavens, R; Rigby, M; Sirinathsinghji, DJS; Dean, DC; Melillo, DG; Patchett, AA; Nargund, R; Griffin, PR; DeMartino, JA; Gupta, SK; Schaeffer, JM; Smith, RG; VanderPloeg, LHT				Howard, AD; Feighner, SD; Cully, DF; Arena, JP; Liberator, PA; Rosenblum, CI; Hamelin, M; Hreniuk, DL; Palyha, OC; Anderson, J; Paress, PS; Diaz, C; Chou, M; Liu, KK; McKee, KK; Pong, SS; Chaung, LY; Elbrecht, A; Dashkevicz, M; Heavens, R; Rigby, M; Sirinathsinghji, DJS; Dean, DC; Melillo, DG; Patchett, AA; Nargund, R; Griffin, PR; DeMartino, JA; Gupta, SK; Schaeffer, JM; Smith, RG; VanderPloeg, LHT			A receptor in pituitary and hypothalamus that functions in growth hormone release	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS RNA; XENOPUS-OOCYTES; ARCUATE NUCLEUS; EXPRESSION; CLONING; SECRETAGOGUE; HEXAPEPTIDE; AVERMECTIN; PEPTIDE-6; AEQUORIN	Small synthetic molecules termed growth hormone secretagogues (GHSs) act on the pituitary gland and the hypothalamus to stimulate and amplify pulsatile growth hormone (GH) release. A heterotrimeric GTP-binding protein (G protein)-coupled receptor (GPC-R) of the pituitary and arcuate ventro-medial and infundibular hypothalamus of swine and humans was cloned and was shown to be the target of the GHSs. On the basis of its pharmacological and molecular characterization, this GPC-R defines a neuroendocrine pathway for the control of pulsatile GH release and supports the notion that the GHSs mimic an undiscovered hormone.	MERCK RES LABS,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,HARLOW CM20 2QR,ESSEX,ENGLAND	Merck & Company; Merck & Company								ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; BOWERS CY, 1994, J CLIN ENDOCR METAB, V79, P940, DOI 10.1210/jc.79.4.940; BRESSONBEPOLDIN L, 1994, CELL CALCIUM, V15, P247, DOI 10.1016/0143-4160(94)90064-7; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; CHENG K, 1991, ENDOCRINOLOGY, V129, P3337; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; DICKSON SL, 1995, J ENDOCRINOL, V146, P519, DOI 10.1677/joe.0.1460519; FROHMAN LA, 1987, ENDOCRINOL METAB, P264; GERTZ BJ, 1993, J CLIN ENDOCR METAB, V77, P1393, DOI 10.1210/jc.77.5.1393; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRYGORCZYK R, IN PRESS J NEUROSCI; HERRINGTON J, 1994, ENDOCRINOLOGY, V135, P1100, DOI 10.1210/en.135.3.1100; HOWARD A, UNPUB; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; Kriegler M., 1990, GENE TRANSFER EXPRES; LEI T, 1995, J MOL ENDOCRINOL, V14, P135, DOI 10.1677/jme.0.0140135; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Pong SS, 1996, MOL ENDOCRINOL, V10, P57, DOI 10.1210/me.10.1.57; PONG SS, 1993, P 75 M END SOC END S, P172; REINHART J, 1992, J BIOL CHEM, V267, P21281; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SIRINATHSINGHJI DJ, UNPUB; SIRINATHSINGHJI DJS, 1995, NEUROREPORT, V6, P1989, DOI 10.1097/00001756-199510010-00009; SIRINATHSINGHJI DJS, 1990, NEUROSCIENCE, V34, P675, DOI 10.1016/0306-4522(90)90174-3; SIRINATHSINGHJI DS, 1993, MOL IMAGING NEUROSCI, P43; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; Smith RG, 1996, RECENT PROG HORM RES, V51, P261; WU D, 1992, J BIOL CHEM, V266, P9309	31	1666	1757	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					974	977		10.1126/science.273.5277.974	http://dx.doi.org/10.1126/science.273.5277.974			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688086				2022-12-28	WOS:A1996VC67000069
J	Lange, FF				Lange, FF			Chemical solution routes to single-crystal thin films	SCIENCE			English	Article							SOL-GEL METHOD; CUBIC ZIRCONIA; GRAIN-GROWTH; EPITAXIAL-GROWTH; LIQUID PRECURSORS; BARIUM-TITANATE; LINBO3 FILMS; METAL OXIDES; HETEROEPITAXY; SAPPHIRE	Epitaxial thin films of inorganic single crystals can be grown on single-crystal substrates with a variety of different solution chemistries. This review emphasizes chemical solution deposition, in which a solution is used to deposit a layer of precursor molecules that decompose to low-density, polycrystalline films during heating. Ways to control film cracking during deposition and heat treatment and why many precursors synthesize metastable crystalline structures are discussed, and the different mechanisms that convert the polycrystalline film into a single crystal are reviewed. Hydrothermal epitaxy, in which single crystal thin films are directly synthesized on templating substrates in an aqueous solution at temperatures <150 degrees C, is also discussed.			Lange, FF (corresponding author), UNIV CALIF SANTA BARBARA,DEPT MAT,SANTA BARBARA,CA 93106, USA.							BALMER ML, 1992, J AM CERAM SOC, V75, P946, DOI 10.1111/j.1151-2916.1992.tb04164.x; BARLINGAY CK, 1992, APPL PHYS LETT, V61, P1278, DOI 10.1063/1.107616; BAUER EG, 1990, J MATER RES, V5, P852, DOI 10.1557/JMR.1990.0852; BILL J, 1995, ADV MATER, V7, P775, DOI 10.1002/adma.19950070903; BIRCHELL JD, 1983, BRIT CERAM TRANS J, V82, P153; BLUM JB, 1985, J MATER SCI, V20, P4479, DOI 10.1007/BF00559337; BORNSIDE DE, 1987, J IMAGING TECHNOL, V13, P122; BRAUNSTEIN G, 1993, J APPL PHYS, V73, P961, DOI 10.1063/1.353310; Brinker C.J., 1990, SOL GEL SCI, DOI [10.1016/B978-0-08-057103-4.50013-1, DOI 10.1016/C2009-0-22386-5]; BUSCH JR, 1992, MATER RES SOC P S, V243, P533; CAIN MG, 1994, J MATER RES, V9, P674, DOI 10.1557/JMR.1994.0674; CHANDLER CD, 1993, CHEM REV, V93, P1205, DOI 10.1021/cr00019a015; CHEN QW, 1995, APPL PHYS LETT, V66, P1608, DOI 10.1063/1.113867; CHEN QW, 1995, MATER LETT, V22, P93, DOI 10.1016/0167-577X(94)00212-6; CHIEN A, UNPUB; CHIEN AT, 1995, J MATER RES, V10, P1784, DOI 10.1557/JMR.1995.1784; DAWSON WJ, 1988, AM CERAM SOC BULL, V67, P1673; DEROUIN TA, IN PRESS; EVANS AG, 1988, J MATER RES, V3, P1043, DOI 10.1557/JMR.1988.1043; GILLE G, 1985, CURRENT TOPICS MATER, V12, pCH7; GOLDEN SJ, 1992, APPL PHYS LETT, V61, P22; HEIMANN D, IN PRESS; Hennings D., 1992, Journal of the European Ceramic Society, V9, P41, DOI 10.1016/0955-2219(92)90075-O; HIRANO S, 1993, J AM CERAM SOC, V76, P1788, DOI 10.1111/j.1151-2916.1993.tb06648.x; HIRANO S, 1992, J AM CERAM SOC, V75, P2785, DOI 10.1111/j.1151-2916.1992.tb05505.x; HIRANO S, 1988, ADV CERAM MATER, V3, P503; HUR NH, 1994, J MATER RES, V9, P980, DOI 10.1557/JMR.1994.0980; Hutchinson J.W., 1991, ADV APPL MECH, P63; JEON NL, 1995, J MATER RES, V10, P2996, DOI 10.1557/JMR.1995.2996; JOSHI V, 1992, MATER RES SOC SYMP P, V271, P377, DOI 10.1557/PROC-271-377; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; LAINE RM, 1993, CHEM MATER, V5, P260, DOI 10.1021/cm00027a007; LANGJAHR P, UNPUB; LANGJAHR PA, 1995, MATER RES SOC S P, V401, P109; LEROY E, 1984, ULTRASTRUCTURE PROCE, P219; LEUNG DK, 1991, J AM CERAM SOC, V74, P2786, DOI 10.1111/j.1151-2916.1991.tb06844.x; LILLEY T, 1989, Patent No. 4764493; LIVAGE J, 1988, PROG SOLID STATE CH, V18, P259, DOI 10.1016/0079-6786(88)90005-2; Mantese J. V., 1989, MRS BULL, V14, P48; MCINTYRE PC, 1990, J APPL PHYS, V68, P4183, DOI 10.1063/1.346233; MILLER KT, 1989, MATER RES SOC SYMP P, V155, P191, DOI 10.1557/PROC-155-191; MILLER KT, 1993, J MATER RES, V8, P169, DOI 10.1557/JMR.1993.0169; MILLER KT, 1991, J MATER RES, V6, P2387, DOI 10.1557/JMR.1991.2387; MILLER KT, 1990, J MATER RES, V5, P151, DOI 10.1557/JMR.1990.0151; NARWANKAR PK, 1995, J MATER RES, V10, P1756, DOI 10.1557/JMR.1995.1756; NASHIMOTO K, 1995, J MATER RES, V10, P2564, DOI 10.1557/JMR.1995.2564; NASHIMOTO K, 1991, MATER LETT, V10, P348, DOI 10.1016/0167-577X(91)90151-U; OKUWADA K, 1990, JPN J APPL PHYS 1, V29, P1153, DOI 10.1143/JJAP.29.1153; OSSEOASARE K, 1988, CERAM T CERAM POWDER, P47; Partlow D. P., 1987, Journal of Materials Research, V2, P595, DOI 10.1557/JMR.1987.0595; POLLI AD, UNPUB; POLLI AD, IN PRESS J AM CERAM; Saito Y, 1996, J CERAM SOC JPN, V104, P143, DOI 10.2109/jcersj.104.143; SALMOVICH EB, 1996, J AM CERAM SOC, V79, P239; SEIFERT A, 1995, J MATER RES, V10, P680, DOI 10.1557/JMR.1995.0680; SEIFERT A, 1993, J AM CERAM SOC, V76, P443, DOI 10.1111/j.1151-2916.1993.tb03804.x; SEIFERT A, IN PRESS J MATER RES; SROLOVITZ DJ, 1986, J APPL PHYS, V60, P247, DOI 10.1063/1.337689; SUTTON AP, 1995, ITNERFACES CRYSTALLI, P129; THOMPSON CV, 1990, J APPL PHYS, V67, P4099, DOI 10.1063/1.344969; THOMPSON CV, 1990, ANNU REV MATER SCI, V20, P245, DOI 10.1146/annurev.ms.20.080190.001333; TUTTLE BA, 1993, J AM CERAM SOC, V76, P1537, DOI 10.1111/j.1151-2916.1993.tb03936.x; VAIDYA KJ, 1994, J MATER RES, V9, P410, DOI 10.1557/JMR.1994.0410; Vest R. W., 1993, CERAMIC FILMS COATIN, P303; YOGO T, 1995, J AM CERAM SOC, V78, P1649, DOI 10.1111/j.1151-2916.1995.tb08864.x; YOON DS, 1994, J MATER RES, V9, P420, DOI 10.1557/JMR.1994.0420; YOSHIMURA M, 1989, JPN J APPL PHYS 2, V28, pL2007, DOI 10.1143/JJAP.28.L2007	67	361	376	5	225	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					903	909		10.1126/science.273.5277.903	http://dx.doi.org/10.1126/science.273.5277.903			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688066				2022-12-28	WOS:A1996VC67000038
J	Grossman, E; Messerli, FH				Grossman, E; Messerli, FH			Diabetic and hypertensive heart disease	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR HYPERTROPHY; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; AUTONOMIC NEUROPATHY; ECHOCARDIOGRAPHIC FEATURES; INSULIN-RESISTANCE; CARDIAC-FUNCTION; PUMP FUNCTION; FOLLOW-UP; MELLITUS	Objective: To review the literature on the cardiac effects of diabetes mellitus and hypertension. Data Sources: A MEDLINE search of English-language articles published between 1980 and January 1996 was done using the terms diabetes mellitus, hypertension or blood pressure, and heart. References cited in identified articles were also reviewed. Study Selection: Selected studies were divided into those addressing coronary artery disease or myocardial ischemia and those addressing nonischemic cardiomyopathy and its sequelae. Preference was given to articles about the cardiac complications of both diabetes mellitus and hypertension. Results: Patients with diabetes and hypertension have a higher incidence of coronary artery disease than do patients with diabetes or hypertension alone. The former patients also show impaired systolic and diastolic function and have more severe left Ventricular hypertrophy as documented by echocardiography and at autopsy. The structural myocardial damage seen in these patients has been attributed primarily to hypertension; the myocellular dysfunction has been attributed primarily to diabetes. In diabetic hypertensive patients with cardiomyopathy, coronary artery disease as well as structural and functional cardiac abnormalities are more pronounced than would be expected from either diabetes or hypertension alone. Conclusions: Considerable evidence from both experimental animal models and humans points to hypertension as a critically important factor in the pathogenesis of severe heart disease in persons with diabetes. The pathogenetic sequelae of diabetes and hypertension ape devastating to the heart and often lead to premature congestive heart failure, sudden cardiac death, and acute myocardial infarction. Strict control of arterial pressure and glycemia may prevent or even ameliorate heart disease in patients with hypertension and diabetes.	ALTON OCHSNER MED FDN & OCHSNER CLIN, NEW ORLEANS, LA 70121 USA	Ochsner Health System	Grossman, E (corresponding author), CHAIM SHEBA MED CTR, HYPERTENS UNIT, IL-52621 TEL HASHOMER, ISRAEL.		Messerli, Franz/AAR-4783-2021	Grossman, Ehud/0000-0001-8353-0661				ALLO SN, 1991, AM J PHYSIOL, V260, pC1165, DOI 10.1152/ajpcell.1991.260.6.C1165; AMBEPITYIA G, 1990, J AM COLL CARDIOL, V15, P72, DOI 10.1016/0735-1097(90)90178-R; [Anonymous], 1991, JAMA, V265, P3255; ARORA GD, 1994, J HUM HYPERTENS, V8, P51; ASSMANN G, 1988, AM HEART J, V116, P1713, DOI 10.1016/0002-8703(88)90220-7; BARNETT AH, 1994, BRIT MED BULL, V50, P397, DOI 10.1093/oxfordjournals.bmb.a072899; BELLAVERE F, 1988, BRIT HEART J, V59, P379; BLACK HR, 1993, HYPERTENSION, V21, P335; BOROW KM, 1990, J AM COLL CARDIOL, V15, P1508, DOI 10.1016/0735-1097(90)92818-M; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BRUSH JE, 1988, NEW ENGL J MED, V319, P1302, DOI 10.1056/NEJM198811173192002; CABIN HS, 1982, AM J CARDIOL, V50, P677, DOI 10.1016/0002-9149(82)91218-8; CHOBANIAN AV, 1986, HYPERTENSION, V8, P15; DANIELSEN R, 1988, ACTA MED SCAND, V224, P249; Davidoff F, 1996, ANN INTERN MED, V124, P65, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00011; DELIA JA, 1979, AM J CARDIOL, V43, P193, DOI 10.1016/S0002-9149(79)80004-1; DEVEREUX RB, 1989, J AM COLL CARDIOL, V13, P337, DOI 10.1016/0735-1097(89)90508-1; DILLMANN WH, 1980, DIABETES, V29, P579, DOI 10.2337/diab.29.7.579; DRAYER JIM, 1987, HYPERTENSION, V9, P61; DUNCKER DJ, 1993, CIRC RES, V72, P579, DOI 10.1161/01.RES.72.3.579; DUNN FG, 1987, AM J CARDIOL, V60, pI19; ELLIOTT TG, 1993, BAILLIERE CLIN ENDOC, V7, P1079, DOI 10.1016/S0950-351X(05)80246-0; EWING DJ, 1976, LANCET, V1, P601, DOI 10.1016/S0140-6736(76)90413-X; EWING DJ, 1991, DIABETOLOGIA, V34, P182, DOI 10.1007/BF00418273; FACTOR SM, 1980, NEW ENGL J MED, V302, P384, DOI 10.1056/NEJM198002143020706; FACTOR SM, 1981, AM J PATHOL, V102, P219; FACTOR SM, 1980, AM HEART J, V99, P446, DOI 10.1016/0002-8703(80)90379-8; Fein F, 1990, DIABETES MELLITUS TH, P812; FEIN FS, 1985, PROG CARDIOVASC DIS, V27, P255, DOI 10.1016/0033-0620(85)90009-X; FERNANDEZ-BRITTO J E, 1991, Zentralblatt fuer Pathologie, V137, P487; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; GANGULY PK, 1983, AM J PHYSIOL, V244, pE528, DOI 10.1152/ajpendo.1983.244.6.E528; GARBER DW, 1983, AM J PHYSIOL, V244, pH592, DOI 10.1152/ajpheart.1983.244.4.H592; Genuth S, 1996, ANN INTERN MED, V124, P104, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00005; GIACOMELLI F, 1979, LAB INVEST, V40, P460; GILES TD, 1989, AM J MED, V87, pS23, DOI 10.1016/0002-9343(89)90491-9; GROSSMAN E, 1991, AM J MED, V91, P502, DOI 10.1016/0002-9343(91)90186-2; GROSSMAN E, 1992, ARCH INTERN MED, V152, P1001, DOI 10.1001/archinte.152.5.1001; GROSSMAN E, 1994, J HUM HYPERTENS, V8, P417; HAIDER B, 1977, CIRC RES, V40, P577, DOI 10.1161/01.RES.40.6.577; HAMBY RI, 1974, JAMA-J AM MED ASSOC, V229, P1749, DOI 10.1001/jama.229.13.1749; HAMBY RI, 1976, CHEST, V70, P251, DOI 10.1378/chest.70.2.251; HERLITZ J, 1988, ACTA MED SCAND, V224, P31; HOFFMAN JIE, 1987, CIRCULATION, V75, P6; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; IWASAKA T, 1994, CORONARY ARTERY DIS, V5, P237, DOI 10.1097/00019501-199403000-00009; IWASAKA T, 1994, CARDIOLOGY, V85, P1, DOI 10.1159/000176638; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KREGER BE, 1987, CIRCULATION, V75, P22; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LEE SL, 1992, MOL CELL BIOCHEM, V109, P173; LEVY D, 1987, AM J CARDIOL, V60, P560, DOI 10.1016/0002-9149(87)90305-5; MACRURY SM, 1990, DIABETIC MED, V7, P285, DOI 10.1111/j.1464-5491.1990.tb01391.x; MALHOTRA A, 1981, CIRC RES, V49, P1243, DOI 10.1161/01.RES.49.6.1243; MARCUS ML, 1987, CIRCULATION, V75, P19; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; Melina D, 1993, Minerva Med, V84, P301; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MUSTONEN JN, 1994, AM J CARDIOL, V73, P1202, DOI 10.1016/0002-9149(94)90182-1; NAGANO N, 1994, HYPERTENSION, V23, P1002, DOI 10.1161/01.HYP.23.6.1002; NESTO RW, 1988, ANN INTERN MED, V108, P170, DOI 10.7326/0003-4819-108-2-170; NIAKAN E, 1986, ARCH INTERN MED, V146, P2229, DOI 10.1001/archinte.146.11.2229; NODA N, 1992, J MOL CELL CARDIOL, V24, P435, DOI 10.1016/0022-2828(92)93197-R; OKELLY BF, 1988, HYPERTENSION, V12, P344; ORLANDER PR, 1994, DIABETES, V43, P897, DOI 10.2337/diabetes.43.7.897; PENPARGKUL S, 1981, J MOL CELL CARDIOL, V13, P303, DOI 10.1016/0022-2828(81)90318-7; PEREZ JE, 1992, J AM COLL CARDIOL, V19, P1154, DOI 10.1016/0735-1097(92)90316-F; PHILLIPS RA, 1989, J AM COLL CARDIOL, V14, P979, DOI 10.1016/0735-1097(89)90476-2; PIERCE GN, 1981, J MOL CELL CARDIOL, V13, P1063, DOI 10.1016/0022-2828(81)90296-0; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Regan T J, 1975, Trans Assoc Am Physicians, V88, P217; REGAN TJ, 1977, J CLIN INVEST, V60, P885, DOI 10.1172/JCI108843; REGAN TJ, 1974, CIRC RES, V35, P222, DOI 10.1161/01.RES.35.2.222; ROBERTSON WB, 1968, LAB INVEST, V18, P538; ROSENTHAL T, 1993, CURR OPIN CARDIOL, V8, P746, DOI 10.1097/00001573-199309000-00005; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; RUDE RK, 1992, POSTGRAD MED, V92, P217; SAHAI A, 1991, AM HEART J, V122, P164, DOI 10.1016/0002-8703(91)90774-C; SAMUELSSON O, 1994, J INTERN MED, V235, P217, DOI 10.1111/j.1365-2796.1994.tb01063.x; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SCHNIDER SL, 1980, J CLIN INVEST, V66, P1179, DOI 10.1172/JCI109950; SHAPIRO LM, 1982, BRIT HEART J, V47, P439; SOHAR E, 1970, AM J MED, V49, P64, DOI 10.1016/S0002-9343(70)80114-0; STRAUER BE, 1979, AM J CARDIOL, V44, P730, DOI 10.1016/0002-9149(79)90295-9; TAEGTMEYER H, 1985, LANCET, V1, P139; TAHILIANI AG, 1986, LIFE SCI, V38, P959, DOI 10.1016/0024-3205(86)90229-8; TANAKA Y, 1992, CARDIOVASC RES, V26, P409, DOI 10.1093/cvr/26.4.409; TOMANEK RJ, 1979, LAB INVEST, V40, P83; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; VENCO A, 1987, CARDIOLOGY, V74, P28, DOI 10.1159/000174171; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5; WEBER KT, 1991, J CARDIOVASC PHARM, V17, pS14, DOI 10.1097/00005344-199117002-00004; 1979, JAMA-J AM MED ASSOC, V242, P2572	100	127	132	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					304	310		10.7326/0003-4819-125-4-199608150-00009	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678395				2022-12-28	WOS:A1996VB68000012
J	Jacoby, GC; DArrigo, RD; Davaajamts, T				Jacoby, GC; DArrigo, RD; Davaajamts, T			Mongolian tree rings and 20th-century warming	SCIENCE			English	Article							TEMPERATURE	A 450-year tree-ring width chronology of Siberian pine (Pinus sibirica Du Tour) growing at timberline (2450 meters) in the Tarvagatay Mountains in west cent;al Mongolia shows wide annual growth rings for the recent century. Ecological site observations and comparisons with instrumental temperature records indicate that the ring widths of these trees are sensitive to annual temperature variations. Low-frequency variations in the Tarvagatay tree-ring record are similar to those in a reconstruction of Arctic annual temperatures, which is based on 20 tree-ring width series from northern North America, Scandinavia, and western Russia. The results indicate that recent warming is unusual relative to temperatures of the past 450 years.	MONGOLIAN ACAD SCI, INST BOT, ULAANBAATAR 210351, MONGOLIA	Mongolian Academy of Sciences	Jacoby, GC (corresponding author), LAMONT DOHERTY EARTH OBSERV, TREE RING LAB, PALISADES, NY 10964 USA.							[Anonymous], 1979, PHYSL WOODY PLANTS; BARTHEL H, 1971, LAND ZWISCHEN TAIGA; Briffa KR, 1996, TREE RINGS, ENVIRONMENT AND HUMANITY, P25; Cook E.R., 2013, METHODS DENDROCHRONO; Crowley TJ, 1996, GEOPHYS RES LETT, V23, P359, DOI 10.1029/96GL00243; DARRIGO RD, 1993, CLIMATIC CHANGE, V25, P163, DOI 10.1007/BF01661204; Fritts H. C., 1976, TREE RINGS CLIMATE; Grove JM, 1988, LITTLE ICE AGE; HANSEN J, 1987, J GEOPHYS RES-ATMOS, V92, P13345, DOI 10.1029/JD092iD11p13345; JACOBY GC, 1995, GLOBAL BIOGEOCHEM CY, V9, P227, DOI 10.1029/95GB00321; JACOBY GC, 1989, CLIMATIC CHANGE, V14, P39, DOI 10.1007/BF00140174; JONES PD, 1992, HOLOCENE, V2, P174; LAMARCHE V C JR, 1974, Tree-Ring Bulletin, V34, P21; LAMARCHE VC, 1974, SCIENCE, V183, P1043, DOI 10.1126/science.183.4129.1043; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; LOVELIUS NV, 1992, DENDROINDICATIONS FO, P32; LUCKMAN B, 1995, REPORT 1995 DENDROEC; MIJIDDORJ R, 1993, 1 PRC MONG WORKSH CL, P11; MIJIDDORJ R, 1995, 2 PRC MONG WORKSH CL, P68; Mirov N. T., 1967, GENUS PINUS; *MONG AC SCI, 1990, NAT ATL MONG PEOPL R; RIND D, 1993, QUATERNARY SCI REV, V12, P357, DOI 10.1016/S0277-3791(05)80002-2; SEVASTYANOV D.V., 1990, IZV VSES GEOGR OVA, V122, P535; Simkin T., 1994, VOLCANOES WORLD; Stahle DW, 1996, TREE RINGS, ENVIRONMENT AND HUMANITY, P119; SWEDA T, 1994, TERR ATMOS OCEAN SCI, V5, P431; Tranquillini W., 1979, PHYSL ECOLOGY ALPINE; YAO TD, 1991, SCI CHINA SER B, V34, P760; ZANG D, 1980, KEXUE TONGBAO, V25, P497; Zhang J., 1992, CLIMATE CHINA; [No title captured]	31	134	156	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					771	773		10.1126/science.273.5276.771	http://dx.doi.org/10.1126/science.273.5276.771			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670411				2022-12-28	WOS:A1996VB42900034
J	Thomas, WA; Astini, RA				Thomas, WA; Astini, RA			The Argentine Precordillera: A traveler from the Ouachita embayment of North American Laurentia	SCIENCE			English	Article							CHILHOWEE GROUP; PASSIVE MARGIN; SOUTHERN; APPALACHIANS; TRANSITION; EVOLUTION; CATOCTIN; VIRGINIA; MODEL; AGES	The Argentine Precordillera is a continental fragment rifted from the Ouachita embayment of the southern margin of Laurentia (North America) during Cambrian time [about 515 million years ago (Ma)] and accreted to the western margin of Gondwana (South America) during Ordovician time (about 455 Ma). Similarities of Cambrian stratigraphic successions and faunas, Grenville basement rocks, and dimensions link the Argentine Precordillera to the Ouachita embayment. Evidence of rifting during Cambrian time and of a wide ocean basin during Ordovician time indicates that the Precordillera traveled as an independent microcontinent to collide with Gondwana.	UNIV NACL CORDOBA, FAC CIENCIAS EXACTAS FIS & NAT, CATEDRA ESTRATIGRAFIA & GEOL HIST, RA-5000 CORDOBA, ARGENTINA	National University of Cordoba	Thomas, WA (corresponding author), UNIV KENTUCKY, DEPT GEOL SCI, LEXINGTON, KY 40506 USA.		Thomas, William/X-7069-2019					ABBRUZZI J, 1993, 12 C GEOL ARG 2 C EX, V3, P331; Albanesi Guillermo L., 1995, Boletin de la Academia Nacional de Ciencias (Cordoba), V60, P519; ALBERSTADT L, 1989, Palaios, V4, P225, DOI 10.2307/3514771; ALEINIKOFF JN, 1995, AM J SCI, V295, P428, DOI 10.2475/ajs.295.4.428; [Anonymous], ORDOVICIAN ODYSSEY; ASTINI RA, 1995, GEOL SOC AM BULL, V107, P253, DOI 10.1130/0016-7606(1995)107<0253:TEPEOT>2.3.CO;2; Astini RA, 1996, GEOL SOC AM BULL, V108, P373; ASTINI RA, 1995, ORDOVICIAN ODYSSEY, P217; ASTINI RA, 13 C GEOL ARG 3 C EX; ASTINI RA, 1995, GEOL SOC AM ABSTR, V27, pA458; ASTINI RA, 1995, ORDOVICIAN ODYSSEY, P177; ASTINI RA, 1991, THESIS U NACL CORDOB; Astini Ricardo A., 1993, Boletin de la Real Sociedad Espanola de Historia Natural Seccion Geologica, V88, P113; BADGER RL, 1988, GEOLOGY, V16, P692, DOI 10.1130/0091-7613(1988)016<0692:AASISO>2.3.CO;2; BARNES VE, 1959, U TEX BUR EC GEOL PU, V5924, P11; Benedetto J. L., 1993, ACTAS 12 CONGRESO GE, V3, P375; BENEDETTO JL, 1994, 2 INT M ABSTR EARL P, P143; Benedetto Juan L., 1995, P181; BORRELLO AV, 1971, CAMBRIAN NEW WORLD, P385; Bowring S.A., 1982, OKLAHOMA GEOLOGICAL, V21, P54; Buffler R. T., 1994, PHANEROZOIC EVOLUTIO, P219, DOI DOI 10.1130/DNAG-COT-PEN.219; Canas Fernando, 1993, Facies, V29, P169, DOI 10.1007/BF02536927; CANAS FL, 1995, ORDOVICIAN ODYSSEY, P221; Dalziel IWD, 1996, GEOL SOC AM BULL, V108, P372, DOI 10.1130/0016-7606(1996)108<0372:TEPEOT>2.3.CO;2; DALZIEL IWD, 1994, GEOL SOC AM BULL, V106, P243, DOI 10.1130/0016-7606(1994)106<0243:PLGIAT>2.3.CO;2; DENISON RE, 1977, S GEOLOGY OUACHITA M, V1, P25; ETHINGTON RL, 1989, GEOLOGY N AM F, V2, P563; FORTEY RA, 1995, GEOL MAG, V132, P15, DOI 10.1017/S0016756800011390; FORTEY RA, 1991, GEOLOGICAL SURVEY CA, V909, P5; GONZALEZ BONORINO F., 1991, REV GEOL CHILE, V18, P97; GROHSKOPF JG, 1955, MO GEOL SURV, V37; HAM WE, 1964, OKLA GEOL SURV B, V95; Hogan J.P., 1996, GEOL SOC AM ABSTR, p[28, 19]; Johnson K. S., 1988, SEDIMENTARY COVER N, VD-2, P307; KAY SM, 1995, INT M FIELD C ABSTR, P19; KELLER GR, 1989, GEOLOGY, V17, P119, DOI 10.1130/0091-7613(1989)017<0119:PCOTIT>2.3.CO;2; KELLER M, 1993, 12 C GEOL ARG 2 C EX, V1, P235; LAMBERT DD, 1988, GEOLOGY, V16, P13, DOI 10.1130/0091-7613(1988)016<0013:RSASNI>2.3.CO;2; MCCONNELL DA, 1986, OKLAHOMA GEOLOGICAL, V23, P11; MELLEN FF, 1977, AAPG BULL, V61, P1897; Palmer A. R., 1962, 374F US GEOL SURV PR; PALMER AR, 1984, GEOLOGY, V12, P91, DOI 10.1130/0091-7613(1984)12<91:GIOMCB>2.0.CO;2; PFEIL RW, 1980, J SEDIMENT PETROL, V50, P91; RAMOS VA, 1986, TECTONICS, V5, P855, DOI 10.1029/TC005i006p00855; RAYMOND DE, 1991, ALA GEOL SURV B, V143; REINHARDT J, 1974, MD GEOL SURV REP INV, V23; RESSER CE, 1938, GEOL SOC AM SPEC PAP, V15; Rodgers J., 1968, STUDIES APPALACHIAN, P141; SALDA LD, 1992, GEOLOGY, V20, P617, DOI 10.1130/0091-7613(1992)020<0617:EPOBOT>2.3.CO;2; SALDA LHD, 1992, GEOLOGY, V20, P1059, DOI 10.1130/0091-7613(1992)020<1059:DTTACI>2.3.CO;2; SIMPSON EL, 1989, GEOL SOC AM BULL, V101, P42, DOI 10.1130/0016-7606(1989)101<0042:SOTUFI>2.3.CO;2; SIMPSON EL, 1987, GEOLOGY, V15, P123, DOI 10.1130/0091-7613(1987)15<123:ECAFSD>2.0.CO;2; STERNBACH LR, 1984, SOC ECON PALEONT MIN, V5, P2; Talent J., 1985, P54; TALENT JA, 1986, INT S SHALLOW TETHYS, V2, P87; Thomas W. A., 1988, GEOLOGY N AM, VD-2, P471; THOMAS WA, 1991, GEOL SOC AM BULL, V103, P415, DOI 10.1130/0016-7606(1991)103<0415:TAORMO>2.3.CO;2; THOMAS WA, 1972, AM ASSOC PETR GEOL B, V56, P81; TOOMEY DF, 1979, FIELDIANA, V2; TOOMEY DONALD FRANCIS, 1967, J PALEONTOL, V41, P981; TUCKER RD, 1995, CAN J EARTH SCI, V32, P368, DOI 10.1139/e95-032; Vaccari N.E., 1994, THESIS U NACL CORDOB; VACCARI NE, 1995, ORDOVICIAN ODYSSEY, P193; VALENTINE JW, 1971, SYST ZOOL, V20, P253, DOI 10.2307/2412339; Viele G.W., 1989, APPALACHIAN OUACHITA, P695; WALKER D, 1994, J SEDIMENT RES A, V64, P807; WILSON JAMES LEE, 1954, JOUR PALEONTOL, V28, P249; 1973, EVOLUTIONARY PALEOEC	68	232	245	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					752	757		10.1126/science.273.5276.752	http://dx.doi.org/10.1126/science.273.5276.752			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670406				2022-12-28	WOS:A1996VB42900029
J	Villanueva, AG; McLoud, TC; Mark, EJ				Villanueva, AG; McLoud, TC; Mark, EJ			A 54-year-old woman with infiltrative lung disease and mild dyspnea - Alveolar proteinosis with marked interstitial scarring.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OBLITERANS ORGANIZING PNEUMONIA; CHRONIC EOSINOPHILIC PNEUMONIA; HIGH-RESOLUTION CT; COMPUTED-TOMOGRAPHY; PULMONARY SARCOIDOSIS; FIBROSING ALVEOLITIS; CHEST RADIOGRAPHY; CONVENTIONAL CT; FOLLOW-UP; DIAGNOSIS		HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University	Villanueva, AG (corresponding author), LAHEY HITCHCOCK CLIN,PULM & CRIT CARE MED SECT,BURLINGTON,MA, USA.							BERGIN CJ, 1985, AM J ROENTGENOL, V145, P505, DOI 10.2214/ajr.145.3.505; BRAUNER MW, 1992, RADIOLOGY, V182, P349, DOI 10.1148/radiology.182.2.1732948; BUECHNER HA, 1969, DIS CHEST, V55, P274, DOI 10.1378/chest.55.4.274; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; COLBY TV, 1988, PATHOLOGY LUNG, P425; CORDIER JF, 1993, CLIN CHEST MED, V14, P677; COSTELLO JF, 1975, THORAX, V30, P121, DOI 10.1136/thx.30.2.121; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EPLER GR, 1992, CHEST, V102, pS2, DOI 10.1378/chest.102.1_Supplement.2S; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; FRASER RG, 1991, DIAGNOSIS DIS CHEST, V4, P2604; FRASER RG, 1991, DIAGNOSIS DIS CHEST, V4, P2572; GAENSLER EA, 1966, NEW ENGL J MED, V274, P113, DOI 10.1056/NEJM196601202740301; GODWIN JD, 1994, SEM RESP CRIT CARE M, V15, P10, DOI 10.1055/s-2007-1006348; GODWIN JD, 1988, RADIOLOGY, V169, P609, DOI 10.1148/radiology.169.3.3186983; GROSS P, 1968, ARCH PATHOL, V86, P255; HOOK GER, 1986, LAB INVEST, V55, P194; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; KELLER CA, 1995, CHEST, V108, P277, DOI 10.1378/chest.108.1.277; LEE JS, 1992, RADIOLOGY, V184, P451, DOI 10.1148/radiology.184.2.1620846; LEUNG AN, 1991, AM J ROENTGENOL, V157, P693, DOI 10.2214/ajr.157.4.1892019; LIEBOW AA, 1965, AM J MED, V39, P369, DOI 10.1016/0002-9343(65)90206-8; LILLINGTON GA, 1987, DIAGNOSTIC APPROACH, P292; LUNN JA, 1967, BRIT J IND MED, V24, P158; LYNCH DA, 1989, J COMPUT ASSIST TOMO, V13, P405, DOI 10.1097/00004728-198905000-00006; MARTIN RJ, 1980, AM REV RESPIR DIS, V121, P819; MAYO JR, 1989, AM J ROENTGENOL, V153, P727; MCEUEN DD, 1978, ENVIRON RES, V17, P334, DOI 10.1016/0013-9351(78)90037-3; MILLER PA, 1981, AM J ROENTGENOL, V137, P1069, DOI 10.2214/ajr.137.5.1069; MILLER RR, 1984, AM REV RESPIR DIS, V130, P312; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1206; MULLER NL, 1986, RADIOLOGY, V160, P585; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1440; MURCH CR, 1989, CLIN RADIOL, V40, P240, DOI 10.1016/S0009-9260(89)80180-1; MURDOCH J, 1992, AM J ROENTGENOL, V159, P473, DOI 10.2214/ajr.159.3.1503008; NISHIMURA K, 1993, RADIOLOGY, V189, P105, DOI 10.1148/radiology.189.1.8372178; NISHIMURA K, 1992, RADIOLOGY, V182, P337, DOI 10.1148/radiology.182.2.1732946; Nishimura K, 1994, RADIOLOGY, V190, P907; PADLEY SPG, 1991, CLIN RADIOL, V44, P222, DOI 10.1016/S0009-9260(05)80183-7; PRAKASH UBS, 1987, MAYO CLIN PROC, V62, P499, DOI 10.1016/S0025-6196(12)65477-9; RAGHU G, 1995, AM J RESP CRIT CARE, V151, P909; RAMIREZ RJ, 1968, AM J MED, V45, P502; RAMIREZRIVERA J, 1966, AM J CLIN PATHOL, V45, P415; REMYJARDIN M, 1991, RADIOLOGY, V181, P157, DOI 10.1148/radiology.181.1.1887026; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; RUBINSTEIN I, 1988, ARCH INTERN MED, V148, P813, DOI 10.1001/archinte.148.4.813; TERRIFF BA, 1992, RADIOLOGY, V184, P445, DOI 10.1148/radiology.184.2.1620845; WEBB WR, 1992, HIGH RESOLUTION CT L, P96	50	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					417	424		10.1056/NEJM199608083350608	http://dx.doi.org/10.1056/NEJM199608083350608			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8676935				2022-12-28	WOS:A1996VA90400008
J	Bakris, GL; Smith, A				Bakris, GL; Smith, A			Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists	ANNALS OF INTERNAL MEDICINE			English	Article							HYPERTENSION; PROTEINURIA; INHIBITION; RATS	Objective: To determine whether sodium intake alters albumin excretion in patients with nephropathy from non-insulin-dependent diabetes mellitus who were treated with two different long-acting calcium antagonists. Design: Prospective, crossover, open-label trial. Setting: Rush-Presbyterian-St. Luke's Medical Center. Patients: 9 men and 6 women (mean age +/- SD, 56 +/- 8 years) with non-insulin-dependent diabetes mellitus, hypertension, renal insufficiency, and macroalbuminuria. Intervention: Diltiazem (mean dose, 392 +/- 27 mg/d) or nifedipine (mean dose, 83 +/- 9 mg/d) was used to decrease blood pressure to less than 140/90 mm Hg. All patients also received furosemide concomitantly for blood pressure control. Results: Blood pressure reduction with once-daily diltiazem decreased urine albumin excretion (2967 +/- 784 mg/d at baseline compared with 1294 +/- 679 mg/d after diltiazem therapy; P < 0.05) at 4 weeks while patients received a diet consisting of 50 mEq of sodium per day. Albumin excretion did not decrease when sodium intake was increased to 250 mEq/d, and blood pressure was reduced to levels similar to those seen with the low-sodium diet. Similar blood pressure reduction with once-daily nifedipine did not significantly alter albumin excretion regardless of sodium intake. Conclusion: Sodium intake affects the albumin-decreasing effects of certain calcium antagonists. Recent studies suggest that antihypertensive medications that reduce albumin excretion and arterial pressure correlate with reduced renal mortality compared with medications that do not have albumin-decreasing effects. Thus, a low-sodium diet should be prescribed to maximize the albumin-decreasing effects of certain calcium antagonists.			Bakris, GL (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, RUSH HYPERTENS CTR, SUITE 117, 1725 W HARRISON ST, CHICAGO, IL 60612 USA.							ABBOTT KC, 1994, ARCH INTERN MED, V154, P146, DOI 10.1001/archinte.154.2.146; ANDERSON S, 1992, KIDNEY INT, V41, P891, DOI 10.1038/ki.1992.136; Bakris G L, 1996, Curr Opin Nephrol Hypertens, V5, P219, DOI 10.1097/00041552-199605000-00006; BAKRIS GL, 1992, KIDNEY INT, V41, P912, DOI 10.1038/ki.1992.139; BAKRIS GL, 1993, AM J HYPERTENS, V6, pS140, DOI 10.1093/ajh/6.4S.140S; BAKRIS GL, 1994, CURRENT SURVEY WORLD, V3, P61; BAKRIS GL, 1996, J AM SOC NEPHROL, V6, P440; BANK N, 1988, AM J PHYSIOL, V254, pF668, DOI 10.1152/ajprenal.1988.254.5.F668; BOHLER J, 1993, EUR J CLIN PHARMACOL, V44, pS57, DOI 10.1007/BF01428396; GABER L, 1994, KIDNEY INT, V46, P161, DOI 10.1038/ki.1994.255; GALL MA, 1994, DIABETOLOGIA, V37, P195, DOI 10.1007/s001250050093; HARTMANN A, 1994, J AM SOC NEPHROL, V5, P1385; HEBERT LA, 1994, KIDNEY INT, V46, P1688, DOI 10.1038/ki.1994.469; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; JYOTHIRMAYI GN, 1993, HYPERTENSION, V21, P795, DOI 10.1161/01.HYP.21.6.795; MAKI DD, 1995, ARCH INTERN MED, V155, P1073, DOI 10.1001/archinte.155.10.1073; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001	17	76	77	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					201	204		10.7326/0003-4819-125-3-199608010-00007	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686978				2022-12-28	WOS:A1996UZ28700006
J	Corey, DP; GarciaAnoveros, J				Corey, DP; GarciaAnoveros, J			Mechanosensation and the DEG/ENaC ion channels	SCIENCE			English	Editorial Material							NEMATODE CAENORHABDITIS-ELEGANS; EPITHELIAL SODIUM-CHANNEL; SENSITIVE NA+ CHANNEL; MECHANOELECTRICAL TRANSDUCTION; MEMBRANE TOPOLOGY; HAIR-CELLS; NEURONS; GENE; NEURODEGENERATION; IDENTIFICATION		HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Corey, DP (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02114 USA.			Garcia-Anoveros, Jaime/0000-0001-6561-9048; Corey, David/0000-0003-4497-6016				CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; COREY DP, 1979, NATURE, V281, P675, DOI 10.1038/281675a0; COREY DP, UNPUB; Denk W, 1995, NEURON, V15, P1311, DOI 10.1016/0896-6273(95)90010-1; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; HAMELIN M, 1995, NATURE, V378, P292; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; PARK EC, 1986, GENETICS, V113, P821; PARK EC, 1986, GENETICS, V113, P853; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; PICKLES JO, 1985, PROG NEUROBIOL, V24, P1, DOI 10.1016/0301-0082(85)90014-0; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SHREFFLER W, 1995, GENETICS, V139, P1261; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; STEWART GWJ, 1996, NEURON, V16, P183; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735	35	87	108	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	1996	273	5273					323	324		10.1126/science.273.5273.323	http://dx.doi.org/10.1126/science.273.5273.323			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8685718				2022-12-28	WOS:A1996UY20200028
J	Goldberg, L				Goldberg, L			Adverse effects of anabolic steroids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ANDROGENIC STEROIDS; TESTOSTERONE; ATHLETE				Goldberg, L (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201, USA.							CREAGH TM, 1988, J CLIN PATHOL, V41, P441, DOI 10.1136/jcp.41.4.441; FRANKLE MA, 1988, ARCH PHYS MED REHAB, V69, P632; GRUNEWALD KK, 1993, SPORTS MED, V15, P90, DOI 10.2165/00007256-199315020-00003; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HEYDENREICH G, 1989, ARCH DERMATOL, V125, P571, DOI 10.1001/archderm.1989.01670160119036; JOHNSON FL, 1975, LANCET, V1, P1294; MAUGHAN RJ, 1995, INT J SPORT NUTR, V5, P94, DOI 10.1123/ijsn.5.2.94; MCDONALD EC, 1978, JAMA-J AM MED ASSOC, V240, P243, DOI 10.1001/jama.240.3.243; MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2; MESSERLI FH, 1979, ARCH INTERN MED, V139, P682, DOI 10.1001/archinte.139.6.682; MOKROHISKY ST, 1977, NEW ENGL J MED, V296, P1411; MOORE WV, 1988, JAMA-J AM MED ASSOC, V260, P3484, DOI 10.1001/jama.260.23.3484; OVERLY WL, 1984, ANN INTERN MED, V100, P158, DOI 10.7326/0003-4819-100-1-158_3; POPE HG, 1988, AM J PSYCHIAT, V145, P487; Ruden T. M., 1996, Medicine and Science in Sports and Exercise, V28, pS81; SCOTT MJ, 1989, JAMA-J AM MED ASSOC, V262, P207, DOI 10.1001/jama.1989.03430020049017; Shephard R J, 1977, Br J Sports Med, V11, P170; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; WEBB OL, 1984, METABOLISM, V33, P971, DOI 10.1016/0026-0495(84)90222-1; [No title captured]	20	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					257	257						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667574				2022-12-28	WOS:A1996UW46900041
J	Fox, NC; Freeborough, PA; Rossor, MN				Fox, NC; Freeborough, PA; Rossor, MN			Visualisation and quantification of rates of atrophy in Alzheimer's disease	LANCET			English	Article							TOMOGRAPHY; MATTER; BRAIN	Background Definitive diagnosis of Alzheimer's disease requires histological examination of brain tissue. In life, brain atrophy can be visualised by computed tomography or magnetic resonance (MR) imaging, but the atrophy due to the disease is difficult to distinguish from that caused by normal ageing. We have investigated use of accurate positional matching (registration) and digital subtraction of serially acquired MR brain scans to allow determination of rates of global and regional atrophy. Methods This technique was applied to eleven patients with clinically diagnosed Alzheimer's disease and eleven age-matched controls. Each individual had two scans approximately 1 year apart; scan intervals were matched between the groups. Findings The median rate atrophy was significantly greater in the Alzheimer's disease group than in the control group (12 . 3 [range 5 . 8 to 23 . 6] vs 0 . 3 (-1 . 2 to 1 . 7) mL per year; p<0 . 0001). There was no overlap between the groups. Furthermore, three non-demented individuals at risk of familiar Alzheimer's disease had scans 6-14 months apart and showed greater rates of volume loss than the controls; these three individuals have subsequently developed symptoms. Interpretation This technique may be useful for the diagnosis of Alzheimer's disease, the assessment of disease progression, and the evaluation of potential treatments.	NATL HOSP NEUROL & NEUROSURG,DEMENTIA RES GRP,LONDON WC1N 3BG,ENGLAND; ST MARYS HOSP,IMPERIAL COLL,SCH MED,LONDON,ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London			Fox, Nick C/B-1319-2009; Rossor, Martin/C-1598-2008; Fox, Nick C/AAE-1849-2021	Fox, Nick C/0000-0002-6660-657X; Fox, Nick C/0000-0002-6660-657X; Rossor, Martin/0000-0001-8215-3120				CONVIT A, 1995, LANCET, V345, P266, DOI 10.1016/S0140-6736(95)90265-1; Convit Antonio, 1993, Psychiatric Quarterly (New York), V64, P371, DOI 10.1007/BF01064929; DAVIS PC, 1995, NEUROLOGY, V45, P178, DOI 10.1212/WNL.45.1.178; DAVIS PC, 1992, NEUROLOGY, V42, P1676, DOI 10.1212/WNL.42.9.1676; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DECARLI C, 1995, PSYCHIAT RES, V57, P119, DOI 10.1016/0165-1781(95)02651-C; DELEON MJ, 1989, AM J ROENTGENOL, V152, P1257, DOI 10.2214/ajr.152.6.1257; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox NC, 1996, ANN NY ACAD SCI, V777, P226, DOI 10.1111/j.1749-6632.1996.tb34423.x; FOX NC, 1996, P INT SOC MAGNETIC R, V1, P234; FOX NC, 1995, NEUROBIOLOGY ALZHEIM, P269; FREEBOROUGH PA, 1996, P EUROGRAPHICS UK C, V2, P261; FREEBOROUGH PA, 1996, P INT SOC MAGNETIC R, V1, P34; HAJNAL JV, 1995, J COMPUT ASSIST TOMO, V19, P289, DOI 10.1097/00004728-199503000-00022; HAJNAL JV, 1995, J COMPUT ASSIST TOMO, V19, P677, DOI 10.1097/00004728-199509000-00001; IKEDA M, 1994, NEURORADIOLOGY, V36, P7, DOI 10.1007/BF00599184; JOBST KA, 1994, LANCET, V343, P829, DOI 10.1016/S0140-6736(94)92028-1; JOBST KA, 1992, LANCET, V340, P1179; KENNEDY AM, 1995, NEUROSCI LETT, V186, P17, DOI 10.1016/0304-3940(95)11270-7; KILLIANY RJ, 1993, ARCH NEUROL-CHICAGO, V50, P949, DOI 10.1001/archneur.1993.00540090052010; LEHERICY S, 1994, AM J NEURORADIOL, V15, P927; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; NEWMAN SK, 1994, J NEUROL NEUROSUR PS, V57, P967, DOI 10.1136/jnnp.57.8.967; RUSINEK H, 1991, RADIOLOGY, V178, P109, DOI 10.1148/radiology.178.1.1984287; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	26	285	288	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					94	97		10.1016/S0140-6736(96)05228-2	http://dx.doi.org/10.1016/S0140-6736(96)05228-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676724				2022-12-28	WOS:A1996UW67300012
J	Hickey, AM; Bury, G; OBoyle, CA; Bradley, F; OKelly, FD; Shannon, W				Hickey, AM; Bury, G; OBoyle, CA; Bradley, F; OKelly, FD; Shannon, W			A new short form individual quality of life measure (SEIQoL-DW): Application in a cohort of individuals with HIV AIDS	BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE	Quality of life is an increasingly important outcome measure in medicine and health care. Many measures of quality of life present patients with predetermined lists of questions that may or may not be relevant to the individual patient. This paper describes a brief measure, the SEIQoL-DW, which is derived from the schedule for evaluation of individual quality of life (SEIQoL). The measure allows respondents to nominate the areas of life which are most important, rate their level of functioning or satisfaction with each, and indicate the relative importance of each to their overall quality of life. Given its practicality and brevity, the measure should prove particularly useful in clinical situations where patient generated data on quality of life is important. This article describes the first clinical application of the measure, assessing the quality of life of a cohort of patients with HIV/AIDS managed in general practice.	NATL UNIV IRELAND UNIV COLL DUBLIN,COOMBE HEALTHCARE CTR,DEPT GEN PRACTICE,DUBLIN 8,IRELAND	Trinity College Dublin; University College Dublin	Hickey, AM (corresponding author), ROYAL COLL SURG IRELAND,DEPT PSYCHOL,LOWER MERCER ST,DUBLIN 2,IRELAND.		Bury, Gerard/D-2985-2019; Bury, Gerard/J-8813-2019	Bury, Gerard/0000-0002-4441-6724; Bury, Gerard/0000-0002-4441-6724; O'Boyle, Ciaran/0000-0003-0254-8603				Bowling A., 1991, MEASURING HLTH REV Q; HAMMOND K. R., 1975, HUMAN JUDGMENT DECIS, P271; KIRWAN JR, 1983, ANN RHEUM DIS, V42, P645; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; O'Boyle C., 1993, SCHEDULE EVALUATION; O'Boyle CA., 1996, MANUAL SEIQOL DW; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; OBOYLE CA, UNPUB MEASURING INDI; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1205, DOI 10.1136/bmj.305.6863.1205; Stewart T.R., 1988, HUMAN JUDGEMENT SJT, P41, DOI [DOI 10.1016/S0166-4115(08)62170-6, 10.1016/S0166-4115(08)62170-6]; THUNEDBORG K, 1993, INT J METHOD PSYCH, V3, P45	12	275	275	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					29	33		10.1136/bmj.313.7048.29	http://dx.doi.org/10.1136/bmj.313.7048.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664768	Green Published			2022-12-28	WOS:A1996UW66700029
J	Sonett, CP; Kvale, EP; Zakharian, A; Chan, MA; Demko, TM				Sonett, CP; Kvale, EP; Zakharian, A; Chan, MA; Demko, TM			Late Proterozoic and Paleozoic tides, retreat of the moon, and rotation of the Earth	SCIENCE			English	Article								The tidal rhythmites in the Proterozoic Big Cottonwood Formation (Utah, United States), the Neoproterozoic Elatina Formation of the Flinders Range (southern Australia), and the Lower Pennsylvanian Pottsville Formation (Alabama, United Slates) and Mansfield Formation (Indiana, United States) indicate that the rate of retreat of the lunar orbit is d xi/dt similar to k(2) sin(2 delta) (where xi is the Earth-moon radius vector, k(2) is the tidal Love number, and delta is the tidal lag angle) and that this rate has been approximately constant since the late Precambrian. When the contribution to tidal friction from the sun is taken into account, these data imply that the length of the terrestrial day 900 million years ago was similar to 18 hours.	UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; INDIANA UNIV, GEOL SURVEY INDIA, BLOOMINGTON, IN 47405 USA; UNIV UTAH, DEPT GEOL & GEOPHYS, SALT LAKE CITY, UT 84112 USA; COLORADO STATE UNIV, DEPT EARTH RESOURCES, FT COLLINS, CO 80523 USA	University of Arizona; Indiana University System; Indiana University Bloomington; Utah System of Higher Education; University of Utah; Colorado State University	Sonett, CP (corresponding author), UNIV ARIZONA, DEPT PLANETARY SCI, TUCSON, AZ 85721 USA.			Demko, Timothy/0000-0002-9125-0907				Allen C. W., 1973, ASTROPHYSICAL QUANTI; ARCHER AW, 1991, CANADIAN SOC PETROLE, V16, P189; Bretthorst G.L., 1988, LECT NOTES STAT, V48; BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; CHAN MA, 1994, GEOLOGY, V22, P791, DOI 10.1130/0091-7613(1994)022<0791:ODEOLS>2.3.CO;2; DEMKO TM, 1990, THESIS U ALABAMA; DICKEY JO, 1994, SCIENCE, V265, P482, DOI 10.1126/science.265.5171.482; Faure G., 1977, PRINCIPLES ISOTOPE G; FELDMAN HR, 1993, PALAIOS, V8, P485, DOI 10.2307/3515022; HANSEN KS, 1982, REV GEOPHYS, V20, P457, DOI 10.1029/RG020i003p00457; KARGEL JS, 1993, ICARUS, V105, P1, DOI 10.1006/icar.1993.1108; Kaula W.M., 1968, INTRO PLANETARY PHYS; KVALE EP, 1989, GEOLOGY, V17, P365, DOI 10.1130/0091-7613(1989)017<0365:DMAYTC>2.3.CO;2; KVALE EP, 1994, GEOLOGY, V22, P331, DOI 10.1130/0091-7613(1994)022<0331:EOSPIP>2.3.CO;2; KVALE EP, 1991, CAN SOC PET GEOL MEM, V16, P179; Lambeck K., 1980, EARTHS VARIABLE ROTA; Munk W.H., 1960, ROTATION EARTH; Pannella G., 1975, GROWTH RHYTHMS HIST, P253; Platzman GW, 1972, J PHYS OCEANOGR, V2, P117, DOI [DOI 10.1175/1520-0485(1972)002<0117:TDFOIN>2.0.CO;2, 10.1175/1520-0485(1972)002<0117:TDFOIN>2.0.CO;2]; Pugh D., 1987, TIDES SURGES MEAN SE; Rosenberg G.D., 1975, GROWTH RHYTHMS HIST, P559; SONETT CP, 1988, NATURE, V335, P806, DOI 10.1038/335806a0; STACEY FD, 1977, PHYSICS EARTH; TAKEUCHI H, 1951, J FS U TOKYO 2, V2, P7; Takeuchi H., 1950, EOS T AM GEOPHYS UN, V5, P651, DOI [10.1029/tr031i005p00651, DOI 10.1029/TR031I005P00651]; VAUTARD R, 1992, PHYSICA D, V58, P95, DOI 10.1016/0167-2789(92)90103-T; WELLS JW, 1963, NATURE, V197, P948, DOI 10.1038/197948a0; WILLIAMS GE, 1989, J GEOL SOC LONDON, V146, P97, DOI 10.1144/gsjgs.146.1.0097	28	75	81	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1996	273	5271					100	104		10.1126/science.273.5271.100	http://dx.doi.org/10.1126/science.273.5271.100			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688061				2022-12-28	WOS:A1996UV47800048
J	Horton, R				Horton, R			Playing with smoke, but not without fire	LANCET			English	Editorial Material																		Carnall D, 1996, BMJ-BRIT MED J, V312, P721; MASSING M, 1996, NEW YORK REV BO 0711, P32; Roberts J, 1996, BMJ-BRIT MED J, V312, P133; Szende B, 1996, EUR J CANCER, V32A, P1102, DOI 10.1016/0959-8049(96)00006-8	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1782	1782		10.1016/S0140-6736(96)91614-1	http://dx.doi.org/10.1016/S0140-6736(96)91614-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667920				2022-12-28	WOS:A1996UU46900007
J	Henry, D; Lim, LLY; Rodriguez, LAG; Gutthann, SP; Carson, JL; Griffin, M; Savage, R; Logan, R; Moride, Y; Hawkey, C; Hill, S; Fries, JT				Henry, D; Lim, LLY; Rodriguez, LAG; Gutthann, SP; Carson, JL; Griffin, M; Savage, R; Logan, R; Moride, Y; Hawkey, C; Hill, S; Fries, JT			Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER; DISEASE	Objective-To compare the relative risks of serious gastrointestinal complications reported with individual non-steroidal anti-inflammatory drugs. Design-Systematic review of controlled epidemiological studies that found a relation between use of the drugs and admission to hospital for haemorrhage or perforation. Setting-Hospital and community based case-control and cohort studies. Main outcome measures-(a) Estimated relative risks of gastrointestinal complications with use of individual drugs, exposure to ibuprofen being used as reference; (b) a ranking that best summarised the sequence of relative risks observed in the studies. Results-12 studies met the inclusion criteria. 11 provided comparative data on ibuprofen and other drugs. Ibuprofen ranked lowest or equal lowest for risk in 10 of the 11 studies. Pooled relative risks calculated with exposure to ibuprofen used as reference were all significantly greater than 1.0 (interval of point estimates 1.6 to 9.2), Overall, ibuprofen was associated with the lowest relative risk, followed by diclofenac. Azapropazone, tolmetin, ketoprofen, and piroxicam ranked highest for risk and indomethacin, naproxen, sulindac, and aspirin occupied intermediate positions. Higher doses of ibuprofen were associated with relative risks similar to those with naproxen and indomethacin. Conclusions-The low risk of serious gastrointestinal complications with ibuprofen seems to be attributable mainly to the low doses of the drug used in clinical practice. In higher doses ibuprofen is associated with a similar risk to other non-steroidal anti-inflammatory drugs. Use of low risk drugs in low dosage as first line treatment would substantially reduce the morbidity and mortality due to serious gastrointestinal toxicity from these drugs.	UNIV NEWCASTLE,FAC MED & HLTH SCI,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA; UNIV COMPLUTENSE MADRID,CTR ESPANOL INVEST,E-28040 MADRID,SPAIN; CIBA GEIGY SA,PHARMACOEPIDEMIOL RES,DEPT MED,E-08013 BARCELONA,SPAIN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DIV GEN INTERNAL MED,NEW BRUNSWICK,NJ 08903; VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37232	University of Newcastle; Complutense University of Madrid; Rutgers State University New Brunswick; Rutgers State University Medical Center; Vanderbilt University			Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020; rodriguez, luis a garcia/B-1980-2010	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242; Perez-Gutthann, Susana/0000-0001-5798-3691				Abenhaim L, 1993, POSTMARKETING SURVEI, V7, P176; BATEMAN DN, 1994, LANCET, V343, P1051, DOI 10.1016/S0140-6736(94)90175-9; BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUTTHANN P, 1994, PHARMACOEIDEMIOLO S1, V3, pS63; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; NOBILI A, 1992, PHARMACOEPIDEM DR S, V1, P65; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; SOMERVILLE K, 1986, LANCET, V1, P462; 1994, SCRIP            DEC, P26	20	626	652	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1563	1566		10.1136/bmj.312.7046.1563	http://dx.doi.org/10.1136/bmj.312.7046.1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664664	Green Published			2022-12-28	WOS:A1996UU80600016
J	Hahn, H; Wicking, C; Zaphiropoulos, PG; Gailani, MR; Shanley, S; Chidambaram, A; Vorechovsky, I; Holmberg, E; Unden, AB; Gillies, S; Negus, K; Smyth, I; Pressman, C; Leffell, DJ; Gerrard, B; Goldstein, AM; Dean, M; Toftgard, R; ChenevixTrench, G; Wainwright, B; Bale, AE				Hahn, H; Wicking, C; Zaphiropoulos, PG; Gailani, MR; Shanley, S; Chidambaram, A; Vorechovsky, I; Holmberg, E; Unden, AB; Gillies, S; Negus, K; Smyth, I; Pressman, C; Leffell, DJ; Gerrard, B; Goldstein, AM; Dean, M; Toftgard, R; ChenevixTrench, G; Wainwright, B; Bale, AE			Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome	CELL			English	Article							TUMOR SUPPRESSOR GENE; GORLIN SYNDROME; COLORECTAL TUMORIGENESIS; POINT MUTATIONS; SEGMENT; PROTEIN; RETINOBLASTOMA; POLARITY; POLYMORPHISMS; ASSOCIATION	The nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple basal cell carcinomas (BCCs), pits of the palms and soles, jaw keratocysts, a variety of other tumors, and developmental abnormalities. NBCCS maps to chromosome 9q22.3. Familial and sporadic BCCs display loss of heterozygosity in this region, consistent with the gene being a tumor suppressor. A human sequence (PTC) with strong homology to the Drosophila segment polarity gene, patched, was isolated from a YAC and cosmid contig of the NBCCS region. Mutation analysis revealed alterations of PTC in NBCCS patients and in related tumors. We propose that a reduction in expression of the patched gene can lead to the developmental abnormalities observed in the syndrome and that complete loss of patched function contributes to transformation of certain cell types.	NCI,VIRAL CARCINOGENESIS LAB,HUMAN GENET SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD 21702; NCI,GENET EPIDEMIOL BRANCH,BETHESDA,MD 20852; KAROLINSKA INST,NOVUM,DEPT BIOSCI,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT DERMATOL,S-17176 STOCKHOLM,SWEDEN; ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06250; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06250; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06250	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Yale University; Yale University; Yale University	Hahn, H (corresponding author), UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019; Chenevix-Trench, Georgia/AAV-2014-2020; Wicking, Carol/J-1814-2014	Dean, Michael C/0000-0003-2234-0631; Chenevix-Trench, Georgia/0000-0002-1878-2587; Zaphiropoulos, Peter/0000-0003-4298-3861; Wainwright, Brandon/0000-0003-0406-2092; Wicking, Carol/0000-0002-7225-3803; Smyth, Ian/0000-0002-1727-7829	NATIONAL CANCER INSTITUTE [P30CA016359, R01CA057605, K11CA060199] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16359, R01CA57605, K11CA60199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1967, AM J HUM GENET, V19, P12; BALE SJ, 1991, AM J MED GENET, V40, P206, DOI 10.1002/ajmg.1320400217; BASTER K, 1994, NATURE, V368, P208; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EVANS DGR, 1993, J MED GENET, V30, P460, DOI 10.1136/jmg.30.6.460; EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P765; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GUTIERREZ MM, 1986, J AM ACAD DERMATOL, V15, P1023, DOI 10.1016/S0190-9622(86)70266-1; HAHN H, 1996, IN PRESS J BIOL CHEM, V271; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOLMBERG E, 1996, IN PRESS BR J CANC; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P2347; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; REIS A, 1992, LANCET, V339, P617, DOI 10.1016/0140-6736(92)90903-G; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sambrook J., 2002, MOL CLONING LAB MANU; SHANLEY S, 1994, AM J MED GENET, V50, P282, DOI 10.1002/ajmg.1320500312; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; SMITH MW, 1994, NAT GENET, V7, P40, DOI 10.1038/ng0594-40; SPRINGATE JE, 1986, J PEDIATR SURG, V21, P908, DOI 10.1016/S0022-3468(86)80023-9; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VALDES JM, 1994, P NATL ACAD SCI USA, V91, P5377, DOI 10.1073/pnas.91.12.5377; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WICKING C, 1994, GENOMICS, V22, P505, DOI 10.1006/geno.1994.1423	64	1538	1606	0	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					841	851		10.1016/S0092-8674(00)81268-4	http://dx.doi.org/10.1016/S0092-8674(00)81268-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681379	hybrid			2022-12-28	WOS:A1996UR60400008
J	Muzio, M; Chinnaiyan, AM; Kischkel, FC; ORourke, K; Shevchenko, A; Ni, J; Scaffidi, C; Bretz, JD; Zhang, M; Gentz, R; Mann, M; Krammer, PH; Peter, ME; Dixit, VM				Muzio, M; Chinnaiyan, AM; Kischkel, FC; ORourke, K; Shevchenko, A; Ni, J; Scaffidi, C; Bretz, JD; Zhang, M; Gentz, R; Mann, M; Krammer, PH; Peter, ME; Dixit, VM			FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex	CELL			English	Article							CELL-SURFACE ANTIGEN; MASS-SPECTROMETRY; FAS ANTIGEN; GENE CED-3; APOPTOSIS; RECEPTOR; ENZYME; PURIFICATION; INDUCTION; ENCODES	To identify CAP3 and CAP4 components of the CD95 (Fas/APO-1) death-inducing signaling complex, we utilized nano-electrospray tandem mass spectrometry, a recently developed technique to sequence femtomole quantities of polyacrylamide gel-separated proteins. Interestingly, CAP4 encodes a novel 55 kDa protein, designated FLICE, which has homology to both FADD and the ICE/CED-3 family of cysteine proteases. FLICE binds to the death effector domain of FADD and upon overexpression induces apoptosis that is blocked by the ICE family inhibitors, CrmA and z-VAD-fmk. CAP3 was identified as the FLICE prodomain which likely remains bound to the receptor after proteolytic activation. Taken together, this is unique biochemical evidence to link a death receptor physically to the proapoptotic proteases of the ICE/CED-3 family.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; EUROPEAN MOLEC BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); GlaxoSmithKline; Human Genome Sciences Inc	Muzio, M (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		Muzio, Marta/J-9360-2018; Mann, Matthias/A-3454-2013; dixit, vishva m/A-4496-2012; Watzl, Carsten/B-4911-2013	Muzio, Marta/0000-0002-7761-759X; Mann, Matthias/0000-0003-1292-4799; dixit, vishva m/0000-0001-6983-0326; Watzl, Carsten/0000-0001-5195-0995; Peter, Marcus Ernst/0000-0003-3216-036X				BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BERKE G, 1995, IMMUNOL TODAY, V16, P343, DOI 10.1016/0167-5699(95)80152-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUAN H, 1996, IN PRESS J BIOL CHEM; DUAN H, 1996, J BIOL CHEM, V271, P35013; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OEHM A, 1992, J BIOL CHEM, V267, P10709; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PETER ME, 1995, CELL DEATH DIFFER, V2, P163; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; QUAN LT, 1996, IN PRESS P NATL ACAD, V93; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sambrook J., 2002, MOL CLONING LAB MANU; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TEWARI M, 1995, MODULAR TEXTS MOL C, P107; THOMBERRY NA, 1992, NATURE, V356, P768; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM M, 1996, ANAL CHEM, V66, P1; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	74	2697	2825	5	127	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					817	827		10.1016/S0092-8674(00)81266-0	http://dx.doi.org/10.1016/S0092-8674(00)81266-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681377	Bronze			2022-12-28	WOS:A1996UR60400006
J	Burgner, D; Festa, M; Isaacs, D				Burgner, D; Festa, M; Isaacs, D			Delayed diagnosis of Kawasaki disease presenting with massive lymphadenopathy and airway obstruction	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ALEXANDRA HOSP CHILDREN,DEPT IMMUNOL & INFECT DIS,WESTMEAD,NSW 2145,AUSTRALIA; ROYAL ALEXANDRA HOSP CHILDREN,DEPT MICROBIOL,WESTMEAD,NSW 2145,AUSTRALIA; ROYAL ALEXANDRA HOSP CHILDREN,DEPT INTENS CARE,WESTMEAD,NSW 2145,AUSTRALIA					Burgner, David/0000-0002-8304-4302				DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; HSU CH, 1993, PEDIATR INFECT DIS J, V12, P509, DOI 10.1097/00006454-199306000-00010; KAZI A, 1992, J PEDIATR-US, V120, P564, DOI 10.1016/S0022-3476(05)82484-9; PONTELL J, 1994, OTOLARYNG HEAD NECK, V110, P428; ROWLEY AH, 1988, REV INFECT DIS, V10, P1; SCHILLER B, 1995, ACTA PAEDIATR, V84, P769, DOI 10.1111/j.1651-2227.1995.tb13753.x; STAMOS JK, 1994, PEDIATRICS, V93, P525; YANAGAWA H, 1995, PEDIATRICS, V95, P475	8	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1471	1472		10.1136/bmj.312.7044.1471	http://dx.doi.org/10.1136/bmj.312.7044.1471			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664632	Green Published			2022-12-28	WOS:A1996UQ29600036
J	Pharoah, PDP; Hollingworth, W				Pharoah, PDP; Hollingworth, W			Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; MORTALITY; DEATH; TIME	Objectives-To estimate the cost effectiveness of statins in lowering serum cholesterol concentration in people at varying risk of fatal cardiovascular disease and to explore the implications of changing the criteria for intervention on cost and cost effectiveness for a purchasing authority. Design-A life table method was used to model the effect of treatment with a statin on survival over 10 years in men and women aged 45-64. The costs of intervention were estimated from the direct costs of treatment, offset by savings associated with a reduction in coronary angiographies, non-fatal myocardial infarctions, and revascularisation procedures. The robustness of the model to various assumptions was tested in a sensitivity analysis. Setting-Population of a typical district health authority. Main outcome measure-Cost per life year saved. Results-The average cost effectiveness of treating men aged 45-64 with no history of coronary heart disease and a cholesterol concentration >6,5 mmol/l for 10 years with a statin was pound 136 000 per life year saved. The average cost effectiveness for patients with pre-existing coronary heart disease and a cholesterol concentration >5.4 mmol/l was pound 32 000. These averages hide enormous differences in cost effectiveness between groups at different risk, ranging from pound 6000 per life year in men aged 55-64 who have had a myocardial infarction and whose cholesterol concentration is above 7.2 mmol/l to pound 361 000 per life year saved in women aged 45-54 with angina and a cholesterol concentration of 5.5-6.0 mmol/l. Conclusions-Lowering serum cholesterol concentration in patients with and without preexisting coronary heart disease is effective and safe, but treatment for all those in whom treatment is likely to be effective is not sustainable within current NHS resources. Data on cost effectiveness data should be taken into account when assessing who should be eligible for treatment.	FULBOURNE HOSP, CAMBRIDGE & HUNTINGDON HLTH COMMISS, CAMBRIDGE CB1 5EF, ENGLAND; UNIV CAMBRIDGE, INST PUBL HLTH, DEPT COMMUNITY MED, HLTH SERV RES GRP, CAMBRIDGE CB2 2SR, ENGLAND	University of Cambridge			Pharoah, Paul/V-6658-2019	Pharoah, Paul/0000-0001-8494-732X; Hollingworth, William/0000-0002-0840-6254				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *BRIT MED ASS, 1995, ROYAL PHARM SOC GREA; BURR ML, 1989, LANCET, V2, P757; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP HLTH, 1992, PUBL HLTH COMM DAT S; FROST PH, 1987, AM HEART J, V113, P1356, DOI 10.1016/0002-8703(87)90648-X; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GRODOS D, 1994, LANCET, V344, P1768; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; Malik I., 1995, European Heart Journal, V16, P463; MARTENS LL, 1989, AM J MED, V87, pS54, DOI 10.1016/S0002-9343(89)80600-X; MARTENS LL, 1994, CLIN THER, V16, P1052; MARTIN MJ, 1986, LANCET, V2, P933; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; *NHS MAN EX, 1994, CAP INV MAN BUS CAS; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SAWITZ E, 1988, JAMA-J AM MED ASSOC, V259, P2419, DOI 10.1001/jama.259.16.2419; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P250; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1994, LANCET, V344, P1766; SUHONEN O, 1988, ACTA MED SCAND, V223, P19; ULVENSTAM G, 1984, PREV MED, V13, P355, DOI 10.1016/0091-7435(84)90027-6; White A, 1993, HLTH SURVEY ENGLAND	29	126	128	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	1996	312	7044					1443	1448		10.1136/bmj.312.7044.1443	http://dx.doi.org/10.1136/bmj.312.7044.1443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664620	Green Published			2022-12-28	WOS:A1996UQ29600022
J	Rhodes, M; Gompertz, H; Armstrong, K; Lennard, T; Rees, B				Rhodes, M; Gompertz, H; Armstrong, K; Lennard, T; Rees, B			Randomised trial of laparoscopic versus small-incision cholecystectomy	LANCET			English	Letter											Rhodes, M (corresponding author), NORFOLK & NORWICH NHS TRUST HOSP,DEPT GEN SURG,GASTROINTESTINAL UNIT,NORWICH NR1 3SR,NORFOLK,ENGLAND.			Gallagher, Anthony G./0000-0003-0887-5613				Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; RHODES M, 1995, BRIT J SURG, V82, P666, DOI 10.1002/bjs.1800820533; RHODES M, 1996, SURG ENDOSC-ULTRAS, V10, P256	3	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1621	1622		10.1016/S0140-6736(96)91109-5	http://dx.doi.org/10.1016/S0140-6736(96)91109-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667886				2022-12-28	WOS:A1996UP66100044
J	Sharp, D				Sharp, D			Piltdown: Another suspect	LANCET			English	Editorial Material																		Gee H, 1996, NATURE, V381, P261, DOI 10.1038/381261a0; SPENCER F, 1990, PILTDOWN SCI FORGERY, P149	2	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1502	1502		10.1016/S0140-6736(96)90668-6	http://dx.doi.org/10.1016/S0140-6736(96)90668-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684099				2022-12-28	WOS:A1996UN47300007
J	Yamanouchi, T; Ogata, N; Tagaya, T; Kawasaki, T; Sekino, N; Funato, H; Akaoka, I; Miyashita, H				Yamanouchi, T; Ogata, N; Tagaya, T; Kawasaki, T; Sekino, N; Funato, H; Akaoka, I; Miyashita, H			Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control	LANCET			English	Article							DIABETES-MELLITUS; PLASMA 1,5-ANHYDRO-D-GLUCITOL; MAJOR POLYOL; HEMOGLOBIN; REDUCTION; RATS; LEVEL	Background To evaluate prospectively the clinical value of measuring serum concentrations of 1,5-anhydroglucitol (1,5AG) in monitoring glycaemia in patients with newly diagnosed non-insulin-dependent diabetes mellitus (NIDDM), we measured serum 1,5AG in 56 such patients. Methods 28 patients (group A) were started on, and continuously received, an oral hypoglycaemic agent for at least 6 weeks. The other 28 patients (group B) were given such agents for 4 weeks, and then stopped taking them for at least 2 weeks. Ail patients were then followed for an additional 10 weeks. Serum 1,5AG, fructosamine, glycated haemoglobin (HbA(1)c), and self-monitoring of blood glucose were monitored every 14 days for 16 weeks. Findings When sudden worsening of glycaemia occurred within 2 weeks, entailing withdrawal of oral treatment, 1,5AG accurately detected the slight change in glycaemia whereas HbA(1)c and fructosamine both failed to detect it. Although the change was detected by measurement of fasting plasma glucose (FPG) concentrations, FPG was less sensitive than 1,5AG. In patients with ''near-normoglycaemia'' (HbA(1)c about 6 . 5%) in the preceding 8 weeks, those who showed a lower concentration of 1,5AG (<10 . 0 mu g/mL) manifested a higher mean daily plasma glucose concentration even though HbA(1)c measurement suggested good control of glycaemia. Results of 1,5AG were correlated more strongly with the FPG (r=0 . 790) and mean daily plasma glucose (r=-0 . 835) estimated on the same day than those estimated in the preceding 2, 4 and 8 weeks, and with a fall in the Spearman correlation coefficient at any preceding time interval. Interpretation Because 1,5AG accurately detected a slight change in glycaemia without delay, it is suitable for use in monitoring for strict control of glycaemia, an important clinical goal.			Yamanouchi, T (corresponding author), TEIKYO UNIV, DEPT INTERNAL MED 2, ITABASHI KU, TOKYO 173, JAPAN.							AKANUMA Y, 1988, DIABETOLOGIA, V31, P831; BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; FRATTALI AL, 1994, CLIN CHEM, V40, P1991; KAMETANI S, 1987, J BIOCHEM-TOKYO, V102, P1599, DOI 10.1093/oxfordjournals.jbchem.a122210; KISHIMOTO M, 1995, DIABETES CARE, V18, P1156, DOI 10.2337/diacare.18.8.1156; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; KOSKINEN PJ, 1993, DIABETES CARE, V16, P1049, DOI 10.2337/diacare.16.7.1049b; NATHAN DM, 1990, NEW ENGL J MED, V323, P1062, DOI 10.1056/NEJM199010113231509; OKUNO Y, 1992, J BIOCHEM-TOKYO, V111, P99, DOI 10.1093/oxfordjournals.jbchem.a123726; ROBERTSON DA, 1993, DIABETIC MED, V10, P56, DOI 10.1111/j.1464-5491.1993.tb01997.x; ROBERTSON DA, 1991, DIABETIC MED, V8, pA22; SERVICE FJ, 1987, DIABETES CARE, V10, P225, DOI 10.2337/diacare.10.2.225; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SUZUKI M, 1988, J BIOCHEM-TOKYO, V104, P956, DOI 10.1093/oxfordjournals.jbchem.a122590; TANABE T, 1994, CLIN CHEM, V40, P2006; YAMANOUCHI T, 1992, METABOLISM, V41, P862, DOI 10.1016/0026-0495(92)90168-A; YAMANOUCHI T, 1989, DIABETES, V38, P723, DOI 10.2337/diabetes.38.6.723; YAMANOUCHI T, 1986, DIABETES, V35, P204, DOI 10.2337/diabetes.35.2.204; YAMANOUCHI T, 1987, DIABETES, V36, P709, DOI 10.2337/diabetes.36.6.709; YAMANOUCHI T, 1992, AM J PHYSIOL, V263, pE268, DOI 10.1152/ajpendo.1992.263.2.E268; YAMANOUCHI T, 1994, DIABETES RES CLIN PR, V24, pS261, DOI 10.1016/0168-8227(94)90259-3; YAMANOUCHI T, 1991, DIABETES, V40, P52, DOI 10.2337/diabetes.40.1.52; YAMANOUCHI T, 1990, AM J PHYSIOL, V258, pE423, DOI 10.1152/ajpendo.1990.258.3.E423; YAMANOUCHI T, 1988, DIABETOLOGIA, V31, P41; YAMANOUCHI T, 1994, J BIOL CHEM, V269, P9664; YUDKIN JS, 1990, DIABETOLOGIA, V33, P208, DOI 10.1007/BF00404798	27	127	135	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1996	347	9014					1514	1518		10.1016/S0140-6736(96)90672-8	http://dx.doi.org/10.1016/S0140-6736(96)90672-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684103				2022-12-28	WOS:A1996UN47300011
J	Horton, R				Horton, R			Ruling out ingelfinger?	LANCET			English	Editorial Material																		ALTMAN LK, 1995, NY TIMES        1011, pA17; ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; CHOO V, 1995, LANCET, V346, P1027, DOI 10.1016/S0140-6736(95)91702-0; *INT COMM MED J ED, 1994, UN REQ MAN SUBM BIOM; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1608, DOI 10.1056/NEJM199406023302211; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1709, DOI 10.1056/NEJM199506223322509; *RR MCCORM TRIB FD, 1994, CANT C SER, P20; 1996, LANCET, V347, P843; 1995, LANCET, V346, P1569	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1423	1424		10.1016/S0140-6736(96)91679-7	http://dx.doi.org/10.1016/S0140-6736(96)91679-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676623				2022-12-28	WOS:A1996UM48500006
J	Sereno, PC; Dutheil, DB; Iarochene, M; Larsson, HCE; Lyon, GH; Magwene, PM; Sidor, CA; Varricchio, DJ; Wilson, JA				Sereno, PC; Dutheil, DB; Iarochene, M; Larsson, HCE; Lyon, GH; Magwene, PM; Sidor, CA; Varricchio, DJ; Wilson, JA			Predatory dinosaurs from the Sahara and Late Cretaceous faunal differentiation	SCIENCE			English	Article								Late Cretaceous (Cenomanian) fossils discovered in the Kem Kem region of Morocco include large predatory dinosaurs that inhabited Africa as it drifted into geographic isolation. One, represented by a skull approximately 1.6 meters in length, is an advanced allosauroid referable to the African genus Carcharodontosaurus. Another, represented by a partial skeleton with slender proportions, is a new basal coelurosaur closely resembling the Egyptian genus Bahariasaurus. Comparisons with Cretaceous theropods from other continents reveal a previously unrecognized global radiation of carcharodontosaurid predators, Substantial geographic differentiation of dinosaurian faunas in response to continental drift appears to have arisen abruptly at the beginning of the Late Cretaceous.	MINIST ENERGIE & MINES,RABAT,MOROCCO; OLD TRAIL MUSEUM,CHOTEAU,MT 59422		Sereno, PC (corresponding author), UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,1027 E 57TH ST,CHICAGO,IL 60637, USA.		Larsson, Hans/AAD-4579-2019; Wilson, Jeffrey/C-2737-2008	Larsson, Hans/0000-0002-6377-4770; Dutheil, Didier/0000-0002-4856-0918; Magwene, Paul/0000-0002-7659-2589				BERMAN DS, 1982, CARNEGIE MUSEUM ANN, V51, P405; Bonaparte J.F., 1985, Ameghiniana, V21, P259; Bonaparte J.F., 1990, NATURAL HIST MUSEUM, V416, P1; Bonaparte J.F, 1991, MUSEO ARGENTINO CIEN, V4, P16; BONAPARTE JF, 1987, 4 S MES TERR EC SHOR, P24; Bonaparte JF., 1980, MEMOIRES SOC GEOLOGI, V139, P19; BOUAZIZ S, 1988, B SOC GEOL FR, P335; Broin de F., 1974, CR HEBD ACAD SCI, V279, P469; BUFFETAUT E, 1995, SCIENCE, V267, P1751; BUFFETAUT E, 1993, AFRICA S AM CONNECTI, P87; BUFFETAUT E, 1989, NEUES JB GEOLOGIE PA, P79; CALVO J, IN PRESS GAIA; Charig A.J., 1990, P127, DOI 10.1017/CBO9780511608377.012; CHATTERJEE S, 1978, J PALEONTOL, V52, P570; CHOUBERT G., 1952, NOTES MEMOIRES SERVI, V100, P75; COOMBS W P JR, 1981, Memoirs of the Queensland Museum, V20, P351; CORIA RA, 1995, NATURE, V377, P224, DOI 10.1038/377224a0; de LAPPARENT ALBERT F., 1960, MEM SOC GEOL FRANCE, V88 A, P1; DELAPPARENT AF, 1951, CR HEBD ACAD SCI, V232, P1430; DELAPPARENT AF, 1957, J PALAEONTOL SOC IND, V2, P109; Deper ~ ~et C., 1896, B SOCIETE GEOLOGIQUE, V24, P176; Deperet C., 1925, CR Acad sci Paris, V181, P1108; DEPERET CH, 1927, BULL SOC GEOL FRANCE, V27, P257; Dominik, 1985, BERLINER GEOWISS A A, V62, P173; FERRANDINI M, 1985, B SOC GEOL FR, V1, P559; GASPARINI Z, 1987, 10 AN C BRAS PAL, P131; Gauthier H., 1957, NOTES MEMOIRES SERVI, V119, P1; GILMORE CW, 1920, US NATL MUS BULL, V110, P1; HARDENBOL J, 1993, CRETACEOUS RES, V14, P449, DOI 10.1006/cres.1993.1031; Harland W.B., 1990, GEOLOGIC TIME SCALE; HOOKER JJ, 1991, ANTARCT SCI, V3, P331, DOI 10.1017/S0954102091000391; KENNEDY WJ, 1987, S AFR J SCI, V83, P173; Kirkland James I., 1994, Journal of Vertebrate Paleontology, V14, p32A; LARSON PL, 1995, PALEONTOL SOC SPEC P, V7, P139; LAVOCAT R, 1951, CR HEBD ACAD SCI, V232, P169; Lavocat R., 1954, NOTES MEM SERV GEOL, V116, P1; LAVOCAT R, 1955, MUSEUM NATURAL HIST, V27, P256; Lavocat R., 1954, C S G OLOGIQUE INT C, V15, P65; MATEER NJ, 1992, CRETACEOUS RES, V13, P273, DOI 10.1016/0195-6671(92)90003-9; McIntosh J.S., 1990, P345; MEISTER C, 1991, GEOBIOS, V25, P55; Molnar R.E., 1990, P169; MOLNAR RE, 1980, MEM SOC GEOL FR, V139, P131; OLIVERO EB, 1987, GEOLOGICAL EVOLUTION, P617; Osborn HF, 1916, B AM MUS NAT HIST, V35, P733; Powell J.E., 1992, DINOSAURIOS ENTORNO, P165; POWELL JE, 1987, MUS ARGENT CIENC NAT, V3, P147; Rauhut Oliver W.M., 1995, Berliner Geowissenschaftliche Abhandlungen Reihe E Palaeobiologie, V16, P357; Rauhut Oliver W. M., 1995, Palaeontologische Zeitschrift, V69, P475; RUSSELL DA, IN PRESS B MUS NAT H; SERENO PC, 1994, SCIENCE, V266, P267, DOI 10.1126/science.266.5183.267; Slaughter BH., 1974, ANN GEOLOGICAL SURVE, V4, P25; SMITH AG, 1994, ATLAS MESOZOIC CENOZ, P38; STOVALL JW, 1950, AM MIDL NAT, V43, P696, DOI 10.2307/2421859; Stromer E., 1931, Abh bayer Akad Wiss Munchen (nf), V9, P1; Stromer E., 1932, ABHANDLUNGEN BAYERIS, V10, P1; STROMER E, 1932, ABH BAYER AKAD WISS, V9, P1; Stromer E, 1915, ABHANDLUNGEN KONIGLI, V28, P1; Stromer E., 1934, ABH BAYER AKAD WISS, V22, P1; SWOFFORD DL, 1993, PAUP 3 1; THULBORN T, 1990, DINOSAUR TRACKS, P190; von Huene F.F., 1929, ANALES MUSEO LA PLAT, V3, P1; von HUENE FRIEDRICH, 1933, MEM GEOL SURV INDIA PALAEONT INDICA, V21, P1; WEISHAMPEL DB, 1990, DINOSAURIA, P109; Werner C., 1989, Palaeo Ichthyologica, V5, P1; Werner Christa, 1994, Berliner Geowissenschaftliche Abhandlungen Reihe E Palaeobiologie, V13, P221	66	327	345	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					986	991		10.1126/science.272.5264.986	http://dx.doi.org/10.1126/science.272.5264.986			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662584				2022-12-28	WOS:A1996UL61900038
J	Jiang, YB; Yung, YL				Jiang, YB; Yung, YL			Concentrations of tropospheric ozone from 1979 to 1992 over tropical Pacific South America from TOMS data	SCIENCE			English	Article							TREND ANALYSIS	An estimate of tropospheric ozone concentrations was obtained from the difference in the Total Ozone Mapping Spectrometer (TOMS) data between the high Andes and the Pacific Ocean. From 1979 to 1992 the tropospheric ozone concentration apparently increased by 1.48 +/- 0.40 percent per year or 0.21 +/- 0.06 Dobson unit per year over South America and the surrounding oceans. An increase in biomass burning in the Southern Hemisphere can account for this trend in tropospheric ozone concentrations.	CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125	California Institute of Technology			Yung, Yuk/AAM-4850-2021	Yung, Yuk/0000-0002-4263-2562				ANGELL JK, 1983, J CLIM APPL METEOROL, V22, P1611, DOI 10.1175/1520-0450(1983)022<1611:GVITOA>2.0.CO;2; FISHMAN J, 1990, J GEOPHYS RES-ATMOS, V95, P3599, DOI 10.1029/JD095iD04p03599; Fishman J., 1993, FIRE ENV ECOLOGICAL, P345; HAO WM, 1994, GLOBAL BIOGEOCHEM CY, V8, P495, DOI 10.1029/94GB02086; HERMAN JR, 1991, J GEOPHYS RES-ATMOS, V96, P17297, DOI 10.1029/91JD01553; HERMAN JR, 1993, J GEOPHYS RES-ATMOS, V98, P12783, DOI 10.1029/93JD00601; HUDSON RD, 1995, J GEOPHYS RES-ATMOS, V100, P11137, DOI 10.1029/94JD02435; KIRCHHOFF VWJH, 1989, GEOPHYS RES LETT, V16, P469, DOI 10.1029/GL016i005p00469; KIRCHHOFF VWJH, 1991, J GEOPHYS RES-ATMOS, V96, P10899, DOI 10.1029/91JD01212; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; LOGAN JA, 1985, J GEOPHYS RES-ATMOS, V90, P10463, DOI 10.1029/JD090iD06p10463; STAEHELIN J, 1991, ATMOS ENVIRON A-GEN, V25, P1739, DOI 10.1016/0960-1686(91)90258-9; TARASICK DW, 1995, GEOPHYS RES LETT, V22, P409, DOI 10.1029/94GL02991; TIAO GC, 1986, J GEOPHYS RES-ATMOS, V91, P3121, DOI 10.1029/JD091iD12p13121; WARMBT W, 1979, Z METEOROL, V29, P24	15	34	35	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					714	716		10.1126/science.272.5262.714	http://dx.doi.org/10.1126/science.272.5262.714			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662568				2022-12-28	WOS:A1996UJ05100048
J	Annas, GJ				Annas, GJ			The promised end - Constitutional aspects of physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Glantz L H, 1987, Law Med Health Care, V15, P231; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Preston T. A., 1996, J PHARM CARE PAIN SY, V4, P183; Sontag S, 1988, AIDS ITS METAPHORS; *STAT TASK FORC LI, 1994, DEATH SOUGHT ASS SUI; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1995, JAMA-J AM MED ASSOC, V274, P1591	12	36	36	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					683	687		10.1056/NEJM199608293350924	http://dx.doi.org/10.1056/NEJM199608293350924			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD425	8687526	Green Published			2022-12-28	WOS:A1996VD42500030
J	Morkved, TL; Lu, M; Urbas, AM; Ehrichs, EE; Jaeger, HM; Mansky, P; Russell, TP				Morkved, TL; Lu, M; Urbas, AM; Ehrichs, EE; Jaeger, HM; Mansky, P; Russell, TP			Local control of microdomain orientation in diblock copolymer thin films with electric fields	SCIENCE			English	Article							BLOCK-COPOLYMER; POLY(METHYL METHACRYLATE); MICROSTRUCTURE; POLYSTYRENE; ALIGNMENT; BLENDS	Local control of the domain orientation in diblock copolymer thin films can be obtained by the application of electric fields on micrometer-length scales. Thin films of an asymmetric polystyrene-polymethylmethacrylate diblock copolymer, with cylindrical polymethylmethacrylate microdomains, were spin-coated onto substrates previously patterned with planar electrodes. The substrates, 100-nanometer-thick silicon nitride membranes, allow direct observation of the electrodes and the copolymer domain structure by transmission electron microscopy. The cylinders aligned parallel to the electric field lines for fields exceeding 30 kilovolts per centimeter, after annealing at 250 degrees C in an inert atmosphere for 24 hours. This technique could find application in nanostructure fabrication.	UNIV CHICAGO,JAMES FRANCK INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHYS,CHICAGO,IL 60637; IBM CORP,ALMADEN RES CTR,DIV RES,SAN JOSE,CA 95120	University of Chicago; University of Chicago; International Business Machines (IBM)			Russell, Thomas Paul/ADL-3689-2022	Russell, Thomas Paul/0000-0001-6384-5826				AMUNDSON K, 1993, MACROMOLECULES, V26, P1324, DOI 10.1021/ma00058a022; AMUNDSON K, 1994, MACROMOLECULES, V27, P6559, DOI 10.1021/ma00100a047; AMUNDSON K, 1991, MACROMOLECULES, V24, P6546, DOI 10.1021/ma00024a030; AMUNDSON K, 1993, MACROMOLECULES, V26, P2698, DOI 10.1021/ma00063a010; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; Boyer R. F., 1970, ENCY POLYM SCI TECHN, V13, P251; GUROVICH E, 1994, MACROMOLECULES, V27, P7063, DOI 10.1021/ma00102a009; HADZIIOANNOU G, 1979, COLLOID POLYM SCI, V257, P136, DOI 10.1007/BF01638138; HENKEE CS, 1988, J MATER SCI, V23, P1685, DOI 10.1007/BF01115708; ISHIZU K, 1993, POLYMER, V34, P2256, DOI 10.1016/0032-3861(93)90805-K; KELLER A, 1970, NATURE, V225, P538, DOI 10.1038/225538a0; KOPPI KA, 1992, J PHYS II, V2, P1941, DOI 10.1051/jp2:1992245; LIU Y, 1994, MACROMOLECULES, V27, P4000, DOI 10.1021/ma00092a047; MANSKY P, 1995, J MATER SCI, V30, P1987, DOI 10.1007/BF00353023; Mansky P, 1996, APPL PHYS LETT, V68, P2586, DOI 10.1063/1.116192; MCCRUM NG, 1967, ANELASTIC DIELECTRIC, P264; MORKVED TL, 1994, APPL PHYS LETT, V64, P422, DOI 10.1063/1.111118; MORKVED TL, UNPUB; NG Y, 1992, CHEM MATER, V4, P24; RUSSELL TP, 1993, MACROMOLECULES, V26, P5819, DOI 10.1021/ma00073a044; RUSSELL TP, 1990, MACROMOLECULES, V23, P890, DOI 10.1021/ma00205a033; SAITO R, 1992, POLYMER, V33, P1099, DOI 10.1016/0032-3861(92)90029-V; SAUNDERS RS, 1991, MACROMOLECULES, V24, P5599, DOI 10.1021/ma00020a019; SERPICO JM, 1992, MACROMOLECULES, V25, P6373, DOI 10.1021/ma00049a040; SPATZ JP, 1995, ADV MATER, V7, P731, DOI 10.1002/adma.19950070811; TASSONI R, 1994, CHEM MATER, V6, P744, DOI 10.1021/cm00042a008; THOMAS EL, 1987, MACROMOLECULES, V20, P2934, DOI 10.1021/ma00177a049; THOMAS EL, 1978, POLYMER, V19, P225, DOI 10.1016/0032-3861(78)90044-7; VENUGOPAL G, 1992, CHEM MATER, V4, P1334, DOI 10.1021/cm00024a038; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191	30	694	727	6	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					931	933		10.1126/science.273.5277.931	http://dx.doi.org/10.1126/science.273.5277.931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688070				2022-12-28	WOS:A1996VC67000053
J	Deschamps, MM; Pape, JW; Hafner, A; Johnson, WD				Deschamps, MM; Pape, JW; Hafner, A; Johnson, WD			Heterosexual transmission of HIV in Haiti	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WOMAN SEXUAL TRANSMISSION; COUPLES; RISK; SEROCONVERSION; HEMOPHILIA; INFECTION; BEHAVIOR; PARTNERS; MEN	Background: Despite the importance of human immunodeficiency virus (HIV) transmission through heterosexual contact, the incidence of HIV infection in heterosexual cohorts has not been well studied, particularly in the developing world. Objective: To 1) determine the incidence of HIV infection in discordant heterosexual couples (couples in which one partner had HIV infection and the other did not) in Haiti and 2) assess risk factors for and methods of preventing HIV infection. Design: Prospective study. Setting: National Institute for Laboratory Research, Port-au-Prince, Haiti. Participants: 475 HIV-infected patients and their noninfected regular sex partners. Measurements: Patients and their partners were evaluated at 3- to 6-month intervals for HIV infection, sexually transmitted diseases, and sexual practices. The efficacy of counseling and provision of free condoms was also evaluated. Results: Among the 177 couples who remained sexually active during the prospective study period, 20 seroconversions to HIV positivity occurred, for an incidence rate of 5.4 per 100 person-years (95% CI 5.16 to 5.64 per 100 person-years). Thirty-eight couples (21.5%) discontinued sexual activity during the study. Only 1 seroconversion occurred among the 42 sexually active couples (23.7% of the 177 sexually active couples) who always used condoms. In contrast, the incidence in sexually active couples who infrequently used or did not use condoms was 6.8 per 100 person-years (CI, 6.49 to 7.14 per 100 person-years). Transmission of HIV was associated with genital ulcer disease, syphilis, and vaginal or penile discharge in the HIV-negative partner and with syphilis in the HIV-infected partner. Conclusion: Counseling and the provision of free condoms contributed to the institution of safe sex practices or abstinence in 45% of discordant heterosexual couples. However, 55% of couples reported that they continued to have unprotected sex, resulting in an incidence of HIV infection of 6.8 per 100 person-years.	CORNELL UNIV MED COLL, DIV INT MED & INFECT DIS, NEW YORK, NY 10021 USA; GHESKIO, PORT AU PRINCE, HAITI	Cornell University					FIC NIH HHS [D43 TW00018] Funding Source: Medline; NIAID NIH HHS [R37 AI22624] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022624] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BULTERYS M, 1989, LANCET, V2, P977; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DEVINCENZI I, 1992, BRIT MED J, V304, P809; DEVINCENZI I, 1989, BRIT MED J, V298, P411; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; JOHNSON AM, 1988, AIDS S1, V2, P549; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; LAGA M, 1994, AIDS, V8, P5119; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; Pape JW, 1988, BAILLIERE CLIN TROP, V3, P31; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; RAGNI MV, 1989, J ACQ IMMUN DEF SYND, V2, P557; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; 1987, MMWR-MORBID MORTAL W, V36, pSU	20	107	110	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					324	330		10.7326/0003-4819-125-4-199608150-00011	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678397	Green Published			2022-12-28	WOS:A1996VB68000014
J	Schacker, T; Collier, AC; Hughes, J; Shea, T; Corey, L				Schacker, T; Collier, AC; Hughes, J; Shea, T; Corey, L			Clinical and epidemiologic features of primary HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; human immunodeficiency virus seropositivity; sexual partners; sex behavior; sexually transmitted diseases, viral	HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL BISEXUAL MEN; SEXUAL-BEHAVIOR; ORAL INTERCOURSE; RISK-FACTORS; SEROCONVERSION; PLASMA; TYPE-1; TRANSMISSION; COHORT	Background: The acute clinical events surrounding the acquisition of human immunodeficiency virus (HIV) have not been well characterized. Objective: To further define the clinical and epidemiologic presentation of primary HIV infection. Design: Descriptive cohort study. Setting: University research clinic. Patients: 46 adults (43 men and 3 women) with primary HIV infection who enrolled in the study a median of 51 days after HIV seroconversion. Measurements: Documentation of recent HIV seroconversion. Standardized collection of demographic characteristics and sexual contact history, results of tests for HIV RNA, HIV culture, and T-cell subsets. Results: 41 of 46 patients (89%) developed an acute retroviral syndrome. Primary HIV infection was infrequently diagnosed at the initial medical encounter, even in persons enrolled in routine HIV screening programs. Median numbers of sexual partners 6 months and 1 month before acquisition of HIV were three and one, respectively; 21 patients (46%) reported having had only one partner in the month before seroconversion. Of the 12 patients who could identify the precise date of and activity leading to seroconversion, 4 reported having only oral-genital contact. Conclusions: Primary HIV infection causes a recognizable clinical syndrome that is often underdiagnosed, even in persons enrolled in a program of routine surveillance for HIV infection. Frequency of sexual contact and overall numbers of sexual partners in this group of homosexual men who acquired HIV were markedly lower than those seen a decade ago. Acquisition of HIV does occur, even in persons with relatively few sexual partners. Increased attention to oral-genital contact as a means of acquiring HIV appears to be warranted.	UNIV WASHINGTON, DIV VIROL, SEATTLE, WA 98144 USA	University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27757, AI-45206] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; HENRARD DR, 1994, TRANSFUSION, V34, P376, DOI 10.1046/j.1537-2995.1994.34594249046.x; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KINGSLEY LA, 1987, LANCET, V1, P345; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LO B, 1989, ANN INTERN MED, V110, P727; LOES SK, 1995, NEW ENGL J MED, V333, P408; MAAYAN S, 1993, ISRAEL J PSYCHIAT, V30, P150; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MURRAY AB, 1991, LANCET, V338, P830, DOI 10.1016/0140-6736(91)90726-6; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; ROZENBAUM W, 1988, LANCET, V1, P1395; SCHECHTER MT, 1988, AM J PUBLIC HEALTH, V78, P1535, DOI 10.2105/AJPH.78.12.1535; SCHWARCZ SK, 1995, AM J EPIDEMIOL, V142, P314, DOI 10.1093/oxfordjournals.aje.a117637; SEAGE GR, 1993, AM J EPIDEMIOL, V137, P899, DOI 10.1093/oxfordjournals.aje.a116751; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VANGRIENSVEN GJP, 1987, AM J EPIDEMIOL, V125, P1048, DOI 10.1093/oxfordjournals.aje.a114620; VANGRIENSVEN GJP, 1988, AM J PUBLIC HEALTH, V78, P1575, DOI 10.2105/AJPH.78.12.1575; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472	32	513	526	2	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					257	+		10.7326/0003-4819-125-4-199608150-00001	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VB680	8678387				2022-12-28	WOS:A1996VB68000004
J	Weber, AM; Lee, JC				Weber, AM; Lee, JC			Use of alternative techniques of hysterectomy in Ohio, 1988-1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSISTED VAGINAL HYSTERECTOMY; UNITED-STATES; LAPAROSCOPIC CHOLECYSTECTOMY; REPRODUCTIVE AGE; MORTALITY; MODEL; WOMEN	Background Laparoscopically assisted vaginal hysterectomy has been promoted as a substitute for both abdominal and vaginal hysterectomy, with claimed benefits of lower costs, shorter hospital stays, and quicker postoperative recovery. Methods Using computerized hospital-discharge data for 1988-1994 from 180 hospitals in Ohio, we analyzed rates of abdominal, vaginal, and laparoscopically assisted vaginal hysterectomy and their association with characteristics of patients, complications, in-hospital mortality, and hospital charges. Results The annual age-adjusted rate of hysterectomy fell 10 percent, from 4.53 per 1000 female state residents in 1988 to 4.07 per 1000 in 1994 (P<0.001). In 1988, 1.1 percent of all hysterectomies were performed by the laparoscopically assisted vaginal technique; this proportion increased to 9.2 percent in 1993 and declined to 7.5 percent in 1994. For gynecologic conditions other than cancer or pregnancy, women undergoing laparoscopically assisted vaginal hysterectomy as compared with one of the other techniques were more likely to have commercial insurance and to have their surgery at an urban hospital for diagnoses related to pain, endometriosis, or pelvic inflammatory disease. With abdominal and laparoscopically assisted vaginal hysterectomy, the complication rates were similar and were higher than those with vaginal hysterectomy. In-hospital mortality was similar for vaginal and laparoscopically assisted vaginal hysterectomy and was lower than for abdominal hysterectomy. Median hospital charges were $8,108 for laparoscopically assisted vaginal hysterectomy, $5,723 for abdominal hysterectomy, and $5,049 for vaginal hysterectomy. Conclusions The rate of hysterectomy in Ohio decreased from 1988 to 1994, as laparoscopically assisted vaginal hysterectomy became more common, Laparoscopically assisted vaginal hysterectomy was associated with higher hospital charges than the other techniques. (C) 1996, Massachusetts Medical Society.	CLEVELAND CLIN FDN,DEPT BIOSTAT & EPIDEMIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	Weber, AM (corresponding author), CLEVELAND CLIN FDN,DEPT OBSTET & GYNECOL,9500 EUCLID AVE A81,CLEVELAND,OH 44195, USA.							Agresti A., 1984, ANAL ORDINAL CATEGOR; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BOIKE GM, 1993, AM J OBSTET GYNECOL, V168, P1690, DOI 10.1016/0002-9378(93)90679-D; BYERLY ER, 1990, CURRENT POPULATI P25, V1106; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; DICKER RC, 1982, JAMA-J AM MED ASSOC, V248, P323, DOI 10.1001/jama.248.3.323; DORSEY JH, 1995, AM J OBSTET GYNECOL, V173, P1452, DOI 10.1016/0002-9378(95)90632-0; ESCARCE JJ, 1995, JAMA-J AM MED ASSOC, V273, P1581, DOI 10.1001/jama.273.20.1581; HARRIS MB, 1994, AM J OBSTET GYNECOL, V171, P340, DOI 10.1016/S0002-9378(94)70032-X; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; KOVAC SR, 1991, MED DECIS MAKING, V11, P19, DOI 10.1177/0272989X9101100103; LILIENFELD AM, 1980, F EPIDEMIOLOGY; LIU CY, 1992, J REPROD MED, V37, P351; LUOTO R, 1994, INT J EPIDEMIOL, V23, P348, DOI 10.1093/ije/23.2.348; NEZHAT C, 1994, OBSTET GYNECOL, V83, P713; PADIAL JG, 1992, J GYNECOL SURG, V8, P81, DOI 10.1089/gyn.1992.8.81; PHIPPS JH, 1993, BRIT J OBSTET GYNAEC, V100, P698, DOI 10.1111/j.1471-0528.1993.tb14246.x; POKRAS R, 1988, AM J PUBLIC HEALTH, V78, P852, DOI 10.2105/AJPH.78.7.852; S. Bureau of the Census, 1990, CENS POP; STEINER CA, 1994, NEW ENGL J MED, V330, P403, DOI 10.1056/NEJM199402103300607; STOVALL TG, 1992, OBSTET GYNECOL, V80, P145; SUMMITT RL, 1992, OBSTET GYNECOL, V80, P895; *US BUR CENS, 1994, CURR POP REP P25, V1111; WILCOX LS, 1994, OBSTET GYNECOL, V83, P549, DOI 10.1097/00006250-199404000-00011; WINGO PA, 1985, AM J OBSTET GYNECOL, V152, P803, DOI 10.1016/S0002-9378(85)80067-3	26	66	67	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					483	489		10.1056/NEJM199608153350706	http://dx.doi.org/10.1056/NEJM199608153350706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672154	Bronze			2022-12-28	WOS:A1996VB84900006
J	Caro, JF; Kolaczynski, JW; Nyce, MR; Ohannesian, JP; Opentanova, I; Goldman, WH; Lynn, RB; Zhang, PL; Sinha, MK; Considine, RV				Caro, JF; Kolaczynski, JW; Nyce, MR; Ohannesian, JP; Opentanova, I; Goldman, WH; Lynn, RB; Zhang, PL; Sinha, MK; Considine, RV			Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance	LANCET			English	Article								Background A receptor for leptin has been cloned from the choroid plexus, the site of cerebrospinal-fluid (CSF) production and the location of the blood/cerebrospinal-fluid barrier. Thus, this receptor might serve as a transporter for leptin. We have studied leptin concentrations in serum and (CSF). Methods and findings We demonstrated by radioimmunoassay and western blot the presence of leptin in human CSF. We then measured leptin in CSF and serum in 31 individuals with a wide range of bodyweight. Mean serum leptin was 318% higher in 8 obese (40.2 [SE 8.6] ng/mL) than in 23 lean individuals (9.6 [1.5] ng/mL, p<0 0005). However, the CSF leptin concentration in obese individuals (0.337 [0.04] ng/mL) was only 30% higher than in lean people (0.259 [0.26] ng/mL, p<0.1). Consequently, the leptin CSF/serum ratio in lean individuals (0.047 [0.010] was 4.3-fold higher than that in obese individuals (0.011 [0.002], p<0.05). The relation between CSF leptin and serum leptin was best described by a logarithmic function (r=0.52, p<0.01). Interpretation Our data suggest that leptin enters the brain by a saturable transport system. The capacity of leptin transport is lower in obese individuals, and may provide a mechanism for leptin resistance.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV GASTROENTEROL & HEPATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT NEUROSURG,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University	Caro, JF (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV ENDOCRINOL DIABET & METAB,1025 WALNUT ST,PHILADELPHIA,PA 19107, USA.				NIDDK NIH HHS [R01 DK45592, R29 DK51140] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051140, R01DK045592] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Considine RV, 1996, BIOCHEM BIOPH RES CO, V220, P735, DOI 10.1006/bbrc.1996.0473; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; CONSIDINE RV, 1996, DIABETES, V19, P992; DAVSON H, 1996, BLOOD BRAIN CSF RELA, P257; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lynn RB, 1996, BIOCHEM BIOPH RES CO, V219, P884, DOI 10.1006/bbrc.1996.0328; Malik KF, 1996, ENDOCRINOLOGY, V137, P1497, DOI 10.1210/en.137.4.1497; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	19	953	997	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					159	161		10.1016/S0140-6736(96)03173-X	http://dx.doi.org/10.1016/S0140-6736(96)03173-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684156				2022-12-28	WOS:A1996UX78900011
J	Steigman, DM				Steigman, DM			Is it ''urban'' or is it ''asthma''?	LANCET			English	Editorial Material									ST VINCENT HOSP,WORCESTER,MA 01606		Steigman, DM (corresponding author), FALLON CLIN INC,DEPT PULM,WORCESTER,MA 01606, USA.							GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546, DOI 10.1093/oxfordjournals.aje.a117470; *US DHHS, 1991, DHHS PUBL	4	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					143	144		10.1016/S0140-6736(05)66107-7	http://dx.doi.org/10.1016/S0140-6736(05)66107-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684151				2022-12-28	WOS:A1996UX78900006
J	Corrigan, E; Mumford, SE; Hull, MGR				Corrigan, E; Mumford, SE; Hull, MGR			Posthumous storage and use of sperm and embryos: Survey of opinion of treatment centres	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRISTOL,ST MICHAELS HOSP,DEPT OBSTET & GYNAECOL,CTR REPROD MED,BRISTOL BS2 8EG,AVON,ENGLAND; UNIV BRISTOL,DEPT LAW,BRISTOL BS8 1RT,AVON,ENGLAND	University of Bristol; University of Bristol								AZIZASHUSTER E, 1994, HUM REPROD, V9, P2182, DOI 10.1093/oxfordjournals.humrep.a138414; Warnock M, 1984, CMND9314	2	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					24	24		10.1136/bmj.313.7048.24	http://dx.doi.org/10.1136/bmj.313.7048.24			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664765	Green Published			2022-12-28	WOS:A1996UW66700026
J	Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V				Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V			Effect of age, breast density, and family history on the sensitivity of first screening mammography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUCTAL CARCINOMA INSITU; MEDICAL AUDIT; FOLLOW-UP; GROWTH-RATES; LOW-COST; CANCER; COMMUNITY	Objective.-To determine factors that influence the sensitivity of modern first screening mammography. Design.-Cross-sectional. Setting.-Nine counties in northern California. Participants.-A total of 28 271 women aged 30 years and older referred for first screening mammography to the Mobile Mammography Screening Program of the University of California, San Francisco, from April 1985 to March 1 992, of whom 238 were subsequently diagnosed as having breast cancer. Measurements.-Breast cancer risk profile, 2 standard mammographic views per breast, breast density, and follow-up of abnormal and normal mammography by contacting women's physicians and by linkage to the regional Surveillance, Epidemiology, and End Results tumor registry to determine the occurrence of any invasive cancer or ductal carcinoma in situ. Results tumor registry to determine the occurrence of any invasive cancer or ductal carcinoma in situ. Results.-For women aged 50 years and older, the sensitivity of first screening mammography was relatively high and decreased slightly with increasing length of follow-up after mammography: 98.5% for 7 months of follow-up, 93.2% for 13 months, and 85.7% for 25 months. Sensitivity was higher among women aged 50 years and older when breast density was primarily fatty rather than primarily dense (98.4% vs 83.7%; P<.01). For women younger than 50 years, the sensitivity of first screening mammography also decreased with increasing length of follow-up but was significantly lower than for older women: 87.5% for 7 months of follow-up, 83.6% for 13 months, and 71.4% for 25 months. For women younger than 50 years, breast density did not affect the sensitivity of mammography (81.8% for those with primarily fatty breasts vs 85.4% for those with primarily dense breasts) and was lower among those with a family history of breast cancer (68.8%). Conclusions.-The sensitivity of modem mammography is highest among women aged 50 years and older who have primarily fatty breast density. Sensitivity is lowest among women younger than 50 years and particularly low when the time between screenings is about 2 years or when women have a family history of breast cancer, possibly because of rapid tumor growth.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kerlikowske, K (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,111A1,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NCI NIH HHS [UO1 CA 63740, CA 58207-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American College of Radiology, 1982, POL STAT GUID MAMM; ARNESSON LG, 1989, BRIT J SURG, V76, P672, DOI 10.1002/bjs.1800760707; BARTOW SA, 1995, AM J EPIDEMIOL, V142, P813, DOI 10.1093/oxfordjournals.aje.a117720; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BIRD RE, 1992, RADIOLOGY, V184, P613, DOI 10.1148/radiology.184.3.1509041; BREKELMANS CTM, 1992, EUR J CANCER, V28A, P893, DOI 10.1016/0959-8049(92)90144-Q; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BURHENNE HJ, 1994, AM J ROENTGENOL, V162, P1067, DOI 10.2214/ajr.162.5.8165983; CALLE EE, 1993, AM J EPIDEMIOL, V138, P675, DOI 10.1093/oxfordjournals.aje.a116904; Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H; DERSHAW DD, 1989, RADIOLOGY, V170, P411, DOI 10.1148/radiology.170.2.2536185; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; ELWOOD JM, 1993, ONLINE J CURR CLIN T, V2; Farrow J H, 1970, Cancer, V25, P468, DOI 10.1002/1097-0142(197002)25:2<468::AID-CNCR2820250226>3.0.CO;2-0; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRANKEL SD, 1995, AM J ROENTGENOL, V164, P1107, DOI 10.2214/ajr.164.5.7717214; HARRIS R, 1995, ANN INTERN MED, V122, P550; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; METTLIN C, 1994, CA-CANCER J CLIN, V44, P248, DOI 10.3322/canjclin.44.4.248; MONTICCIOLO DL, 1990, AM J ROENTGENOL, V155, P751, DOI 10.2214/ajr.155.4.2119104; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PEETERS PHM, 1989, INT J CANCER, V43, P226, DOI 10.1002/ijc.2910430209; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; SICKLES EA, 1986, RADIOLOGY, V160, P95, DOI 10.1148/radiology.160.1.3715053; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SICKLES EA, 1987, RADIOL CLIN N AM, V25, P1015; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SIENKO DG, 1993, CANCER-AM CANCER SOC, V71, P1801, DOI 10.1002/1097-0142(19930301)71:5<1801::AID-CNCR2820710515>3.0.CO;2-W; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SMART CR, 1995, CANCER, V76, P2788; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; SPRATT JS, 1986, CANCER RES, V46, P970; STOMPER PC, 1992, AM J ROENTGENOL, V159, P483, DOI 10.2214/ajr.159.3.1323923; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H	43	497	505	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					33	38		10.1001/jama.276.1.33	http://dx.doi.org/10.1001/jama.276.1.33			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667536				2022-12-28	WOS:A1996UU43900024
J	Shaw, M; Tomlinson, D; Higginson, I				Shaw, M; Tomlinson, D; Higginson, I			Survey of HIV patients' views on confidentiality and non-discrimination policies in general practice	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; PRACTITIONER; ATTITUDES; AIDS		CHELSEA WESTMINSTER COMMISS AGCY,LONDON W2 6LX,ENGLAND		Shaw, M (corresponding author), ST MARYS NHS HOSP TRUST,DEPT GENITOURINARY MED,PRAED ST,LONDON W2 1NY,ENGLAND.		Higginson, Irene Julie/C-7309-2012	Higginson, Irene Julie/0000-0002-3687-1313				BROWNPETERSIDE P, 1991, BRIT J GEN PRACT, V41, P401; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1463	1464		10.1136/bmj.312.7044.1463	http://dx.doi.org/10.1136/bmj.312.7044.1463			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664629	Green Published			2022-12-28	WOS:A1996UQ29600032
J	Catanzaro, A				Catanzaro, A			Value of direct amplified test for diagnosis of tuberculosis	LANCET			English	Editorial Material											Catanzaro, A (corresponding author), UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103, USA.							BATES JH, 1979, CHEST, V76, P757, DOI 10.1378/chest.76.6.757; Catanzaro A., 1994, Tubercle and Lung Disease, V75, P36, DOI 10.1016/0962-8479(94)90814-1; CHIN DP, 1995, AM J RESP CRIT CARE, V151, P1872, DOI 10.1164/ajrccm.151.6.7767534; Condos R, 1996, LANCET, V347, P1082, DOI 10.1016/S0140-6736(96)90281-0; Pfyffer GE, 1996, J CLIN MICROBIOL, V34, P834, DOI 10.1128/JCM.34.4.834-841.1996; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993	6	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1500	1501		10.1016/S0140-6736(96)90666-2	http://dx.doi.org/10.1016/S0140-6736(96)90666-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684097				2022-12-28	WOS:A1996UN47300005
J	Frank, CW; Rao, V; Despotopoulou, MM; Pease, RFW; Hinsberg, WD; Miller, RD; Rabolt, JF				Frank, CW; Rao, V; Despotopoulou, MM; Pease, RFW; Hinsberg, WD; Miller, RD; Rabolt, JF			Structure in thin and ultrathin spin-cast polymer films	SCIENCE			English	Article							ISOTHERMAL CRYSTALLIZATION KINETICS; THEORETICAL APPROACH; BLENDS; TRANSITION; SIMULATIONS; TEMPERATURE; THICKNESS; COMPLEXES; PLATES; ORIGIN	The molecular organization in ultrathin polymer films (thicknesses less than 1000 angstroms) and thin polymer films (thicknesses between 1000 and 10,000 angstroms) may differ substantially from that of bulk polymers, which can lead to important differences in resulting thermophysical properties, Such constrained geometry films have been fabricated from amorphous poly(3-methyl-4-hydroxy styrene) (PMHS) and semicrystalline poly(di-n-hexyl silane) (PD6S) by means of spin-casting. The residual solvent content is substantially greater in ultrathin PMHS films, which suggests a higher glass transition temperature that results from a stronger hydrogen-bonded network as compared with that in thicker films. Crystallization of PD6S is substantially hindered in ultrathin films, in which a critical thickness of 150 angstroms is needed for crystalline morphology to exist and in which the rate of crystallization is initially slow but increases rapidly as the film approaches 500 angstroms in thickness.	STANFORD UNIV,DEPT ELECT ENGN,STANFORD,CA 94305; IBM CORP,ALMADEN RES CTR,DIV RES,SAN JOSE,CA 95120	Stanford University; International Business Machines (IBM)	Frank, CW (corresponding author), STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305, USA.							Avrami M, 1941, J CHEM PHYS, V9, P177, DOI 10.1063/1.1750872; Avrami M, 1939, J CHEM PHYS, V7, P1103, DOI 10.1063/1.1750380; Avrami M, 1940, J CHEM PHYS, V8, P212, DOI [10.1063/1.1750631, DOI 10.1063/1.1750631]; BEUCHEMIN BT, 1994, SPIE, V2195, P610; BILLON N, 1989, COLLOID POLYM SCI, V267, P668, DOI 10.1007/BF01524369; BILLON N, 1994, COLLOID POLYM SCI, V272, P633, DOI 10.1007/BF00659278; BILLON N, 1990, ANN CHIM-SCI MAT, V15, P249; BILLON N, 1989, COLLOID POLYM SCI, V267, P1064, DOI 10.1007/BF01496926; BITSANIS I, 1990, J CHEM PHYS, V92, P3827, DOI 10.1063/1.457840; BORNSIDE DE, 1987, J IMAG TECH, V13, P123; COHEN Y, 1981, J POLYM SCI POL PHYS, V19, P599, DOI 10.1002/pol.1981.180190404; COLEMAN MM, 1984, APPL SPECTROSC REV, V20, P255, DOI 10.1080/05704928408060422; CROLL SG, 1979, J APPL POLYM SCI, V23, P847, DOI 10.1002/app.1979.070230319; DESPOTOPOULOU MM, IN PRESS J POLYM PP; DESPOTOPOULOU MM, IN PRESS MACROMOLECU; ESCLEINE JM, 1984, COLLOID POLYM SCI, V262, P366, DOI 10.1007/BF01410254; EVANS UR, 1945, T FARADAY SOC, V41, P365, DOI 10.1039/tf9454100365; KUMAR SK, 1988, J CHEM PHYS, V89, P5206, DOI 10.1063/1.455611; KUZMANY H, 1986, J CHEM PHYS, V85, P7413, DOI 10.1063/1.451330; KWEI TK, 1984, J POLYM SCI POL LETT, V22, P307, DOI 10.1002/pol.1984.130220603; LICHKUS AM, 1988, MACROMOLECULES, V21, P2636, DOI 10.1021/ma00186a054; MILLER RD, 1985, J AM CHEM SOC, V107, P2172, DOI 10.1021/ja00293a058; MILLER RD, 1989, CHEM REV, V89, P1359, DOI 10.1021/cr00096a006; MILLER RD, 1987, B AM PHYS SOC, V32, P886; MOSKALA EJ, 1985, POLYMER, V26, P228, DOI 10.1016/0032-3861(85)90034-5; PAINTER PC, 1991, MACROMOLECULES, V24, P5623, DOI 10.1021/ma00020a022; PATNAIK SS, 1992, POLYMER, V33, P4443, DOI 10.1016/0032-3861(92)90398-G; PREST WM, 1980, J APPL PHYS, V51, P5170, DOI 10.1063/1.327464; PREST WM, 1979, J APPL PHYS, V50, P6067, DOI 10.1063/1.325795; RAO V, 1994, THESIS STANFORD U; REE M, 1993, POLYMER, V34, P1423, DOI 10.1016/0032-3861(93)90855-5; SANCHEZ IC, 1992, PHYSICS POLYM SURFAC; SCHILLING FC, 1990, ACS S SERIES, V224, pCH21; SCHLEGEL L, 1991, J VAC SCI TECHNOL B, V9, P278, DOI 10.1116/1.585607; SPERLING LH, 1992, INTRO PHYSICAL POLYM, P357; STEIN RS, 1962, J POLYM SCI, V56, P59; SUZUKI T, 1992, POLYMER, V33, P198, DOI 10.1016/0032-3861(92)90584-J; TACHIBANA H, 1993, MACROMOLECULES, V26, P2520, DOI 10.1021/ma00062a020; TENBRINKE G, 1988, J CHEM PHYS, V89, P4374, DOI 10.1063/1.454823; THEODOROU DN, 1992, PHYSICS POLYM SURFAC, pCH7; vanZanten JH, 1996, PHYS REV E, V53, pR2053, DOI 10.1103/PhysRevE.53.R2053; WALLACE WE, 1995, PHYS REV E, V52, pR3329, DOI 10.1103/PhysRevE.52.R3329; WANG LF, 1991, J POLYM SCI POL PHYS, V29, P619, DOI 10.1002/polb.1991.090290511; WU WL, 1995, MACROMOLECULES, V28, P771, DOI 10.1021/ma00107a013	44	435	444	9	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					912	915		10.1126/science.273.5277.912	http://dx.doi.org/10.1126/science.273.5277.912			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688068				2022-12-28	WOS:A1996VC67000040
J	Sim, BC; Zerva, L; Greene, MI; Gascoigne, NRJ				Sim, BC; Zerva, L; Greene, MI; Gascoigne, NRJ			Control of MHC restriction by TCR V-alpha CDR1 and CDR2	SCIENCE			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; TRANSGENIC MICE; POSITIVE SELECTION; NEGATIVE SELECTION; EXPRESSION; LYMPHOCYTES; RECOGNITION; MOLECULES; ANTIBODY	Individual T cell receptor (TCR) V-alpha elements are expressed preferentially in CD4 or CD8 peripheral T cell subsets. The closely related V(alpha)3.1 and V(alpha)3.2 elements show reciprocal selection into CD4 and CD8 subsets, respectively. Transgenic mice expressing site-directed mutants of a V alpha 3.1 gene were used to show that individual residues in either the complementarity-determining region 1 (CDR1) or CDR2 were sufficient to change selection from the CD4 subset to the CD8 subset. Thus, the germline-encoded V-alpha elements are a major influence on major histocompatibility class complex (MHC) restriction, most likely by a preferential interaction with one or the other class of MHC molecule.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048002] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48002] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arden Bernhard, 1995, Immunogenetics, V42, P501; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CARBONE FR, 1992, INT IMMUNOL, V4, P861, DOI 10.1093/intimm/4.8.861; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DERSIMONIAN H, 1991, J EXP MED, V174, P639, DOI 10.1084/jem.174.3.639; DIANZANI U, 1992, J IMMUNOL, V148, P678; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Gascoigne Nicholas R. J., 1995, P288; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JAMESON SC, 1990, J IMMUNOL, V145, P1324; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY CA, 1996, SEMIN IMMUNOL, V8, P109; JOUVINMARCHE E, 1990, EMBO J, V9, P2141, DOI 10.1002/j.1460-2075.1990.tb07383.x; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SAOUAF SJ, 1994, TRANSGENICS, V1, P185; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOMONARI K, 1992, IMMUNOGENETICS, V35, P291; UTSUNOMIYA Y, 1989, J IMMUNOL, V143, P2602; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001	29	138	140	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					963	966		10.1126/science.273.5277.963	http://dx.doi.org/10.1126/science.273.5277.963			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688082				2022-12-28	WOS:A1996VC67000065
J	Cole, NB; Smith, CL; Sciaky, N; Terasaki, M; Edidin, M; LippincottSchwartz, J				Cole, NB; Smith, CL; Sciaky, N; Terasaki, M; Edidin, M; LippincottSchwartz, J			Diffusional mobility of Golgi proteins in membranes of living cells	SCIENCE			English	Article							HUMAN KDEL RECEPTOR; ENDOPLASMIC-RETICULUM; BREFELDIN-A; ELECTRON-MICROSCOPY; RETROGRADE TRANSPORT; LATERAL DIFFUSION; COMPLEX; RETENTION; APPARATUS; FLUORESCENCE	The mechanism by which Golgi membrane proteins are retained with in the Golgi complex in the midst of a continuous flow of protein and lipid is not yet understood. The diffusional mobilities of mammalian Golgi membrane proteins fused with green fluorescent protein from Aequorea victoria were measured in living HeLa cells with the fluorescence photobleaching recovery technique. The diffusion coefficients ranged from 3 x 10(-9) square centimeters per second to 5 x 10(-9) square centimeters per second, with greater than 90 percent of the chimeric proteins mobile. Extensive lateral diffusion of the chimeric proteins occurred between Golgi stacks. Thus, the chimeras diffuse rapidly and freely in Golgi membranes, which suggests that Golgi targeting and retention of these molecules does not depend on protein immobilization.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; NINCDS, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PHYSIOL, FARMINGTON, CT 06032 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Johns Hopkins University; University of Connecticut			Smith, Christina/GXG-6941-2022		NIAID NIH HHS [R37 AI14584] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014584] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; Edidin M., 1994, MOBILITY PROXIMITY B, P109; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JAFFE LA, 1993, DEV BIOL, V156, P566, DOI 10.1006/dbio.1993.1103; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; PETERS P, UNPUB; PRASHER DC, 1992, GENE, V15, P111; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; STORRIE B, 1994, J CELL SCI, V107, P1309; TANAKA K, 1986, J SUBMICR CYTOL PATH, V18, P1; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WEIDMAN PJ, 1995, TRENDS CELL BIOL, V5, P302, DOI 10.1016/S0962-8924(00)89046-7; WEY CL, 1981, BIOPHYS J, V33, P225, DOI 10.1016/S0006-3495(81)84883-7; WIER ML, 1986, J CELL BIOL, V103, P215, DOI 10.1083/jcb.103.1.215	36	394	407	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					797	801		10.1126/science.273.5276.797	http://dx.doi.org/10.1126/science.273.5276.797			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670420				2022-12-28	WOS:A1996VB42900043
J	Kuttner, R				Kuttner, R			Columbia/HCA and the resurgence of the for-profit hospital business .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Kuttner, R (corresponding author), AMER PROSPECT,6 UNIV RD,CAMBRIDGE,MA 02138, USA.							*AM HLTH CONS, 1996, PAT FOC CAR, P62; *AM NURS ASS, 1996, NAT NURS SURV; BARRETT MP, 1995, COMMUNICATION   0516; BELL JE, 1996, AM PROSPECT, V26, P60; *BLUE CROSS BLUE S, 1996, BCBSO COL T CLEV; BOISTURE RA, 1995, STATE ATTORNEYS GEN; BURDA D, 1996, MODERN HEALTHCA 0108, P40; Cohen Sarah, 1995, ST PETERSBURG T 1108, p1E; *COWG NEWS SERV, 1996, 133 COWG NEWS SERV O; DAME L, 1996, FAILURE PRIVATE HOSP; Fox DM, 1996, HEALTH AFFAIR, V15, P202, DOI 10.1377/hlthaff.15.1.202; GREENE J, 1996, MODERN HEALTHCA 0624, P64; HILZENRATH DS, 1994, WASH POST       0712, pA1; Iglehart JK, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.4.131; JAFFE G, 1995, WALL STREET J   1101, pS1; JUDD A, 1996, SARASOTA HERALD 0218, pA22; JUDD A, 1996, SARASOTA HERALD 0218, pA1; MEYER H, 1995, HOSP HLTH NETWO 0605, V22; MEYER H, 1995, HOSP HLTH NETWO 0605, V28; MEYER H, 1995, HOSP HLTH NETWO 0605, V24; MEYER H, 1995, HOSP HLTH NETWO 0605, V26; ORWELL G, 1946, ANIMAL FARM, P128; TOMSHO R, 1996, WALL ST J       0131, pB3; TREZONA JC, 1994, COMMUNICATION   0324; *VHA, 1996, COMP STRAT NOT PROF, P19; *VHA, 1996, REAL BROAD VIS, P2; [No title captured]; [No title captured]	28	32	32	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					446	451		10.1056/NEJM199608083350620	http://dx.doi.org/10.1056/NEJM199608083350620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8676952				2022-12-28	WOS:A1996VA90400031
J	Shafran, SD; Singer, J; Zarowny, DP; Phillips, P; Salit, I; Walmsley, SL; Fong, IW; Gill, MJ; Rachlis, AR; Lalonde, RG; Fanning, MM; Tsoukas, CM				Shafran, SD; Singer, J; Zarowny, DP; Phillips, P; Salit, I; Walmsley, SL; Fong, IW; Gill, MJ; Rachlis, AR; Lalonde, RG; Fanning, MM; Tsoukas, CM			A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in aids: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NATURAL-HISTORY; INFECTION; DISEASE; SURVIVAL; THERAPY; TRIALS	Background Bacteremia with the Mycobacterium avium complex is common in patients with the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this infection remains unclear. Methods We randomly assigned 229 patients with AIDS and M. avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group). In the three-drug group the dose of rifabutin was reduced by half after 125 patients were randomized, because 24 of 63 patients had uveitis. Results Among 187 patients who could be evaluated, blood cultures became negative more often in the three-drug group than in the four-drug group (69 percent vs. 29 percent, P<0.001). Among patients treated for at least four weeks, the bacteremia resolved more frequently in the three-drug group (78 percent vs. 40 percent, P<0.001). In the three-drug group, bacteremia resolved more often with the 600-mg dose of rifabutin than with the 300-mg dose (P=0.025), but the latter regimen was more effective than the four-drug regimen (P<0.05). The median survival was 8.6 months in the three-drug group and 5.2 months in the four-drug group (P=0.001). The median Karnofsky performance score was higher in the three-drug group than in the four-drug group from week 2 to week 16 (P<0.05). Mild uveitis developed in 3 of the 53 patients receiving the 300-mg dose of rifabutin, an incidence about one quarter that observed with the 600-mg dose (P<0.001). Conclusions In patients with AIDS and M. avium complex bacteremia, treatment with the three-drug regimen of rifabutin, ethambutol, and clarithromycin leads to resolution of the bacteremia more frequently and more rapidly than treatment with rifampin, ethambutol, clofazimine, and ciprofloxacin, and survival rates are better. (C) 1996, Massachusetts Medical Society.	CANADIAN HIV TRIALS NETWORK,NATL CTR,VANCOUVER,BC,CANADA; ST PAULS HOSP,DIV INFECT DIS,VANCOUVER,BC V6Z 1Y6,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA; TORONTO HOSP,DIV INFECT DIS,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; ST MICHAELS HOSP,DIV INFECT DIS,TORONTO,ON M5B 1W8,CANADA; UNIV CALGARY,DIV INFECT DIS,CALGARY,AB,CANADA; SUNNYBROOK HLTH SCI CTR,DIV INFECT DIS,TORONTO,ON M4N 3M5,CANADA; MONTREAL CHEST INST,DIV INFECT DIS,MONTREAL,PQ,CANADA; MCGILL UNIV,MONTREAL,PQ,CANADA; UNIV TORONTO,WELLESLEY HOSP,DIV INFECT DIS,TORONTO,ON M4Y 1J3,CANADA; MONTREAL GEN HOSP,DIV IMMUNOL,MONTREAL,PQ H3G 1A4,CANADA	St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Calgary; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McGill University	Shafran, SD (corresponding author), UNIV ALBERTA,DEPT MED,DIV INFECT DIS,WALTER C MACKENZIE HLTH SCI CTR 2E411,8440-112 ST,EDMONTON,AB T6G 2B7,CANADA.		Dodsley, Maria/G-7083-2016; Gill, Michael John/G-7083-2016	Dodsley, Maria/0000-0001-7587-558X; Gill, Michael John/0000-0002-8546-8790; Walmsley, Sharon/0000-0002-3959-5692				*AM SOC MICR, 1994, 34 INT C ANT AG CHEM; BENSON CA, 1993, CLIN INFECT DIS, V17, P7, DOI 10.1093/clinids/17.1.7; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHAISSON RE, 1992, 32ND INT C ANT AG CH, P259; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; COHN DL, 1996, 11 INT C AIDS VANC; DAUTZENBERG B, 1994, 34 INT C ANT AG CHEM, P6; ELLNER JJ, 1991, J INFECT DIS, V163, P1326, DOI 10.1093/infdis/163.6.1326; FLEGG PJ, 1995, QJM-MON J ASSOC PHYS, V88, P617; HEIFETS L, 1993, ANTIMICROB AGENTS CH, V37, P2364, DOI 10.1128/AAC.37.11.2364; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; HORSBURGH CR, 1994, J INFECT DIS, V170, P573, DOI 10.1093/infdis/170.3.573; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266, DOI 10.1128/CMR.6.3.266-310.1993; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KEMPER CA, 1994, J INFECT DIS, V170, P157, DOI 10.1093/infdis/170.1.157; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; KERLIKOWSKE KM, 1992, ARCH INTERN MED, V152, P813, DOI 10.1001/archinte.152.4.813; MAY T, 1995, 35 INT C ANT AG CHEM, P11; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SALFINGER M, 1988, J CLIN MICROBIOL, V26, P1225, DOI 10.1128/JCM.26.6.1225-1226.1988; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; SHAFRAN SD, 1995, 35 INT C ANT AG CHEM, P242; SULLAM PM, 1994, CLIN INFECT DIS, V19, P84, DOI 10.1093/clinids/19.1.84; WALLACE RJ, 1995, J INFECT DIS, V171, P747, DOI 10.1093/infdis/171.3.747; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; 1993, MMWR-MORBID MORTAL W, V43, P14	34	225	237	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					377	383		10.1056/NEJM199608083350602	http://dx.doi.org/10.1056/NEJM199608083350602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8676931				2022-12-28	WOS:A1996VA90400002
J	Tomee, JFC; Mannes, GPM; vanderBij, W; vanderWerf, TS; deBoer, WJ; Koeter, GH; Kauffman, HF				Tomee, JFC; Mannes, GPM; vanderBij, W; vanderWerf, TS; deBoer, WJ; Koeter, GH; Kauffman, HF			Serodiagnosis and monitoring of Aspergillus infections after lung transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; RECIPIENTS; DIAGNOSIS; REJECTION; DISEASE	Objective: To determine whether quantification of specific antifungal antibody responses in serum can provide supplemental information for the diagnosis of Aspergillus fumigatus infections and the monitoring of antifungal treatment in patients after lung transplantation. Design: Retrospective study. Setting: Center for lung transplantation, University Hospital Groningen, the Netherlands. Patients: 4 patients with proven A. fumigatus infections after lung transplantation and fatal outcome. Measurements: The IgG antibody response specific for A. fumigatus antigens was measured by enzyme-linked immunosorbent assay and was compared with radiographic features, cytologic findings, microbiological cultures, and clinical diagnosis. Results: Increasing IgG antibody responses specific for A. fumigatus antigens closely paralleled cytologic or microbiological identification of A. fumigatus from bronchoalveolar ravage fluid and decrease of lung function. Increasing specific IgG antibody responses were found to precede radiographic identification of lung cavitation by 1 to 2 weeks, precede the diagnosis of aspergillosis by 2 to 20 weeks, and detect fungal reinfection. In most cases, successful antifungal treatment decreased specific IgG antibody response. A decrease in specific IgG antibody response correlated with the inability to culture or identify A. fumigatus in bronchoalveolar lavage fluid and with radiographic and clinical improvement. Conclusions: Specific IgG antibody responses in serum correlate with radiographic, cytologic, and microbiological findings and with the clinical diagnosis of A. fumigatus infections in patients who have had lung transplantation. Increased IgG antibody responses in serum may provide important information that is helpful in the diagnosis and early treatment of pulmonary fungal infections and in monitoring antifungal treatment.	UNIV GRONINGEN HOSP, DEPT ALLERGOL, CLIN INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; UNIV GRONINGEN HOSP, DEPT PULM, CLIN INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; UNIV GRONINGEN HOSP, DEPT CARDIOTHORAC SURG, NL-9713 GZ GRONINGEN, NETHERLANDS	University of Groningen; University of Groningen; University of Groningen				van der Werf, Tjip/0000-0002-4824-1642				BECKER FS, 1994, AM J RESP CRIT CARE, V150, P159, DOI 10.1164/ajrccm.150.1.8025743; BROOKS RG, 1985, AM J MED, V79, P412, DOI 10.1016/0002-9343(85)90027-0; DUMMER JS, 1986, TRANSPLANTATION, V41, P725, DOI 10.1097/00007890-198606000-00012; DUNCAN SR, 1992, AM REV RESPIR DIS, V146, P1419, DOI 10.1164/ajrccm/146.6.1419; EGAN TM, 1992, ANN THORAC SURG, V53, P590, DOI 10.1016/0003-4975(92)90316-V; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; HIGENBOTTAM T, 1988, TRANSPLANTATION, V46, P532, DOI 10.1097/00007890-198810000-00013; KRAMER MR, 1993, ARCH INTERN MED, V153, P2010, DOI 10.1001/archinte.153.17.2010; MAURER JR, 1992, CHEST, V101, P1056, DOI 10.1378/chest.101.4.1056; MCDOUGALL JC, 1993, ANN THORAC SURG, V56, P176, DOI 10.1016/0003-4975(93)90433-I; MEDINA LS, 1994, AM J ROENTGENOL, V162, P969, DOI 10.2214/ajr.162.4.8141028; MILLET B, 1989, AM REV RESPIR DIS, V140, P62, DOI 10.1164/ajrccm/140.1.62; Paradis I L, 1993, Semin Respir Infect, V8, P207; SMYTH RL, 1989, RESP MED, V83, P459, DOI 10.1016/S0954-6111(89)80126-X; TOMEE JF, IN PRESS AM J RESP C; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; TOMEE JFC, 1995, AM J RESP CRIT CARE, V151, P199, DOI 10.1164/ajrccm.151.1.7812553; VANDERGIESSEN M, 1990, CLIN EXP IMMUNOL, V80, P56; WEILAND D, 1983, ANN SURG, V198, P622, DOI 10.1097/00000658-198311000-00011; WILKES DS, 1995, AM J RESP CELL MOL, V13, P621, DOI 10.1165/ajrcmb.13.5.7576699	20	30	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					197	201		10.7326/0003-4819-125-3-199608010-00006	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686977				2022-12-28	WOS:A1996UZ28700005
J	Ginsburg, GS; Agil, A; OToole, M; Rimm, E; Douglas, PS; Rifai, N				Ginsburg, GS; Agil, A; OToole, M; Rimm, E; Douglas, PS; Rifai, N			Effects of a single bout of ultraendurance exercise on lipid levels and susceptibility of lipids to peroxidation in triathletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN; IRON; RISK; MEN; PLASMA; CELLS	Objective.-To determine the effects of a single bout of ultraendurance exercise, as a model for physiologic stress, on lipid and lipoprotein levels, and oxidative susceptibility of lipids in highly trained athletes. Design.-Observational trial. Population and Setting.-Thirty-nine volunteer subjects (26 men, 13 women; mean age, 38+/-10 years) who competed in and completed the 1994 Hawaii Ironman World Championship Triathlon consisting of a consecutive 3.9-km (2.4-mi) swim, 180.2-km (112-mi) bike ride, and a 42.2-km (26.2-mi) run. Subjects answered questionnaires and had blood samples obtained 2 days prior to and within 15 minutes of completion of the triathlon. Main Outcome Measures.-Prerace vs postrace changes in lipid and lipoprotein levels, and susceptibility of lipids to peroxidation. Results.-The mean duration of exercise was 753+/-128 minutes. With exercise, plasma volume-corrected levels of triglycerides decreased 39% from 1.58+/-0.83 to 0.97+/-0.68 mmol/L (139.6+/-73.6 to 85.8+/-60.5 mg/dL) (P<.001). Levels of total cholesterol decreased 9% from 4.94+/-0.88 to 4.50+/-0.79 mmol/L (190.8+/-33.8 to 173.8+/-30.6 mg/dL) (P<.001), low-density lipoprotein cholesterol decreased 11% from 2.59+/-0.77 to 2.30+/-0.86 mmol/L (100.1+/-29.9 to 88.7+/-33.3 mg/dL) (P=.02), and apolipoprotein B decreased 10% from 0.91+/-0.20 to 0.82+/-0.18 g/L (90.7+/-20.0 to 82.0+/-17.9 mg/dL) (P<.001). High-density lipoprotein cholesterol and apolipoprotein A-I increased with exercise but not significantly. The susceptibility of lipids to peroxidation decreased significantly (4.51+/-1.91 mu mol/L, preexercise, vs 2.42+/-2.27 mu mol/L, postexercise, P<.001), an effect that was not related to antioxidant use or levels of vitamins A, C, or E. Serum iron, a potential pro-oxidant, also decreased by 45% with exercise from 15.75+/-5.55 to 8.59+/-4.30 mu mol/L (88+/-31 to 48+/-24 mu g/dL) (P<.001), an effect that was weakly correlated with changes in lipid peroxidation (P=.05). Conclusions.-These data suggest that a single bout of prolonged exercise can reduce lipid and lipoprotein risk factors for developing cardiovascular disease. Moreover, susceptibility of lipids to peroxidation is reduced by exercise, thereby adding to the benefits of physical activity. This effect appears to be independent of antioxidant supplement use and may be mediated by induction of endogenous antioxidants. These observations may explain in part the reduced risk of developing vascular and other diseases in individuals who are physically active.	CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT LAB MED,BOSTON,MA 02115; UNIV GRANADA,DEPT PHARMACOL,E-18071 GRANADA,SPAIN; UNIV TENNESSEE,DEPT ORTHOPED,MEMPHIS,TN; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Granada; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ginsburg, GS (corresponding author), BETH ISRAEL HOSP,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Agil, Ahmad/D-9620-2014	Douglas, Pamela/0000-0001-9876-4049; Agil, Ahmad/0000-0003-0164-9648				AGIL A, 1995, CLIN CHEM, V41, P220; APPLEGATE E A, 1989, Medicine and Science in Sports and Exercise, V21, pS48; ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CATIGNANI GL, 1983, CLIN CHEM, V29, P708; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DEMBACH AR, 1993, J APPL PHYSIOL, V74, P2140; DILL DB, 1974, J APPL PHYSIOL, V37, P247, DOI 10.1152/jappl.1974.37.2.247; Durstine J L, 1994, Exerc Sport Sci Rev, V22, P477; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; KANTER MM, 1994, INT J SPORT NUTR, V4, P205, DOI 10.1123/ijsn.4.3.205; Murray MJ, 1991, ARTERIOSCLER THROMB, V11, p1479A; OTOOLE ML, 1995, CLIN J SPORT MED, V5, P116, DOI 10.1097/00042752-199504000-00008; OTOOLE ML, 1989, MED SCI SPORT EXER, V21, pS209; OTTLINGER ME, 1995, CLIN CHEM, V41, pS158; PIOTROWSKI JJ, 1990, LIFE SCI, V46, P715, DOI 10.1016/0024-3205(90)90077-5; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALMINEN A, 1983, ACTA PHYSIOL SCAND, V117, P109, DOI 10.1111/j.1748-1716.1983.tb07184.x; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Salonen Jukka T., 1993, Current Opinion in Lipidology, V4, P277, DOI 10.1097/00041433-199308000-00003; SAS Institute Inc, 1993, SAS US GUID STAT VER; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; SJODIN B, 1990, SPORTS MED, V10, P236; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; TAYLOR C, 1987, J APPL PHYSIOL, V62, P464, DOI 10.1152/jappl.1987.62.2.464; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WU LL, 1989, CLIN CHEM, V35, P1486; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	30	59	59	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					221	225		10.1001/jama.276.3.221	http://dx.doi.org/10.1001/jama.276.3.221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667567				2022-12-28	WOS:A1996UW46900034
J	Gilligan, T; Raffin, TA				Gilligan, T; Raffin, TA			Whose death is it, anyway?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									STANFORD UNIV, MED CTR, DIV PULM & CRIT CARE MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR BIOMED ETH, STANFORD, CA 94305 USA	Stanford University; Stanford University			Gilligan, Timothy/AAC-6693-2019; Gilligan, Timothy/HGA-7460-2022	Gilligan, Timothy/0000-0003-2308-9303; 				[Anonymous], 1990, CRIT CARE MED, V18, P1435; BELENKY MF, 1986, WOMENS WAYS KNOWING, P100; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; COWLEY LT, 1992, CRIT CARE MED, V20, P1473, DOI 10.1097/00003246-199210000-00018; Gilligan C., 1982, DIFFERENT VOICE; GILLIGAN T, 1996, CHEST, V108, P1047; Hansot E, 1996, ANN INTERN MED, V125, P149, DOI 10.7326/0003-4819-125-2-199607150-00016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MARSH FA, 1994, LEGAL MED, P283; Miles S H, 1990, Law Med Health Care, V18, P85; PAOLA FA, 1995, LEGAL MED LEGAL DYNA, P404; RAFFIN TA, 1995, JAMA-J AM MED ASSOC, V273, P738, DOI 10.1001/jama.273.9.738; REINES HD, 1992, CRIT CARE MED, V20, P316, DOI 10.1097/00003246-199203000-00002; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106	16	34	35	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					137	141		10.7326/0003-4819-125-2-199607150-00010	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678368				2022-12-28	WOS:A1996UV92100012
J	Hansot, E				Hansot, E			A letter from a patient's daughter	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hansot, E (corresponding author), STANFORD UNIV, DEPT POLIT SCI,MED CTR,DIV PULM & CRIT CARE MED, MC 5236,300 PASTEUR DR, ROOM H3151, STANFORD, CA 94305 USA.								0	26	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					149	151		10.7326/0003-4819-125-2-199607150-00016	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678372				2022-12-28	WOS:A1996UV92100017
J	Knight, DJ; Gilbert, FJ; Hutchison, JD				Knight, DJ; Gilbert, FJ; Hutchison, JD			Septic arthritis in osteoarthritic hips	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,DEPT ORTHOPAED,ABERDEEN,SCOTLAND; ABERDEEN ROYAL INFIRM,DEPT RADIOL,ABERDEEN,SCOTLAND	University of Aberdeen; University of Aberdeen				Gilbert, Fiona/0000-0002-0124-9962				GARDNER GC, 1990, AM J MED, V88, P503, DOI 10.1016/0002-9343(90)90430-L; GOLDENBERG DL, 1976, AM J MED, V60, P369, DOI 10.1016/0002-9343(76)90753-1; VINCENT GM, 1991, CLIN ORTHOPAEDICS, V251, P241	3	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					40	41		10.1136/bmj.313.7048.40	http://dx.doi.org/10.1136/bmj.313.7048.40			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664774	Green Published			2022-12-28	WOS:A1996UW66700032
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Comparing several groups using analysis of variance	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	Altman, DG (corresponding author), INST HLTH SCI,CTR STAT MED,IRCF,MED STAT GRP,POB 777,OXFORD OX3 7LF,ENGLAND.							ARMITAGE P, 1994, STAT METHODS RES WOR; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; GODFREY K, 1992, MED USES STAT, P233	3	57	57	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1472	1473		10.1136/bmj.312.7044.1472	http://dx.doi.org/10.1136/bmj.312.7044.1472			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664633	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1996UQ29600037
J	Maritan, A; Colaiori, F; Flammini, A; Cieplak, M; Banavar, JR				Maritan, A; Colaiori, F; Flammini, A; Cieplak, M; Banavar, JR			Universality classes of optimal channel networks	SCIENCE			English	Article							RIVER NETWORKS; FRACTAL DIMENSION; DRAINAGE NETWORKS; STREAM NETWORKS; ENERGY	Energy minimization of both homogeneous and heterogeneous river networks shows that, over a range of parameter values, there are only three distinct universality classes. The exponents for all three classes of behavior are calculated.	PENN STATE UNIV, DEPT PHYS, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR PHYS MAT, UNIVERSITY PK, PA 16802 USA; SCH ADV INT STUDIES, IST NAZL FIS MAT, I-34014 GRIGNANO, TRIESTE, ITALY; SEZ INFN, TRIESTE, ITALY; POLISH ACAD SCI, INST PHYS, PL-02668 WARSAW, POLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); International School for Advanced Studies (SISSA); Gran Sasso Science Institute (GSSI); Polish Academy of Sciences; Institute of Physics - Polish Academy of Sciences			Colaiori, Francesca/K-6533-2015; Flammini, alessandro/A-8887-2009	Colaiori, Francesca/0000-0001-7165-1941; 				BREYER SP, 1992, GEOMORPHOLOGY, V5, P143, DOI 10.1016/0169-555X(92)90062-S; FISHER ME, 1974, REV MOD PHYS, V46, P597, DOI 10.1103/RevModPhys.46.597; Hack J., 1957, 294B US GEOL SURV; HORTON RE, 1945, GEOL SOC AM BULL, V56, P275, DOI 10.1130/0016-7606(1945)56[275:edosat]2.0.co;2; Horton RE, 1932, EOS T AM GEOPHYS UN, V13, P350; HOWARD AD, 1971, WATER RESOUR RES, V7, P863, DOI 10.1029/WR007i004p00863; HOWARD AD, 1990, WATER RESOUR RES, V26, P2107, DOI 10.1029/WR026i009p02107; HUSE DA, 1985, PHYS REV LETT, V54, P2708, DOI 10.1103/PhysRevLett.54.2708; HUSE DA, 1985, PHYS REV LETT, V55, P2924, DOI 10.1103/PhysRevLett.55.2924; KARDAR M, 1985, PHYS REV LETT, V55, P2923, DOI 10.1103/PhysRevLett.55.2923; LABARBERA P, 1989, WATER RESOUR RES, V25, P735, DOI 10.1029/WR025i004p00735; Leopold L B, 1962, GEOL SURV PROF PAPER, V500-A; Maritan A, 1996, PHYS REV E, V53, P1510, DOI 10.1103/PhysRevE.53.1510; MEAKIN P, 1991, PHYSICA A, V176, P409, DOI 10.1016/0378-4371(91)90221-W; MONTGOMERY DR, 1992, SCIENCE, V255, P826, DOI 10.1126/science.255.5046.826; RINALDO A, 1993, PHYS REV LETT, V70, P822, DOI 10.1103/PhysRevLett.70.822; RODRIGUEZ-ITURBE I, 1992, GEOPHYS RES LETT, V19, P889, DOI 10.1029/92GL00938; RODRIGUEZ-ITURBE I, 1992, WATER RESOUR RES, V28, P1095, DOI 10.1029/91WR03034; RODRIGUEZITURBE I, 1996, FRACTAL RIVER BASINS; SCHEIDEGGER AE, 1967, B IASH, V12, P15, DOI DOI 10.1080/02626666709493507; SHREVE RL, 1967, J GEOL, V75, P178, DOI 10.1086/627245; SHREVE RL, 1966, J GEOL, V74, P17, DOI 10.1086/627137; SHREVE RL, 1969, J GEOL, V77, P397, DOI 10.1086/628366; STEVENS PS, 1974, PATTERNS NATURE; SUN T, 1994, PHYS REV E, V49, P4865, DOI 10.1103/PhysRevE.49.4865; SUN T, 1995, PHYS REV E, V51, P5353, DOI 10.1103/PhysRevE.51.5353; SUN T, 1994, WATER RESOUR RES, V30, P2599, DOI 10.1029/94WR01050; TAKAYASU H, 1991, J STAT PHYS, V65, P725, DOI 10.1007/BF01053751; TARBOTON DG, 1990, WATER RESOUR RES, V26, P2243, DOI 10.1029/WR026i009p02243; TARBOTON DG, 1988, WATER RESOUR RES, V24, P1317, DOI 10.1029/WR024i008p01317; TARBOTON DG, 1989, WATER RESOUR RES, V25, P2037, DOI 10.1029/WR025i009p02037; TROUTMAN BM, 1992, WATER RESOUR RES, V28, P563, DOI 10.1029/91WR02648; YAM P, 1994, SCI AM, V271, P26; YANG CT, 1971, WATER RESOUR RES, V7, P311, DOI 10.1029/WR007i002p00311	34	96	97	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1996	272	5264					984	986		10.1126/science.272.5264.984	http://dx.doi.org/10.1126/science.272.5264.984			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662583				2022-12-28	WOS:A1996UL61900037
J	Colman, JJ; Xu, XP; Thiemens, MH; Trogler, WC				Colman, JJ; Xu, XP; Thiemens, MH; Trogler, WC			Photopolymerization and mass-independent sulfur isotope fractionations in carbon disulfide	SCIENCE			English	Article							COMET SHOEMAKER-LEVY-9; CS2; JUPITER	Irradiation of gaseous carbon disulfide [CS2(g)] at 313 nanometers produces a dark brown aerosol of (CS2)(x). Its thermal decomposition products include disulfur (S-2), carbon monosulfide (CS), and (CS)(x). The photopolymerization process is accompanied by a large mass-independent isotopic fractionation of sulfur (a 5 to 10 per mil sulfur-33 excess and a 61 to 84 per mil sulfur-36 deficit). Excess sulfur-33 has been observed in several classes of meteorites, Photochemical production of (CS2)(x) may be important in the origin and evolution of cosmochemical environments such as the presolar nebula, meteorites, asteroids, and planetary atmospheres.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego			Trogler, William C/F-9515-2011	Trogler, William C/0000-0001-6098-7685				Bridgman PW, 1942, P AM ACAD ARTS SCI, V74, P399, DOI 10.2307/20023421; BRUS LE, 1971, CHEM PHYS LETT, V12, P116, DOI 10.1016/0009-2614(71)80629-2; CHEN FZ, 1995, GEOPHYS RES LETT, V22, P2131, DOI 10.1029/95GL01898; CHIN M, 1993, GLOBAL BIOGEOCHEM CY, V7, P321, DOI 10.1029/93GB00568; COLMAN JJ, 1995, J AM CHEM SOC, V117, P11270, DOI 10.1021/ja00150a026; COLMAN JJ, 1994, 207 NAT M AM CHEM SO; COOPER GW, 1995, METEORITICS, V30, P500; CROVISIER J, 1991, ICARUS, V93, P246, DOI 10.1016/0019-1035(91)90210-K; DOUGLAS AE, 1964, J CHEM PHYS, V41, P357, DOI 10.1063/1.1725874; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; GOODRICH CA, 1992, METEORITICS, V27, P327, DOI 10.1111/j.1945-5100.1992.tb00215.x; HABIB A, 1994, J CHEM PHYS, V101, P2752, DOI 10.1063/1.467658; JACKSON WM, 1986, ASTROPHYS J, V304, P515, DOI 10.1086/164185; LAMBERT C, 1973, CAN J CHEM, V51, P2601, DOI 10.1139/v73-393; LELBUCH E, 1995, NATURE, V373, P592; MOSES JI, 1995, GEOPHYS RES LETT, V22, P1597, DOI 10.1029/95GL01200; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; REES CE, 1977, GEOCHIM COSMOCHIM AC, V41, P1697; THIEMENS MH, 1992, ACS SYM SER, V502, P138; THIEMENS MH, 1995, LUNAR PLANET SCI, V26, P1405; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WIELER R, 1991, GEOCHIM COSMOCHIM AC, V55, P1709, DOI 10.1016/0016-7037(91)90141-Q; ZAHNLE K, 1995, GEOPHYS RES LETT, V22, P1593, DOI 10.1029/95GL01190	25	44	44	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					774	776		10.1126/science.273.5276.774	http://dx.doi.org/10.1126/science.273.5276.774			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670412				2022-12-28	WOS:A1996VB42900035
J	Tokiwa, G; Dikic, I; Lev, S; Schlessinger, J				Tokiwa, G; Dikic, I; Lev, S; Schlessinger, J			Activation of Pyk2 by stress signals and coupling with JNK signaling pathway	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; RAS; CDC42HS; IDENTIFICATION; SUBFAMILY; DOMAIN; BINDS; CELLS; RAC1; ERK	The c-Jun amino-terminal kinase (JNK) is activated by various heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors, inflammatory cytokines, and stress signals. Yet, upstream mediators that link extracellular signals with the JNK signaling pathway are currently unknown. The tyrosine kinase Pyk2 was activated by tumor necrosis factor alpha, by ultraviolet irradiation, and by changes in osmolarity. Overexpression of Pyke led to activation of JNK, and a dominant-negative mutant of Pyk2 interfered with ultraviolet light- or osmotic shock-induced activation of JNK. Pyk2 represents a cell type-specific, stress-sensitive mediator of the JNK signaling pathway.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUGEN,REDWOOD CITY,CA 94063	New York University			Lev, Sima/AAP-7880-2020; Dikic, Ivan/O-4650-2015	Lev, Sima/0000-0002-2108-3330; Dikic, Ivan/0000-0001-8156-9511				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIKIC I, UNPUB; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOKIWA G, UNPUB	24	286	291	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					792	794		10.1126/science.273.5276.792	http://dx.doi.org/10.1126/science.273.5276.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670418				2022-12-28	WOS:A1996VB42900041
J	Faden, RR; Feinberg, KR; Glatstein, E; Lederer, SE; Macklin, R; Norris, LL; Oleinick, NL; Royal, HD; Russell, PK; Stevenson, MA; Thomas, DC; Tuckson, RV				Faden, RR; Feinberg, KR; Glatstein, E; Lederer, SE; Macklin, R; Norris, LL; Oleinick, NL; Royal, HD; Russell, PK; Stevenson, MA; Thomas, DC; Tuckson, RV			Research ethics and the medical profession - Report of the advisory committee on human radiation experiments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMED CONSENT; PHASE-I; TRIALS	The Advisory Committee on Human Radiation Experiments was convened by President Clinton in January 1994 in response to allegations of unethical practices in radiation experiments involving human subjects that were sponsored by the US government between 1944 and 1974. The committee's Final Report was released in October 1995. In addition to analyzing the history of the ethics of medical research involving human subjects, the committee reviewed current federal policies and procedures for protection of human subjects. In this article, the committee's findings are discussed as they relate to the patient-physician relationship, the issue of trust, and the specific role of the physician-investigator in all types of human experimentation. The committee found evidence of discussion of the conduct of human research at the highest levels of the government and within the medical profession, particularly with regard to risk, during the 1940s and 1950s. However, in both federal policy and professional practice, requirements for consent were more likely to apply to ''healthy volunteers'' than to patient-subjects (ie, those with disease or illness). Today, consensus exists that duties to obtain informed consent apply to all human subjects, whether healthy or sick, regardless of the risk or potential for medical benefit from participation in the research and regardless of the nature of sponsorship or funding (eg, federal, military, or private). Based on a finding of serious deficiencies in the current system of protections for human subjects, the committee offers a number of recommendations, including changes in institutional review boards, in the interpretation of ethics rules and policies; in oversight, accountability, and sanctions for ethics violation: and in compensation for research injuries. More than public policy changes, however, the committee recommends that the medical profession intensify its commitment to the ethics of research involving human subjects.	GEORGETOWN UNIV,KENNEDY INST ETH,WASHINGTON,DC 20057; KENNETH R FEINBERG & ASSOCIATES,WASHINGTON,DC; UNIV PENN,PHILADELPHIA,PA 19104; YALE UNIV,SCH LAW,NEW HAVEN,CT 06520; PENN STATE UNIV,COLL MED,HERSHEY,PA; ALBERT EINSTEIN COLL MED,BRONX,NY 10467; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV WASHINGTON,MED CTR,ST LOUIS,MO; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV SO CALIF,SCH MED,LOS ANGELES,CA; CHARLES R DREW UNIV MED & SCI,LOS ANGELES,CA 90059; GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC	Georgetown University; University of Pennsylvania; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University; Washington University (WUSTL); Johns Hopkins University; Harvard University; Harvard Medical School; University of Southern California; Charles R. Drew University of Medicine & Science; Georgetown University	Faden, RR (corresponding author), JOHNS HOPKINS UNIV,INST BIOETH,624 N BROADWAY,HAMPTON HOUSE 511,BALTIMORE,MD 21205, USA.							Advisory Committee on Human Radiation Experiments, 1996, HUM RAD EXP FIN REP; [Anonymous], 1986, HIST THEORY INFORM C; BEESON P, 1994, ACHRE RES PROJECT SE, P16; Bujorian G A, 1988, Oncol Nurs Forum, V15, P779; CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; DECOSTER G, 1990, ANN ONCOL, V2, P175; ESTEY E, 1986, CANCER TREAT REP, V70, P1105; KASS NE, 1991, FED REG         0618, V56, P28002; KATZ J, 1987, IRB, V9, P5; Katz J., 1972, EXPT HUMAN BEINGS; KING NMP, 1993, HASTINGS CTR REP, V25, P6; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; MALTBY JR, 1993, CAN J ANAESTH, V40, P897, DOI 10.1007/BF03009265; Natl. Comm. Prot. Hum. Subj. Biomed. Behav. Res, 1978, BELM REP ETH PRINC G; *NIH, 1953, HHS090794A NIH ACHRE; *NIH, 1954, HHS090794A NIH ACHRE; OCKENE IS, 1991, CLIN RES, V39, P13; Pellegrino E., 1988, PATIENTS GOOD RESTOR; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; RIECKEN HW, 1982, JAMA-J AM MED ASSOC, V248, P344, DOI 10.1001/jama.248.3.344; SAGAN L, 1994, ACHRE RES PROJECT SE, P13; TANAKANOW RM, 1992, AM J HOSP PHARM, V49, P633; VONHOFF DD, 1991, INVEST NEW DRUG, V9, P115, DOI 10.1007/BF00194562	24	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					403	409						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683820				2022-12-28	WOS:A1996UZ77600023
J	Nice, DS; Garland, CF; Hilton, SM; Baggett, JC; Mitchell, RE				Nice, DS; Garland, CF; Hilton, SM; Baggett, JC; Mitchell, RE			Long-term health outcomes and medical effects of torture among US navy prisoners of war in Vietnam	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REQUIRING PROLONGED OBSERVATION; FOLLOW-UP; FORMER PRISONERS; PSYCHIATRIC-ILLNESS; CAMPYLOBACTER-PYLORI; ERA PRISONER; MORBIDITY; PREVALENCE; MORTALITY; JAPANESE	Objective.-To characterize incidence of illnesses and injuries from 1979 to 1993 in former naval aviator prisoners of war (POWs) from the Vietnam War and a comparison group of naval aviators from the same war. Design.-Cohort analytic study. Setting.-A US Navy primary care clinic. Participants.-Volunteer sample consisting of 70 former naval aviator POWs (white men, aged 47 to 69 years in 1993) and a comparison group of 55 naval aviators who served in Vietnam but were not POWs, matched on race, age, marital status, education, rank, year of entry into the navy, and pilot status, Subjects participated in an annual health screening program. This study reports data sampled on a biennial basis from subjects screened both in 1979 and 1993. Main Outcome Measure.-Medically diagnosed incidence of illness and injury based on a standard protocol. Results.-POWs had higher incidence rates than the comparison group did of disorders of the peripheral nervous system (relative risk [RR], 8.4; 95% confidence interval [CI], 2.7-25.9: P<.001). joints (RR, 1.5, 95% CI, 1.2-2.0; P<.006), and back (RR, 1.8; 95% CI, 1.0-3.0; P<.037). These findings also were statistically significant according to Kaplan-Meier survival analyses that included 131 (95%) of 138 POWs and 115 (83%) of the 138 members of the comparison group. Survival analyses revealed that, in addition to these disorders, POWs had higher hazard rates of peptic ulcer (P<.01). Conclusions.-During captivity, ropes, ratchet handcuffs, leg irons, or stocks were used to put tightly constrictive pressure around the extremities of POWs as a means of torture, resulting in painful ischemia and subsequent neuropathies. Being a former POW was associated with increased cumulative incidence rates of chronic disorders of the peripheral nervous system. joints, and back and an increased hazard rate of peptic ulcer.	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,SAN DIEGO,CA; USN,AEROSP & OPERAT MED INST,PENSACOLA,FL	University of California System; University of California San Diego; United States Department of Defense; United States Navy	Nice, DS (corresponding author), USN,HLTH RES CTR,POB 85122,SAN DIEGO,CA 92186, USA.		Hilton, Susan/A-3324-2009					American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 1968, DIAGN STAT MAN MENT; ANDERSEN RS, 1975, PSYCHIATRY, V38, P65, DOI 10.1080/00332747.1975.11023835; BEEBE GW, 1975, AM J EPIDEMIOL, V101, P400, DOI 10.1093/oxfordjournals.aje.a112108; BERG SW, 1977, MIL MED, V141, P514; BERG WS, 1977, MIL MED, V141, P757; COHEN BM, 1954, VET ADM MED MONOGRAP; Dahlstrom W. G., 1972, MMPI HDB, VI; DEATON JE, 1977, J APPL SOC PSYCHOL, V7, P239, DOI 10.1111/j.1559-1816.1977.tb00749.x; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; EBERLY RE, 1991, HOSP COMMUNITY PSYCH, V42, P807; Fisher RA, 1934, STAT METHODS RES WOR, V5; GILL GV, 1981, PRACTITIONER, V225, P531; GILL GV, 1982, J NEUROL NEUROSUR PS, V45, P861, DOI 10.1136/jnnp.45.10.861; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; GOODWIN CS, 1990, MED J AUSTRALIA, V153, P66, DOI 10.5694/j.1326-5377.1990.tb136793.x; GOULSTON KJ, 1985, MED J AUSTRALIA, V143, P6, DOI 10.5694/j.1326-5377.1985.tb122757.x; HALL RCW, 1976, AM J PSYCHIAT, V133, P786; Hunter E. J., 1978, STRESS DISORDERS VIE, P188; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; KEEHN RJ, 1980, AM J EPIDEMIOL, V111, P194, DOI 10.1093/oxfordjournals.aje.a112887; KLUZNIK JC, 1986, AM J PSYCHIAT, V143, P1443; MILLS RM, 1995, AM J CARDIOL, V75, P98, DOI 10.1016/S0002-9149(99)80542-6; NEFZGER MD, 1970, AM J EPIDEMIOL, V91, P123, DOI 10.1093/oxfordjournals.aje.a121120; NICE DS, 1981, J MARRIAGE FAM, V43, P432; PAGE WF, 1991, J NERV MENT DIS, V179, P670, DOI 10.1097/00005053-199111000-00004; Page WF, 1992, HLTH FORMER PRISONER; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PINALS RS, 1989, ARTHRITIS ALLIED CON; RICHLIN M, 1980, US NAVY MED, V71, P18; ROWAN SA, 1973, THEY WOULDNT LET US; Siegel S, 1988, NONPARAMETRIC STAT B, P103; SKELTON W, 1995, FED PRACTITIONER, V12, P42; SPAUDLING RC, 1978, 7822 NAV HLTH RES CT; SUTKER PB, 1990, PSYCHOL REP, V66, P912, DOI 10.2466/PR0.66.3.912-914; TENNANT C, 1986, PSYCHOL MED, V16, P833, DOI 10.1017/S0033291700011843; TENNANT C, 1988, AUST NZ J PSYCHIAT, V24, P29; URSANO RJ, 1981, AM J PSYCHIAT, V138, P315; URSANO RJ, 1990, MIL MED, V155, P176, DOI 10.1093/milmed/155.4.176; URSANO RJ, 1986, J NERV MENT DIS, V174, P707, DOI 10.1097/00005053-198612000-00001; URSANO RJ, 1981, AM J PSYCHIAT, V138, P310; *US DEP DEF, 1972, REPATRIATED PRISONER, P179; US PHS, 1988, INT CLASS DIS 9 REV; VENN AJ, 1991, MED J AUSTRALIA, V155, P705, DOI 10.5694/j.1326-5377.1991.tb93966.x; WHEATLEY RD, 1982, AVIAT SPACE ENVIR MD, V53, P251; ZEISS RA, 1989, J CLIN PSYCHOL, V45, P80, DOI 10.1002/1097-4679(198901)45:1<80::AID-JCLP2270450112>3.0.CO;2-V	49	57	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					375	381		10.1001/jama.276.5.375	http://dx.doi.org/10.1001/jama.276.5.375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ776	8683815				2022-12-28	WOS:A1996UZ77600018
J	Wang, FS; Wolenski, JS; Cheney, RE; Mooseker, MS; Jay, DG				Wang, FS; Wolenski, JS; Cheney, RE; Mooseker, MS; Jay, DG			Function of myosin-V in filopodial extension of neuronal growth cones	SCIENCE			English	Article							ASSISTED LASER INACTIVATION; GRASSHOPPER PIONEER NEURONS; UNCONVENTIONAL MYOSIN; NERVE GROWTH; PROTEIN FUNCTION; MOTOR-ACTIVITY; FASCICLIN-I; MOTILITY; CELLS; IDENTIFICATION	The molecular mechanisms underlying directed motility of growth cones have not been determined, The role of myosin-V, an unconventional myosin, in growth cone dynamics was examined by chromophore-assisted laser inactivation (CALI), CALI of purified chick brain myosin-V absorbed onto nitrocellulose-coated cover slips inhibited the ability of myosin-V to translocate actin filaments. CALI of myosin-V in growth cones of chick dorsal root ganglion neurons resulted in rapid filopodial retraction, The rate of filopodial extension was significantly decreased, whereas the rate of filopodial retraction was not affected, which suggests a specific role for myosin-V in filopodial extension.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Harvard University; Yale University				Cheney, Richard/0000-0001-6565-7888	NINDS NIH HHS [NS-34699, NS-29007] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029007, R01NS029007, R01NS034699] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P11767; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Bray D., 1991, CULTURING NERVE CELL, P119; BUETTNER HM, 1994, DEV BIOL, V163, P407, DOI 10.1006/dbio.1994.1158; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DAVENPORT RW, 1993, NATURE, V361, P721, DOI 10.1038/361721a0; DIAMOND P, 1993, NEURON, V11, P409, DOI 10.1016/0896-6273(93)90146-I; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; LIAO JC, 1995, PHOTOCHEM PHOTOBIOL, V62, P923; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LINDEN KG, 1992, BIOPHYS J, V61, P956, DOI 10.1016/S0006-3495(92)81902-1; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVAK KD, 1992, MOL BIOL CELL, V3, pA3; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; SCHMUCKER D, 1994, P NATL ACAD SCI USA, V91, P2664, DOI 10.1073/pnas.91.7.2664; SCHROEDER R, IN PRESS DEV GENES F; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SPRINGER ML, 1994, DEVELOPMENT, V120, P2651; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; SYDOR AM, IN PRESS J CELL BIOL; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WOLENSKI JS, 1995, J CELL SCI, V108, P1489; WOLENSKI JS, 1993, J EXP ZOOL, V267, P33, DOI 10.1002/jez.1402670106; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	40	164	165	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					660	663		10.1126/science.273.5275.660	http://dx.doi.org/10.1126/science.273.5275.660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662560				2022-12-28	WOS:A1996VA24900052
J	Koppe, JG				Koppe, JG			Prevention of brain haemorrhage and ischaemic injury in premature babies	LANCET			English	Editorial Material							RANDOMIZED TRIAL; INFANTS				Koppe, JG (corresponding author), UNIV AMSTERDAM, ACAD ZIEKENHUIS, DEPT NEONATOL, KRUISLAAN 403, NL-1105 AZ AMSTERDAM, NETHERLANDS.							DEVRIES LS, 1985, LANCET, V2, P137; EKEN P, 1996, THESIS U UTRECHT; GILL AB, 1993, ARCH DIS CHILD-FETAL, V68, P17, DOI 10.1136/adc.68.1_Spec_No.17; GILSTRAP LC, 1995, AM J OBSTET GYNECOL, V173, P246; KINMOND S, 1993, BMJ-BRIT MED J, V306, P172, DOI 10.1136/bmj.306.6871.172; MENT LR, 1994, PEDIATRICS, V93, P543; Oh W, 1996, PEDIATR RES, V39, P1392	7	1	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 27	1996	348	9022					208	209		10.1016/S0140-6736(05)65539-0	http://dx.doi.org/10.1016/S0140-6736(05)65539-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684193				2022-12-28	WOS:A1996UZ28600003
J	Rencken, ML; Chesnut, CH; Drinkwater, BL				Rencken, ML; Chesnut, CH; Drinkwater, BL			Bone density at multiple skeletal sites in amenorrheic athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINERAL-CONTENT; WOMEN	Objective.-To determine if there is a generalized loss of bone mass at multiple skeletal sites in amenorrheic athletes compared with a group of eumenorrheic athletes. Design.-A case-control study examining the differences in bone mineral density (BMD) between amenorrheic and eumenorrheic athletes. Setting.-Seattle, Wash, and surrounding communities. Participants.-Forty-nine athletes, aged 17 to 39 years, were selected from those responding to advertisements in local sporting-goods stores and track-and-field newsletter. Athletes were defined as amenorrheic if they had had fewer than 2 menstrual cycles in the last 12 months or none in the past 6 months, or eumenorrheic if they had had 10 to 13 cycles in the previous year. Only women who met these criteria, confirmed by tests for estradiol and progesterone levels, were enrolled in the study. Main Outcome Measures.-Bone mineral density measured by dual-energy x-ray absorptiometry. Results.-Amenorrheic athletes had significantly lower BMD (P<.01) at the lumbar spine, femoral neck, trochanter, Ward triangle, intertrochanteric region, femoral shaft, and tibia. No difference was noted at the fibula. Body weight combined with months of amenorrhea and age of menarche predicted the BMD of the lumbar spine far amenorrheic athletes. Duration of amenorrhea and body weight of amenorrheic athletes predicted BMD at the femoral neck, trochanter, intertrochanteric region, and tibia. Weight alone predicted BMD at the femoral shaft and tibia. Age plus weight predicted lumbar BMD of eumenorrheic women. Conclusion.-Extended periods of amenorrhea may result in low bone density at multiple skeletal sites including those subjected to impact loading during exercise.	UNIV WASHINGTON,MED CTR,DEPT RADIOL,DIV NUCL MED,SEATTLE,WA 98195; PACIFIC MED CTR,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle								BENNELL KL, 1995, CLIN J SPORT MED, V5, P229, DOI 10.1097/00042752-199510000-00004; CANN CE, 1984, JAMA-J AM MED ASSOC, V251, P626, DOI 10.1001/jama.251.5.626; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; DRINKWATER BL, 1990, JAMA-J AM MED ASSOC, V263, P545, DOI 10.1001/jama.263.4.545; FISHER EC, 1986, J CLIN ENDOCR METAB, V62, P1232, DOI 10.1210/jcem-62-6-1232; GULEKLI B, 1994, CLIN ENDOCRINOL, V41, P275, DOI 10.1111/j.1365-2265.1994.tb02545.x; HAENGGI W, 1994, OSTEOPOROSIS INT, V4, P99, DOI 10.1007/BF01623232; JOHNSTON CC, 1990, PRIMER METABOLIC BON, P93; JOHNSTON CC, 1991, AM J MED, V91, pB5; JONNAVITHULA S, 1993, OBSTET GYNECOL, V81, P669; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KEEN AD, 1995, J BONE MINER RES, V10, pS243; LINDBERG JS, 1984, ANN INTERN MED, V101, P647, DOI 10.7326/0003-4819-101-5-647; LLOYD T, 1986, MED SCI SPORT EXER, V18, P374; MARCUS R, 1985, ANN INTERN MED, V102, P158, DOI 10.7326/0003-4819-102-2-158; MYBURGH KH, 1990, ANN INTERN MED, V113, P754, DOI 10.7326/0003-4819-113-10-754; MYBURGH KH, 1993, MED SCI SPORT EXER, V25, P1197; NICHOLS DL, 1994, MED SCI SPORT EXER, V26, P1220; OKANO H, 1995, J ENDOCRINOL, V42, P271; ROBINSON TL, 1995, J BONE MINER RES, V10, P26; WILSON JH, 1994, BRIT J RHEUMATOL, V33, P480	21	116	117	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					238	240		10.1001/jama.276.3.238	http://dx.doi.org/10.1001/jama.276.3.238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667570				2022-12-28	WOS:A1996UW46900037
J	Masur, H; Whitcup, SM; Cartwright, C; Polis, M; Nussenblatt, R				Masur, H; Whitcup, SM; Cartwright, C; Polis, M; Nussenblatt, R			Advances in the management of AIDS-related cytomegalovirus retinitis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							IMMUNE-DEFICIENCY-SYNDROME; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POLYMERASE CHAIN-REACTION; PERIPHERAL-BLOOD LEUKOCYTES; OCULAR MANIFESTATIONS; RETINAL DETACHMENTS; VIRUS INFECTION; GANCICLOVIR; FOSCARNET; DISEASE		NEI, BETHESDA, MD 20892 USA; NIAID, BETHESDA, MD 20892 USA; JOHNSON & JOHNSON CLIN DIAGNOST, NUCLE ACIDS DIV, ROCHESTER, NY 14650 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johnson & Johnson	Masur, H (corresponding author), NIH, DEPT CRIT CARE MED, BLDG 10, ROOM 7D43, BETHESDA, MD 20892 USA.			Polis, Michael/0000-0002-9151-2268				ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; BOIVIN G, 1996, 3 C RETR OPP INF WAS, P11; BROSGART CL, 1995, 35 INT C ANT AG CHEM; *CHIR GANDD IMPL T, 1995, 35 INT C ANT AG CHEM, P1215; COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348; COLLIER AC, 1987, AM J MED, V82, P593, DOI 10.1016/0002-9343(87)90105-7; DIAZLLOPIS M, 1994, BRIT J OPHTHALMOL, V78, P120, DOI 10.1136/bjo.78.2.120; DIETERICH DT, 1993, J INFECT DIS, V167, P1184, DOI 10.1093/infdis/167.5.1184; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; DREW WL, 1995, INT C ANT AG CHEM WA, pH135; DROUET E, 1993, AIDS, V7, P665, DOI 10.1097/00002030-199305000-00009; ENGSTROM RE, 1995, AM J OPHTHALMOL, V120, P376, DOI 10.1016/S0002-9394(14)72168-3; ENGSTROM RE, 1994, OPHTHALMOLOGY, V101, P1488; ERICE A, 1992, J CLIN MICROBIOL, V30, P2822, DOI 10.1128/JCM.30.11.2822-2825.1992; FRANCISCI D, 1995, EUR J CLIN MICROBIOL, V14, P498, DOI 10.1007/BF02113427; FRASCINO RJ, 1995, 35 INT C ANT AG CHEM, pA27; FREEMAN WR, 1993, AM J OPHTHALMOL, V116, P713, DOI 10.1016/S0002-9394(14)73471-3; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GERNA G, 1991, MOL CELL PROBE, V5, P365, DOI 10.1016/S0890-8508(06)80008-3; GERNA G, 1994, ANTIMICROB AGENTS CH, V38, P38, DOI 10.1128/AAC.38.1.38; GRIFFITHS PD, 1996, 3 C RETR OPP INF WAS, P10; HANSEN KK, 1994, J INFECT DIS, V170, P1271, DOI 10.1093/infdis/170.5.1271; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; HOLLAND GN, 1988, AM J OPHTHALMOL, V106, P653, DOI 10.1016/0002-9394(88)90697-6; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JABS DA, 1991, ARCH OPHTHALMOL-CHIC, V109, P794, DOI 10.1001/archopht.1991.01080060058024; JABS DA, 1989, OPHTHALMOLOGY, V96, P1092; JABS DA, 1994, OPHTHALMOLOGY, V101, P1250; KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2; KOVACS JA, 1995, 35 INT C ANT AG CHEM; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; KUPPERMANN BD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1359, DOI 10.1001/archopht.1993.01090100067029; LALEZARI J, 1995, 35 INT C ANT AG CHEM, pL8; LALEZARI JP, 1995, J INFECT DIS, V171, P788, DOI 10.1093/infdis/171.4.788; Lewis RA, 1996, ARCH OPHTHALMOL-CHIC, V114, P23; LEWIS RA, 1995, ARCH INTERN MED, V155, P65, DOI 10.1001/archinte.155.1.65; MACGREGOR RR, 1995, J ACQ IMMUN DEF SYND, V10, P324; MACLEAN H, 1993, INT J STD AIDS, V4, P322, DOI 10.1177/095646249300400603; MARGOLIS TP, 1991, AM J OPHTHALMOL, V112, P119, DOI 10.1016/S0002-9394(14)76690-5; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; MCGRATH MS, 1991, J ACQ IMMUN DEF SYND, V4, P408; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; NEWSOME DA, 1984, AM J OPHTHALMOL, V98, P590, DOI 10.1016/0002-9394(84)90245-9; ORELLANA J, 1991, OPHTHALMOLOGY, V98, P939; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1995, INVEST OPHTH VIS SCI, V36, pS181; PALESTINE AG, 1994, 10 INT C AIDS YOK, pB332; PERSING DH, 1993, DIAGN MICR INFEC DIS, V16, P159, DOI 10.1016/0732-8893(93)90015-Y; PETERS M, 1994, SCAND J INFECT DIS, V26, P49, DOI 10.3109/00365549409008590; POLIS MA, 1995, ANTIMICROB AGENTS CH, V39, P882, DOI 10.1128/AAC.39.4.882; POLIS MA, 1993, 31 ANN M INF DIS SOC, P187; RASMUSSEN L, 1995, J INFECT DIS, V171, P177, DOI 10.1093/infdis/171.1.177; REVELLO MG, 1992, J GEN VIROL, V73, P437, DOI 10.1099/0022-1317-73-2-437; SALMON D, 1990, J MED VIROL, V32, P160, DOI 10.1002/jmv.1890320306; SELIK RM, 1995, ANN INTERN MED, V123, P933, DOI 10.7326/0003-4819-123-12-199512150-00006; Shepp DH, 1996, J ACQ IMMUN DEF SYND, V11, P460, DOI 10.1097/00042560-199604150-00006; SIDIKARO Y, 1991, OPHTHALMOLOGY, V98, P129; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; SPECTOR SA, 1995, J INFECT DIS, V171, P1431, DOI 10.1093/infdis/171.6.1431; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; STEWART JA, 1995, CLIN INFECT DIS, V21, pS114, DOI 10.1093/clinids/21.Supplement_1.S114; TOLPIN M, 1993, 9 INT C AIDS AFF 4 S; WOLITZ R, 1996, 3 C RETR OPP INF WAS; ZIPETO D, 1992, J CLIN MICROBIOL, V30, P527, DOI 10.1128/JCM.30.2.527-530.1992; ZURLO JJ, 1993, ANN INTERN MED, V118, P12, DOI 10.7326/0003-4819-118-1-199301010-00003; 1995, CLIN INFECT DIS   S1, V21, P532	69	54	55	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					126	136		10.7326/0003-4819-125-2-199607150-00009	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678367				2022-12-28	WOS:A1996UV92100011
J	Dawson, JK; Abernethy, VE; Graham, DR; Lynch, MP				Dawson, JK; Abernethy, VE; Graham, DR; Lynch, MP			A woman who took cod-liver oil and smoked	LANCET			English	Article							LIPOID PNEUMONIA		KNOWSLEY HOSP,DEPT RHEUMATOL,ST HELENS,MERSEYSIDE,ENGLAND; WHISTON HOSP,DEPT RESP MED,PRESCOT,MERSEYSIDE,ENGLAND	Whiston Hospital	Dawson, JK (corresponding author), ST HELENS HOSP,DEPT RHEUMATOL,MARSHALLS CROSS RD,ST HELENS,MERSEYSIDE,ENGLAND.							BRECHOT JM, 1991, THORAX, V46, P738, DOI 10.1136/thx.46.10.738; HARRIS WS, 1989, J LIPID RES, V30, P785; KRAMER JM, 1987, ANN INTERN MED, V106, P497; LEE KS, 1995, J COMPUT ASSIST TOMO, V19, P48, DOI 10.1097/00004728-199501000-00009; VENUTA F, 1990, ANN THORAC SURG, V49, P1026, DOI 10.1016/0003-4975(90)90903-J	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1804	1804		10.1016/S0140-6736(96)91620-7	http://dx.doi.org/10.1016/S0140-6736(96)91620-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667926				2022-12-28	WOS:A1996UU46900013
J	Billeter, M; Guntert, P; Luginbuhl, P; Wuthrich, K				Billeter, M; Guntert, P; Luginbuhl, P; Wuthrich, K			Hydration and DNA recognition by homeodomains	CELL			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; ANTENNAPEDIA HOMEODOMAIN; MOLECULAR-DYNAMICS; AQUEOUS-SOLUTION; WATER-MOLECULES; AMINO-ACID; COMPLEX; PROTEIN; SPECIFICITY	A 2-nanosecond molecular dynamics (MD) simulation of an Antennapedia homeodomain-DNA complex in explicit solvent water at ambient temperature and pressure was performed to supplement experimental nuclear magnetic resonance (NMR) data on the structure and dynamics of this complex. In addition to direct protein-DNA contacts, the MD trajectory attributes an essential role for specific DNA recognition to hydration water molecules that mediate intermolecular contacts. The simulation provides a detailed description of the pathways of hydration water molecules exchanging in and out of the protein-DNA interface and indicates that the residence times of these ''interior'' waters are on the nanosecond time scale, near the lower end of the range determined by NMR.			Billeter, M (corresponding author), ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.		Billeter, Martin/A-8293-2010; Güntert, Peter/L-5577-2013	Güntert, Peter/0000-0002-2911-7574				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Billeter M, 1995, PROG NUCL MAG RES SP, V27, P635, DOI 10.1016/0079-6565(95)01015-7; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; BRUNNE RM, 1993, J MOL BIOL, V231, P1040, DOI 10.1006/jmbi.1993.1350; DENISOV VP, 1995, J MOL BIOL, V245, P682, DOI 10.1006/jmbi.1994.0055; DOTSCH V, 1995, J AM CHEM SOC, V117, P6064; Drenth J, 1994, PRINCIPLES PROTEIN X; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FREY M, 1994, ACTA CRYSTALLOGR D, V50, P663, DOI 10.1107/S0907444993013368; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEWIRTH DT, 1995, STRUCT BIOL, V2, P386; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; KARPLUS PA, 1994, CURR OPIN STRUC BIOL, V4, P770, DOI 10.1016/S0959-440X(94)90178-3; KORADI R, 1996, IN PRESS J MOL GRAPH, V27; OTTING G, 1991, J AM CHEM SOC, V113, P4363, DOI 10.1021/ja00011a068; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1990, EMBO J, V11, P382; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; QIAN YQ, 1993, J AM CHEM SOC, V115, P1189, DOI 10.1021/ja00056a077; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SCHIFFER CA, 1995, BIOCHEMISTRY-US, V34, P15057, DOI 10.1021/bi00046a011; THANKI N, 1988, J MOL BIOL, V202, P637, DOI 10.1016/0022-2836(88)90292-6; TREISMAN J, 1989, CELL, V59, P553; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wiithrich K., 1995, NMR STRUCTURAL BIOL; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WUTHRICH K, 1993, COLD SPRING HARB SYM, V58, P149, DOI 10.1101/SQB.1993.058.01.019; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG XJ, 1994, PROTEIN SCI, V3, P1031, DOI 10.1002/pro.5560030705	35	106	107	3	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1057	1065		10.1016/S0092-8674(00)81306-9	http://dx.doi.org/10.1016/S0092-8674(00)81306-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674112	Bronze			2022-12-28	WOS:A1996UV48400012
J	Wuarin, J; Nurse, P				Wuarin, J; Nurse, P			Regulating S phase: CDKs, licensing and proteolysis	CELL			English	Review											Wuarin, J (corresponding author), IMPERIAL CANC RES FUND,CELL CYCLE LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V349, P388; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1	19	95	96	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					785	787		10.1016/S0092-8674(00)81261-1	http://dx.doi.org/10.1016/S0092-8674(00)81261-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681373	Bronze			2022-12-28	WOS:A1996UR60400002
J	Seim, A; Sivertsen, B; Eriksen, BC; Hunskaar, S				Seim, A; Sivertsen, B; Eriksen, BC; Hunskaar, S			Treatment of urinary incontinence in women in general practice: Observational study	BRITISH MEDICAL JOURNAL			English	Article							URGE INCONTINENCE; PELVIC FLOOR; PREVALENCE	Objective-To examine what is attainable when treating urinary incontinence in women in general practice. Design-Observational study with 12 months' follow up. Interview and clinical examination before, during, and after treatment of women seeking help for urinary incontinence in general practice. Setting-General practice in the rural district of Rissa, Norway. Subjects-105 women aged 20 or more with urinary incontinence. Interventions-Treatment with pelvic floor exercises, electrostimulation, oestrogen, anticholinergic drugs, bladder training, and protective pads. Main outcome measures-Subjective and objective measures of urinary incontinence; number of patients referred to a specialist. Results-After 12 months' follow up 70% (69/99) of the women were cured or much better; the mean score on a 100 mm visual analogue scale decreased from 37 to 20 mm; and the proportion of women who were greatly bothered by their incontinence decreased by 62%. 20% (20/98) of women became continent, and the percentage of women with severe incontinence decreased from 64% (63/99) to 28% (27/98). Mean leakage per 24 hours measured by a pad test decreased from 28 g at the start of treatment to 13 g after 12 months. The number of light weight pads or sanitary towels decreased from 1.6 to 0.6 a day. In all, 17/105 (16%) patients were referred to a specialist. Conclusions-Urinary incontinence in women can be effectively managed ire general practice with fairly simple treatment. Most women will be satisfied with the results.	UNIV BERGEN,DEPT PUBL HLTH & PRIMARY HLTH CARE,DIV GEN PRACTICE,N-5009 BERGEN,NORWAY; UNIV TRONDHEIM HOSP,DEPT OBSTET & GYNAECOL,TRONDHEIM,NORWAY; MED OFF HLTH,RISSA,NORWAY	University of Bergen; Norwegian University of Science & Technology (NTNU)								Abrams P, 1988, Scand J Urol Nephrol Suppl, V114, P5; BO K, 1990, NEUROUROL URODYNAM, V9, P489, DOI 10.1002/nau.1930090505; BROCKLEHURST JC, 1993, BRIT MED J, V306, P832, DOI 10.1136/bmj.306.6881.832; BURGIO KL, 1991, J UROLOGY, V146, P1255, DOI 10.1016/S0022-5347(17)38063-1; ERIKSEN BC, 1989, NEUROUROL URODYNAM, V8, P219, DOI 10.1002/nau.1930080305; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; Flynn L, 1994, J Gerontol Nurs, V20, P23; JOLLEYS JV, 1989, J ROY COLL GEN PRACT, V39, P277; Klovning Atle, 1994, Tidsskrift for den Norske Laegeforening, V114, P3068; LAGROJANSSEN ALM, 1992, FAM PRACT, V9, P284, DOI 10.1093/fampra/9.3.284; LOSE G, 1990, ANN MED, V22, P449, DOI 10.3109/07853899009147285; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; REKERS H, 1992, EUR J OBSTET GYN R B, V43, P229, DOI 10.1016/0028-2243(92)90178-2; SANDVIK H, 1990, Scandinavian Journal of Primary Health Care, V8, P3, DOI 10.3109/02813439008994922; Sandvik H, 1993, Scand J Caring Sci, V7, P53; SANDVIK H, 1993, J EPIDEMIOL COMMUN H, V47, P497, DOI 10.1136/jech.47.6.497; SANDVIK H, 1995, J AGING HEALTH, V7, P417, DOI 10.1177/089826439500700305; SEIM A, 1995, FAM PRACT, V12, P18, DOI 10.1093/fampra/12.1.18; U.S. Department of Health and Human Services, 1992, AHCPR PUBL, V92-0047	20	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1459	1462		10.1136/bmj.312.7044.1459	http://dx.doi.org/10.1136/bmj.312.7044.1459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664627	Green Published			2022-12-28	WOS:A1996UQ29600030
J	Ginsburg, J				Ginsburg, J			Tackling environmental endocrine disrupters	LANCET			English	Editorial Material											Ginsburg, J (corresponding author), UNIV LONDON,ROYAL FREE HOSP & SCH MED,DEPT MED,LONDON,ENGLAND.							Colborn T., 1996, OUR STOLEN FUTURE; *DAN MIN EN ENV, 1995, 290 DAN MIN EN ENV; *I ENV HLTH, 1995, IEH ASS ENV OESTR CO; KAVLOCK RJ, IN PRESS ENV HLTH PE; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; *UMW BUND, 1955, END ACT CHEM ENV; 1995, LANCET, V345, P933	7	12	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1501	1502		10.1016/S0140-6736(96)90667-4	http://dx.doi.org/10.1016/S0140-6736(96)90667-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684098				2022-12-28	WOS:A1996UN47300006
J	Johansson, A; Hoa, HT; Lap, NT; Diwan, V; Eriksson, B				Johansson, A; Hoa, HT; Lap, NT; Diwan, V; Eriksson, B			Population policies and reproductive patterns in Vietnam	LANCET			English	Article								Background Vietnam's population policy since the 1980s had stipulated a limit on family size to two children, born 3-5 years apart, and recommends a minimum age of 19 for the mother of a first child, We analysed trends in the timing of marriages and births, and in fertility and abortion rates, among women born between 1945 and 1970, to assess the impact of these policies on reproductive patterns. Methods Reproductive histories were recorded in a random sample of 1432 married women aged 15-49 in a rural province in northern Vietnam. Mean age at marriage and at birth of the first child, birth intervals, fertility, and abortion rates were examined in relation to the woman's year of birth. Findings Later-born women married and had their first child at a younger age than women born earlier. Birth intervals had increased among later-born women but 25% still had only a 1-year interval between first and second child, Fertility had gradually decreased while abortion ratios had increased rapidly. Childbearing patterns had become ''earlier, longer, and fewer'' rather than ''later, longer, and fewer'' as stipulated by the policies. The results also show that women with more schooling married and had their first child later, Women involved in farming had shorter spacing between children. Interpretation There are signs that Vietnam's population policy has focused too strongly on contraception and abortion while ignoring the connection between fertility and women's opportunities for education and employment. In these respects, rural women are at particular risk.	HANOI SCH MED,DEPT HYG ENVIRONM & EPIDEMIOL,HANOI,VIETNAM; CTR RES GENDER FAMILY & ENVIRONM DEV,HANOI,VIETNAM; NORD SCH PUBL HLTH,GOTHENBURG,SWEDEN	Hanoi Medical University	Johansson, A (corresponding author), KAROLINSKA INST,IHCAR,DEPT INT HLTH & SOCIAL MED,S-17177 STOCKHOLM,SWEDEN.							Banister J., 1993, VIETNAM POPULATION D; Blackburn J. L., 1993, SOCIAL RES DEV COUNT, P193; BONGAARTS J, 1985, POPUL DEV REV, V4, P586; Cochrane S.H., 1980, POPULATION, V35, P985; COX DR, 1989, ANAL SURVIVAL DATA; Dixon-Muller R., 1993, POPULATION POLICY WO; FONG SM, 1994, GENDER POVERTY VIETN; *GEN STAT OFF, 1992, VIETN POP CENS 1989; GOODKIND A, 1994, STUD FAM PLAN, V26, P342; HENSHAW SK, 1990, INDUCED ABORTIONS S; Hieu Do Trong, 1993, ASIA PACIFIC POP J, V8, P3; HOA HT, IN PRESS BMJ; JOHANSSON A, IN PRESS INT FAM PLA; *KIEN XUONG STAT O, 1995, THAI BINH; LOC N, 1993, J BIOSOC SCI, V25, P303; MARTIN TC, 1995, STUD FAMILY PLANN, V26, P187, DOI 10.2307/2137845; *NAT COMM POP FAM, 1990, VIETN DEM HLTH SURV; NHAN VQ, 1994, VIETNAM SOC SCI REV, V39, P3; RAJARETNAM T, 1993, J FAM WELFARE, V34, P3; RELE JR, 1993, REVOLUTION ASIAN FER; SAN PB, 1992, DEMOGRAPHIC TRANSITI; *STAT PLANN COMM G, 1995, VIETN LIV STAND SURV; *UN, 1992, POP STUD, V120; *UNICEF, 1994, COND WOM CHILDR VIET; VALDELIN J, 1993, 1992 93 SIDA; 1989, POPUL DEV REV, V15, P169	26	7	7	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1529	1532		10.1016/S0140-6736(96)90676-5	http://dx.doi.org/10.1016/S0140-6736(96)90676-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN473	8684107	Bronze			2022-12-28	WOS:A1996UN47300015
J	Nestler, JE; Jakubowicz, DJ				Nestler, JE; Jakubowicz, DJ			Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE-BINDING GLOBULIN; GROWTH FACTOR-I; GONADOTROPIN-RELEASING-HORMONE; FOLLICLE-STIMULATING-HORMONE; HUMAN THECAL CELLS; LUTEINIZING-HORMONE; OBESE WOMEN; ANDROGEN PRODUCTION; ADOLESCENT GIRLS; RESISTANCE	Background Insulin resistance and increased ovarian cytochrome P450c17 alpha activity are both features of the polycystic ovary syndrome. P450c17 alpha, which is involved in androgen biosynthesis, has both 17 alpha-hydroxylase and 17,20-lyase activities. Increased activity of this enzyme results in exaggerated conversion of progesterone to 17 alpha-hydroxyprogesterone in response to stimulation by gonadotropin. We hypothesized that hyperinsulinemia stimulates ovarian P450c17 alpha activity. Methods We measured serum steroid concentrations during fasting and the response of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotropin-releasing hormone agonist, and performed oral glucose-tolerance tests before and after oral administration of either metformin (500 mg three times daily) or placebo for four to eight weeks in 24 obese women with the polycystic ovary syndrome. Results In the 11 women given metformin, the mean (+/-SE) area under the serum insulin curve after oral glucose administration decreased from 9303+/-1603 to 4982+/-911 mu U per milliliter per minute (56+/-10 to 30+/-6 nmol per liter per minute) (P = 0.004). This decrease was associated with a reduction in the basal serum 17 alpha-hydroxyprogesterone concentration from 135+/-21 to 66+/-7 ng per deciliter (4.1+/-0.6 to 2.0+/-0.2 nmol per liter) (P = 0.01) and a reduction in the leuprolide-stimulated peak serum 17 alpha-hydroxyprogesterone concentration from 455+/-54 to 281+/-52 ng per deciliter (13.7+/-1.6 to 8.5+/-1.6 nmol per liter) (P = 0.01), The serum 17 alpha-hydroxyprogesterone va rues increased slightly in the placebo group. In the metformin group, the basal serum luteinizing hormone concentration decreased from 8.5+/-2.2 to 2.8+/-0.5 mlU per milliliter (P = 0.01), the serum free testosterone concentration decreased from 0.34+/-0.07 to 0.19+/-0.05 ng per deciliter (12+/-3 to 7+/-2 pmol per liter) (P = 0.009), and the serum sex hormone-binding globulin concentration increased from 0.8+/-0.2 to 2.3+/-0.6 mu g per deciliter (29+/-7 to 80+/-21 nmol per liter) (P < 0.001). None of these values changed significantly in the placebo group. Conclusions In obese women with the polycystic ovary syndrome, decreasing serum insulin concentrations with metformin reduces ovarian cytochrome P450c17 alpha activity and ameliorates hyperandrogenism. (C) 1996, Massachusetts Medical Society.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT OBSTET & GYNECOL, DIV ENDOCRINOL & METAB, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, DIV ENDOCRINOL & METAB, RICHMOND, VA 23298 USA; HOSP CLIN CARACAS, DEPT INTERNAL MED, CARACAS, VENEZUELA	Virginia Commonwealth University; Virginia Commonwealth University	Nestler, JE (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, POB 980111, RICHMOND, VA 23298 USA.				NCI NIH HHS [R01CA64500] Funding Source: Medline; NIA NIH HHS [R01AG11227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADASHI EY, 1981, ENDOCRINOLOGY, V108, P1441, DOI 10.1210/endo-108-4-1441; APTER D, 1995, J CLIN ENDOCR METAB, V80, P2966, DOI 10.1210/jc.80.10.2966; BARBIERI RL, 1986, J CLIN ENDOCR METAB, V62, P904, DOI 10.1210/jcem-62-5-904; BERGA SL, 1993, J CLIN ENDOCR METAB, V77, P895, DOI 10.1210/jc.77.4.895; BERGH C, 1993, FERTIL STERIL, V59, P323; BLANKSTEIN J, 1987, J CLIN ENDOCR METAB, V65, P1164, DOI 10.1210/jcem-65-6-1164; CARA JF, 1988, ENDOCRINOLOGY, V123, P733, DOI 10.1210/endo-123-2-733; CARMINA E, 1992, AM J OBSTET GYNECOL, V167, P1807, DOI 10.1016/0002-9378(92)91779-A; CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356, DOI 10.1210/jcem-57-2-356; CIARALDI TP, 1992, J CLIN ENDOCR METAB, V75, P577, DOI 10.1210/jc.75.2.577; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DUNAIF A, 1995, J CLIN INVEST, V96, P801, DOI 10.1172/JCI118126; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; DUNAIF A, 1990, J CLIN ENDOCR METAB, V70, P699, DOI 10.1210/jcem-70-3-699; DUNAIF A, 1986, J CLIN ENDOCR METAB, V63, P215; EHRMANN DA, 1992, NEW ENGL J MED, V327, P157, DOI 10.1056/NEJM199207163270304; EHRMANN DA, 1995, J CLIN INVEST, V96, P520, DOI 10.1172/JCI118064; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; FRANKS S, 1995, NEW ENGL J MED, V333, P1435; IBANEZ L, 1994, J CLIN ENDOCR METAB, V79, P1778, DOI 10.1210/jc.79.6.1778; KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x; KIDDY DS, 1989, CLIN ENDOCRINOL, V31, P757, DOI 10.1111/j.1365-2265.1989.tb01297.x; LUPPA P, 1995, J CLIN ENDOCR METAB, V80, P280, DOI 10.1210/jc.80.1.280; Moghetti P, 1996, J CLIN ENDOCR METAB, V81, P881, DOI 10.1210/jc.81.3.881; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NAHUM R, 1995, HUM REPROD, V10, P75, DOI 10.1093/humrep/10.1.75; NESTLER JE, 1989, J CLIN ENDOCR METAB, V68, P1027, DOI 10.1210/jcem-68-6-1027; NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83; NESTLER JE, 1994, J CLIN ENDOCR METAB, V78, P549, DOI 10.1210/jc.78.3.549; NESTLER JE, 1994, INT CONGR SER, V1046, P103; PLYMATE SR, 1988, J CLIN ENDOCR METAB, V67, P460, DOI 10.1210/jcem-67-3-460; ROSENFIELD RL, 1994, J CLIN ENDOCR METAB, V79, P1686, DOI 10.1210/jc.79.6.1686; SPINDER T, 1989, J CLIN ENDOCR METAB, V69, P151, DOI 10.1210/jcem-69-1-151; UNGER JW, 1991, PROG NEUROBIOL, V36, P343, DOI 10.1016/0301-0082(91)90015-S; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; WHITE D, 1995, CLIN ENDOCRINOL, V42, P475, DOI 10.1111/j.1365-2265.1995.tb02665.x; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; YEN SSC, 1993, ANN NY ACAD SCI, V687, P98	39	570	598	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					617	623		10.1056/NEJM199608293350902	http://dx.doi.org/10.1056/NEJM199608293350902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8687515				2022-12-28	WOS:A1996VD42500002
J	Orentlicher, D				Orentlicher, D			The legalization of physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DOCTORS; OREGON; KILL				Orentlicher, D (corresponding author), INDIANA UNIV, SCH LAW INDIANAPOLIS, CTR LAW & HLTH, 735 W NEW YORK ST, INDIANAPOLIS, IN 46202 USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1995, ETHICAL ISSUES SUICI, P206; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; generally, 1994, ISSUES LAW MED, V10, P91; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KASS LR, 1989, PUBLIC INTEREST, P25; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LESSENBERRY J, 1996, NY TIMES        0504, P10; LEWIN T, 1996, NY TIMES        0521, pA14; MCFADDEN RD, 1985, NY TIMES        0612, pA1; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RUBENFELD J, 1989, HARVARD LAW REV, V102, P737, DOI 10.2307/1341305; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, NY TIMES        1005, pD23	30	54	54	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					663	667		10.1056/NEJM199608293350912	http://dx.doi.org/10.1056/NEJM199608293350912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD425	8687525				2022-12-28	WOS:A1996VD42500012
J	Kobayashi, K; Manabe, T; Takahashi, T				Kobayashi, K; Manabe, T; Takahashi, T			Presynaptic long-term depression at the hippocampal mossy fiber-CA3 synapse	SCIENCE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA3 PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; VISUAL-CORTEX; AREA CA1; 2 FORMS; POTENTIATION; MECHANISMS; INDUCTION; EXPRESSION	Long-term potentiation (LTP) and long-term depression (LTD) of synaptic strength may underlie learning and memory in the brain. The induction of LTP occurs in postsynaptic cells in the hippocampal CA1 region but is presynaptic in CA3. LTD is also well characterized in CA1 but not in CA3. Low-frequency stimulation of mouse hippocampal slices caused homosynaptic LTD at the messy fiber-CA3 synapse, which may be induced presynaptically by activation of metabotropic glutamate receptors. Thus, the efficacy of messy fiber-CA3 synapses can be regulated bidirectionally, which may contribute to neuronal information processing.	UNIV TOKYO,FAC MED,INST BRAIN RES,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Kobayashi, Katsunori/V-5326-2018; Takahashi, Tomoyuki/G-5951-2015	Kobayashi, Katsunori/0000-0001-8537-8448; Takahashi, Tomoyuki/0000-0002-8771-7666				BATTISTIN T, 1994, EUR J NEUROSCI, V6, P1750, DOI 10.1111/j.1460-9568.1994.tb00567.x; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BRADLER JE, 1989, SYNAPSE, V4, P132, DOI 10.1002/syn.890040207; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARUTA H, 1994, NEUROREPORT, V5, P1829, DOI 10.1097/00001756-199409080-00036; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REGEHR WG, 1994, J NEUROSCI, V14, P523; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; SHIGEMOTO R, 1995, INT BRAIN RES ORG AB, V4; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, 1993, J NEUROSCI, V13, P1372; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; YAMAMOTO C, 1992, NEUROSCI LETT, V138, P111, DOI 10.1016/0304-3940(92)90484-O; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	33	130	136	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					648	650		10.1126/science.273.5275.648	http://dx.doi.org/10.1126/science.273.5275.648			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662556				2022-12-28	WOS:A1996VA24900048
J	EnriquezSarano, M; Klodas, E; Garratt, KN; Bailey, KR; Tajik, AJ; Holmes, DR				EnriquezSarano, M; Klodas, E; Garratt, KN; Bailey, KR; Tajik, AJ; Holmes, DR			Secular trends in coronary atherosclerosis - Analysis in patients with valvular regurgitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; HONOLULU HEART PROGRAM; ARTERY DISEASE; UNITED-STATES; RISK-FACTORS; VALVE REPLACEMENT; UNSTABLE ANGINA; ORIFICE AREA; FOLLOW-UP; AUTOPSY	Background Between 1980 and 1989, mortality due to coronary artery disease decreased considerably in the United States, suggesting a possible decrease in the prevalence of coronary atherosclerosis. We examined this possibility in patients with valvular regurgitation who, often in the absence of angina, underwent coronary angiography before valve-replacement surgery. Methods We studied 601 patients with isolated, nonischemic valvular regurgitation who were operated on between 1980 and 1989 and who had undergone preoperative coronary angiography. From the angiograms we determined the prevalence of clinically significant coronary artery disease and of multivessel disease, assessed the mean degree of stenosis, and analyzed the trends in the data over the years of the study. Results The prevalence of coronary artery disease (35 percent in 1980-1981, 37 percent in 1982-1983, 34 percent in 1984-1985, 37 percent in 1986-1987, and 35 percent in 1988-1989; P=0.97) did not change significantly during the study period. We found no significant change in the prevalence of multivessel disease (24 percent in 1980-1981 and 23 percent in 1988-1989, P=0.99) or in the mean (+/-SD) degree of stenosis (11+/-13 percent in 1980-1981 and 13+/-14 percent in 1988-1989, P=0.07). When these measures of coronary atherosclerosis were adjusted for age and sex, there were still no significant changes over time (P=0.39 for the prevalence of coronary artery disease, P=0.81 for that of multivessel disease, and P=0.57 for the mean degree of stenosis). The patients' mean total cholesterol level decreased from 219+/-48 mg per deciliter (5.66+/-1.24 mmol per liter) to 206+/-44 mg per deciliter (5.33+/-1.14 mmol per liter) between 1980 and 1989 (P=0.04). Conclusions From 1980 to 1989, no significant change was observed in angiographic measures of coronary atherosclerosis in patients with nonischemic valvular regurgitation, in contrast to the marked decrease in mortality due to coronary disease in the general population, These findings suggest that the well-documented reduction in mortality due to coronary disease may not be due to a reduction in the prevalence of coronary atherosclerosis. (C) 1996, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic	EnriquezSarano, M (corresponding author), MAYO CLIN & MAYO FDN,DIV CARDIOVASC DIS & INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ACAR J, 1985, Z KARDIOL S2, V75, P53; ALDERMAN EL, 1993, J AM COLL CARDIOL, V22, P1141, DOI 10.1016/0735-1097(93)90429-5; AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; BEAGLEHOLE R, 1990, EPIDEMIOL REV, V12, P1; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CUPPLES LA, 1992, CIRCULATION SI, V85, P1; CZER LSC, 1984, CIRCULATION, V70, P198; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DAVIS K, 1979, CIRCULATION, V59, P1105, DOI 10.1161/01.CIR.59.6.1105; DEROUEN TA, 1977, CIRCULATION, V55, P324, DOI 10.1161/01.CIR.55.2.324; DESTEFANO F, 1993, ARCH INTERN MED, V153, P2489, DOI 10.1001/archinte.153.21.2489; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; EDLAVITCH SA, 1991, CIRCULATION, V83, P492, DOI 10.1161/01.CIR.83.2.492; ELVEBACK L, 1984, CIRCULATION, V70, P345, DOI 10.1161/01.CIR.70.3.345; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V23, P443, DOI 10.1016/0735-1097(94)90432-4; FALK E, 1992, CIRCULATION, V86, P30; FEINLEIB M, 1979, ATHEROSCLEROSIS, V34, P145, DOI 10.1016/0021-9150(79)90136-9; FISHER LD, 1982, CATHETER CARDIO DIAG, V8, P565, DOI 10.1002/ccd.1810080605; FREEDMAN DS, 1993, ATHEROSCLEROSIS, V104, P37, DOI 10.1016/0021-9150(93)90174-S; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GILLUM RF, 1987, AM HEART J, V113, P804, DOI 10.1016/0002-8703(87)90723-X; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HUMPHRIE.JO, 1974, CIRCULATION, V49, P489, DOI 10.1161/01.CIR.49.3.489; Joseph A, 1993, J AM COLL CARDIOL, V22, P459, DOI 10.1016/0735-1097(93)90050-B; JUDKINS MP, 1967, RADIOLOGY, V89, P815, DOI 10.1148/89.5.815; KEREIAKES DJ, 1991, J AM COLL CARDIOL, V17, P304, DOI 10.1016/S0735-1097(10)80091-9; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LIPTON RB, 1994, AM J EPIDEMIOL, V139, P964; LIPTON RB, 1993, AM J EPIDEMIOL, V138, P826, DOI 10.1093/oxfordjournals.aje.a116786; LOZNER EC, 1989, CATHETER CARDIO DIAG, V17, P11, DOI 10.1002/ccd.1810170104; LYTLE BW, 1983, CIRCULATION, V68, P1149, DOI 10.1161/01.CIR.68.6.1149; MACLEAN CJ, 1987, AM J EPIDEMIOL, V126, P226, DOI 10.1093/aje/126.2.226; MARTIN MJ, 1986, LANCET, V2, P933; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MULLANY CJ, 1987, J AM COLL CARDIOL, V10, P66, DOI 10.1016/S0735-1097(87)80161-4; NEWMAN WP, 1988, MODERN PATHOL, V1, P109; OLOFSSON BO, 1985, ACTA MED SCAND, V218, P365; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PEARSON TA, 1989, INT J EPIDEMIOL, V18, pS217; PEARSON TA, 1991, AM J EPIDEMIOL, V134, P123, DOI 10.1093/oxfordjournals.aje.a116064; RAMSDALE DR, 1986, Z KARDIOL, V75, P61; RAMSDALE DR, 1984, EUR HEART J, V5, P716, DOI 10.1093/oxfordjournals.eurheartj.a061732; REED D, 1991, AM J EPIDEMIOL, V134, P111, DOI 10.1093/oxfordjournals.aje.a116063; RHOADS GG, 1978, LAB INVEST, V38, P304; RUMBERGER JA, 1994, AM J CARDIOL, V73, P1169, DOI 10.1016/0002-9149(94)90176-7; SCHWARTZ JN, 1975, AM J CARDIOL, V36, P174, DOI 10.1016/0002-9149(75)90522-6; SORLIE PD, 1981, AM J PATHOL, V103, P345; STEHBENS WE, 1993, J CLIN EPIDEMIOL, V46, P1337, DOI 10.1016/0895-4356(93)90133-L; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; SUTHERLAND JE, 1993, JAMA-J AM MED ASSOC, V269, P991; VANDERVOORT PM, 1993, CIRCULATION, V88, P1150, DOI 10.1161/01.CIR.88.3.1150; WHITNEY EJ, 1992, AM J CARDIOL, V70, P738, DOI 10.1016/0002-9149(92)90551-9; WILLERSON JT, 1985, CIRCULATION, V72, P3; 1981, CIRCULATION SI, V63, P1	59	63	65	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					316	322		10.1056/NEJM199608013350504	http://dx.doi.org/10.1056/NEJM199608013350504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663854	Bronze			2022-12-28	WOS:A1996UY98200004
J	Matsumoto, M; Lo, SF; Carruthers, CJL; Min, JJ; Mariathasan, S; Huang, GM; Plas, DR; Martin, SM; Geha, RS; Nahm, MH; Chaplin, DD				Matsumoto, M; Lo, SF; Carruthers, CJL; Min, JJ; Mariathasan, S; Huang, GM; Plas, DR; Martin, SM; Geha, RS; Nahm, MH; Chaplin, DD			Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; B-CELL; IMMUNE-RESPONSE; SOMATIC HYPERMUTATION; PRIMARY IMMUNIZATION; COMPLEMENT RECEPTOR; ANTIBODY MUTANTS; LYMPHOCYTES-B; T-CELL; CENTERS	AFFINITY maturation by somatic hypermutation is thought to occur within germinal centres(1-4). Mice deficient in lymphotoxin-alpha (LT alpha(-/-) mice) have no lymph nodes or Peyer's patches(5,6), and fail to form germinal centres in the spleen(7). We tested whether germinal centres are essential for maturation of antibody responses to T-cell-dependent antigens. LT alpha(-/-) mice immunized with low doses of (4-hydroxy-3-nitrophenyl)acetyl-ovalbumin (NP-OVA) showed dramatically impaired production of high-affinity anti-NP IgG1. However, LT alpha(-/-) mice immunized with high doses of NP-OVA, even though they failed to produce germinal centres, manifested a high-affinity anti-NP IgG1 response similar to wild-type mice. Furthermore, when LT alpha(-/-) mice were multiply immunized with high doses of NP-OVA, the predominantly expressed anti-NP Vu gene segment VH186.2 showed somatic mutations typical of affinity maturation(8). Thus, B-cell memory and affinity maturation are not absolutely dependent on the presence of germinal centres.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02138	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Harvard University; Harvard Medical School				Nahm, Moon/0000-0002-6922-1042; Chaplin, David/0000-0002-1354-3069				ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BANKS TA, 1995, J IMMUNOL, V155, P1685; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BLIER PR, 1987, J IMMUNOL, V139, P3996; CERNY A, 1988, CELL TISSUE RES, V254, P449; CLARK EA, 1992, J IMMUNOL, V148, P3327; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KAPASI ZF, 1993, J IMMUNOL, V150, P2648; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; NOSSAL GJV, 1968, J EXP MED, V127, P263, DOI 10.1084/jem.127.2.263; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; RYFFEL B, 1993, INT REV EXP PATHOL, V34, P149; SCHRIEVER F, 1992, ADV IMMUNOL, V51, P243, DOI 10.1016/S0065-2776(08)60489-7; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; WEISS U, 1992, EUR J IMMUNOL, V22, P511, DOI 10.1002/eji.1830220233; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681; YOSHIDA K, 1994, EUR J IMMUNOL, V24, P464, DOI 10.1002/eji.1830240230	29	285	299	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					462	466		10.1038/382462a0	http://dx.doi.org/10.1038/382462a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684487	Bronze			2022-12-28	WOS:A1996VA25100060
J	Wells, JA				Wells, JA			Hormone mimicry	SCIENCE			English	Editorial Material							HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; PEPTIDE LIBRARIES; RECEPTOR; PHAGE; PROTEIN; LIGANDS; DISPLAY; SELECTION; ANTIGENS				Wells, JA (corresponding author), GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ADEY NB, 1995, GENE, V156, P27, DOI 10.1016/0378-1119(95)00058-E; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAISTED AC, IN PRESS P NATL ACAD; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HOESS RH, 1993, CURR OPIN STRUC BIOL, V3, P572, DOI 10.1016/0959-440X(93)90085-Y; Johnson D. B., UNPUB; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; NAVIA MA, 1992, CURR OPIN STRUC BIOL, V2, P202; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WRIGHTON NC, UNPUB	27	57	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					449	450		10.1126/science.273.5274.449	http://dx.doi.org/10.1126/science.273.5274.449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8677438				2022-12-28	WOS:A1996UY98300028
J	Alpagut, B; Andrews, P; Fortelius, M; Kappelman, J; Temizsoy, I; Celebi, H; Lindsay, W				Alpagut, B; Andrews, P; Fortelius, M; Kappelman, J; Temizsoy, I; Celebi, H; Lindsay, W			A new specimen of Ankarapithecus meteai from the Sinap Formation of central Anatolia	NATURE			English	Article							HOMINOID EVOLUTION; SIVAPITHECUS	HOMINOID fossils from the Middle and Late Miocene are exceedingly rare, yet such material is necessary for determining hominoid phylogeny, We report here the discovery of a fossil hominoid partial skull from the Upper Miocene Sinap Formation(1,2) of central Turkey that is the most complete known from the period of 18 to 3 Myr. Our fieldwork places the hominoid locality within a precisely dated geochronological and biostratigraphical framework(3) that permits detailed comparisons with other fossil hominoids. Earlier discoveries of more fragmentary remains of Ankarapithecus meteai suggested affinities with the Asian hominoids Sivapithecus and Pongo(4). This new and nearly complete specimen reveals a combination of facial, mandibular, and dental features including a relatively narrow interorbital region, extensive frontal and maxillary sinuses, moderately developed supraorbital tori, square orbits, robust mandibular corpus, and incisor heteromorphy that is not matched in any extant or fossil hominoid. This configuration of features seems to support its placement as a stem member of the great ape and human clade.	UNIV TEXAS,DEPT ANTHROPOL,AUSTIN,TX 78712; NAT HIST MUSEUM,LONDON SW7 5BD,ENGLAND; UNIV HELSINKI,FINNISH MUSEUM NAT HIST,FIN-00014 HELSINKI,FINLAND; ANADOLU MEDENYETLERI MUZESI,ANKARA,TURKEY; ANKARA UNIV,ANKARA,TURKEY	University of Texas System; University of Texas Austin; Natural History Museum London; University of Helsinki; Ministry of Culture & Tourism - Turkey; Ankara University			Klein, Richard G/B-5910-2009	Alpagut, Berna/0000-0002-5640-1036				Agusti J, 1996, J HUM EVOL, V31, P143, DOI 10.1006/jhev.1996.0055; ALPAGUT B, 1989, ARASTIRMA SONUCLAN T, V8, P55; ALPAGUT B, 1993, ARASTIRMA SONUCLAN T, V12, P177; ANDREWS P, 1982, NATURE, V297, P541, DOI 10.1038/297541a0; Andrews P., 1980, Palaeontology (Oxford), V23, P85; Barry J.C., 1986, P93; BEGUN DR, 1995, J HUM EVOL, V29, P169, DOI 10.1006/jhev.1995.1052; BEGUN DR, 1993, J HUM EVOL, V25, P271, DOI 10.1006/jhev.1993.1049; BEGUN DR, 1995, AM J PHYS ANTHR S, V20, P63; BONIS L, 1990, NATURE, V345, P712; Brown B., 1988, P247; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; CAVE AJE, 1940, J ANAT, V72, P493; Coolidge HJ, 1933, AM J PHYS ANTHROPOL, V18, P1, DOI 10.1002/ajpa.1330180113; de Bonis L, 1977, Geobios Lyon, V10, P849, DOI 10.1016/S0016-6995(77)80081-8; DEBONIS L, 1993, J HUM EVOL, V24, P469, DOI 10.1006/jhev.1993.1032; KAPPELMAN J, 1991, J HUM EVOL, V21, P61, DOI 10.1016/0047-2484(91)90036-U; KAPPELMAN J, IN PRESS EVOLUTION W; KELLEY J, 1995, J HUM EVOL, V28, P503, DOI 10.1006/jhev.1995.1039; MARTIN L, 1985, NATURE, V314, P260, DOI 10.1038/314260a0; Moya Sola Salvadoor, 1995, Journal of Human Evolution, V29, P101; MoyaSola S, 1996, NATURE, V379, P156, DOI 10.1038/379156a0; MOYASOLA S, 1993, NATURE, V365, P543, DOI DOI 10.1038/365543A0; Ozansoy F., 1957, Bulletin Mineral Research and Exploration Institute Turkey, VNo. 49, P29; OZANSOY F, 1955, CR HEBD ACAD SCI, V240, P992; SHEA BT, 1985, AM J PHYS ANTHROPOL, V68, P329, DOI 10.1002/ajpa.1330680304; SIMONS EL, 1965, FOLIA PRIMATOL, V3, P81, DOI 10.1159/000155026; Szalay F.S., 1979, EVOLUTIONARY HIST PR; Ward S.C., 1983, P211; Ward S.C., 1986, P413	30	44	45	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					349	351		10.1038/382349a0	http://dx.doi.org/10.1038/382349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UY950	8684462				2022-12-28	WOS:A1996UY95000050
J	Gurtler, L				Gurtler, L			Difficulties and strategies of HIV diagnosis	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WESTERN-BLOT; INFECTION; ANTIBODY; TESTS; SENSITIVITY; REACTIVITY; SUBTYPE; ASSAYS	HIV infection Is commonly diagnosed by detection of antibodies (anti-HIV) by ELISA or agglutination. Reactive results are confirmed by western blot (immunoblot) or further specific tests such as competitive ELISA, which, when evaluated quantitatively, allow the differentiation of HIV types and partially subtypes. Detection of infection of newborn babies, characterisation of individual strains for subtyping and forensic Identification, and therapeutic monitoring are the domain of nucleic-acid-based assays. Nucleic-acid-based assays narrow the serological diagnostic window period in early HIV infection and, when quantified, give some indication of clinical status.			Gurtler, L (corresponding author), UNIV MUNICH, WHO, COLLABORATING CTR REFERENCE & RES AIDS, D-80336 MUNICH, GERMANY.			Gurtler, Lutz/0000-0003-3435-9030				Banatvala JE, 1996, LANCET, V347, P1058, DOI 10.1016/S0140-6736(96)90272-X; Barin Francis R., 1994, P109; BULTERYS M, 1995, AIDS, V9, P93; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; CONSTANTINE NT, 1994, AIDS, V8, P1715, DOI 10.1097/00002030-199412000-00012; CONSTANTINE NT, 1993, AIDS, V7, P1, DOI 10.1097/00002030-199301000-00001; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; GNANN JW, 1987, J VIROL, V61, P2639, DOI 10.1128/JVI.61.8.2639-2641.1987; GURTLER LG, 1994, J VIROL, V68, P1581; GURTLER LG, 1995, J VIROL METHODS, V51, P177, DOI 10.1016/0166-0934(94)00102-M; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; MORTIMER J, 1992, B WORLD HEALTH ORGAN, V70, P751; Myers GK, 1995, HUMAN RETROVIRUSES A; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; ROZIERS NBD, 1995, AIDS, V9, P528, DOI 10.1097/00002030-199509050-00018; SATO PA, 1994, B WORLD HEALTH ORGAN, V72, P129; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Sharp P.M., 1994, AIDS S1, V8, pS27; SNINSKY JJ, 1993, AIDS, V7, pS29, DOI 10.1097/00002030-199311002-00007; TEDDER RS, 1988, LANCET, V2, P927; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; URDEA MS, 1993, AIDS, V7, pS11, DOI 10.1097/00002030-199311002-00004; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994; VANDERGROEN G, 1991, B WORLD HEALTH ORGAN, V69, P747; WANGEMEN B, 1993, AIDS S2, V7, pS107; ZAAIJER HL, 1992, LANCET, V340, P770, DOI 10.1016/0140-6736(92)92303-W	30	61	62	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	1996	348	9021					176	179		10.1016/S0140-6736(96)01036-7	http://dx.doi.org/10.1016/S0140-6736(96)01036-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684160				2022-12-28	WOS:A1996UX78900022
J	Pelliccia, A; Maron, BJ; Culasso, F; Spataro, A; Caselli, G				Pelliccia, A; Maron, BJ; Culasso, F; Spataro, A; Caselli, G			Athlete's heart in women - Echocardiographic characterization of highly trained elite female athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR DIMENSIONS; M-MODE ECHOCARDIOGRAPHY; HYPERTROPHIC CARDIOMYOPATHY; CLINICAL MANIFESTATIONS; DILATED CARDIOMYOPATHY; NONINVASIVE ASSESSMENT; CARDIAC-HYPERTROPHY; DIASTOLIC FUNCTION; DYNAMIC EXERCISE; PATHO-PHYSIOLOGY	Objectives-To define the expression of ''athlete's heart'' in women by determining the alterations in cardiac dimensions associated with long-term intense conditioning in elite female athletes. Design-Prospective cardiovascular assessment conducted from 1986 through 1993. Subjects were evaluated using 2-dimensional, M-mode, and Doppler echocardiographic studies. Setting-Institute of Sports Science, Italian National Olympic Committee, Rome, Italy. Participants-A total of 600 elite female athletes (mean age, 21 years; range, 12-49 years) who had participated in vigorous training (mean duration, 9 years; range, 2-32 years) and had competed in 27 sports, including 211 athletes at the international level and 389 at the national level, A control group consisted of 65 sedentary volunteer women (mean age, 23.7 years; range, 14-41 years) who were free of cardiovascular disease and who did not participate in regular athletic training. Main Outcome Measures-Left ventricular end-diastolic cavity dimension and wall thickness, Results-Athletes demonstrated larger left ventricular end-diastolic cavity dimension (mean+/-SD)(49+/-4 mm) and greater maximal wall thickness (8.2+/-0.9 mm) than controls (46+/-3 mm and 7.2+/-0.6 mm; P<.001). These dimensions were 6% and 14% larger in athletes. Among athletes, left ventricular cavity dimension was 40 mm to 66 mm, exceeded normal limits (>54 mm) in 47 women (8%), and was within the range consistent with primary dilated cardiomyopathy (greater than or equal to 60 mm) in 4 athletes (1%), Training for endurance sports, such as cycling, cross-country skiing, and rowing had the greatest effect on cavity dimension. Left ventricular wall thickness was 6 mm to 12 mm in athletes and did not exceed normal limits or extend into the borderline gray zone with hypertrophic cardiomyopathy in any subject. Compared with data from 738 previously studied male athletes, female athletes showed significantly smaller left ventricular cavity dimension (11% less; P<.001) and wall thickness (23% less; P<.001). Conclusions-Highly trained women athletes frequently demonstrate cardiac dimensional changes as an adaptation to physical training, although absolute left ventricular cavity size exceeding normal limits was evident in a minority (8%) of women athletes and was rarely (1% of athletes) within the range of dilated cardiomyopathy. Athletic training was not a stimulus for substantial increases in absolute left ventricular wall thickness, which was within normal limits for all women athletes. These findings suggest that the clinical differentiation of athlete's heart and hypertrophic cardiomyopathy appears to be a diagnostic dilemma that is limited to male athletes.	MINNEAPOLIS HEART INST FDN,MINNEAPOLIS,MN 55407; ITALIAN NATL OLYMP COMM,INST SPORTS SCI,DEPT MED,ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT EXPTL MED,ROME,ITALY	Minneapolis Heart Institute Foundation; Sapienza University Rome				Spataro, Antonio/0000-0002-7727-665X				ARMITAGE P, 1994, STAT METHODS MED RES, P277; Astrand PO, 1986, TXB WORK PHYSL PHYSL, P414; CROUSE SF, 1992, RES Q EXERCISE SPORT, V63, P393, DOI 10.1080/02701367.1992.10608761; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DIXON WJ, 1992, BMDP STAT SOFTWARE M, P145; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; FAGARD R, 1987, EUR HEART J, V8, P1305, DOI 10.1093/oxfordjournals.eurheartj.a062217; FORD LE, 1976, CIRC RES, V39, P297, DOI 10.1161/01.RES.39.3.297; GANDHI MM, 1994, J AM COLL CARDIOL, V23, P74, DOI 10.1016/0735-1097(94)90504-5; GAVAZZI A, 1993, AM HEART J, V125, P410; GEORGE KP, 1995, MED SCI SPORT EXER, V27, P1362; GLEIM GW, 1991, AM HEART J, V121, P524, DOI 10.1016/0002-8703(91)90721-S; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; KEUL J, 1981, CIRC RES, V48, P162; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; KNUTSEN KM, 1989, J INTERN MED, V225, P111, DOI 10.1111/j.1365-2796.1989.tb00049.x; KOENIG H, 1982, CIRC RES, V50, P782, DOI 10.1161/01.RES.50.6.782; KUHN FE, 1993, ARCH INTERN MED, V153, P2626, DOI 10.1001/archinte.153.23.2626; LONGHURST JC, 1981, CIRC RES, V48, P171; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MCGILL HC, 1980, SCIENCE, V207, P775, DOI 10.1126/science.6766222; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MICKELSON JK, 1986, AM HEART J, V112, P1251, DOI 10.1016/0002-8703(86)90356-X; MORALES MC, 1992, AM HEART J, V124, P1104, DOI 10.1016/0002-8703(92)91008-O; ORENCIA A, 1993, JAMA-J AM MED ASSOC, V269, P2392, DOI 10.1001/jama.269.18.2392; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; PELLICCIA A, 1993, AM J CARDIOL, V72, P1048, DOI 10.1016/0002-9149(93)90861-6; PETROFSKY JS, 1975, J APPL PHYSIOL, V38, P863, DOI 10.1152/jappl.1975.38.5.863; POLLAK SJ, 1987, INT J SPORTS MED, V8, P81; REDFIELD MM, 1994, AM J CARDIOL, V74, P737, DOI 10.1016/0002-9149(94)90323-9; RILEYHAGAN M, 1992, AM J CARDIOL, V69, P1067, DOI 10.1016/0002-9149(92)90865-V; ROST R, 1983, INT J SPORTS MED, V4, P147, DOI 10.1055/s-2008-1026028; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SPIRITO P, 1994, AM J CARDIOL, V74, P802, DOI 10.1016/0002-9149(94)90439-1; SPIRITO P, 1988, BRIT HEART J, V59, P672; ZELDIS SM, 1978, J APPL PHYSIOL, V44, P849, DOI 10.1152/jappl.1978.44.6.849	47	261	265	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					211	215		10.1001/jama.276.3.211	http://dx.doi.org/10.1001/jama.276.3.211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667565				2022-12-28	WOS:A1996UW46900032
J	Beer, JH; Vogt, A; Neftel, K; Cottagnoud, P				Beer, JH; Vogt, A; Neftel, K; Cottagnoud, P			False positive results for leucocytes in urine dipstick test with common antibiotics	BRITISH MEDICAL JOURNAL			English	Article									ZIEGLER CITY HOSP,BERN,SWITZERLAND		Beer, JH (corresponding author), UNIV HOSP BERN,DEPT MED,CH-3010 BERN,SWITZERLAND.			Beer, Jurg Hans/0000-0002-7199-0406				BONNARDEAUX A, 1994, CLIN NEPHROL, V41, P167; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; MENDEZ R, 1992, CHEM PHARM BULL, V40, P3228, DOI 10.1248/cpb.40.3228; VERSTRAETEN L, 1992, CLIN CHEM, V38, P2557	4	25	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					25	25		10.1136/bmj.313.7048.25	http://dx.doi.org/10.1136/bmj.313.7048.25			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664766	Green Published			2022-12-28	WOS:A1996UW66700027
J	Gammon, D; Snow, ES; Shanabrook, BV; Katzer, DS; Park, D				Gammon, D; Snow, ES; Shanabrook, BV; Katzer, DS; Park, D			Homogeneous linewidths in the optical spectrum of a single gallium arsenide quantum dot	SCIENCE			English	Article							WELL STRUCTURES; FREE-EXCITONS; RADIATIVE LIFETIMES; GAAS; LOCALIZATION; RELAXATION	The homogeneous linewidths in the photoluminescence excitation spectrum of a single, naturally formed gallium arsenide (GaAs) quantum dot have been measured with high spatial and spectral resolution. The energies and linewidths of the homogeneous spectrum provide a new perspective on the dephasing dynamics of the exciton in a quantum-confined, solid-state system. The origins of the linewidths are discussed in terms of the dynamics of the exciton in zero dimensions, in particular, in terms of lifetime broadening through the emission or absorption of phonons and photons.			Gammon, D (corresponding author), USN, RES LAB, WASHINGTON, DC 20375 USA.		Katzer, D. Scott/N-7841-2013					ANDREANI LC, 1991, SOLID STATE COMMUN, V77, P641, DOI 10.1016/0038-1098(91)90761-J; ANDREANI LC, 1995, NATO ADV SCI INST SE, V340, P57; BENISTY H, 1995, PHYS REV B, V51, P13281, DOI 10.1103/PhysRevB.51.13281; BLACKWOOD E, 1994, PHYS REV B, V50, P14246, DOI 10.1103/PhysRevB.50.14246; BOCKELMANN U, 1993, PHYS REV B, V48, P17637, DOI 10.1103/PhysRevB.48.17637; BRUNNER K, 1994, APPL PHYS LETT, V64, P3320, DOI 10.1063/1.111265; BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; CITRIN DS, 1993, PHYS REV B, V47, P3832, DOI 10.1103/PhysRevB.47.3832; DEVEAUD B, 1991, PHYS REV LETT, V67, P2355, DOI 10.1103/PhysRevLett.67.2355; GAMMON D, 1990, APPL PHYS LETT, V57, P2710, DOI 10.1063/1.103807; GAMMON D, 1995, APPL PHYS LETT, V67, P2391, DOI 10.1063/1.114557; GAMMON D, 1995, PHYS REV B, V51, P16785, DOI 10.1103/PhysRevB.51.16785; Gammon D, 1996, PHYS REV LETT, V76, P3005, DOI 10.1103/PhysRevLett.76.3005; HEGARTY J, 1984, PHYS REV B, V30, P7346, DOI 10.1103/PhysRevB.30.7346; HEGARTY J, 1982, PHYS REV LETT, V49, P930, DOI 10.1103/PhysRevLett.49.930; HEGARTY J, 1985, J OPT SOC AM B, V2, P1143, DOI 10.1364/JOSAB.2.001143; HESS HF, 1994, SCIENCE, V264, P1740, DOI 10.1126/science.264.5166.1740; KUHL J, 1989, FESTKOR-ADV SOLID ST, V29, P157; SHIELDS AJ, 1993, PHYS REV B, V48, P17338, DOI 10.1103/PhysRevB.48.17338; SRINIVAS V, 1992, PHYS REV B, V46, P10193, DOI 10.1103/PhysRevB.46.10193; TAKAGAHARA T, 1989, J LUMIN, V44, P347, DOI 10.1016/0022-2313(89)90066-5; VANKESTEREN HW, 1990, PHYS REV B, V41, P5283, DOI 10.1103/PhysRevB.41.5283; VINATTIERI A, 1994, PHYS REV B, V50, P10868, DOI 10.1103/PhysRevB.50.10868; WANG H, 1990, PHYS REV LETT, V65, P1255, DOI 10.1103/PhysRevLett.65.1255; WEBB MD, 1991, PHYS REV B, V43, P12658, DOI 10.1103/PhysRevB.43.12658; ZRENNER A, 1994, PHYS REV LETT, V72, P3382, DOI 10.1103/PhysRevLett.72.3382; ZUCKER JE, 1987, PHYS REV B, V35, P2892, DOI 10.1103/PhysRevB.35.2892	27	486	489	1	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1996	273	5271					87	90		10.1126/science.273.5271.87	http://dx.doi.org/10.1126/science.273.5271.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688056				2022-12-28	WOS:A1996UV47800043
J	Enderby, P; Emerson, J				Enderby, P; Emerson, J			Speech and language therapy: Does it work?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; DYSARTHRIC SPEAKER; APHASIA; CHILDREN; STROKE; TRIAL		FRENCHAY HOSP, SPEECH & LANGUAGE THERAPY RES UNIT, BRISTOL BS16 1LE, AVON, ENGLAND		Enderby, P (corresponding author), UNIV SHEFFIELD, NO GEN HOSP, DEPT HLTH CARE ELDERLY PEOPLE, COMMUNITY SCI CTR, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND.			Enderby, Pamela/0000-0002-4371-9053				ALBERY L, 1984, BRIT J DISORD COMMUN, V19, P115; ANDREWS G, 1980, J SPEECH HEAR DISORD, V45, P287, DOI 10.1044/jshd.4503.287; BASSO A, 1979, ARCH NEUROL-CHICAGO, V36, P190, DOI 10.1001/archneur.1979.00500400044005; BELLAIRE K, 1986, J COMMUN DISORD, V19, P271, DOI 10.1016/0021-9924(86)90033-X; BEUKELMAN DR, 1977, J SPEECH HEAR DISORD, V42, P265, DOI 10.1044/jshd.4202.265; BRYEN DN, 1985, J SPEC EDUC, V19, P7, DOI 10.1177/002246698501900103; CARDING PN, 1992, EUR J DISORDER COMM, V27, P137; DAVID RM, 1982, BRIT J DISORDERS COM, V14, P85; Dodd B., 1990, AUSTR J HUMAN COMMUN, V18, P29, DOI [10.3109/asl2.1990.18.issue-1.03, DOI 10.3109/ASL2.1990.18.ISSUE-1.03]; Eiserman W. D., 1990, J EARLY INTERVENTION, V14, P297; Enderby P, 1992, Health Trends, V24, P61; ENDERBY P., 1995, DOES SPEECH LANGUAGE; ENDERBY P, 1989, RECENT ADV CLIN DYSA; LANCER JM, 1988, J LARYNGOL OTOL, V102, P423, DOI 10.1017/S0022215100105250; LINCOLN NB, 1984, LANCET, V1, P1197; MASTERSON JJ, 1993, AJSLT, V1, P5; MEIKLE M, 1979, BRIT MED J, V2, P87, DOI 10.1136/bmj.2.6182.87; OLSWANG LB, 1991, LANG SPEECH HEAR SER, V22, P255; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PEARSON VAH, 1995, PUBLIC HEALTH, V109, P143, DOI 10.1016/S0033-3506(05)80008-3; PERRY A, 1988, BRIT J DISORD COMMUN, V23, P23; ROBERTSON SJ, 1984, BRIT J DISORD COMMUN, V19, P213; ROULSTONE S, 1996, RCSLT B, V528, P16; ROY N, 1993, J VOICE, V7, P242, DOI 10.1016/S0892-1997(05)80333-9; SCARBOROUGH HS, 1990, J SPEECH HEAR RES, V33, P70, DOI 10.1044/jshr.3301.70; SCOTT S, 1983, J NEUROL NEUROSUR PS, V46, P140, DOI 10.1136/jnnp.46.2.140; SCOTT S, 1984, J NEUROL NEUROSUR PS, V47, P302, DOI 10.1136/jnnp.47.3.302; SHEWAN CM, 1984, BRAIN LANG, V23, P272, DOI 10.1016/0093-934X(84)90068-3; SUBBARAO SP, 1991, INDIAN J CANC, V28, P218; VANDEMARK DR, 1986, CLEFT PALATE J, V23, P215; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WERTZ RT, 1986, ARCH NEUROL-CHICAGO, V43, P653, DOI 10.1001/archneur.1986.00520070011008; WERTZ RT, 1987, TOP LANG DISORD, V8, P1, DOI 10.1097/00011363-198712000-00003; YAMAGUCHI H, 1993, J VOICE, V7, P250, DOI 10.1016/S0892-1997(05)80334-0	34	25	25	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	1996	312	7047					1655	1658		10.1136/bmj.312.7047.1655	http://dx.doi.org/10.1136/bmj.312.7047.1655			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV489	8664724	Green Published			2022-12-28	WOS:A1996UV48900030
J	Entwistle, VA; Watt, IS; Bradbury, R; Pehl, LJ				Entwistle, VA; Watt, IS; Bradbury, R; Pehl, LJ			Media coverage of the Child B case	BRITISH MEDICAL JOURNAL			English	Article								The case of a girl with leukaemia, known as Child B, hit the headlines in March 1995 when her father refused to accept the advice of doctors who counselled against further treatment and took Cambridge and Huntingdon Health Authority to court for refusing to fund chemotherapy and a second bone transplant for her in the private sector. British national newspapers varied greatly in the way they covered the case. Some paid little attention to clinical considerations and presented the case as an example of rationing based on financial considerations. Their selective presentations meant that anyone reading just one newspaper would have received only limited and partial information. If members of the public are to participate in debates about treatment decisions and health care rationing, means other than the media will need to be found to inform and involve them.			Entwistle, VA (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				ALLEN D, 1995, NEWS WORLD      0312, P20; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; ENTWISTLE VA, IN PRESS CONTROVERSI, V2; LEFANU J, 1995, DAILY TELEGRAPH 0311, P23; *NHS EX, 1995, PRIOR PLANN GUID 199; PALMER J, 1995, DAILY MIRROR    0313, P4; Sheldon T, 1993, RATIONING ACTION, P3; SMITH R, 1995, BRIT MED J, V310, P686, DOI 10.1136/bmj.310.6981.686; STUTTAFORD T, 1995, TIMES           0313, P3; WEALE S, 1995, GUARDIAN        0310, P1; 1995, DAILY EXPRESS   0311, P8; 1995, DAILY TELEGRAPH 0313, P20; 1995, TIMES           0311, P17	13	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1587	1591		10.1136/bmj.312.7046.1587	http://dx.doi.org/10.1136/bmj.312.7046.1587			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664671	Green Published			2022-12-28	WOS:A1996UU80600024
J	StanhopeBaker, P; Hudson, KM; Shaffer, AL; Constantinescu, A; Schlissel, MS				StanhopeBaker, P; Hudson, KM; Shaffer, AL; Constantinescu, A; Schlissel, MS			Cell type-specific chromatin structure determines the targeting of V(D)J recombinase activity in vitro	CELL			English	Article							PRE-B-CELLS; IMMUNOGLOBULIN GENE REARRANGEMENT; BROKEN DNA-MOLECULES; ALLELIC EXCLUSION; MOUSE THYMOCYTES; BONE-MARROW; TRANSCRIPTION; SEGMENTS; ACTIVATION; MICE	A common V(D)J recombinase that recognizes a conserved recombination signal sequence (RSS) mediates the assembly of immunoglobulin (Ig) and T cell receptor (TCR) genes in B and T cell precursors. The rearrangement of particular Ig and TCR gene segments, however, is tightly regulated with respect to cell lineage and developmental stage. Using an in vitro system, we analyzed recombinase cleavage of RSSs flanking Ig and TCR gene segments in nuclei. We found that both the lineage-specificity and temporal ordering of gene rearrangement is reflected in the accessibility of RSSs within chromatin to in vitro cleavage.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University	StanhopeBaker, P (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205, USA.				NHLBI NIH HHS [R01 HL48702] Funding Source: Medline; NIAID NIH HHS [R01 AI22833, T32-AI07247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022833, T32AI007247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; FERNEX C, 1995, MOL CELL BIOL, V15, P3217; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiramatsu R, 1995, CELL, V83, P1113, DOI 10.1016/0092-8674(95)90138-8; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Krop I, 1996, EUR J IMMUNOL, V26, P238, DOI 10.1002/eji.1830260137; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH MG, 1986, EMBO J, V5, P2131, DOI 10.1002/j.1460-2075.1986.tb04476.x; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	45	259	260	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					887	897		10.1016/S0092-8674(00)81272-6	http://dx.doi.org/10.1016/S0092-8674(00)81272-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681383	hybrid			2022-12-28	WOS:A1996UR60400012
J	Johnson, AP; Speller, DCE; George, RC; Warner, M; Domingue, G; Efstratiou, A				Johnson, AP; Speller, DCE; George, RC; Warner, M; Domingue, G; Efstratiou, A			Prevalence of antibiotic resistance and serotypes in Pneumococci in England and Wales: Results of observational surveys in 1990 and 1995	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the prevalence of antibiotic resistance and serotype distribution among pneumococci in England and Wales in 1990 and 1995. Design-Observational surveys in March 1990 and March 1995. During two weeks in each survey period all pneumococci isolated in public health laboratories in England and Wales were collected and assessed for sensitivity to antibiotics and the distribution of serogroups or serotypes. Setting-The network of public health laboratories throughout England and Wales. Subjects-1127 individual patient isolates of Streptococcus pneumoniae obtained during the two surveys. Main outcome measures-Sensitivity or resistance to a range of antibiotics; serogroup or serotype. Results-The prevalence of intermediate or full resistance to penicillin increased from 1.5% in 1990 to 3.9% in 1995 and resistance to erythromycin increased from 2.8% to 8.6%. About 92% of isolates belonged to serogroups or serotypes included in the currently available pneumococcal vaccine. Conclusion-Resistance to penicillin and erythromycin has increased among pneumococci in England and Wales. Continued surveillance to assess further increases in the prevalence of pneumococcal resistance to antibiotics is essential.	CENT PUBL HLTH LAB,STREPTOCOCCUS & DIPHTHERIA REFERENCE UNIT,RESP & SYST INFECT LAB,LONDON NW9 5HT,ENGLAND	Public Health England	Johnson, AP (corresponding author), CENT PUBL HLTH LAB,ANTIBIOT REFERENCE UNIT,LAB HOSP INFECT,LONDON NW9 5HT,ENGLAND.		Johnson, Alan P/F-4420-2014					APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; ASZKENASY OM, 1995, COMMUNICAB DIS REP, V5, P45; BARRY AL, 1995, ANTIMICROB AGENTS CH, V39, P238, DOI 10.1128/AAC.39.1.238; BOSWELL TC, 1994, J ANTIMICROB CHEMOTH, V34, P844, DOI 10.1093/jac/34.5.844; FRIEDLAND IR, 1995, CURR OPIN INFECT DIS, V8, P213; George R C, 1992, Commun Dis Rep CDR Rev, V2, pR37; JOHNSON AP, 1995, J ANTIMICROB CHEMOTH, V35, P443, DOI 10.1093/jac/35.3.443; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P2448, DOI 10.1128/JCM.32.10.2448-2459.1994; Klein DL, 1995, MICROB DRUG RESIST, V1, P49, DOI 10.1089/mdr.1995.1.49; KLUGMAN KP, 1994, EUR J CLIN MICROBIOL, V13, P1, DOI 10.1007/BF02026115; KLUGMAN KP, 1995, ANTIMICROB AGENTS CH, V39, P1988, DOI 10.1128/AAC.39.9.1988; LONKS JR, 1993, ANTIMICROB AGENTS CH, V37, P1742, DOI 10.1128/AAC.37.9.1742; RIDGWAY EJ, 1991, J HOSP INFECT, V17, P15, DOI 10.1016/0195-6701(91)90073-H; 1989, MMWR-MORBID MORTAL W, V38, P64; 1991, J ANTIMICROB CHEM SD, V27; 1989, MMWR-MORBID MORTAL W, V38, P73; 1995, COMMUNICAB DIS REP, V5, P187	17	74	74	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1454	1456		10.1136/bmj.312.7044.1454	http://dx.doi.org/10.1136/bmj.312.7044.1454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664623	Green Published			2022-12-28	WOS:A1996UQ29600026
J	Slattery, J				Slattery, J			Endarterectomy for moderate symptomatic carotid stenosis: Interim results from the MRC European Carotid Surgery Trial	LANCET			English	Article								Background The objective of this study was to assess whether carotid endarterectomy is an appropriate treatment for patients with recent cerebrovascular events in the territory supplied by a moderately stenosed (30-69%) internal carotid artery. Results have previously been reported for severe (70-99%) and mild (0-29%) stenosis. Methods A multicentre randomised controlled trial recruited 1599 patients with moderate stenosis treated in 97 hospitals from 15 countries, 60% of patients were allocated to receive and 40% to avoid carotid endarterectomy. The analysis was by intention to treat. Findings Nine patients were omitted from the analysis because no follow-up data were received. Stroke-free life expectancy (curtailed at 8 years) was shorter in the surgery patients than in the non-surgery control groups (patients with 30-49% stenosis, life expectancy=6.16 years [controls: 6.63 years]; patients with 50-69% stenosis, life expectancy=5.93 [6.14] years). It remains possible that patients might derive some benefit from surgery in the very long term; however, our data show that no benefit would be gained over a period of <4-5 years in patients with 50-69% stenosis and <6-7 years in patients with 30-49% stenosis. Interpretation Previous interim results from this study showed that surgery is beneficial in patients with severe stenosis but harmful in those with mild stenosis. With more randomised patients and longer follow-up, the study now shows that endarterectomy is not indicated for most, possibly all, patients with moderate symptomatic carotid stenosis.			Slattery, J (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	4	213	223	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1996	347	9015					1591	1593						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667868				2022-12-28	WOS:A1996UP66100011
J	Davies, HD; McGeer, A; Schwartz, B; Green, K; Cann, D; Simor, AE; Low, DE; Fletcher, A; Kaul, R; Scriver, S; Willey, B; Demers, B; Gold, W; Lovgren, M; Talbot, J; Naus, M				Davies, HD; McGeer, A; Schwartz, B; Green, K; Cann, D; Simor, AE; Low, DE; Fletcher, A; Kaul, R; Scriver, S; Willey, B; Demers, B; Gold, W; Lovgren, M; Talbot, J; Naus, M			Invasive group a streptococcal infections in Ontario, Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SHOCK-LIKE SYNDROME; GROUP-A STREPTOCOCCI; CHANGING EPIDEMIOLOGY; WOUND INFECTIONS; NURSING-HOME; PYOGENES; OUTBREAK; CHILDREN; ASSOCIATION; BACTEREMIA	Background Several reports suggest that the incidence of invasive group A streptococcal infections, including streptococcal toxic shock syndrome and necrotizing fasciitis, is increasing. Methods During 1992 and 1993 we conducted prospective, population-based surveillance of invasive group A streptococcal disease in Ontario, Canada. We reviewed clinical and laboratory records, searched for secondary cases of invasive disease, and cultured specimens from household contacts. Results We identified 323 patients with invasive group A streptococcal infections, for an annual incidence of 1.5 cases per 100,000 population. The rates were highest in young children and the elderly. Fifty-six percent of the patients had underlying chronic illness. Risk factors for disease included infection with the human immunodeficiency virus, cancer, diabetes, alcohol abuse, and chickenpox. The most common clinical presentations were soft-tissue infection (48 percent), bacteremia with no septic focus (14 percent), and pneumonia (11 percent). Necrotizing fasciitis occurred in 6 percent of patients, and toxic shock in 13 percent. The mortality rate was 15 percent overall, but it was 29 percent among those over 64 years of age (P<0.001) and 81 percent among those with toxic shock (P<0.001). Fourteen percent of the cases were nosocomial, and 4 percent occurred in nursing home residents, often in association with disease outbreaks. Invasive disease occurred in 2 household contacts of patients with infection, for an estimated risk of 3.2 per 1000 household contacts (95 percent confidence interval, 0.39 to 12 per 1000). Conclusions The elderly and those with underlying medical conditions are at greatest risk for invasive group A streptococcal disease, toxic shock, and necrotizing fasciitis. Invasive streptococcal infection is associated with a substantial risk of transmission in households and health care institutions. (C) 1996, Massachusetts Medical Society.	MT SINAI HOSP,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; PRINCESS MARGARET HOSP,TORONTO,ON M4X 1K9,CANADA; HOSP SICK CHILDREN,DIV INFECT DIS,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MICROBIOL,TORONTO,ON M5S 1A1,CANADA; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; INST PASTEUR,PARIS,FRANCE; TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA; NATL CTR STREPTOCOCCUS,EDMONTON,AB,CANADA; ONTARIO MINIST HLTH,TORONTO,ON M5W 1R5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Centers for Disease Control & Prevention - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Toronto; University Toronto Affiliates; University Health Network Toronto			McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014; Low, Donald/B-1726-2012	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137; 				*AM AC PED, 1994, 1994 REDBOOK, P430; ARMITAGE P, 1987, STAT METHODS MED RES, P134; AUERBACH SB, 1992, ARCH INTERN MED, V152, P1017, DOI 10.1001/archinte.152.5.1017; BIBLER MR, 1986, REV INFECT DIS, V8, P941; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; COLMAN G, 1993, J MED MICROBIOL, V39, P165, DOI 10.1099/00222615-39-3-165; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; DAVIES HD, 1994, PEDIATR INFECT DIS J, V13, P49, DOI 10.1097/00006454-199401000-00011; DEMERS B, 1993, CLIN INFECT DIS, V16, P792, DOI 10.1093/clind/16.6.792; DIPERSIO JR, 1995, 95 GEN M AM SOC MICR; FRANCIS J, 1988, Q J MED, V68, P603; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARNER JS, 1988, AM J INFECT CONTROL, V16, P177; GONZALEZRUIZ A, 1995, CLIN INFECT DIS, V20, P1058, DOI 10.1093/clinids/20.4.1058; Griffith F, 1934, J HYG-CAMBRIDGE, V34, P542, DOI 10.1017/S0022172400043308; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P1638; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; MASTRO TD, 1990, NEW ENGL J MED, V323, P968, DOI 10.1056/NEJM199010043231406; MAXTED WR, 1973, J MED MICROBIOL, V6, P83, DOI 10.1099/00222615-6-1-83; *ONT MIN HLTH, 1992, 1990 ONT MIN HLTH; PAUL SM, 1990, INFECT CONT HOSP EP, V11, P643; PREBLUD SR, 1984, PEDIATR INFECT DIS J, V3, P505, DOI 10.1097/00006454-198411000-00004; ROTTA J, 1971, J EXP MED, V134, P1298, DOI 10.1084/jem.134.5.1298; SCHAFFNER W, 1969, NEW ENGL J MED, V280, P1224, DOI 10.1056/NEJM196905292802209; SCHWARTZ B, 1992, INFECT CONT HOSP EP, V13, P742; SCHWARTZ B, 1992, CLIN INFECT DIS, V15, P277, DOI 10.1093/clinids/15.2.277; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SINGLE LA, 1992, FEMS MICROBIOL LETT, V91, P85, DOI 10.1111/j.1574-6968.1992.tb05188.x; STAMM WE, 1978, J INFECT DIS, V138, P287, DOI 10.1093/infdis/138.3.287; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; TYLER SD, 1992, J CLIN MICROBIOL, V30, P3127, DOI 10.1128/JCM.30.12.3127-3131.1992; VALENZUELA TD, 1991, ANN EMERG MED, V20, P90, DOI 10.1016/S0196-0644(05)81129-1; VIGLIONESE A, 1991, AM J MED, V91, pS329, DOI 10.1016/0002-9343(91)90391-A; WATANABEOHNISHI R, 1995, J INFECT DIS, V171, P74, DOI 10.1093/infdis/171.1.74; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; WILSON GJ, 1995, CLIN INFECT DIS, V20, P1333, DOI 10.1093/clinids/20.5.1333; 1993, JAMA-J AM MED ASSOC, V269, P390; 1976, J INFECT DIS, V134, P201; 1976, JAMA-J AM MED ASSOC, V235, P261	43	519	530	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					547	554		10.1056/NEJM199608223350803	http://dx.doi.org/10.1056/NEJM199608223350803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8684408	Green Published			2022-12-28	WOS:A1996VD30200003
J	Bennett, MJ; Marchant, A; Green, HG; May, ST; Ward, SP; Millner, PA; Walker, AR; Schulz, B; Feldmann, KA				Bennett, MJ; Marchant, A; Green, HG; May, ST; Ward, SP; Millner, PA; Walker, AR; Schulz, B; Feldmann, KA			Arabidopsis AUX1 gene: A permease-like regulator of root gravitropism	SCIENCE			English	Article							THALIANA; ACID; TRANSPORT; EXPRESSION; PROTEINS; SPECIFICITY; RESISTANCE; RESPONSES; MEMBRANE; MUTANTS	The plant hormone auxin regulates various developmental processes including root formation, vascular development, and gravitropism. Mutations within the AUX1 gene confer an auxin-resistant root growth phenotype and abolish root gravitropic curvature. Polypeptide sequence similarity to amino acid permeases suggests that AUX1 mediates the transport of an amino acid-like signaling molecule. Indole-3-acetic acid, the major form of auxin in higher plants, is structurally similar to tryptophan and is a likely substrate for the AUX1 gene product. The cloned AUX1 gene can restore the auxin-responsiveness of transgenic aux1 roots. Spatially, AUX1 is expressed in root apical tissues that regulate root gravitropic curvature.	UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV CAMBRIDGE,DEPT PLANT SCI,CAMBRIDGE CB2 1TN,ENGLAND; UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721	University of Leeds; University of Cambridge; University of Arizona	Bennett, MJ (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.		Walker, Mandy/C-4957-2012; Bennett, Malcolm/G-4004-2010; may, sean t/B-6838-2012; Marchant, Alan/I-4395-2012	Walker, Mandy/0000-0002-7596-8484; Bennett, Malcolm/0000-0003-0475-390X; may, sean t/0000-0001-5282-3250; Marchant, Alan/0000-0002-8293-2332				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; CIAROS M, 1994, CABIOS, V10, P685; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESTELLE M, 1992, BIOESSAYS, V14, P439, DOI 10.1002/bies.950140703; EVANS ML, 1994, PLANTA, V194, P215, DOI 10.1007/BF01101680; EVANS ML, 1991, PLANT PHYSIOL, V95, P1, DOI 10.1104/pp.95.1.1; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; HASENSTEIN KH, 1988, PLANT PHYSIOL, V86, P890, DOI 10.1104/pp.86.3.890; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JONES AM, 1994, ANN REV PLANT PHYSL, V45, P394; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LELANNE EB, 1994, GENETICS, V138, P61; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LOMAX TL, 1992, BIOCHEM SOC T, V20, P64, DOI 10.1042/bst0200064; LOMAX TL, 1994, PLANT HORMONES THEIR, P509; LUDEVID D, 1992, PLANT PHYSIOL, V100, P1633, DOI 10.1104/pp.100.4.1633; MAHER EP, 1980, BIOCHEM GENET, V18, P1041, DOI 10.1007/BF00484337; MAY S, UNPUB; MUDAY GK, 1994, PLANT PHYSIOL BIOCH, V32, P193; NORMANLY J, 1993, P NATL ACAD SCI USA, V90, P10355, DOI 10.1073/pnas.90.21.10355; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; PICKETT FB, 1990, PLANT PHYSIOL, V94, P1462, DOI 10.1104/pp.94.3.1462; RAYLE DL, 1992, PLANT PHYSIOL, V99, P1271, DOI 10.1104/pp.99.4.1271; ROST B, 1995, PROTEIN SCI, V4, P521; RUBERY PH, 1974, PLANTA, V118, P101, DOI 10.1007/BF00388387; SCHULZ B, 1994, PLANT MOL BIOL MANUA; TSURUMI S, 1978, PLANT CELL PHYSIOL, V19, P1195; VESPER MJ, 1990, PLANTA, V182, P486, DOI 10.1007/BF02341022; Ward S., UNPUB; ZETTL R, 1992, P NATL ACAD SCI USA, V89, P480, DOI 10.1073/pnas.89.2.480	33	732	766	5	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					948	950		10.1126/science.273.5277.948	http://dx.doi.org/10.1126/science.273.5277.948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688077				2022-12-28	WOS:A1996VC67000060
J	Wong, RCK; VanDam, J				Wong, RCK; VanDam, J			Endoscopic palliation of malignant dysphagia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Wong, RCK (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA 02115, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					475	475		10.1056/NEJM199608153350704	http://dx.doi.org/10.1056/NEJM199608153350704			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8676953				2022-12-28	WOS:A1996VB84900004
J	Senkevich, TG; Bugert, JJ; Sisler, JR; Koonin, EV; Darai, G; Moss, B				Senkevich, TG; Bugert, JJ; Sisler, JR; Koonin, EV; Darai, G; Moss, B			Genome sequence of a human tumorigenic poxvirus: Prediction of specific host response-evasion genes	SCIENCE			English	Article							MOLLUSCUM-CONTAGIOSUM VIRUS; EPIDERMAL GROWTH-FACTOR; VACCINIA VIRUS; NUCLEOTIDE-SEQUENCE; RING FINGER; ZINC-FINGER; DNA; PROTEIN; VARIOLA; HOMOLOG	Molluscum contagiosum virus (MCV) commonly causes asymptomatic cutaneous neoplasms in children and sexually active adults as well as persistent opportunistic acquired immunodeficiency syndrome (AIDS)-associated disease. Sequencing the 190-kilobase pair genome of MCV has now revealed that the virus potentially encodes 163 proteins, of which 103 have homologs in the smallpox virus. MCV lacks counterparts to 83 genes of the smallpox virus, including those important in suppression of host responses to infection, nucleotide biosynthesis, and cell proliferation. MCV possesses 59 genes that are predicted to encode previously uncharacterized proteins, including major histocompatibility complex class I, chemokine, and glutathione peroxidase homologs, which suggests that there are MCV-specific strategies for coexistence with the human host.	NIAID, VIRAL DIS LAB, NIH, BETHESDA, MD 20892 USA; NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20892 USA; UNIV HEIDELBERG, INST MED VIROL, D-69120 HEIDELBERG, GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Ruprecht Karls University Heidelberg			Bugert, Joachim/AAK-6459-2021; Bugert, Joachim J/D-1705-2012	Bugert, Joachim J/0000-0002-0556-3211; Moss, Bernard/0000-0002-2154-8564				AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BLAKE NW, 1991, J VIROL, V65, P3583, DOI 10.1128/JVI.65.7.3583-3589.1991; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BORODOVSKY M, COMMUNICATION; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; Bugert J, 1989, Virus Genes, V3, P159; BUGERT JJ, 1993, VIROLOGY, V192, P391, DOI 10.1006/viro.1993.1050; BUGERT JJ, 1991, J MED VIROL, V33, P211, DOI 10.1002/jmv.1890330313; BULLER RML, 1995, VIROLOGY, V213, P655, DOI 10.1006/viro.1995.0037; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; DARAI G, 1986, J MED VIROL, V18, P29, DOI 10.1002/jmv.1890180105; FAHNESTOCK ML, 1995, IMMUNITY, V3, P583, DOI 10.1016/1074-7613(95)90129-9; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FENNER F, 1966, FIELDS VIROLOGY, P2703; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Goebel S.J., 1990, VIROLOGY, V179, P517; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HADASCH RP, 1993, INTERVIROLOGY, V36, P32; Henderson DA, 1988, SMALLPOX ITS ERADICA; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MOSS B, 1966, FIELDS VIROLOGY, P2637; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; PARR RP, 1977, VIROLOGY, V81, P247, DOI 10.1016/0042-6822(77)90141-6; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1988, COMPUT APPL BIOSCI, V4, P11; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; Porter C D, 1992, Mol Cell Biol Hum Dis Ser, V1, P233; PORTER CD, 1987, J GEN VIROL, V68, P673, DOI 10.1099/0022-1317-68-3-673; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; ROST B, 1995, PROTEIN SCI, V4, P521; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SENKEVICH TG, 1994, VIROLOGY, V198, P118, DOI 10.1006/viro.1994.1014; SENKEVICH TG, 1995, J VIROL, V69, P4103, DOI 10.1128/JVI.69.7.4103-4111.1995; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SONNTAG KC, 1995, VIROLOGY, V210, P471, DOI 10.1006/viro.1995.1364; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UPTON C, 1994, J VIROL, V68, P4186, DOI 10.1128/JVI.68.7.4186-4195.1994; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x	58	256	283	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					813	816		10.1126/science.273.5276.813	http://dx.doi.org/10.1126/science.273.5276.813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670425				2022-12-28	WOS:A1996VB42900048
J	Burns, RB; McCarthy, EP; Freund, KM; Marwill, SL; Shwartz, M; Ash, A; Moskowitz, MA				Burns, RB; McCarthy, EP; Freund, KM; Marwill, SL; Shwartz, M; Ash, A; Moskowitz, MA			Black women receive less mammography even with similar use of primary care	ANNALS OF INTERNAL MEDICINE			English	Article						mammography; blacks; breast neoplasms; physicians, family; primary health care	BREAST-CANCER; SCREENING MAMMOGRAPHY; RACIAL-DIFFERENCES; CERVICAL-CANCER; MORTALITY; DIAGNOSIS; BARRIER; TRIAL; STAGE; COST	Background: Black women with breast cancer have a decreased 5-year survival rate in comparison with white women, possibly because of less frequent use of mammography. Having a regular provider or source of health care is the most important determinant of mammography use. Objective: To examine whether the difference in mammography use between elderly black women and elderly white women is related to the number of visits made to a primary care physician. Design: Retrospective review of 1990 Health Care Financing Administration billing files (Medicare part B) from 10 states. Setting: Outpatient mammography services in 10 states. Participants: Black women and white women, 65 years of age and older, residing in one of the 10 states. Measurements: Any mammogram. Predictors included race, number of visits to a primary care physician (O, 1, 2, or 3 or more), median income of ZIP code of residence (a surrogate measure of income), and state. Results: The following are findings from Georgia; similar results were found in each state studied. The mean age of the 335 680 women was 75 years; 20% were black. Sixty-eight percent of the black women and 69% of the white women made at least one visit to a primary care physician. Overall, 14% of the women had had mammography; black women had mammography less often than white women (9% compared with 15%). At each primary care visit level (1, 2, or 3 or more visits), black women had mammography less often than white women (1 visit, 7% compared with 15%; 2 visits, 12% compared with 21%, and 3 or more visits, 12% compared with 20%). Even among women who had made at least one visit to a primary care physician, a deficit for blacks occurred in each income quintile (lowest quintile, 13% compared with 20%; low, 10% compared with 18%; middle, 12% compared with 18%; high, 10% compared with 19%; and highest, 12% compared with 22%) and in each state (in Georgia, for example, the percentages were 14% compared with 21%). An age-, income-, and state-adjusted logistic model predicting mammography use for 2.9 million white women in all 10 states shows the powerful effect of primary care use on mammography (odds ratios for 1, 2, and 3 or more visits were, respectively, 2.73 [95% Cl, 2.70 to 2.77]; 3.98 [Cl, 3.93 to 4.03]; and 4.62 [Cl, 4.58 to 4.67]). The same model fit to 250 000 black women shows a lesser effect (analogous odds ratios were 1.77 [Cl, 1.67 to 1.87]; 2.49 [Cl, 2.36 to 2.63]; and 3.15 [Cl, 3.04 to 3.25]). Conclusions: Among older women, mammography is used less often for blacks than for whites. More frequent use of mammography is associated with more visits to a primary care physician in both groups, but the deficit for black women persists at each income level and in each state, even after primary care use is considered. Primary care visits are less likely to ''boost'' mammography use for black women than for white women.	BOSTON UNIV, MED CTR HOSP, EVANS DEPT MED, GEN INTERNAL MED SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MANAGEMENT, BOSTON, MA 02215 USA	Boston University; Boston University			Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Freund, Karen/0000-0002-9049-5574				*AM MED ASS, 1990, PHYS CURR PROC TERM; ANDERSON LM, 1995, AM J PUBLIC HEALTH, V85, P840, DOI 10.2105/AJPH.85.6.840; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDREWS HF, 1994, AM J PUBLIC HEALTH, V84, P56, DOI 10.2105/AJPH.84.1.56; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; BREEN N, 1994, AM J PUBLIC HEALTH, V84, P62, DOI 10.2105/AJPH.84.1.62; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CAPLAN LS, 1992, J GERONTOL, V47, P101; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; GRADY KE, 1992, PREV MED, V21, P766, DOI 10.1016/0091-7435(92)90083-T; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P145; Horton J A, 1992, Womens Health Issues, V2, P180, DOI 10.1016/S1049-3867(05)80169-0; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KIEFE CI, 1994, ARCH INTERN MED, V154, P1217, DOI 10.1001/archinte.154.11.1217; Makuc DM, 1994, ADV DATA, V254, P1; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; RIES LAG, 1994, NIH PUB; *SAS I, 1985, SAS US GUID; SELDMAN H, 1987, CA-CANCER J CLIN, V37, P258; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; URBAN N, 1994, AM J PUBLIC HEALTH, V84, P50, DOI 10.2105/AJPH.84.1.50; VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; 1993, MMWR-MORBID MORTAL W, V42, P737; 1992, MEDICARE MEDICAID GU, V50, P27201; 1990, JAMA-J AM MED ASSOC, V264, P54; 1995, MMWR-MORBID MORTAL W, V44, P777; 1990, MMWR-MORBID MORTAL W, V39, P621	32	166	166	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					173	+		10.7326/0003-4819-125-3-199608010-00002	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686974				2022-12-28	WOS:A1996UZ28700002
J	Donnelly, SC; Strieter, RM; Reid, PT; Kunkel, SL; Burdick, MD; Armstrong, I; Mackenzie, A; Haslett, C				Donnelly, SC; Strieter, RM; Reid, PT; Kunkel, SL; Burdick, MD; Armstrong, I; Mackenzie, A; Haslett, C			The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						cytokines; respiratory distress syndrome, adult; tumor necrosis factor; interleukin-1; interleukin-10	TUMOR-NECROSIS-FACTOR; INHIBITS CYTOKINE PRODUCTION; IL-1; INVIVO; TRAUMA	Objectives: To determine the relation between 1) intraalveolar concentrations of the proinflammatory cytokines (tumor necrosis factor, interleukin-1 beta, and interleukin-8) and the anti-inflammatory cytokines (interleukin-10 and interleukin-1 receptor antagonist) in patients with early adult respiratory distress syndrome (ARDS) and 2) subsequent patient mortality rates. Design: Prospective cohort study. Setting: University medical center. Patients: 28 consecutive patients in whom ARDS was prospectively identified during hospitalization and 9 ventilated controls. Measurements: Concentrations of proinflammatory cytokines and anti-inflammatory cytokines in bronchoalveolar lavage fluid. Results: The concentrations of proinflammatory and anti-inflammatory cytokines within the alveolar air spaces were significantly elevated in patients with ARDS compared with controls (P = 0.01 for tumor necrosis factor [median, 90 pg/mL (range, 0 to 2500 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 118 pg/mL) for controls]; P = 0.001 for interleukin-1 beta [median, 179 pg/mL (range, 0 to 2200 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 80 pg/mL) for controls]; P = 0.0001 for interleukin-8 [median, 628 pg/mL (range, 0 to 4700 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 278 pg/mL) for controls]; P = 0.0005 for interleukin-10 [median, 100 pg/mL (range, 0 to 1600 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 50 pg/mL) for controls], and P = 0.002 for interleukin-1 receptor antagonist [median, 820 pg/mL (range, 0 to 18 900 pg/mL) for patients with ARDS; median, 50 pg/mL (range, 0 to 240 pg/mL) for controls]). A highly significant correlation was found between low concentrations of anti-inflammatory cytokines and subsequent patient mortality rates (P = 0.003 for interleukin-10 [median, 120 pg/mL (range, 30 to 1600 pg/mL) for survivors; median, 40 pg/mL (range, 0 to 110 pg/mL) for nonsurvivors]; P = 0.008 for interleukin-1 receptor antagonist [median, 1600 pg/mL (range, 80 to 18 900 pg/mL) for survivors; median, 90 pg/mL (range, 0 to 3400 pg/mL) for nonsurvivors. No significant correlation was found between the concentrations of the proinflammatory cytokines and mortality rates. Conclusion: Low concentrations of the anti-inflammatory cytokines interleukin-10 and interleukin-1 receptor antagonist in bronchoalveolar lavage fluid obtained from patients with early ARDS are closely associated with poor prognosis. These findings support the hypothesis that failure to mount a localized intrapulmonary anti-inflammatory response early in the pathogenesis of ARDS contributes to more severe organ injury and worse prognosis. Our findings suggest that augmenting anti-inflammatory cytokine defenses would be a beneficial therapeutic approach to patients with ARDS and other inflammatory diseases.	UNIV EDINBURGH, SCH MED, RAYNE LAB, RESP MED UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV MICHIGAN, DEPT MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DIV PULM & CRIT CARE MED, ANN ARBOR, MI 48109 USA; ROYAL INFIRM, EDINBURGH, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Royal Infirmary of Edinburgh; University of Edinburgh				Donnelly, Seamas/0000-0001-7145-1843				AREND WP, 1989, J IMMUNOL, V143, P1851; BACHOFEN M, 1974, CHEST, V65, pS14, DOI 10.1378/chest.65.4_Supplement.14S; BALDWIN SR, 1986, LANCET, V1, P11; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EVANOFF HL, 1992, IMMUNOL INVEST, V21, P39, DOI 10.3109/08820139209069361; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FUKUDA Y, 1987, AM J PATHOL, V126, P171; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HYERS TM, 1991, AM REV RESPIR DIS, V144, P268, DOI 10.1164/ajrccm/144.2.268; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; MACNAUGHTON PD, 1992, LANCET, V339, P469, DOI 10.1016/0140-6736(92)91068-J; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; MILLAR AB, 1989, LANCET, V2, P712, DOI 10.1016/S0140-6736(89)90772-1; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; ROCKER GM, 1989, LANCET, V1, P120; SHANLEY TP, 1995, J IMMUNOL, V154, P3454; SMITH DR, 1994, AM J PATHOL, V145, P18; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; VELDE AAT, 1992, J IMMUNOL, V149, P4048; WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797	31	195	210	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					191	+		10.7326/0003-4819-125-3-199608010-00005	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686976				2022-12-28	WOS:A1996UZ28700004
J	Seemuller, E; Lupas, A; Baumeister, W				Seemuller, E; Lupas, A; Baumeister, W			Autocatalytic processing of the 20S proteasome	NATURE			English	Article							MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; COMPLEX; ACYLASE	THE Ntn (N-terminal nucleophile) hydrolases are enzymes with an unusual four-layer alpha \ beta fold(1-5). The amino-terminal residue (cysteine, serine or threonine) of the mature protein is the catalytic nucleophile(6-10), and its side chain is activated nucleophilic attack by transfer of its proton to the free N terminus(2), although other active-site residues may also be involved(4,8). The four currently known Ntn hydrolases (glutamine PRPP amidotransferase(1,6), penicillin acylase(2,7), the 20S proteasome(3,8,9) and aspartylglucosaminidase(4,10)) are encoded as inactive precursors, and are activated by cleavage of the peptide bond preceding the catalytic residue. It has been suggested that autocatalytic processing is a common Feature of Ntn hydrolases, and proceeds by an intramolecular mechanism determined by their common fold(5). Here we show that propeptide processing In the proteasome from Thermoplasma acidophilum is Indeed autocatalytic, but is probably intermolecular. Processing is not required for assembly, is largely unaffected by propeptide length and sequence, and occurs before beta-subunit folding is completed. Although serine is an acceptable active-site nucleophile for proteolysis, and cysteine for processing, only threonine is fully functional in both. This explains why threonine is universally conserved in active proteasome subunits.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; GRZLWA A, 1994, EUR J BIOCHEM, V233, P1061; GRZLWA A, 1991, FEBS LETT, V290, P186; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; OLNONEN C, 1995, NAT STRUCT BIOL, V2, P1102; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	28	180	182	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					468	470		10.1038/382468a0	http://dx.doi.org/10.1038/382468a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684489				2022-12-28	WOS:A1996VA25100062
J	Catlin, DH; Murray, TH				Catlin, DH; Murray, TH			Performance-enhancing drugs, fair competition, and Olympic sport	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TESTOSTERONE	Drug control has become an important component of Olympic sport, At the Atlanta Centennial Olympic Games, urine samples will be tested for prohibited substances, including stimulants, narcotics, anabolic agents, diuretics, peptides, and glycoprotein hormones as well as prohibited methods of enhancing performance, including blood doping and pharmacological, chemical, and physical manipulation of the urine. Drug testing programs must address short-acting stimulants, beta-blockers, and diuretics; training drugs such as anabolic steroids; and drugs affecting the detectability of other drugs. Programs include short- or no-notice testing during training periods, testing at qualifying competitions, and testing at the Olympic Games, Procedures and disposition that occur when a prohibited substance is found in an athlete competing in an Olympic sport are discussed, An analysis of the ethics of the use of performance-enhancing drugs in sports and of drug control in terms of fair competition and the impact of enhancement technologies of the meaning of sports also is presented.	UNIV CALIF LOS ANGELES, DEPT MOL & MED PHARMACOL, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; CASE WESTERN RESERVE UNIV, CTR BIOMED ETH, CLEVELAND, OH 44106 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Case Western Reserve University	Catlin, DH (corresponding author), UNIV CALIF LOS ANGELES, OLYMP ANALYT LAB, 2122 GRANVILLE AVE, LOS ANGELES, CA 90025 USA.							Aguilera R, 1996, J MASS SPECTROM, V31, P169, DOI 10.1002/(SICI)1096-9888(199602)31:2<169::AID-JMS276>3.0.CO;2-I; Beckett A H, 1978, Br J Sports Med, V12, P185; BECKETT AH, 1967, J PHARM PHARMACOL, V19, P273, DOI 10.1111/j.2042-7158.1967.tb08089.x; BERTRAND M, 1978, FARMACEUTISCHE TIJDS, V3, P85; BROOKS RV, 1979, J STEROID BIOCHEM, V11, P913, DOI 10.1016/0022-4731(79)90029-3; CARLSTROM K, 1992, CLIN CHEM, V38, P1779; CATLIN DH, 1987, CLIN CHEM, V33, P319; CATLIN DH, 1992, CLIN CHEM, V38, P1685; CATLIN DH, 1990, ADV INTERNAL MED, V36, P381; CROYLE PH, 1979, JAMA-J AM MED ASSOC, V241, P827, DOI 10.1001/jama.241.8.827; de Pencier J.C., 1994, BLOOD SAMPLES DOPING, P3; DEHENNIN L, 1994, CLIN CHEM, V40, P106; DELATORRE X, 1995, J MASS SPECTROM, V30, P1393, DOI 10.1002/jms.1190301004; DEMERODE A, 1979, J SPORT MED PHYS FIT, V19, P91; DONIKE M, 1972, MEDITSINSKAIA TEKHNI, V92, P153; Donike M, 1994, BLOOD SAMPLES DOPING, P75; Donike Manfred, 1983, SPORT LEISTUNG GESUN, P293; Fagerhol M, 1994, BLOOD SAMPLES DOPING, P161; FOST N, 1986, HASTINGS CENT REP, V16, P5, DOI 10.2307/3563105; Gareau R, 1996, NATURE, V380, P113, DOI 10.1038/380113a0; KICMAN AT, 1993, CLIN CHEM, V39, P1798; KRUSE P, 1986, J APPL PHYSIOL, V61, P417, DOI 10.1152/jappl.1986.61.2.417; LAIDLER P, 1995, RAPID COMMUN MASS SP, V9, P1021, DOI 10.1002/rcm.1290091110; LATIES VG, 1981, FED PROC, V40, P2689; MARTIN WR, 1971, CLIN PHARMACOL THER, V12, P245; MURRAY TH, 1983, HASTINGS CENT REP, V13, P24, DOI 10.2307/3561718; NAMBA O, 1989, HORMONES SPORT, P275; RAYNAUD E, 1992, LANCET, V340, P1468, DOI 10.1016/0140-6736(92)92657-2; RYU JC, 1992, J APPL TOXICOL, V12, P385, DOI 10.1002/jat.2550120605; SALLERAS L, 1995, PUBLIC HEALTH REP, V110, P338; SCHANZER W, IN PRESS J CHROMATOG; SIMON TL, 1994, SEMIN HEMATOL, V31, P128; SPANN C, 1995, ANN PHARMACOTHER, V29, P75, DOI 10.1177/106002809502900114; WADE N, 1972, SCIENCE, V176, P1399, DOI 10.1126/science.176.4042.1399; 1994, NCAA NEWS       0608; 1993, NCAA NEWS       0927; 1995, NCAA NEWS       0614; 1992, NCAA NEWS       0902; 1993, NCAA NEWS       0606	39	51	56	1	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					231	237		10.1001/jama.276.3.231	http://dx.doi.org/10.1001/jama.276.3.231			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667569				2022-12-28	WOS:A1996UW46900036
J	Sharpley, A				Sharpley, A			Impact of daytime sleepiness underrated	LANCET			English	Editorial Material											Sharpley, A (corresponding author), LITTLEMORE HOSP,PSYCHOPHARMACOL RES UNIT,OXFORD OX4 4XN,ENGLAND.			Sharpley, Ann L/0000-0002-0623-1067				BINNIE GA, 1983, BRIT MED J, V287, P1349, DOI 10.1136/bmj.287.6402.1349; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Hublin C, 1996, J INTERN MED, V239, P417, DOI 10.1046/j.1365-2796.1996.475826000.x; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Ray W A, 1993, Clin Geriatr Med, V9, P413	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					71	71		10.1016/S0140-6736(05)64601-6	http://dx.doi.org/10.1016/S0140-6736(05)64601-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676715				2022-12-28	WOS:A1996UW67300003
J	Tiemessen, CHJ; Evers, JLH; Bots, RSGM				Tiemessen, CHJ; Evers, JLH; Bots, RSGM			Tight-fitting underwear and sperm quality	LANCET			English	Letter									ACAD ZIEKENHUIS MAASTRICHT,DEPT OBSTET & GYNAECOL,6202 AZ MAASTRICHT,NETHERLANDS; ST ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,TILBURG,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Elisabeth-TweeSteden Ziekenhuis (ETZ)			Evers, Johannes L/F-6000-2012	Evers, Johannes/0000-0001-8079-1436				BRINDLEY GS, 1982, BRIT J UROL, V54, P49, DOI 10.1111/j.1464-410X.1982.tb13510.x; MIEUSSET R, 1985, FERTIL STERIL, V43, P589; ROCK J, 1965, AM J OBSTET GYNECOL, V93, P793, DOI 10.1016/0002-9378(65)90080-3	3	39	39	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1844	1845		10.1016/S0140-6736(96)91670-0	http://dx.doi.org/10.1016/S0140-6736(96)91670-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667967				2022-12-28	WOS:A1996UU46900074
J	Graham, A; Green, L; Glasier, AF				Graham, A; Green, L; Glasier, AF			Teenagers' knowledge of emergency contraception: Questionnaire survey in south east Scotland	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCIES	Objective-To determine the level of knowledge of emergency contraception among 14 and 15 year olds. Design-Confidential questionnaire survey. Setting-10 secondary schools in Lothian, south east Scotland. Subjects-1206 pupils predominantly (98.7%) aged 14 and 15 in the fourth year of secondary school. Main outcome measures-Knowledge of the existence of emergency contraception; of its safety, efficacy, and time limits; and of where to obtain it. Results-1121 (93.0%) fourth year pupils aged 14-16 had heard of emergency contraception. 194 girls (32.7%) and 168 boys (27.5%) had experienced sexual intercourse. Of girls who had experienced sexual intercourse, 61 (31.4%) had used emergency contraception. Knowledge of correct time limits was poor, sexually active girls being the most knowledgeable. Pupils attending schools ranked lower than the national average for academic attainment were less likely to have heard of emergency contraception and more likely to have been sexually active. 861 (76.8%) pupils knew they could obtain emergency contraception from their doctor. 925 (82.5%) pupils believed emergency contraception to be effective but 398 (35.5%) thought it more dangerous than the oral contraceptive pill. Conclusions-One third of sexually active girls aged under 16 in Lothian have used emergency contraception. This may help explain the fairly constant teenage pregnancy rates despite increasing sexual activity. Scottish teenagers are well informed about the existence of emergency contraception. However, many do not know when and how to access it properly. Health education initiatives should target teenagers from less academic schools as they are more likely to be sexually active at a young age and are less well informed about emergency contraception.	EDINBURGH HEALTHCARE NHS TRUST,FAMILY PLANNING & WELL WOMAN SERV,EDINBURGH EH4 1NL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh								ALLABY MAK, 1995, BRIT MED J, V310, P1641, DOI 10.1136/bmj.310.6995.1641; *AUD UN HER MAJ IN, 1995, EX RES SCOTT SCH 199; BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; BURTON R, 1990, BRIT J GEN PRACT, V40, P326; BURTON R, 1990, BR J FAM PLANN, V15, P119; Department of Health, 1992, GEN HOUS SURV; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; GEORGE J, 1994, BRIT J GEN PRACT, V44, P451; Johnson AM, 1994, SEXUAL ATTITUDES LIF; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; MELLANBY AR, 1995, BRIT MED J, V311, P414, DOI 10.1136/bmj.311.7002.414; PEARSON VAH, 1995, BRIT MED J, V310, P1644, DOI 10.1136/bmj.310.6995.1644; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SMITH T, 1993, BRIT MED J, V306, P1232, DOI 10.1136/bmj.306.6887.1232; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857	15	67	67	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1567	1569		10.1136/bmj.312.7046.1567	http://dx.doi.org/10.1136/bmj.312.7046.1567			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664665	Green Published			2022-12-28	WOS:A1996UU80600017
J	Latronico, N; Fenzi, F; Recupero, D; Guarneri, B; Tomelleri, G; Tonin, P; DeMaria, G; Antonini, L; Rizzuto, N; Candiani, A				Latronico, N; Fenzi, F; Recupero, D; Guarneri, B; Tomelleri, G; Tonin, P; DeMaria, G; Antonini, L; Rizzuto, N; Candiani, A			Critical illness myopathy and neuropathy	LANCET			English	Article							MULTIPLE ORGAN FAILURE; SEPSIS; POLYNEUROPATHY; DEFINITIONS	Background Critically ill patients may develop muscle weakness or paralysis during the course of sepsis and multiple-organ failure. We studied peripheral nerve and muscle disorders (NMD) in comatose patients. Methods Comatose patients who developed paralysis associated with absent deep-tendon reflexes had electroneuromyography (ENMG) and muscle-nerve biopsy specimens taken. Onset and duration of sepsis, multiple-organ dysfunction and failure, biochemical alterations, and drugs potentially interfering with nerve-muscle function were recorded. Findings 24 patients became quadriparetic or quadriplegic; muscle changes were found in 23. Axonal neuropathy was found in eight of 22 patients examined. All patients had prolonged sepsis and multiple-organ dysfunction, but only 14 had multiple-organ failure. Drugs such as steroids, neuromuscular-blocking agents, and aminoglycosides were not responsible for paresis, and the part played by hyperglycaemia and hypoalbuminaemia is uncertain. Attending physicians predicted a fatal outcome in all cases, although six of seven survivors fully recovered within 115-210 days from the onset of paralysis. Interpretation Comatose patients may become completely paralysed because of NMD. The diagnosis is important to avoid unnecessary investigations and unreasonably pessimistic prognosis. ENMG is essential for the diagnosis and for planning further clinical management. Biopsy needs to be done only when it is necessary to properly classify NMD.	UNIV BRESCIA, SPEDALI CIVILE, SERV NEUROFISIOPATOL, BRESCIA, ITALY; UNIV VERONA, OSPED BORGO ROMA, I-37100 VERONA, ITALY	Hospital Spedali Civili Brescia; University of Brescia; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Latronico, N (corresponding author), UNIV BRESCIA, SPEDALI CIVILI, IST ANESTESIA & REANIMAZ, PIAZZALE OSPED CIVILI 1, I-25125 BRESCIA, ITALY.		LATRONICO, Nicola/F-1557-2010	LATRONICO, Nicola/0000-0002-2521-5871				BAUE AE, 1991, SURG CLIN N AM, V71, P549; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; BOLTON CF, 1986, J NEUROL NEUROSUR PS, V49, P563, DOI 10.1136/jnnp.49.5.563; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; DECOUL AAWO, 1991, CLIN NEUROL NEUROSUR, V93, P27, DOI 10.1016/0303-8467(91)90005-A; FIACCADORI E, 1991, RIV ITALIANA NUTR PA, V9, P187; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNOCHEL JP, 1982, AM J MED, V72, P521, DOI 10.1016/0002-9343(82)90522-8; KUPFER Y, 1992, ANN INTERN MED, V117, P484, DOI 10.7326/0003-4819-117-6-484; LACOMIS D, 1993, MUSCLE NERVE, V16, P84, DOI 10.1002/mus.880160114; LYCHLAMA A, 1987, HDB CLIN NEUROLOGY, V7, P575; MCQUILLE.MP, 1968, ARCH NEUROL-CHICAGO, V18, P402, DOI 10.1001/archneur.1968.00470340088008; SCHUSTER DP, 1992, CRITICAL CARE, P407; TEASDALE G, 1974, LANCET, V2, P81; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819; ZOCHODNE DW, 1994, MUSCLE NERVE, V17, P285, DOI 10.1002/mus.880170305	20	300	307	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1996	347	9015					1579	1582		10.1016/S0140-6736(96)91074-0	http://dx.doi.org/10.1016/S0140-6736(96)91074-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667865				2022-12-28	WOS:A1996UP66100008
J	Carswell, F				Carswell, F			Whole-population screening for carriers of cystic fibrosis gene	LANCET			English	Editorial Material									UNIV BRISTOL,BRISTOL,AVON,ENGLAND	University of Bristol	Carswell, F (corresponding author), ROYAL HOSP SICK CHILDREN,BRISTOL BS2 8BJ,AVON,ENGLAND.							BROCK DJH, 1995, EUR J HUM GENET, V3, P2; Brock DJH, 1996, LANCET, V347, P148, DOI 10.1016/S0140-6736(96)90340-2; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; FADEN RR, 1994, AM J MED GENET, V50, P1, DOI 10.1002/ajmg.1320500102; GREEN MR, 1993, ARCH DIS CHILD, V68, P472; LIVINGSTONE J, 1993, CLIN GENET, V43, P57, DOI 10.1111/j.1399-0004.1993.tb04427.x; MIEDZYBRODZKA ZH, 1995, BRIT MED J, V310, P353, DOI 10.1136/bmj.310.6976.353; RANIERI E, 1991, BRIT MED J, V302, P1237, DOI 10.1136/bmj.302.6787.1237; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; RYLEY HC, 1993, BR MED B, V48, P805; SUPER M, 1994, BRIT MED J, V209, P877	11	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1421	1422		10.1016/S0140-6736(96)91676-1	http://dx.doi.org/10.1016/S0140-6736(96)91676-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676620				2022-12-28	WOS:A1996UM48500003
J	Chen, GL; Li, BS; Liebermann, RC				Chen, GL; Li, BS; Liebermann, RC			Selected elastic moduli of single-crystal olivines from ultrasonic experiments to mantle pressures	SCIENCE			English	Article							VELOCITIES	Ultrasonic interferometric measurements, developed for polycrystalline samples in a multi-anvil apparatus, were extended to single-crystal samples of San Carlos olivine and forsterite. The elastic moduli, C-22 and C-55 of San Carlos olivine and C-55 of pure forsterite, were measured to about 13 gigapascals. These data on C-22 for San Carlos olivine and C-55 for forsterite are consistent with earlier measurements and extrapolations. The C-55 for San Cartes olivine increases linearly as a function of increasing pressure, unlike the earlier nonlinear behavior observed at high pressure with impulsive stimulated scattering techniques.			Chen, GL (corresponding author), SUNY STONY BROOK, DEPT EARTH & SPACE SCI, CTR HIGH PRESSURE RES, STONY BROOK, NY 11794 USA.		Li, Baosheng/C-1813-2013					BASSETT WA, 1982, HIGH PRESSURE RES GE, P115; DUFFY CS, 1995, NATURE, V378, P170; DUFFY TS, 1989, J GEOPHYS RES-SOLID, V94, P1895, DOI 10.1029/JB094iB02p01895; GRAHAM EK, 1969, J GEOPHYS RES, V74, P5949, DOI 10.1029/JB074i025p05949; KUMAZAWA M, 1969, J GEOPHYS RES, V74, P5961, DOI 10.1029/JB074i025p05961; KUSABA K, 1993, PURE APPL GEOPHYS, V141, P643, DOI 10.1007/BF00998350; Li B. A., UNPUB; LLOYD EC, 1971, NBS SPEC PUBL, V326, P1; NOMURA M, 1982, JPN J APPL PHYS 1, V21, P936, DOI 10.1143/JJAP.21.936; WEBB SL, 1989, PHYS CHEM MINER, V16, P684; YONEDA A, 1992, HIGH PRESSURE RES AP, P207; ZAUG JM, 1993, SCIENCE, V260, P1487, DOI 10.1126/science.260.5113.1487; ZHA CS, IN PRESS J GEOPHYS R	13	38	39	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					979	980		10.1126/science.272.5264.979	http://dx.doi.org/10.1126/science.272.5264.979			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662581				2022-12-28	WOS:A1996UL61900035
J	Zhou, YF; Leon, MB; Waclawiw, MA; Popma, JJ; Yu, ZX; Finkel, T; Epstein, SE				Zhou, YF; Leon, MB; Waclawiw, MA; Popma, JJ; Yu, ZX; Finkel, T; Epstein, SE			Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL-CELLS; ANGIOPLASTY; SURFACE; VIRUS; ATHEROSCLEROSIS; FIBROBLASTS; ADHESION	Background Restenosis occurs commonly after coronary angioplasty and atherectomy, but the causes of restenosis are poorly understood. Recently, it has been found that cytomegalovirus (CMV) DNA is present in restenotic lesions from atherectomy specimens. This and other evidence suggest that CMV may have a role in the process of restenosis. Methods We prospectively studied 75 consecutive patients undergoing directional coronary atherectomy for symptomatic coronary artery disease. Before atherectomy was performed, we measured blood levels of anti-CMV IgG antibodies to determine whether previous exposure to CMV increased the risk of restenosis, as determined by coronary angiography performed six months after atherectomy. Results After atherectomy, the mean (+/-SD) minimal luminal diameter of the target vessel was greater in the 49 patients who were seropositive for CMV than in the 26 patients who were seronegative (3.18+/-0.51 mm vs. 2.89+/-0.45 mm, P=0.01). After six months, however, the seropositive patients had a greater reduction in the luminal diameter (1.24+/-0.83 mm vs, 0.68+/-0.69 mm, P=0.003), resulting in a significantly higher rate of restenosis in the seropositive patients (43 percent vs. 8 percent, P=0.002). In a multivariable logistic-regression model, CMV seropositivity and the CMV titer were independently predictive of restenosis (odds ratios, 12.9 and 8.1, respectively). There was no evidence of acute infection, since the titer of anti-CMV IgG antibodies did not increase over time and tests for anti-CMV IgM antibodies were negative in all patients. Conclusions Prior infection with CMV is a strong independent risk factor for restenosis after coronary atherectomy. If confirmed, these findings may help identify patients at risk for restenosis. (C) 1996, Massachusetts Medical Society.	NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA; WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); MedStar Washington Hospital Center								ALCAMI J, 1991, J GEN VIROL, V72, P2765, DOI 10.1099/0022-1317-72-11-2765; BACH R, 1994, THROMB RES, V74, pS55; BANKS TA, 1992, CLIN INFECT DIS, V14, P933, DOI 10.1093/clinids/14.4.933; BRUGGEMAN CA, 1993, VIRCHOWS ARCH B, V64, P325, DOI 10.1007/BF02915131; DZAVIK V, 1995, AM J CARDIOL, V75, P936, DOI 10.1016/S0002-9149(99)80691-2; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; ETINGIN OR, 1993, P NATL ACAD SCI USA, V90, P5153, DOI 10.1073/pnas.90.11.5153; FAXON DP, 1995, ANN NY ACAD SCI, V748, P419; FOLEY DP, 1994, CIRCULATION, V90, P1239, DOI 10.1161/01.CIR.90.3.1239; GEIST LJ, 1991, AM J RESP CELL MOL, V5, P292, DOI 10.1165/ajrcmb/5.3.292; GONCZOL E, 1984, J GEN VIROL, V65, P1833, DOI 10.1099/0022-1317-65-10-1833; GRUNDY JE, 1993, IMMUNOLOGY, V78, P405; HERMANS WRM, 1993, J CARDIOVASC PHARM, V22, pS45, DOI 10.1097/00005344-199322004-00007; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; JORDAN MC, 1973, ANN INTERN MED, V79, P153, DOI 10.7326/0003-4819-79-2-153; KLACSMANN P, 1977, DEL MED J, V49, P399; KOWALIK TF, 1993, IMMUNOLOGY, V78, P405; LEFEUVRE C, 1994, AM J CARDIOL, V73, P840, DOI 10.1016/0002-9149(94)90806-0; MELNICK JL, 1993, EUR HEART J, V14, P30; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PRYZDIAL ELG, 1994, BLOOD, V84, P3749, DOI 10.1182/blood.V84.11.3749.bloodjournal84113749; SCHULMAN LL, 1991, ARCH INTERN MED, V151, P1118, DOI 10.1001/archinte.151.6.1118; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SOUTHERN P, 1986, NEW ENGL J MED, V314, P359, DOI 10.1056/NEJM198602063140606; SPAN AHM, 1991, EUR J CLIN INVEST, V21, P331, DOI 10.1111/j.1365-2362.1991.tb01378.x; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; STEIN B, 1995, CIRCULATION, V91, P979, DOI 10.1161/01.CIR.91.4.979; VANDAMMIERAS MCE, 1992, THROMB HAEMOSTASIS, V68, P364; ZHOU H, 1995, J VIROL, V69, P7960; ZHOU YF, 1995, J AM COLL CARDIOL, V25, pA242; ZHOU YF, 1995, CIRCULATION S1, V92, P162	31	400	427	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					624	630		10.1056/NEJM199608293350903	http://dx.doi.org/10.1056/NEJM199608293350903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8687516				2022-12-28	WOS:A1996VD42500003
J	Layer, PW; Kroner, A; McWilliams, M				Layer, PW; Kroner, A; McWilliams, M			An Archean geomagnetic reversal in the Kaap Valley pluton, South Africa	SCIENCE			English	Article							BARBERTON GREENSTONE-BELT; PALEOMAGNETIC EVIDENCE; FIELD; AGE	The Kaap Valley pluton in South Africa is a tonalite intrusion associated with the Archean Barberton Greenstone Belt. Antipodal paleomagnetic directions determined from the central and marginal parts of the pluton record a geomagnetic reversal that occurred as the pluton cooled. The age of the reversal is constrained by an 40Ar/39Ar plateau age from hornblende at 3214 +/- 4 million years, making it the oldest known reversal. The data presented here suggest that Earth has had a reversing, perhaps dipolar, magnetic field since at least 3.2 billion years ago.	UNIV MAINZ, INST GEOWISSENSCH, D-55099 MAINZ, GERMANY; STANFORD UNIV, DEPT GEOPHYS, STANFORD, CA 94305 USA	Johannes Gutenberg University of Mainz; Stanford University	Layer, PW (corresponding author), UNIV ALASKA, INST GEOPHYS, FAIRBANKS, AK 99775 USA.		McWilliams, Michael O/A-9548-2011; Layer, Paul W/F-5465-2010	McWilliams, Michael O/0000-0002-4107-7069; 				ARMSTRONG RA, 1990, EARTH PLANET SC LETT, V101, P90, DOI 10.1016/0012-821X(90)90127-J; BARTON ES, 1994, GEOLOGY, V22, P343, DOI 10.1130/0091-7613(1994)022<0343:UPZAFA>2.3.CO;2; FISHER R, 1953, PROC R SOC LON SER-A, V217, P295, DOI 10.1098/rspa.1953.0064; HALE CJ, 1984, GEOPHYS RES LETT, V11, P97, DOI 10.1029/GL011i002p00097; HARGRAVE.RB, 1970, J GEOL, V78, P253, DOI 10.1086/627516; HATTINGH PJ, 1983, THESIS U PRETORIA; KAMO SL, 1990, GEOL SOC AUST ABSTR, V23, P53; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; KRONER A, 1992, SCIENCE, V256, P1405, DOI 10.1126/science.256.5062.1405; KRUNER A, 1991, EARTH PLANET SC LETT, V103, P41, DOI 10.1016/0012-821X(91)90148-B; LAYER PW, 1992, GEOLOGY, V20, P717, DOI 10.1130/0091-7613(1992)020<0717:PMTHOT>2.3.CO;2; LAYER PW, 1988, J GEOPHYS RES-SOLID, V93, P2191, DOI 10.1029/JB093iB03p02191; LAYER PW, 1988, J GEOPHYS RES-SOLID, V93, P449, DOI 10.1029/JB093iB01p00449; LAYER PW, 1989, EOS, V70, P1064; LAYER PW, 1983, EOS, V45, P689; MCELHINNY MW, 1980, J GEOPHYS RES, V85, P3523, DOI 10.1029/JB085iB07p03523; ROBB LJ, 1986, PRECAMBRIAN RES, V31, P1, DOI 10.1016/0301-9268(86)90063-X; TEGTMEYER AR, 1987, PRECAMBRIAN RES, V36, P1, DOI 10.1016/0301-9268(87)90014-3; VANALSTINE DR, 1980, GEOPHYS J ROY ASTR S, V61, P101, DOI 10.1111/j.1365-246X.1980.tb04307.x	19	28	29	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1996	273	5277					943	946		10.1126/science.273.5277.943	http://dx.doi.org/10.1126/science.273.5277.943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688075				2022-12-28	WOS:A1996VC67000058
J	Dorsey, JH; Holtz, PM; Griffiths, RI; McGrath, MM; Steinberg, EP				Dorsey, JH; Holtz, PM; Griffiths, RI; McGrath, MM; Steinberg, EP			Costs and charges associated with three alternative techniques of hysterectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSISTED VAGINAL HYSTERECTOMY; LAPAROSCOPIC HYSTERECTOMY; TECHNOLOGY FOLLIES; EXPERIENCE	Background Many hysterectomies are now performed by a laparoscopically assisted vaginal technique. This procedure is controversial, partly because of concern about cost. We studied hospital charges and costs for the procedure as compared with those for total abdominal hysterectomy and total vaginal hysterectomy in clinically similar groups of patients. Methods From hospital-discharge data and patients' charts, we identified hysterectomies performed in 1993 and 1994 by 96 surgeons at a community teaching hospital to treat benign conditions. The patients were grouped according to the surgical procedures performed in conjunction with the hysterectomy. Data on hospital charges and cost-to-charge ratios for 64 hospital cost centers were used to assess charges and costs for specific resources, as well as for the hospitalization overall. Results Of 1049 patients studied, 26 percent underwent laparoscopically assisted vaginal hysterectomy, 54 percent underwent abdominal hysterectomy, and 20 percent underwent vaginal hysterectomy. The average hospital stays were 2.6, 3.9, and 2.9 days, respectively, and the mean total charges (facility charges plus professional fees) for the hospitalizations were $6,116, $5,084, and $4,221 (P<0.001 for the comparison of the laparoscopic technique with both other techniques). The mean facility costs were $4,914, $3,954, and $3,116, respectively (P<0.001 for the same comparison), with similar findings in all subgroups. The higher charges and costs for laparoscopically assisted vaginal hysterectomy were due to higher supply costs, particularly when disposable supplies were used, and to longer operating-room time. Conclusions Despite shorter hospital stays, in-hospital charges and costs for laparoscopically assisted vaginal hysterectomy are higher than for either alternative procedure, because of the disposable supplies that are typically used and the longer operating-room time. (C) 1996, Massachusetts Medical Society.	CORNING HTA,WASHINGTON,DC		Dorsey, JH (corresponding author), GREATER BALTIMORE MED CTR,DEPT GYNECOL,6569 N CHARLES ST,SUITE 307,BALTIMORE,MD 21204, USA.							BOIKE GM, 1993, AM J OBSTET GYNECOL, V168, P1690, DOI 10.1016/0002-9378(93)90679-D; DANIELL JF, 1993, J REPROD MED, V38, P537; DORSEY JH, 1993, JAMA-J AM MED ASSOC, V270, P2298, DOI 10.1001/jama.1993.03510190052015; DORSEYJH, 1995, AM J OBSTET GYNECOL, V173, P1452; GRIMES DA, 1993, JAMA-J AM MED ASSOC, V269, P3030, DOI 10.1001/jama.269.23.3030; HARRIS MB, 1994, AM J OBSTET GYNECOL, V171, P340, DOI 10.1016/S0002-9378(94)70032-X; LANGEBREKKE A, 1992, ACTA OBSTET GYN SCAN, V71, P226, DOI 10.3109/00016349209009924; NEZHAT F, 1992, J REPROD MED, V37, P247; PITKIN RM, 1992, OBSTET GYNECOL, V79, P441; Rawlings O., 1998, APPL REGRESSION ANAL, VSecond, P372, DOI DOI 10.1007/B98890; REICH H, 1989, J GYNECOL SURG, V5, P213, DOI 10.1089/gyn.1989.5.213; Thompson J. D., 1992, TELINDES OPERATIVE G, P663; Zar JH., 1999, BIOSTAT ANAL	13	135	144	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					476	482		10.1056/NEJM199608153350705	http://dx.doi.org/10.1056/NEJM199608153350705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672153				2022-12-28	WOS:A1996VB84900005
J	Moll, S				Moll, S			Vitamin B-12 deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Moll, S (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC 27710, USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					323	323		10.1056/NEJM199608013350505	http://dx.doi.org/10.1056/NEJM199608013350505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8668215				2022-12-28	WOS:A1996UY98200005
J	Horie, S; Okubo, Y; Suzuki, JI; Isobe, M				Horie, S; Okubo, Y; Suzuki, JI; Isobe, M			An emaciated man with eosinophilic pneumonia	LANCET			English	Article							COLONY-STIMULATING FACTOR; CARCINOMA				Horie, S (corresponding author), SHINSHU UNIV,SCH MED,DEPT INTERNAL MED 1,3-1-1 ASAHI MATSUMOTO,MATSUMOTO,NAGANO 390,JAPAN.							KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KODAMA T, 1984, CANCER, V54, P2313, DOI 10.1002/1097-0142(19841115)54:10<2313::AID-CNCR2820541044>3.0.CO;2-I; NUOVO GJ, 1994, AM J PATHOL, V144, P659; SAWYERS CL, 1992, CANCER, V69, P1342, DOI 10.1002/1097-0142(19920315)69:6<1342::AID-CNCR2820690607>3.0.CO;2-U; SLUNGAARD A, 1983, NEW ENGL J MED, V309, P778, DOI 10.1056/NEJM198309293091307	5	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					166	166		10.1016/S0140-6736(96)00145-6	http://dx.doi.org/10.1016/S0140-6736(96)00145-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684158				2022-12-28	WOS:A1996UX78900013
J	Hakem, R; delaPompa, JL; Sirard, C; Mo, R; Woo, M; Hakem, A; Wakeham, A; Potter, J; Reitmair, A; Billia, F; Firpo, E; Hui, CC; Roberts, J; Rossant, J; Mak, TW				Hakem, R; delaPompa, JL; Sirard, C; Mo, R; Woo, M; Hakem, A; Wakeham, A; Potter, J; Reitmair, A; Billia, F; Firpo, E; Hui, CC; Roberts, J; Rossant, J; Mak, TW			The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse	CELL			English	Article							FAMILIAL BREAST; PROTEIN; MORPHOGENESIS; GASTRULATION; LINKAGE; ENCODES; COMPLEX; CANCER; GROWTH; ONSET	Mutations of the BRCA1 gene in humans are associated with predisposition to breast and ovarian cancers. We show here that Brca1(+/-) mice are normal and fertile and lack tumors by age eleven months. Homozygous Brca1(5-6) mutant mice die before day 7.5 of embryogenesis. Mutant embryos are poorly developed, with no evidence of mesoderm formation. The extraembryonic region is abnormal, but aggregation with wild-type tetraploid embryos does not rescue the lethality. In vivo, mutant embryos do not exhibit increased apoptosis but show reduced cell proliferation accompanied by decreased expression of cyclin E and mdm-2, a regulator of p53 activity. The expression of cyclin-dependent kinase inhibitor p21 is dramatically increased in the mutant embryos. Buttressing these in vivo observations is the fact that mutant blastocyst growth is grossly impaired in vitro. Thus, the death of Brca1(5-6) mutant embryos prior to gastrulation may be due to a failure of the proliferative burst required for the development of the different germ layers.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, DEPT MED & MOLEC GENET, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT OBSTET & GYNECOL, TORONTO, ON M5S 1A1, CANADA; HOSP SICK CHILDREN, DIV ENDOCRINOL RES INST, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Fred Hutchinson Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Hakem, R (corresponding author), UNIV TORONTO, AMGEN INST, 100 COLL ST, TORONTO, ON M5G 2C1, CANADA.		Billia, Filio/B-3011-2014; De La Pompa, José Luis/F-9719-2014	Billia, Filio/0000-0002-2824-1215; De La Pompa, José Luis/0000-0001-6761-7265; Hakem, Razqallah/0000-0001-5948-7931				BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARPER JW, 1993, CELL, V75, P805; HAYASHI Y, 1988, J HISTOCHEM CYTOCHEM, V36, P511, DOI 10.1177/36.5.3282006; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUNA RMD, 1995, NATURE, V378, P203; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Nagy A., 1993, Gene targeting: a practical approach., P147; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POWER MA, 1993, ANAT EMBRYOL, V187, P493; Rao VN, 1996, ONCOGENE, V12, P523; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; VARMUZA S, 1988, DEVELOPMENT, V102, P127; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	550	560	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					1009	1023		10.1016/S0092-8674(00)81302-1	http://dx.doi.org/10.1016/S0092-8674(00)81302-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674108	Bronze			2022-12-28	WOS:A1996UV48400008
J	Dobson, M; Peel, D; Khallaf, N				Dobson, M; Peel, D; Khallaf, N			Field trial of oxygen concentrators in upper Egypt	LANCET			English	Article							DEVELOPING-COUNTRIES	Technical problems in developing countries often require more than just technological solutions. Many small hospitals in rural areas are without a reliable oxygen supply; small oxygen concentrators offer a solution, but simply sending out machines is ineffective. This account details the setting up and first year's operation of a project to test oxygen concentrations in a developing country. A co-ordinated strategy has been developed to include machines, supplies, education, training, and feedback. Initial results are encouraging, and support the idea that suitably installed and maintained concentrations can have a valuable role in bringing oxygen therapy to patients and hospitals in countries which have so far been denied it.	NATL ARI PROGRAM,CAIRO,EGYPT		Dobson, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT ANAESTHET,OXFORD OX3 9DU,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x; FENTON PM, 1989, ANAESTHESIA, V44, P498, DOI 10.1111/j.1365-2044.1989.tb11380.x; GOULD GA, 1985, THORAX, V40, P811, DOI 10.1136/thx.40.11.811; PEDERSEN J, 1991, BRIT J ANAESTH, V66, P264, DOI 10.1093/bja/66.2.264; *WHO, 1991, 912 WHO ARI	6	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1597	1599		10.1016/S0140-6736(96)91080-6	http://dx.doi.org/10.1016/S0140-6736(96)91080-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667871				2022-12-28	WOS:A1996UP66100014
J	Hart, JT; Dieppe, P				Hart, JT; Dieppe, P			Caring effects	LANCET			English	Editorial Material							CONTROLLED TRIAL; HEALTH		UNIV BRISTOL, SCH MED, BRISTOL BS8 1TH, AVON, ENGLAND	University of Bristol	Hart, JT (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PRIMARY HLTH CARE, INT SECT, LONDON NW3 2PF, ENGLAND.							AIKEN LH, 1994, MED CARE, V32, P771, DOI 10.1097/00005650-199408000-00002; ANTONOVSKY A, 1985, ISRAEL J PSYCHIAT, V22, P273; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; Goodridge D M, 1982, J R Coll Gen Pract, V32, P239; Hart JT, 1995, EUR J GEN PRACT, V1, P34; HUYGEN FJA, 1992, BRIT J GEN PRACT, V42, P141; INFANTERIVARD C, 1988, J AM GERIATR SOC, V36, P306, DOI 10.1111/j.1532-5415.1988.tb02356.x; KENNELL J, 1991, JAMA-J AM MED ASSOC, V265, P2197, DOI 10.1001/jama.265.17.2197; MILLS M, 1994, BRIT MED J, V309, P583, DOI 10.1136/bmj.309.6954.583; MORGAN HG, 1993, BRIT J PSYCHIAT, V163, P111, DOI 10.1192/bjp.163.1.111; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; PEARCE JMS, 1995, QJM-INT J MED, V88, P215; REDELHEIMER DA, 1995, LANCET, V346, P1131; Roethlisberger F. J., 1939, MANAGEMENT WORKER; VIJAYARAGHAVAN K, 1992, LANCET, V340, P1358, DOI 10.1016/0140-6736(92)92547-S; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; WEINBERGER M, 1993, ARTHRITIS RHEUM, V36, P243, DOI 10.1002/art.1780360216; 1980, NEW ENGL J MED, V303, P1038	19	30	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1996	347	9015					1606	1608		10.1016/S0140-6736(96)91083-1	http://dx.doi.org/10.1016/S0140-6736(96)91083-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667874				2022-12-28	WOS:A1996UP66100017
J	Noble, J				Noble, J			Influence of physician perceptions on putting knowledge into practice	LANCET			English	Editorial Material											Noble, J (corresponding author), BOSTON UNIV,SCH MED,GEN INTERNAL MED SECT,BOSTON,MA 02118, USA.							Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; MEDALIE JH, 1976, AM J MED, V60, P910, DOI 10.1016/0002-9343(76)90921-9	2	1	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1571	1571		10.1016/S0140-6736(96)91071-5	http://dx.doi.org/10.1016/S0140-6736(96)91071-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667862				2022-12-28	WOS:A1996UP66100005
J	Sato, O; Iyoda, T; Fujishima, A; Hashimoto, K				Sato, O; Iyoda, T; Fujishima, A; Hashimoto, K			Photoinduced magnetization of a cobalt-iron cyanide	SCIENCE			English	Article							VALENCE	Photoinduced magnetization was observed in a Prussian blue analog, K0.2Co1-4[Fe(CN)(6)]. 6.9H(2)O. An increase in the critical temperature from 16 to 19 kelvin was observed as a result of red light illumination, Moreover, the magnetization in the ferrimagnetic region below 16 kelvin was substantially increased after illumination and could be restored almost to its original level by thermal treatment, These effects are thought to be caused by an internal photochemical redox reaction, Furthermore, blue light illumination could be used to partly remove the enhancement of the magnetization. Such control over magnetic properties by optical stimuli may have application in magneto-optical devices.	UNIV TOKYO,DEPT APPL CHEM,BUNKYO KU,TOKYO 113,JAPAN; KANAGAWA ACAD SCI & TECHNOL,TOKYO INST POLYTECH,ATSUGI,KANAGAWA 24302,JAPAN	University of Tokyo; Kanagawa Academy Science & Technology			Iyoda, Tomokazu/F-4731-2015; HASHIMOTO, Kazuhito/C-5011-2012; Fujishima, Akira/G-7701-2012	Iyoda, Tomokazu/0000-0002-9393-5387; HASHIMOTO, Kazuhito/0000-0002-8384-8749; 				BERTRAN JF, 1988, REACT SOLID, V5, P95, DOI 10.1016/0168-7336(88)80079-2; DECURTINS S, 1984, CHEM PHYS LETT, V105, P1, DOI 10.1016/0009-2614(84)80403-0; ENTLEY WR, 1994, INORG CHEM, V33, P5165, DOI 10.1021/ic00101a003; ENTLEY WR, 1995, SCIENCE, V268, P397, DOI 10.1126/science.268.5209.397; FERLAY S, 1995, NATURE, V378, P701, DOI 10.1038/378701a0; GATTESCHI D, 1994, ADV MATER, V6, P635, DOI 10.1002/adma.19940060903; GRIEBLER WD, 1982, Z NATURFORSCH B, V37, P832; GUTLICH P, 1994, ANGEW CHEM INT EDIT, V33, P2024, DOI 10.1002/anie.199420241; HENKEL H, 1984, Z NATURFORSCH B, V39, P880; JUSZCZYK S, 1994, J PHYS-CONDENS MAT, V6, P5697, DOI 10.1088/0953-8984/6/29/012; Kahn O., 1993, MOL MAGNETISM; KAHN O, 1991, MAGNETIC MOL MAT E, V198; MALLAH T, 1993, SCIENCE, V262, P1554, DOI 10.1126/science.262.5139.1554; MILLER JS, 1994, ANGEW CHEM INT EDIT, V33, P385, DOI 10.1002/anie.199403851; RAJCA A, 1994, CHEM REV, V94, P871, DOI 10.1021/cr00028a002; REGUERA E, 1990, HYPERFINE INTERACT, V53, P391, DOI 10.1007/BF02101072; Sato O, 1996, SCIENCE, V271, P49, DOI 10.1126/science.271.5245.49; VERDAGUER M, 1993, CONTRIBUTIONS DEV CO; WOJTOWICZ T, 1993, PHYS REV LETT, V70, P2317, DOI 10.1103/PhysRevLett.70.2317	19	1620	1632	7	380	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					704	705		10.1126/science.272.5262.704	http://dx.doi.org/10.1126/science.272.5262.704			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662564				2022-12-28	WOS:A1996UJ05100044
J	Tarr, PI; Fouser, LS; Stapleton, AE; Wilson, RA; Kim, HH; Vary, JC; Clausen, CR				Tarr, PI; Fouser, LS; Stapleton, AE; Wilson, RA; Kim, HH; Vary, JC; Clausen, CR			Hemolytic-uremic syndrome in a six-year-old girl after a urinary tract infection with shiga-toxin-producing Escherichia coli O103:H2	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-CULTURE CELLS; O157-H7; LIPOPOLYSACCHARIDE; DETERMINANTS; CYSTITIS; ADHESION; ASSAY	IN the United States, the hemolytic-uremic syndrome of childhood typically follows gastrointestinal infection with Escherichia coli O157:H7.(1-3) It is presumed that the absorption from the gastrointestinal tract of Shiga toxins 1, 2, or both (formerly called Shiga-like toxins(4)) produced by E. coli O157:H7 causes microangiopathic hemolytic anemia as a result of endothelial-cell injury.(5) Shiga-toxin-producing E. coli belonging to serotypes other than O157:H7 can also cause the hemolytic-uremic syndrome.(5,6) However, even though such organisms have been implicated as causes of sporadic cases(7) or outbreakss of gastroenteritis, they are not believed to be important causes of the hemolytic-uremic syndrome in this country. The hemolytic-uremic syndrome occasionally follows urinary tract infections.(9-14) In two cases, the syndrome was atypical: it was recurrent in one case(9) and associated with familial hypocomplementemia in another.(10) In two other reports that associated the hemolytic-uremic syndrome with urinary tract infection, E. coli O157:H7 was recovered from the urine of one child with hemorrhagic colitis and cystitis,(13) and Shiga-toxin-producing E. coli O17:H18 was recovered from the urine and blood of a child with antecedent diarrhea.(14) We describe a child who had the hemolytic-uremic syndrome but no prodromal diarrhea after a nonbacteremic urinary tract infection with E. coli O103:H2 that produced Shiga toxin 1. We also describe the characteristics of the infecting organism.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; PENN STATE UNIV,DEPT VET SCI,UNIVERSITY PK,PA 16802; PENN STATE UNIV,INST MOL EVOLUT GENET,UNIVERSITY PK,PA 16802	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Tarr, PI (corresponding author), CHILDRENS HOSP & MED CTR,DIV GASTROENTEROL,MAIL STOP CH-24,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.		Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659; Vary, James/0000-0001-5390-5426	NIAID NIH HHS [AI01115] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001115] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASTA M, 1989, J CLIN MICROBIOL, V27, P1617, DOI 10.1128/JCM.27.7.1617-1622.1989; BOKETE TN, 1993, GASTROENTEROLOGY, V105, P1724, DOI 10.1016/0016-5085(93)91069-T; Calderwood SB, 1996, ASM NEWS, V62, P118; CARRERAS L, 1981, JAMA-J AM MED ASSOC, V245, P602, DOI 10.1001/jama.245.6.602; DORN CR, 1993, VET MICROBIOL, V36, P149, DOI 10.1016/0378-1135(93)90136-U; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; GENTRY MK, 1980, J CLIN MICROBIOL, V12, P361, DOI 10.1128/JCM.12.3.361-366.1980; GRANSDEN WR, 1985, LANCET, V2, P150; GREATOREX JS, 1994, J CLIN MICROBIOL, V32, P1172, DOI 10.1128/JCM.32.5.1172-1178.1994; HEYDERMAN RS, 1994, LANCET, V343, P1042, DOI 10.1016/S0140-6736(94)90165-1; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Johnson JR, 1996, J INFECT DIS, V173, P920, DOI 10.1093/infdis/173.4.920; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LAVOCAT MP, 1989, PEDIATRIE, V44, P641; LAW D, 1994, CLIN MICROBIOL REV, V7, P152, DOI 10.1128/CMR.7.2.152-173.1994; LOIRAT C, 1984, ACTA PAEDIATR SCAND, V73, P505, DOI 10.1111/j.1651-2227.1984.tb09962.x; LUZZI I, 1995, J INFECT DIS, V171, P514, DOI 10.1093/infdis/171.2.514; MARIANIKURKDJIAN P, 1993, J CLIN MICROBIOL, V31, P296, DOI 10.1128/JCM.31.2.296-301.1993; MARIANIKURKDJIAN P, 1994, J CLIN MICROBIOL, V32, P860, DOI 10.1128/JCM.32.3.860-.1994; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; NEWLAND JW, 1988, J CLIN MICROBIOL, V26, P1292, DOI 10.1128/JCM.26.7.1292-1297.1988; OSTROFF SM, 1989, J INFECT DIS, V160, P994, DOI 10.1093/infdis/160.6.994; PARK CH, 1996, 96 AM SOC MICR GEN M, P65; PICKERING LK, 1994, PEDIATR INFECT DIS J, V13, P459, DOI 10.1097/00006454-199406000-00001; POLLARD DR, 1990, J CLIN MICROBIOL, V28, P540, DOI 10.1128/JCM.28.3.540-545.1990; POLLARD DR, 1990, J CLIN MICROBIOL, V28, P1491; RAO SP, 1979, NEW YORK STATE J MED, V79, P1763; Sambrook J., 2002, MOL CLONING LAB MANU; STAPLETON A, 1991, J INFECT DIS, V163, P773, DOI 10.1093/infdis/163.4.773; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; 1995, JAMA-J AM MED ASSOC, V274, P529	34	94	94	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					635	638		10.1056/NEJM199608293350905	http://dx.doi.org/10.1056/NEJM199608293350905			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8687518				2022-12-28	WOS:A1996VD42500005
J	Johnson, TC; Scholz, CA; Talbot, MR; Kelts, K; Ricketts, RD; Ngobi, G; Beuning, K; Ssemmanda, I; McGill, JW				Johnson, TC; Scholz, CA; Talbot, MR; Kelts, K; Ricketts, RD; Ngobi, G; Beuning, K; Ssemmanda, I; McGill, JW			Late pleistocene desiccation of Lake Victoria and rapid evolution of cichlid fishes	SCIENCE			English	Article								Lake Victoria is the largest lake in Africa and harbors more than 300 endemic species of haplochromine cichlid fish. Seismic reflection profiles and piston cores show that the lake not only was at a low stand but dried up completely during the Late Pleistocene, before 12,400 carbon-14 years before the present. These results imply that the rate of speciation of cichlid fish in this tropical lake has been extremely rapid.	UNIV MIAMI,ROSENSTIEL SCH MARINE & ATMOSPHER SCI,MIAMI,FL 33149; UNIV BERGEN,INST GEOL,N-5007 BERGEN,NORWAY; UNIV MINNESOTA,LIMNOL RES CTR,MINNEAPOLIS,MN 55455; MAKERERE UNIV,DEPT GEOL,KAMPALA,UGANDA; EMBANGWENI HOSP,EMBANGWENI,MALAWI	University of Miami; University of Bergen; University of Minnesota System; University of Minnesota Twin Cities; Makerere University	Johnson, TC (corresponding author), UNIV MINNESOTA,LARGE LAKES OBSERV,DULUTH,MN 55812, USA.		Johnson, Thomas/C-1423-2010					Bishop WW, 1966, Q J GEOL SOC LOND, V122, P385, DOI DOI 10.1144/GSJGS.122.1.0385; BISHOP WW, 1966, UGANDA J, V24, P44; DOORNKAMP JC, 1966, GEOGR J, V132, P238, DOI 10.2307/1792339; FEIBEL CS, 1991, J HUM EVOL, V21, P221, DOI 10.1016/0047-2484(91)90063-2; Flohn H., 1985, Z GLETSCHKD GLAZIALG, V21, P125; Greenwood P.H., 1980, Bulletin of the British Museum (Natural History) Zoology, V39, P1; KAUFMAN L, 1993, CONSERV BIOL, V7, P719, DOI 10.1046/j.1523-1739.1993.07030719.x; KENT PE, 1944, GEOGR J, V100, P22; McCune A. R., 1984, EVOLUTION FISH SPECI, P27; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; Meyer A., 1996, P303; MEYER A, 1991, NATURE, V350, P467, DOI 10.1038/350467c0; OWEN RB, 1990, PROC R SOC SER B-BIO, V240, P519, DOI 10.1098/rspb.1990.0052; SCHOLZ CA, 1990, J AFR EARTH SCI, V11, P25, DOI 10.1016/0899-5362(90)90073-N; SENE KJ, 1994, HYDROLOG SCI J, V39, P47, DOI 10.1080/02626669409492719; STAGER JC, 1986, FRESHWATER BIOL, V15, P15; TALBOT MR, 1989, PALAEOGEOGR PALAEOCL, V70, P121, DOI 10.1016/0031-0182(89)90084-9; Vail P.R., 1977, GEOPHYS RES LETT, V26, P49	18	399	406	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1091	1093		10.1126/science.273.5278.1091	http://dx.doi.org/10.1126/science.273.5278.1091			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VD428	8688092				2022-12-28	WOS:A1996VD42800033
J	Yan, J; Suga, N				Yan, J; Suga, N			Corticofugal modulation of time-domain processing of biosonar information in bats	SCIENCE			English	Article							COMBINATION-SENSITIVE NEURONS; MEDIAL GENICULATE-BODY; AUDITORY-CORTEX; INFERIOR COLLICULUS; MUSTACHED BAT; TARGET RANGE; MOUSTACHED BAT; CONNECTIONS; PROJECTIONS; STIMULATION	The Jamaican mustached bar has delay-tuned neurons in the inferior colliculus, medial geniculate body, and auditory cortex. The responses of these neurons to an echo are facilitated by a biosonar pulse emitted by the bat when the echo returns with a particular delay from a target located at a particular distance. Electrical stimulation of cortical delay-tuned neurons increases the delay-tuned responses of collicular neurons tuned to the same echo delay as the cortical neurons and decreases those of collicular neurons tuned to different echo delays, Cortical neurons improve information processing in the inferior colliculus by way of the corticocollicular projection.			Yan, J (corresponding author), WASHINGTON UNIV, DEPT BIOL, 1 BROOKINGS DR, ST LOUIS, MO 63130 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000175] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC 00175] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANDERSEN P, 1973, BRAIN BEHAV EVOLUT, V6, P170, DOI 10.1159/000123705; ANDERSEN RA, 1980, J COMP NEUROL, V191, P479, DOI 10.1002/cne.901910310; CARRASCAL E, 1991, Society for Neuroscience Abstracts, V17, P305; FELICIANO M, 1995, J NEUROCHEM, V65, P1348; Feliciano M., 1995, AUDIT NEUROSCI, V1, P287; GAMES KD, 1988, HEARING RES, V34, P1, DOI 10.1016/0378-5955(88)90047-0; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; HORIKAWA J, 1994, HEARING RES, V76, P45, DOI 10.1016/0378-5955(94)90085-X; HUFFMAN RF, 1990, BRAIN RES REV, V15, P295, DOI 10.1016/0165-0173(90)90005-9; KELLY JP, 1981, BRAIN RES, V212, P1, DOI 10.1016/0006-8993(81)90027-5; LUETHKE LE, 1989, J COMP NEUROL, V285, P487, DOI 10.1002/cne.902850406; MASSOPUST LC, 1962, EXP NEUROL, V6, P465, DOI 10.1016/0014-4886(62)90072-9; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MITANI A, 1983, NEUROSCI LETT, V42, P185, DOI 10.1016/0304-3940(83)90404-4; MITTMANN DH, 1995, EHAR RES, V90, P185; MOREL A, 1992, J COMP NEUROL, V318, P27, DOI 10.1002/cne.903180104; OJIMA H, 1996, CEREB CORTEX, V6, P646; OLSEN JF, 1991, J NEUROPHYSIOL, V65, P1275, DOI 10.1152/jn.1991.65.6.1275; OLSEN JF, 1986, THESIS WASHINGTON U; ONEILL WE, 1982, J NEUROSCI, V2, P17; RYUGO DK, 1976, EXP NEUROL, V51, P377, DOI 10.1016/0014-4886(76)90262-4; Saldana E, 1996, J COMP NEUROL, V371, P15, DOI 10.1002/(SICI)1096-9861(19960715)371:1<15::AID-CNE2>3.0.CO;2-O; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1979, SCIENCE, V206, P351, DOI 10.1126/science.482944; SUGA N, 1983, J NEUROPHYSIOL, V49, P1573, DOI 10.1152/jn.1983.49.6.1573; SUGA N, 1986, J NEUROPHYSIOL, V55, P776, DOI 10.1152/jn.1986.55.4.776; Suga N, 1984, DYNAMIC ASPECTS NEOC, P315; SUGA N, 1995, ACTIVE HEARING, P13; SUN X, 1989, BRAIN RES, V495, P1, DOI 10.1016/0006-8993(89)91212-2; SYKA J, 1984, NEUROSCI LETT, V51, P235, DOI 10.1016/0304-3940(84)90557-3; VATER M, 1992, J COMP NEUROL, V325, P183, DOI 10.1002/cne.903250205; VILLA AEP, 1991, EXP BRAIN RES, V86, P506, DOI 10.1007/BF00230524; WATANABE T, 1966, EXP BRAIN RES, V2, P302; Yan J, 1996, HEARING RES, V93, P102, DOI 10.1016/0378-5955(95)00209-X	35	160	165	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1996	273	5278					1100	1103		10.1126/science.273.5278.1100	http://dx.doi.org/10.1126/science.273.5278.1100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688095				2022-12-28	WOS:A1996VD42800036
J	Desbois, C; Rousset, R; Bantignies, F; Jalinot, P				Desbois, C; Rousset, R; Bantignies, F; Jalinot, P			Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I tax oncoprotein	SCIENCE			English	Article							VIRUS TYPE-I; T-CELL LEUKEMIA; RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; RAR-ALPHA; PROTEINS; TRANSFORMATION; LOCALIZATION; LYMPHOCYTES; ASSOCIATION	The Tax transactivator of the human T cell leukemia virus type I (HTLV-I) exhibits oncogenic properties. A screen for proteins interacting with Tax yielded a complementary DNA (cDNA) encoding the human Int-6 protein, In mice, the Int-6 gene can be converted into a putative dominant negative oncogene after retroviral insertion. Here, Int-6 was localized in the cell nucleus to give a speckled staining pattern superposed to that of the promyelocytic leukemia (PML) protein. The binding of Tax to Int-6 caused its redistribution from the nuclear domains to the cytoplasm. Thus, Int-6 is a component of the PML nuclear bodies and Tax disrupts its normal cellular localization by binding to it.	ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR49,F-69364 LYON 07,FRANCE	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Rousset, Raphael/E-5908-2017; Morris, Christelle/M-8168-2014	Rousset, Raphael/0000-0002-4999-403X; Morris, Christelle/0000-0003-1575-4609				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DETHE H, 1991, SCIENCE, V254, P1371; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GESSAIN A, 1985, LANCET, V2, P407; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STUURMAN N, 1992, J CELL SCI, V101, P773; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TERRIS B, 1995, CANCER RES, V55, P1590; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	31	132	142	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					951	953		10.1126/science.273.5277.951	http://dx.doi.org/10.1126/science.273.5277.951			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688078				2022-12-28	WOS:A1996VC67000061
J	Hilgemann, DW; Ball, R				Hilgemann, DW; Ball, R			Regulation of cardiac Na+,Ca2+ exchange and K-ATP potassium channels by PIP2	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; PHOSPHOLIPASE-C; NA+-CA2+ EXCHANGER; DIACYLGLYCEROL KINASE; SULFONYLUREA RECEPTOR; CA2+-BINDING DOMAIN; MEMBRANE PATCHES; BACILLUS-CEREUS; PROTEIN-KINASE; INHIBITION	Cardiac Na+,Ca2+ exchange is activated by a mechanism that requires hydrolysis of adenosine triphosphate (ATP) but is not mediated by protein kinases. In giant cardiac membrane patches, ATP acted to generate phosphatidylinositol-4,5-bisphosphate (PIP2) from phosphatidylinositol (PI). The action of ATP was abolished by a PI-specific phospholipase C (PLC) and recovered after addition of exogenous PI; it was reversed by a PIP2-specific PLC; and it was mimicked by exogenous PIP2. High concentrations of free Ca2+ (5 to 20 mu M) accelerated reversal oi the ATP effect, and PLC activity in myocyte membranes was activated with a similar Ca2+ dependence, Aluminum reversed the ATP effect by binding with high affinity to PIP2. ATP-inhibited potassium channels (K-ATP) were also sensitive to PIP2, whereas Na+,K+ pumps and Na+ channels were not. Thus, PIP2 may be an important regulator oi both ion transporters and channels.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hilgemann, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NHLBI NIH HHS [5-R1-HL51323-03] Funding Source: Medline; NIGMS NIH HHS [GM49993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BIRCHALL JD, 1988, CLIN CHEM, V34, P265; BUSER CA, 1995, MOL MEMBR BIOL, V12, P69, DOI 10.3109/09687689509038498; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; COLLINS A, 1993, PFLUG ARCH EUR J PHY, V423, P347, DOI 10.1007/BF00374927; COLLINS A, 1992, J PHYSL, V454, P37; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GILMORE AP, 1996, NATURE, V381, P5311; GOTO K, 1995, P NATL ACAD SCI USA, V50, P235; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hilgemann Donald W., 1995, P307; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HILGEMANN DW, UNPUB; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1993, J BIOL CHEM, V268, P11489; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LUCIANI S, 1993, ANN NY ACAD SCI, V639, P156; Martell A. E., 1977, CRITICAL STABILITY C; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MCDONALD LJ, 1995, J LIPID MEDIAT CELL, V11, P81, DOI 10.1016/0929-7855(94)00029-C; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; REDMAN C, 1995, BIOCHEM PHARMACOL, V50, P235, DOI 10.1016/0006-2952(95)00118-J; REITER M, 1988, PHARMACOL REV, V40, P189; RIBALET B, 1994, J MEMBRANE BIOL, V142, P395; RIBALET B, 1989, J GEN PHYSIOL, V94, P693, DOI 10.1085/jgp.94.4.693; SCHOFL C, 1990, BIOCHEM J, V269, P547, DOI 10.1042/bj2690547; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHANNON TR, 1994, AM J PHYSIOL, V266, pC1350, DOI 10.1152/ajpcell.1994.266.5.C1350; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TAKANO M, 1990, AM J PHYSIOL, V258, pH45, DOI 10.1152/ajpheart.1990.258.1.H45; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Tsien R W, 1977, Adv Cyclic Nucleotide Res, V8, P363; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; WEBER G, 1982, BIOCHIM BIOPHYS ACTA, V694, P1	54	544	556	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					956	959		10.1126/science.273.5277.956	http://dx.doi.org/10.1126/science.273.5277.956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688080				2022-12-28	WOS:A1996VC67000063
J	Nellis, WJ; Weir, ST; Mitchell, AC				Nellis, WJ; Weir, ST; Mitchell, AC			Metallization and electrical conductivity of hydrogen in Jupiter	SCIENCE			English	Article							GIANT PLANETS; MOLECULAR-HYDROGEN; SOLID HYDROGEN; STATE; PRESSURES; EQUATION; INTERIOR	Electrical conductivities of molecular hydrogen in Jupiter were calculated by scaling electrical conductivities measured at shock pressures in the range of 10 to 180 gigapascals (0.1 to 1.8 megabars) and temperatures to 4000 kelvin, representative of conditions inside Jupiter. Jupiter's magnetic field is caused by convective dynamo motion of electrically conducting fluid hydrogen. The data imply that Jupiter should become metallic at 140 gigapascals in the fluid, and the electrical conductivity in the jovian molecular envelope at pressures up to metallization is about an order of magnitude larger than expected previously. The large magnetic field is produced in the molecular envelope closer to the surface than previously thought.			Nellis, WJ (corresponding author), LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550, USA.		Weir, Samuel/H-5046-2012					ABRIKOSOV AA, 1964, SOV PHYS JETP-USSR, V18, P1399; ASHCROFT NW, 1990, PHYS REV B, V41, P10963, DOI 10.1103/PhysRevB.41.10963; ASHCROFT NW, 1968, PHYS REV LETT, V21, P1748, DOI 10.1103/PhysRevLett.21.1748; CEPERLEY DM, 1987, PHYS REV B, V36, P2092, DOI 10.1103/PhysRevB.36.2092; FREIDLI C, 1977, PHYS REV B, V16, P662; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; Hensel F, 1996, PHYS WORLD, V9, P43, DOI 10.1088/2058-7058/9/4/25; HIDE R, 1979, NATURE, V280, P42, DOI 10.1038/280042a0; Holmes NC, 1995, PHYS REV B, V52, P15835, DOI 10.1103/PhysRevB.52.15835; HUBBARD WB, 1969, ASTROPHYS J SUPPL S, V18, P297, DOI 10.1086/190192; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; HUBBARD WB, 1984, PLANETARY INTERIORS, P141; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; MIN BI, 1986, PHYS REV B, V33, P6383, DOI 10.1103/PhysRevB.33.6383; MOTT NF, 1971, ELECT PROCESSES NONC, P81; MOTT NF, 1971, PHILOS MAG, V24, P2; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; NELLIS WJ, 1992, PHYS REV LETT, V68, P2937, DOI 10.1103/PhysRevLett.68.2937; NELLIS WJ, 1995, SCIENCE, V269, P1249, DOI 10.1126/science.7652570; ROSS M, 1981, PHILOS T R SOC A, V303, P303, DOI 10.1098/rsta.1981.0204; SAUMON D, 1995, ASTROPHYS J SUPPL S, V99, P713, DOI 10.1086/192204; Smith E. J., 1976, JUPITER, P788; SMOLUCHOWSKI R, 1975, ASTROPHYS J, V200, pL119, DOI 10.1086/181911; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; STEVENSON DJ, 1974, PHYS REV A, V9, P782, DOI 10.1103/PhysRevA.9.782; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; Zharkov V. N., 1992, HIGH PRESSURE RES AP, P393; ZHARKOV VN, 1976, JUPITER, P145	32	92	96	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					936	938		10.1126/science.273.5277.936	http://dx.doi.org/10.1126/science.273.5277.936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688072				2022-12-28	WOS:A1996VC67000055
J	Golzari, H; Cebul, RD; Bahler, RC				Golzari, H; Cebul, RD; Bahler, RC			Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy	ANNALS OF INTERNAL MEDICINE			English	Review							PARKINSON-WHITE SYNDROME; TACHYCARDIA-INDUCED CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; LEFT-VENTRICULAR DYSFUNCTION; DIRECT-CURRENT CARDIOVERSION; LOW-DOSE AMIODARONE; OPEN-HEART-SURGERY; ACUTE CONVERSION; ELECTRICAL CARDIOVERSION; INTRAVENOUS FLECAINIDE	Purpose: To review the efficacy and safety of electrical and pharmacologic conversion of atrial fibrillation, strategies for maintenance of sinus rhythm, and the importance of antithrombotic therapy. Data Sources: English-language trials were identified from the MEDLINE database through 1995, bibliographic references, Current Contents, textbooks, and recent abstracts. Study Selection: Randomized trials (including abstracts) were selected. Cohort studies were used if randomized trials were not available. Data Extraction: Study design and data were extracted from clinical trials. Statistical analysis of combined data was not appropriate, given the marked variations in study designs and study populations. Data Synthesis: Cardioversion restores sinus rhythm in more than 80% of patients. In atrial fibrillation of recent onset, pharmacologic regimens have a success rate of 40% to 90%. Sinus rhythm at 1 year is maintained in 30% of patients without antiarrhythmic therapy but in 50% of patients with such therapy. The efficacy and safety of antiarrhythmic drugs relative to one another are not established because trials done to date have been small and cases vary. Successful cardioversion and maintenance of sinus rhythm are most predictable when the duration of atrial fibrillation is brief. Warfarin reduces the incidence of ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per year. Aspirin (325 mg/d) appears to be equally effective in patients younger than 75 years of age who do not have hypertension or a history of thromboembolism or recent heart failure. Although warfarin is more effective than aspirin in preventing embolic strokes in patients older than 75 years of age, it may increase the incidence of hemorrhagic stroke and result in a similar rate of disabling stroke. Conclusion: Cardioversion remains the preferred method with which to re-establish sinus rhythm. Longterm antiarrhythmic therapy is warranted only if recurrences or initial clinical instability are seen; pro-arrhythmic concerns and potential side effects should guide drug selection. Antithrombotic therapy is indicated for all patients older than 60 years of age and in all patients younger than 60 yea rs of age who have clinical evidence of a primary cardiac disorder.	METROHLTH MED CTR, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA	MetroHealth System; Case Western Reserve University								ALTAMURA G, 1996, PACING CLIN ELECTR 2, V18, P194; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ASPLUND K, 1993, EUR HEART J, V14, P1427; ATWOOD JE, 1989, AM HEART J, V118, P913, DOI 10.1016/0002-8703(89)90223-8; ATWOOD JE, 1988, J AM COLL CARDIOL, V11, P508, DOI 10.1016/0735-1097(88)91524-0; ATWOOD JE, 1993, HERZ, V18, P27; BAILEY GWH, 1968, ANN INTERN MED, V69, P13, DOI 10.7326/0003-4819-69-1-13; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BIALY D, 1992, Journal of the American College of Cardiology, V19, p41A; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; Boissel J P, 1981, Eur Heart J, V2, P49; BORGGREFE M, 1991, CIRCULATION, V84, P412; BORIANI G, 1995, CHEST, V108, P355, DOI 10.1378/chest.108.2.355; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BRIGNOLE M, 1994, AM J CARDIOL, V74, P242, DOI 10.1016/0002-9149(94)90364-6; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CAMPBELL TJ, 1985, BRIT HEART J, V54, P86; CAMPBELL TJ, 1980, AUST NZ J MED, V10, P644, DOI 10.1111/j.1445-5994.1980.tb04246.x; CAPUCCI A, 1994, INT J CARDIOL, V43, P305, DOI 10.1016/0167-5273(94)90211-9; CAPUCCI A, 1992, AM J CARDIOL, V70, P69, DOI 10.1016/0002-9149(92)91392-H; CAPUCCI A, 1994, AM J CARDIOL, V74, P503, DOI 10.1016/0002-9149(94)90915-6; CASTELLANOS A, 1965, AM J MED SCI, V250, P254, DOI 10.1097/00000441-196509000-00002; CASTELLANOS A, 1965, ARCH INTERN MED, V115, P426, DOI 10.1001/archinte.1965.03860160052009; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1557, DOI 10.1056/NEJM199011293232209; CHUN PKC, 1981, CIRCULATION, V63, P220, DOI 10.1161/01.CIR.63.1.220; CHUN SH, 1995, AM J CARDIOL, V76, P47, DOI 10.1016/S0002-9149(99)80799-1; CIACCHERI M, 1981, ACTA CARDIOL, V36, P125; COLLINS LJ, 1995, CIRCULATION, V92, P160, DOI 10.1161/01.CIR.92.2.160; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CONNOLLY SJ, 1989, AM J CARDIOL, V63, P817, DOI 10.1016/0002-9149(89)90049-0; CONNOLLY SJ, 1987, J AM COLL CARDIOL, V10, P1145, DOI 10.1016/S0735-1097(87)80359-5; COOPER RAS, 1993, CIRCULATION, V87, P1673, DOI 10.1161/01.CIR.87.5.1673; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COUMEL P, 1990, CLIN CARDIOL, V13, P209, DOI 10.1002/clc.4960130311; COUMEL P, 1982, ATRIAL FIBRILLATION, P158; COWAN JC, 1986, J CARDIOVASC PHARM, V8, P252, DOI 10.1097/00005344-198603000-00005; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; CRIJNS HJGM, 1988, EUR HEART J, V9, P634, DOI 10.1093/oxfordjournals.eurheartj.a062553; DALZELL GWN, 1990, Q J MED, V76, P903; DAS G, 1981, PACE, V4, P487, DOI 10.1111/j.1540-8159.1981.tb06215.x; DAVIES MJ, 1972, BRIT HEART J, V34, P520; DAVIES P, 1965, BRIT MED J, V2, P517, DOI 10.1136/bmj.2.5460.517; DAVIS PH, 1987, ANN NEUROL, V22, P319, DOI 10.1002/ana.410220307; DESILVA RA, 1980, AM HEART J, V100, P881, DOI 10.1016/0002-8703(80)90071-X; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; DITTRICH HC, 1989, AM J CARDIOL, V63, P193, DOI 10.1016/0002-9149(89)90284-1; DONOVAN KD, 1995, AM J CARDIOL, V75, P693, DOI 10.1016/S0002-9149(99)80655-9; DONOVAN KD, 1991, AM J CARDIOL, V67, P137, DOI 10.1016/0002-9149(91)90435-N; EDHAG O, 1982, OPUSC MED, V27, P22; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FALK RH, 1991, ANN INTERN MED, V114, P573, DOI 10.7326/0003-4819-114-7-573; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; Feinberg M S, 1995, J Am Soc Echocardiogr, V8, P139, DOI 10.1016/S0894-7317(05)80403-1; FEINBERG WM, 1990, ARCH INTERN MED, V150, P2340, DOI 10.1001/archinte.150.11.2340; FELD GK, 1988, AM HEART J, V115, P102, DOI 10.1016/0002-8703(88)90524-8; FERGUSON TB, 1993, HERZ, V18, P39; FLEGEL KM, 1987, LANCET, V1, P526; FRIEDBER.CK, 1965, CIRCULATION, V32, P89; GARDNER JD, 1982, CHEST, V81, P429, DOI 10.1378/chest.81.4.429; GAVAGHAN TP, 1988, BRIT HEART J, V60, P497; GILLETTE PC, 1985, JAMA-J AM MED ASSOC, V253, P391, DOI 10.1001/jama.253.3.391; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRANDE P, 1986, CIRCULATION, V74, P101; GROGAN M, 1992, AM J CARDIOL, V69, P1570, DOI 10.1016/0002-9149(92)90705-4; GROGONO AW, 1963, LANCET, V2, P1039; GUARNIERI T, 1991, PACE, V14, P1007, DOI 10.1111/j.1540-8159.1991.tb04150.x; GUIRAUDON GM, 1993, HERZ, V18, P51; GUNNING JF, 1970, BRIT HEART J, V32, P462; GUSTAFSSON KS, 1986, CIRCULATION, V74, P101; HALINEN MO, 1995, AM J CARDIOL, V76, P495, DOI 10.1016/S0002-9149(99)80137-4; HALL JI, 1968, BRIT HEART J, V30, P84; HART RG, 1987, ARCH INTERN MED, V147, P636; HARTEL G, 1970, BRIT HEART J, V32, P57; HARTEL G, 1974, CLIN PHARMACOL THER, V15, P551; HEINZ G, 1992, AM J CARDIOL, V69, P489, DOI 10.1016/0002-9149(92)90991-7; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HILLESTAD L, 1972, BRIT HEART J, V34, P139; HJELMS E, 1992, SCAND J THORAC CARD, V26, P193, DOI 10.3109/14017439209099077; HOHNLOSER SH, 1994, ANN INTERN MED, V121, P529, DOI 10.7326/0003-4819-121-7-199410010-00009; HOLZMAN D, 1951, AM J MED SCI, V222, P644, DOI 10.1097/00000441-195112000-00005; HOU ZY, 1995, EUR HEART J, V16, P521, DOI 10.1093/oxfordjournals.eurheartj.a060945; JACK CM, 1987, IRISH J MED SCI, V156, P330, DOI 10.1007/BF02951266; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JANSSEN J, 1986, ANGIOLOGY, V37, P601, DOI 10.1177/000331978603700807; JATENE MB, 1994, CIRCULATION, V90, P595; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KALMAN JM, 1992, PACE, V15, P1332; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; KARLSON BW, 1988, EUR HEART J, V9, P284, DOI 10.1093/oxfordjournals.eurheartj.a062498; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KENNELLY BM, 1977, BRIT HEART J, V39, P540; KIENY JR, 1992, EUR HEART J, V13, P1290, DOI 10.1093/oxfordjournals.eurheartj.a060351; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KONDILI A, 1990, WIEN KLIN WOCHENSCHR, V102, P510; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOPELMAN HA, 1989, PROG CARDIOVASC DIS, V31, P355, DOI 10.1016/0033-0620(89)90030-3; KOSAKAI Y, 1994, CIRCULATION, V90, P587; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOWEY PR, 1992, AM J CARDIOL, V69, P963, DOI 10.1016/0002-9149(92)90802-6; KOWEY PR, 1979, CIRCULATION, V60, P253; KUMAGAI K, 1991, PACE, V14, P1571, DOI 10.1111/j.1540-8159.1991.tb02730.x; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEVINE PA, 1983, J AM COLL CARDIOL, V1, P1413, DOI 10.1016/S0735-1097(83)80044-8; LEVY S, 1988, J AM COLL CARDIOL, V12, P514, DOI 10.1016/0735-1097(88)90428-7; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; LEVY S, 1992, CLIN CARDIOL, V15, P445, DOI 10.1002/clc.4960150611; LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X; LINDSAY J, 1967, AM HEART J, V74, P434, DOI 10.1016/0002-8703(67)90086-5; LLOYD EA, 1984, S AFR MED J, V65, P367; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; LOWN B, 1967, BRIT HEART J, V29, P469; LOWN B, 1962, AM J CARDIOL, V10, P223, DOI 10.1016/0002-9149(62)90299-0; MADRID AH, 1993, EUR HEART J, V14, P1127, DOI 10.1093/eurheartj/14.8.1127; MANNING WJ, 1994, J AM COLL CARDIOL, V23, P1535, DOI 10.1016/0735-1097(94)90652-1; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1989, J AM COLL CARDIOL, V13, P617, DOI 10.1016/0735-1097(89)90602-5; MCALISTER HF, 1990, J THORAC CARDIOV SUR, V99, P911; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCARTHY C, 1969, BRIT HEART J, V31, P496; MCLARAN CJ, 1985, BRIT HEART J, V53, P323; MEIJLER FL, 1985, J AM COLL CARDIOL, V5, pB17, DOI 10.1016/S0735-1097(85)80520-9; MEIJLER FL, 1985, J AM COLL CARDIOL, V5, pA60, DOI 10.1016/S0735-1097(85)80464-2; MIDDLEKAUFF HR, 1992, ANN INTERN MED, V116, P1017, DOI 10.7326/0003-4819-116-12-1017; MOREIRA DAR, 1989, PACE, V12, P761, DOI 10.1111/j.1540-8159.1989.tb01898.x; MOREYRA E, 1995, AM HEART J, V129, P71, DOI 10.1016/0002-8703(95)90045-4; MOSTOW ND, 1990, AM HEART J, V120, P1356, DOI 10.1016/0002-8703(90)90248-V; MURGATROYD FD, 1995, J AM COLL CARDIOL, V25, P1347, DOI 10.1016/0735-1097(94)00555-5; Noble R J, 1973, Cardiovasc Clin, V5, P97; NOC M, 1990, AM J CARDIOL, V65, P679, DOI 10.1016/0002-9149(90)91053-9; NORMAND JP, 1976, BRIT HEART J, V38, P381; OKEEFFE DB, 1984, BRIT HEART J, V51, P103; OLSSON SB, 1980, ACTA MED SCAND, V207, P5; ORMEROD OJM, 1984, BRIT HEART J, V51, P618; PACKER DL, 1986, AM J CARDIOL, V57, P563, DOI 10.1016/0002-9149(86)90836-2; PAULK EA, 1965, AM HEART J, V70, P248, DOI 10.1016/0002-8703(65)90074-8; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PHILLIPS E, 1949, AM J MED, V7, P478, DOI 10.1016/0002-9343(49)90397-6; PILATI G, 1991, CURR THER RES CLIN E, V49, P140; PLATIA EV, 1989, AM J CARDIOL, V63, P925, DOI 10.1016/0002-9149(89)90141-0; PODRID PJ, 1993, HERZ, V18, P9; PORTERFIELD JG, 1989, AM J CARDIOL, V63, P114, DOI 10.1016/0002-9149(89)91091-6; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; PRITCHETT ELC, 1988, AM J CARDIOL, V62, pD1; RASMUSSEN K, 1988, European Heart Journal, V9, P52; RASMUSSEN K, 1981, ACTA MED SCAND, P23; RAWLES JM, 1990, BRIT HEART J, V63, P225; REIMOLD SC, 1993, AM J CARDIOL, V71, P558, DOI 10.1016/0002-9149(93)90511-A; RESNEKOV L, 1967, BRIT HEART J, V29, P700; RESNEKOV L, 1976, MED CLIN N AM, V60, P325, DOI 10.1016/S0025-7125(16)31913-7; RESNEKOV L, 1971, BRIT HEART J, V33, P339; ROBERTS SA, 1993, AM J CARDIOL, V72, P567, DOI 10.1016/0002-9149(93)90353-E; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; ROWLAND E, 1986, BRIT J CLIN PRACT, V40, P39; SANFILIPPO AJ, 1990, CIRCULATION, V82, P792, DOI 10.1161/01.CIR.82.3.792; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; Santos A L, 1979, Acta Med Port, V1, P15; SAREMBOCK IJ, 1988, S AFR MED J, V73, P484; Scott M E, 1968, Ulster Med J, V37, P155; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHAPIRO W, 1968, CIRCULATION, V38, P1074, DOI 10.1161/01.CIR.38.6.1074; SHAVER JA, 1965, AM J CARDIOL, V15, P146, DOI 10.1016/0002-9149(65)90677-6; SIMON RP, 1991, MED KNOWLEDGE SELF A, P104; SIMS BA, 1972, BRIT HEART J, V34, P336; SINGH S, 1991, AM J CARDIOL, V68, P1227, DOI 10.1016/0002-9149(91)90200-5; SODERMARK T, 1975, BRIT HEART J, V37, P486; SOMBERG JC, 1983, CIRCULATION, V68, P56; STODDARD MF, 1995, AM HEART J, V129, P1204, DOI 10.1016/0002-8703(95)90405-0; SUAREZ GS, 1991, CLIN CARDIOL, V14, P652, DOI 10.1002/clc.4960140806; SUN JP, 1988, J CARDIOVASC ULTRAS, V7, P247; SUTTON RB, 1970, CHEST, V57, P191, DOI 10.1378/chest.57.2.191; SUTTORP MJ, 1989, AM J CARDIOL, V63, P693, DOI 10.1016/0002-9149(89)90253-1; SUTTORP MJ, 1990, J AM COLL CARDIOL, V16, P1722, DOI 10.1016/0735-1097(90)90326-K; SWARTZ JF, 1994, CIRCULATION, V90, P335; SZEKELY P, 1964, BMJ-BRIT MED J, V1, P1209, DOI 10.1136/bmj.1.5392.1209; THOMSON GW, 1956, CIRCULATION, V14, P757, DOI 10.1161/01.CIR.14.5.757; TISCHLER MD, 1990, AM J CARDIOL, V66, P721, DOI 10.1016/0002-9149(90)91137-U; TOIVONEN LK, 1986, BRIT HEART J, V55, P176; TOUBOUL P, 1991, CIRCULATION, V84, P127; UESHIMA K, 1993, AM HEART J, V125, P1301, DOI 10.1016/0002-8703(93)90998-O; UPKIN DP, 1988, BRIT HEART J, V59, P572; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; VANGELDER IC, 1993, AM J CARDIOL, V72, P560, DOI 10.1016/0002-9149(93)90352-D; VANGELDER IC, 1989, AM J CARDIOL, V64, P1317, DOI 10.1016/0002-9149(89)90574-2; VITA JA, 1989, AM J CARDIOL, V63, P1275, DOI 10.1016/0002-9149(89)90191-4; VITOLO E, 1981, ACTA CARDIOL, V36, P431; WAFA SS, 1989, AM J CARDIOL, V63, P1058, DOI 10.1016/0002-9149(89)90078-7; WAGNER G S, 1969, Progress in Cardiovascular Diseases, V11, P431, DOI 10.1016/0033-0620(69)90030-9; WHEELDON NM, 1995, EUR HEART J, V16, P302, DOI 10.1093/oxfordjournals.eurheartj.a060911; WHITE HD, 1994, LANCET, V343, P683, DOI 10.1016/S0140-6736(94)91573-3; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; WOO KS, 1980, CIRCULATION, V62, P181; YIGITBASI O, 1967, CARDIOLOGIA, V51, P307, DOI 10.1159/000165826; 1993, LANCET, V342, P1255; 1983, STROKE, V14, P668	205	70	72	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					311	323		10.7326/0003-4819-125-4-199608150-00010	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678396				2022-12-28	WOS:A1996VB68000013
J	Camps, P; Prevot, M				Camps, P; Prevot, M			A statistical model of the fluctuations in the geomagnetic field from paleosecular variation to reversal	SCIENCE			English	Article							EARTHS MAGNETIC-FIELD; AVERAGED PALEOMAGNETIC FIELD; SECULAR VARIATION; LASCHAMP EXCURSION; TRANSITION FIELDS; RECORDS; MANTLE; PALEOINTENSITY; LAVAS; FLOW	The statistical characteristics of the local magnetic field of Earth during paleosecular variation, excursions, and reversals are described on the basis of a database that gathers the cleaned mean direction and average remanent intensity of 2741 lava flows that have erupted over the last 20 million years. A model consisting of a normally distributed axial dipole component plus an independent isotropic set of vectors With a Maxwellian distribution that simulates secular variation fits the range of geomagnetic fluctuations, in terms of both direction and intensity. This result suggests that the magnitude of secular variation vectors is independent of the magnitude of Earth's axial dipole moment and that the amplitude of secular variation is unchanged during reversals.			Camps, P (corresponding author), UNIV MONTPELLIER 2,UNITE ASSOCIEE CNRS CASE 060,LAB TECTON & GEOPHYS,PL EUGENE BATAILLON,F-34095 MONTPELLIER 5,FRANCE.		CAMPS, Pierre/F-2084-2013	CAMPS, Pierre/0000-0002-6637-4342				CAMPS P, UNPUB; CHAUVIN A, 1990, J GEOPHYS RES-SOLID, V95, P2727, DOI 10.1029/JB095iB03p02727; COE RS, 1984, J GEOPHYS RES, V89, P1059, DOI 10.1029/JB089iB02p01059; CONSTABLE C, 1990, J GEOPHYS RES-SOLID, V95, P4587, DOI 10.1029/JB095iB04p04587; COX A, 1970, GEOPHYS J ROY ASTR S, V20, P253, DOI 10.1111/j.1365-246X.1970.tb06069.x; COX A, 1964, GEOPHYS J ROY ASTR S, V8, P345, DOI 10.1111/j.1365-246X.1964.tb03856.x; FISHER NI, 1987, STAT ANAL SPHERICAL, P165; GLATZMAIER GA, 1995, NATURE, V377, P203, DOI 10.1038/377203a0; GUBBINS D, 1988, J GEOPHYS RES-SOLID, V93, P3413, DOI 10.1029/JB093iB04p03413; GUBBINS D, 1993, NATURE, V362, P51, DOI 10.1038/362051a0; GUBBINS D, 1994, REV GEOPHYS, V32, P61, DOI 10.1029/93RG02602; HARRISON CGA, 1995, J GEOMAGN GEOELECTR, V47, P131, DOI 10.5636/jgg.47.131; HIRANO K, 1982, ENCY STAT SCI, V7, P647; HOFFMAN KA, 1977, SCIENCE, V196, P1329, DOI 10.1126/science.196.4296.1329; HULOT G, 1994, PHYS EARTH PLANET IN, V82, P167, DOI 10.1016/0031-9201(94)90070-1; IRVING E, 1964, PURE APPL GEOPHYS, V57, P47, DOI DOI 10.1007/BF00879707; Johnson CL, 1996, PHILOS T R SOC A, V354, P89, DOI 10.1098/rsta.1996.0004; KRISTJANSSON L, 1982, GEOPHYS J ROY ASTR S, V68, P273, DOI 10.1111/j.1365-246X.1982.tb04901.x; LEE S, 1983, THESIS AUSTR NATL U; LEMOUEL JL, 1984, NATURE, V311, P734, DOI 10.1038/311734a0; LEVI S, 1990, EARTH PLANET SC LETT, V96, P443, DOI 10.1016/0012-821X(90)90019-T; LIN JL, 1994, GEOPHYS RES LETT, V21, P525, DOI 10.1029/94GL00397; MARDIA KV, 1972, STAT DIRECTIONAL DAT, P232; MARSHALL M, 1988, J GEOPHYS RES-SOLID, V93, P11681, DOI 10.1029/JB093iB10p11681; MARY C, 1993, J GEOPHYS RES-SOL EA, V98, P22461, DOI 10.1029/93JB02174; MCFADDEN PL, 1984, GEOPHYS J ROY ASTR S, V78, P809, DOI 10.1111/j.1365-246X.1984.tb05072.x; MCFADDEN PL, 1988, J GEOPHYS RES-SOLID, V93, P11583, DOI 10.1029/JB093iB10p11583; MERRILL RT, 1977, REV GEOPHYS, V15, P309, DOI 10.1029/RG015i003p00309; PREVOT M, 1990, EARTH PLANET SC LETT, V97, P129, DOI 10.1016/0012-821X(90)90104-6; PREVOT M, 1993, NATURE, V366, P53, DOI 10.1038/366053a0; PREVOT M, 1985, J GEOPHYS RES-SOLID, V90, P417, DOI 10.1029/JB090iB12p10417; QUIDELLEUR X, 1994, GEOPHYS RES LETT, V21, P1639, DOI 10.1029/94GL01105; ROPERCH P, 1988, EARTH PLANET SC LETT, V88, P209, DOI 10.1016/0012-821X(88)90058-1; SCHNEPP E, 1994, GEOPHYS J INT, V116, P688, DOI 10.1111/j.1365-246X.1994.tb03291.x; STEPHENS MA, 1974, J AM STAT ASSOC, V69, P730, DOI 10.2307/2286009; WILLIAMS I, 1981, J GEOPHYS RES, V86, P1657, DOI 10.1029/JB086iB12p11657; WILSON RL, 1972, GEOPHYS J ROY ASTR S, V28, P213, DOI 10.1111/j.1365-246X.1972.tb06124.x	37	34	34	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					776	779		10.1126/science.273.5276.776	http://dx.doi.org/10.1126/science.273.5276.776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670413				2022-12-28	WOS:A1996VB42900036
J	Leitges, M; Schmedt, C; Guinamard, R; Davoust, J; Schaal, S; Stabel, S; Tarakhovsky, A				Leitges, M; Schmedt, C; Guinamard, R; Davoust, J; Schaal, S; Stabel, S; Tarakhovsky, A			Immunodeficiency in protein kinase C beta-deficient mice	SCIENCE			English	Article							BRUTON TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; SIGNAL-TRANSDUCTION PATHWAYS; B-CELL-DIFFERENTIATION; CBA-N MICE; MEDIATED PROLIFERATION; SURFACE-IMMUNOGLOBULIN; T-LYMPHOCYTES; XID MICE; EXPRESSION	Cross-linking of the antigen receptor on lymphocytes by antigens or antibodies to the receptor results in activation of enzymes of the protein kinase C (PKC) family. Mice homozygous for a targeted disruption of the gene encoding the PKC-beta I and PKC-beta II isoforms develop an immunodeficiency characterized by impaired humoral immune responses and reduced cellular responses of B cells, which is similar to X-linked immunodeficiency in mice. Thus PKC-beta I and PKC-beta II play an important role in B cell activation and may be functionally linked to Bruton's tyrosine kinase in antigen receptor-mediated signal transduction.	MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; CNRS, INSERM MARSEILLE LUMINY, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Max Planck Society; University of Cologne; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Leitges, M (corresponding author), MAX PLANCK INST IMMUNBIOL, STUBEWEG 51, D-79108 FREIBURG, GERMANY.		Leitges, Michael/AAN-1953-2021; Guinamard, Rodolphe/P-9804-2016	Guinamard, Rodolphe/0000-0002-7400-582X; Davoust, Jean/0000-0002-3098-7665				AMSBAUGH DF, 1972, J EXP MED, V136, P931, DOI 10.1084/jem.136.4.931; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; COHEN DP, 1991, J IMMUNOL, V146, P2921; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; FRANCOIS DT, 1988, J IMMUNOL, V140, P3338; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; HUBER B, 1979, EUR J IMMUNOL, V9, P827, DOI 10.1002/eji.1830091016; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KELLEHER D, 1992, FEBS LETT, V301, P310, DOI 10.1016/0014-5793(92)80264-H; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KLAUS GGB, 1990, EUR J IMMUNOL, V20, P2301, DOI 10.1002/eji.1830201020; KORETZKY GA, 1989, J IMMUNOL, V143, P1692; LEITGES M, UNPUB; LINDSBERG ML, 1991, J IMMUNOL, V147, P3774; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MOND JJ, 1995, CURR OPIN IMMUNOL, V7, P349, DOI 10.1016/0952-7915(95)80109-X; MOND JJ, 1983, J IMMUNOL, V131, P2107; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; PERLMUTTER RM, 1979, J EXP MED, V149, P993, DOI 10.1084/jem.149.4.993; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCHER I, 1979, J IMMUNOL, V123, P477; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; SMITH CIE, 1994, J IMMUNOL, V152, P557; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TARANTINO N, 1994, FEBS LETT, V338, P339, DOI 10.1016/0014-5793(94)80295-5; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P51, DOI 10.1093/hmg/4.1.51; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	51	394	405	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					788	791		10.1126/science.273.5276.788	http://dx.doi.org/10.1126/science.273.5276.788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670417				2022-12-28	WOS:A1996VB42900040
J	Geldmacher, DS; Whitehouse, PJ				Geldmacher, DS; Whitehouse, PJ			Current concepts - Evaluation of dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; DIAGNOSTIC-CRITERIA; SENILE DEMENTIA; DISTURBANCES; POPULATION; GENETICS; APHASIA		UNIV HOSP CLEVELAND,UNIV ALZHEIMER CTR,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROL,CLEVELAND,OH 44106	University Hospitals of Cleveland; Case Western Reserve University					NATIONAL INSTITUTE ON AGING [P50AG008012] Funding Source: NIH RePORTER; NIA NIH HHS [AG08012] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER EM, 1995, J AM GERIATR SOC, V43, P138, DOI 10.1111/j.1532-5415.1995.tb06378.x; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; CHARLETTA D, 1995, NEUROLOGY, V45, P1456, DOI 10.1212/WNL.45.8.1456; CHATTERJEE A, 1992, ARCH NEUROL-CHICAGO, V49, P486, DOI 10.1001/archneur.1992.00530290070014; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; CIVIL RH, 1993, CONT NEUROLOGY SERIE, V40, P167; COREYBLOOM J, 1995, NEUROLOGY, V45, P211, DOI 10.1212/WNL.45.2.211; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; CUMMINGS JL, 1985, NEUROLOGY, V35, P394, DOI 10.1212/WNL.35.3.394; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GIBB WRG, 1989, J NEUROL NEUROSUR PS, V52, P185, DOI 10.1136/jnnp.52.2.185; HANSEN L, 1990, NEUROLOGY, V40, P1; HESTON LL, 1987, ARCH GEN PSYCHIAT, V44, P409; HOLMAN RC, 1995, NEUROEPIDEMIOLOGY, V14, P174, DOI 10.1159/000109793; JACOBS DM, 1995, NEUROLOGY, V45, P957, DOI 10.1212/WNL.45.5.957; KARNAZE DS, 1990, ARCH NEUROL-CHICAGO, V47, P1008, DOI 10.1001/archneur.1990.00530090082017; KOTSORIS H, 1987, STROKE, V18, P138, DOI 10.1161/01.STR.18.1.138; MAYEUX R, 1993, CONT NEUROLOGY SERIE, V40, P92; MCKEITH IG, 1994, NEUROLOGY, V44, P872, DOI 10.1212/WNL.44.5.872; Mendez M F, 1990, J Neuropsychiatry Clin Neurosci, V2, P28; MENDEZ MF, 1990, NEUROLOGY, V40, P439, DOI 10.1212/WNL.40.3_Part_1.439; MENDEZ MF, 1991, J NEUROL NEUROSUR PS, V54, P542, DOI 10.1136/jnnp.54.6.542; MORRIS JC, 1994, CLIN GERIATR MED, V10, P257, DOI 10.1016/S0749-0690(18)30345-8; NEARY D, 1988, J NEUROL NEUROSUR PS, V51, P353, DOI 10.1136/jnnp.51.3.353; PARASURAMAN R, 1992, BRAIN, V115, P711, DOI 10.1093/brain/115.3.711; Patterson M B, 1990, J Geriatr Psychiatry Neurol, V3, P21, DOI 10.1177/089198879000300106; POST SG, 1994, J AM GERIATR SOC, V42, P782, DOI 10.1111/j.1532-5415.1994.tb06542.x; POST SG, 1995, J AM GERIATR SOC, V43, P1423, DOI 10.1111/j.1532-5415.1995.tb06625.x; RICHARDS M, 1993, ANN NEUROL, V33, P267, DOI 10.1002/ana.410330307; RIPICH DN, 1991, BRAIN LANG, V40, P330, DOI 10.1016/0093-934X(91)90133-L; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; WEYTINGH MD, 1995, J NEUROL, V242, P446; White L R, 1986, Annu Rev Gerontol Geriatr, V6, P215; WHITEHOUSE PJ, 1993, CONT NEUROLOGY SERIE, V40; WIKKELSO C, 1986, ACTA NEUROL SCAND, V73, P566, DOI 10.1111/j.1600-0404.1986.tb04601.x; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	39	143	151	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					330	336		10.1056/NEJM199608013350507	http://dx.doi.org/10.1056/NEJM199608013350507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UY982	8663868				2022-12-28	WOS:A1996UY98200007
J	Solomon, PR; Knapp, MJ; Gracon, SI; Groccia, M; Pendlebury, WW				Solomon, PR; Knapp, MJ; Gracon, SI; Groccia, M; Pendlebury, WW			Long-term tacrine treatment in patients with Alzheimer's disease	LANCET			English	Letter									WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMCOL RES DIV,DEPT CLIN RES,ANN ARBOR,MI; UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT; UNIV VERMONT,COLL MED,DEPT NEUROL,BURLINGTON,VT; SW VERMONT MED CTR,MEMORY DISORDERS CLIN,BENNINGTON,VT	Pfizer; University of Vermont; University of Vermont	Solomon, PR (corresponding author), WILLIAMS COLL,DEPT PSYCHOL,PROGRAM NEUROSCI,WILLIAMSTOWN,MA 01267, USA.							AMBERLA K, 1993, ACTA NEUROL SCAND  S, V149, P55; EAGGER SA, 1994, INT J GERIATR PSYCH, V9, P643, DOI 10.1002/gps.930090808; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KNOPMAN D, IN PRESS NEUROLOGY; WILCOCK GK, 1994, LANCET, V343, P294, DOI 10.1016/S0140-6736(94)91140-1	5	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					275	276		10.1016/S0140-6736(05)65594-8	http://dx.doi.org/10.1016/S0140-6736(05)65594-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ286	8684234				2022-12-28	WOS:A1996UZ28600064
J	Garnick, MB; Fair, WR				Garnick, MB; Fair, WR			Prostate cancer: Emerging concepts .1.	ANNALS OF INTERNAL MEDICINE			English	Article							PREDICT PATHOLOGICAL STAGE; RADICAL PROSTATECTOMY; ANTIGEN LEVELS; CLINICAL STAGE; MEN; DIAGNOSIS; ENHANCE; MARGINS; THERAPY	Objective: To review important topics related to prostate cancer that have arisen since this subject was last covered in Annals in 1993. The review consists of two parts; Part 1 describes advances in prostate-specific antigen (PSA) interpretation (including PSA density and velocity, age-specific reference ranges, ''free'' and ''bound'' PSA ratios, the utility of PSA in defining the pathologic extent of prostate cancer, and the use of these concepts in helping define appropriate treatment strategies), the management of patients with organ-confined prostate cancer, and pathologic interpretation of prostatectomy specimens. Study Selection: Randomized studies identified through a MEDLINE search (1992 to 1996); large, single-institution conferences and consortiums; and studies presented at regional, national, and international symposia. Data Synthesis: Both qualitative and quantitative data are reported. Most of the data presented in part I concern advances in the interpretation of PSA results and characterization of the pathologic findings of prostatectomy specimens. Studies show that almost 50% of patients with clinically organ-confined prostate cancer have disease that is beyond the confines of the prostatic capsule. The chances of developing clinical (radiographic) and biochemical failure (that is, elevation of PSA levels) are 3% and 6%, respectively, for pathologically organ-confined cancer and 10% and 26%, respectively, for non-specimen-confined prostate cancer. Actual progression-free survival rates 10 years after radical prostatectomy are 70% for patients with organ-confined cancer and 39% for patients with cancer that has spread through the capsule. Conclusions: Prostate cancer is being detected with increasing frequency, and many patients with this condition are receiving such treatments as radical prostatectomy and radiation therapy. Although refinements in PSA-based testing have contributed substantially to the increased detection rate of prostate cancer, the incidence of disease was increasing dramatically even before the detection of PSA was possible. Yet, despite earlier detection, the optimal therapy for the early form of the disease remains enigmatic. Further studies and longer follow-up of patients who participated in completed studies are needed to better define the outcomes of prostate cancer therapies and to help determine the importance of the therapies. Increased research efforts are necessary to help elucidate the reasons for the great increase in the incidence of the disease; such efforts should help define strategies to ultimately prevent prostate cancer.	MEM SLOAN KETTERING CANC CTR, DEPT SURG, UROL SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Garnick, MB (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; ANDRIOLE GL, 1992, J UROLOGY, V147, P474, DOI 10.1016/S0022-5347(17)37282-8; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BOSTWICK DG, 1994, SEMIN SURG ONCOL, V10, P60, DOI 10.1002/ssu.2980100110; BRAWER MK, 1993, J UROLOGY, V150, P369, DOI 10.1016/S0022-5347(17)35485-X; CALCIANO R, 1995, PATIENT CARE, V29, P84; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1994, J UROLOGY, V152, P1837, DOI 10.1016/S0022-5347(17)32397-2; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8; DEANTONI EP, 1995, CANCER, V75, P1874, DOI 10.1002/1097-0142(19950401)75:7+<1874::AID-CNCR2820751618>3.0.CO;2-I; Dugan JA, 1996, JAMA-J AM MED ASSOC, V275, P288, DOI 10.1001/jama.275.4.288; EISBRUCH A, 1994, CANCER, V73, P384, DOI 10.1002/1097-0142(19940115)73:2<384::AID-CNCR2820730224>3.0.CO;2-4; EPSTEIN JI, 1990, AM J SURG PATHOL, V14, P626, DOI 10.1097/00000478-199007000-00003; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FLESHNER N, 1996, IN PRESS BR J UROL; FLESHNER NE, 1995, J UROLOGY, V154, P1642, DOI 10.1016/S0022-5347(01)66734-X; Frohmuller H G, 1995, Eur J Surg Oncol, V21, P336, DOI 10.1016/S0748-7983(95)92120-6; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GARNICK MB, 1994, SCI AM, V270, P72, DOI 10.1038/scientificamerican0494-72; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KLEER E, 1993, UROLOGY, V41, P207, DOI 10.1016/0090-4295(93)90558-R; KLOTZ LH, 1986, CANCER, V58, P2546, DOI 10.1002/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LANGE PH, 1990, J UROLOGY, V144, P927, DOI 10.1016/S0022-5347(17)39624-6; Lilja Hans, 1994, Journal of Urology, V151, p400A; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; MCNEAL JE, 1990, AM J SURG PATHOL, V14, P240, DOI 10.1097/00000478-199003000-00005; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; MURPHY GP, 1994, J UROLOGY, V152, P1817, DOI 10.1016/S0022-5347(17)32392-3; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; OESTERLING JE, 1995, J UROLOGY, V154, P1090, DOI 10.1016/S0022-5347(01)66984-2; OHORI M, 1995, J UROLOGY, V154, P1818, DOI 10.1016/S0022-5347(01)66792-2; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARTIN AW, 1993, J UROLOGY, V150, P110, DOI 10.1016/S0022-5347(17)35410-1; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; PAULSON DF, 1994, J UROLOGY, V152, P1826, DOI 10.1016/S0022-5347(17)32395-9; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; RUSSO P, 1986, Surgical Forum (Chicago), V37, P654; STEIN A, 1992, J UROLOGY, V147, P942, DOI 10.1016/S0022-5347(17)37429-3; VANDENOUDEN D, 1993, BRIT J UROL, V72, P489; VIEWEG J, 1994, CANCER RES, V54, P1760; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; WHITMORE W F JR, 1988, NCI (National Cancer Institute) Monographs, P7; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	49	39	39	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					118	125		10.7326/0003-4819-125-2-199607150-00008	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678366				2022-12-28	WOS:A1996UV92100010
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Measurement error and correlation coefficients	BRITISH MEDICAL JOURNAL			English	Article									INST HLTH SCI,CTR STAT MED,IMPERIAL CANC RES FUND,MED STAT GRP,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Altman DG, 1996, BRIT MED J, V312, P1472, DOI 10.1136/bmj.312.7044.1472; Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654	2	485	497	0	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					41	42		10.1136/bmj.313.7048.41	http://dx.doi.org/10.1136/bmj.313.7048.41			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664775	Green Published			2022-12-28	WOS:A1996UW66700033
J	Daley, J; Delbanco, T; Walzer, J				Daley, J; Delbanco, T; Walzer, J			A 50-year-old woman with disabling spinal stenosis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		GARFIN SR, 1995, JAMA-J AM MED ASSOC, V274, P1949	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					66	66						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667542				2022-12-28	WOS:A1996UU43900030
J	Harding, C; Knox, WF; Faragher, EB; Baildam, A; Bundred, NJ				Harding, C; Knox, WF; Faragher, EB; Baildam, A; Bundred, NJ			Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER M20 2LR,LANCS,ENGLAND; UNIV MANCHESTER,UNIV S MANCHESTER HOSP,DEPT HISTOPATHOL,MANCHESTER M20 2LR,LANCS,ENGLAND	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; GAMBRELL RD, 1992, AM FAM PHYSICIAN, V46, pS87; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x	5	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1646	1647		10.1136/bmj.312.7047.1646	http://dx.doi.org/10.1136/bmj.312.7047.1646			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664718	Green Published			2022-12-28	WOS:A1996UV48900023
J	Sallis, JF				Sallis, JF			Sports for all or physical activity for all?	LANCET			English	Editorial Material											Sallis, JF (corresponding author), SAN DIEGO STATE UNIV,DEPT PSYCHOL,SAN DIEGO,CA 92182, USA.		Sallis, James F/D-3001-2014	Sallis, James F/0000-0003-2555-9452				[Anonymous], 1994, PEDIATR EXERC SCI, DOI 10.1123/pes.6.4.434; CALFAS KJ, 1994, PEDIATR EXERC SCI, V6, P406, DOI 10.1123/pes.6.4.406; LEUPKER RV, 1996, JAMA-J AM MED ASSOC, V275, P768; SALLIS JF, 1992, MED SCI SPORT EXER, V24, pS248; SIMONSMORTON BG, 1994, PREV MED, V23, P437, DOI 10.1006/pmed.1994.1059; *SPORTS COUNC HLT, 1993, ALL DUNB NAT FITN SU	6	1	1	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1779	1779		10.1016/S0140-6736(96)91610-4	http://dx.doi.org/10.1016/S0140-6736(96)91610-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667916				2022-12-28	WOS:A1996UU46900003
J	Lawrence, PA; Struhl, G				Lawrence, PA; Struhl, G			Morphogens, compartments, and pattern: Lessons from Drosophila?	CELL			English	Review							GRADIENT MORPHOGEN; BITHORAX COMPLEX; BICOID PROTEIN; HEDGEHOG GENE; EXPRESSION; EMBRYO; WINGLESS; CELLS; MELANOGASTER; SEGMENTATION		COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Lawrence, PA (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Lawrence, Peter/0000-0002-9554-8268				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BOHN H, 1974, J EMBRYOL EXP MORPH, V32, P81; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Cohen Stephen M., 1993, P747; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUNCAN IM, 1982, GENETICS, V102, P49; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1979, SCI AM, V241, P102, DOI 10.1038/scientificamerican0779-102; GARCIABELLIDO A, 1992, ANNU REV GENET, V26, P277, DOI 10.1146/annurev.ge.26.120192.001425; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Graham A, 1996, DEVELOPMENT, V122, P473; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GUILLEN I, 1995, DEVELOPMENT, V121, P3447; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; HOPPLER S, 1994, CELL, V76, P689, DOI 10.1016/0092-8674(94)90508-8; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE PA, 1973, J EMBRYOL EXP MORPH, V30, P681; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LAWRENCE PA, 1972, J CELL SCI, V11, P815; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE M, 1959, J EXP BIOL, V36, P459; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; Ma XG, 1996, DEVELOPMENT, V122, P1195; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MULLER J, 1995, DEVELOPMENT, V121, P2847; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1986, NATURE, V324, P120; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SANICOLA M, 1995, GENETICS, V139, P745; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUMPF HF, 1966, NATURE, V212, P430, DOI 10.1038/212430a0; STUMPF HF, 1968, J EXP BIOL, V49, P49; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TIONG SYK, 1995, DEVELOPMENT, V121, P1649; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; ZECCA M, 1995, DEVELOPMENT, V121, P2265	100	490	495	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					951	961		10.1016/S0092-8674(00)81297-0	http://dx.doi.org/10.1016/S0092-8674(00)81297-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674123	hybrid			2022-12-28	WOS:A1996UV48400003
J	Lin, SQ; Cicala, C; Scharenberg, AM; Kinet, JP				Lin, SQ; Cicala, C; Scharenberg, AM; Kinet, JP			The Fc epsilon RI beta subunit functions as an amplifier of Fc epsilon RI gamma-mediated cell activation signals	CELL			English	Article							AFFINITY IGE RECEPTOR; IMMUNOGLOBULIN-E; MAST-CELL; TRANSFECTED CELLS; EXPRESSION; CHROMOSOME-11Q; CYTOKINES; RESPONSES; LINKAGE; BINDING	The high affinity IgE receptor (Fc epsilon RI) plays a central role in the initiation of allergic responses. Fc epsilon RI is multimeric and is expressed as either alpha gamma(2) trimers or alpha beta gamma(2) tetramers. Recently, polymorphisms of the beta chain gene have been associated with the development of various allergic phenotypes. Until now, the role of beta in Fc epsilon RI-dependent signaling was largely unknown. For that reason, we compared the signaling characteristics of various wild-type and mutant alpha gamma(2) and alpha beta gamma(2) Fc epsilon RI complexes. These studies demonstrate that the gamma dimer functions as an autonomous activation module, while beta functions as an amplifier that provides a gain of 5- to 7-fold, as measured by Syk activation and calcium mobilization.			Lin, SQ (corresponding author), HARVARD UNIV, SCH MED,BETH ISRAEL HOSP,DEPT PATHOL, LAB ALLERGY & IMMUNOL, 99 BROOKLINE AVE, BOSTON, MA 02215 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; COOKSON WOCM, 1989, LANCET, V1, P1292; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GEHA RS, 1992, J ALLERGY CLIN IMMUN, V90, P143, DOI 10.1016/0091-6749(92)90064-9; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KINET JP, 1985, BIOCHEMISTRY-US, V24, P4117, DOI 10.1021/bi00336a046; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MEYERS DA, 1991, GENET EPIDEMIOL, V8, P351, DOI 10.1002/gepi.1370080507; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PARKS T, 1990, HUM HERED, V40, P69, DOI 10.1159/000153908; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	39	281	287	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					985	995		10.1016/S0092-8674(00)81300-8	http://dx.doi.org/10.1016/S0092-8674(00)81300-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674126	Bronze			2022-12-28	WOS:A1996UV48400006
J	Krook, A; Soos, MA; Kumar, S; Siddle, K; ORahilly, S				Krook, A; Soos, MA; Kumar, S; Siddle, K; ORahilly, S			Functional activation of mutant human insulin receptor by monoclonal antibody	LANCET			English	Article							GROWTH FACTOR-I; RESISTANCE; KINASE	Background A mutant insulin receptor, Ser323Leu, has been reported in two severely insulin-resistant patients with Rabson-Mendenhall syndrome. In both cases, extreme be controlled by conventional Ser323Leu mutant insulin receptor is inserted normally in the plasma membrane but has very low binding affinity for insulin. A monoclonal antibody directed against the extracellular domain of the insulin receptor (83.14) can mimic the natural ligand as far as the first step after ligand binding-autophosphorylation of the intracellular domain of the receptor. We have investigated whether antibody binding can imitate autophosphorylation of the Ser323Leu mutant receptor and lead to metabolic events within the cell. Methods The effects of insulin and the insulin-receptor monoclonal antibody on receptor autophosphorylation and glycogen synthesis were compared in Chinese hamster ovary cells expressing the wild-type human insulin receptor, mock-transfected cells, cells expressing an insulin-receptor mutant without autophosphorylation capacity, and cells expressing the Ser323Leu mutant receptor. Findings Cells expressing the Ser323Leu mutant receptor had very low specific insulin binding and, expressing wild-type insulin receptors, did autophosphorylation or stimulation of glycogen synthesis in response to insulin. However, exposure of cells expressing the Ser323Leu mutant receptor to monoclonal antibody 83.14 resulted in autophosphorylation and stimulation of glycogen synthesis similar to that seen in cells expressing wild-type insulin receptors. Interpretation Although insulin does not bind to cells expressing the Ser323Leu mutation, insulin signalling can be mimicked by exposure of the cells to an antibody to the extracellular domain of the insulin receptor. Activation by monoclonal antibodies of mutant transmembrane receptors that show normal cell-surface expression but defective ligand binding may provide an approach to the therapy of some subtypes of inherited hormone resistance for which little effective treatment is available.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QR,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham			O'Rahilly, Stephen/ABF-6509-2020; Krook, Anna/K-1192-2015; kumar, sudhesh/D-6945-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Krook, Anna/0000-0002-0891-0258; kumar, sudhesh/0000-0003-4326-5941	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CLARK AJL, 1993, LANCET, V341, P461, DOI 10.1016/0140-6736(93)90208-X; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DYER MJS, 1989, BLOOD, V73, P1431; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; KOLACZYNSKI JW, 1994, ANN INTERN MED, V120, P47, DOI 10.7326/0003-4819-120-1-199401010-00009; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; KUZUYA H, 1993, DIABETES, V42, P696, DOI 10.2337/diabetes.42.5.696; LEBRUN C, 1993, J BIOL CHEM, V268, P11272; Moller David E., 1993, P49; ORAHILLY S, 1992, CLIN ENDOCRINOL, V36, P121, DOI 10.1111/j.1365-2265.1992.tb00945.x; PEARCE SHS, 1995, QJM-MON J ASSOC PHYS, V88, P3; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SMITH RM, 1992, SCI PROG, V76, P323; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; THART LM, IN PRESS J BIOL CHEM; UTIGER RD, 1995, NEW ENGL J MED, V332, P183, DOI 10.1056/NEJM199501193320311; WALDMANN H, 1993, IMMUNOL TODAY, V14, P247, DOI 10.1016/0167-5699(93)90040-R; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WINTER G, 1993, IMMUNOL TODAY, V14, P243, DOI 10.1016/0167-5699(93)90039-N; ZENOBI PD, 1993, DIABETOLOGIA, V36, P465, DOI 10.1007/BF00402285	22	20	22	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1586	1590		10.1016/S0140-6736(96)91076-4	http://dx.doi.org/10.1016/S0140-6736(96)91076-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667867				2022-12-28	WOS:A1996UP66100010
J	Nelkin, D				Nelkin, D			An uneasy relationship: The tensions between medicine and the media	LANCET			English	Editorial Material								The enduring tensions between medicine and the media are largely due to the different perspectives of biomedical scientists and journalists, as this final essay in the series on medicine and the media underscores. These tensions arise because of perceived differences in defining science news, conflicts over styles of science reporting, and most of all disagreement about the role of the media. In the 1990s, scientists are especially concerned by media messages that question their credibility. Since scientists and journalists depend on each other in the communication of science and the shaping of the public meaning of science and medicine, the tensions are likely to increase.			Nelkin, D (corresponding author), NYU,DEPT SOCIOL,269 MERCER ST,NEW YORK,NY 10003, USA.							Altman LK, 1996, LANCET, V347, P1382, DOI 10.1016/S0140-6736(96)91016-8; Altman LK, 1996, LANCET, V347, P1459, DOI 10.1016/S0140-6736(96)91689-X; Angier N, 1993, NY TIMES        0324, pA1; *ASS AM MED COLL, 1992, FRAM I CONS MAN ALL; CREWDSON J, 1994, CHICAGO TRIBUNE 0313; CULVER K, 1993, SCIENCES, V1, P18; deSemir V, 1996, LANCET, V347, P1163, DOI 10.1016/S0140-6736(96)90614-5; DEWITT P, 1994, TIME            1017, P46; DUNWOODY S, 1982, IEEE T PROFESSIO DEC, P196; Gross Paul R., 1995, HIGHER SUPERSTITION; Guston D, 1994, THE FRAGILE CONTRACT; JASANOFF S, 1994, 5 BRANCH; KRIMSKY S, 1991, BIOTECHNICS SOC, P71; LEWENSTEIN BV, 1992, OSIRIS, V7, P135, DOI 10.1086/368708; LYNCH L, 1990, SCI WRITER       WIN, P15; LYON J, 1995, ALTERED FATE; MAYNARDMOODY S, 1995, DILEMMA FETUS; National Institute of Health, 1994, REP HUM EMBR RES PAN; Nelkin D., 1995, DNA MYSTIQUE GENE CU; Nelkin D, 1995, SELLING SCI PRESS CO; Radford T, 1996, LANCET, V347, P1533, DOI 10.1016/S0140-6736(96)90677-7; SCHILLER D, 1991, OBJECTIVITY NEWS; SEA G, 1994, COLUMBIA J REV   MAR, P37; SHINN T, 1985, EXPOSITORY SCI; Sibbison Jim, 1988, COLUMBIA JOURNAL JUL, P36; SLOSSON EE, 1979, THESIS U N CAROLINA; Turney J, 1996, LANCET, V347, P1087, DOI 10.1016/S0140-6736(96)90283-4; Turow J, 1996, LANCET, V347, P1240, DOI 10.1016/S0140-6736(96)90747-3; Wilkie T, 1996, LANCET, V347, P1308, DOI 10.1016/S0140-6736(96)90947-2; 1990, NEWSWEEK        0326; 1993, TIME            1108	31	109	110	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1600	1603		10.1016/S0140-6736(96)91081-8	http://dx.doi.org/10.1016/S0140-6736(96)91081-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667872	hybrid			2022-12-28	WOS:A1996UP66100015
J	Peel, NFA; Smith, AG; Hannon, RA; Eastell, R				Peel, NFA; Smith, AG; Hannon, RA; Eastell, R			Rate of bone loss from lumbar spine in women with distal forearm fracture	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD,S YORKSHIRE,ENGLAND	University of Sheffield			Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				ALFFRAM PA, 1962, J BONE JOINT SURG AM, V44, P105, DOI 10.2106/00004623-196244010-00009; PARFITT AM, 1982, CONTINUING ED FA APR, P46; PEEL NFA, 1994, BRIT MED J, V308, P1543, DOI 10.1136/bmj.308.6943.1543; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919	5	4	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1457	1457		10.1136/bmj.312.7044.1457	http://dx.doi.org/10.1136/bmj.312.7044.1457			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664625	Green Published			2022-12-28	WOS:A1996UQ29600028
J	Kaiser, L; Lew, D; Hirschel, B; Auckenthaler, R; Morabia, A; Heald, A; Benedict, P; Terrier, F; Wunderli, W; Matter, L; Germann, D; Voegeli, J; Stalder, H				Kaiser, L; Lew, D; Hirschel, B; Auckenthaler, R; Morabia, A; Heald, A; Benedict, P; Terrier, F; Wunderli, W; Matter, L; Germann, D; Voegeli, J; Stalder, H			Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions	LANCET			English	Article							SINUSITIS; COMMUNITY	Background Upper-respiratory-tract infection is one of the main causes of overuse of antibiotics. We have found previously that bacteria such as Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae can be isolated from the nasopharyngeal secretions of a substantial proportion of adults with upper-respiratory-tract infections, We have assessed the efficacy of co-amoxiclav in patients with common colds but no clinical signs of sinusitis or other indications for antibiotics, Methods Between January, 1992, and March, 1994, 314 patients who presented to our outpatient clinic with common colds were enrolled in the double-blind, placebo-controlled study. They were randomly assigned 5 days' treatment with co-amoxiclav (375 mg three times daily) or identical placebo. Clinical examinations were done at enrolment and on day 5-7 to assess outcome (cured, persistent symptoms, worse symptoms). Seven patients were excluded after randomisation, seven did not have nasopharyngeal aspiration, and 12 did not return for followup assessment. Findings Of 300 patients with nasopharyngeal aspirates, 72 had negative bacterial cultures, 167 had cultures positive only for bacteria unrelated to respiratory infections, and 61 had cultures positive for H influenzae, M catarrhalis, or S pneumoniae. At 5-day follow-up of these culture-positive patients, the distribution of outcome was significantly better among co-amoxiclav-treated (n=30) than placebo-treated (n=28) patients (cured 27 vs 4%; persistent symptoms 70 vs 60%; worse symptoms 3 vs 36%; p=0.001). Patients on co-amoxiclav also scored their symptoms significantly lower than patients on placebo (p=0.008). Among culture-negative patients (n=230), the outcome distribution did not differ between the treatment groups(p=0.392). Interpretation The majority of patients with upper-respiratory-tract infection do not benefit from antibiotics and side-effects are frequent. However, for the subgroup whose nasopharyngeal secretions contain H influenzae, M catarrhalis, or S pneumoniae, antibiotics are clinically beneficial.	UNIV HOSP GENEVA,DIV CLIN EPIDEMIOL,CH-1211 GENEVA,SWITZERLAND; UNIV HOSP GENEVA,MED POLICLIN,CH-1211 GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DIV RADIODIAGNOST & INTERVENT RADIOL,CH-1211 GENEVA,SWITZERLAND; UNIV HOSP GENEVA,CENT LAB VIROL,CH-1211 GENEVA,SWITZERLAND; UNIV BERN,INST MED MICROBIOL,BERN,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Bern	Kaiser, L (corresponding author), UNIV HOSP GENEVA,DIV INFECT DIS,RUE MICHELI-DU-CREST 24,CH-1211 GENEVA,SWITZERLAND.							AGRESTI A, 1990, MULTINOMIAL RESPONSE, P315; DOUGLAS RG, 1986, NEW ENGL J MED, V314, P114, DOI 10.1056/NEJM198601093140209; DRUCE HM, 1994, MICROBIOLOGY SINUSIT, P41; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Gwaltney J.M., 1995, PRINCIPLES PRACTICE, V4th ed., P561; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HARDY LM, 1956, J PEDIATR-US, V48, P146, DOI 10.1016/S0022-3476(56)80160-1; HEALD A, 1993, J GEN INTERN MED, V8, P667, DOI 10.1007/BF02598283; HOAGLAND RJ, 1950, NEW ENGL J MED, V243, P773, DOI 10.1056/NEJM195011162432003; JONES PN, 1953, JAMA-J AM MED ASSOC, V153, P262, DOI 10.1001/jama.1953.02940210004002; JOUSIMIESSOMER HR, 1989, J CLIN MICROBIOL, V27, P2736, DOI 10.1128/JCM.27.12.2736-2743.1989; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SOYKA LF, 1975, PEDIATRICS, V55, P552; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; 1965, BRIT MED J, V2, P319	21	137	140	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1507	1510		10.1016/S0140-6736(96)90670-4	http://dx.doi.org/10.1016/S0140-6736(96)90670-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684101	Bronze			2022-12-28	WOS:A1996UN47300009
J	Lupton, JE				Lupton, JE			A far-field hydrothermal plume from Loihi Seamount	SCIENCE			English	Article							HAWAII; XENOLITHS; BASALTS; ISLAND; MANTLE; SUMMIT; GASES	An extensive helium plume in the north central Pacific emanates from Loihi Seamount on the flanks of Hawaii. The maximum helium signal is found at a depth of about 1100 meters, the same depth as the near-field plume directly above Loihi Seamount. Although this helium plume is strongest near Hawaii, where the He-3/He-4 ratio at a depth of about 1100 meters reaches values 28 percent above the atmospheric ratio, it can be detected quite clearly at latitude 24 degrees N, over 400 kilometers to the north. Excess He-3 is also present on the same isopycnal between 15 degrees N and 20 degrees N at 135 degrees W, some 2000 kilometers east of the Hawaiian Islands.			Lupton, JE (corresponding author), NOAA,PACIFIC MARINE ENVIRONM LAB,NEWPORT,OR 97365, USA.							BAKER ET, 1994, EARTH PLANET SC LETT, V128, P1, DOI 10.1016/0012-821X(94)90022-1; BURKOV VA, 1973, OCEANOLOGY-USSR, V13, P325; CHEMINEE JL, 1991, EARTH PLANET SC LETT, V107, P318, DOI 10.1016/0012-821X(91)90079-W; CRAIG H, 1988, EOS T AM GEOPHYS UN, V69, P1478; CRAIG H, 1987, EOS T AM GEOPHYS UN, V68, P1553; GAMO T, 1987, GEOCHIM COSMOCHIM AC, V51, P2857, DOI 10.1016/0016-7037(87)90163-3; HORIBE Y, 1983, EOS T AM GEOPHYS UN, V64, P724; JENKINS WH, COMMUNICATION; KANEOKA I, 1983, EARTH PLANET SC LETT, V66, P427, DOI 10.1016/0012-821X(83)90156-5; KARL DM, 1988, NATURE, V335, P532, DOI 10.1038/335532a0; KIM K, 1983, EOS, V64, P724; KODERA M, 1988, EARTH PLANET SC LETT, V87, P266, DOI 10.1016/0012-821X(88)90014-3; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; LUPTON J, 1989, EOS S, V70, P1131; LUPTON JE, 1990, J GEOPHYS RES-SOLID, V95, P12829, DOI 10.1029/JB095iB08p12829; LUPTON JE, 1976, EARTH PLANET SC LETT, V32, P371, DOI 10.1016/0012-821X(76)90077-7; LUPTON JE, 1981, SCIENCE, V214, P13, DOI 10.1126/science.214.4516.13; LUPTON JE, 1983, ANNU REV EARTH PL SC, V11, P371, DOI 10.1146/annurev.ea.11.050183.002103; LUPTON JE, 1993, UNPUB PISCES; MALAHOFF A, 1987, VOLCANISM HAWAII, P133; MOORE JG, IN PRESS GEOPHYSICAL; Reid J. L., 1981, EVOLUTION PHYSICAL O, V623, P70; REID JL, 1978, J PHYS OCEANOGR, V8, P946, DOI 10.1175/1520-0485(1978)008<0946:OTMDCO>2.0.CO;2; RISON W, 1983, EARTH PLANET SC LETT, V66, P407, DOI 10.1016/0012-821X(83)90155-3; SAKAI H, 1987, GEOCHEM J, V21, P11, DOI 10.2343/geochemj.21.11; SANSONE FJ, 1994, EOS S, V75, P313; SEDWICK PN, 1992, GEOCHIM COSMOCHIM AC, V56, P3643, DOI 10.1016/0016-7037(92)90159-G; SEDWICK PN, 1994, GEOCHIM COSMOCHIM AC, V58, P1219, DOI 10.1016/0016-7037(94)90587-8; STOMMEL H, 1960, DEEP-SEA RES, V6, P217; Talley L., COMMUNICATION; WIJFFELS SE, IN PRESS DEEP SEA RE; Yoshida K., 1967, J OCEANOGRAPHICAL SO, V23, P88, DOI [10.5928/kaiyou1942.23.88, DOI 10.5928/KAIYOU1942.23.88]; Yoshida K., 1967, J OCEANOGRAPHICAL SO, V23, P231, DOI [10.5928/kaiyou1942.23.231, DOI 10.5928/KAIYOU1942.23.231]; Young C., 1983, EOS T AM GEOPHYS UN, V64, P735	34	31	33	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					976	979		10.1126/science.272.5264.976	http://dx.doi.org/10.1126/science.272.5264.976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662580				2022-12-28	WOS:A1996UL61900034
J	Rossi, AF; Rittenhouse, CD; Paradiso, MA				Rossi, AF; Rittenhouse, CD; Paradiso, MA			The representation of brightness in primary visual cortex	SCIENCE			English	Article							ILLUSORY CONTOURS; RESPONSES; CATS	Although neurons in primary visual cortex are sensitive to the spatial distribution and intensity of light, their responses have not been thought to correlate with the perception of brightness. Indeed, primary visual cortex is often described as an initial processing stage that sends information to higher cortical areas where perception of brightness, color, and form occurs. However, a significant percentage of neurons in primary visual cortex were shown to respond in a manner correlated with perceived brightness, rather than responding strictly to the light level in the receptive fields of the cells. This finding suggests that even at the first stage of visual cortical processing, spatial integration of information yields perceptual qualities that are only indirectly related to the pattern of illumination of the retina.			Rossi, AF (corresponding author), BROWN UNIV, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.							BRAVO M, 1988, VISION RES, V28, P861, DOI 10.1016/0042-6989(88)90095-8; DEVALOIS RL, 1971, SCIENCE, V171, P694, DOI 10.1126/science.171.3972.694; DEVALOIS RL, 1986, VISION RES, V26, P887, DOI 10.1016/0042-6989(86)90147-1; HERING E, 1878, LEHRE VOM LICHTSINN; HESS C, 1894, GRAEFES ARCH OPHTHAL, V15, P1; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LANDIS C, 1954, PHYSIOL REV, V34, P259, DOI 10.1152/physrev.1954.34.2.259; NEWSOME WT, 1990, COLD SPRING HARB SYM, V55, P697; REDIES C, 1986, EXP BRAIN RES, V61, P469; Rossi AF, 1996, VISION RES, V36, P1391, DOI 10.1016/0042-6989(95)00206-5; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	17	205	207	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1104	1107		10.1126/science.273.5278.1104	http://dx.doi.org/10.1126/science.273.5278.1104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688096				2022-12-28	WOS:A1996VD42800037
J	MauserBunschoten, EP; Damen, M; Reesink, HW; Roosendaal, G; Chamuleau, RAFM; vandenBerg, HM				MauserBunschoten, EP; Damen, M; Reesink, HW; Roosendaal, G; Chamuleau, RAFM; vandenBerg, HM			Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							ALPHA-INTERFERON; INHIBITORS; THERAPY	Objective: To evaluate the risk for development of antibodies to factor VIII (factor VIII inhibitors) during and after interferon therapy in patients with hemophilia A and chronic hepatitis C infection. Design: Patients were divided into two treatment groups and an untreated control group. Test results from the two treatment groups were compared with those from the control group. Setting: 3 clinical centers in the Netherlands. Patients: 35 men with hemophilia A who had acquired hepatitis C through the use of plasma-derived clotting factor concentrates, Measurements: Patients were tested for factor VIII inhibitors before the start of interferon therapy and every 6 months thereafter. Results: 21 patients with hemophilia A received interferon therapy for chronic hepatitis C infection for a mean of 19.5 months (range, 0.5 to 36 months). In 2 patients, inhibitors were detected on one occasion (maximum titer, 1.2 Bethesda units/mL) during interferon therapy. In 3 patients who were known to have had inhibitors before interferon therapy, no anamnestic reaction was seen during treatment. In 3 of 14 untreated controls who were followed for a mean of 28 months (range, 18 to 40 months), inhibitors were detected on one occasion (maximum titer, 2.3 Bethesda units/mL). Conclusion: Long-term interferon therapy in patients with hemophilia did not increase the risk for development of factor VIII inhibitors.	WILHELMINA CHILDRENS HOSP, UTRECHT, NETHERLANDS; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB,RED CROSS BLOOD BANK, DEPT VIRUS DIAGNOST, NL-1006 AD AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT HEPATOL, NL-1105 AZ AMSTERDAM, NETHERLANDS	Wilhelmina Kinderziekenhuis; University of Amsterdam; Academic Medical Center Amsterdam	MauserBunschoten, EP (corresponding author), UNIV UTRECHT HOSP, VAN CREVELD CLIN, POSTBOX 85500, NL-3508 AG UTRECHT, NETHERLANDS.							BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; BOUMA BN, 1974, HAEMOSTASIS, V3, P94; Bresters D., 1994, V61, P121; BRESTERS D, 1993, THESIS U UTRECHT AMS, P145; CASTENSKIOLD EC, 1994, BRIT J HAEMATOL, V87, P434, DOI 10.1111/j.1365-2141.1994.tb04941.x; DIANZANI F, 1990, J HEPATOL, V11, pS5, DOI 10.1016/0168-8278(90)90156-L; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; LEE ML, 1993, THROMB HAEMOSTASIS, V69, P87; MAUSERBUNSCHOTEN EP, 1995, J MED VIROL, V45, P241, DOI 10.1002/jmv.1890450302; MAUSERBUNSCHOTEN EP, 1995, HAEMOPHILIA, V1, P45, DOI 10.1111/j.1365-2516.1995.tb00039.x; MCMILLAN CW, 1988, BLOOD, V71, P344; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; ROSENDAAL FR, 1993, BLOOD, V81, P2180; STRICKER RB, 1994, J RHEUMATOL, V21, P350	14	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					297	299		10.7326/0003-4819-125-4-199608150-00007	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678393				2022-12-28	WOS:A1996VB68000010
J	Fekade, D; Knox, K; Hussein, K; Melka, A; Lalloo, DG; Coxon, RE; Warrell, DA				Fekade, D; Knox, K; Hussein, K; Melka, A; Lalloo, DG; Coxon, RE; Warrell, DA			Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELAPSING FEVER; SEPTIC SHOCK; MONOCLONAL-ANTIBODY; SEPSIS; CACHECTIN; THERAPY; TNF; ENDOTOXIN; DISEASE	Background In patients with louse-borne relapsing fever (Borrelia recurrentis infection), antimicrobial treatment is often followed by sudden fever, rigors, and persistent hypotension (Jarisch-Herxheimer reactions) that are associated with increases in plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interleukin-8. We attempted to determine whether sheep polyclonal Fab antibody fragments against TNF-alpha (anti-TNF-alpha Fab) could suppress the Jarisch-Herxheimer reaction. Methods We conducted a randomized, double-blind, placebo-controlled trial in 49 patients with proven louse-borne relapsing fever. Immediately before the intramuscular injection of penicillin, the patients received an intravenous infusion of either anti-TNF-alpha Fab or a control solution. Results Ten of the 20 patients given anti-TNF-alpha Fab had Jarisch-Herxheimer reactions with rigors, as compared with 26 of the 29 control patients (P = 0.006). The controls had significantly greater mean maximal increases in temperature (1.5 vs. 0.8 degrees C, P<0.001), pulse rate (31 vs, 13 per minute, P<0.001), and systolic blood pressure (25 vs. 15 mm Hg, P<0.003), as well as higher mean peak plasma concentrations of interleukin-6 (50 vs. 17 mu g per liter) and interleukin-8 (2000 vs. 205 ng per liter) (P<0.001 for both comparisons). Levels of TNF-alpha were undetectable after treatment with anti-TNF-alpha Fab. Conclusions Pretreatment with sheep anti-TNF-alpha Fab suppresses Jarisch-Herxheimer reactions that occur after penicillin treatment for louse-borne relapsing fever, reduces the associated increases in plasma concentrations of interleukin-6 and interleukin-8, and may be useful in other forms of sepsis. (C) 1996, Massachusetts Medical Society.	UNIV OXFORD,JOHN RADCLIFFE HOSP,CTR TROP MED,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; BLACK LION HOSP,DEPT INTERNAL MED,INFECT DIS UNIT,ADDIS ABABA,ETHIOPIA; ST BARTHOLOMEWS HOSP,COLL MED,DEPT CHEM PATHOL,LONDON,ENGLAND	University of Oxford; University of London; Queen Mary University London				Lalloo, David/0000-0001-7680-2200				ABRAHAM E, 1994, JAMA-J AM MED ASSOC, V271, P1876, DOI 10.1001/jama.271.23.1876; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BRYCESON AD, 1970, Q J MED, V39, P129; BUTLER T, 1985, ANN INTERN MED, V102, P397, DOI 10.7326/0003-4819-102-3-397; BUTLER T, 1978, J INFECT DIS, V137, P573, DOI 10.1093/infdis/137.5.573; CHRISTMAN JW, 1992, CHEST, V102, P613, DOI 10.1378/chest.102.2.613; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; DERKX B, 1993, LANCET, V342, P173, DOI 10.1016/0140-6736(93)91375-V; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; Herxheimer K, 1902, DEUT MED WOCHENSCHR, V28, P895, DOI 10.1055/s-0028-1139096; Jarisch A., 1895, WIEN MED WOCHENSCHR, V45, P721; KWIATKOWSKI D, 1993, Q J MED, V86, P91; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; RADOLF JD, 1991, J IMMUNOL, V147, P1968; SMITH MB, 1989, ANAESTHESIA, V44, P737; SPOONER CE, 1992, CLIN IMMUNOL IMMUNOP, V62, pS11, DOI 10.1016/0090-1229(92)90036-N; TEKLU B, 1983, LANCET, V1, P835; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WAAGE A, 1987, LANCET, V1, P355; WARRELL DA, 1970, CLIN SCI, V39, P123, DOI 10.1042/cs0390123	26	142	145	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					311	315		10.1056/NEJM199608013350503	http://dx.doi.org/10.1056/NEJM199608013350503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663853				2022-12-28	WOS:A1996UY98200003
J	Allos, BM; Gensheimer, KF; Bloch, AB; Parrotte, D; Horan, JM; Lewis, V; Schaffner, W				Allos, BM; Gensheimer, KF; Bloch, AB; Parrotte, D; Horan, JM; Lewis, V; Schaffner, W			Management of an outbreak of tuberculosis in a small community	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; MYCOBACTERIUM-TUBERCULOSIS	Objective: To investigate an outbreak of tuberculosis, determine the number of active cases and infections, and examine efforts to control the spread of disease. Setting: A small town in Maine, in which no cases of tuberculosis had been reported in the previous 3 years. Design: Epidemiologic investigation of an outbreak of tuberculosis infection and disease. Measurements: A patient with an active case of tuberculosis was defined as a resident of the town or the surrounding area or an employee of the local shipyard who had a culture of sputum or tissue that was positive for Mycobacterium tuberculosis between June 1989 and May 1992. A case of tuberculous infection was defined as a positive tuberculin skin test result in a person with no previous positive test result. Results: 21 active cases of tuberculosis occurred among shipyard workers and persons residing in the affected community between 1989 and 1992. One patient was the source of the outbreak; 8 months lapsed between the onset of this patient's illness and appropriate diagnosis and treatment. The M. tuberculosis strains isolated from this patient and from six other patients belonged to phage type I, auxiliary 14. All isolates were susceptible to drug treatment. Of 9898 persons who were tested, 697 (7%) were newly infected. Because isoniazid prophylaxis was not routinely offered to infected persons older than 35 years of age, only 341 (49%) infected persons completed isoniazid prophylaxis. Conclusions: Many secondary cases of tuberculosis occurred throughout this small Maine community because of delayed diagnosis and treatment of the source patient, delayed outbreak investigation, and failure to promote isoniazid prophylaxis to all persons infected during the outbreak. Aggressive efforts to identify persons with new infection are of limited value in controlling tuberculosis unless they are accompanied by an equally aggressive use of isoniazid prophylaxis.	MAINE BUR HLTH, AUGUSTA, ME 04333 USA; CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; VANDERBILT UNIV, SCH MED, DEPT PREVENT MED, NASHVILLE, TN 37233 USA; BATH IRON WORKS, BATH, AVON, ENGLAND	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Vanderbilt University	Allos, BM (corresponding author), VANDERBILT UNIV, SCH MED, DIV INFECT DIS, A3310 MED CTR N, NASHVILLE, TN 37233 USA.							BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CROSS ER, 1990, AM J PUBLIC HEALTH, V80, P435, DOI 10.2105/AJPH.80.4.435; DEAN AG, 1994, EPI INFO MANUAL VERS; HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410; *HHS, 1981, HHS PUBL; JONES WD, 1982, AM REV RESPIR DIS, V125, P640; NARAIN R, 1979, AM REV RESPIR DIS, V119, P1039; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SNIDER DE, 1984, AM REV RESPIR DIS, V130, P1095; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; STEAD WW, 1995, ANN INTERN MED, V122, P906, DOI 10.7326/0003-4819-122-12-199506150-00003; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, pA722; 1994, TB MONITOR       JAN, P5; 1990, MMWR-MORBID MORTAL W, V39, P9; 1983, AM REV RESPIR DIS, V128, P336	20	33	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					114	117		10.7326/0003-4819-125-2-199607150-00007	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678365				2022-12-28	WOS:A1996UV92100009
J	Watt, G; Chouriyagune, C; Ruangweerayud, R; Watcharapichat, P; Phulsuksombati, D; Jongsakul, K; TejaIsavadharm, P; Bhodhidatta, D; Corcoran, KD; Dasch, GA; Strickman, D				Watt, G; Chouriyagune, C; Ruangweerayud, R; Watcharapichat, P; Phulsuksombati, D; Jongsakul, K; TejaIsavadharm, P; Bhodhidatta, D; Corcoran, KD; Dasch, GA; Strickman, D			Scrub typhus infections poorly responsive to antibiotics in northern Thailand	LANCET			English	Article							DOXYCYCLINE; THERAPY	Background Rickettsia tsutsugamushi, the aetiological agent of scrub typhus, is common in Asia and readily infects visitors to areas where disease transmission occurs. Rapid defervescence after antibiotic treatment is so characteristic that it is used as a diagnostic test R tsutsugamushi infection, Reports from local physicians that patients with scrub typhus in Chiangrai, northern Thailand responded badly to appropriate antibiotic therapy prompted us to do a prospective clinical evaluation and antibiotic susceptibility testing of human rickettsial isolates. Methods The clinical response to doxycycline treatment in patients with early, mild scrub typhus in northern Thailand was compared with the results of treatment in Mae Sod, western Thailand. Prototype and naturally occurring strains of R tsutsugamushi were tested for susceptibility to chloramphenicol and doxycycline in mice and in cell culture. Findings By the third day of treatment, fever had cleared in all seven patients from Mae Sod, but in only five of the 12 (40%) from Chiangrai (p<0 . 01). Median fever clearance time in Chiangrai (80 h; range 15-190) was significantly longer than in Mae Sod (30 h; range 4-58; p<0 . 005). Conjunctival suffusion resolved significantly more slowly in Chiangrai (p<0 . 05). Antibiotics prevented death in mice infected by Chiangrai strains of R tsutsugamushi less often than after infection by the prototype strain (p<0 . 05). Only one of three Chiangrai strains tested in cell culture was fully susceptible to doxycycline, Interpretation Chloramphenicol-resistant and doxycycline-resistant. strains of R tsutsugamushi occur in Chiangrai, Thailand,This is the first evidence of naturally occurring antimicrobial resistance in the genus Rickettsia.	AFRIMS,DEPT ENTOMOL,APO,AP 96546; AFRIMS,DEPT IMMUNOL,APO,AP 96546; AFRIMS,DEPT VET MED,USA COMPONENT,APO,AP 96546; AFRIMS,ROYAL THAI ARMY COMPONENT,DIV ANALYT,BANGKOK,THAILAND; CHIANGRAI PRACHANUCHROA HOSP,DEPT MED,CHIANGRAI,THAILAND; MAE SOD HOSP,DEPT MED,MAE SOT,THAILAND; USN,MED RES INST,BETHESDA,MD	Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy	Watt, G (corresponding author), AFRIMS,DEPT MED,APO,AP 96546, USA.							BERMAN SJ, 1973, ANN INTERN MED, V79, P26, DOI 10.7326/0003-4819-79-1-26; BROWN GW, 1978, T ROY SOC TROP MED H, V72, P412, DOI 10.1016/0035-9203(78)90138-4; Brown GW, 1988, BIOL RICKETTSIAL DIS, V1, P94; CHOURIYAGUNE C, 1992, INTERNAL MED, V8, P29; Christie A. B., 1980, INFECT DIS EPIDEMIOL; ELSOM KA, 1961, ANN INTERN MED, V55, P784, DOI 10.7326/0003-4819-55-5-784; IRONS EN, 1946, AM J TROP MED, V26, P165; KAWAMURA A, 1988, JPN J EXP MED, V58, P169; KELLY DJ, 1988, AM J TROP MED HYG, V38, P400, DOI 10.4269/ajtmh.1988.38.400; MCCLAIN JB, 1988, ANTIMICROB AGENTS CH, V32, P285, DOI 10.1128/AAC.32.2.285; NIEDER M, 1988, CHROMATOGRAPHIA, V25, P526, DOI 10.1007/BF02324827; NORRIS S, 1990, PRINCIPLES PRACTICE, P434; OLSON JG, 1980, AM J TROP MED HYG, V29, P989, DOI 10.4269/ajtmh.1980.29.989; RAOULT D, 1991, ANTIMICROB AGENTS CH, V35, P2457, DOI 10.1128/AAC.35.12.2457; SHEEHY TW, 1973, ARCH INTERN MED, V132, P77, DOI 10.1001/archinte.132.1.77; SMADEL JE, 1952, AM J HYG, V56, P294, DOI 10.1093/oxfordjournals.aje.a119553; SMADEL JE, 1954, AM J MED, V1626, P246; Standiford H. C., 1990, PRINCIPLES PRACTICE, P284; TWARTZ JC, 1982, J INFECT DIS, V146, P811, DOI 10.1093/infdis/146.6.811; WATT G, 1994, CLIN INFECT DIS, V18, P624, DOI 10.1093/clinids/18.4.624; WEISS W, 1960, AM J HYG, V71, P292; WISSEMAN CL, 1990, MICROBIOLOGY, P687; Wisseman CL, 1991, HUNTERS TROPICAL MED, P256	23	190	199	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					86	89		10.1016/S0140-6736(96)02501-9	http://dx.doi.org/10.1016/S0140-6736(96)02501-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676722				2022-12-28	WOS:A1996UW67300010
J	Williams, K; Chambers, M; Logan, S; Robinson, D				Williams, K; Chambers, M; Logan, S; Robinson, D			Association of common health symptoms with bullying in primary school children	BRITISH MEDICAL JOURNAL			English	Article							MIDDLE	Objectives-To estimate the prevalence of bullying in primary school children and to examine its association with common symptoms in childhood. Design-Semistructured health interview conducted by school nurses as part of a school medical. Setting-Newham, east London. Subjects-All children in year 4 of school during the academic year 1992-93. Main outcome measures-Reported bullying and common health symptoms. Results-2962 children (93.1% of those on the school roll) were interviewed (ages 7.6 to 10.0 years). Information about bullying was not recorded for 114 children. 22.4% (95% confidence interval 20.9 to 24.0) of children for whom information was available reported that they had been bullied. There was an association between children reporting being bullied sometimes or more often and reporting not sleeping well (odds ratio 3.6, 2.5 to 5.2), bed wetting (1.7, 1.3 to 2.4), feeling sad (3.6, 1.9 to 6.8), and experiencing more than occasional headaches (2.4, 1.8 to 3.4) and tummy aches (2.4, 1.8 to 3.3). A significant trend for increasing risk of symptoms with increased frequency of bullying was shown for all reported health symptoms (P<0.001). Conclusions-Health professionals seeing primary schoolchildren who present with headaches, tummy ache, feeling sad or very sad, bed wetting, and sleeping difficulties should consider bullying as a possible contributory factor.	INST CHILD HLTH,DEPT EPIDEMIOL,LONDON WC1N 1EH,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND; NEWHAM HLTH CARE,LONDON E15 4EE,ENGLAND	University of London; University College London; University of London; Queen Mary University London			Williams, Katrina/B-6828-2015	Williams, Katrina/0000-0002-1686-4458; Logan, Stuart/0000-0002-9279-261X				AHMAD YS, 1990, NEWSLETTER ASS CHILD, V15, P26; BOULTON MJ, 1992, BRIT J EDUC PSYCHOL, V62, P73, DOI 10.1111/j.2044-8279.1992.tb01000.x; CORNFIELD J, 1956, P 3 BERK S BERK, V4; Dean A.G., 1994, EPI INFO VERSION 6 W; ERLING R, 1994, BULLYING SCH, P21; GARDNER SB, 1991, CIA CONFIDENCE INTER; Olweus D., 1993, AGGRESSIVE BEHAV CUR; OMOORE AM, 1989, IRISH J PSYCHOL, V10, P426, DOI 10.1080/03033910.1989.10557759; SHARP S, 1992, EARLY CHILD DEV CARE, V77, P47; WHITNEY I, 1993, EDUC RES, V35, P3, DOI 10.1080/0013188930350101	10	234	238	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					17	19		10.1136/bmj.313.7048.17	http://dx.doi.org/10.1136/bmj.313.7048.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UW667	8664762	Green Published			2022-12-28	WOS:A1996UW66700024
J	Andrews, MR; Mewes, MO; vanDruten, NJ; Durfee, DS; Kurn, DM; Ketterle, W				Andrews, MR; Mewes, MO; vanDruten, NJ; Durfee, DS; Kurn, DM; Ketterle, W			Direct, nondestructive observation of a bose condensate	SCIENCE			English	Article								The spatial obsewation of a Bose condensate is reported. Dispersive light scattering was used to observe the separation between the condensed and normal components of the Bose gas inside a magnetic trap. This technique is nondestructive, and about a hundred images of the same condensate can be taken. The width of the angular distribution of scattered light increased suddenly at the phase transition.	MIT,ELECTR RES LAB,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	Andrews, MR (corresponding author), MIT,DEPT PHYS,CAMBRIDGE,MA 02139, USA.		Stamper-Kurn, Dan/B-5442-2015	Stamper-Kurn, Dan/0000-0002-4845-5835				ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; ARIMONDO E, 1992, P INT SCH PHYS E FER; Baym G, 1996, PHYS REV LETT, V76, P6, DOI 10.1103/PhysRevLett.76.6; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; BRUNE M, 1990, PHYS REV LETT, V65, P976, DOI 10.1103/PhysRevLett.65.976; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; DAVIS KB, 1995, PHYS REV LETT, V74, P5202, DOI 10.1103/PhysRevLett.74.5202; DEGROOT SR, 1950, PROC R SOC LON SER-A, V203, P266, DOI 10.1098/rspa.1950.0139; Greytak T J, 1995, BOSE EINSTEIN CONDEN, P131; GRIFFIN A, 1995, BOSEEINSTEIN CONDENS; Hecht E., 1989, OPTICS; HUANG K, 1987, STATISTICAL MECHANIC; JAVANAINEN JH, 1994, PHYS REV LETT, V72, P2375, DOI 10.1103/PhysRevLett.72.2375; KETTERLE W, IN PRESS ADV ATOMIC, V37; Lamb WE, 1941, PHYS REV, V59, P677, DOI 10.1103/PhysRev.59.677.2; LIN JL, 1993, PHYS REV LETT, V71, P1222, DOI 10.1103/PhysRevLett.71.1222; MEWES MO, IN PRESS PHYS REV LE; MORICE O, 1995, PHYS REV A, V51, P3896, DOI 10.1103/PhysRevA.51.3896; PETRICH W, 1995, PHYS REV LETT, V74, P3352, DOI 10.1103/PhysRevLett.74.3352; Pritchard D. E., 1989, ATOMIC PHYSICS, p179 ; You L, 1996, PHYS REV A, V53, P329, DOI 10.1103/PhysRevA.53.329; 1996, WORKSH COLL EFF ULTR, P1; [No title captured]	23	320	320	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					84	87		10.1126/science.273.5271.84	http://dx.doi.org/10.1126/science.273.5271.84			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688055	Green Submitted			2022-12-28	WOS:A1996UV47800042
J	Haigh, S				Haigh, S			12 years on: Co-proxamol revisited	LANCET			English	Letter							PROPOXYPHENE HYDROCHLORIDE				Haigh, S (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PHARM,NOTTINGHAM NG7 2UH,ENGLAND.							Beaver W T, 1984, Hum Toxicol, V3 Suppl, p191S; Drug and Therapeutics Bulletin, 1983, DRUG THER B, V21, P17; HOPKINSON JH, 1973, J CLIN PHARMACOL, V13, P251, DOI 10.1002/j.1552-4604.1973.tb00265.x; HOPKINSON JH, 1976, CURR THER RES CLIN E, V19, P622; MILLER RR, 1970, J AMER MED ASSOC, V213, P996, DOI 10.1001/jama.213.6.996	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1840	1841		10.1016/S0140-6736(96)91665-7	http://dx.doi.org/10.1016/S0140-6736(96)91665-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667959				2022-12-28	WOS:A1996UU46900065
J	SantamariaFries, M; Fajardo, LF; Sogin, ML; Olson, PD; Relman, DA				SantamariaFries, M; Fajardo, LF; Sogin, ML; Olson, PD; Relman, DA			Lethal infection by a previously unrecognised metazoan parasite	LANCET			English	Article							AIDS	Background New microbial pathogens or variant clinical manifestations of known organisms may be first found in immunodeficient patients. An HIV-infected man developed a rapidly-enlarging abdominal mass, suggestive of a neoplasm, that subsequently invaded his liver and caused death. Initial studies showed unusual tissue morphology that could not be matched with any known disease process. Methods Tissues obtained from biopsy at laparotomy and necropsy were studied by light microscopy, immunohistochemistry, electron microscopy, and broad-range ribosomal DNA-amplification and sequence analysis. Findings Tissue lesions were characterised by peculiar cytoplasmic sacs containing minute cells with very prominent nucleoli. The pathological process was recognised as a parasitic infection, although its features were different from those of any known eukaryotic pathogen. Phylogenetic analysis of a 357 bp 18S rDNA sequence amplified directly from the involved tissue indicated that the causative agent was previously-uncharacterised cestode. Interpretation Fatal disease produced by this newly recognised cestode may not be limited to immunodeficient hosts. Awareness of this metazoan infection may allow early diagnosis-by morphology and DNA sequence analysis-and perhaps successful treatment of subsequent cases.	STANFORD UNIV,DEPT PATHOL 113,VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA; KAISER PERMANENTE MED CTR,DEPT PATHOL,SANTA CLARA,CA; MARINE BIOL LAB,CTR MOLEC EVOLUT,WOODS HOLE,MA 02543; UNIV CONNECTICUT,DEPT ECOL & EVOLUTIONARY BIOL,STORRS,CT 06269; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Kaiser Permanente; Marine Biological Laboratory - Woods Hole; University of Connecticut; Stanford University; Stanford University			Olson, Peter/D-4643-2009; Sogin, Mitchell/AAE-7186-2019	Olson, Peter/0000-0002-4183-4533; Relman, David A./0000-0001-8331-1354	NIGMS NIH HHS [GM32964] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032964] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO K, 1991, INT J PARASITOL, V21, P891, DOI 10.1016/0020-7519(91)90163-2; BERRADARKHAMI O, 1990, PARASITOL RES, V76, P251, DOI 10.1007/BF00930822; CONNOR DH, 1976, ARCH PATHOL LAB MED, V100, P65; DESOETE G, 1983, PSYCHOMETRIKA, V48, P621, DOI 10.1007/BF02293884; GUTIERREZ Y, 1990, DIAGNOSTIC PATHOLOGY; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Orihel T.C., 1995, PARASITES HUMAN TISS; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; WITTNER M, 1993, INFECT DIS CLIN N AM, V7, P569; ZUMLA A, 1992, PARASITOLOGY, V105, pS93, DOI 10.1017/S0031182000075405	12	17	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1797	1801		10.1016/S0140-6736(96)91618-9	http://dx.doi.org/10.1016/S0140-6736(96)91618-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667924	Green Submitted			2022-12-28	WOS:A1996UU46900011
J	Mueser, TC; Nossal, NG; Hyde, CC				Mueser, TC; Nossal, NG; Hyde, CC			Structure of bacteriophage T4 RNase H, a 5' to 3' RNA-DNA and DNA-DNA exonuclease with sequence similarity to the RAD2 family of eukaryotic proteins	CELL			English	Article							ESCHERICHIA-COLI; REPLICATION; POLYMERASE	Bacteriophage T4 RNase H is a 5' to 3' exonuclease that removes RNA primers from the lagging strand of the DNA replication fork and is a member of the RAD2 family of eukaryotic and prokaryotic replication and repair nucleases. The crystal structure of the full-length native form of T4 RNase H has been solved at 2.06 Angstrom resolution in the presence of Mg2+ but in the absence of nucleic acids. The most conserved residues are clustered together in a large cleft with two Mg2+ in the proposed active site. This structure suggests the way in which the widely separated conserved regions in the larger nucleotide excision repair proteins, such as human XPG, could assemble into a structure like that of the smaller replication nucleases.	NIDDK,NIH,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mueser, TC (corresponding author), NIAMSD,NIH,STRUCT BIOL RES LAB,BETHESDA,MD 20892, USA.							BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; FUREY W, 1995, IN PRESS METH ENZYMO; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGASHI T, 1990, PROCESS PROGRAM INDE; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUBERTS P, 1995, GENE, V164, P133, DOI 10.1016/0378-1119(95)00453-D; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WOODWARD DL, 1996, IN PRESS GENETICS; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	42	161	163	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1101	1112		10.1016/S0092-8674(00)81310-0	http://dx.doi.org/10.1016/S0092-8674(00)81310-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674116	Bronze			2022-12-28	WOS:A1996UV48400016
J	Radford, T				Radford, T			Influence and power of the media	LANCET			English	Editorial Material								People tend to get most of their information beyond work and family horizons from the press, radio, and television. So, do they really believe media stories that suggest, for example, there is no link between HIV and AIDS? This is unlikely, but there is a curious paradox-namely, that at the same time, people to varying degrees are open minded about such stories as unidentified flying objects, astrology, reincarnation, and alien abduction. Yet, people are discerning and seem able to spot the dangerous rubbish, happy to be entertained and unlikely to be misled by the things that will really alter their lives.			Radford, T (corresponding author), THE GUARDIAN,119 FARRINGDON RD,LONDON EC1R 3ER,ENGLAND.							CREUTZFELDTJAKO, 1995, BRIT MED J, V311, P1415; GARROD LP, 1979, BRIT MED J, V1, P1607, DOI 10.1136/bmj.1.6178.1607; Mailer Norman, 1965, PRESIDENTIAL PAPERS	3	19	20	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1533	1535		10.1016/S0140-6736(96)90677-7	http://dx.doi.org/10.1016/S0140-6736(96)90677-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684108				2022-12-28	WOS:A1996UN47300016
J	Kandela, P				Kandela, P			Medical response to operation grapes	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1466	1467		10.1016/S0140-6736(96)91691-8	http://dx.doi.org/10.1016/S0140-6736(96)91691-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676634				2022-12-28	WOS:A1996UM48500018
J	Beebe, RF; Simon, AA; Huber, LF				Beebe, RF; Simon, AA; Huber, LF			Comparison of Galileo probe and Earth-based translation rates of Jupiter's equatorial clouds	SCIENCE			English	Article								The Doppler wind speeds derived from Galileo probe data are comparable with the maximum translation speeds observed in the equatorial zone by Voyager 1 and the Hubble Space Telescope, Slower published values of east-west winds are based on measurements of larger features and should be interpreted as translation rates of large weather systems interacting with the wind. The nature of the hot-spot region that the Galileo probe entered is compatible with a high-speed jet at 6 degrees north, The hot spot is associated with an equatorial weather system that spans 5 degrees of latitude and translates at 103 meters per second.			Beebe, RF (corresponding author), NEW MEXICO STATE UNIV,DEPT ASTRON,DEPT 4500,BOX 30001,LAS CRUCES,NM 88001, USA.		Simon, Amy/C-8020-2012	Simon, Amy/0000-0003-4641-6186				Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; Beebe R. F., 1989, NASA, V494, P245; GIERASCH PJ, 1993, J GEOPHYS RES-PLANET, V98, P5459, DOI 10.1029/92JE01897; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927	7	25	25	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					841	841		10.1126/science.272.5263.841	http://dx.doi.org/10.1126/science.272.5263.841			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662572				2022-12-28	WOS:A1996UK75700046
J	Patten, TE; Xia, JH; Abernathy, T; Matyjaszewski, K				Patten, TE; Xia, JH; Abernathy, T; Matyjaszewski, K			Polymers with very low polydispersities from atom transfer radical polymerization	SCIENCE			English	Article								A radical polymerization process that yields well-defined polymers normally obtained only through anionic polymerizations is reported. Atom transfer radical polymerizations of styrene were conducted with several solubilizing ligands for the copper(l) halides: 4,4'-di-tert-butyl, 4,4'-di-n-heptyl, and 4,4'-di-(5-nonyl)-2,2'-dipyridyl. The resulting polymerizations have all of the characteristics of a living polymerization and displayed linear semilogarithmic kinetic plots, a linear correlation between the number-average molecular weight and the monomer conversion, and low polydispersities (ratio of the weight-average to number-average molecular weights of 1.04 to 1.05). Similar results were obtained for the polymerization of acrylates.	CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213	Carnegie Mellon University			Matyjaszewski, Krzysztof/A-2508-2008	Matyjaszewski, Krzysztof/0000-0003-1960-3402				GAYNOR SG, 1995, MACROMOLECULES, V28, P8051, DOI 10.1021/ma00128a012; GEORGES MK, 1994, MACROMOLECULES, V27, P7228, DOI 10.1021/ma00102a039; GRESZTA D, 1994, MACROMOLECULES, V27, P638, DOI 10.1021/ma00081a002; HADDA TB, 1988, POLYHEDRON, V7, P575; HARWOOD HJ, 1994, POLYM PREPR AM CHEM, V35, P549; KATO M, 1995, MACROMOLECULES, V28, P1721, DOI 10.1021/ma00109a056; LEHN JM, 1993, ANGEW CHEM INT EDIT, V32, P703; MARDARE D, 1994, MACROMOLECULES, V27, P645, DOI 10.1021/ma00081a003; MATYJASZEWSKI K, UNPUB; Rizzardo E., 1987, CHEM AUST, V54, P32; SZWARC M, 1956, NATURE, V178, P1168, DOI 10.1038/1781168a0; SZWARC M, 1956, J AM CHEM SOC, V78, P2657; WANG JS, 1995, MACROMOLECULES, V28, P7901, DOI 10.1021/ma00127a042; WANG JS, 1995, J AM CHEM SOC, V117, P5614, DOI 10.1021/ja00125a035; WAYLAND BB, 1994, J AM CHEM SOC, V116, P7943, DOI 10.1021/ja00096a080; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887	16	857	906	4	208	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					866	868		10.1126/science.272.5263.866	http://dx.doi.org/10.1126/science.272.5263.866			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8662578				2022-12-28	WOS:A1996UK75700057
J	Hakim, RB; Teno, JM; Harrell, FE; Knaus, WA; Wenger, N; Phillips, RS; Layde, P; Califf, R; Connors, AF; Lynn, J				Hakim, RB; Teno, JM; Harrell, FE; Knaus, WA; Wenger, N; Phillips, RS; Layde, P; Califf, R; Connors, AF; Lynn, J			Factors associated with do-not-resuscitate orders: Patients' preferences, prognoses, and physicians' judgments	ANNALS OF INTERNAL MEDICINE			English	Article						resuscitation orders; patient participation; cardiopulmonary resuscitation; physician's role; decision making	INTENSIVE-CARE UNIT; HOSPITAL CARDIOPULMONARY-RESUSCITATION; CRITICALLY ILL PATIENTS; PROBABILITY-MODELS; MORTALITY; DECISIONS; SUPPORT; ADULTS; SYSTEM	Background: Medical treatment decisions should be based on the preferences of in-formed patients or their proxies and on the expected outcomes of treatment. Because seriously ill patients are at risk for cardiac arrest, examination of do-not-resuscitate (DNR) practices affecting them provides useful insights into the associations between various factors and medical decision making. Objective: To examine the association between patients' preferences for resuscitation (along with other patient and physician characteristics) and the frequency and timing of DNR orders. Design: Prospective cohort study. Setting: 5 teaching hospitals. Patients: 6802 seriously ill hospitalized patients enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT) between 1989 and 1994. Measurements: Patients and their surrogates were interviewed about patients' cardiopulmonary resuscitation preferences, medical records were reviewed to determine disease severity, and a multivariable regression model was constructed to predict the time to the first DNR order. Results: The patients' preference for cardiopulmonary resuscitation was the most important predictor of the timing of DNR orders, but only 52% of patients who preferred not to be resuscitated actually had DNR orders written. The probability of surviving for 2 months was the next most important predictor of the timing of DNF( orders. Although DNR orders were not linearly related to the probability of surviving for 2 months, they were written earlier and more frequently for patients with a 50% or lower probability of surviving for 2 months. Orders were written more quickly for patients older than 75 years of age, regardless of prognosis, After adjustment for these and other influential patient characteristics, the use and timing of DNR orders varied significantly among physician specialties and among hospitals. Conclusions: Patients' preferences and short-term prognoses are associated with the timing of DNR orders. However, the substantial variation seen among hospital sites and among physician specialties suggests that there is room for improvement, In this study, DNR orders were written earlier for patients older than 75 years of age, regardless of prognosis. This finding suggests that physicians may be using age in a way that is inconsistent with the reported association between age and survival. The process for making decisions about DNR orders needs to be improved if such orders are to routinely and accurately reflect; patients' preferences and probable outcomes.	GEORGE WASHINGTON UNIV, MED CTR, CTR IMPROVE CARE DYING, WASHINGTON, DC 20037 USA; DUKE UNIV, MED CTR, DURHAM, NC 27706 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MED COLL WISCONSIN, DFCM, MILWAUKEE, WI 53226 USA; MARSHFIELD CLIN FDN MED RES & EDUC, MARSHFIELD, WI USA; METROHLTH MED CTR, CLEVELAND, OH 44109 USA	George Washington University; Duke University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Beth Israel Deaconess Medical Center; Medical College of Wisconsin; Marshfield Clinic; MetroHealth System			Knaus, William/AAX-2138-2020	Connors, Alfred F./0000-0001-7123-3360				BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; Daniels N, 1988, AM I MY PARENTS KEEP; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; EBELL MH, 1991, AM J MED, V91, P255, DOI 10.1016/0002-9343(91)90124-G; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; *IND U PR, 1987, GUID TERM LIF SUST T; JUCHEMS R, 1993, RESUSCITATION, V26, P23, DOI 10.1016/0300-9572(93)90159-N; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LAYDE PM, IN PRESS J CLIN EPID; LEGALL JR, 1995, JAMA-J AM MED ASSOC, V273, P644, DOI 10.1001/jama.273.8.644; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; MAKSOUD A, 1993, ARCH INTERN MED, V153, P1249, DOI 10.1001/archinte.153.10.1249; MILLER DL, 1993, ARCH INTERN MED, V153, P1999, DOI 10.1001/archinte.153.17.1999; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; *NAT CTR STAT COUR, 1991, COORD COUNC LIF SUST; PETERSON MW, 1991, CHEST, V100, P168, DOI 10.1378/chest.100.1.168; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; ROSEWICZ B, 1994, WALL STREET J   1110, pA9; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Sox HC, 1988, MED DECISION MAKING; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TEASDALE G, 1974, LANCET, V2, P81; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; THOMASMA DC, 1989, J AM GERIATR SOC, V37, P169, DOI 10.1111/j.1532-5415.1989.tb05879.x; VEATCH RM, 1988, HASTINGS CENT REP, V18, P34, DOI 10.2307/3563234; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351	40	218	219	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					284	+		10.7326/0003-4819-125-4-199608150-00005	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678391				2022-12-28	WOS:A1996VB68000008
J	Brezina, V; Orekhova, IV; Weiss, KR				Brezina, V; Orekhova, IV; Weiss, KR			Functional uncoupling of linked neurotransmitter effects by combinatorial convergence	SCIENCE			English	Article							CHOLINERGIC MOTOR NEURONS; RADULA CLOSER MUSCLE; PEPTIDE COTRANSMITTERS; APLYSIA-CALIFORNICA; NEUROPEPTIDE COTRANSMITTERS; ARC MUSCLE; K-CURRENT; CONTRACTIONS; MODULATION; NEUROMODULATORS	Physiological signaling pathways both diverge and converge-a single neurotransmitter can have multiple effects acid multiple transmitters can have the same effects-in the same target cell. Divergence couples the effects of a transmitter together in a relatively fixed ratio. Different physiological circumstances may require a different ratio, however, the coupling must be made modifiable. This can be achieved through convergence. If two transmitters couple the effects in different ratios, then combinations of the transmitters can yield all intermediate ratios of the effects, thus functionally uncoupling them. This mechanism is analyzed in a well-understood, simple invertebrate neuromuscular circuit.	MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai	Brezina, V (corresponding author), MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,BOX 1218,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000987, R01MH036730, R37MH036730] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM320099] Funding Source: Medline; NIMH NIH HHS [MH36730, K21 MH00987] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOOM FE, 1988, FASEB J, V2, P32, DOI 10.1096/fasebj.2.1.2891578; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; Brezina V., 1995, Biophysical Journal, V68, pA277; Brezina V., 1993, Society for Neuroscience Abstracts, V19, P1262; BREZINA V, 1995, J NEUROPHYSIOL, V74, P54, DOI 10.1152/jn.1995.74.1.54; BREZINA V, 1994, J NEUROSCI, V14, P4412; BREZINA V, 1994, J NEUROSCI, V14, P4393; BREZINA V, 1995, J NEUROPHYSIOL, V73, P993, DOI 10.1152/jn.1995.73.3.993; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; CHURCH PJ, 1994, J NEUROPHYSIOL, V72, P1794, DOI 10.1152/jn.1994.72.4.1794; COHEN JL, 1978, J NEUROPHYSIOL, V41, P157, DOI 10.1152/jn.1978.41.1.157; CROPPER EC, 1991, PEPTIDES, V12, P683, DOI 10.1016/0196-9781(91)90120-E; CROPPER EC, 1994, J NEUROPHYSIOL, V72, P2181, DOI 10.1152/jn.1994.72.5.2181; CROPPER EC, 1990, BRAIN RES, V522, P176, DOI 10.1016/0006-8993(90)91598-B; CROPPER EC, 1988, P NATL ACAD SCI USA, V85, P6177, DOI 10.1073/pnas.85.16.6177; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P3486, DOI 10.1073/pnas.84.10.3486; CROPPER EC, 1990, P NATL ACAD SCI USA, V87, P933, DOI 10.1073/pnas.87.3.933; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HOOPER SL, 1994, BRAIN RES, V657, P337, DOI 10.1016/0006-8993(94)90988-1; HOOPER SL, 1994, NEUROSCI LETT, V179, P167, DOI 10.1016/0304-3940(94)90960-1; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; KUPFERMANN I, IN PRESS NEURONS NET; LLOYD PE, 1984, P NATL ACAD SCI-BIOL, V81, P2934, DOI 10.1073/pnas.81.9.2934; LLOYD PE, 1986, TRENDS NEUROSCI, V9, P428, DOI 10.1016/0166-2236(86)90138-4; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; SUSSWEIN AJ, 1978, J COMP PHYSIOL, V123, P31, DOI 10.1007/BF00657341; WEISS KR, 1979, J NEUROPHYSIOL, V42, P791, DOI 10.1152/jn.1979.42.3.791; WEISS KR, 1978, J NEUROPHYSIOL, V41, P181, DOI 10.1152/jn.1978.41.1.181; WEISS KR, 1993, J PHYSIOLOGY-PARIS, V87, P141, DOI 10.1016/0928-4257(93)90025-O; WHIM MD, 1989, P NATL ACAD SCI USA, V86, P9034, DOI 10.1073/pnas.86.22.9034; WHIM MD, 1990, J NEUROSCI, V10, P3313; 1992, TRENDS BIOCH SCI, V17	34	70	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					806	810		10.1126/science.273.5276.806	http://dx.doi.org/10.1126/science.273.5276.806			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670423				2022-12-28	WOS:A1996VB42900046
J	Likharev, KK; Korotkov, AN				Likharev, KK; Korotkov, AN			''Single-electron parametron'': Reversible computation in a discrete-state system	SCIENCE			English	Article								The energy dissipation in a proposed digital device in which discrete degrees of freedom are used to represent digital information (a ''single-electron parametron'') was analyzed. If the switching speed is not too high, the device may operate reversibly (adiabatically), and the energy dissipation E per bit may be much less than the thermal energy scale k(B)T (where k(B) is Boltzmann's constant and T is temperature). The energy-time E(tau) is, however, much greater than Planck's constant HBAR, at least in the standard ''orthodox'' model of single-electron tunneling that was used in these calculations.			Likharev, KK (corresponding author), SUNY STONY BROOK, DEPT PHYS, STONY BROOK, NY 11794 USA.							Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; AVERIN DV, 1992, NATO ADV SCI I B-PHY, V294, P311; AVERIN DV, 1990, J LOW TEMP PHYS, V80, P173, DOI 10.1007/BF00683484; BENNETT CH, 1973, IBM J RES DEV, V17, P525, DOI 10.1147/rd.176.0525; CHUANG IL, 1995, SCIENCE, V270, P1633, DOI 10.1126/science.270.5242.1633; KASTNER MA, 1992, REV MOD PHYS, V64, P849, DOI 10.1103/RevModPhys.64.849; KEYES RW, 1970, IBM J RES DEV, V14, P152, DOI 10.1147/rd.142.0152; KOROTKOV AN, 1995, APPL PHYS LETT, V67, P2412, DOI 10.1063/1.114564; KOROTKOV AN, 1996, INT C QUANT DEV CIRC; LANDAUER R, 1961, IBM J RES DEV, V5, P183, DOI 10.1147/rd.53.0183; Likharev KK, 1991, IEEE T APPL SUPERCON, V1, P3, DOI 10.1109/77.80745; LIKHAREV KK, 1977, IEEE T MAGN, V13, P242, DOI 10.1109/TMAG.1977.1059351; LIKHAREV KK, 1982, INT J THEOR PHYS, V21, P311, DOI 10.1007/BF01857733; LIKHAREV KK, 1995, 4 INT WORKSH COMP EL, P5; LOE KF, 1985, IEEE T MAGN, V21, P884, DOI 10.1109/TMAG.1985.1063734	15	40	41	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					763	765		10.1126/science.273.5276.763	http://dx.doi.org/10.1126/science.273.5276.763			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670408	Green Submitted			2022-12-28	WOS:A1996VB42900031
J	Yokoi, M; Kobayashi, K; Manabe, T; Takahashi, T; Sakaguchi, I; Katsuura, G; Shigemoto, R; Ohishi, H; Nomura, S; Nakamura, K; Nakao, K; Katsuki, M; Nakanishi, S				Yokoi, M; Kobayashi, K; Manabe, T; Takahashi, T; Sakaguchi, I; Katsuura, G; Shigemoto, R; Ohishi, H; Nomura, S; Nakamura, K; Nakao, K; Katsuki, M; Nakanishi, S			Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2	SCIENCE			English	Article							LONG-TERM POTENTIATION; METABOTROPIC GLUTAMATE RECEPTORS; GUINEA-PIG; SYNAPTIC TRANSMISSION; TARGETED DISRUPTION; 2 FORMS; RAT; LOCALIZATION; MODULATION; RESPONSES	Subtype 2 of the metabotropic glutamate receptor (mGluR2) is expressed in the presynaptic elements of hippocampal messy fiber-GAS synapses. Knockout mice deficient in mGluR2 showed no histological changes and no alterations in basal synaptic transmission, paired-pulse facilitation, or tetanus-induced long-term potentiation (LTP) al the messy fiber-CA3 synapses. Long-term depression (LTD) induced by low-frequency stimulation, however, was almost fully abolished. The mutant mice performed normally in water maze learning tasks. Thus, the presynaptic mGluR2 is essential for inducing LTD at the mossy fiber-CA3 synapses, but this hippocampal LTD does not seem to be required for spatial learning.	KYOTO UNIV, FAC MED, DEPT BIOL SCI, KYOTO 606, JAPAN; UNIV TOKYO, FAC MED, BRAIN RES INST, DEPT NEUROPHYSIOL, TOKYO 113, JAPAN; SHIONOGI & CO LTD, ABURAHI LABS, SHIGA 52034, JAPAN; KYOTO UNIV, FAC MED, DEPT MORPHOL BRAIN SCI, KYOTO 606, JAPAN; KYOTO UNIV, COLL MED TECHNOL, KYOTO 606, JAPAN; KYUSHU UNIV, MED INST BIOREGULAT, FUKUOKA 812, JAPAN	Kyoto University; University of Tokyo; Shionogi & Company Limited; Kyoto University; Kyoto University; Kyushu University			Kobayashi, Katsunori/V-5326-2018; Takahashi, Tomoyuki/G-5951-2015; Shigemoto, Ryuichi/E-3628-2013	Kobayashi, Katsunori/0000-0001-8537-8448; Takahashi, Tomoyuki/0000-0002-8771-7666; Shigemoto, Ryuichi/0000-0001-8761-9444				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kobayashi K, 1996, SCIENCE, V273, P648, DOI 10.1126/science.273.5275.648; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; SHIGEMOTO R, 1995, INT BRAIN RES ORG AB, V4; SHIGEMOTO R, 1995, SOC NEUR ABSTR, V21, P33820; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	24	291	313	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1996	273	5275					645	647		10.1126/science.273.5275.645	http://dx.doi.org/10.1126/science.273.5275.645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662555				2022-12-28	WOS:A1996VA24900047
J	Welch, HG; Wennberg, DE; Welch, WP				Welch, HG; Wennberg, DE; Welch, WP			The use of Medicare home health care services	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Medicare's home health care program, consisting primarily of home visits by nurses and health aides, was conceived as a means to facilitate hospital discharge. Because home health care is now one of the fastest-growing categories of Medicare expenditures, we analyzed Medicare claims data to determine current patterns of use. Methods We used 1993 data from Medicare's National Claims History File to examine the temporal relation between home visits and hospital discharge, as well as the number of months Medicare enrollees received home health care. To determine whether home visits replaced hospital services, we calculated population-based utilization rates, adjusted for age and sex, for enrollees living in the 310 U.S. metropolitan statistical areas and determined whether the areas with higher rates of home health care also had lower admission rates or shorter lengths of stay. Finally, we compared the geographic variation in use of home health care with that of other Medicare services. Results Roughly 3 million Medicare enrollees received over 160 million home health care visits in 1993. Seventy-eight percent of the visits either occurred more than a month after hospital discharge (35 percent) or were not associated with any inpatient care during the previous six months (43 percent), Home health care often represented a long term intervention: 61 percent of the visits were to enrollees who received home health care for six months or more. We could find no evidence that home health care was substituted for hospital care; the metropolitan statistical areas with higher rates of home health care did not have fewer hospital admissions or shorter lengths of stay. There was more geographic variation in the use of home health care than in the use of other major categories of Medicare services (e.g., hospital admissions and physicians' services), Five states (all in the South) had more than 9000 visits per 1000 enrollees, and 14 states had fewer than 3000 visits per 1000 enrollees. Conclusions Home health care visits are used primarily to provide long-term care. There is no evidence that services provided at home replace hospital services, and the dramatic geographic variation in home visits suggests a lack of consensus about their appropriate use. (C) 1996, Massachusetts Medical Society.	DARTMOUTH COLL SCH MED,CTR EVALUAT CLIN SCI,HANOVER,NH; MAINE MED ASSESSMENT FDN,AUGUSTA,ME; MAINE MED CTR,PORTLAND,ME 04102; URBAN INST,WASHINGTON,DC 20037	Dartmouth College; Maine Medical Center; Urban Institute	Welch, HG (corresponding author), VET AFFAIRS MED CTR,VET AFFAIRS OUTCOMES GRP 111B,WHITE RIVER JCT,VT 05009, USA.							BISHOP C, 1993, HEALTH AFFAIR, V12, P95, DOI 10.1377/hlthaff.12.3.95; *BUR NAT AFF, 1995, 6 BUR NAT AFF, P959; *BUR NAT AFF, 1996, 7 BUR NAT AFF, P158; CAMPION EW, 1995, NEW ENGL J MED, V333, P1213, DOI 10.1056/NEJM199511023331810; DELFOSSE R, 1991, VITAL HLTH STAT, V13; GAUMER GL, 1986, MED CARE, V24, P641, DOI 10.1097/00005650-198607000-00007; *GEN ACC OFF, 1996, PUBL; GOLDBERG HB, 1994, HEALTH CARE FINANC R, V16, P109; HALAMANDARIS V, 1995, BASIC STAT HOME CARE; Helbing C, 1992, Health Care Financ Rev Annu Suppl, P125; *HOUS COMM WAYS ME, 1994, PUBL HOUS COMM WAYS; HUGHES SL, 1990, MED CARE, V28, P135, DOI 10.1097/00005650-199002000-00004; KEMPER P, 1988, HEALTH SERV RES, V23, P161; KENNEY GM, 1991, INQUIRY-J HEALTH CAR, V28, P129; KENNEY GM, 1992, MED CARE, V30, P43, DOI 10.1097/00005650-199201000-00004; LADD RC, 1995, STATE LONG TERM CARE; MAUSER E, 1994, HEALTH CARE FINANC R, V16, P17; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; SHAUGHNESSY PW, 1990, NEW ENGL J MED, V322, P21, DOI 10.1056/NEJM199001043220105; SOULE DN, 1993, HLTH MAINES HOSP PAT, P16; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Swan J H, 1990, Health Serv Res, V25, P479; WEISSERT WG, 1994, J AM GERIATR SOC, V42, P348, DOI 10.1111/j.1532-5415.1994.tb01763.x; WELCH WP, 1995, 643300402 URB I; WENNBERG JE, 1984, NEW ENGL J MED, V311, P295, DOI 10.1056/NEJM198408023110505; 1991, JAMA-J AM MED ASSOC, V265, P769; 1991, JAMA-J AM MED ASSOC, V265, P2340; 1995, FED REGISTER, V60, P8389	28	124	124	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					324	329		10.1056/NEJM199608013350506	http://dx.doi.org/10.1056/NEJM199608013350506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UY982	8663855	Bronze			2022-12-28	WOS:A1996UY98200006
J	Bergan, JJ				Bergan, JJ			New technology and recurrent varicose veins	LANCET			English	Editorial Material											Bergan, JJ (corresponding author), SCRIPPS CLIN & HOSP,LA JOLLA,CA 92037, USA.							BRADBURY AW, 1994, BRIT J SURG, V81, P373, DOI 10.1002/bjs.1800810316; BRADBURY AW, 1993, BRIT J SURG, V80, P373; DARKE SG, 1992, EUR J VASCULAR SURG, V6, P512, DOI 10.1016/S0950-821X(05)80626-7; JAKOBSEN BH, 1979, BRIT J SURG, V66, P182, DOI 10.1002/bjs.1800660313; Khaira HS, 1996, ANN ROY COLL SURG, V78, P139; Labropoulos N, 1996, SURGERY, V119, P406, DOI 10.1016/S0039-6060(96)80140-1; MUNN SR, 1981, BRIT J SURG, V68, P426, DOI 10.1002/bjs.1800680621; ODONNELL TF, 1977, ARCH SURG-CHICAGO, V112, P31; PHILLIPS GWL, 1995, CLIN RADIOL, V50, P20, DOI 10.1016/S0009-9260(05)82960-5; Sales CM, 1996, ANN VASC SURG, V10, P186, DOI 10.1007/BF02000764; Walsh J C, 1994, Ann Vasc Surg, V8, P566, DOI 10.1007/BF02017413	11	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					210	211		10.1016/S0140-6736(05)65541-9	http://dx.doi.org/10.1016/S0140-6736(05)65541-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684195				2022-12-28	WOS:A1996UZ28600005
J	Evans, I				Evans, I			What do you do, Partner?	LANCET			English	Editorial Material																			0	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					211	212		10.1016/S0140-6736(05)65542-0	http://dx.doi.org/10.1016/S0140-6736(05)65542-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684196				2022-12-28	WOS:A1996UZ28600006
J	Bray, GA				Bray, GA			Leptin and leptinomania	LANCET			English	Editorial Material											Bray, GA (corresponding author), LOUISIANA STATE UNIV,PENNINGTON BIOMED RES CTR,BATON ROUGE,LA 70808, USA.							Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAZUZAKI H, 1995, DIABETES, V44, P855; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; SCHWARTZ MW, 1996, NATURE MED, V2, P587; Shimizu H, 1993, Obes Res, V1, P377; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TARTAGLIA LA, 1995, CELL, V83, P1; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	12	42	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					140	141		10.1016/S0140-6736(05)66103-X	http://dx.doi.org/10.1016/S0140-6736(05)66103-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684147				2022-12-28	WOS:A1996UX78900002
J	Kujala, UM; Sarna, S; Kaprio, J; Koskenvuo, M				Kujala, UM; Sarna, S; Kaprio, J; Koskenvuo, M			Hospital care in later life among former world-class Finnish athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; EXPECTANCY; MORTALITY; LONGEVITY; HEALTH	Objective.-To investigate the use of hospital care from all causes among former top-level athletes from different vigorous sports to determine whether health benefits or adverse effects have the greater influence. Design.-National, population-based cohort study with a 21-year follow-up. Setting.-Finland. Subjects.-A total of 2049 male athletes who had represented Finland during 1920 to 1965, and 1403 male controls classified healthy at 20 years of age. Main Outcome Measure.-In-hospital care from all causes was extracted from the national hospital discharge registry for the period 1970 through 1990 expressed as hospital days per person-yeats of exposure, Results.-Compared with controls, the rate ratios (RRs) for all-cause hospital days per person-years of exposure were lower in athletes from endurance sports (RR, 0.71; 95% confidence interval [CI], 0.70-0.73), mixed sports (including endurance and weight training) (RR, 0.86; 95% CI, 0.85-0.87), and power sports(RR, 0.95; 95% CI, 0.94-0.96) (P<.001 for all comparisons) after adjustment for age and occupational group. The lower RR among athletes from endurance sports and other sports involving aerobic activity was largely explained by lower rates of hospital care for heart disease, respiratory disease, and neoplasms, but not for musculoskeletal disorders, Conclusions.-Former elite athletes, particularly those in aerobic sports, use less hospital care. Other beneficial health habits are known to be associated with a physically active lifestyle.	UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20500 TURKU,FINLAND	University of Helsinki; University of Turku	Kujala, UM (corresponding author), UNIV HELSINKI,INST BIOMED,UNIT SPORTS & EXERCISE MED,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,FIN-00250 HELSINKI,FINLAND.		Kaprio, Jaakko/A-1820-2008; Kujala, Urho/AAP-2547-2020	Kaprio, Jaakko/0000-0002-3716-2455; Kujala, Urho/0000-0002-9262-1992; Sarna, Seppo/0000-0003-3458-1627				ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; Astrand P.O., 1986, TXB WORK PHYSL PHYSL; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; *FINLAND CENTR STA, 1972, ALPH LIST OCC CLASS; FOGELHOLM M, 1994, MED SCI SPORT EXER, V26, P224, DOI 10.1249/00005768-199402000-00013; GORNICK M, 1993, HLTH AFF, V12, P999; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Howard D.R., 1992, J SPORT MANAGE, V6, DOI [10.1123/jsm.6.3.191, DOI 10.1123/JSM.6.3.191]; KAPRIO J, 1988, J CLIN EPIDEMIOL, V41, P139, DOI 10.1016/0895-4356(88)90088-1; KARVONEN MJ, 1974, MED SCI SPORT EXER, V6, P49; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KOSKENVUO M, 1979, SOC SCI MED-MED SOC, V13, P691, DOI 10.1016/0271-7123(79)90114-7; KUJALA UM, 1995, ARTHRITIS RHEUM, V38, P539, DOI 10.1002/art.1780380413; KUJALA UM, 1994, BRIT MED J, V308, P231, DOI 10.1136/bmj.308.6923.231; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SARNA S, 1994, SPORTS MED, V17, P149, DOI 10.2165/00007256-199417030-00001; SARNA S, 1993, MED SCI SPORT EXER, V25, P237; SCHNOHR P, 1971, LANCET, V2, P1364; *WHO, 1977, WHO ICD9; *WHO, 1969, WHO ICD8; YAMAJI K, 1977, Journal of Human Ergology, V6, P15; 1990, EGRET STAT SOFTWARE	28	58	58	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					216	220		10.1001/jama.276.3.216	http://dx.doi.org/10.1001/jama.276.3.216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667566				2022-12-28	WOS:A1996UW46900033
J	McLellan, MF; Jones, AH				McLellan, MF; Jones, AH			Why literature and medicine?	LANCET			English	Article									UNIV TEXAS, MED BRANCH, INST MED HUMANITIES, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	McLellan, MF (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, GALVESTON, TX 77555 USA.			McLellan, Faith/0000-0003-0744-1450				Aristotle, 1958, POETRY STYLE; BANKS JT, 1987, LIT MED CLAIM DISCIP, P17; BURRELL D, 1977, FDN ETHICS ITS RELAT, V2, P111; CHARON R, 1986, LIT MED, V5, P58; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; CHARON R, 1989, SOUNDINGS, V72, P137; CHARON R, 1994, FERMENT US BIOETHICS, P260; Churchill L, 1979, Soundings, V62, P24; COLES R, 1979, NEW ENGL J MED, V301, P444, DOI 10.1056/NEJM197908233010831; Daniel S L, 1986, Theor Med, V7, P195, DOI 10.1007/BF00489230; Frank AW., 2013, WOUNDED STORYTELLER; Gorelick K., 1989, J POETRY THERAPY, V3, P5; Hawkins Anne Hunsaker, 1999, RECONSTRUCTING ILLNE; Hillman J., 1983, HEALING FICTION; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; HUNTER KM, 1986, CONNECTICUT SCHOLAR, V8, P27; JONES AH, 1994, LIT MED, V13, P190; Jones AH, 1996, J MED PHILOS, V21, P267; JONES AH, 1990, ST COMPAR L, V22, P11; JONES AH, 1986, CONNECTICUT SCHOLAR, V8, P38; JONES AH, 1983, LIT MED, V2, P1; JONES AH, 1995, MED HUM REV, V9, P9; Jones Anne Hudson, 1987, LIT MED CLAIM DISCIP, P29; KOCH K, 1977, I NEVER TOLD ANYBODY; Leedy J.J., 1969, POETRY THERAPY; LERNER A, 1981, HDB INNOVATIVE PSYCH; MCLELLAN F, 1994, MED HUMANITIES REV, V8, P9; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Moore AR, 1978, MISSING MED TEXT HUM; Pellegrino E. D., 1982, LIT MED, V1, P19; PESCHEL ER, 1980, MED LIT; PROGOFF I, 1975, JUNG WORKSHOP; RABUZZI KA, 1982, LIT MED, V1, P1; SHAFER A, 1994, LIT MED, V13, P124; SMITHERS DW, 1989, THIS IDLE TRADE DOCT; Trautmann J., 1982, LIT MED, V1, P1, DOI [10.1353/lm.2011.0206, DOI 10.1353/LM.2011.0206]; TRAUTMANN J, 1978, ROLE HUMANITIES MED, P36; Trautmann J., 1981, HEALING ARTS DIALOGU	38	50	54	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					109	111		10.1016/S0140-6736(96)03521-0	http://dx.doi.org/10.1016/S0140-6736(96)03521-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676678				2022-12-28	WOS:A1996UW67300016
J	Dresser, R				Dresser, R			Mentally disabled research subjects - The enduring policy issues	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSENT; DEMENTIA	Mentally disabled adults often serve as subjects in research on mental illness, developmental disabilities, dementia, and other conditions associated with mental impairment. Since US regulatory policy fails to resolve many ethical issues presented by such research, investigators and institutional review boards must determine the appropriate standards and procedures for studies involving adults with mental disabilities. Procedures for capacity assessment and information disclosure should enhance the autonomy of capable subjects and accurately identify subjects incapable of independent choice. Research teams should inform proxy decision makers of their ethical responsibilities. Decisionally incapable adults objecting to research involvement should rarely be included in studies. Researchers, institutional review boards, advocacy groups, and federal officials should collaborate to improve evaluation of risks and potential benefits to decisionally incapable subjects. These groups should also seek consensus on appropriate risk limits in studies presenting no prospect of direct benefit to decisionally incapable subjects; Finally, subject populations should be represented in research planning and review activities.	CASE WESTERN RESERVE UNIV, SCH MED, CTR BIOMED ETH, CLEVELAND, OH 44106 USA	Case Western Reserve University	Dresser, R (corresponding author), CASE WESTERN RESERVE UNIV, SCH LAW, 11075 EAST BLVD, CLEVELAND, OH 44106 USA.							ADDINGTON D, 1995, CAN J PSYCHIAT, V40, P171, DOI 10.1177/070674379504000403; *ADV COMM HUM RAD, 1995, FIN REP, P705; ANNAS GJ, 1986, NEW ENGL J MED, V315, P1157, DOI 10.1056/NEJM198610303151809; Appelbaum Paul S, 1996, IRB, V18, P1, DOI 10.2307/3563910; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; APPELBAUM PS, 1995, LAW HUMAN BEHAV, V19, P105, DOI 10.1007/BF01499321; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P50; Caplan Arthur L, 1994, J Calif Alliance Ment Ill, V5, P36; CAPRON AM, 1986, BIOLAW; COOKDEEGAN RM, 1992, NEW ENGL J MED, V327, P61; COTRELL V, 1993, GERONTOLOGIST, V33, P205, DOI 10.1093/geront/33.2.205; DERENZO E, 1994, CAMB Q HEALTHC ETHIC, V3, P539, DOI 10.1017/S0963180100005429; DERENZO EG, 1994, IRB REV HUM SUBJECT, V16, P11; DeRenzo Evan Gaines, 1994, IRB, V16, P7, DOI 10.2307/3563879; ERIKSON J, 1995, SCIENCE, V269, P1508, DOI 10.1126/science.7667631; FLETCHER JC, 1987, PSYCHOPHARMACOL BULL, V23, P382; FREEDMAN B, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562813; GOSTIN LO, 1995, JAMA-J AM MED ASSOC, V274, P844; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P127, DOI 10.1007/BF01499322; hhs, 1979, BELM REP ETH PRINC G; HIGH DM, 1994, ALZ DIS ASSOC DIS, V8, P66, DOI 10.1097/00002093-199400000-00008; Jonas H., 1970, EXPT HUMAN SUBJECTS, P1; Katz Jay, 1993, St Louis Univ Law J, V38, P7; KEYSERLINGK EW, 1995, PERSPECT BIOL MED, V38, P319; KOPELMAN LM, 1995, ENCY BIOETHICS, P2291; LEVINE C, 1995, ENCY BIOETHICS, P2296; LEVINE RJ, 1995, JAMA-J AM MED ASSOC, V273, P1300, DOI 10.1001/jama.273.16.1300; Levine RJ, 1986, ETHICS REGULATION CL, V2nd; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; MELNICK VL, 1984, J AM GERIATR SOC, V32, P531, DOI 10.1111/j.1532-5415.1984.tb02240.x; *NAT COMM PROT HUM, 1978, REP REC RES INV THOS; Nelson HL NJ, 1995, PATIENT FAMILY ETHIC; *OFF PROT RES RISK, 1994, EV HUM SUBJ PROT SCH; Sachs G A, 1990, Law Med Health Care, V18, P234; SACHS GA, 1994, CLIN RES, V42, P403; SACHS GA, 1994, ALZ DIS ASSOC DIS, V8, P19, DOI 10.1097/00002093-199400000-00003; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; 1995, FED REG         1003, V60, P52063; 1991, FED REG         0618, V56, P28012	42	88	89	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					67	72		10.1001/jama.276.1.67	http://dx.doi.org/10.1001/jama.276.1.67			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU439	8667543				2022-12-28	WOS:A1996UU43900031
J	Arroyo, AG; Yang, JT; Rayburn, H; Hynes, RO				Arroyo, AG; Yang, JT; Rayburn, H; Hynes, RO			Differential requirements for alpha 4 integrins during fetal and adult hematopoiesis	CELL			English	Article							MARROW STROMAL CELLS; BONE-MARROW; B-CELL; PROGENITOR CELLS; MOUSE THYMUS; VLA-4; MICE; FIBRONECTIN; ADHESION; BINDING	Mice chimeric for the expression of alpha 4 integrins were used to dissect the roles of these receptors in development and traffic of lymphoid and myeloid cells. During fetal life, T cell development is alpha 4 independent, but after birth further production of T cells becomes alpha 4 dependent. Precursors for both T and B cells require alpha 4 integrins for normal development within the bone marrow. In contrast, monocytes and natural killer cells can develop normally without alpha 4 integrins. Thus, there are lymphocyte-specific, developmentally regulated requirements for alpha 4 integrins in hematopoiesis in the bone marrow. We also show that alpha 4 integrins are essential for T cell homing to Peyer's patches, but not to other secondary lymphoid organs, including spleen, lymph nodes, and intestinal epithelium.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Arroyo, AG (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Arroyo, Alicia G./L-2796-2014; Arroyo, Alicia G/M-2507-2018	Arroyo, Alicia G./0000-0002-1536-3846; Arroyo, Alicia G/0000-0002-1536-3846	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTEVOGT P, 1995, J EXP MED, V182, P345, DOI 10.1084/jem.182.2.345; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; GEORGE EL, 1994, METHOD ENZYMOL, V245, P386; GISLER RH, 1987, J IMMUNOL, V138, P2427; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HAMANN A, 1994, J IMMUNOL, V152, P3282; HARDIN JA, 1995, CELL IMMUNOL, V161, P50, DOI 10.1006/cimm.1995.1008; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JARVIS LJ, 1995, J IMMUNOL, V155, P2359; JOTEREAU F, 1987, J IMMUNOL, V138, P1026; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KERST JM, 1993, BLOOD, V81, P344; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; LEE MG, 1994, J IMMUNOL, V152, P5653; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; Merville P, 1996, J EXP MED, V183, P227, DOI 10.1084/jem.183.1.227; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; RUIZ P, 1995, EUR J IMMUNOL, V25, P2034, DOI 10.1002/eji.1830250735; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SALOMON DR, 1994, J EXP MED, V179, P1573, DOI 10.1084/jem.179.5.1573; SANCHEZMADRID F, 1992, SEMIN CELL BIOL, V8, P1735; SAWADA M, 1992, J IMMUNOL, V149, P3517; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCOLLAY R, 1986, IMMUNOL REV, V91, P129, DOI 10.1111/j.1600-065X.1986.tb01487.x; SHEPPARD AM, 1994, CELL ADHES COMMUN, V2, P27, DOI 10.3109/15419069409014200; SIMMONS PJ, 1992, BLOOD, V80, P388; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRASSER A, 1989, J EXP MED, V170, P1973, DOI 10.1084/jem.170.6.1973; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TELXIDO J, 1992, J CLIN INVEST, V90, P358; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UTSUMI K, 1991, P NATL ACAD SCI USA, V88, P5685, DOI 10.1073/pnas.88.13.5685; VELS DJ, 1993, CELL, V75, P229; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YANG JT, 1995, DEVELOPMENT, V121, P549; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	65	278	287	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					997	1008		10.1016/S0092-8674(00)81301-X	http://dx.doi.org/10.1016/S0092-8674(00)81301-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674127	Bronze, Green Submitted			2022-12-28	WOS:A1996UV48400007
J	Darby, SC; Ewart, DW; Giangrande, PLF; Spooner, RJD; Rizza, CR				Darby, SC; Ewart, DW; Giangrande, PLF; Spooner, RJD; Rizza, CR			Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THROMBOCYTOPENIC PURPURA; HEMOPHILIACS	Background Greater age at infection with HIV-1 is known to be associated with shorter time to development of AIDS, but the size of the differences between people infected in infancy and those infected in old age has not been examined in a single large population of patients with death as an endpoint. We, therefore, investigated the role of age at seroconversion in the entire UK population of haemophiliacs. Methods We studied 1216 HIV-1-infected haemophilia patients in the UK who were registered with the National Haemophilia Register and were alive on Jan 1, 1985. Their estimated ages at HIV-1 seroconversion ranged from 8 months to 79 years. Findings 10 years after seroconversion 67% (95% CI 64-69) of the population were still alive. Survival was strongly related to age at seroconversion (86% [82-90], 72% [68-76], 45% [39-51], and 12% [5-21] at 10 years among those patients who seroconverted at ages <15, 15-34, 35-54, and greater than or equal to 55). This steep age-gradient in survival was not explained by deaths expected in the absence of HIV infection or by confounding with other factors such as haemophilia type or severity. The age-gradient was steeper for survival tie, time from HIV-1 infection to death) than for time to diagnosis of AIDS, partly because survival after an AIDS diagnosis was poorer in older patients, and there was also a substantial increase in mortality among HIV-infected patients who did not satisfy the formal AIDS definition and this increase was greater in older patients. Interpretation Age at infection with HIV-1 is a more important determinant of survival than has previously been appreciated. Age should, therefore, be considered in future studies of disease progression, and studies that compare people infected at different ages should provide insight into the biology of the immune response to HIV-1.	CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	University of Oxford	Darby, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.							BALTIMORE D, 1995, NEW ENGL J MED, V332, P259, DOI 10.1056/NEJM199501263320410; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DIAMONDSTONE LS, 1995, AM J EPIDEMIOL, V142, P304, DOI 10.1093/oxfordjournals.aje.a117636; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; FLETCHER MA, 1992, BLOOD, V80, P831; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MOULIGNIER A, 1995, AM J MED, V99, P64, DOI 10.1016/S0002-9343(99)80106-5; PARK RAA, 1992, LANCET, V339, P671, DOI 10.1016/0140-6736(92)90815-K; POWERS DC, 1993, J AM GERIATR SOC, V41, P1; RAGNI MV, 1990, BLOOD, V75, P1267; RATNER L, 1989, AM J MED, V86, P194, DOI 10.1016/0002-9343(89)90268-4; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; SCHINAIA N, 1994, THROMB HAEMOSTASIS, V72, P33; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; *WHO, 1988, MAN INT STAT CLASS D; 1982, MMWR-MORBID MORTAL W, V31, P507; 1985, MMWR-MORBID MORTAL W, V34, P373; 1989, PHILOS T R SOC LON B, V325, P179; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1991, LANCET, V337, P253	25	165	171	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1573	1579						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667864				2022-12-28	WOS:A1996UP66100007
J	Altman, LK				Altman, LK			The ingelfinger rule, embargoes, and journal peer review .2.	LANCET			English	Editorial Material								Peer review is one of the main reasons put forward in support of the Ingelfinger rule. As the second of the two-part article The Ingelfinger rule, embargoes, and journal peer review shows, however, the economic interests in controlling information may be equally important. Not least is the rule's contribution to journal profits by raising circulation and advertising revenues. An additional effect has been to frighten authors into silence, sometimes delaying the release of important findings that bear on the public health. Moreover, the resulting poor cooperation between researchers and journalists risks unintentional errors in reporting. Unless there is evidence that the rule improves and assures the quality of what journals publish, the 27-year-old Ingelfinger rule should be dropped.			Altman, LK (corresponding author), NEW YORK TIMES CO,229 W 23RD ST,NEW YORK,NY 10024, USA.							ALTMAN LK, 1996, NY TIMES        0213; ALTMAN LK, 1988, NY TIMES        0128; BARTRIP P, 1992, MED J MED KNOWLEDGE; BEAN WB, 1961, WO APHORISMS HIS BED; BISHOP JE, 1981, NASW NEWSLETTER  JUN; BLOOM M, 1979, NASW NEWSLETTER 1110; BROOK R, 1993, DOING MORE GOOD HARM; COOK HJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P147; FLETCHER RH, 1992, J INTERN MED, V232, P215, DOI 10.1111/j.1365-2796.1992.tb00575.x; GORNER P, 1988, CHICAGO TRIBUNE 0202; GRANT RH, 1971, FED PROC, V30, P816; GRANT RH, 1971, FDN P, V30, P825; HOLDEN C, 1988, SCIENCE, V239, P862, DOI 10.1126/science.3340865; HORTON R, 1995, LANCET, V346, P1610, DOI 10.1016/S0140-6736(95)91935-X; INGELFINGER FJ, 1968, LANCET, V2, P766; INGELFINGER FJ, 1969, NEW ENGL J MED, V281, P526, DOI 10.1056/NEJM196909042811005; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1608, DOI 10.1056/NEJM199406023302211; KASSIRER JP, 1991, NEW ENGL J MED, V325, P58, DOI 10.1056/NEJM199107043250111; KNOLL E, 1992, MED J MED KNOWLEDGE; KURTZ H, 1991, WASHINGTON POST 0616; MADDOX J, 1995, NATURE, V378, P521, DOI 10.1038/378521a0; *NIH, 1996, 8 ANN M NAT COOP VAC; PALCA J, 1991, SCIENCE, V251, P374, DOI 10.1126/science.1989071; PICKERING GW, 1956, BRIT MED J, V2, P113, DOI 10.1136/bmj.2.4985.113; REINHARDT UE, 1988, NY TIMES        0210; Relman A S, 1979, Trans Assoc Am Physicians, V92, P40; RELMAN AS, 1988, NEW ENGL J MED, V318, P1125, DOI 10.1056/NEJM198804283181709; RELMAN AS, 1980, NEW ENGL J MED, V303, P277, DOI 10.1056/NEJM198007313030509; RELMAN AS, 1979, NASW NEWSLETTER  NOV, P9; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P2543, DOI 10.1001/jama.261.17.2543; ROSENBERG S, 1995, MED MEDIA CHANGING R, P16; ROUSH W, 1995, SCIENCE, V269, P627, DOI 10.1126/science.7624787; SCHEINBERG IH, 1988, NY TIMES        0210; SMITH R, 1994, BRIT MED J, V309, P143, DOI 10.1136/bmj.309.6948.143; SPENCER ER, 1981, SOC PHYSICIANS ACCOU; SUNSHINE JH, 1992, NEW ENGL J MED, V326, P957; THOMPSON L, 1988, WASHINGTON POST 1019; 1982, NASW NEWSLETTER  APR, P56; 1986, YANKEE           FEB, P84; 1996, LANCET, V347, P592; 1986, YANKEE           FEB, P132	41	39	40	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1459	1463		10.1016/S0140-6736(96)91689-X	http://dx.doi.org/10.1016/S0140-6736(96)91689-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676632				2022-12-28	WOS:A1996UM48500016
J	Trau, M; Saville, DA; Aksay, IA				Trau, M; Saville, DA; Aksay, IA			Field-induced layering of colloidal crystals	SCIENCE			English	Article							CRYSTALLIZATION; SPHERES; GROWTH	An electrohydrodynamic methodology has been developed that makes possible the precise assembly of two- and three-dimensional colloidal crystals on electrode surfaces. Electrophoretically deposited colloidal particles were observed to move toward one another over very large distances (greater than five particle diameters) to form two-dimensional colloidal crystals for both micrometer- and nanometer-size particles, This coalescence of particles with the same charge is opposite to what is expected from electrostatic considerations and appears to result from electrohydrodynamic fluid flow arising from an ionic current flowing through the solution. The ability to modulate this ''lateral attraction'' between particles, by adjusting field strength or frequency, facilitates the reversible formation of two-dimensional fluid and crystalline colloidal states on the electrode surface. Further manipulation allows controlled structures to be assembled.	PRINCETON UNIV, DEPT CHEM ENGN, PRINCETON, NJ 08544 USA; PRINCETON UNIV, PRINCETON MAT INST, PRINCETON, NJ 08544 USA	Princeton University; Princeton University			Trau, Matt/E-3944-2015; Aksay, Ilhan A/B-9281-2008	Trau, Matt/0000-0001-5516-1280; 				AASTUEN DJW, 1986, PHYS REV LETT, V57, P1733, DOI 10.1103/PhysRevLett.57.1733; Bockris J.O., 1993, SURFACE ELECTROCHEMI, DOI [10.1007/978-1-4615-3040-4, DOI 10.1007/978-1-4615-3040-4]; FLEURY V, 1994, NATURE, V367, P435, DOI 10.1038/367435a0; FREEMAN RG, 1995, SCIENCE, V267, P1629, DOI 10.1126/science.267.5204.1629; GELL M, 1994, JOM-J MIN MET MAT S, V46, P30, DOI 10.1007/BF03222605; GIERSIG M, 1993, LANGMUIR, V9, P3408, DOI 10.1021/la00036a014; GIERSIG M, 1993, J PHYS CHEM-US, V97, P6334, DOI 10.1021/j100126a003; HEALY TW, 1994, ADV CHEM SER, V234, P146; Jankowski AF, 1995, NANOSTRUCT MATER, V6, P179, DOI 10.1016/0965-9773(95)00041-0; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; KOLATA G, 1985, SCIENCE, V229, P370, DOI 10.1126/science.229.4711.370; Levich V.G., 1962, PHYSICOCHEMICAL HYDR; LIU J, 1990, PHYS REV A, V41, P3206, DOI 10.1103/PhysRevA.41.3206; LIVERMORE C, 1994, PHYS REV LETT, V72, P3847, DOI 10.1103/PhysRevLett.72.3847; MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466; McPherson A, 1982, PREPARATION ANAL PRO; OKUBO T, 1994, LANGMUIR, V10, P1695, DOI 10.1021/la00018a016; ONODA GY, 1985, PHYS REV LETT, V55, P226, DOI 10.1103/PhysRevLett.55.226; PIERANSKI P, 1983, CONTEMP PHYS, V24, P25, DOI 10.1080/00107518308227471; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; RICHETTI F, 1987, PHYSICS COMPLEX SUPE, P387; RICHETTI P, 1984, J PHYS LETT-PARIS, V45, P1137, DOI 10.1051/jphyslet:0198400450230113700; ROSENBERGER F, 1986, J CRYST GROWTH, V76, P618, DOI 10.1016/0022-0248(86)90179-X; SCHATZEL K, 1992, PHYS REV LETT, V68, P337, DOI 10.1103/PhysRevLett.68.337; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; SIEGEL RW, 1993, PHYS TODAY, V46, P64, DOI 10.1063/1.881365; TRAU M, UNPUB; TSAKALAKOS T, 1983, J APPL PHYS, V54, P734, DOI 10.1063/1.332083; TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055; VANMEGEN W, 1993, NATURE, V362, P616, DOI 10.1038/362616a0; VANWINKLE DH, 1986, PHYS REV A, V34, P562, DOI 10.1103/PhysRevA.34.562; VIGIL G, 1994, J COLLOID INTERF SCI, V165, P367, DOI 10.1006/jcis.1994.1242; WANG M, 1994, NATURE, V367, P438, DOI 10.1038/367438a0; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191	34	584	608	4	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1996	272	5262					706	709		10.1126/science.272.5262.706	http://dx.doi.org/10.1126/science.272.5262.706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8662565				2022-12-28	WOS:A1996UJ05100045
J	Sheats, JR; Antoniadis, H; Hueschen, M; Leonard, W; Miller, J; Moon, R; Roitman, D; Stocking, A				Sheats, JR; Antoniadis, H; Hueschen, M; Leonard, W; Miller, J; Moon, R; Roitman, D; Stocking, A			Organic electroluminescent devices	SCIENCE			English	Article							LIGHT-EMITTING-DIODES; CONJUGATED POLYMERS; TRANSPORT; DEGRADATION; FILMS; MOLECULES; AL	Electroluminescence from organic materials has the potential to enable low-cost, full-color flat-panel displays, as well as other emissive products. Some materials have now demonstrated adequate efficiencies (1 to 15 lumens/watt) and lifetimes (>5000 hours) for practical use; however, the factors that govern lifetime remain poorly understood. This article provides a brief review of device principles and applications requirements and focuses on the understanding of reliability issues.			Sheats, JR (corresponding author), HEWLETT PACKARD LABS,3500 DEER CREEK RD,PALO ALTO,CA 94304, USA.							ABKOWITZ MA, 1987, P INT S POLYM ADV TE, P225; Alvelda P., 1995, Journal of the Society for Information Display, V3, P181, DOI 10.1889/1.1984964; ANTONIADIS H, 1994, APPL PHYS LETT, V65, P2030, DOI 10.1063/1.112784; ANTONIADIS HA, 1996, P 1996 EL MAT C SANT, P15; BARD AJ, COMMUNICATION; Borsenberger P.M., 1993, ORGANIC PHOTORECEPTO; BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0; BURROWS PE, 1994, APPL PHYS LETT, V65, P2922, DOI 10.1063/1.112532; BURROWS PE, 1994, APPL PHYS LETT, V64, P2285, DOI 10.1063/1.111645; CACIALLI F, 1994, SYNTHETIC MET, V67, P157, DOI 10.1016/0379-6779(94)90031-0; CRAFORD GM, 1992, IEEE CIRCUIT DEV SEP, P24; CUMPSTON BH, 1995, SYNTHETIC MET, V73, P195, DOI 10.1016/0379-6779(95)80015-8; DANNETUN P, 1994, J CHEM PHYS, V100, P6765, DOI 10.1063/1.467035; DO LM, 1994, J APPL PHYS, V76, P5118, DOI 10.1063/1.357224; DODABALAPUR A, 1994, APPL PHYS LETT, V65, P2308, DOI 10.1063/1.112726; Faulkner L. R., 1977, ELECTROANAL CHEM, V10, P1; Greenham N. C., 1995, SOLID STATE PHYS, V49, P1; HAN EM, 1994, CHEM LETT, P969, DOI 10.1246/cl.1994.969; HAN EM, 1995, CHEM LETT, P57, DOI 10.1246/cl.1995.57; HOSOKAWA C, 1995, P 49 ANN C SOC IM SC, P408; JAGUIRO PB, 1995, 1995 SID INT S DIG T, P470; KIDO J, 1995, SCIENCE, V267, P1332, DOI 10.1126/science.267.5202.1332; KUWABARA Y, 1994, ADV MATER, V6, P677, DOI 10.1002/adma.19940060913; MACKIE WA, 1994, J VAC SCI TECHNOL B, V12, P722, DOI 10.1116/1.587380; MCELVAINE J, UNPUB; MEHL W, 1965, Z PHYS CHEM NEUE FOL, V47, P76, DOI 10.1524/zpch.1965.47.1_2.076; MOON RL, 1995, P IS T 48 ANN C, P386; NITZAN A, 1994, J PHYS CHEM-US, V98, P1765, DOI 10.1021/j100058a009; PAPADIMITRAKOPOULOS F, 1994, MOL CRYST LIQ CRYS A, V256, P663, DOI 10.1080/10587259408039307; Papadimitrakopoulos F, 1996, CHEM MATER, V8, P1363, DOI 10.1021/cm960152m; PARKER ID, 1994, J APPL PHYS, V75, P1656, DOI 10.1063/1.356350; PARTRIDGE R, 1976, Patent No. 3995299; PARTRIDGE RH, 1983, POLYMER, V24, P755, DOI 10.1016/0032-3861(83)90015-0; PAULSON B, 1993, J PHYS CHEM-US, V97, P13042, DOI 10.1021/j100152a002; PEI QB, 1995, SCIENCE, V269, P1086, DOI 10.1126/science.269.5227.1086; POPE M, 1963, J CHEM PHYS, V38, P2042, DOI 10.1063/1.1733929; REGAN JJ, 1993, J PHYS CHEM-US, V97, P13083, DOI 10.1021/j100152a009; RICHTER MM, 1994, CHEM PHYS LETT, V226, P115, DOI 10.1016/0009-2614(94)00716-0; RIKKEN GLJA, 1994, APPL PHYS LETT, V65, P219, DOI 10.1063/1.112678; ROBERTS GG, 1979, SOLID STATE COMMUN, V32, P683, DOI 10.1016/0038-1098(79)90728-2; ROITMAN D, 1995, P 49 ANN C SOC IM SC, P414; ROITMAN DB, 1995, INT SAMPE C SER, V27, P681; RUBNER MF, 1995, P 49 ANN C SOC IM SC, P408; SATO Y, 1994, MOL CRYST LIQ CRYS A, V252, P435; Scott JC, 1996, J APPL PHYS, V79, P2745, DOI 10.1063/1.361096; SCURLOCK RD, 1995, J AM CHEM SOC, V117, P10194, DOI 10.1021/ja00146a004; SHEATS JR, UNPUB; SMITH DL, 1996, P 1996 EL MAT C SANT, P14; SOMORJAL GA, 1972, PRINCIPLES SURFACE C; STR UNL, 1995, LIGHT SOURC, P2; Tang C. W., 1996, 1996 SID International Symposium. Digest of Technical Papers. First Edition, P181; TANG CW, 1989, J APPL PHYS, V65, P3610, DOI 10.1063/1.343409; TANG CW, 1987, APPL PHYS LETT, V51, P913, DOI 10.1063/1.98799; TANG CW, 1994, Patent No. 5294869; TANG VW, 1994, Patent No. 5294870; VESTWEBER H, 1995, SYNTHETIC MET, V68, P263, DOI 10.1016/0379-6779(94)02301-E; VINCETT PS, 1982, THIN SOLID FILMS, V94, P171, DOI 10.1016/0040-6090(82)90509-0; VISCO RE, 1964, J AM CHEM SOC, V86, P5350, DOI 10.1021/ja01077a073; Wakimoto T., 1996, 1996 SID International Symposium. Digest of Technical Papers. First Edition, P849; YAN M, 1994, PHYS REV LETT, V72, P1104, DOI 10.1103/PhysRevLett.72.1104; YANG Y, 1994, APPL PHYS LETT, V64, P1245, DOI 10.1063/1.110853; YU G, 1995, CAN J CHEM, V73, P1893; YU G, 1996, MAT RES SOC M SAN FR; 1980, HDB CHEM PHYS, pE83	64	1076	1114	2	177	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					884	888		10.1126/science.273.5277.884	http://dx.doi.org/10.1126/science.273.5277.884			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688062				2022-12-28	WOS:A1996VC67000034
J	Xing, J; Ginty, DD; Greenberg, ME				Xing, J; Ginty, DD; Greenberg, ME			Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase	SCIENCE			English	Article							SERUM RESPONSE FACTOR; RIBOSOMAL S6 KINASE; C-FOS PROMOTER; PROTEIN-KINASE; IN-VIVO; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; SEQUENCE; SPECIFICITY	A signaling pathway has been elucidated whereby growth factors activate the transcription factor cyclic adenosine monophosphate response element-binding protein (CREB), a critical regulator of immediate early gene transcription. Growth factor-stimulated CREB phosphorylation at serine-133 is mediated by the RAS-mitogen-activated protein kinase (MAPK) pathway. MAPK activates CREB kinase, which in turn phosphorylates and activates CREB. Purification, sequencing, and biochemical characterization of CREB kinase revealed that it is identical to a member of the pp90(RSK) family, RSK2. RSK2 was shown to mediate growth factor induction of CREB serine-133 phosphorylation both in vitro and in vivo. These findings identify a cellular function for RSK2 and define a mechanism whereby growth factor signals mediated by RAS and MAPK are transmitted to the nucleus to activate gene expression.	CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034814, R29NS034814, R01NS034814] Funding Source: NIH RePORTER; NCI NIH HHS [CA43855] Funding Source: Medline; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NINDS NIH HHS [NS34814-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Sambrook J., 1989, MOL CLONING; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; XING J, UNPUB; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	36	1062	1085	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					959	963		10.1126/science.273.5277.959	http://dx.doi.org/10.1126/science.273.5277.959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688081				2022-12-28	WOS:A1996VC67000064
J	Guo, S; Kemphues, KJ				Guo, S; Kemphues, KJ			A non-muscle myosin required for embryonic polarity in Caenorhabditis elegans	NATURE			English	Article							HEAVY-CHAIN FUNCTION; C-ELEGANS; CYTOPLASMIC LOCALIZATION; PROTEIN; GENES; DROSOPHILA; SEQUENCE; ENCODES; IDENTIFICATION; MICROFILAMENTS	DAUGHTER cells with distinct fates can arise through intrinsically asymmetrical divisions'. Before such divisions, factors crucial for determining cell fates become asymmetrically localized in the mother cell(2,3). In Caenorhabditis elegans, PAR proteins are required for the early asymmetrical divisions that establish embryonic polarity(4,8), and are asymmetrically localized in early blastomeres(9,10), although the mechanism of their distribution is not known. Here we report the identification in C. elegans of a nonmuscle myosin II heavy chain (designated NMY-2) by means of its interaction with the PAR-1 protein, a putative Ser/Thr protein kinase. Furthermore, injections of nmy-2 antisense RNA into ovaries of adult worms cause embryonic partitioning defects and lead to mislocalization of PAR proteins. We therefore conclude that NMY-2 is required for establishing cellular polarity in C. elegans embryos.	CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853	Cornell University								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; CHENG NN, 1995, GENETICS, V139, P549; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MORTON DG, 1992, GENETICS, V130, P771; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPUDICH JA, 1989, CELL REGUL, V1, P1; SULSTON J, 1983, DEV BIOL, V100, P67; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	26	219	229	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					455	458		10.1038/382455a0	http://dx.doi.org/10.1038/382455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684486				2022-12-28	WOS:A1996VA25100058
J	Heald, R; Tournebize, R; Blank, T; Sandaltzopoulos, R; Becker, P; Hyman, A; Karsenti, E				Heald, R; Tournebize, R; Blank, T; Sandaltzopoulos, R; Becker, P; Hyman, A; Karsenti, E			Self-organization of microtubules into bipolar spindles around artificial chromosomes in Xenopus egg extracts	NATURE			English	Article							CYTOPLASMIC DYNEIN; IDENTIFICATION; CENTROSOMES; KINESIN; LOCALIZATION; KINETOCHORES; CHROMATIN; POLARITY; MOTILITY; MITOSIS	Functional nuclei and mitotic spindles are shown to assemble around DNA-coated beads incubated in Xenopus egg extracts. Bipolar spindles assemble in the absence of centrosomes and kinetochores, indicating that bipolarity is an intrinsic property of microtubules assembling around chromatin in a mitotic cytoplasm. Microtubules nucleated at dispersed sites with random polarity rearrange into two arrays of uniform polarity. Spindle-pole formation requires cytoplasmic dynein-dependent translocation of microtubules across one another. It is proposed that spindles form in the absence of centrosomes by motor-dependent sorting of microtubules according to their polarity.	EUROPEAN MOLEC BIOL LAB, GENE EXPRESS PROGRAM, D-69117 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	Heald, R (corresponding author), EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, MITOT SPINDLE GRP, MEYERHOFSTR 1, D-69117 HEIDELBERG, GERMANY.		Tournebize, Regis/K-7847-2018; Hyman, Tony/F-1923-2011	Tournebize, Regis/0000-0003-3718-3130; Heald, Rebecca/0000-0001-6671-6528				Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; BAJER AS, 1981, COLD SPRING HARB SYM, V46, P263; DOTEROM M, 1996, J CELL BIOL, V133, P125; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1991, J CELL SCI, P125; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lambert Anne Marie, 1994, V13, P325; LOURIM D, 1993, J CELL BIOL, V123, P501, DOI 10.1083/jcb.123.3.501; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWANSON CP, 1981, CYTOGENETICS, P494; TELZER BR, 1981, J CELL BIOL, V89, P373, DOI 10.1083/jcb.89.2.373; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VEMOS I, 1996, CURR OPIN CELL BIOL, V8, P4; VEMOS I, 1995, TRENDS CELL BIOL, V5, P297; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	34	773	779	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1996	382	6590					420	425		10.1038/382420a0	http://dx.doi.org/10.1038/382420a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684481				2022-12-28	WOS:A1996VA25100047
J	Wagner, N; Lohler, J; Kunkel, EJ; Ley, K; Leung, E; Krissansen, G; Rajewsky, K; Muller, W				Wagner, N; Lohler, J; Kunkel, EJ; Ley, K; Leung, E; Krissansen, G; Rajewsky, K; Muller, W			Critical role for beta 7 integrins in formation of the gut-associated lymphoid tissue	NATURE			English	Article							MUCOSAL IMMUNE-SYSTEM; ALPHA-CHAIN; DEFICIENT MICE; LYMPHOCYTES; POPULATIONS; ADHESION; CELLS; EXPRESSION; GENERATION; RECEPTOR	IMMUNE defence against pathogens entering the gut is accomplished by lymphocytes in the gut-associated lymphoid tissue (GALT), a major compartment of the immune system(1). The GALT, comprising Peyer's patches, lamina propria lymphocytes and intra-epithelial lymphocytes of the intestine, is populated by lymphocytes that migrate there from the vasculature(2,3). Here we report that, in mice deficient for the beta 7 integrin subfamily of adhesion molecules, the formation of the GALT is severely impaired. This is probably due to a failure of beta 7(-/-) lymphocytes to arrest and adhere to the vasculature at the site of transmigration into the GALT.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; UNIV VIRGINIA, DEPT BIOMED ENGN, CHARLOTTESVILLE, VA 22908 USA; UNIV AUCKLAND, DEPT MOLEC MED, AUCKLAND, NEW ZEALAND	Heinrich Pette Institute; University of Hamburg; University of Virginia; University of Auckland	Wagner, N (corresponding author), UNIV COLOGNE, INST GENET, D-50937 COLOGNE, GERMANY.		Muller, Werner/B-9044-2008; Leung, Euphemia/D-2642-2009	Muller, Werner/0000-0002-1297-9725; Leung, Euphemia/0000-0002-6932-3188; Rajewsky, Klaus/0000-0002-6633-6370				ANDREW DP, 1994, J IMMUNOL, V153, P3847; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; BUTCHER EC, 1979, J IMMUNOL, V123, P1996; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Griebel PJ, 1996, IMMUNOL TODAY, V17, P30, DOI 10.1016/0167-5699(96)80566-4; GUYGRAND D, 1992, EUR J IMMUNOL, V22, P505, DOI 10.1002/eji.1830220232; HAMANN A, 1994, J IMMUNOL, V152, P3282; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; SIM GK, 1994, INT IMMUNOL, V6, P1287, DOI 10.1093/intimm/6.9.1287; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUNDBERG JP, 1994, GASTROENTEROLOGY, V107, P1726, DOI 10.1016/0016-5085(94)90813-3; ZOU YR, 1993, EMBO J, V12, P811, DOI 10.1002/j.1460-2075.1993.tb05721.x	30	456	464	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1996	382	6589					366	370		10.1038/382366a0	http://dx.doi.org/10.1038/382366a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684468				2022-12-28	WOS:A1996UY95000056
J	Blair, SN; Kampert, JB; Kohl, HW; Barlow, CE; Macera, CA; Paffenbarger, RS; Gibbons, LW				Blair, SN; Kampert, JB; Kohl, HW; Barlow, CE; Macera, CA; Paffenbarger, RS; Gibbons, LW			Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; EXERCISE; PROTOCOLS	Objective.-To quantify the relation of cardiorespiratory fitness to cardiovascular disease (CVD) mortality and to all-cause mortality within strata of other personal characteristics that predispose to early mortality. Design.-Observational cohort study. We calculated CVD and all-cause death rates for low (least fit 20%), moderate (next 40%), and high (most fit 40%) fitness categories by strata of smoking habit, cholesterol level, blood pressure, and health status. Setting.-Preventive medicine clinic. Study Participants.-Participants were 25 341 men and 7080 women who completed preventive medical examinations, including a maximal exercise test. Main Outcome Measures.-Cardiovascular disease and all-cause mortality. Results.-There were 601 deaths during 211 996 man-years of follow-up, and 89 deaths during 52 982 woman-years of follow-up. Independent predictors of mortality among men, with adjusted relative risks (RRs) and 95% confidence intervals (Cls), were low fitness (RR, 1.52; 95% CI, 1.28-1.82), smoking (RR, 1.65; 95% CI, 1.39-1.97), abnormal electrocardiogram (RR, 1.64; 95% CI, 1.34-2.01), chronic illness (RR, 1.63; 95% CI, 1.37-1.95), increased cholesterol level (RR, 1.34; 95% CI, 1.13-1.59), and elevated systolic blood pressure (RR, 1.34; 95% CI, 1.13-1.59), The only statistically significant independent predictors of mortality in women were low fitness (RR, 2.10; 95% CI, 1.36-3.21) and smoking (RR, 1.99; 95% CI, 1.25-3.17). Inverse gradients were seen for mortality across fitness categories within strata of other mortality predictors for both sexes. Fit persons with any combination of smoking, elevated blood pressure, or elevated cholesterol level had lower adjusted death rates than low-fit persons with none of these characteristics. Conclusions.-Low fitness is an important precursor of mortality. The protective effect of fitness held for smokers and nonsmokers, those with and without elevated cholesterol levels or elevated blood pressure, and unhealthy and healthy persons. Moderate fitness seems to protect against the influence of these other predictors on mortality. Physicians should encourage sedentary patients to become physically active and thereby reduce the risk of premature mortality.	COOPER CLIN, DALLAS, TX USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV S CAROLINA, SCH PUBL HLTH, COLUMBIA, SC 29208 USA; STANFORD UNIV, SCH MED, PALO ALTO, CA 94304 USA	Cooper Institute; Baylor College of Medicine; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Stanford University	Blair, SN (corresponding author), COOPER INST AEROB RES, 12330 PRESTON RD, DALLAS, TX 75230 USA.		wright, beth/V-7496-2019		NIA NIH HHS [AG06945] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1990, MED SCI SPORT EXER, V22, P265; [Anonymous], 1993, Med Sci Sports Exerc, V25, P1; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bouchard C, 1994, PHYSICAL ACTIVITY FI, P569; COX DR, 1972, J R STAT SOC B, V34, P187; FAGARD RH, 1994, PHYSICAL ACTIVITY FI, P633; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Kriska A M, 1994, Exerc Sport Sci Rev, V22, P121; MORRIS JN, 1990, BRIT HEART J, V63, P325; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; POLLOCK ML, 1982, AM HEART J, V103, P363, DOI 10.1016/0002-8703(82)90275-7; Stefanovic-Racic M., 1994, P417	18	1251	1276	3	136	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					205	210		10.1001/jama.276.3.205	http://dx.doi.org/10.1001/jama.276.3.205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667564				2022-12-28	WOS:A1996UW46900031
J	Klesges, RC; Ward, KD; Shelton, ML; Applegate, WB; Cantler, ED; Palmieri, GMA; Harmon, K; Davis, J				Klesges, RC; Ward, KD; Shelton, ML; Applegate, WB; Cantler, ED; Palmieri, GMA; Harmon, K; Davis, J			Changes in bone mineral content in male athletes - Mechanisms of action and intervention effects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY ABSORPTIOMETRY; LONG-DISTANCE RUNNERS; BODY-COMPOSITION; DENSITY; EXERCISE; MASS	Objectives.-To determine changes in bane mineral content (BMC) in male athletes, to examine the mechanisms of changes, and to evaluate the effects of intervention. Design.-Dual-energy x-ray absorptiometry (DEXA) tests were administered over a 2-year period, and calcium loss during training was determined by analysis of sweat and urine. Calcium supplementation was administered during year 2. Setting.-A midsouth university. Participants.-Eleven members of a college Division I-A basketball team. Intervention.-Based on observed calcium loss, athletes received differential levels of calcium supplementation. intervention commenced the week prior to the fall training season and continued through postseason play. Main Outcome Measure.-Changes in BMC. Results.-Total body BMC decreased 3.8% from preseason to midseason of year 1 (mean decrease, 133.4 g, P=.02), increased nonsignificantly by 1.1% (mean increase, 35.3 g, P=.22) during the offseason, but decreased an additional 3.3% during summer months when practices resumed (mean decrease, 113.1 g, P=.01). Dermal calcium loss averaged 422 mg per training session, From preseason to late summer, there was an overall decrease of 6.1% in total BMC and a 10.5% decrease in BMC of the legs, Calcium supplementation was associated with significant increases in BMC and lean body mass. Conclusions.-Bone loss is calcium related and exercise is positively related to BMC provided that calcium intake is sufficient to offset dermal loss.	MEMPHIS UNIV,DEPT ATHLET,MEMPHIS,TN 38152; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN; UNIV TENNESSEE,DEPT UNIV PHARM,MEMPHIS,TN	University of Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Klesges, RC (corresponding author), MEMPHIS UNIV,DEPT PSYCHOL,UNIV PREVENT CTR,MEMPHIS,TN 38152, USA.							BILANIN JE, 1989, MED SCI SPORT EXER, V21, P66, DOI 10.1249/00005768-198902000-00012; CHARLES P, 1991, AM J CLIN NUTR, V54, pS266, DOI 10.1093/ajcn/54.1.266S; CHU JY, 1979, AM J CLIN NUTR, V32, P1699, DOI 10.1093/ajcn/32.8.1699; CUMMINGS SR, 1995, AM J MED S2A, V98, P245; GOING SB, 1993, AM J CLIN NUTR, V57, P845, DOI 10.1093/ajcn/57.6.845; GUTIN B, 1992, OSTEOPOROSIS INT, V2, P55, DOI 10.1007/BF01623838; Hertzler A. A., 1994, Topics in Clinical Nutrition, V9, P76; HETLAND ML, 1993, J CLIN ENDOCR METAB, V77, P770, DOI 10.1210/jc.77.3.770; JOHNSON AW, 1994, AM J SPORT MED, V22, P248, DOI 10.1177/036354659402200216; KELLIE SE, 1992, JAMA-J AM MED ASSOC, V267, P286; KIRBY CR, 1986, J APPL PHYSIOL, V61, P969; MACDOUGALL JD, 1992, J APPL PHYSIOL, V73, P1165, DOI 10.1152/jappl.1992.73.3.1165; MARCUS R, 1988, ADV SPORTS MED FITNE, V1, P63; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MYBURGH KH, 1990, ANN INTERN MED, V113, P754, DOI 10.7326/0003-4819-113-10-754; NELSON ME, 1991, AM J CLIN NUTR, V53, P1303; PALMIERI GMA, 1995, MINER ELECTROL METAB, V21, P236; PATTEN BM, 1974, ANN INTERN MED, V80, P182, DOI 10.7326/0003-4819-80-2-182; RICO H, 1993, J SPORT MED PHYS FIT, V33, P278; ROUBENOFF R, 1993, AM J CLIN NUTR, V58, P589, DOI 10.1093/ajcn/58.5.589; Scrimshaw NS, 1988, AM J CLIN NUTR S, V48, P1086; SUOMINEN H, 1993, SPORTS MED, V16, P316, DOI 10.2165/00007256-199316050-00003; TIPTON K, 1993, INT J SPORT NUTR, V3, P261, DOI 10.1123/ijsn.3.3.261; VOELLKOPF W, 1995, ATOM SPECTROSC, V16, P19; Williams M H, 1989, Int J Vitam Nutr Res Suppl, V30, P163; 1994, JAMA-J AM MED ASSOC, V272, P1942	26	109	113	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					226	230		10.1001/jama.276.3.226	http://dx.doi.org/10.1001/jama.276.3.226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667568				2022-12-28	WOS:A1996UW46900035
J	Jones, E; Jarvis, P; Lewis, JA; Ebbutt, AF				Jones, E; Jarvis, P; Lewis, JA; Ebbutt, AF			Trials to assess equivalence: The importance of rigorous methods	BMJ-BRITISH MEDICAL JOURNAL			English	Article								The aim of an equivalence trial Is to show the therapeutic equivalence of two treatments, usually a new drug under development and an existing drug for the same disease used as a standard active comparator. Unfortunately the principles that govern the design, conduct, and analysis of equivalence trials are not as well understood as they should be. Consequently such trials often include too few patients or have intrinsic design biases which tend towards the conclusion of no difference. In addition the application of hypo; thesis testing in analysing and interpreting data from such trials sometimes compounds the drawing of inappropriate conclusions, and the inclusion and exclusion of patients from analysis may be poorly managed. The design of equivalence trials should mirror that of earlier successful trials of the active comparator as closely as possible, Patient losses and other deviations from the protocol should be minimised; analysis strategies to deal with unavoidable problems should not centre on an ''intention to treat'' analysis but should seek to show the similarity of results from a range of approaches, Analysis should be based on confidence intervals, and this also carries implications for the estimation of the required numbers of patients at the design stage.	DE MONTFORT UNIV, SCH COMP SCI, DEPT MED STAT, LEICESTER LE1 9BH, LEICS, ENGLAND; GLAXO WELLCOME LTD, GREENFORD UB6 0HE, MIDDX, ENGLAND	De Montfort University; GlaxoSmithKline								ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; HENRY D, 1995, BMJ-BRIT MED J, V310, P1279, DOI 10.1136/bmj.310.6990.1279; LEWIS JA, 1995, STAT MED, V14, P1655, DOI 10.1002/sim.4780141506; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MAKUCH RW, 1990, STAT ISSUES DRUG RES, P225; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SALSBURG D, 1994, PHARMACOEPIDEM DR S, V3, P329; TAUBES G, 1995, SCIENCE, V267, P25, DOI 10.1126/science.7809605; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; 1995, STAT MED, V14, P1658; 1995, NEW ENGL J MED, V332, P60	14	745	758	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	1996	313	7048					36	39		10.1136/bmj.313.7048.36	http://dx.doi.org/10.1136/bmj.313.7048.36			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664772	Green Published			2022-12-28	WOS:A1996UW66700031
J	Nightingale, SL				Nightingale, SL			Comments requested on direct-to-consumer promotion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKLAND,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					14	14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667525				2022-12-28	WOS:A1996UU43900005
J	Duyff, RF; Davies, G; Vos, J				Duyff, RF; Davies, G; Vos, J			Dissociation between cerebral imaging and clinical picture	LANCET			English	Letter									ST LUCAS ANDREAS HOSP,DEPT NEUROL,1061 AE AMSTERDAM,NETHERLANDS; ST LUCAS ANDREAS HOSP,DEPT RADIOL,1061 AE AMSTERDAM,NETHERLANDS	Sint Lucas Andreas Hospital; Sint Lucas Andreas Hospital								Baudoin D, 1996, LANCET, V347, P965, DOI 10.1016/S0140-6736(96)91447-6; ROBERTSON SJ, 1989, AM J NEURORADIOL, V10, P1007	2	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1829	1830		10.1016/S0140-6736(96)91649-9	http://dx.doi.org/10.1016/S0140-6736(96)91649-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667935				2022-12-28	WOS:A1996UU46900040
J	GoldschmidtClermont, PJ; Shear, WS; Schwartzberg, J; Varga, CF; Bray, PF				GoldschmidtClermont, PJ; Shear, WS; Schwartzberg, J; Varga, CF; Bray, PF			Clues to the death of an Olympic champion	LANCET			English	Letter									JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; ADIRONDACK MED CTR,DEPT FAMILY MED,LAKE PLACID,NY 12946; ADIRONDACK MED CTR,DEPT PATHOL,LAKE PLACID,NY 12946	Johns Hopkins University								ROBINSON K, 1994, CLEV CLIN J MED, V61, P438, DOI 10.3949/ccjm.61.6.438; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Williams R R, 1992, Clin Exp Pharmacol Physiol Suppl, V20, P1	3	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1833	1833		10.1016/S0140-6736(96)91652-9	http://dx.doi.org/10.1016/S0140-6736(96)91652-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667943				2022-12-28	WOS:A1996UU46900048
J	Walczak, CE; Mitchison, TJ				Walczak, CE; Mitchison, TJ			Kinesin-related proteins at mitotic spindle poles: Function and regulation	CELL			English	Review							FISSION YEAST; GENE; MITOSIS; MOTOR				Walczak, CE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; COLE DG, 1994, J BIOL CHEM, V269, P22913; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; PAGE BD, 1993, ANNU REV MICROBIOL, V47, P231, DOI 10.1146/annurev.micro.47.1.231; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X	18	105	106	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					943	946		10.1016/S0092-8674(00)81295-7	http://dx.doi.org/10.1016/S0092-8674(00)81295-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674121	Bronze			2022-12-28	WOS:A1996UV48400001
J	Lazcano, A; Miller, SL				Lazcano, A; Miller, SL			The origin and early evolution of life: Prebiotic chemistry, the pre-RNA world, and time	CELL			English	Review							EARLY EARTH; SPRINGS	In the last few years, there have been a number of developments in origin of life studies that merit review. We will discuss primitive atmospheres, submarine vents, autotrophic versus heterotrophic origin, the RNA and pre-RNA worlds, and the time required for life to arise and evolve to cyanobacteria. Topics such as prebiotic synthesis, template polymerizations, and evolution of specific metabolic pathways will not be discussed here.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego	Lazcano, A (corresponding author), NATL AUTONOMOUS UNIV MEXICO,FAC CIENCIAS,DEPT BIOL,APARTADO POSTAL 70-407,MEXICO CITY 04510,DF,MEXICO.			Lazcano, Antonio/0000-0001-7365-8557				ANDERS E, 1989, NATURE, V342, P255, DOI 10.1038/342255a0; ANDERSON RP, 1977, ANNU REV MICROBIOL, V31, P473, DOI 10.1146/annurev.mi.31.100177.002353; BADA JL, 1994, P NATL ACAD SCI USA, V91, P1248, DOI 10.1073/pnas.91.4.1248; BORK P, 1995, MOL MICROBIOL, V16, P955, DOI 10.1111/j.1365-2958.1995.tb02321.x; CAIRNSSMITH AG, 1982, GENETIC TAKEOVER; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; CLARKE PH, 1980, J MOL EVOL, V15, P333, DOI 10.1007/BF01733139; Corliss J. B., 1981, Oceanologica Acta, V4, P59; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; de Duve C, 1991, BLUEPRINT CELL NATUR; ESCHENMOSER A, 1994, ORIGINS LIFE EVOL B, V24, P389, DOI 10.1007/BF01582017; Fani R, 1995, J MOL EVOL, V41, P760; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GESTELAND RF, 1993, RNA WORLD; HAFENBRADL D, 1995, TETRAHEDRON LETT, V36, P5179; HALL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3529, DOI 10.1073/pnas.77.6.3529; HARTMAN H, 1975, J MOL EVOL, V4, P359, DOI 10.1007/BF01732537; Herdman M., 1985, EVOLUTION GENOME SIZ, P37; HOLM NG, 1992, ORIGINS LIFE EVOL B, V22, P1, DOI 10.1007/BF01808014; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Kauffman S.A., 1993, ORIGINS ORDER; Keefe AD, 1995, J MOL EVOL, V41, P693; KEEFE AD, 1995, P NATL ACAD SCI USA, V92, P11904, DOI 10.1073/pnas.92.25.11904; LARRALDE R, 1995, P NATL ACAD SCI USA, V92, P8158, DOI 10.1073/pnas.92.18.8158; LAZCANO A, 1994, J MOL EVOL, V39, P546, DOI 10.1007/BF00160399; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MADEN BEH, 1995, TRENDS BIOCHEM SCI, V20, P337, DOI 10.1016/S0968-0004(00)89069-6; MAHER KA, 1988, NATURE, V331, P612, DOI 10.1038/331612a0; Miller S. L., 1981, ORIGINS LIFE, P135; MILLER SL, 1988, NATURE, V334, P609, DOI 10.1038/334609a0; Miller SL, 1995, J MOL EVOL, V41, P689; MULLER D, 1990, HELV CHIM ACTA, V73, P1410, DOI 10.1002/hlca.19900730526; NIELSEN PE, 1993, ORIGINS LIFE EVOL B, V23, P323, DOI 10.1007/BF01582083; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Oparin A. I., 1938, ORIGINS LIFE EVOL B; Peltzer E T, 1984, Adv Space Res, V4, P69, DOI 10.1016/0273-1177(84)90546-5; SCANLAN TS, 1995, CHEM BIOL, V2, P71, DOI 10.1016/1074-5521(95)90278-3; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; SHAPIRO R, 1988, ORIGINS LIFE EVOL B, V18, P71, DOI 10.1007/BF01808782; SHAPIRO R, 1995, ORIGINS LIFE EVOL B, V25, P83, DOI 10.1007/BF01581575; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; STRIBLING R, 1987, ORIGINS LIFE EVOL B, V17, P261, DOI 10.1007/BF02386466; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; YAMAGATA Y, 1991, NATURE, V352, P516, DOI 10.1038/352516a0; Yarus M., 1993, RNA WORLD, P205	52	226	237	3	155	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					793	798		10.1016/S0092-8674(00)81263-5	http://dx.doi.org/10.1016/S0092-8674(00)81263-5			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681375	Bronze			2022-12-28	WOS:A1996UR60400004
J	Crowther, MA; Heddle, N; Hayward, CPM; Warkentin, T; Kelton, JG				Crowther, MA; Heddle, N; Hayward, CPM; Warkentin, T; Kelton, JG			Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura	ANNALS OF INTERNAL MEDICINE			English	Article							PLASMA-EXCHANGE; INFUSION	Objective: To assess whether splenectomy done during hematologic remission reduces the relapse rate in patients with relapsing thrombotic thrombocytopenic purpura. Design: Consecutive case series. Setting: Tertiary care teaching hospital. Patients: 6 consecutive patients seen during a 10-year period who had had one or more relapses of thrombotic thrombocytopenic purpura. Interventions: All patients had elective splenectomy while in hematologic remission and were iol[owed after surgery for as long as 8.0 years. Measurements: At-tack rates (events per year) were calculated for each patient from time of presentation to time of splenectomy and from time of splenectomy to January 1996. Results: A total of 26 episodes of thrombotic thrombocytopenic purpura occurred over 22.3 patient-years before splenectomy. After splenectomy, 3 acute episodes occurred over 22.7 patient-years, The attack rate (+/- 1 SD) decreased from 2.3 +/- 2.0 events per year to 0.1 +/- 0.1 events per year. Conclusion: In patients who have had one or more relapses of thrombotic thrombocytopenic purpura, splenectomy done during hematologic remission reduces the frequency of acute relapse and the resulting need for medical therapy.	MCMASTER UNIV, MED CTR, BLOOD BANK, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON, ON L8N 3Z5, CANADA; CANADIAN RED CROSS BLOOD TRANSFUS SERV, HAMILTON, ON, CANADA	McMaster University; McMaster University				Hayward, Catherine/0000-0002-2843-0817				HAYWARD CPM, 1994, ARCH INTERN MED, V154, P982, DOI 10.1001/archinte.154.9.982; LENZ HJ, 1990, LANCET, V335, P1593, DOI 10.1016/0140-6736(90)91422-7; LIU ET, 1986, AM J HEMATOL, V23, P347, DOI 10.1002/ajh.2830230407; ONUNDARSON PT, 1992, ARCH INTERN MED, V152, P791, DOI 10.1001/archinte.152.4.791; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROSE M, 1993, BLOOD REV, V7, P94, DOI 10.1016/S0268-960X(05)80019-0; ROSE M, 1987, AM J MED, V83, P437, DOI 10.1016/0002-9343(87)90753-4; SCHNEIDER PA, 1985, ANN SURG, V202, P318, DOI 10.1097/00000658-198509000-00007; SHUMAK KH, 1995, ANN INTERN MED, V122, P569, DOI 10.7326/0003-4819-122-8-199504150-00002; STURGESS AD, 1986, SCAND J HAEMATOL, V37, P319; THOMPSON HW, 1983, ARCH INTERN MED, V143, P2117, DOI 10.1001/archinte.143.11.2117; WELLS AD, 1991, BRIT J SURG, V78, P1389, DOI 10.1002/bjs.1800781139	12	68	70	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					294	296		10.7326/0003-4819-125-4-199608150-00006	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678392				2022-12-28	WOS:A1996VB68000009
J	Feinberg, MB				Feinberg, MB			Changing the natural history of HIV disease	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CLINICAL COURSE; INFECTION; PROGRESSION; DEFECTS; PLASMA; AIDS; PCR	Our understanding of the pathogenesis of AIDS has advanced considerably since the disease was first reported 15 years ago. We now know that the primary damage inflicted by HIV-1 is mainly brought about by active virus replication. With the advent of sensitive tools for monitoring HIV replication in vivo, an individual's risk of disease progression can be assessed early in the course of the infection and the efficacy of antiviral therapies can now be determined accurately and expeditiously. When used appropriately, potent combinations of antiviral drugs seem to be able to circumvent the inherent tendency of HIV-1 to generate drug-resistant viruses, the main reason for failure of all antiviral therapies, and are significantly more effective than earlier approaches. For the first time, rational approaches to contain and perhaps eliminate HIV-1 infection can be pursued.			Feinberg, MB (corresponding author), NIH,OFF AIDS RES,BLDG 31,ROOM 4C06,31 CTR DR,BETHESDA,MD 20892, USA.							CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COOMBS RW, IN PRESS J INFECT DI; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FEINBERG MB, 1995, SCI AM MED, V7, P1; GULLICK RM, 1996, 11 INT C AIDS VANC, P19; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAPLAN JE, 1995, JAMA-J AM MED ASSOC, V274, P347, DOI 10.1001/jama.274.4.347; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; KOVACS JA, 1995, NEW ENGL J MED, P332; LOES SK, 1995, NEW ENGL J MED, V333, P408; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SAKSELA K, 1995, ANN INTERN MED, V123, P641, DOI 10.7326/0003-4819-123-9-199511010-00001; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; STEIN DS, 1994, ANN INTERN MED, V121, P100, DOI 10.7326/0003-4819-121-2-199407150-00004; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; VANDAMME AM, 1995, J VIROL METHODS, V52, P121, DOI 10.1016/0166-0934(94)00151-6; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; WELLS SL, IN PRESS J INFECT DI; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; 1996, ANN INTERN MED, V124, P348	48	102	103	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					239	246		10.1016/S0140-6736(96)06231-9	http://dx.doi.org/10.1016/S0140-6736(96)06231-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684203				2022-12-28	WOS:A1996UZ28600014
J	Turnbull, D; Holmes, A; Shields, N; Cheyne, H; Twaddle, S; Gilmour, WH; McGinley, M; Reid, M; Johnstone, I; Geer, I; McIlwaine, G; Lunan, CB				Turnbull, D; Holmes, A; Shields, N; Cheyne, H; Twaddle, S; Gilmour, WH; McGinley, M; Reid, M; Johnstone, I; Geer, I; McIlwaine, G; Lunan, CB			Randomised, controlled trial of efficacy of midwife-managed care	LANCET			English	Article							DELIVERY	Background Midwife-managed programmes of care are being widely implemented although there has been little investigation of their efficacy. We have compared midwife-managed care with shared care (ie, care divided among midwives, hospital doctors, and general practitioners) in terms of clinical efficacy and women's satisfaction. Methods We carried out a randomised controlled trial of 1299 pregnant women who had no adverse characteristics at booking (consent rate 81.9%). 648 women were assigned midwife-managed care and 651 shared care. The research hypothesis was that compared with shared care, midwife-managed care would produce fewer interventions, similar (or more favourable) outcomes, similar complications, and greater satisfaction with care. Data were collected by retrospective review of case records and self-report questionnaires. Analysis was by intention to treat. Findings Interventions were similar in the two groups or lower with midwife-managed care. For example, women in the midwife-managed group were less likely than women in shared care to have induction of labour (146 [23.9%] vs 199 [33.3%]; 95% Cl for difference 4.4-14.5). Women in the midwife-managed group were more likely to have an intact perineum and less likely to have had an episiotomy (p=0.02), with no significant difference in perineal tears. Complication rates were similar. Overall, 32.8% of women were permanently transferred from midwife-managed care (28.7% for clinical reasons, 3.7% for non-clinical reasons). Women in both groups reported satisfaction with their care but the midwife-managed group were significantly more satisfied with their antenatal (difference in mean scores 0.48 [95% Cl 0.41-0.55]), intrapartum (0.28 [0.18-0.37]), hospital-based postnatal care (0.57 [0.45-0.70]), and home-based postnatal care (0.33 [0.25-0.42]). Interpretation We conclude that midwife-managed care for healthy women, integrated within existing services, is clinically effective and enhances women's satisfaction with maternity care.	GLASGOW ROYAL MATERN HOSP,MIDWIFERY DEV UNIT,GLASGOW G4 ONA,LANARK,SCOTLAND; GLASGOW ROYAL MATERN HOSP,MIDWIFERY SERV,GLASGOW G4 ONA,LANARK,SCOTLAND; GLASGOW ROYAL MATERN HOSP,GYNECOL & PERINATAL DIRECTORATE,GLASGOW G4 ONA,LANARK,SCOTLAND; GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT OBSTET & GYNAECOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow				Cheyne, Helen/0000-0001-5738-8390				CAMPBELL R, 1994, WHERE TO BE BORN DEB; Carstairs V., 1991, DEPRIVATION HLTH SCO; COCKBURN J, 1991, EUR J CANCER, V27, P827, DOI 10.1016/0277-5379(91)90126-X; Department of Health (DoH), 1993, CHANGING CHILDBIRTH; *GREAT GLASG HLTH, 1992, 1991 1992 DEP PUBL H; *HOUS COMM SEL COM, 1992, 2 HOUS COMM SEL COMM; HUNDLEY VA, 1994, BRIT MED J, V309, P1400, DOI 10.1136/bmj.309.6966.1400; Likert R.A., 1932, ARCH PSYCHOL, V22, P5, DOI DOI 10.1111/J.1540-5834.2010.00585.X; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; Mason V., 1989, WOMENS EXPERIENCE MA; *MED RES COUNC, 1979, NORM BOYS GIRLS; *MIN REV BIRTH SER, 1990, FIN REP STUD GROUP R; *MIN TASK FORC OBS, 1989, FIN REP MIN TASK FOR; Murphy-Black T, 1992, Midwifery, V8, P113, DOI 10.1016/S0266-6138(05)80079-8; NEILSON JP, 1995, PREGNANCY CHILDBIRTH; Renfrew MJ, 1995, PREGNANCY CHILDBIRTH; *ROYAL COLL OBST G, 1982, REP RCOG WORK PART A; *SCOTT OFF HOM HLT, 1993, PROV MAT SERV SCOTL; *SCOTT PER MORT RE, 1990, IN DEPTH ENQ CERT CA; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; TURNBULL D, 1995, MIDWIFERY, V11, P110, DOI 10.1016/0266-6138(95)90025-X; WRAIGHT A, 1993, I MANPOWER STUDIES R, V242; [No title captured]; [No title captured]	24	139	143	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					213	218						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684197				2022-12-28	WOS:A1996UZ28600008
J	Ghosh, P; Shabat, D; Kumar, S; Sinha, SC; Grynszpan, F; Li, J; Noodleman, L; Keinan, E				Ghosh, P; Shabat, D; Kumar, S; Sinha, SC; Grynszpan, F; Li, J; Noodleman, L; Keinan, E			Using antibodies to perturb the coordination sphere of a transition metal complex	NATURE			English	Article							DENSITY-FUNCTIONAL CALCULATIONS; ELECTRONIC-STRUCTURE; COPPER(I) COMPLEXES; ENERGIES; DERIVATIVES	METAL ions in the active sites of many metalloenzymes exhibit distinctive spectral and chemical features which are different from those of small inorganic complexes(1,2). These features are the result of the unusual geometric and electronic constraints that are imposed on the metal ion within the protein environment(3). Much effort has been invested to try to mimic this feature of metalloenzymes in synthetic systems, but this remains a formidable task Here we show that one of the key lessons learned from the science of catalytic antibodies-that binding energy can be converted into chemical energy(4)-can be exploited to 'fine-tune' the physicochemical properties of a metal complex. We show that an antibody's binding site can reversibly perturb the coordination geometry of a metal ion, and can stabilize a high-energy coordinated species(5). Specifically, antibodies designed to bind the organosilicon compound 1 (Fig, 1) also bind the geometrically similar Cu(I) complex 2. However, the antibody binds a slightly compressed form of 2, which is closer in size to 1. This distortion is manifested by a spectral shift-an 'immunochromic' effect.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; TECHNION ISRAEL INST TECHNOL, DEPT CHEM, IL-32000 HAIFA, ISRAEL	Scripps Research Institute; Technion Israel Institute of Technology			Kumar, Sandeep/E-5140-2012; Grynszpan, Flavio/V-5379-2019; noodleman, louis/A-3750-2008; Grynszpan, Flavio/P-2107-2014; KUMAR, SANDEEP/GZA-7182-2022	Grynszpan, Flavio/0000-0003-2445-5416; noodleman, louis/0000-0001-8176-4448; Kumar, Sandeep/0000-0003-4789-5158				Baerends E. J., 1992, J COMPUT PHYS, V99, P84, DOI DOI 10.1016/0021-9991(92)90277-6; BARD AJ, 1983, ENCY ELECTROCHEMIS A, V9, P172; BECKE AD, 1986, J CHEM PHYS, V84, P4524, DOI 10.1063/1.450025; FOLEY J, 1994, J CHEM SOC DA, V1, P1; Hathaway B.J., 1987, COMPREHENSIVE COORDI, P533; JOHNSON JE, 1971, J CHEM SOC A, P1371, DOI 10.1039/j19710001371; JONES DH, 1993, INORG CHEM, V32, P2092, DOI 10.1021/ic00062a035; KARLIN KD, 1984, INORG CHEM, V23, P1184, DOI 10.1021/ic00177a003; KEINAN E, 1992, INORG CHEM, V31, P5433, DOI 10.1021/ic00052a019; KITAGAWA S, 1981, INORG CHEM, V20, P2261, DOI 10.1021/ic50221a064; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; LEWIS C, 1993, J AM CHEM SOC, V115, P1410, DOI 10.1021/ja00057a025; NABESHIMA T, 1993, INORG CHEM, V32, P1407, DOI 10.1021/ic00060a015; NOODLEMAN L, 1984, J AM CHEM SOC, V106, P2316, DOI 10.1021/ja00320a017; PALMER RA, 1966, INORG CHEM, V5, P864, DOI 10.1021/ic50039a034; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; ROSA A, 1994, INORG CHEM, V33, P584, DOI 10.1021/ic00081a029; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHABAT D, 1995, NATURE, V374, P143, DOI 10.1038/374143a0; SHOKAT KM, 1988, ANGEW CHEM INT EDIT, V27, P1172, DOI 10.1002/anie.198811721; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; STEWARD MW, 1983, ANTIBODY AFFINITY TH, P76; VALLEE BL, 1968, P NATL ACAD SCI USA, V59, P498, DOI 10.1073/pnas.59.2.498; VOSKO SH, 1980, CAN J PHYS, V58, P1200, DOI 10.1139/p80-159; WILLIAMS RJP, 1955, J CHEM SOC, P137, DOI 10.1039/jr9550000137; WILLIAMS RJP, 1995, EUR J BIOCHEM, V234, P363, DOI 10.1111/j.1432-1033.1995.363_b.x; ZEIGLER T, 1995, CAN J CHEM, V73, P743; ZIEGLER T, 1977, THEOR CHIM ACTA, V43, P261, DOI 10.1007/BF00551551	29	26	26	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					339	341		10.1038/382339a0	http://dx.doi.org/10.1038/382339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684461				2022-12-28	WOS:A1996UY95000046
J	Steel, CM				Steel, CM			Read before you cite	LANCET			English	Editorial Material											Steel, CM (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9TS,FIFE,SCOTLAND.							Brenner S, 1995, Curr Biol, V5, P964, DOI 10.1016/S0960-9822(95)00187-4; LARSSON KS, 1995, J INTERN MED, V238, P445, DOI 10.1111/j.1365-2796.1995.tb01222.x; Painter TS, 1923, J EXP ZOOL, V37, P291, DOI 10.1002/jez.1400370303; STEEL JM, 1987, BRIT MED J, V295, P1135, DOI 10.1136/bmj.295.6606.1135-c; STEWART LA, 1995, COCHRANE WORKING GRO, V14, P2057; Tjio J. H., 1956, HEREDITAS, V42, P1, DOI [10.1007/978-94-011-6621-8_13, DOI 10.1111/J.1601-5223.1956.TB03010.X]	6	15	15	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					144	144		10.1016/S0140-6736(05)66108-9	http://dx.doi.org/10.1016/S0140-6736(05)66108-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684152				2022-12-28	WOS:A1996UX78900007
J	Lai, RS; Chiang, AA; Wu, MT; Wang, JS; Lai, NS; Lu, JY; Ger, LP; Roggli, V				Lai, RS; Chiang, AA; Wu, MT; Wang, JS; Lai, NS; Lu, JY; Ger, LP; Roggli, V			Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan	LANCET			English	Article								Background In August, 1995, there was an outbreak in Taiwan of rapidly progressive respiratory distress associated with consumption of uncooked Sauropus androgynus, a vegetable with a claimed yet unconfirmed effect on weight control. We report on 23 patients with strikingly similar clinical presentations. Methods A structured questionnaire for clinical manifestations was completed. Radiographic findings, pulmonary physiological changes, immunological and microbiological studies, and pathological examination were evaluated. Findings All patients were young and middle-aged women (mean age 39 years [range 21-52]). They took uncooked S androgynus juice, generally mixed with guava or pineapple juice, for a mean duration of 10 weeks. Progressive dyspnoea and persistent cough were the main symptoms on presentation. Pulmonary function testing uniformly revealed moderate to severe airflow obstruction with mean forced expiratory volume in 1 s (FEV(1)) of 0 . 66 L (26% of predicted). No bronchodilator response was observed. Room-air arterial blood gas analysis showed hypoxaemia (mean PaO2 9 . 6 [SD 1 . 6] kPa). Chest radiographs were essentially normal. High-resolution computed tomography showed bilateral bronchiectasis and patchy low attenuation of lung parenchyma with mosaic perfusion. Ventilation-perfusion scintigraphic findings were compatible with obstructive lung disease. Histopathology of open lung biopsy specimens in four patients confirmed the presence of bronchiolitis obliterans. Immunohistochemical stains of the open lung biopsy specimens showed predominance of T cells over B cells. Immunofluorescent stains for IgG, IgM, IgA, C1q, C3, and C4 were negative. Serum concentrations of tumour necrosis factor a were higher than those of normal controls. Clinical response to prednisolone was limited. Interpretation We describe an unusual association between bronchiolitis obliterans and ingestion of the vegetable S androgynus. T-cell mediated immunity may be involved in the pathogenesis.	VET GEN HOSP, DEPT RADIOL, KAOHSIUNG, TAIWAN; VET GEN HOSP, DEPT PATHOL, KAOHSIUNG, TAIWAN; VET GEN HOSP, DEPT MED RES, KAOHSIUNG, TAIWAN; VET GEN HOSP, DIV RHEUMATOL & IMMUNOL, TAICHUNG, TAIWAN; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	Lai, RS (corresponding author), VET GEN HOSP, DEPT MED, DIV CHEST MED, 386 TACHUNG 1ST RD, KAOHSIUNG, TAIWAN.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P1299; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bender A. E., 1975, Plant Foods for Man, V1, P139; COLBY TV, 1992, SEMIN RESPIR MED, V13, P119, DOI 10.1055/s-2007-1006264; KING TE, 1993, CLIN CHEST MED, V14, P607; MULLER NL, 1995, RADIOLOGY, V196, P3; PADMAVATHI P, 1990, PLANT FOOD HUM NUTR, V40, P107, DOI 10.1007/BF02193767; WEBB WR, 1995, HIGH RESOLUTION CT L, P206; WRIGHT JL, 1992, AM REV RESPIR DIS, V146, P240, DOI 10.1164/ajrccm/146.1.240; YANG SC, 1993, J FORMOS MED ASS S3, V92, P152; YUNG C-H, 1990, Chinese Journal of Microbiology and Immunology (Taipei), V23, P312	11	66	66	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	1996	348	9020					83	85		10.1016/S0140-6736(96)00450-3	http://dx.doi.org/10.1016/S0140-6736(96)00450-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676721				2022-12-28	WOS:A1996UW67300009
J	Soll, RF				Soll, RF			Neonatal extracorporeal membrane oxygenation - A bridging technique	LANCET			English	Editorial Material							RESPIRATORY-FAILURE; CIRCULATION				Soll, RF (corresponding author), UNIV VERMONT,DEPT PEDIAT,BURLINGTON,VT 05405, USA.							BARTLETT RH, 1985, PEDIATRICS, V76, P479; BARTLETT RH, 1982, SURGERY, V92, P425; BARTLETT RH, 1976, T AM SOC ART INT ORG, V22, P80; GREER AL, 1993, NIH PUBLICATION; KANTO WP, 1994, J PEDIATR, V124, P35; WALSHSUKYS M, 1994, J PEDIATR-US, V124, P427; WARE JH, 1985, PEDIATRICS, V76, P849; 1988, LANCET, V2, P1289	8	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					70	71						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676714				2022-12-28	WOS:A1996UW67300002
J	Lambert, TW; Goldacre, MJ; Edwards, C; Parkhouse, J				Lambert, TW; Goldacre, MJ; Edwards, C; Parkhouse, J			Career preferences of doctors who qualified in the United Kingdom in 1993 compared with those of doctors qualifying in 1974, 1977, 1980, and 1983	BRITISH MEDICAL JOURNAL			English	Article								Objective-To report the career preferences of doctors who qualified in the United Kingdom in 1993 and to compare their choices with those of earlier cohorts of qualifiers. Design-Postal questionnaires with structured questions, including questions about choice of future long term career, were sent to doctors a year after qualification. Setting-United Kingdom. Subjects-All medical qualifiers of 1993, comparing their replies with those from earlier studies of the qualifiers of 1974, 1977, 1980, and 1983. Main outcome measures-Choice of future long term career and certainty of choice expressed at the end of the first year after qualification. Results-Questionnaires were sent to 3657 doctors. 2621 (71.7%) replied. Of the 2621 respondents, 70.5% (1849) stated that their first preference was for a career in hospital practice, 25.8% (677) specified general practice, 1.0% (25) specified public health medicine or community health, 1.4% (36) specified careers outside medicine, and 1.3% (34) did not state a choice. By contrast, 44.7% (1416/3168) of the doctors in the 1983 cohort had specified that their first preference was general practice. Among the 1993 qualifiers, general practice was the first career choice of 17.5% of men (227/1297) and 34.0% of women (450/1324). Only 7.4% of men (96/1297) stated that they definitely wanted to enter general practice. Only 7.8% (103/1324) of women qualifiers in 1993 expressed a career preference for surgical specialties. Within hospital practice, comparing 1993 with 1983, choices for the medical specialties and for accident and emergency medicine rose and those for pathology fell. Women were less definite than men about their choice of future long term career. Conclusions-If the 1993 cohort is typical of the current generation of young doctors, there has been a substantial shift away from general practice as a career choice expressed at the end of the preregistration year. General practice was much more popular among women than men. Few women opted for surgery. The sex imbalance in the percentage of doctors who choose different mainstreams of medical practice seems set to continue.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,UNIT HLTH CARE EPIDEMIOL,MED CAREERS RES GRP,OXFORD OX3 7LF,ENGLAND	University of Oxford				Lambert, Trevor/0000-0001-9688-3036				Allen I., 1994, DOCTORS THEIR CAREER; *DEP HLTH WELSH OF, 1989, GEN PRACT NAT HLTH S; Everitt B., 1994, ANAL CONTINGENCY TAB; HABERMAN SJ, 1973, BIOMETRICS, V29, P205, DOI 10.2307/2529686; PARKHOUSE J, 1991, DOCTORS CAREERS AIMS; Report Todd, 1968, CMND3569; *SECR STAT HLTH WA, 1989, CMD555; Wilson R, 1994, Health Trends, V26, P70; *WORK GROUP SPEC M, 1993, 1992 3 WORK GROUP SP	9	128	128	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					19	24		10.1136/bmj.313.7048.19	http://dx.doi.org/10.1136/bmj.313.7048.19			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664763	Green Published			2022-12-28	WOS:A1996UW66700025
J	Johari, GP; Hallbrucker, A; Mayer, E				Johari, GP; Hallbrucker, A; Mayer, E			Two calorimetrically distinct states of liquid water below 150 kelvin	SCIENCE			English	Article							PRESSURE-INDUCED AMORPHIZATION; HYPERQUENCHED GLASSY WATER; DILUTE AQUEOUS-SOLUTIONS; DENSITY AMORPHOUS WATER; ICE-I; X-RAY; NEUTRON-SCATTERING; MOLECULAR-DYNAMICS; HEXAGONAL ICE; SOLID WATER	Vapor-deposited amorphous solid and hyperquenched glassy water were found to irreversibly transform, on compression at 77 kelvin, to a high-density amorphous solid. On heating at atmospheric pressure, this solid became viscous water (water B), with a reversible glass-liquid transition onset at 129 +/- 2 kelvin. A different form of viscous water (water A) was formed by heating the uncompressed vapor-deposited amorphous solid and hyperquenched liquid water. On thermal cycling up to 148 kelvin, water B remained kinetically and thermodynamically distinct from water A. The occurrence of these two states, which do not interconvert, helps explain both the configurational relaxation of water and stress-induced amorphization.	UNIV INNSBRUCK, INST ALLGEMEINE ANORGAN & THEORET CHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	Johari, GP (corresponding author), MCMASTER UNIV, DEPT MAT SCI & ENGN, HAMILTON, ON L8S 4L7, CANADA.							ANGELL CA, 1993, J PHYS CHEM-US, V97, P6339, DOI 10.1021/j100126a005; BELLISSENTFUNEL MC, 1987, J CHEM PHYS, V87, P2231, DOI 10.1063/1.453150; BLUMBERG RL, 1984, J CHEM PHYS, V80, P5230, DOI 10.1063/1.446593; BOSIO L, 1986, PHYS REV LETT, V56, P460, DOI 10.1103/PhysRevLett.56.460; BRUGGELLER P, 1980, NATURE, V288, P569, DOI 10.1038/288569a0; BUCH V, 1992, J CHEM PHYS, V96, P3814, DOI 10.1063/1.461886; Burton E. F., 1935, P ROY SOC LOND A MAT, V153, P166, DOI 10.1098/rspa.1935.0229; CORONGIU G, 1992, J CHEM PHYS, V97, P2030, DOI 10.1063/1.463140; CORONGIU G, 1993, J CHEM PHYS, V98, P2241, DOI 10.1063/1.464204; FISHER M, 1995, J PHYS CHEM-US, V99, P11584, DOI 10.1021/j100029a041; FLORIANO MA, 1989, J CHEM PHYS, V91, P7187, DOI 10.1063/1.457285; FLORIANO MA, 1986, PHYS REV LETT, V57, P3062, DOI 10.1103/PhysRevLett.57.3062; Geiger A., 1992, ZH STRUKT KHIM, V33, P79; GIGUERE PA, 1987, J CHEM PHYS, V87, P4835, DOI 10.1063/1.452845; HALLBRUCKER A, 1990, J CHEM SOC FARADAY T, V86, P3785, DOI 10.1039/ft9908603785; HALLBRUCKER A, 1989, J PHYS CHEM-US, V93, P4986, DOI 10.1021/j100349a061; HALLBRUCKER A, 1989, J PHYS CHEM-US, V93, P7751, DOI 10.1021/j100360a003; HANDA YP, 1988, J PHYS CHEM-US, V92, P3323, DOI 10.1021/j100323a005; HENN AR, 1989, J PHYS CHEM-US, V93, P3770, DOI 10.1021/j100346a078; JOHARI GP, 1994, J PHYS CHEM-US, V98, P4719, DOI 10.1021/j100068a038; JOHARI GP, 1990, J PHYS CHEM-US, V94, P1212, DOI 10.1021/j100367a003; JOHARI GP, 1990, J CHEM PHYS, V92, P6742, DOI 10.1063/1.458593; JOHARI GP, 1995, J CHEM PHYS, V102, P6224, DOI 10.1063/1.469068; JOHARI GP, 1986, PHILOS MAG B, V54, P311, DOI 10.1080/13642818608239031; JOHARI GP, 1987, NATURE, V330, P552, DOI 10.1038/330552a0; MAYER E, 1985, J PHYS CHEM-US, V89, P3474, DOI 10.1021/j100262a011; MAYER E, 1985, J APPL PHYS, V58, P663, DOI 10.1063/1.336179; MAYER E, 1995, J PHYS CHEM-US, V99, P5161, DOI 10.1021/j100014a041; MAYER E, 1986, J PHYS CHEM-US, V90, P4455, DOI 10.1021/j100409a048; MISHIMA O, 1994, J CHEM PHYS, V100, P5910, DOI 10.1063/1.467103; MISHIMA O, 1985, NATURE, V314, P76, DOI 10.1038/314076a0; MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0; POOLE PH, 1993, PHYS REV E, V48, P4605, DOI 10.1103/PhysRevE.48.4605; POOLE PH, 1993, PHYS REV E, V48, P3799, DOI 10.1103/PhysRevE.48.3799; POOLE PH, 1994, PHYS REV LETT, V73, P1632, DOI 10.1103/PhysRevLett.73.1632; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; SCIORTINO F, 1992, J CHEM PHYS, V96, P3857, DOI 10.1063/1.461890; SCIORTINO F, 1991, NATURE, V354, P218, DOI 10.1038/354218a0; SPEEDY RJ, 1984, J PHYS CHEM-US, V88, P3364, DOI 10.1021/j150659a046; SPEEDY RJ, 1992, J PHYS CHEM-US, V96, P2322, DOI 10.1021/j100184a056; SPEEDY RJ, 1987, J PHYS CHEM-US, V91, P909, DOI 10.1021/j100288a029; SPEEDY RJ, 1985, J PHYS CHEM-US, V89, P171, DOI 10.1021/j100247a035; SPEEDY RJ, 1995, PHYSICAL CHEM AQUEOU, P347; STANLEY HE, 1994, PHYSICA A, V205, P122, DOI 10.1016/0378-4371(94)90495-2; STILLINGER FH, 1980, SCIENCE, V209, P451, DOI 10.1126/science.209.4455.451; Tanaka H, 1996, NATURE, V380, P328, DOI 10.1038/380328a0; TSE JS, 1990, J CHEM PHYS, V92, P3992, DOI 10.1063/1.457812; TSE JS, 1987, PHYS REV LETT, V58, P1672, DOI 10.1103/PhysRevLett.58.1672; TSE JS, 1992, J CHEM PHYS, V96, P5482, DOI 10.1063/1.462732; TSE JS, 1988, J PHYS CHEM-US, V92, P315, DOI 10.1021/j100313a015; WALRAFEN GE, 1995, J PHYS CHEM-US, V99, P10635, DOI 10.1021/j100026a030; WHALLEY E, 1984, NATO ASI SER, V156, P9; WONG CF, 1989, CHEM PHYS LETT, V154, P151, DOI 10.1016/S0009-2614(89)87278-1; ZHANG Q, 1990, J CHEM PHYS, V92, P5004, DOI 10.1063/1.458536	54	103	107	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					90	92		10.1126/science.273.5271.90	http://dx.doi.org/10.1126/science.273.5271.90			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688057				2022-12-28	WOS:A1996UV47800044
J	Subramanian, MA; Toby, BH; Ramirez, AP; Marshall, WJ; Sleight, AW; Kwei, GH				Subramanian, MA; Toby, BH; Ramirez, AP; Marshall, WJ; Sleight, AW; Kwei, GH			Colossal magnetoresistance without Mn3+/Mn4+ double exchange in the stoichiometric pyrochlore Tl2Mn2O7	SCIENCE			English	Article							DIFFRACTION	Structural analysis from powder neutron and single-crystal x-ray diffraction data for a sample of the Tl2Mn2O7 pyrochlore, which exhibits colossal magnetoresistance (CMR), shows no deviations from ideal stoichiometry. This analysis gives an Mn-O distance of 1.90 angstroms, which is significantly shorter than the Mn-O distances (1.94 to 2.00 angstroms) observed in phases based on LaMnO3 perovskites that exhibit CMR, Both results in Tl2Mn2O7 indicate oxidation states very close to Tl-2 + Mn24+O7. Thus, Tl2Mn2O7 has neither mixed valence for a double-exchange magnetic interaction nor a Jahn-Teller cation such as Mn3+, both of which were thought to have an important function in CMR materials. An alternate mechanism for CMR in Tl2Mn2O7 based on magnetic ordering driven by superexchange and strong spin-fluctuation scattering above the Curie temperature is proposed here.	NATL INST STAND & TECHNOL, DIV REACTOR RADIAT, GAITHERSBURG, MD 20899 USA; AT&T BELL LABS, LUCENT TECHNOL, MURRAY HILL, NJ 07974 USA; OREGON STATE UNIV, DEPT CHEM, CORVALLIS, OR 97331 USA; LAWRENCE LIVERMORE NATL LAB, DEPT CHEM & MAT SCI, LIVERMORE, CA 94550 USA	National Institute of Standards & Technology (NIST) - USA; Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs; Oregon State University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Subramanian, MA (corresponding author), DUPONT CO INC, CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA.		Subramanian, Mas A./E-2002-2011; Toby, Brian H/F-3176-2013; Ramirez, Arthur/HGD-6619-2022	Toby, Brian H/0000-0001-8793-8285; 				ANDERSON PW, 1955, PHYS REV, V100, P675, DOI 10.1103/PhysRev.100.675; DEGENNES PG, 1960, PHYS REV, V118, P141, DOI 10.1103/PhysRev.118.141; FISHER ME, 1968, PHYS REV LETT, V20, P665, DOI 10.1103/PhysRevLett.20.665; FUJINAKA H, 1979, MATER RES BULL, V14, P1133, DOI 10.1016/0025-5408(79)90207-1; GOODENOUGH JB, 1976, MAGNETISM CHEM BOND, P184; JARRETT HS, 1977, VALENCE INSTABILITIE, P545; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; JIRAK Z, 1985, J MAGN MAGN MATER, V53, P153, DOI 10.1016/0304-8853(85)90144-1; JONKER GH, 1956, PHYSICA, V22, P707, DOI 10.1016/S0031-8914(56)90023-4; JONKER GH, 1950, PHYSICA, V16, P337, DOI 10.1016/0031-8914(50)90033-4; Larson A., 1986, LAUR86748 LOS AL NAT; LE BAIL A, 1988, MATER RES BULL, V23, P447, DOI 10.1016/0025-5408(88)90019-0; LIU NLH, 1979, PHYS REV LETT, V42, P71, DOI 10.1103/PhysRevLett.42.71; MILLIS AJ, 1995, PHYS REV LETT, V74, P5144, DOI 10.1103/PhysRevLett.74.5144; RAJU NP, 1994, PHYS REV B, V49, P1086, DOI 10.1103/PhysRevB.49.1086; Roder H, 1996, PHYS REV LETT, V76, P1356, DOI 10.1103/PhysRevLett.76.1356; ROSENFELD HD, UNPUB; SCHIFFER P, 1995, PHYS REV LETT, V75, P3336, DOI 10.1103/PhysRevLett.75.3336; SEARLE CW, 1969, CAN J PHYS, V47, P2703, DOI 10.1139/p69-329; SEARLE CW, 1970, CAN J PHYS, V48, P2023, DOI 10.1139/p70-257; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Shimakawa Y, 1996, NATURE, V379, P53, DOI 10.1038/379053a0; SHIRANE G, 1959, ACTA CRYSTALLOGR, V12, P282, DOI 10.1107/S0365110X59000871; Subramanian M., 1993, HANDB PHYSI, V16, P225; SUBRAMANIAN MA, 1983, PROG SOLID STATE CH, V15, P55, DOI 10.1016/0079-6786(83)90001-8; SUBRAMANIAN MA, 1988, J SOLID STATE CHEM, V72, P24, DOI 10.1016/0022-4596(88)90004-7; VOLGER J, 1954, PHYSICA, V20, P49, DOI 10.1016/S0031-8914(54)80015-2; VONMOLNA.S, 1967, J APPL PHYS, V38, P959, DOI 10.1063/1.1709702; WOLLAN EO, 1955, PHYS REV, V100, P545, DOI 10.1103/PhysRev.100.545; ZENER C, 1951, PHYS REV, V82, P403, DOI 10.1103/PhysRev.82.403	30	296	300	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1996	273	5271					81	84		10.1126/science.273.5271.81	http://dx.doi.org/10.1126/science.273.5271.81			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688054	Green Submitted			2022-12-28	WOS:A1996UV47800041
J	Mummenbrauer, T; Janus, F; Muller, B; Wiesmuller, L; Deppert, W; Grosse, F				Mummenbrauer, T; Janus, F; Muller, B; Wiesmuller, L; Deppert, W; Grosse, F			p53 protein exhibits 3'-to-5' exonuclease activity	CELL			English	Article							WILD-TYPE P53; POLYMERASE-ALPHA-PRIMASE; DNA MISMATCH CORRECTION; NUCLEAR ACCUMULATION; GENE-EXPRESSION; BINDING-SITE; CALF THYMUS; REPLICATION; GROWTH; REPAIR	Highly purified p53 protein from different sources was able to degrade DNA with a 3'-to-5' polarity, yielding deoxynucleoside monophosphates as reaction products. This exonuclease activity was dependent on Mg2+ and inhibited by addition of 5 mM nucleoside monophosphates. This exonuclease activity is intrinsic to the wild-type p53 protein: it copurified with p53 during p53 preparation; only purified wild-type p53, but not identically purified mutant p53 proteins displayed exonuclease activity; the exonuclease activity could be reconstituted from SDS gel-purified and urea-renatured p53 protein and mapped to the core domain of the p53 molecule; and finally, purified p53 protein could be UV cross-linked to GMP. A p53-intrinsic exonuclease activity should substantially extend our view on the role of p53 as a ''guardian of the genome.''	INST MOL BIOTECHNOL,BIOCHEM ABT,D-07745 JENA,GERMANY		Mummenbrauer, T (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,D-20251 HAMBURG,GERMANY.							BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BIALEK G, 1993, J BIOL CHEM, V268, P6024; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BRAIN R, 1994, ONCOGENE, V9, P1775; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Grosse Frank, 1993, V16, P95; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOHN KT, 1987, BIOCHEMISTRY-US, V26, P2870, DOI 10.1021/bi00384a031; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kornberg A., 1991, DNA REPLICATION; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linn S.M., 1993, NUCLEASES; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P371; MIYASHITA T, 1995, CELL, V80, P293; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MULLER B, 1996, IN PRESS ONCOGENE; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RADMAN M, 1993, NATURE, V366, P722, DOI 10.1038/366722a0; ROLLEY N, 1995, ONCOGENE, V11, P763; Sambrook J., 2002, MOL CLONING LAB MANU; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEINMEYER K, 1988, ONCOGENE, V3, P501; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wiesmuller L, 1996, J VIROL, V70, P737; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	82	238	239	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1089	1099		10.1016/S0092-8674(00)81309-4	http://dx.doi.org/10.1016/S0092-8674(00)81309-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674115	Bronze			2022-12-28	WOS:A1996UV48400015
J	Pascu, O; Duca, S				Pascu, O; Duca, S			Randomised trial of laparoscopic versus small-incision cholecystectomy - Reply	LANCET			English	Letter											Pascu, O (corresponding author), 3RD MED & SURG CLIN,DEPT GASTROENTEROL,R-3400 CLUJ NAPOCA,ROMANIA.							GERALD MF, 1994, AM J SURG, V167, P35; VARGAS C, 1995, AM J GASTROENTEROL, V90, P1258; WAYAND W, 1996, AUSTR EXPERIENCE PRO, V22, P63	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1624	1624						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667891				2022-12-28	WOS:A1996UP66100049
J	Lacomblez, L; Bensimon, G; Leigh, PN; Guillet, P; Meininger, V				Lacomblez, L; Bensimon, G; Leigh, PN; Guillet, P; Meininger, V			Dose-ranging study of riluzole in amyotrophic lateral sclerosis	LANCET			English	Article								Background Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective treatment. In an initial study, riluzole decreased mortality and slowed muscle-strength deterioration in ALS patients. We have carried out a double-blind, placebo-controlled, multicentre study to confirm those findings and to assess drug efficacy at different doses. Methods 959 patients with clinically probable or definite ALS of less than 5 years' duration were randomly assigned treatment with placebo or 50 mg, 100 mg, or 200 mg riluzole daily; randomisation was stratified by centre and site of disease onset (bulbar or limb). The primary outcome was survival without a tracheostomy. Secondary outcomes were rates of change in functional measures (muscle strength, functional status, respiratory function, patient's assessments of fasciculation, cramps, stiffness, and tiredness). The primary analysis was the comparison of the 100 mg dose with placebo by intention-to-treat. Drug-effect on survival was assessed before (log-rank test) and after adjustment for known prognostic factors (Cox's model). Findings At the end of the study, after median follow-up of 18 months, 122 (50 . 4%) placebo-treated patients and 134 (56 . 8%) of those who received 100 mg/day riluzole were alive without tracheostomy (unadjusted risk 0 . 79, p=0 . 076; adjusted risk 0 . 65, p=0 . 002). In the groups receiving 50 mg and 200 mg riluzole daily, 131 (55 . 3%) and 141 (57 . 8%) patients were alive without tracheostomy (relative to placebo 50 mg adjusted risk 0 . 76, p=0 . 04; 200 mg 0 . 61, p=0 . 0004). There was a significant inverse dose response in risk of death. No functional scale discriminated between the treatment groups. The most common adverse reactions were asthenia, dizziness, gastrointestinal disorders, and rises in liver enzyme activities; they were commonest with the 200 mg dose. Interpretation Overall, efficacy and safety results suggest that the 100 mg dose of riluzole has the best benefit-to-risk ratio. This study confirms that riluzole is well tolerated and lengthens survival of patients with ALS.	HOP LA PITIE SALPETRIERE, DIV MAZARIN, SERV NEUROL, DEPT NEUROL, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, DEPT PHARMACOL, F-75651 PARIS 13, FRANCE; INST PSYCHIAT, DEPT NEUROSCI, LONDON SE5 8AF, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON WC2R 2LS, ENGLAND; RHONE POULENC RORER, ANTONY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; King's College London; University of London; King's College London; Sanofi-Aventis			Leigh, Peter/AAD-5638-2019					[Anonymous], 1992, DESIGN ANAL SEQUENTI; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; COURATIER P, 1994, NEUROREPORT, V5, P1012, DOI 10.1097/00001756-199404000-00040; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; EISEN A, 1993, MUSCLE NERVE, V16, P27, DOI 10.1002/mus.880160107; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; HUBERT JP, 1994, BRIT J PHARMACOL, V113, P261, DOI 10.1111/j.1476-5381.1994.tb16203.x; JABLECKI CK, 1989, MUSCLE NERVE, V12, P833, DOI 10.1002/mus.880121008; KONDO K, 1984, Neuroepidemiology, V3, P129, DOI 10.1159/000110849; KURTZKE JF, 1991, ADV NEUROL, V56, P245; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MALGOURIS C, 1994, NEUROSCI LETT, V177, P95, DOI 10.1016/0304-3940(94)90053-1; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; MELDRUM B, 1993, BRAIN RES REV, V18, P293, DOI 10.1016/0165-0173(93)90014-Q; NORRIS F, 1993, J NEUROL SCI, V118, P48, DOI 10.1016/0022-510X(93)90245-T; PETO R, 1982, TREATMENT CANCER, P868; ROTHSTEIN JD, 1995, ADV NEUROL, V68, P7; SHAW PJ, 1994, J NEUROL SCI, V124, P6, DOI 10.1016/0022-510X(94)90170-8; TARONE RE, 1975, BIOMETRIKA, V62, P679; TYSNES OB, 1994, NEUROEPIDEMIOLOGY, V13, P226, DOI 10.1159/000110384; Woods JH, 1991, EXCITATORY AMINO ACI, P237; WU MC, 1988, BIOMETRICS, V44, P175, DOI 10.2307/2531905	25	939	969	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1996	347	9013					1425	1431		10.1016/S0140-6736(96)91680-3	http://dx.doi.org/10.1016/S0140-6736(96)91680-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676624				2022-12-28	WOS:A1996UM48500007
J	Haigh, JD				Haigh, JD			The impact of solar variability on climate	SCIENCE			English	Article							GENERAL-CIRCULATION MODEL; MIDDLE ATMOSPHERE; CYCLE; OZONE; IRRADIANCE	A general circulation model that simulated changes in solar irradiance and stratospheric ozone was used to investigate the response of the atmosphere to the 11-year solar activity cycle. At solar maximum, a warming of the summer stratosphere was found to strengthen easterly winds, which penetrated into the equatorial upper troposphere, causing poleward shifts in the positions of the subtropical westerly jets, broadening of the tropical Hadley circulations, and poleward shifts of the storm tracks, These effects are similar to, although generally smaller in magnitude than, those observed in nature. A simulation in which only solar irradiance was changed showed a much weaker response.			Haigh, JD (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,LONDON SW7 2BZ,ENGLAND.		Haigh, Joanna D/F-6847-2014	Haigh, Joanna D/0000-0001-5504-4754				BALACHANDRAN NK, 1995, J CLIMATE, V8, P2058, DOI 10.1175/1520-0442(1995)008<2058:MTEOUV>2.0.CO;2; BROWN GM, 1979, J ATMOS TERR PHYS, V41, P43, DOI 10.1016/0021-9169(79)90045-X; CHANDRA S, 1991, GEOPHYS RES LETT, V18, P837, DOI 10.1029/91GL00850; CHANG EKM, 1995, J ATMOS SCI, V52, P2006, DOI 10.1175/1520-0469(1995)052<2006:TIOHCI>2.0.CO;2; FLEMING EL, 1995, J ATMOS TERR PHYS, V57, P333, DOI 10.1016/0021-9169(94)E0013-D; GARCIA RR, 1984, PLANET SPACE SCI, V32, P411, DOI 10.1016/0032-0633(84)90121-1; HAIGH JD, 1994, NATURE, V370, P544, DOI 10.1038/370544a0; Herschel W., 1801, PHILOS T R SOC LOND, V91, P265, DOI [10.1098/rstl.1801.0015, DOI 10.1098/RSTL.1801.0015]; HOOD LL, 1993, J ATMOS SCI, V50, P3941, DOI 10.1175/1520-0469(1993)050<3941:QDVOTS>2.0.CO;2; HOOD LL, 1992, GEOPHYS RES LETT, V19, P2309, DOI 10.1029/92GL02638; HOOD LL, 1986, J GEOPHYS RES-ATMOS, V91, P5264, DOI 10.1029/JD091iD04p05264; HOOD LL, IN PRESS J GEOPHYS R; HUANG TYW, 1993, J GEOPHYS RES-ATMOS, V98, P20413, DOI 10.1029/93JD02187; JAMES IN, 1994, INTRO CIRCULATING AT; KODERA K, 1991, GEOPHYS RES LETT, V18, P1209, DOI 10.1029/91GL01610; KODERA K, 1995, J GEOPHYS RES-ATMOS, V100, P14077, DOI 10.1029/95JD01172; LABITZKE K, 1992, J CLIMATE, V5, P240, DOI 10.1175/1520-0442(1992)005<0240:ABTYSC>2.0.CO;2; LABITZKE K, 1994, METEOROL, V3, P259; LEAN J, 1991, REV GEOPHYS, V29, P505, DOI 10.1029/91RG01895; LEAN J, 1989, SCIENCE, V244, P197, DOI 10.1126/science.244.4901.197; MORCRETTE JJ, 1991, J GEOPHYS RES-ATMOS, V96, P9121, DOI 10.1029/89JD01597; NESMERIBES E, 1993, J GEOPHYS RES-SPACE, V98, P18923, DOI 10.1029/93JA00305; RIND D, 1995, J CLIMATE, V8, P2080, DOI 10.1175/1520-0442(1995)008<2080:MTEOUV>2.0.CO;2; RIND D, 1993, QUATERNARY SCI REV, V12, P357, DOI 10.1016/S0277-3791(05)80002-2; SLINGO J, 1994, Q J ROY METEOR SOC, V120, P881, DOI 10.1002/qj.49712051807; WETHERALD RT, 1975, J ATMOS SCI, V32, P2044, DOI 10.1175/1520-0469(1975)032<2044:TEOCTS>2.0.CO;2	26	520	547	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					981	984		10.1126/science.272.5264.981	http://dx.doi.org/10.1126/science.272.5264.981			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8662582				2022-12-28	WOS:A1996UL61900036
J	Binzel, RP; Bus, SJ; Burbine, TH; Sunshine, JM				Binzel, RP; Bus, SJ; Burbine, TH; Sunshine, JM			Spectral properties of near-Earth asteroids: Evidence for sources of ordinary chondrite meteorites	SCIENCE			English	Article							SPECTROSCOPY; DISCOVERY	Although ordinary chondrite (OC) meteorites dominate observed falls, the identification of near-Earth and main-belt asteroid sources has remained elusive, Telescopic measurements of 35 near-Earth asteroids (similar to 3 kilometers in diameter) revealed six that have visible wavelength spectra similar to laboratory spectra of OC meteorites. Near-Earth asteroids were found to have spectral properties that span the range between the previously separated domains of OC meteorites and the most common (S class) asteroids, suggesting a link. This range of spectral properties could arise through a diversity of mineralogies and regolith particle sizes, as well as through a time-dependent surface weathering process.	SCI APPLICAT INT CORP,CHANTILLY,VA 22021	Science Applications International Corporation (SAIC)	Binzel, RP (corresponding author), MIT,DEPT EARTH ATMOSPHER & PLANETARY SCI,CAMBRIDGE,MA 02139, USA.			Sunshine, Jessica/0000-0002-9413-8785				Bell J.F., 1989, ASTEROIDS, P921; BINZEL RP, 1993, SCIENCE, V262, P1541, DOI 10.1126/science.262.5139.1541; BINZEL RP, 1992, SCIENCE, V257, P779, DOI 10.1126/science.257.5071.779; BINZEL RP, 1993, SCIENCE, V260, P186, DOI 10.1126/science.260.5105.186; BINZEL RP, UNPUB; BURNS RG, 1983, MINERALOGICAL APPLIC; CHAPMAN C, UNPUB; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; DAVIS DR, 1989, ASTEROIDS, V2, P805; DIMARTINO M, 1995, ASTRON ASTROPHYS, V302, P609; Gaffey M.J., 1989, ASTEROIDS, P98; GAFFEY MJ, 1993, METEORITICS, V28, P161, DOI 10.1111/j.1945-5100.1993.tb00755.x; GAFFEY MJ, 1976, J GEOPHYS RES, V81, P905, DOI 10.1029/JB081i005p00905; GAFFEY MJ, 1993, ICARUS, V106, P573, DOI 10.1006/icar.1993.1194; GAFFEY MJ, 1984, ICARUS, V60, P83, DOI 10.1016/0019-1035(84)90140-4; GAFFEY MJ, 1996, LUNAR PLANET SCI, V27, P391; MCFADDEN LA, 1985, SCIENCE, V229, P160, DOI 10.1126/science.229.4709.160; MCSWEEN HY, 1987, METEORITES THEIR SOU; PIETERS CM, 1984, METEORITICS, V19, P290; PIETERS CM, 1993, J GEOPHYS RES-PLANET, V98, P20817, DOI 10.1029/93JE02467; Tholen D.J., 1989, ASTEROIDS, VII, P298; Wetherill G., 1988, METEORITES EARLY SOL, P35; WETHERILL GW, 1987, PHILOS T R SOC A, V323, P323, DOI 10.1098/rsta.1987.0089; WISDOM J, 1985, NATURE, V315, P731, DOI 10.1038/315731a0; WISDOM J, 1983, ICARUS, V56, P51, DOI 10.1016/0019-1035(83)90127-6; XU S, 1995, ICARUS, V115, P1, DOI 10.1006/icar.1995.1075; ZELLNER B, 1985, ICARUS, V61, P355, DOI 10.1016/0019-1035(85)90133-2	27	109	110	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					946	948		10.1126/science.273.5277.946	http://dx.doi.org/10.1126/science.273.5277.946			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688076				2022-12-28	WOS:A1996VC67000059
J	Omont, A; Petitjean, P; Guilloteau, S; McMahon, RG; Solomon, PM; Pecontal, E				Omont, A; Petitjean, P; Guilloteau, S; McMahon, RG; Solomon, PM; Pecontal, E			Molecular gas and dust around a radio-quiet quasar at redshift 4.69	NATURE			English	Article							GALAXY IRAS 10214+4724; EMISSION; MASS; F10214+4724	GALAXIES are believed to have formed a large proportion of their stars in giant bursts of star formation early in their lives, but when and how this took place are still very uncertain. The presence(1-6) of large amounts of dust in quasars and radio galaxies at redshifts z > 4 shows that some synthesis of heavy elements had already occurred at this time. This implies that molecular gas-the building material of stars-should also be present, as it is in galaxies at lower redshifts (z approximate to 2.5, refs 7-10). Here we report the detection of emission from dust and carbon monoxide in the radio-quiet quasar BR1202 - 0725, at redshift z = 4.69. Maps of these emissions reveal two objects, separated by a few are seconds, which could indicate either the presence of a companion to the quasar of gravitational lensing of the quasar itself. Regardless of the precise interpretation of the maps, the detection of carbon monoxide confirms the presence of a large mass of molecular gas in one of the most distant galaxies known, and shows that conditions conducive to huge bursts of star formation existed in the very early Universe.	OBSERV PARIS,DAEC,CNRS,URA 173,F-92195 MEUDON,FRANCE; INST RADIO ASTRON MILLIMETR,F-38460 ST MARTIN DHERES,FRANCE; INST ASTRON,CAMBRIDGE CB3 0HA,ENGLAND; SUNY STONY BROOK,ASTRON PROGRAM,STONY BROOK,NY 11794; CTR RECH ASTRON LYON,CNRS,UMR 142,F-69561 ST GENIS LAVAL,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Cambridge; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Centre National de la Recherche Scientifique (CNRS)	Omont, A (corresponding author), CNRS,INST ASTROPHYS,98BIS BD ARAGO,F-75014 PARIS,FRANCE.		McMahon, Richard/G-4260-2012	McMahon, Richard/0000-0001-8447-8869				BARVAINIS R, 1994, NATURE, V371, P586, DOI 10.1038/371586a0; BARVAINIS R, IN PRESS COLD GAS HI; BROADHURST T, 1995, ASTROPHYS J, V450, pL41, DOI 10.1086/316774; BROWN RL, 1992, ASTROPHYS J, V397, pL19, DOI 10.1086/186534; CHINI R, 1994, ASTRON ASTROPHYS, V288, pL33; DJORGOVSKI S, 1992, MON NOT R ASTRON SOC, V257, P240, DOI 10.1093/mnras/257.2.240; Djorgovski S. G., 1995, Science with VLT. Proceedings of the ESO Workshop, P351; DOWNES D, 1992, ASTROPHYS J, V398, pL25, DOI 10.1086/186568; DOWNES D, 1993, ASTROPHYS J, V414, pL13, DOI 10.1086/186984; DOWNES D, 1995, ASTROPHYS J, V453, pL65, DOI 10.1086/309754; DUNLOP JS, 1994, NATURE, V370, P347, DOI 10.1038/370347a0; Eisenhardt PR, 1996, ASTROPHYS J, V461, P72, DOI 10.1086/177038; Elston R, 1996, ASTROPHYS J, V456, pL13, DOI 10.1086/309853; FONTANA A, IN PRESS MON NOT R A; FRANCESCHINI A, UNPUB MON NOT R ASTR; HAEHNELT MG, 1993, MON NOT R ASTRON SOC, V263, P168, DOI 10.1093/mnras/263.1.168; Hu EM, 1996, ASTROPHYS J, V459, pL53, DOI 10.1086/309958; ISAAK KG, 1994, MON NOT R ASTRON SOC, V269, pL28, DOI 10.1093/mnras/269.1.L28; IVISON RJ, 1995, MON NOT R ASTRON SOC, V275, pL33, DOI 10.1093/mnras/275.1.L33; Lu LM, 1996, ASTROPHYS J, V457, pL1; MAGAIN P, 1988, NATURE, V334, P325, DOI 10.1038/334325a0; MCMAHON RG, 1994, MON NOT R ASTRON SOC, V267, pL9, DOI 10.1093/mnras/267.1.L9; OMONT A, IN PRESS ASTR ASTROP; Petitjean P, 1996, NATURE, V380, P411, DOI 10.1038/380411a0; SCOVILLE NZ, IN PRESS COLD GAS HI; SOLOMON PM, 1992, ASTROPHYS J, V398, pL29, DOI 10.1086/186569; SOLOMON PM, IN PRESS ASTROPHYS J; STORRIELOMBARDI LJ, IN PRESS ASTROPHYS J; VARVAINIS R, 1995, ASTROPHYS J, V451, pL9; WAMPLER EJ, IN PRESS ASTR ASTROP	30	237	237	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					428	431		10.1038/382428a0	http://dx.doi.org/10.1038/382428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684483	Green Submitted			2022-12-28	WOS:A1996VA25100049
J	Berger, D; Fukunishi, I				Berger, D; Fukunishi, I			Psychiatric drug development in Japan	SCIENCE			English	Editorial Material									ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Berger, D (corresponding author), TOKYO INST PSYCHIAT, SETAGAYA KU, 2-1-8 KAMIKITAZAWA, TOKYO 156, JAPAN.							ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; FUKUSHIMA M, 1989, NATURE, V342, P850, DOI 10.1038/342850a0; HAYASHI K, 1995, MED ASAHI, V24, P43; LIN KM, 1988, J CLIN PSYCHOPHARM, V8, P195; MIZUSHIMA Y, 1995, NIHON ENSHOU GAKKAI, V15, P93; MIZUSHIMA Y, 1995, NIHON ENSHOU GAKKAI, V15, P193; OKADA F, 1993, HUM PSYCHOPHARM CLIN, V8, P371, DOI 10.1002/hup.470080512; OKADA F, 1995, ANN PHARMACOTHER, V29, P432, DOI 10.1177/106002809502900419; PICKAR D, 1995, JAMA-J AM MED ASSOC, V274, P981; 1996, ASAHI SHINBUN   0229, P39; 1995, ASAHI SHINBUN   1107, P2; 1994, NATURE, V371, P89	12	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	1996	273	5273					318	319		10.1126/science.273.5273.318	http://dx.doi.org/10.1126/science.273.5273.318			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UY202	8685717				2022-12-28	WOS:A1996UY20200025
J	Marshall, FF				Marshall, FF			Is nephron-sparing surgery appropriate for a small renal-cell carcinoma?	LANCET			English	Editorial Material											Marshall, FF (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BRADY UROL INST,BALTIMORE,MD 21287, USA.							BELL ET, 1950, RENAL DISEASES, P435; Eschwege P, 1996, J UROLOGY, V155, P1196, DOI 10.1016/S0022-5347(01)66213-X; LICHT MR, 1993, J UROLOGY, V149, P1; POLASCIK TJ, 1995, J UROLOGY, V154, P1312, DOI 10.1016/S0022-5347(01)66845-9; POLASCIK TJ, 1995, J UROLOGY, V154, P1676, DOI 10.1016/S0022-5347(01)66748-X; ROBSON CJ, 1969, J UROLOGY, V101, P297, DOI 10.1016/S0022-5347(17)62331-0; STEINBACH F, 1992, J UROLOGY, V148, P24, DOI 10.1016/S0022-5347(17)36499-6; STOCKLE M, 1996, PARENCHYMA SAVING SU	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					72	73						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676717				2022-12-28	WOS:A1996UW67300005
J	Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V				Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V			Likelihood ratios for modern screening mammography - Risk of breast cancer based on age and mammographic interpretation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY HISTORY; MEDICAL AUDIT; COMMUNITY	Objective.-To determine the sensitivity, specificity, and likelihood ratios (LRs) for modern screening mammography by decade of age and mammographic interpretation. Design.-Cross-sectional. Setting.-Nine counties in northern California. Participants.-A total of 26 057 women aged 30 years and older who underwent a total of 41 747 first and subsequent screening mammographic examinations at the Mobile Mammography Screening Program of the University of California, San Francisco, from April 1985 to September 1991. Measurements.-Breast cancer risk profile, 2 standard mammographic views per breast, and follow-up of abnormal and normal mammograms by contacting women's physicians and by linkage to the regional Surveillance, Epidemiology, and End Results tumor registry. False-negative examinations were normal examinations that occurred within 13 months of a diagnosis of invasive breast cancer or ductal carcinoma in situ. Results.-The sensitivity of first screening mammography increased with age: 77.3% for ages 30 to 39 years, 86.7% for ages 40 to 49 years, 93.6% for ages 50 to 59 years, 94.1% for ages 60 to 69 years, and 91.?% for ages 70 years and older (P=.04). Specificity was similar for all ages, ranging from 92.6% to 95.2%. Of all abnormal first screening examinations, 92.9% were reported as ''additional evaluation needed.'' The LRs for that category ranged from 5.2 to 8.8 and did not vary with age. Based on the risk of breast cancer before mammography, which increases with age, the risk of breast cancer after mammography associated with these LRs were 0.01 for ages 30 to 39 years, 0.02 for ages 40 to 49 years, 0.05 for ages 50 to 59 years, 0.07 for ages 60 to 69 years, and 0.07 for ages 70 years and older. The LRs for mammography reported as ''suspicious for malignancy'' ranged from 88 to 144 and did not vary across age groups. These LRs were associated with a risk of breast cancer about 10 times greater than when mammography was reported as ''additional evaluation needed.'' Conclusions.-Most abnormal first screening mammography are interpreted as ''additional evaluation needed'' and are associated with LRs of about 7. Given this low LR, the risk of breast cancer after mammography is primarily influenced by a woman's age-specific risk of breast cancer before mammography. The LRs for screening mammography interpreted as ''suspicious for malignancy'' are high (about 124) and are associated with a substantial increase in the risk of breast cancer irrespective of age, but these interpretations comprise only a small proportion of abnormal mammagraphy.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS,GEN INTERNAL MED SECT,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [1 O1 CA63740, CA58207-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BURHENNE HJ, 1994, AM J ROENTGENOL, V162, P1067, DOI 10.2214/ajr.162.5.8165983; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FRANKEL SD, 1995, AM J ROENTGENOL, V164, P1107, DOI 10.2214/ajr.164.5.7717214; GIARD RWM, 1993, CYTOPATHOLOGY, V4, P131, DOI 10.1111/j.1365-2303.1993.tb00078.x; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HARRIS R, 1995, ANN INTERN MED, V122, P550; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; RUSSELL LB, 1994, SCREENING PROSTATE C, P30; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SIENKO DG, 1993, CANCER-AM CANCER SOC, V71, P1801, DOI 10.1002/1097-0142(19930301)71:5<1801::AID-CNCR2820710515>3.0.CO;2-W; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SMART CR, 1995, CANCER, V76, P2788; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; 1992, BRIT MED J, V304, P346; 1992, MMWR-MORBID MORTAL W, V41, P17	26	127	129	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					39	43		10.1001/jama.276.1.39	http://dx.doi.org/10.1001/jama.276.1.39			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667537				2022-12-28	WOS:A1996UU43900025
J	Nightingale, SL				Nightingale, SL			HIV home test system approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKLAND,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					14	14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667525				2022-12-28	WOS:A1996UU43900007
J	Arnold, WN				Arnold, WN			King George III's urine and indigo blue	LANCET			English	Article											Arnold, WN (corresponding author), UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.							BRODE WR, 1954, J AM CHEM SOC, V76, P1034, DOI 10.1021/ja01633a033; DEALLER SF, 1988, J CLIN MICROBIOL, V26, P2125; Dean G, 1971, PORPHYRIAS STORY INH; DRUMMOND KN, 1964, AM J MED, V37, P928, DOI 10.1016/0002-9343(64)90134-2; FORDTRAN JS, 1964, J LAB CLIN MED, V64, P125; GEHAUF B, 1957, ANAL CHEM, V29, P276, DOI 10.1021/ac60122a029; GUILBAULT GG, 1965, ANAL CHEM, V37, P120, DOI 10.1021/ac60220a031; HALFORD H, 1833, ESSAYS ORATIONS READ; JEPSON JB, 1972, METABOLIC BASIS INHE, P1486; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; LUDWIG GD, 1961, ANN INTERN MED, V55, P81, DOI 10.7326/0003-4819-55-1-81; MACALPINE I, 1966, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.5479.65; Macalpine I., 1968, PORPHYRIA ROYAL MALA; Macalpine Ida, 1969, GEORGE 3 MAD BUSINES, P3; MARKO AM, 1960, CAN J BIOCHEM PHYS, V38, P253; MUNK W, 1895, LIFE H HALFORD; PRICE JM, 1959, NEUROLOGY, V9, P456, DOI 10.1212/WNL.9.7.456; RIMINGTON C, 1946, BIOCHEM J, V40, P669, DOI 10.1042/bj0400669; RODNIGHT R, 1955, J MENT SCI, V101, P884, DOI 10.1192/bjp.101.425.884; SPRINCE H, 1961, CLIN CHEM, V7, P203; WESTALL RG, 1952, NATURE, V170, P614, DOI 10.1038/170614a0; WOOD WA, 1947, J BIOL CHEM, V170, P313	22	31	31	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1811	1813		10.1016/S0140-6736(96)91622-0	http://dx.doi.org/10.1016/S0140-6736(96)91622-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667928				2022-12-28	WOS:A1996UU46900015
J	Doyle, DA; Lee, A; Lewis, J; Kim, E; Sheng, M; MacKinnon, R				Doyle, DA; Lee, A; Lewis, J; Kim, E; Sheng, M; MacKinnon, R			Crystal structures of a complexed and peptide-free membrane protein-binding domain: Molecular basis of peptide recognition by PDZ	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; HOMOLOG	Modular PDZ domains, found in many cell junction-associated proteins, mediate the clustering of membrane ion channels by binding to their C-terminus. The X-ray crystallographic structures of the third PDZ domain from the synaptic protein PSD-95 in complex with and in the absence of its peptide ligand have been determined at 1.8 Angstrom and 2.3 Angstrom resolution, respectively. The structures reveal that a four-residue C-terminal stretch (X-Thr/Ser-X-Val-COO-) engages the PDZ domain through antiparallel main chain interactions with a beta sheet of the domain. Recognition of the terminal carboxylate group of the peptide is conferred by a cradle of main chain amides provided by a Gly-Leu-Gly-Phe loop as well as by an arginine side chain. Specific side chain interactions and a prominent hydrophobic pocket explain the selective recognition of the C-terminal consensus sequence.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Doyle, DA (corresponding author), ROCKEFELLER UNIV,LAB MOL NEUROBIOL & BIOPHYS,NEW YORK,NY 10021, USA.		Kim, Eunjoon/C-1566-2011	Sheng, Morgan/0000-0002-8703-5366				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; HALL AV, 1994, J BIOL CHEM, V269, P33082; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; JESAITIS LA, 1994, J CELL BIOL, V124, P946; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIEGEL TM, 1993, BIOCHEMISTRY-US, V33, P148; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURIYAN J, 1993, CURR SCI INDIA, V64, P85; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niethammer M, 1996, J NEUROSCI, V16, P2157; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; THEISEN H, 1994, DEVELOPMENT, V120, P347; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANG B, 1994, J BIOL CHEM, V269, P6040; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	39	942	989	1	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1067	1076		10.1016/S0092-8674(00)81307-0	http://dx.doi.org/10.1016/S0092-8674(00)81307-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674113	Bronze			2022-12-28	WOS:A1996UV48400013
J	Murray, V; Walker, HW; Mitchell, C; Pelosi, AJ				Murray, V; Walker, HW; Mitchell, C; Pelosi, AJ			Needs for care from a demand led community psychiatric service: A study of patients with major mental illness	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure needs for care of patients aged 18-65 years with major; mental illness. Design-Identification of everyone in one area seen by a health professional within the previous five years because of a psychotic disorder. Interview of a one in three sample of patients and their main carers with the cardinal needs schedule. Setting-Hamilton, a socially deprived district of Scotland. Subjects-71 subjects were interviewed from the original sample of 263 patients. Main outcome measures-''Cardinal problems'' in seven clinical and eight social areas of functioning; these are defined as problems requiring action. ''Needs''-cardinal problems for which suitable interventions exist but have not been tried recently. Results High levels of morbidity were found. 30 interviewed patients (42%; 95% confidence interval 31% to 54%) had one or more clinical needs. 35 (49%; 38% to 61%) had one or more social needs. Skills to deal with all but seven needs in the sample were available at the time of investigation. Patients not being seen by the community mental health team were similar in severity and levels of need to those who were on the community team's caseload. Care was unequivocally and severely inadequate for four patients. Shortcomings in service delivery usually arose from failure to monitor some patients at home. Problems were not due to shortage of acute psychiatric beds nor the absence of an elaborate assertive community care team. Conclusions-Systematic assessment of needs with research instruments can give valuable insights into the successes and failures of community care of people with major mental illness. Most needs could be dealt with in these patients but in our area (and probably most other parts of the United Kingdom) this would entail diversion of resources from people with less severe disorders.	HAIRMYRES HOSP,LANARKSHIRE HEALTHCARE NHS TRUST,E KILBRIDE G75 8RG,LANARK,SCOTLAND	University Hospital Hairmyres				Pelosi, Anthony/0000-0002-5501-2661				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BAKER R, 1988, SCHIZOPHRENIA BULL, V14, P97, DOI 10.1093/schbul/14.1.97; Bhugra D., 1993, PRINCIPLES SOCIAL PS; Carstairs V., 1991, DEPRIVATION HLTH SCO; *CONF INQ HOM SUIC, 1994, HOM; DEAN C, 1994, SLOW TRAIN COMING BR; *DEP HLTH, 1994, INTR SUP REG MENT IL; EASTMAN N, 1995, BRIT MED J, V310, P1081, DOI 10.1136/bmj.310.6987.1081; FAULKNER A, 1994, SURVEY ADULT MENTAL; GRINSTEAD P, 1993, HOSP DOCTOR, P32; HOULT J, 1990, RECENT ADV CRISIS IN, V1, P45; JOHNSTONE EC, 1991, DISABILITIES CIRCUMS; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; Leff J., 1991, EVALUATION COMPREHEN, P79; Lelliot P., 1995, PSYCHIAT B, V19, P273; MACDONALD NJ, 1989, BRIT MED J, V299, P1426, DOI 10.1136/bmj.299.6713.1426; MARKS IM, 1994, BRIT J PSYCHIAT, V165, P179, DOI 10.1192/bjp.165.2.179; MARSHALL M, 1995, PSYCHOL MED, V25, P605, DOI 10.1017/S0033291700033511; Marshall M., 1994, PHILOS PSYCHOL PSYCH, V1, P27; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P645; PECK E, 1994, J MENTAL HLTH, V3, P151; PELOSI AJ, 1993, J MENTAL HLTH, V2, P1; POWELL R, 1994, J MENTAL HLTH, V3, P430; RICHMAN A, 1985, BRIT J PSYCHIAT, V146, P164, DOI 10.1192/bjp.146.2.164; RITCHIE JH, 1994, PRINCIPLES SOCIAL PS; *SCOTT FOR PUBL HL, 1994, SCOTT NEEDS ASS PROG; Stevens A, 1991, Health Trends, V23, P20; THORNICROFT G, 1994, BRIT MED J, V309, P970, DOI 10.1136/bmj.309.6960.970; Thornicroft G, 1992, MEASURING MENTAL HLT; Wing J, 1992, MEASURING MENTAL HLT, P1; WOOFF K, 1988, BRIT J PSYCHIAT, V152, P783, DOI 10.1192/bjp.152.6.783; 1995, LANCET, V345, P399	32	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1582	1586		10.1136/bmj.312.7046.1582	http://dx.doi.org/10.1136/bmj.312.7046.1582			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU806	8664670	Green Published			2022-12-28	WOS:A1996UU80600022
J	Narayan, KMV; Chadha, SL; Hanson, RL; Tandon, R; Shekhawat, S; Fernandes, RJ; Gopinath, N				Narayan, KMV; Chadha, SL; Hanson, RL; Tandon, R; Shekhawat, S; Fernandes, RJ; Gopinath, N			Prevalence and patterns of smoking in Delhi: Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CIGARETTE-SMOKING; INDIA; ACCULTURATION; POPULATION; HISPANICS	Objective-To determine the prevalence and predictors of smoking in urban India. Design-Cross sectional. Setting-Delhi, urban India, 1985-6. Subjects-Random sample of 13 558 men and women aged 25-64 years. Main outcome measure-Smoking prevalence; subjects who were currently smoking and who had smoked. greater than or equal to 100 cigarettes or beedis or chuttas in their lifetime were defined as smokers. Results-45% (95% confidence interval 43.8 to 46.2) of men and 7% (6.4 to 7.6) of women were smokers. Education was the strongest predictor of smoking, and men with no education were 1.8 (1.5 to 2.0) times more likely to be smokers than those with college education, and women with no education were 3.7 (2.9 to 4.8) times more likely, Among smokers, 52.6% of men and 4.9% of women smoked only cigarettes white the others also smoked beedi or chutta. Compared with cigarette smokers, people smoking beedi or chutta were more likely to be older and married; have lower education, manual occupations, incomes, and body mass index; and not drink alcohol or take part in leisure exercise. Conclusion-There are two subpopulations of smokers in urban India, and the prevention strategy required for each may be different, The educated, white collar cigarette smoker in India might respond to measures that make nonsmoking fashionable, while the less educated, low income people who smoke beedi or chutta may need strategies aimed at socioeconomic improvement.	SITARAM BHARTIA INST SCI & RES,NEW DELHI 16,INDIA	Sitaram Bhartia Institute of Science & Research	Narayan, KMV (corresponding author), NIDDKD,DIABETES & ARTHRITIS EPIDEMIOL SECT,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ 85014, USA.		Narayan, K.M. Venkat/J-9819-2012; Hanson, Robert L/O-3238-2015	Narayan, K.M. Venkat/0000-0001-8621-5405; Hanson, Robert L/0000-0002-4252-7068				BARNUM H, 1994, TOB CONTROL, V3, P358; BEWLEY BR, 1974, BRIT J PREV SOC MED, V28, P37; BOTVIN G, 1981, ADV DIS PREVENTION, P222; BOTVIN GJ, 1992, ADDICT BEHAV, V17, P97, DOI 10.1016/0306-4603(92)90014-M; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; FOSS R, 1973, J HEALTH SOC BEHAV, V14, P279, DOI 10.2307/2137120; GAVARASANA S, 1992, JPN J CANCER RES, V83, P340, DOI 10.1111/j.1349-7006.1992.tb00112.x; George A, 1994, J Cancer Educ, V9, P111; GUPTA PC, 1990, LANCET, V335, P594, DOI 10.1016/0140-6736(90)90364-B; JESSOR R, 1968, Q J STUD ALCOHOL, V29, P101; JESSOR R, 1977, PROBLEM BEHAVIOR PSY; KUTTY VR, 1993, INT J CARDIOL, V39, P59; MACKAY J, 1994, PREV MED, V23, P535, DOI 10.1006/pmed.1994.1074; MARIN G, 1989, AM J PUBLIC HEALTH, V79, P196, DOI 10.2105/AJPH.79.2.196; MARKIDES KS, 1987, AM J PUBLIC HEALTH, V77, P708, DOI 10.2105/AJPH.77.6.708; MARKS G, 1990, AM J PUBLIC HEALTH, V80, P20, DOI 10.2105/AJPH.80.Suppl.20; MASIRONI R, 1988, World Health Statistics Quarterly, V41, P228; NEWMAN IM, 1971, J SCHOOL HEALTH, V41, P497, DOI 10.1111/j.1746-1561.1971.tb05158.x; PETO R, 1994, MORTALITY SMOKING; PIERCE JP, 1989, AM J PUBLIC HEALTH, V79, P152, DOI 10.2105/AJPH.79.2.152; REYNOLDS C, 1976, PSYCHOL REP, V28, P251; SAMET JM, 1992, CANCER EPIDEM BIOMAR, V1, P235; SCULL R, 1986, WORLD TOBACCO, V9, P35; *US DHHS, 1990, DHHS CDC908416 PUBL; *US DHHS, 1988, DHHS CDC888406 PUBL; *WORLD BANK, 1989, 7965CHA WORLD BANK; *WORLD BANK, 1993, 1993 WORLD BANK WORL	27	53	54	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1576	1579		10.1136/bmj.312.7046.1576	http://dx.doi.org/10.1136/bmj.312.7046.1576			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU806	8664667	Green Published			2022-12-28	WOS:A1996UU80600019
J	Tong, SL; Baghurst, P; McMichael, A; Sawyer, M; Mudge, J				Tong, SL; Baghurst, P; McMichael, A; Sawyer, M; Mudge, J			Lifetime exposure to environmental lead and children's intelligence at 11-13 years: The Port Pirie cohort study	BRITISH MEDICAL JOURNAL			English	Article							NEUROPSYCHOLOGICAL DEVELOPMENT; COGNITIVE-DEVELOPMENT; ADULT MONKEYS; BLOOD LEAD; CHILDHOOD; AGE; DEFICITS	Objective-To examine the association between environmental exposure to lead and children's intelligence at age 11-13 years, and to assess the implications of exposure in the first seven years of life for later childhood development. Design-Prospective cohort study. Subjects-375 children born in or around the lead smelting town of Port Pirie, Australia, between 1979 and 1982. Main outcome measure-Children's intelligence quotient (IQ) measured at 11-13 years of age. Results-IQ was inversely associated with both antenatal and postnatal blood lead concentrations, Verbal, performance, and full scale IQ were inversely related to blood lead concentration with no apparent threshold, Multivariate analyses indicated that after adjustment for a wide range of confounders, the postnatal blood lead concentrations (particularly within the age range 15 months to 7 years) exhibited inverse associations with IQ, Strong associations with IQ were observed for lifetime average blood lead concentrations at various ages. The expected mean full scale IQ declined by 3.0 points (95% confidence interval 0.07 to 5.93) for an increase in lifetime average blood lead concentration from 0.48 to 0.96 mu mol/l (10 to 20 mu g/dl). Conclusions-Exposure to environmental lead during the first seven years of life is associated with cognitive deficits that seem to persist into later childhood.	CSIRO,DIV HUMAN NUTR,ADELAIDE,SA 5000,AUSTRALIA; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; WOMENS & CHILDRENS HOSP,EVALUAT UNIT,ADELAIDE,SA 5000,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of London; London School of Hygiene & Tropical Medicine; Womens & Childrens Hospital Australia								*AUSTR COMM DEP HU, 1994, RED LEAD EXP AUSTR A; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Caldwell BM, 1985, HOME OBSERVATION MEA; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; COONEY GH, 1989, DEV MED CHILD NEUROL, V31, P640; DANIEL A, 1984, COMMUNITY HLTH STUDI, V3, P218; DIETRICH KN, 1993, PEDIATRICS, V91, P301; DIETRICH KN, 1991, NEUROTOXICOL TERATOL, V13, P203, DOI 10.1016/0892-0362(91)90012-L; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FERGUSSON DM, 1993, INT J EPIDEMIOL, V22, P891, DOI 10.1093/ije/22.5.891; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; GOLDSTEIN GW, 1992, PEDIATR ANN, V21, P384, DOI 10.3928/0090-4481-19920601-11; KAUFMAN AS, 1979, INTELLIGENT TESTING, P1; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEVIN ED, 1987, PSYCHOPHARMACOLOGY, V91, P334, DOI 10.1007/BF00518187; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MCMICHAEL AJ, 1992, NEUROTOXICOL TERATOL, V14, P321, DOI 10.1016/0892-0362(92)90038-C; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; POCOCK SJ, 1994, BRIT MED J, V309, P1189, DOI 10.1136/bmj.309.6963.1189; POCOCK SJ, 1987, LANCET, V2, P53; RICE DC, 1988, NEUROTOXICOL TERATOL, V10, P207, DOI 10.1016/0892-0362(88)90019-0; RIUS RA, 1988, SCI TOTAL ENVIRON, V71, P441, DOI 10.1016/0048-9697(88)90216-1; RONNBACK L, 1992, BRIT J IND MED, V49, P233; SATTLER JM, 1988, ASSESSMENT CHILDREN, P61; Silbergeld EK, 1983, LEAD VERSUS HLTH, P191; SMITH M, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P3; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; *STAND ASS AUSTR, 1985, WHOLE BLOOD DET LEAD; *US EPA, 1986, EPA600883028AFDF; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler DW., 1999, INTELLIGENCE SCALE C; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213	44	138	140	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1569	1575		10.1136/bmj.312.7046.1569	http://dx.doi.org/10.1136/bmj.312.7046.1569			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664666	Green Published			2022-12-28	WOS:A1996UU80600018
J	Boldin, MP; Goncharov, TM; Goltsev, YV; Wallach, D				Boldin, MP; Goncharov, TM; Goltsev, YV; Wallach, D			Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death	CELL			English	Article							FAS ANTIGEN; C-ELEGANS; NECROSIS; EXPRESSION; APOPTOSIS; CLEAVAGE; ENZYME; DOMAIN	Fas/APO-1 and p55 tumor necrosis factor (TNF) receptor (p55-R) activate cellular mechanisms that result in cell death. Upon activation of these receptors, Fas/APO-1 binds a protein called MORT1 (or FADD) and p55-R binds a protein called TRADD. MORT1 and TRADD can also bind to each other. We have cloned a novel protein, MACH, that binds to MORT1. This protein exists in multiple isoforms, some of which contain a region that has proteolytic activity and shows marked sequence homology to proteases of the ICE/CED-3 family. Cellular expression of the proteolytic MACH isoforms results in cell death. Expression of MACH isoforms that contain an incomplete ICE/CEDE region provides effective protection against the cytotoxicity induced by Fas/APO-1 or p55-R triggering. These findings suggest that MACH is the most upstream enzymatic component in the Fas/APO-1- and p55-R-induced cell death signaling cascades.			Boldin, MP (corresponding author), WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL.		Roszak, Joanna/F-4003-2010	Boldin, Mark/0000-0003-4593-0669				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEITZEN M, 1980, J IMMUNOL, V125, P719; WONG GHW, 1994, J IMMUNOL, V152, P1751; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	56	2056	2150	2	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					803	815		10.1016/S0092-8674(00)81265-9	http://dx.doi.org/10.1016/S0092-8674(00)81265-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681376	Bronze			2022-12-28	WOS:A1996UR60400005
J	Steinhoff, MC				Steinhoff, MC			Japanese encephalitis: A Chinese solution?	LANCET			English	Editorial Material											Steinhoff, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,615 N WOLFE ST,BALTIMORE,MD 21218, USA.							Gowal D, 1995, INDIAN J MED RES, V102, P267; HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004; Luo D, 1994, Southeast Asian J Trop Med Public Health, V25, P643; PUGACHEV KV, 1995, VIROLOGY, V212, P587, DOI 10.1006/viro.1995.1516; Shepard D.S., 1993, DIS CONTROL PRIORITI, P303; TSAI TF, 1995, VACCINES, P671; UNICEF, 1994, STAT WORLDS CHILDR, P82; VAUGHN DW, 1992, EPIDEMIOL REV, V14, P197, DOI 10.1093/oxfordjournals.epirev.a036087; 1993, MMWR-MORBID MORTAL W, V42, P1	9	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1570	1571		10.1016/S0140-6736(96)91070-3	http://dx.doi.org/10.1016/S0140-6736(96)91070-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667861				2022-12-28	WOS:A1996UP66100004
J	Tobutt, C; Oppenheimer, E; Laranjeira, R				Tobutt, C; Oppenheimer, E; Laranjeira, R			Health of cohort of heroin addicts from London clinics: 22 year follow up	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,NATL ADDICT CTR,ADDICT RES UNIT,LONDON SE5 8AF,ENGLAND	University of London; King's College London								LEHMAN WEK, 1990, OPIOID ADDICTION TRE; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x; SIMPSON DD, 1986, ADDICTION CAREERS SU; Stimson G., 1982, HEROIN ADDICTION TRE; VAILLANT GE, 1973, ARCH GEN PSYCHIAT, V29, P237	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1458	1458		10.1136/bmj.312.7044.1458	http://dx.doi.org/10.1136/bmj.312.7044.1458			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UQ296	8664626	Green Published			2022-12-28	WOS:A1996UQ29600029
J	Cox, J; Joseph, SA; Francis, RM				Cox, J; Joseph, SA; Francis, RM			Confusion over a missing social security cheque	LANCET			English	Article							WERNICKES ENCEPHALOPATHY				Cox, J (corresponding author), NEWCASTLE GEN HOSP,WESTGATE RD,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.			Cox, Julie/0000-0002-9971-3363				BERGIN PS, 1992, BRIT MED J, V305, P517, DOI 10.1136/bmj.305.6852.517; HEYE N, 1994, INTENS CARE MED, V20, P282, DOI 10.1007/BF01708966; PERKIN GD, 1983, BRIT J HOSP MED, V30, P331; REULER JB, 1985, NEW ENGL J MED, V312, P1035, DOI 10.1056/NEJM198504183121606; SPITTLE B, 1993, AUST NZ J PSYCHIAT, V27, P638, DOI 10.3109/00048679309075827	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1452	1452		10.1016/S0140-6736(96)91686-4	http://dx.doi.org/10.1016/S0140-6736(96)91686-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM485	8676630				2022-12-28	WOS:A1996UM48500013
J	Hylek, EM; Skates, SJ; Sheehan, MA; Singer, DE				Hylek, EM; Skates, SJ; Sheehan, MA; Singer, DE			An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; WARFARIN; STROKE; COMPLICATIONS; OUTPATIENTS; PREVENTION; THROMBOSIS; ASPIRIN; THERAPY; SMOKING	Background To avert major hemorrhage, physicians need to know the lowest intensity of anticoagulation that is effective in preventing stroke in patients with atrial fibrillation. Since the low rate of stroke has made it difficult to perform prospective studies to resolve this issue, we conducted a case-control study. Methods We studied 74, consecutive patients with atrial fibrillation who were admitted to our hospital from 1989 through 1994 after having an ischemic stroke while taking warfarin. For each patient with stroke, three controls with nonrheumatic atrial fibrillation who were treated as our patients were randomly selected from the 1994 registry of the anticoagulant-therapy unit (222 controls). We used the international normalized ratio (INR) to measure the intensity of anticoagulation. For The patients with stroke, we used the INR at admission; for the controls, we selected the INR that was measured closest to the month and day of the matched case patient's hospital admission. Results The risk of stroke rose steeply at INRs below 2.0. At an INR of 1.7, the adjusted odds ratio for stroke, as compared with the risk at an INR of 2.0, was 2.0 (95 percent confidence interval, 1.6 to 2.4); at an INR of 1.5, it was 3.3 (95 percent confidence interval, 2.4 to 4.6); and at an INR of 1.3, it was 6.0 (95 percent confidence interval, 3.6 to 9.8). Other independent risk factors were previous stroke (odds ratio, 10.4; 95 percent confidence interval, 4.4 to 24.5), diabetes mellitus (odds ratio, 2.9; 95 percent confidence interval, 1.3 to 6.5), hypertension (odds ratio, 2.5; 95 percent confidence interval, 1.1 to 5.7), and current smoking (odds ratio, 5.7; 95 percent confidence Interval, 1.4 to 24.0). Conclusions Among patients with atrial fibrillation, anticoagulant prophylaxis is effective at INRs of 2.0 or greater. Since previous studies have indicated that the risk of hemorrhage rises rapidly at INRs greater than 4.0 to 5.0, tight control of anticoagulant therapy to maintain the INR between 2.0 and 3.0 is a better strategy than targeting lower, less effective levels of anticoagulation. (C) 1996. Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, DEPT MED, CLIN EPIDEMIOL UNIT, DIV GEN INTERNAL MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Hylek, Elaine/0000-0001-8263-8304				[Anonymous], 1994, ARCH INTERN MED, V154, P2254; [Anonymous], 1996, INT CLASSIFICATION D; ANSELL JE, 1995, ARCH INTERN MED, V155, P2185, DOI 10.1001/archinte.155.20.2185; BERN MM, 1986, SURGERY, V99, P216; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1993, NEW ENGL J MED, V328, P148; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HOSMER DW, 1989, APPL LOGISTIC REGRES, P187; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; PETERSEN P, 1989, LANCET, V1, P175; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; *STATSC, 1993, S PLUS REF MAN VERS; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; 1995, STROKE, V26, P1978; 1993, LANCET, V342, P1255; 1995, STROKE, V26, P1981	32	648	688	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					540	546		10.1056/NEJM199608223350802	http://dx.doi.org/10.1056/NEJM199608223350802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8678931				2022-12-28	WOS:A1996VD30200002
J	Tin, W; Wariyar, U; Hey, E; Grant, A; Milligan, D; Richmond, S; Sinha, S; Platt, MW; McCoy, L; Atkinson, L; Leak, S; Ellis, L; WhyteEarl, S; Richardson, S; Tunstall, D; Turner, S; Barritt, G; Harrison, M; Asl, H; McKinnell, H; Harbottle, J; Swailes, K; Lampson, A; Greensitt, D; Watson, B; Cook, S; Golder, S; Malcolm, L; Harrison, B; Shilling, S; Martin, J; Tedford, H				Tin, W; Wariyar, U; Hey, E; Grant, A; Milligan, D; Richmond, S; Sinha, S; Platt, MW; McCoy, L; Atkinson, L; Leak, S; Ellis, L; WhyteEarl, S; Richardson, S; Tunstall, D; Turner, S; Barritt, G; Harrison, M; Asl, H; McKinnell, H; Harbottle, J; Swailes, K; Lampson, A; Greensitt, D; Watson, B; Cook, S; Golder, S; Malcolm, L; Harrison, B; Shilling, S; Martin, J; Tedford, H			Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: Outcome at 2 years	LANCET			English	Article							INTRAVENTRICULAR HEMORRHAGE; BLOOD-PRESSURE; INFANTS; PREVENTION; VOLUME	Background Preterm babies are at risk of haemorrhagic and ischaemic brain injury. One controlled trial suggested that prophylactic fresh-frozen plasma (FFP) may reduce that risk but did not clarify whether the reduction in periventricular haemorrhage seen on ultrasonography was due to a haemostatic effect or stabilisation of intravascular volume by FFP. We undertook a trial of 776 babies of gestational age at birth less than 32 weeks to look at the short-term and long-term outcome after early prophylactic FFP. Methods The defined primary trial outcome was survival without identifiable major disability 2 years after birth. The babies were randomly allocated, within 2 h of birth, 20 mL/kg FFP followed by a further 10 mL/kg after 24 h; or the same volumes of a gelatin-based plasma substitute; or maintenance infusion of glucose (control). The three groups were similar at trial entry. Outcome at discharge from hospital after birth (reported elsewhere) was similar in the three groups. Findings No child was lost to follow-up, and all the surviving children underwent neurological and developmental assessment at the age of 2 years. The proportions dying (21.0%, 24.9%, 20.5%), and the proportions of survivors with a severe disability (11.3%, 11.2%, 14.1%) did not differ significantly between the randomised groups. The survivors had similar mean developmental quotients at age 2 (Griffiths' quotients 94, 97, and 95). Interpretation This trial provides no evidence that the routine early use of FFP, or some other form of intravascular volume expansion, affects the risk of death or disability in babies born more than 8 weeks before term.			Tin, W (corresponding author), S CLEVELAND HOSP, DEPT PAEDIAT, MIDDLESBROUGH TS4 3BW, CLEVELAND, ENGLAND.		Asl, Hanieh Davatgari/AAO-1513-2021					BAUER K, 1993, ARCH DIS CHILD-FETAL, V69, P521, DOI 10.1136/adc.69.5_Spec_No.521; BEVERLEY DW, 1985, ARCH DIS CHILD, V60, P710, DOI 10.1136/adc.60.8.710; GAIRDNER D, 1958, ARCH DIS CHILD, V33, P489, DOI 10.1136/adc.33.172.489; GILL AB, 1993, ARCH DIS CHILD-FETAL, V69, P284, DOI 10.1136/adc.69.3_Spec_No.284; HEY EN, 1984, BRIT MED J, V288, P1717; Horbar Jeffrey D., 1992, P562; LINDERKAMP O, 1978, EUR J PEDIATR, V129, P73, DOI 10.1007/BF00442366; LINDERKAMP O, 1978, EUR J PEDIATR, V127, P91, DOI 10.1007/BF00445764; MENT LR, 1994, PEDIATRICS, V93, P543; National Perinatal Epidemiology Unit, 1994, DIS PER CAR MEAS HLT; ROTH SC, 1993, DEV MED CHILD NEUROL, V35, P755; SOLA A, 1992, LANCET, V340, P1363; TYSZCZUK L, IN PRESS EARLY HUM D; VARARIGOU A, 1996, JAMA-J AM MED ASSOC, V275, P539; WARIYAR U, 1989, ARCH DIS CHILD, V64, P678, DOI 10.1136/adc.64.5.678; WRIGHT IMR, 1995, BRIT PAED ASS 67 ANN, V67, P52; IN PRESS EUR J PEDIA	17	78	77	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 27	1996	348	9022					229	232						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684200				2022-12-28	WOS:A1996UZ28600011
J	Ekland, EH; Bartel, DP				Ekland, EH; Bartel, DP			RNA-catalysed RNA polymerization using nucleoside triphosphates	NATURE			English	Article							COMPLEMENTARY-STRAND RNA; SELF-SPLICING RNA; TETRAHYMENA RIBOZYME; REPLICATION; POLYMERASE; TEMPLATE; LIFE; ORIGINS; MODEL; VIRUS	THE hypothesis that certain RNA molecules may be able to catalyse RNA replication is central to current theories of the early evolution of life(1-6). In support of this idea, we describe here an RNA that synthesizes RNA using the same reaction as that employed by protein enzymes that catalyse RNA polymerization. In the presence of the appropriate template RNA and nucleoside triphosphates, the ribozyme extends an RNA primer by successive addition of up to six mononucleotides. The added nucleotides are joined to the growing RNA chain by 3',5'-phosphodiester linkages. The ribozyme shows marked template fidelity: extension by nucleotides complementary to the template is up to 1,000 times more efficient than is extension by mismatched nucleotides.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BARTEL DP, 1991, MOL CELL BIOL, V11, P3390, DOI 10.1128/MCB.11.6.3390; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CHAPMAN KB, 1995, CHEM BIOL, V2, P325, DOI 10.1016/1074-5521(95)90051-9; CHOWRIRA BM, 1993, EMBO J, V12, P3599, DOI 10.1002/j.1460-2075.1993.tb06033.x; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; JOSHI RL, 1983, EMBO J, V2, P1123, DOI 10.1002/j.1460-2075.1983.tb01556.x; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MUELLER MW, 1993, SCIENCE, V261, P1035, DOI 10.1126/science.8351516; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; SAVILLE BJ, 1991, P NATL ACAD SCI USA, V88, P8826, DOI 10.1073/pnas.88.19.8826; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STEINHAUER DA, 1986, J VIROL, V57, P219, DOI 10.1128/JVI.57.1.219-228.1986; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VANTOL H, 1991, VIROLOGY, V180, P23, DOI 10.1016/0042-6822(91)90005-V; WARD CD, 1992, J VIROL, V66, P3784, DOI 10.1128/JVI.66.6.3784-3793.1992; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	169	179	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1996	382	6589					373	376		10.1038/382373a0	http://dx.doi.org/10.1038/382373a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684470				2022-12-28	WOS:A1996UY95000058
J	Loomis, CA; Harris, E; Michaud, J; Wurst, W; Hanks, M; Joyner, AL				Loomis, CA; Harris, E; Michaud, J; Wurst, W; Hanks, M; Joyner, AL			The mouse Engrailed-1 gene and ventral limb patterning	NATURE			English	Article							PROTO-ONCOGENE INT-1; ECTODERMAL CONTROL; EXPRESSION; SUGGEST; EMBRYO; BMP-2A; EN-1	DURING vertebrate limb development, positional information must be specified along three distinct axes. Although much progress has been made in our understanding of the molecular interactions involved in anterior-posterior and proximal-distal limb patterning, less is known about dorsal-ventral patterning(1-3). The genes Wnt-7a and Lmx-1,which are expressed in dorsal limb ectoderm and mesoderm, respectively, are thought to be important regulators of dorsal limb differentiation(4-6). Whether a complementary set of molecules controls ventral limb development has not been clear. Here we report that Engrailed-1, a homeodamain-containing transcription factor expressed in embryonic central limb ectoderm(7,8), is essential for ventral limb patterning. Loss of Engrailed-1 function in mice results in dorsal transformations of ventral paw structures, and in subtle alterations along the proximal-distal limb ads. Engrailed-1 seems to act in part by repressing dorsal differentiation induced by Wnt-7a, and is essential for proper formation of the apical ectodermal ridge.	NYU,SCH MED,SKIRBALL INST BIOMOL MED,DEV GENET PROGRAM,NEW YORK,NY 10016; NYU,SCH MED,RONALD PERELMAN DEPT DERMATOL,NEW YORK,NY 10016; NYU,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,SCH MED,DEPT PHYSIOL & NEUROSCI,NEW YORK,NY 10016; COLL FRANCE,INST EMBRYOL CELLULAIRE & MOLEC,F-94736 NOGENT SUR MARNE,FRANCE; CNRS,INST EMBRYOL CELLULAIRE & MOLEC,F-94736 NOGENT SUR MARNE,FRANCE; GSF MUNICH,RES CTR,D-85758 MUNICH,GERMANY	New York University; New York University; New York University; New York University; UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Wurst, Wolfgang/0000-0003-4422-7410				CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PATAU MP, 1977, VERTEBRATE LIMB SOMI, P257; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; SANICOLA M, 1995, GENETICS, V139, P745; TABATA T, 1995, DEVELOPMENT, V121, P3359; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WURST W, 1994, DEVELOPMENT, V120, P2065; ZECCA M, 1995, DEVELOPMENT, V121, P2265	23	237	243	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					360	363		10.1038/382360a0	http://dx.doi.org/10.1038/382360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684466				2022-12-28	WOS:A1996UY95000054
J	Anda, P; SanchezYebra, W; Vitutia, MD; Pastrana, EP; Rodriguez, I; Miller, NS; Backenson, PB; Benach, JL				Anda, P; SanchezYebra, W; Vitutia, MD; Pastrana, EP; Rodriguez, I; Miller, NS; Backenson, PB; Benach, JL			A new Borrelia species isolated from patients with relapsing fever in Spain	LANCET			English	Article							LYME BORRELIOSIS; SP-NOV; DISEASE; BURGDORFERI; EVOLUTION	Background Lyme disease and tick-borne relapsing fever are worldwide systemic borrelioses caused by several Borrelia species transmitted by hard ticks (family Ixodidae) and soft ticks (family Argasidae), respectively. A previous seroepidemiological study of Lyme borreliosis showed several serologically reactive patients with clinically atypical presentations, and this discovery led to the hypothesis that some of the cases of Lyme borreliosis had been caused by another borrelia organism. Methods Blood from patients in southern Spain who had suspected Lyme disease or relapsing-fever borreliosis was cultured before treatment began, isolates of Borrelia spp were inoculated into several strains of mice of different ages. The 16S rRNA and flagellin genes of Borrelia spp were sequenced by PCR and assessed by phylogenetic analyses. Findings We isolated a species of Borrelia from three patients with relapsing fever and from Ornithodorus spp ticks in southern Spain. This organism (refractory to in-vitro cultivation) caused a relapsing spirochaetaemia with multiple organ involvement in laboratory mice that recreated the human disease. Phylogenetic analysis showed that this organism is a previously unrecognised species. Interpretation We have discovered a new borrelia pathogen that is closely related to the other tick-borne agents of relapsing fever in Europe and Africa, and which causes a relapsing systemic disease with serological similarities to Lyme borreliosis.	HOSP GEN BASICO,MALAGA,SPAIN; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,NEW YORK STATE DEPT HLTH,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Anda, P (corresponding author), INST SALUD CARLOS III,CTR NACL MICROBIOL VIROL & INMUNOL SANIT,E-28220 MAJADAHONDA,MADRID,SPAIN.		Anda, Pedro/V-8436-2019	Anda, Pedro/0000-0001-9081-8188; Miller, Nancy/0000-0001-5878-0896; Sanchez-Yebra Romera, Waldo/0000-0001-8546-1989	PHS HHS [A1-27044] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDA P, 1993, CLIN INFECT DIS, V16, P310, DOI 10.1093/clind/16.2.310; AZNAR Pedro, 1926, Arch. Inst. Nac. Higiene de Alfonso XIII, V4, P121; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; Barbour AG, 1996, J INFECT DIS, V173, P403, DOI 10.1093/infdis/173.2.403; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARTHOLD SW, 1991, AM J PATHOL, V139, P263; BERNEDO JU, 1977, ACTA DERMOSIFILOG, V68, P109; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CANICA MM, 1993, SCAND J INFECT DIS, V25, P441, DOI 10.3109/00365549309008525; DEBUEN E, 1931, B TECN DIR SAN, V6, P193; DELOPE ML, 1985, MED CLIN-BARCELONA, V85, P111; FELSENFELD O, 1965, BACTERIOL REV, V29, P46, DOI 10.1128/MMBR.29.1.46-74.1965; FELSENSTEIN J, 1994, PHYLIP VERSION 3 5C; FUKUNAGA M, 1995, INT J SYST BACTERIOL, V45, P804, DOI 10.1099/00207713-45-4-804; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; LOPEZCORTES L, 1989, J INFECT DIS, V159, P804, DOI 10.1093/infdis/159.4.804; MONCO JCG, 1991, MED CLIN-BARCELONA, V98, P89; MONCO JCG, 1995, ANN NEUROL, V37, P691; NOPPA L, 1995, MICROBIOL-UK, V141, P85, DOI 10.1099/00221287-141-1-85; PORTO AS, 1991, ENFERM INFEC MICR CL, V9, P125; SCHWARTZ JJ, 1992, J BACTERIOL, V174, P3757, DOI 10.1128/JB.174.11.3757-3765.1992; SOUTHERN PM, 1969, MEDICINE, V48, P129, DOI 10.1097/00005792-196903000-00002; Swofford D.L., 1993, PHYLOGENETIC ANAL US; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	25	57	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					162	165		10.1016/S0140-6736(96)02332-X	http://dx.doi.org/10.1016/S0140-6736(96)02332-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684157				2022-12-28	WOS:A1996UX78900012
J	Rustin, G; Tuxen, M				Rustin, G; Tuxen, M			Use of CA 125 in follow-up of ovarian cancer	LANCET			English	Letter									UNIV COPENHAGEN,HERLEV HOSP,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	Rustin, G (corresponding author), MT VERNON HOSP,DEPT MED ONCOL,NORTHWOOD HA6 2RN,MIDDX,ENGLAND.		Rustin, Gordon J. S./J-9763-2019					Rustin GJS, 1996, ANN ONCOL, V7, P361; VANDERBURG MEL, 1990, ANN ONCOL, V1, P301, DOI 10.1093/oxfordjournals.annonc.a057754	2	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					191	192		10.1016/S0140-6736(05)66133-8	http://dx.doi.org/10.1016/S0140-6736(05)66133-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684165				2022-12-28	WOS:A1996UX78900041
J	Burnell, RH				Burnell, RH			An echo of the Spanish lady	LANCET			English	Article											Burnell, RH (corresponding author), UNIV ADELAIDE,WOMENS & CHILDRENS HOSP,DEPT PAEDIAT,ADELAIDE,SA 5006,AUSTRALIA.							Abrahams A, 1919, LANCET, V1, P1; BICKLE LW, 1990, AUSTR MED GAZETTE, V9, P225; Collier R, 1974, PLAGUE SPANISH LADY; ROBERTS GBS, 1957, LANCET, V2, P944	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					98	98		10.1016/S0140-6736(96)04141-4	http://dx.doi.org/10.1016/S0140-6736(96)04141-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676725				2022-12-28	WOS:A1996UW67300013
J	Quinn, TC				Quinn, TC			Global burden of the HIV pandemic	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PREVALENCE; AFRICA; WOMEN; AIDS; RISK	Within the global pandemic of HIV infection there are many different epidemics, each with its own dynamics and each influenced by many factors including time of introduction of the virus, population density, and cultural and social issues. Effective management strategies depend on knowledge of all these factors. By the year 2000, WHO projections are that 26 million persons will be infected with HIV, more than 90% of whom will be in developing countries. io control AIDS, countries must not only promote changes in individual behaviour but also address social issues such as unemployment, rapid urbanisation, migration, and the status of women.	JOHNS HOPKINS UNIV,BALTIMORE,MD 21205	Johns Hopkins University	Quinn, TC (corresponding author), NIAID,BALTIMORE,MD 21205, USA.		Quinn, Thomas/A-2494-2010					BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; BROWN T, 1994, AIDS, V8, pS131; BROWN T, 1995, ASIA PACIFIC POPULAT, V35; CHENG HH, 1994, LANCET, V344, P953, DOI 10.1016/S0140-6736(94)92304-3; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; Cohen B., 1996, PREVENTING MITIGATIN, Veditors; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DADA AJ, 1993, J ACQ IMMUN DEF SYND, V269, P2853; DAQUILA RT, 1996, CURRENT CLIN TOPICS, P84; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOSAS J, 1995, LANCET, V346, P826, DOI 10.1016/S0140-6736(95)91631-8; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; *GLOB PROGR AIDS, 1995, CURR GLOB SIT HIV AI; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HAVERKOS HW, 1995, INT J STD AIDS, V6, P227, DOI 10.1177/095646249500600401; KALDOR JM, 1994, AIDS, V8, pS165; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LAGA M, 1994, AIDS S1, V8, pS119; MANN J, AIDS WORLD, V2; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; MIOTTI PG, 1990, AIDS, V4, P733, DOI 10.1097/00002030-199008000-00003; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MYERS G, 1995, HUMAN RETROVIRUSES A; NELSON KE, 1995, ARCH INTERN MED, V155, P1305, DOI 10.1001/archinte.155.12.1305; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; PAPE J, 1993, CLIN INFECT DIS, V17, pS341, DOI 10.1093/clinids/17.Supplement_2.S341; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; POKROVSKY VV, 1990, ZH MIKROBIOL EPIDEMI, V2, P26; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; QUINN TC, 1994, HARRISONS PRINCIPL S, V9, P1; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; SWANEVELDER R, 1995, EPIDEMIOLOGICAL COMM, V22, P90; *US BUR CENS, 1995, 20 US BUR CENS; WATERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115; WENIGER BG, 1994, AIDS, V8, pS13; WHEELER VW, 1994, INT J STD AIDS, V5, P79, DOI 10.1177/095646249400500201; *WORLD BANK, 1993, 1993 WORLD BANK; World Health Organization (WHO), 1995, OV SEL CUR SEX TRANS; 1995, HIV AIDS SURVEILLANC, V7, P1; 1995, WKLY EPIDEMIOL REC, V70, P353; 1996, MMWR-MORBID MORTAL W, V45, P121; 1995, J ACQ IMMUN DEF SYND, V8, P1495; 1994, LANCET, V343, P1464	50	234	242	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					99	106		10.1016/S0140-6736(96)01029-X	http://dx.doi.org/10.1016/S0140-6736(96)01029-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676726	hybrid			2022-12-28	WOS:A1996UW67300014
J	Bloor, K; Maynard, A; Freemantle, N				Bloor, K; Maynard, A; Freemantle, N			Lessons from international experience in controlling pharmaceutical expenditure .3. Regulating industry	BRITISH MEDICAL JOURNAL			English	Article								This is the third of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies regulating the supply of drugs, particularly licensing and reimbursement controls, price and profit regulation. Price and profit controls contain few incentives for improving cost effective use of drugs, and focus on cost containment and profitability of domestic industry. Carefully monitored economic evaluation could lead to improvements in efficiency and benefits to patients and the health care system.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; NUFFIELD PROV HOSP TRUST,LONDON W1M 7RD,ENGLAND	University of York - UK	Bloor, K (corresponding author), UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Bloor, Karen/0000-0003-4852-9854; Freemantle, Nick/0000-0001-5807-5740				Canadian Coordinating Office for Health Technology Assessment, 1994, GUID EC EV PHARM CAN, V1st; *COMM AUSTR, 1990, DRAFT GUID PHARM IND; *COMM DEP HLTH HOU, 1995, GUID PHARM IND PREP; *DEP HLTH, 1994, GUID EC EV PHARM; *DEP HLTH, 1993, PHARM PRIC REG SCHEM; Detsky A S, 1993, Pharmacoeconomics, V3, P354, DOI 10.2165/00019053-199303050-00003; FREEMANTLE N, 1995, BRIT MED J, V310, P955, DOI 10.1136/bmj.310.6985.955; GARATTINI L, 1994, PHARMACOECONOMICS, V6, P417, DOI 10.2165/00019053-199406050-00003; *GEN ACC OFF, 1994, GAOHEHS94194FS; GREENFIELD PR, 1982, REP SECR STAT SOC SE; Gross D J, 1994, Health Care Financ Rev, V15, P127; HUTTON J, 1994, HEALTH AFFAIR, V13, P98, DOI 10.1377/hlthaff.13.3.98; JONSSON B, 1994, PHARMACOECONOMICS, V6, P51; Lyons J S, 1992, Pharmacoeconomics, V2, P91, DOI 10.2165/00019053-199202020-00001; *ONT MIN HLTH, 1991, ONT GUID EC AN PHARM; *ONT MIN HLTH, 1994, ONT GUID EC AN PHARM; PELC A, 1994, PHARMACOECONOMICS, V6, P28, DOI 10.2165/00019053-199400061-00009; Reeder C E, 1993, Pharmacoeconomics, V4, P92, DOI 10.2165/00019053-199304020-00004; RIGTER H, 1994, PHARMACOECONOMICS, V6, P15, DOI 10.2165/00019053-199400061-00007; *ROYAL PHARM SOC, 1992, PHARM CAR FUT COMM P; SCHULENBURG JM, 1994, HEALTH ECON, V3, P301; *WHO, 1994, DRUG PRIC SYST EUR O; *ZIEK, 1994, ADV CONTR COSTS PHAR; 1995, SCRIP           0310, P2; 1994, SCRIP           0830, P2; 1995, SCRIP           0414, P23; 1994, SCRIP           1223, P22	27	41	42	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					33	35		10.1136/bmj.313.7048.33	http://dx.doi.org/10.1136/bmj.313.7048.33			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664771	Green Published			2022-12-28	WOS:A1996UW66700030
J	Jing, SQ; Wen, DZ; Yu, YB; Holst, PL; Luo, Y; Fang, M; Tamir, R; Antonio, L; Hu, Z; Cupples, R; Louis, JC; Hu, S; Altrock, BW; Fox, GM				Jing, SQ; Wen, DZ; Yu, YB; Holst, PL; Luo, Y; Fang, M; Tamir, R; Antonio, L; Hu, Z; Cupples, R; Louis, JC; Hu, S; Altrock, BW; Fox, GM			GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF	CELL			English	Article							NEUROTROPHIC FACTOR; EXPRESSION SYSTEM; SIGNAL SEQUENCE; PROTOONCOGENE; CLONING; CDNA; MUTATIONS; NEURONS	We report the expression cloning and characterization of GDNFR-alpha, a novel glycosylphosphatidylinositol-linked cell surface receptor for glial cell line-derived neurotrophic factor (GDNF). GDNFR-alpha binds GDNF specifically and mediates activation of the Ret protein-tyrosine kinase (PTK). Treatment of Neuro-2a cells expressing GDNFR-alpha with GDNF rapidly stimulates Ret autophosphorylation. Ret is also activated by treatment with a combination of GDNF and soluble GDNFR-alpha in cells lacking GDNFR-alpha, and this effect is blocked by a soluble Ret-Fc fusion protein. Ret activation by GDNF was also observed in cultured embryonic rat spinal cord motor neurons, a cell type that responds to GDNF in vivo. A model for the stepwise formation of a GDNF signal-transducing complex including GDNF, GDNFR-alpha, and the Ret PTK is proposed.	AMGEN INC,DEPT MAMALIAN CELL MOL BIOL,THOUSAND OAKS,CA 91320; AMGEN INC,DEPT NEUROBIOL,THOUSAND OAKS,CA 91320; AMGEN INC,DEPT DEV BIOL,THOUSAND OAKS,CA 91320	Amgen; Amgen; Amgen	Jing, SQ (corresponding author), AMGEN INC,DEPT IMMUNOL,THOUSAND OAKS,CA 91320, USA.							ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; CAMU W, 1992, J NEUROSCI METH, V44, P59, DOI 10.1016/0165-0270(92)90114-S; Choi-Lundberg D L, 1995, Brain Res Dev Brain Res, V85, P80; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOUIS JC, 1992, J PHARMACOL EXP THER, V262, P1274; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANCHEZ M, 1996, IN PRESS NATURE; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Saxen L, 1987, DEV CELL BIOL SERIES; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909	40	990	1069	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1113	1124		10.1016/S0092-8674(00)81311-2	http://dx.doi.org/10.1016/S0092-8674(00)81311-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674117	Bronze			2022-12-28	WOS:A1996UV48400017
J	Arlt, H; Tauer, R; Feldmann, H; Neupert, W; Langer, T				Arlt, H; Tauer, R; Feldmann, H; Neupert, W; Langer, T			The YTA10-12 complex, an AAA protease with chaperone-like activity in the inner membrane of mitochondria	CELL			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEASES; PROTEOLYSIS; YEAST; BIOGENESIS; BACTERIAL; PRODUCTS; MUTANTS; MEMBER	The mitochondrial members of the highly conserved AAA family, Yta10p and Yta12p, constitute a membrane-embedded complex of about 850 kDa. As an ATP dependent metallopeptidase (AAA protease), the YTA10-12 complex mediates the degradation of nonassembled inner membrane proteins. In contrast to nucleotide-dependent complex formation and substrate binding, proteolysis of bound polypeptides depends on the hydrolysis of ATP and the metallopeptidase activity of both subunits. Independent of its proteolytic function, the chaperone-like activity of the YTA10-12 complex is required for assembly of the membrane-associated ATP synthase. We propose that proteolytic and chaperone-like activities in the YTA10-12 complex mediate assembly and degradation processes of membrane protein complexes and thereby exert key functions in the maintenance of membrane integrity.			Arlt, H (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.			Langer, Thomas/0000-0003-1250-1462				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; CAMPBELL CL, 1994, MOL BIOL CELL, V5, P899, DOI 10.1091/mbc.5.8.899; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMMANN JM, 1994, J CELL BIOL, V127, P893; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HUGUENEY P, 1995, P NATL ACAD SCI USA, V92, P5630, DOI 10.1073/pnas.92.12.5630; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KALNOV SL, 1979, BIOCHEM J, V182, P195, DOI 10.1042/bj1820195; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Langer T, 1995, METHOD ENZYMOL, V260, P495, DOI 10.1016/0076-6879(95)60161-9; LEONHARD K, 1996, IN PRESS EMBO J; LOWE J, 1995, SCIENCE, V268, P633; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PEARCE DA, 1995, J BIOL CHEM, V270, P1; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SHERMAN MY, 1992, EMBO J, V11, P71; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; TZAGOLOFF A, 1972, J BIOL CHEM, V247, P6517; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; YASUHARA T, 1994, J BIOCHEM-TOKYO, V115, P1166, DOI 10.1093/oxfordjournals.jbchem.a124474	47	236	244	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					875	885		10.1016/S0092-8674(00)81271-4	http://dx.doi.org/10.1016/S0092-8674(00)81271-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681382	Bronze			2022-12-28	WOS:A1996UR60400011
J	Rothwell, PM; Staines, A; Smail, P; Wadsworth, E; McKinney, P				Rothwell, PM; Staines, A; Smail, P; Wadsworth, E; McKinney, P			Seasonality of birth of patients with childhood diabetes in Britain	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; CHILDREN		UNIV LEEDS,LEUKAEMIA RES FUND CTR CLIN EPIDEMIOL,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND; ROYAL ABERDEEN CHILDRENS HOSP,ABERDEEN AB9 2ZG,SCOTLAND; INST CHILD HLTH,BRISTOL BS8 8BJ,AVON,ENGLAND; UNIV LEEDS,PAEDIAT EPIDEMIOL GRP,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds; University of Aberdeen; University of Bristol; University of Leeds	Rothwell, PM (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Wadsworth, Emma/D-1679-2009; Staines, Anthony/AFQ-7565-2022; Rothwell, Peter/ABE-5913-2020	Staines, Anthony/0000-0001-9161-1357; Rothwell, Peter/0000-0001-9739-9211				LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PATTERSON CC, 1988, DIABETIC MED, V5, P160, DOI 10.1111/j.1464-5491.1988.tb00964.x; STAINES A, 1993, DIABETOLOGIA, V36, P1282, DOI 10.1007/BF00400806; WALTER SD, 1975, BRIT J PREV SOC MED, V29, P18	5	70	70	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1456	1457		10.1136/bmj.312.7044.1456	http://dx.doi.org/10.1136/bmj.312.7044.1456			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664624	Green Published			2022-12-28	WOS:A1996UQ29600027
J	Hardwick, KG; Weiss, E; Luca, FC; Winey, M; Murray, AW				Hardwick, KG; Weiss, E; Luca, FC; Winey, M; Murray, AW			Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption	SCIENCE			English	Article							POLE BODY DUPLICATION; CELL-CYCLE ARREST; PROTEIN-KINASE; MITOSIS; ENCODES; MPS1	The spindle assembly checkpoint keeps cells with defective spindles from initiating chromosome segregation. The protein kinase Mps1 phosphorylates the yeast protein Mad1p when this checkpoint is activated, and the overexpression of Mps1p induces modification of Mad1p and arrests wild-type yeast cells in mitosis with morphologically normal spindles. Spindle assembly checkpoint mutants overexpressing Mps1p pass through mitosis without delay and can produce viable progeny, which demonstrates that the arrest of wild-type cells results from inappropriate activation of the checkpoint in cells whose spindle is fully functional. Ectopic activation of cell-cycle checkpoints might be used to exploit the differences in checkpoint status between normal and tumor cells and thus improve the selectivity of chemotherapy.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV COLORADO,DEPT MOL CELLULAR & DEV BIOL,BOULDER,CO 80309	University of California System; University of California San Francisco; University of Colorado System; University of Colorado Boulder				Hardwick, Kevin/0000-0002-6462-1047				Byers B, 1981, MOL BIOL YEAST SACCH, P59; BYERS B, 1991, METHOD ENZYMOL, V194, P608; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; HARDWICK KG, UNPUB; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; POCH O, 1994, MOL GEN GENET, V243, P641, DOI 10.1007/BF00279573; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	22	284	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					953	956		10.1126/science.273.5277.953	http://dx.doi.org/10.1126/science.273.5277.953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688079				2022-12-28	WOS:A1996VC67000062
J	Cohn, JN				Cohn, JN			Drug therapy - The management of chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR DYSFUNCTION; CONVERTING-ENZYME-INHIBITOR; IDIOPATHIC DILATED CARDIOMYOPATHY; ACUTE MYOCARDIAL-INFARCTION; RENIN-ANGIOTENSIN SYSTEM; VASODILATOR THERAPY; EJECTION FRACTION; ISOSORBIDE DINITRATE; RANDOMIZED TRIAL; PLASMA NOREPINEPHRINE				Cohn, JN (corresponding author), UNIV MINNESOTA, SCH MED,DEPT MED,DIV CARDIOVASC,BOX 508 UMHC, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.							AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; ANDERSON JL, 1985, AM J CARDIOL, V55, P471, DOI 10.1016/0002-9149(85)90396-0; [Anonymous], 1990, Lancet, V336, P1; BALL SG, 1993, LANCET, V342, P821; BAUER JA, 1991, CIRCULATION, V84, P35, DOI 10.1161/01.CIR.84.1.35; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; BURCH GE, 1963, JAMA-J AM MED ASSOC, V183, P81; CHRISTIAN TF, 1995, CIRCULATION, V92, P2143; CINTRON G, 1993, CIRCULATION, V87, P17; CLELAND JGF, 1987, BRIT HEART J, V57, P436; CODY RJ, 1993, CIRCULATION, V87, P1064; CODY RJ, 1992, CIRCULATION, V85, P504, DOI 10.1161/01.CIR.85.2.504; COHN J N, 1973, Circulation, V48, P5; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1993, CIRCULATION, V87, P5; COHN JN, 1995, CIRCULATION, V91, P2504, DOI 10.1161/01.CIR.91.10.2504; COHN JN, 1974, ANN INTERN MED, V81, P777, DOI 10.7326/0003-4819-81-6-777; COHN JN, 1990, CIRCULATION, V81, P48; COHN JN, 1992, CIRCULATION, V86, P252; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COHN JN, 1982, PERICARDIAL DISEASE, P249; COHN JN, 1995, CIRCULATION S1, V92, P143; CURTISS C, 1978, CIRCULATION, V58, P763, DOI 10.1161/01.CIR.58.5.763; Davis J O, 1995, J Card Fail, V1, P179, DOI 10.1016/1071-9164(95)90020-9; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; DUNKMAN WB, 1993, CIRCULATION, V87, P94; EDMONDS CJ, 1972, LANCET, V11, P8; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FINKELSTEIN SM, 1985, AM J CARDIOL, V55, P423, DOI 10.1016/0002-9149(85)90387-X; FRANCIOSA JA, 1978, AM J MED, V64, P207, DOI 10.1016/0002-9343(78)90047-5; GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; GOGIA H, 1995, J AM COLL CARDIOL, V26, P1575, DOI 10.1016/0735-1097(95)00368-1; GOULD L, 1971, J AMER MED ASSOC, V218, P1799, DOI 10.1001/jama.218.12.1799; GUIHA NH, 1974, NEW ENGL J MED, V291, P587, DOI 10.1056/NEJM197409192911201; JOHNSON G, 1993, CIRCULATION, V87, P32; KASS DA, 1995, CIRCULATION, V91, P2314, DOI 10.1161/01.CIR.91.9.2314; KOMURO I, 1990, J BIOL CHEM, V265, P3595; Konstam M A, 1995, J Card Fail, V1, P183, DOI 10.1016/1071-9164(95)90021-7; KONSTAM MA, 1992, CIRCULATION, V86, P431, DOI 10.1161/01.CIR.86.2.431; KUBO SH, 1992, CIRCULATION, V85, P942, DOI 10.1161/01.CIR.85.3.942; KUBO SH, 1991, CIRCULATION, V84, P1589, DOI 10.1161/01.CIR.84.4.1589; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; LEIER CV, 1981, AM J CARDIOL, V48, P1115, DOI 10.1016/0002-9149(81)90329-5; LEIER CV, 1983, CIRCULATION, V67, P817, DOI 10.1161/01.CIR.67.4.817; LEIMBACH WN, 1986, CIRCULATION, V73, P913, DOI 10.1161/01.CIR.73.5.913; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; LEVINE TB, 1982, BRIT HEART J, V47, P161; LEVINE TB, 1984, CIRCULATION, V69, P548, DOI 10.1161/01.CIR.69.3.548; MASSIE BM, 1993, CIRCULATION, V88, P492, DOI 10.1161/01.CIR.88.2.492; MASSIE BM, 1983, J AM COLL CARDIOL, V2, P338, DOI 10.1016/S0735-1097(83)80172-7; MCDONALD KM, 1990, T ASSOC AM PHYSICIAN, V103, P229; MCDONALD KM, 1992, J AM COLL CARDIOL, V19, P460, DOI 10.1016/0735-1097(92)90506-I; MITCHELL JH, 1974, ANNU REV MED, V25, P369, DOI 10.1146/annurev.me.25.020174.002101; NERI R, 1987, AM HEART J, V113, P707, DOI 10.1016/0002-8703(87)90711-3; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OCONNELL JB, 1992, CIRCULATION, V86, P1061, DOI 10.1161/01.CIR.86.3.1061; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1990, CIRCULATION, V82, P2254, DOI 10.1161/01.CIR.82.6.2254; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PFEFFER MA, 1985, CIRCULATION, V72, P406, DOI 10.1161/01.CIR.72.2.406; PIERPONT GL, 1978, CHEST, V73, P8, DOI 10.1378/chest.73.1.8; SABBAH HN, 1994, CIRCULATION, V89, P2852, DOI 10.1161/01.CIR.89.6.2852; SALISBURY PF, 1963, AM HEART J, V66, P650, DOI 10.1016/0002-8703(63)90321-1; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; SPONER G, 1987, Journal of Cardiovascular Pharmacology, V10, pS42, DOI 10.1097/00005344-198710110-00007; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; SWEDBERG K, 1980, BRIT HEART J, V44, P117; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; THOMAS JA, 1978, AM J CARDIOL, V41, P233, DOI 10.1016/0002-9149(78)90162-5; TRISTANI FE, 1987, CIRCULATION, V76, P54; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WASSERMAN K, 1964, AM J CARDIOL, V14, P844, DOI 10.1016/0002-9149(64)90012-8; WILLIAMS JF, 1995, CIRCULATION, V92, P2764; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; IN PRESS CLIN TRIALS; 1992, NEW ENGL J MED, V327, P1768; 1990, LANCET, V336, P698	92	247	319	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					490	498		10.1056/NEJM199608153350707	http://dx.doi.org/10.1056/NEJM199608153350707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672155				2022-12-28	WOS:A1996VB84900007
J	Arking, A				Arking, A			Absorption of solar energy in the atmosphere: Discrepancy between model and observations	SCIENCE			English	Article							SURFACE; RADIATION; DATASET; FLUXES; CLOUDS; BUDGET	An atmospheric general circulation model, which assimilates data from daily observations of temperature, humidity, wind, and sea-level air pressure, was compared with a set of observations that combines satellite and ground based measurements of solar flux. The comparison reveals that the model underestimates by 25 to 30 watts per square meter the amount of solar energy absorbed by Earth's atmosphere. Contrary to some recent reports, clouds have little or no overall effect on atmospheric absorption, a consistent feature of both the observations and the model. Of several variables considered, water vapor appears to be the dominant influence on atmospheric absorption.			Arking, A (corresponding author), JOHNS HOPKINS UNIV,DEPT EARTH & PLANETARY SCI,BALTIMORE,MD 21218, USA.							Arking A, 1996, GEOPHYS RES LETT, V23, P829, DOI 10.1029/96GL00775; BARKSTROM B, 1989, B AM METEOROL SOC, V70, P1254, DOI 10.1175/1520-0477(1989)070<1254:ERBEAA>2.0.CO;2; CESS RD, 1995, SCIENCE, V267, P496, DOI 10.1126/science.267.5197.496; CHOU MD, 1995, GEOPHYS RES LETT, V22, P1885, DOI 10.1029/95GL01350; Darnell WL, 1988, J CLIMATE, V1, P820, DOI 10.1175/1520-0442(1988)001<0820:EOSIUS>2.0.CO;2; GARRATT JR, 1994, J CLIMATE, V7, P72, DOI 10.1175/1520-0442(1994)007<0072:ISFATS>2.0.CO;2; IMRE DG, IN PRESS J APPL METE; KIEHL JT, 1995, J CLIMATE, V8, P2200, DOI 10.1175/1520-0442(1995)008<2200:SOAGCT>2.0.CO;2; LI Z, IN PRESS B AM METEOR; LI ZQ, 1995, J CLIMATE, V8, P315, DOI 10.1175/1520-0442(1995)008<0315:AOTGMM>2.0.CO;2; Li ZQ, 1996, J APPL METEOROL, V35, P653, DOI 10.1175/1520-0450(1996)035<0653:AOASAB>2.0.CO;2; LI ZQ, 1995, NATURE, V376, P486, DOI 10.1038/376486a0; Ohmura A., 1993, GEOPH MONOG SERIES, P93, DOI 10.1029/GM075p0093; PILEWSKIE P, 1995, SCIENCE, V267, P1626, DOI 10.1126/science.267.5204.1626; PINKER RT, 1992, J APPL METEOROL, V31, P194, DOI 10.1175/1520-0450(1992)031<0194:MSSIFS>2.0.CO;2; RAMANATHAN V, 1995, SCIENCE, V267, P499, DOI 10.1126/science.267.5197.499; ROSSOW WB, 1991, B AM METEOROL SOC, V72, P2, DOI 10.1175/1520-0477(1991)072<0002:ICDP>2.0.CO;2; SCHUBERT SD, 1993, B AM METEOROL SOC, V74, P2331, DOI 10.1175/1520-0477(1993)074<2331:AADFES>2.0.CO;2; Stephens GL, 1996, SCIENCE, V271, P1131, DOI 10.1126/science.271.5252.1131; WHITLOCK CH, 1995, B AM METEOROL SOC, V76, P905, DOI 10.1175/1520-0477(1995)076<0905:FGWSSR>2.0.CO;2; WILD M, 1995, J CLIMATE, V8, P1309, DOI 10.1175/1520-0442(1995)008<1309:VOGCMR>2.0.CO;2	21	145	154	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					779	782		10.1126/science.273.5276.779	http://dx.doi.org/10.1126/science.273.5276.779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670414				2022-12-28	WOS:A1996VB42900037
J	Kassirer, JP				Kassirer, JP			The new health care game	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		Hasan MM, 1996, NEW ENGL J MED, V334, P1055, DOI 10.1056/NEJM199604183341610; Kuttner R, 1996, NEW ENGL J MED, V335, P362, DOI 10.1056/NEJM199608013350524; Kuttner R, 1996, NEW ENGL J MED, V335, P446, DOI 10.1056/NEJM199608083350620; 1996, NEW ENGL J MED, V335, P438; 1996, NEW ENGL J MED, V335, P433	5	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1996	335	6					433	433		10.1056/NEJM199608083350612	http://dx.doi.org/10.1056/NEJM199608083350612			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA904	8663877				2022-12-28	WOS:A1996VA90400012
J	Bow, EJ; Mandell, LA; Louie, TJ; Feld, R; Palmer, M; Zee, B; Pater, J				Bow, EJ; Mandell, LA; Louie, TJ; Feld, R; Palmer, M; Zee, B; Pater, J			Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity	ANNALS OF INTERNAL MEDICINE			English	Article						neutropenia; quinolones; rifampin; norfloxacin	BONE-MARROW TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; ACUTE-LEUKEMIA; GRANULOCYTOPENIC PATIENTS; BACTERIAL-INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE; DOUBLE-BLIND; HEMATOLOGICAL MALIGNANCIES; PREVENTION; PROPHYLAXIS	Objective: To determine whether augmented quinolone-based antibacterial prophylaxis in neutropenic patients with cancer reduces infections caused by grampositive cocci and preserves the protective effect against aerobic gram-negative bacilli. Design: Open, randomized, controlled, multicenter clinical trial. Setting: Centers participating in the National Cancer Institute of Canada Clinical Trials Group. Patients: 111 eligible and evaluable patients hospitalized for severe neutropenia (neutrophil count < 0.5 x 10(9)/L lasting at least 14 days) who were receiving cytotoxic therapy for acute leukemia or bone marrow autografting. Intervention: One of three oral antibacterial prophylactic regimens (norfloxacin, 400 mg every 12 hours; ofloxacin, 400 mg every 12 hours; or ofloxacin, 400 mg, plus rifampin, 300 mg every 12 hours) beginning with cytotoxic therapy. Measurements: Incidence and cause of suspected or proven infection. Results: Microbiologically documented overall infection rates for norfloxacin, ofloxacin, and ofloxacin plus rifampin were 47%, 24%, and 9%, respectively (P < 0.001). Corresponding rates were 24%, 13%, and 3%, respectively for staphylococcal bacteremia (P = 0.03) and, 21%, 3%, and 3%, respectively for streptococcal bacteremia (P < 0.01). The pattern of bacteremia suggested that rifampin played a role in suppressing staphylococcal infection. Both ofloxacin alone and ofloxacin plus rifampin had a clinically significant antistreptococcal effect. Aerobic gram-negative rods were cleared from rectal surveillance cultures in all patients after a median of 5.5 days and caused infection in only one patient (0.9%). The reductions in the number of microbiologically documented infections among ofloxacin recipients and ofloxacin plus rifampin recipients were offset by concomitant increases in the number of unexplained fevers (24% of norfloxacin recipients, 53% of ofloxacin recipients, and 49% of ofloxacin plus rifampin recipients; P = 0.02). No statistically significant difference was found among the treatment arms with respect to the overall incidence of febrile neutropenic episodes as defined for this trial (79% for the norfloxacin group, 82% for the ofloxacin group, and 77% for the ofloxacin plus rifampin group). Conclusions: Quinolone-based antibacterial chemoprophylaxis protected patients from aerobic gram-negative bacillary infections. Augmentation of the gram-positive activity reduced the incidence of gram-positive infections but did not influence the overall incidence:of febrile neutropenic episodes.	HENDERSON GEN HOSP, MCMASTER MED UNIT, HAMILTON, ON L8V 1C3, CANADA; PRINCESS MARGARET HOSP, TORONTO, ON M4X 1K9, CANADA; QUEENS UNIV, NATL CANC INST CANADA, CLIN TRIALS GRP, KINGSTON, ON K7L 3N6, CANADA	McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Queens University - Canada; Canadian Cancer Trials Group	Bow, EJ (corresponding author), HLTH SCI CTR, ROOM GD600, 820 SHERBROOK ST, WINNIPEG, MB R3A 1R9, CANADA.		Zee, Benny Chung Ying/G-5606-2017	Zee, Benny Chung Ying/0000-0002-7238-845X				ARNING M, 1990, J ANTIMICROB CHEMOTH, V26, P137, DOI 10.1093/jac/26.suppl_D.137; ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; BALL P, 1995, CLIN INFECT DIS, V20, P561, DOI 10.1093/clinids/20.3.561; BISHOP JF, 1990, BLOOD, V75, P27; BOCHUD PY, 1994, AM J MED, V97, P256, DOI 10.1016/0002-9343(94)90009-4; BOCHUD PY, 1994, CLIN INFECT DIS, V18, P25, DOI 10.1093/clinids/18.1.25; BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; BOW EJ, 1993, CLIN INFECT DIS, V17, P333, DOI 10.1093/clinids/17.3.333; BOW EJ, 1995, CLIN INFECT DIS, V20, P907, DOI 10.1093/clinids/20.4.907; BOW EJ, 1984, AM J MED, V76, P223, DOI 10.1016/0002-9343(84)90777-0; BOW EJ, 1995, CLIN INFECT DIS, V21, P361, DOI 10.1093/clinids/21.2.361; CALANDRA T, 1991, J INFECT DIS, V163, P951; CARRATALA J, 1995, CLIN INFECT DIS, V20, P557, DOI 10.1093/clinids/20.3.557; COX DR, 1972, J R STAT SOC B, V34, P187; DEKKER AW, 1987, ANN INTERN MED, V106, P7, DOI 10.7326/0003-4819-106-1-7; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DEMARIE S, 1993, EUR J CLIN MICROBIOL, V12, P897; DONNELLY JP, 1992, EUR J CANCER, V28A, P873; Fuchs P C, 1989, Am J Med, V87, p10S; GILBERT C, 1994, J CLIN ONCOL, V12, P1005, DOI 10.1200/JCO.1994.12.5.1005; GLUCKMAN E, 1991, CHEMOTHERAPY, V37, P33, DOI 10.1159/000238904; GUIOT HFL, 1992, ANN HEMATOL, V64, P260, DOI 10.1007/BF01695467; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; JACKSON SK, 1993, EUR J CLIN INVEST, V23, P540, DOI 10.1111/j.1365-2362.1993.tb00963.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KARP JE, 1986, AM J MED, V81, P237, DOI 10.1016/0002-9343(86)90257-3; KERN W, 1990, INFECTION, V18, P138, DOI 10.1007/BF01642101; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P681, DOI 10.1128/AAC.38.4.681; KONNO K, 1973, AM REV RESPIR DIS, V107, P1006; KRAMER BS, 1984, CANCER, V53, P329, DOI 10.1002/1097-0142(19840115)53:2<329::AID-CNCR2820530226>3.0.CO;2-X; LEW MA, 1995, J CLIN ONCOL, V13, P239, DOI 10.1200/JCO.1995.13.1.239; LEW MA, 1991, TRANSPLANTATION, V51, P630, DOI 10.1097/00007890-199103000-00017; LIANG RHS, 1990, ANTIMICROB AGENTS CH, V34, P215, DOI 10.1128/AAC.34.2.215; LOUIE TJ, 1989, REV INFECT DIS, V11, pS1242; PENA C, 1995, ANTIMICROB AGENTS CH, V39, P520, DOI 10.1128/AAC.39.2.520; PIZZO PA, 1990, J INFECT DIS, V161, P397, DOI 10.1093/infdis/161.3.397; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; ROZENBERGARSKA M, 1983, INFECTION, V11, P167, DOI 10.1007/BF01641298; ROZENBERGARSKA M, 1989, INFECTION, V17, P240, DOI 10.1007/BF01639528; SAWADA H, 1991, CHEMOTHERAPY, V37, P25, DOI 10.1159/000238903; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; TANCREDE CH, 1985, J INFECT DIS, V152, P99, DOI 10.1093/infdis/152.1.99; THORNSBERRY C, 1983, REV INFECT DIS, V5, pS412; WARREN RE, 1990, J ANTIMICROB CHEMOTH, V26, P109, DOI 10.1093/jac/26.suppl_F.109; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1990, AM J MED, V88, P36, DOI 10.1016/0002-9343(90)90125-W; WINSTON DJ, 1987, AM J MED, V82, P40, DOI 10.1016/0002-9343(87)90617-6	49	50	52	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					183	+		10.7326/0003-4819-125-3-199608010-00004	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686975				2022-12-28	WOS:A1996UZ28700003
J	Kuttner, R				Kuttner, R			Columbia/HCA and the resurgence of the for-profit hospital business .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Kuttner, R (corresponding author), AMER PROSPECT,6 UNIV RD,CAMBRIDGE,MA 02138, USA.							*AM HOSP ASS, 1995, HOSP STAT EM TRENDS; *AM HOSP ASS, 1995, HOSP STAT EM TRENDS, P2; ARROW KJ, 1963, AM ECON REV, V53, P941; BURDA D, 1996, MODERN HEALTHC  0415, P2; BURDA D, 1996, MODERN HEALTHC  0415, P8; *CAIN BROTH, 1996, PHYS PRACT ACQ WHAT; *COL HOSP CORP, 1993, DRAFT REP; FLOWER J, 1995, HEALTHCARE FORUM MAR, P71; GABAY K, 1996, WHO CONTROLS LOCAL H; *GEORG STAT HLTH P, 1994, HOSP IND CAR SURV TA; GRAY B, 1986, FOR PROFIT ENTERPRIS; *HCA HEALTHC, 1993, 1993 HCA HEALTHC; *HCA HEALTHC, 1995, 1995 HCA HEALTHC; *HCA HEALTHC, 1994, 1994 HCA HEALTHC; *HEALTHC MAN DEC, 1995, COMM BEN TAX EX STAT, P13; HEINECCIUS L, 1995, COLUMBIA HCA NATL PR; *I LEV ASS, 1996, HOSP ACQ REP; KANE NM, 1994, NONPROFIT HOSP STATU; LUTZ S, 1995, PROFIT HEALTHCARE RE, V9, P51; LUTZ S, 1995, MODERN HEALTHCA 1218, P43; McCue MJ, 1996, HEALTH CARE MANAGE R, V21, P38, DOI 10.1097/00004010-199605000-00006; *PARK HUDS RAIN DO, 1994, TENN NOT FOR PROF AN; *PARK HUDS RAIN DO, 1994, FLOR VOL HOSP M HEAL; PATTISON RV, 1983, NEW ENGL J MED, V309, P347, DOI 10.1056/NEJM198308113090606; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; SCOTT RL, 1996, PROFIT HEALTHCARE RE, pR10; *VHA INC, 1995, FLOR HOSP AN; *VHA INC, 1995, VIRG HOSP AN; WATT JM, 1986, NEW ENGL J MED, V314, P89, DOI 10.1056/NEJM198601093140206; [No title captured]; [No title captured]	31	65	65	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					362	367		10.1056/NEJM199608013350524	http://dx.doi.org/10.1056/NEJM199608013350524			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8668228				2022-12-28	WOS:A1996UY98200032
J	Bergmann, JF; Caulin, C				Bergmann, JF; Caulin, C			Heparin prophylaxis in bedridden patients	LANCET			English	Letter							PREVENTION				Bergmann, JF (corresponding author), HOP LARIBOISIERE,CLIN THERAPEUT,F-75475 PARIS 10,FRANCE.		Bergmann, Jean-Francois/L-6044-2017	Bergmann, Jean-Francois/0000-0001-6861-9748				CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; CLEMENT DI, 1994, PREVENTION VENOUS TH, P319; DAHAN R, 1986, HAEMOSTASIS, V16, P159; GARLUND B, 1996, LANCET, V347, P1357; 1992, BRIT MED J, V305, P567	5	63	63	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					205	206		10.1016/S0140-6736(05)66160-0	http://dx.doi.org/10.1016/S0140-6736(05)66160-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684189				2022-12-28	WOS:A1996UX78900068
J	Saunders, AM; Hulette, C; WelshBohmer, KA; Schmechel, DE; Crain, B; Burke, JR; Alberts, MJ; Strittmatter, WJ; Breitner, JCS; Rosenberg, C; Scott, SV; Gaskell, PC; PericakVance, MA; Roses, AD				Saunders, AM; Hulette, C; WelshBohmer, KA; Schmechel, DE; Crain, B; Burke, JR; Alberts, MJ; Strittmatter, WJ; Breitner, JCS; Rosenberg, C; Scott, SV; Gaskell, PC; PericakVance, MA; Roses, AD			Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease	LANCET			English	Article							ADRDA WORK GROUP; CLINICAL-DIAGNOSIS; TYPE-4 ALLELE; FREQUENCY; CRITERIA	Background We aimed to determine the specificity, sensitivity, and predictive value of apolipoprotein E(APOE) genotyping in 67 consecutive Patients with clinical diagnoses of sporadic Alzheimer's disease (AD) who underwent necropsy. Methods We studied patients who attended the Duke Memory Disorders Clinic and were diagnosed as having probable AD. These patients were followed up until they died, APOE genotyping was done during life in most cases, but in some brain tissue obtained at necropsy was used. Members of known AD families were excluded. Findings After neuropathological examination 57 (85%) of 67 of our patients were confirmed as having AD including all 43 who had at least one APOE-is an element of 4 allele. None of the patients found not to have AD carried an is an element of 4 allele, In this series, the specificity of the is an element of 4 allele was 100%, the sensitivity 75%, the positive predictive value 100%, and the negative predictive value 42%. In this necropsy-confirmed series, the is an element of 4/is an element of 4 genotype predicted AD with 100% accuracy. The is an element of 3/is an element of 4 and is an element of 2/is an element of 4 genotypes were also unexpectedly highly specific for AD. Interpretation Data from hundreds of necropsy-confirmed non-AD patients in other longitudinal necropsy series will allow the predictive value oi APOE genotypes to be assessed with useful confidence limits.	DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DEPT MED NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PSYCHIAT,DURHAM,NC 27710	Duke University; Duke University; Duke University			Welsh-Bohmer, Kathleen/AAA-3178-2020; Burke, James R/E-4245-2016	Burke, James R/0000-0002-3408-7787	NIA NIH HHS [5P50 AG-05128] Funding Source: Medline; NINDS NIH HHS [NS-31135] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005128] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRD TD, 1995, ANN NEUROL, V38, P2, DOI 10.1002/ana.410380103; Breitner JCS, 1996, LANCET, V347, P1184, DOI 10.1016/S0140-6736(96)90642-X; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELSTON RC, 1994, ESSENTIAL BIOSTATIST; FARRER LA, 1995, JAMA-J AM MED ASSOC, V274, P1627, DOI 10.1001/jama.1995.03530200063039; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NALBANTOGLU J, 1994, ANN NEUROL, V36, P889, DOI 10.1002/ana.410360614; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; ROSES AD, 1995, EMERY RIMOINS PRINCI; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TIERNEY MC, 1988, NEUROLOGY, V38, P359, DOI 10.1212/WNL.38.3.359; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; YOSHIZAWA T, 1994, ANN NEUROL, V36, P656, DOI 10.1002/ana.410360416	33	215	222	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					90	93		10.1016/S0140-6736(96)01251-2	http://dx.doi.org/10.1016/S0140-6736(96)01251-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676723				2022-12-28	WOS:A1996UW67300011
J	Lloyd, KR; Jenkins, R; Mann, A				Lloyd, KR; Jenkins, R; Mann, A			Long term outcome of patients with neurotic illness in general practice	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; COMMUNITY; INTERVIEW; MORTALITY	Objective-To determine the 11 year outcome of neurotic disorder in general practice. Design-Cohort study over 11 years. Setting-Two general practices in Warwickshire England. Subjects-100 patients selected to be representative of those identified nationally by general practitioners as having neurotic disorders. Main outcome measures-Mortality, morbidity, and use of health services. Results-At 11 years 87 subjects were traced. The 11 year standardised mortality ratio was 173 (95% confidence interval 164 to 200). 47 were cases on the general health questionnaire, 32 had a relapsing or chronic psychiatric course, and 49 a relapsing or chronic physical course. Treatment for psychiatric illness was mainly drugs. The mean number of consultations per year was 10.8 (median 8.7). A persistent psychiatric diagnosis at one year follow up was associated with high attendance (>12 visits a year for 11 years) at follow up after age, sea, and physical illness were adjusted for. Severity of psychiatric illness (general health questionnaire score) at outset predicted general health questionnaire score at 11 year follow up, course of psychiatric illness, and high consultation rate. Conclusion-These data support the view that a neurotic illness can become chronic and is associated with raised mortality from all causes and high use of services. Such patients need effective intervention, particularly those with a more severe illness who do not recover within one year.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	Lloyd, KR (corresponding author), UNIV EXETER,MENTAL HLTH RES UNIT,EXETER EX2 5DW,DEVON,ENGLAND.		Jenkins, Rachel/E-4287-2010; lloyd, keith/H-7458-2012; Jenkins, Rachel/H-2953-2019	Jenkins, Rachel/0000-0002-2958-0331; Jenkins, Rachel/0000-0002-2958-0331				CORNEY R, 1988, SOC PSYCH PSYCH EPID, V23, P39, DOI 10.1007/BF01788441; DOWRICK C, 1995, BMJ-BRIT MED J, V311, P1274, DOI 10.1136/bmj.311.7015.1274; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; ESCOBAR JI, 1987, ARCH GEN PSYCHIAT, V44, P713; GERRARD TJ, 1986, BRIT MED J, V98, P530; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; GOLDBERG DP, 1970, BRIT J PREV SOC MED, V24, P18; Goldberg DP., 1992, COMMON MENTAL DISORD; JENKINS R, 1981, SOC SCI MED-MED PSYC, V15, P195, DOI 10.1016/0271-5384(81)90013-2; Lloyd K, 1993, Int J Soc Psychiatry, V39, P1, DOI 10.1177/002076409303900101; LLOYD K, 1995, BRIT J PSYCHIAT, V166, P60, DOI 10.1192/S0007125000293410; LLOYD K, 1995, ADV PSYCHIAT TREATME, V1, P186; MANN AH, 1981, PSYCHOL MED, V11, P535, DOI 10.1017/S0033291700052855; MANN AH, 1981, PSYCHOL MED, V11, P838; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; SHARP D, 1989, SCI APPROACHES EPIDE, P404; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; SIMS A, 1973, LANCET, V2, P1072; SIMS A, 1978, BRIT J PSYCHIAT, V133, P299, DOI 10.1192/bjp.133.4.299; TAYRER P, 1994, PSYCHIAT GEN PRACTIC, P180; WILLIAMS P, 1989, PSYCHOL DISORDERS GE, P21	21	63	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					26	28		10.1136/bmj.313.7048.26	http://dx.doi.org/10.1136/bmj.313.7048.26			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UW667	8664767	Green Published			2022-12-28	WOS:A1996UW66700028
J	Goldstein, KP; Philipson, TJ; Joe, H; Daum, RS				Goldstein, KP; Philipson, TJ; Joe, H; Daum, RS			The effect of epidemic measles on immunization rates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISSED OPPORTUNITIES; UNITED-STATES; VACCINATION	Objective.-To evaluate whether immunization against a vaccine-preventable disease is sought to avoid the naturally occurring disease itself, we hypothesized that the rate of ''on-time'' measles immunization would increase during an epidemic of that disease. If such an effect occurred, we wondered whether it would have an impact on on-time administration of other recommended immunizations. Design.-Retrospective evaluation of immunization rates of children at their second birthday with the use of computerized health records for children entering kindergarten in an 8-year interval spanning the onset of epidemic measles in Chicago, III, in 1989 and 1990. Setting.-Children entering Chicago public schools. Main Outcome Measures.-Rates of receipt of measles-containing vaccine (MCV), 1 to 4 doses of a diphtheria toxoid-tetanus toxoid-pertussis (DTP) or diphtheria toxoid-tetanus toroid (DT) vaccine, 1 to 3 doses of oral or inactivated polio vaccine (OPV/IPV), and the full series of these vaccines (4:3:1) that are required to be ''up-to-date'' by the second birthday. Results.-The rate of on-time MCV receipt increased from 56% to 58% in the years prior to the epidemic to 70% during the epidemic (1989 and 1990). A similar increase did not occur for DTP/DT 4 or OPV/IPV 3. Moreover, among older children delayed in MCV receipt, evidence of catch-up immunization also occurred during the epidemic years; similar catch-up for delayed DTP/DT 4 or OPV/IPV 3 immunization did not occur. Conclusions.-Dramatic increases in on-time and catch-up MCV receipt occurred during the Chicago measles epidemic of 1989 and 1990. The lack of similar increases in DTP/DT 4 and OPV/IPV 3 suggests MCV receipt was not associated with receipt of other recommended immunizations during that time.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT ECON,CHICAGO,IL 60637	University of Chicago; University of Chicago								ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BOBO JK, 1991, PEDIATRICS, V92, P308; BRUNELL P, 1984, NEWS COMM AM ACAD PE, V35, P12; *COMM INF DIS, 1991, REP COMM INF DIS; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; FARIZO KM, 1992, PEDIATRICS, V89, P589; GUYER B, 1994, PEDIATRICS, V94, P53; LIEU TA, 1994, PEDIATRICS, V93, P373; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; MILLER LA, 1994, PEDIATRICS, V94, P213; MURPHY TV, 1995, PEDIATR INFECT DIS J, V14, P561, DOI 10.1097/00006454-199507000-00002; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; SAS, 1996, SAS STAT SOFTW REL 6; *STATA CORP, 1995, STATA STAT SOFTW REL; SZILAGYI PG, 1994, PEDIATRICS, V94, P517; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; WOOD D, 1995, PEDIATRICS, V96, P295; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1989, MMWR-MORBID MORTAL W, V38, P219; 1984, MMWR-MORBID MORTAL W, V33, P695; 1989, MMWR-MORBID MORTAL W, V39, P317; 1989, MMWR-MORBID MORTAL W, V38, P205; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1995, MMWR-MORBID MORTAL W, V444, P613; 1989, PEDIATRICS, V84, P110	26	22	24	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					56	58		10.1001/jama.276.1.56	http://dx.doi.org/10.1001/jama.276.1.56			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667540				2022-12-28	WOS:A1996UU43900028
J	Lipsitz, LA; Delbanco, TL				Lipsitz, LA; Delbanco, TL			An 85-year-old woman with a history of falls	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ELDERLY PERSONS; RECURRENT FALLS; RISK-FACTORS; PREDICTORS; POPULATION		HARVARD UNIV, SCH MED, BOSTON, MA USA; HEBREW REHABIL CTR AGED, RES & TRAINING INST, BOSTON, MA 02131 USA	Harvard University; Harvard Medical School								ALEXANDER NB, 1994, J AM GERIATR SOC, V42, P93, DOI 10.1111/j.1532-5415.1994.tb06081.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; JANSEN RWMM, 1995, ARCH INTERN MED, V155, P945, DOI 10.1001/archinte.155.9.945; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518, DOI 10.1001/archinte.150.7.1518; KIEL DP, 1991, MED CARE, V29, P221; KING MB, 1995, J AM GERIATR SOC, V43, P1146, DOI 10.1111/j.1532-5415.1995.tb07017.x; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; Lipsitz L A, 1985, Clin Geriatr Med, V1, P637; LIPSITZ LA, 1985, Q J MED, V55, P45; LIPSITZ LA, 1991, J GERONTOL, V46, pM114, DOI 10.1093/geronj/46.4.M114; LIPSITZ LA, 1989, NEW ENGL J MED, V321, P952; MEISSNER I, 1986, NEUROLOGY, V36, P1029, DOI 10.1212/WNL.36.8.1029; MUNRO NC, 1994, J AM GERIATR SOC, V42, P1248, DOI 10.1111/j.1532-5415.1994.tb06505.x; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; SUDARSKY L, 1983, ARCH NEUROL-CHICAGO, V40, P740, DOI 10.1001/archneur.1983.04050110058009; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; WOLFSON L, 1992, PRINCIPLES GERIATRIC, P281; WOOLLACOTT MH, 1990, TOP GERIATR REHABIL, P1	31	9	9	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					59	66		10.1001/jama.276.1.59	http://dx.doi.org/10.1001/jama.276.1.59			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU439	8667541				2022-12-28	WOS:A1996UU43900029
J	Long, AF; Fairfield, G				Long, AF; Fairfield, G			Confusion of levels in monitoring outcomes and/or process	LANCET			English	Editorial Material											Long, AF (corresponding author), NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND.							BECKINGHAM A, 1994, HLTH SUMMARY, V11, P11; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; Dixon P, 1995, OUTCOMES BRIEFING, V6, P4; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; Sheldon T A, 1993, Qual Health Care, V2, P149, DOI 10.1136/qshc.2.3.149; *STROK UN TRIAL CO, 1995, SYST REV SPEC MULT T; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; WIEBERS DO, 1995, EVIDENCE BASED MED, V1, P11	11	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1572	1572		10.1016/S0140-6736(96)91072-7	http://dx.doi.org/10.1016/S0140-6736(96)91072-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667863				2022-12-28	WOS:A1996UP66100006
J	Fournier, AM				Fournier, AM			The longest house call	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Fournier, AM (corresponding author), S SHORE HOSP, 600 ALTON RD, SUITE 502, MIAMI BEACH, FL 33139 USA.								0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					341	342		10.7326/0003-4819-125-4-199608150-00015	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678400				2022-12-28	WOS:A1996VB68000017
J	Heron, E; Chatellier, G; Billaud, E; Foos, E; Plouin, PF				Heron, E; Chatellier, G; Billaud, E; Foos, E; Plouin, PF			The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma	ANNALS OF INTERNAL MEDICINE			English	Article							LIQUID-CHROMATOGRAPHY; METABOLITES	Objective: To compare the operating characteristics of two tests for diagnosing pheochromocytoma: 1) measurement of the ratio between urinary metanephrine and creatinine levels and 2) measurement of urinary metanephrine levels alone. A second objective was to ascertain the reasons for false-positive test results. Design: Cross-sectional study. Setting: Hypertension referral center. Patients: 1013 patients referred for hypertension and tested for pheochromocytoma. Measurements: 24-hour urinary levels of metanephrine (measured using liquid chromatography) and creatinine. The presence of pheochromocytoma was confirmed at surgery. In patients with positive test results, the absence of pheochromocytoma was documented by negative results of retests and imaging procedures. Results: Of 58 patients with increased metanephrine levels or increased metanephrine-to-creatinine ratios, 20 had pheochromocytoma and 38 did not. Of the 38 patients without pheochromocytoma, 15 had high metanephrine levels but normal metanephrine-to-creatinine ratios. The respective operating characteristics of measurement of urinary metanephrine levels and measurement of the metanephrine-to-creatinine ratio were as follows: sensitivity, 95% and 100%; specificity, 98% and 98%; positive predictive value, 46% and 47%; and negative predictive value, 100% and 100%. In 13 of the 23 patients who had a high metanephrine-to-creatinine ratio, various acute events may have caused hypersecretion of catecholamines. Conclusions: Measurement of the metanephrine-to-creatinine ratio is a sensitive and specific test for pheochromocytoma, However, acute events may increase urinary metanephrine excretion to the level that occurs with tumors.	HOP BROUSSAIS, F-75674 PARIS 14, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite								BRAVO EL, 1984, NEW ENGL J MED, V311, P1298, DOI 10.1056/NEJM198411153112007; CROUT R, 1964, J CLIN INVEST, V43, P853; CRYER PE, 1980, NEW ENGL J MED, V303, P436; FUNCKBRENTANO C, 1987, BRIT HEART J, V57, P487; GITLOW SE, 1970, AM J CARDIOL, V26, P270, DOI 10.1016/0002-9149(70)90794-0; KRSTULOVIC AM, 1982, J CHROMATOGR, V229, P1, DOI 10.1016/S0378-4347(00)86033-8; LENDERS JWM, 1995, ANN INTERN MED, V123, P101, DOI 10.7326/0003-4819-123-2-199507150-00004; MANU P, 1984, AM J EPIDEMIOL, V120, P788, DOI 10.1093/oxfordjournals.aje.a113947; PISANO JJ, 1960, CLIN CHIM ACTA, V5, P406; Plouin P F, 1988, Adv Nephrol Necker Hosp, V17, P275; PLOUIN PF, 1981, BRIT MED J, V282, P853, DOI 10.1136/bmj.282.6267.853; SCHATZBERG AF, 1989, ARCH GEN PSYCHIAT, V46, P260; SHIMIZU K, 1993, BAILLIERE CLIN ENDOC, V7, P439, DOI 10.1016/S0950-351X(05)80183-1; SONE H, 1994, LANCET, V344, P476, DOI 10.1016/S0140-6736(94)91809-0; TAUSSKY HH, 1956, CLIN CHIM ACTA, V1, P210, DOI 10.1016/0009-8981(56)90067-5; TROUVIN JH, 1987, J LIQ CHROMATOGR, V10, P731, DOI 10.1080/01483918708069022	16	75	75	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					300	303		10.7326/0003-4819-125-4-199608150-00008	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678394				2022-12-28	WOS:A1996VB68000011
J	Oh, KJ; Zhan, HJ; Cui, C; Hideg, K; Collier, RJ; Hubbell, WL				Oh, KJ; Zhan, HJ; Cui, C; Hideg, K; Collier, RJ; Hubbell, WL			Organization of diphtheria toxin T domain in bilayers: A site-directed spin labeling study	SCIENCE			English	Article							MEMBRANE TRANSLOCATION; TRANSMEMBRANE DOMAIN; PLASMA-MEMBRANE; B-FRAGMENT; LOW PH; CHANNELS; ENTRY; BACTERIORHODOPSIN; INSERTION; RECEPTOR	The diphtheria toxin transmembrane (T) domain was spin-labeled at consecutive residues in a helical segment, TH9. After binding of the T domain to membranes at low pH, the nitroxide side chains generated by spin labeling were measured with respect to their frequency of collision with polar and nonpolar reagents. The data showed that the helical structure of TH9 in solution is conserved, with one face exposed to water and the other to the hydrophobic interior of the bilayer. Measurement of the depth of the nitroxide side chains from the membrane surfaces revealed an incremental change of about 5 angstroms perturn, which is consistent with a transmembrane orientation of an alpha helix. These results indicate that the helix forms the lining of a transmembrane water-filled channel.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90095; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; University of Pecs				OH, KYOUNG JOON/0000-0002-4729-9674; Collier, R John/0000-0002-2427-4239	NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021, R01AI022848] Funding Source: NIH RePORTER; NEI NIH HHS [EY-05216] Funding Source: Medline; NIAID NIH HHS [AI-22848, AI-22021] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; CABIAUX V, 1994, MOL MICROBIOL, V11, P43, DOI 10.1111/j.1365-2958.1994.tb00288.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1968, J BIOL CHEM, V243, P3553; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; HUBBELL WL, 1994, MEMBRANE PROTEIN STR, P00224; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCHAOURAB H, IN PRESS BIOCHEMISTR; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSS J, 1995, BACTERIAL TOXINS VIR, V8; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; VANNESS BG, 1980, J BIOL CHEM, V255, P717; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	34	113	114	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					810	812		10.1126/science.273.5276.810	http://dx.doi.org/10.1126/science.273.5276.810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670424				2022-12-28	WOS:A1996VB42900047
J	Mallonee, S; Shariat, S; Stennies, G; Waxweiler, R; Hogan, D; Jordan, F				Mallonee, S; Shariat, S; Stennies, G; Waxweiler, R; Hogan, D; Jordan, F			Physical injuries and fatalities resulting from the Oklahoma City bombing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLAST INJURY; TERRORIST; CASUALTIES; EXPLOSION	Objective.-To provide an epidemiologic description of physical injuries and fatalities resulting from the April 19, 1995, bombing of the Alfred P. Murrah Federal Building in Oklahoma City. Design and Setting.-Descriptive epidemiologic study of all persons injured by the bombing and of all at-risk occupants of the federal building and 4 adjacent buildings. Data were gathered from hospital emergency and medical records departments, medical examiner records. and surveys of area physicians. building occupants, and survivors. Study Population.-All persons known to have been exposed to the blast. Main Outcome Measures.-Characteristics of fatalities and injuries, injury maps, and injury rates by building location. Results.-A total of 759 persons sustained injuries. 167 persons died. 83 survivors were hospitalized, and 509 persons were treated as outpatients, Of the 361 persons who were in the federal building, 319 (88%) were injured, of whom 163 (45%) died. including 19 children. Persons in the collapsed part of the federal building were significantly more likely to die (153/175, 87%) than those in other parts of the building (10/186, 5%) (risk ratio [RR], 16.3, 95% confidence interval [CI], 8.9-29.8). In 4 adjacent buildings, injury rates varied from 38% to 100%; 3 persons in these buildings and 1 person in an outdoor location died. The mast frequent cause of death was multiple injuries. Among survivors, soft tissue injuries, fractures, sprains, strains, and head injuries were most common: these injuries were most often caused by flying glass and other debris and collapsed ceilings. Conclusions.-The Oklahoma City bombing resulted in the largest number of fatalities of any terrorist act in the United Stales, and there were 4 times as many nonfatal injuries as fatalities, Disaster management plans should include the possibility of terrorist bombing, and medical preparedness should anticipate that most injuries will be nonfatal, The role of building collapse in fatal injuries and the role of glass and other flying debris in minor to moderate injuries should be considered in the design of buildings at high risk of being bombed so as to reduce injuries.	CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; UNIV OKLAHOMA,COLL MED,OKLAHOMA CITY,OK; OFF CHIEF MED EXAMINER,OKLAHOMA CITY,OK	Centers for Disease Control & Prevention - USA; University of Oklahoma System; University of Oklahoma Health Sciences Center	Mallonee, S (corresponding author), OKLAHOMA DEPT HLTH,INJURY PREVENT SERV 0307,1000 NE 10TH ST,OKLAHOMA CITY,OK 73177, USA.							ADLER J, 1983, ISRAEL J MED SCI, V19, P189; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; *AUT INC, 1994, AUT REL 13; BELLAMY RF, 1991, CONVENTIONAL WARFA 1, V5, P2; Boffard K D, 1993, Surg Annu, V25 Pt 1, P29; BRYSMAR B, 1982, J TRAUMA, V22, P216; COOPER GJ, 1983, J TRAUMA, V23, P955, DOI 10.1097/00005373-198311000-00001; *CTR DIS CONTR PRE, 1994, EPI INF VERS 6; *FED BUR INV, 1995, 1994 BOMB SUMM; FRYKBERG ER, 1989, AM SURGEON, V55, P134; FRYKBERG ER, 1988, ANN SURG, V28, P569; HADDEN WA, 1978, BRIT J SURG, V65, P525, DOI 10.1002/bjs.1800650802; HILL JF, 1979, ANN ROY COLL SURG, V61, P4; HULL J B, 1992, Journal of Audiovisual Media in Medicine, V15, P121, DOI 10.3109/17453059209018366; KARMYJONES R, 1994, MIL MED, V159, P536, DOI 10.1093/milmed/159.7.536; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; MCMANAMY R, 1995, ENG NEWS RECORD 0501, P10; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; Mellor S G, 1988, Br J Hosp Med, V39, P536; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; National Research Council, 1995, PROT BUILD BOMB DAM; Phillips Y.Y., 1991, CONVENTIONAL WARFARE, P221; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; STAPCZYNSKI JS, 1992, ANN EMERG MED, V11, P687; WHITE CS, 1968, ANN NY ACAD SCI, V152, P89, DOI 10.1111/j.1749-6632.1968.tb11969.x; WOLF M, 1991, MIL MED, V156, P651, DOI 10.1093/milmed/156.12.651	26	174	177	2	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					382	387		10.1001/jama.276.5.382	http://dx.doi.org/10.1001/jama.276.5.382			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683816				2022-12-28	WOS:A1996UZ77600019
J	Michael, M				Michael, M			Medical supplies donated to hospitals in Bosnia and Croatia, 1994-1995 - Report of a survey evaluating humanitarian aid in war	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate access to and distribution and quality of medical supplies donated by humanitarian aid organizations to hospitals and health services during the war in Bosnia and Croatia. Design.-Retrospective survey of 68 representatives of hospitals and field hospitals regularly caring for inpatients between May 1994 and April 1995. Setting.-Three study areas: the Republic and Federation of Bosnia-Herzegovina, Republika Srpska (part of Bosnia-Herzegovina controlled by Bosnian Serbs), and Republika Srpska Krajina (part of Croatia controlled by Croatian Serbs during the study period). Participants.-Of 68 hospital representatives: 44 completed the survey (65% response rate). Respondents did not include representatives from 11 hospitals and field hospitals that could not be contacted because of operational obstacles resulting from the ongoing war. Results.-Lack of supplies was reported as an important limitation by 62%, (26/42) of respondents, followed by lack of staff and security, physical isolation, and lack of infrastructure. Antibiotics were mentioned by 76% (32/42) of respondents as the unavailable drug or item most urgently needed. The majority of drug and medical supplies used to treat patients had been supplied by 5 humanitarian aid organizations. The frequency with which respondents mentioned their ''own means'' (eg, from the ministry of health or respective municipalities) was relatively low (9%), reflecting the high degree of dependency on humanitarian aid. All respondents rated the quality of donated supplies and the working relationship with the donating organization as ''very good'' or ''satisfactory''; 93% (41/44) of respondents indicated that the donated supplies were appropriate. Six of 44 respondents preferred to receive supplies as part of assembled kits: 70% (31/44) preferred to receive such assistance as loose supplies according to demand. Conclusion.-During war, access and security are beyond the control of humanitarian agencies. Assistance coordination. however. must be provided. Although a consensus on policies and objectives between different humanitarian organizations is difficult to reach, satisfactory complementarity can be achieved. The systematic and continuous gathering of information at the recipient and user level. beginning at the early phase of the conflict, is recommended to maintain appropriate assistance.			Michael, M (corresponding author), RED CROSS,HLTH DIV,INT COMM,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							ADAMS M, 1994, ORG ADAPTATION CONFL; CASSEN R, 1986, SYSTEMIC EFFECTS AID; DUFFIELD M, 1994, ACCOUNT RELIEF OPERA; ROSS DJ, 1990, PUBLIC ADMIN DEVELOP, V10, P331, DOI 10.1002/pad.4230100308; *UN HIGH COMM REF, 1994, PREW CENS WART POP E; *WHO, 1995, 1994 WHO REG OFF EUR; World Health Organization, 1992, WHO TECHN REP SER, V825; ZWI A, 1989, SOC SCI MED, V28, P633, DOI 10.1016/0277-9536(89)90210-4	8	7	7	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					364	368		10.1001/jama.276.5.364	http://dx.doi.org/10.1001/jama.276.5.364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ776	8683809				2022-12-28	WOS:A1996UZ77600006
J	Li, H; Helling, R; Tang, C; Wingreen, N				Li, H; Helling, R; Tang, C; Wingreen, N			Emergence of preferred structures in a simple model of protein folding	SCIENCE			English	Article							GLOBULAR-PROTEINS; STABILITY; FORCES	Protein structures in nature often exhibit a high degree of regularity (for example, secondary structure and tertiary symmetries) that is absent from random compact conformations. With the use of a simple lattice model of protein folding, it was demonstrated that structural regularities are related to high ''designability'' and evolutionary stability. The designability of each compact structure is measured by the number oi sequences that can design the structure-that is, sequences that possess the structure as their nondegenerate ground state. Compact structures differ markedly in terms of their designability; highly designable structures emerge with a number of associated sequences much larger than the average. These highly designable structures possess ''proteinlike'' secondary structure and even tertiary symmetries. In addition, they are thermodynamically more stable than other structures. These results suggest that protein structures arg selected in nature because they are readily designed and stable against mutations, and that such a selection simultaneously leads to thermodynamic stability.	NEC RES INST,PRINCETON,NJ 08540	NEC Corporation				Tang, Chao/0000-0003-1474-3705				ABKEVICH VI, 1995, J MOL BIOL, V252, P460, DOI 10.1006/jmbi.1995.0511; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Chan HS, 1996, PROTEINS, V24, P335, DOI 10.1002/(SICI)1097-0134(199603)24:3<335::AID-PROT6>3.0.CO;2-F; CHAN HS, 1991, J CHEM PHYS, V95, P3775, DOI 10.1063/1.460828; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; CREIGHTON TE, 1992, PROTEIN FOLDING; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; GOVINDARAJAN S, 1995, BIOPOLYMERS, V36, P43, DOI 10.1002/bip.360360105; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAU KF, 1990, P NATL ACAD SCI USA, V87, P638, DOI 10.1073/pnas.87.2.638; LAU KF, 1989, MACROMOLECULES, V22, P3986, DOI 10.1021/ma00200a030; Li H., COMMUNICATION; Melin R., UNPUB; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; YUE K, 1995, P NATL ACAD SCI USA, V92, P146, DOI 10.1073/pnas.92.1.146	21	551	576	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					666	669		10.1126/science.273.5275.666	http://dx.doi.org/10.1126/science.273.5275.666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662562	Green Submitted			2022-12-28	WOS:A1996VA24900054
J	Ducy, P; Desbois, C; Boyce, B; Pinero, G; Story, B; Dunstan, C; Smith, E; Bonadio, J; Goldstein, S; Gundberg, C; Bradley, A; Karsenty, G				Ducy, P; Desbois, C; Boyce, B; Pinero, G; Story, B; Dunstan, C; Smith, E; Bonadio, J; Goldstein, S; Gundberg, C; Bradley, A; Karsenty, G			Increased bone formation in osteocalcin-deficient mice	NATURE			English	Article							MATRIX GLA PROTEIN; RAT BONE; MOUSE; EXPRESSION; GENE; INTERLEUKIN-6; OSTEOPONTIN; OSTEOCLASTS; MARKER; FORM	VERTEBRATES constantly remodel bone. The resorption of preexisting bone by osteoclasts and the formation of new hone by osteoblasts is strictly coordinated to maintain bone mass within defined limits. A fen molecular determinants of bone remodelling that affect osteoclast activity(1-3) have been characterized, bot the molecular determinants of osteoblast activity are unknown. To investigate the role of osteocalcin, the most abundant osteoblast-specific non-collagenous protein(4) we have generated osteocalcin-deficient mice. These mice develop a phenotype marked by higher bone mass and bones of Improved functional quality. Histomorphometric studies done before and after ovariectomy showed that the absence of osteocalcin leads to an increase in bone formation without impairing bone resorption. To our knowledge, this study provides the first evidence that osteocalcin is a determinant of bone formation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; UNIV TEXAS,DENT BRANCH,DEPT BASIC SCI,HOUSTON,TX 77030; UNIV MICHIGAN,SCH MED,DEPT ORTHOPAED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; YALE UNIV,SCH MED,DEPT ORTHOPAED,NEW HAVEN,CT 06510; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine			Morris, Christelle/M-8168-2014; Dunstan, Colin/G-6214-2013	Morris, Christelle/0000-0003-1575-4609; Dunstan, Colin/0000-0001-7586-4071; Bradley, Allan/0000-0002-2349-8839				ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; BAIN SD, 1993, J BONE MINER RES, V8, P435; BOIVIN G, 1990, VIRCHOWS ARCH A, V417, P505, DOI 10.1007/BF01625731; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; GRIGORIADIS AE, 1994, SCIENCE, V266, P143; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LUO GB, 1995, J BONE MINER RES, V10, P325; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1988, OSTEOPOROSIS ETIOLOG, P501; Partlow D. P., 1987, Journal of Materials Research, V2, P595, DOI 10.1557/JMR.1987.0595; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SONANO P, 1991, CELL, V64, P693; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VIGNERY A, 1980, ANAT REC, V196, P191, DOI 10.1002/ar.1091960210; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEINREB M, 1990, J BONE MINER RES, V5, P831	25	1256	1320	2	108	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					448	452		10.1038/382448a0	http://dx.doi.org/10.1038/382448a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684484	Green Submitted			2022-12-28	WOS:A1996VA25100056
J	Day, NPJ; Phu, NH; Bethell, DP; Mai, NTH; Chau, TTH; Hien, TT; White, NJ				Day, NPJ; Phu, NH; Bethell, DP; Mai, NTH; Chau, TTH; Hien, TT; White, NJ			The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection	LANCET			English	Article							SEPTIC SHOCK; OXYGEN-TRANSPORT; LACTIC-ACIDOSIS; EPINEPHRINE; HEMODYNAMICS; HYPOGLYCEMIA; SEPSIS	Background Adrenaline is used increasingly in the management of septic shock, but its efficacy and safety are uncertain. Methods In an open, randomised, crossover study we compared the effects of stepped doses of adrenaline 0.1 to 0.5 mu g/kg per min and dopamine 2.5 to 10 mu g/kg per min on the haemodynamic and acid-base status of 23 patients critically ill with severe sepsis (n=10) or severe malaria (n=13). Findings All patients completed the dopamine study whereas in 16 (84%) patients the adrenaline infusion had to be terminated before reaching, or during, the maximum dose because of lactic acidosis (p<0.0002). Adrenaline was associated with a mean (95% Cl) increase in plasma lactate of 3.2 (2.6 to 3.8) mmol/L, and mean falls in arterial pH of 0.052 (0.035-0.068) pH units and base excess of 3.8 (2.8-4.7) mmol/L. The geometric mean (95% CI) lactate increment per unit adrenaline dose was 8.2 (5.8-10.5) mmol/L per mu g/kg per min. In contrast dopamine was associated with a fall in lactate of 1.0 (0.4-1.5) mmol/L, a rise in base excess of 1.4 (0.7 to 2.0) mmol/L (p<0.0001 in each case), and no effect on arterial pH. Both drugs induced significant increases in cardiac index and oxygen delivery with smaller increases in oxygen consumption and falls in systemic vascular resistance which were similar in severe malaria and severe sepsis (p>0.1 in each case), but there was no increase in oxygen consumption. Interpretation Infusion of inotropic doses of adrenaline in severe infections causes lactic acidosis.	UNIV OXFORD,NUFFIELD DEPT CLIN MED,CTR TROP MED,OXFORD,ENGLAND; CHO QUAN HOSP,CTR TROP DIS,WELLCOME TRUST CLIN RES UNIT,HO CHI MIHN,VIETNAM	University of Oxford	Day, NPJ (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,CTR TROP MED,LEVEL 7,OXFORD OX3 8AJ,ENGLAND.		White, Nick/AAC-6527-2019; Thi, Nguyen/AAM-7074-2020; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEARN AG, 1951, J PHYSIOL-LONDON, V115, P430, DOI 10.1113/jphysiol.1951.sp004679; BOLLAERT PE, 1990, CHEST, V98, P949, DOI 10.1378/chest.98.4.949; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CLUTTER WE, 1980, J CLIN INVEST, V66, P94, DOI 10.1172/JCI109840; COHEN RD, 1992, HYPOXIA METABOLIC AC, P85; CORRALL RJM, 1981, EUR J CLIN INVEST, V11, P279, DOI 10.1111/j.1365-2362.1981.tb02117.x; Edwards J. D., 1993, OXYGEN TRANSPORT PRI; EINSINGER H, 1992, EUR J ANAESTH, V9, P435; FRIEDMAN G, 1995, CRIT CARE MED, V23, P1184, DOI 10.1097/00003246-199507000-00006; GAESSER GA, 1994, J APPL PHYSIOL, V77, P2413, DOI 10.1152/jappl.1994.77.5.2413; GILBERT EM, 1986, AM REV RESPIR DIS, V134, P873, DOI 10.1164/arrd.1986.134.5.873; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5; LUNDHOLM L, 1965, ACTA PHYSIOL SCAND, V65, P344, DOI 10.1111/j.1748-1716.1965.tb04283.x; MACKENZIE SJ, 1991, INTENS CARE MED, V17, P36, DOI 10.1007/BF01708407; MURPHY FT, 1995, SOUTHERN MED J, V88, P577; ORRINGER CE, 1977, NEW ENGL J MED, V297, P796, DOI 10.1056/NEJM197710132971502; PUKRITTAYAMAKAM.S, 1991, CLIN SCI, V82, P63; RIVERS E, 1994, CHEST, V106, P1315; RUOKONEN E, 1993, CRIT CARE MED, V21, P1296; SALWAY JG, 1994, METABOLISM GLANCE; WARRELL DA, 1988, LANCET, V2, P534; WILSON W, 1992, ANAESTH INTENS CARE, V20, P470, DOI 10.1177/0310057X9202000413; 1990, T ROY SOC TROP ME S2, V84, P1	24	152	161	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					219	223		10.1016/S0140-6736(96)09096-4	http://dx.doi.org/10.1016/S0140-6736(96)09096-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684198				2022-12-28	WOS:A1996UZ28600009
J	Field, D; Davis, C; Elbourne, D; Grant, A; Johnson, A; Macrae, D				Field, D; Davis, C; Elbourne, D; Grant, A; Johnson, A; Macrae, D			UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation	LANCET			English	Article							PERSISTENT PULMONARY-HYPERTENSION	Background Extracorporeal membrane oxygenation (ECMO) is a complex and expensive technology that can be used to provide temporary support during respiratory failure. Its value for mature newborn infants is controversial because of varying interpretation of the available evidence. We undertook a collaborative trial throughout the UK to assess whether a policy of referral for ECMO has a beneficial effect on survival to 1 year without severe disability in comparison with conventional management. Methods Between 1993 and 1995, 185 mature (gestational age at birth greater than or equal to 35 weeks, birthweight greater than or equal to 2 kg) newborn infants with severe respiratory failure (oxygenation index greater than or equal to 40) were enrolled from 55 hospitals in a randomised comparison of either referral to one of five specialist centres for consideration of ECMO or continued intensive conventional management at the original hospital. The most common diagnoses were persistent pulmonary hypertension due to meconium aspiration, congenital diaphragmatic hernia, isolated persistent fetal circulation, sepsis, and idiopathic respiratory distress syndrome. Of the infants allocated ECMO, 84% received this support. Recruitment to the trial was stopped early (November, 1995) by the trial steering committee on the advice of the independent data-monitoring committee, because the data accumulated showed a clear advantage with ECMO, 124 children were enrolled before December, 1994; those who survived to 1 year of age have undergone neurological assessment at that age (by one of three developmental paediatricians unaware of treatment allocation). Findings Overall, 81 (44%) infants died before leaving hospital, and two are known to have died later. Death rates differed between the two trial groups; 30 of 93 infants allocated ECMO died compared 54 of 92 allocated conventional care. The relative was 0 . 55 (95% CI 0 . 39-0 . 77; p=0 . 0005), which is equivalent to one extra survivor for every three to four infants allocated ECMO. The difference in survival applied irrespective of the primary diagnosis, disease severity, and type of referral centre. The benefit of ECMO was also found for the primary outcome measure of death or disability at 1 year (among 124 children enrolled before December, 1994). One child in each group has severe disability (overall Griffiths' developmental quotient <50, or untestable), and 16 (ten ECMO, six conventional management) have impairments with a lesser degree of disability. Interpretation These preliminary results demonstrate the clinical effectiveness of a well-staffed and organised neonatal ECMO service. ECMO support should be actively considered for neonates with severe but potentially reversible respiratory failure.			Field, D (corresponding author), UNIV LEICESTER, LEICESTER ROYAL INFIRM, DEPT CHILD HLTH, CLIN SCI BLDG, LEICESTER LE1 5WW, LEICS, ENGLAND.		Macrae, Duncan/AAC-9564-2020	Johnson, Anne/0000-0003-1330-7100	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTLETT RH, 1990, CURR PROB SURG, V27, P623; BIFANO E M, 1992, Pediatric Research, V31, p196A; BOEDY RF, 1990, J PEDIATR-US, V117, P462, DOI 10.1016/S0022-3476(05)81098-4; *DEP HLTH, 1993, ANN REP DEP HLTH, V2, P119; DWORETZ AR, 1989, PEDIATRICS, V84, P1; FIELD D, 1995, LANCET, V345, P1370; GREENOUGH A, 1990, LANCET, V336, P760, DOI 10.1016/0140-6736(90)92264-I; GROSS SJ, 1994, PEDIATR RES, V36, pA17, DOI 10.1203/00006450-199407000-00086; Hallam L, 1996, HEALTH ECON, V5, P167, DOI 10.1002/(SICI)1099-1050(199603)5:2<167::AID-HEC192>3.0.CO;2-N; HALLMAN M, 1985, J PEDIATR-US, V106, P963, DOI 10.1016/S0022-3476(85)80253-5; HOWARD S, 1995, HEALTH ECON, V4, P265, DOI 10.1002/hec.4730040403; Howard S, 1996, INT J TECHNOL ASSESS, V12, P80, DOI 10.1017/S0266462300009417; Mok Q, 1996, BRIT MED J, V312, P119; OROURKE PP, 1989, PEDIATRICS, V84, P957; RIVERS R, 1994, ARCH DIS CHILD-FETAL, V70, pF160, DOI 10.1136/fn.70.2.F160; Schumacher R E, 1993, ASAIO J, V39, P873, DOI 10.1097/00002480-199310000-00010; SMITH R, 1991, BRIT MED J, V302, P1304; STOLAR CJH, 1991, J PEDIATR SURG, V26, P563, DOI 10.1016/0022-3468(91)90708-2; TARNOWMORDI WO, 1992, MRC NEWS, V57, P16; *WHO, 1980, INT CLASS IMP DIS HA, P143; World Health Organization, 1980, INT CLASS IMP DIS HA, P47; 1988, LANCET, V2, P1289; 1989, STAT SCI, V4, P298	23	521	526	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	1996	348	9020					75	82						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676720				2022-12-28	WOS:A1996UW67300008
J	Parker, LJ; Atou, T; Badding, JV				Parker, LJ; Atou, T; Badding, JV			Transition element-like chemistry for potassium under pressure	SCIENCE			English	Article							EARTHS CORE; SIDEROPHILE ELEMENTS; PHASE-TRANSITIONS; CESIUM; IRON; TEMPERATURES; KBAR; GPA; RB	At high pressure the alkali metals potassium, rubidium, and cesium transform to metals that have a d(1) electron configuration, becoming transition metal-like. As a result, compounds were shown to form between potassium and the transition metal nickel. These results demonstrate that the chemical behavior of the alkali metals under pressure is very different from that under ambient conditions, where alkali metals and transition metals do not react because of large differences in size and electronic structure. They also have significant implications for the hypothesis that potassium is incorporated into Earth's core.	PENN STATE UNIV,DEPT CHEM,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Atou, Toshiyuki/F-2849-2014; Badding, John/A-2737-2011	Badding, John/0000-0002-4517-830X				ATOU T, 1995, REV SCI INSTRUM, V66, P4496, DOI 10.1063/1.1145348; ATOU T, UNPUB; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; BUKOWINSKI MST, 1977, HIGH PRESSURE RES AP, P367; Goettel K. A., 1976, Geophysical Surveys, V2, P369, DOI 10.1007/BF01454192; Goettel K. A., 1972, Physics of the Earth and Planetary Interiors, V6, P161, DOI 10.1016/0031-9201(72)90049-0; HILLGREN VJ, 1994, SCIENCE, V264, P1442, DOI 10.1126/science.264.5164.1442; ITO E, 1993, GEOPHYS RES LETT, V20, P1651, DOI 10.1029/93GL01538; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; JEANLOZ R, 1989, ANNU REV PHYS CHEM, V40, P237; JONES JH, 1992, SCIENCE, V257, P1281, DOI 10.1126/science.257.5074.1281; LIU L, 1986, GEOPHYS RES LETT, V13, P1145, DOI 10.1029/GL013i011p01145; LIU LG, 1986, J PHYS CHEM SOLIDS, V47, P1067, DOI 10.1016/0022-3697(86)90073-9; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; Massalski T.B., 1996, BINARY ALLOY PHASE D, Vsecond; MIEDEMA AR, 1980, PHYSICA B & C, V100, P1, DOI 10.1016/0378-4363(80)90054-6; MURTHY VR, 1991, SCIENCE, V253, P303, DOI 10.1126/science.253.5017.303; OLIJNYK H, 1983, PHYS LETT A, V99, P381, DOI 10.1016/0375-9601(83)90298-0; PETTIFOR DG, 1987, SOLID STATE PHYS, V40, P4392; SHEN GY, 1993, PHYS CHEM MINER, V20, P91; SHERMAN DM, 1990, GEOPHYS RES LETT, V17, P693, DOI 10.1029/GL017i006p00693; TAKEMURA K, 1985, PHYS REV B, V32, P2213, DOI 10.1103/PhysRevB.32.2213; TAKEMURA K, 1982, PHYS REV LETT, V49, P1772, DOI 10.1103/PhysRevLett.49.1772; TAKEMURA K, 1991, PHYS REV LETT, V66, P2014, DOI 10.1103/PhysRevLett.66.2014; TAKEMURA K, 1983, PHYS REV B, V28, P1193, DOI 10.1103/PhysRevB.28.1193; TUPS H, 1982, PHYS REV LETT, V49, P1776, DOI 10.1103/PhysRevLett.49.1776; VIJAYAKUMAR V, 1991, PHYS LETT A, V152, P353, DOI 10.1016/0375-9601(91)90737-S; VONSCHNERING HG, 1987, ANGEW CHEM INT EDIT, V26, P1059, DOI 10.1002/anie.198710593; WINZENICK M, 1994, PHYS REV B, V50, P12381, DOI 10.1103/PhysRevB.50.12381; WINZENICK M, 1994, PHYS REV B, V50, P381; WITTIG J, 1970, PHYS REV LETT, V24, P812, DOI 10.1103/PhysRevLett.24.812; Young DA, 1991, PHASE DIAGRAMS ELEME	32	105	107	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					95	97		10.1126/science.273.5271.95	http://dx.doi.org/10.1126/science.273.5271.95			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688059				2022-12-28	WOS:A1996UV47800046
J	[Anonymous]				[Anonymous]			The Ljubljana Charter on reforming health care	BRITISH MEDICAL JOURNAL			English	Article																			0	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1664	1665						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664727				2022-12-28	WOS:A1996UV48900033
J	McClure, N; Gallagher, AG; McGuigan, J				McClure, N; Gallagher, AG; McGuigan, J			Randomised trial of laparoscopic versus small-incision cholecystectomy	LANCET			English	Letter									QUEENS UNIV BELFAST,DEPT SURG,QUCENTR,INST CLIN SCI,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND	Queens University Belfast				Gallagher, Anthony G./0000-0003-0887-5613				WHERRY DC, 1994, ANN SURG, V220, P626, DOI 10.1097/00000658-199411000-00005	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1623	1623						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667889				2022-12-28	WOS:A1996UP66100047
J	Volberding, PA				Volberding, PA			Age as a predictor of progression in HIV infection	LANCET			English	Editorial Material							IMMUNODEFICIENCY				Volberding, PA (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,SCH MED,AIDS PROGRAM,SAN FRANCISCO,CA 94110, USA.							APOLONIO EG, 1995, J INFECT DIS, V171, P829, DOI 10.1093/infdis/171.4.829; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; ROSENBERG PS, 1994, AIDS, V8, P804; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; VEUGELERS PJ, 1994, AIDS, V8, P1471, DOI 10.1097/00002030-199410000-00015	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1569	1570		10.1016/S0140-6736(96)91069-7	http://dx.doi.org/10.1016/S0140-6736(96)91069-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667860				2022-12-28	WOS:A1996UP66100003
J	vonMutius, E; Illi, S; Nicolai, T; Martinez, FD				vonMutius, E; Illi, S; Nicolai, T; Martinez, FD			Relation of indoor heating with asthma, allergic sensitisation, and bronchial responsiveness: Survey of children in south Bavaria	BRITISH MEDICAL JOURNAL			English	Article							WOOD-BURNING STOVES; AIR	Objective-To investigate the relation between different types of heating and the prevalence of atopic diseases, skin test reactivity, and bronchial hyperresponsiveness. Design-Cross sectional survey-among school-children aged 9-11 years. Skin prick tests, pulmonary function tests, and bronchial challenge in the children and self completion of a written questionnaire by the children's parents. Subjects-1958 children in a rural area in southern Bavaria, Germany. Main outcome measures-Prevalence of asthma, hay fever, and atopic dermatitis as determined by parents' answers to a questionnaire; the atopic status of the child assessed by skin prick tests; and bronchial responsiveness to cold air challenge in the children. Resuls-After possible confounders were controlled for, the risk of developing hay fever (odds ratio=0.57; 95% confidence interval 0.34 to 0.98), atopy defined as at least one positive reaction to a panel of common aeroallergens (0.67; 0.49 to 0.93), sensitisation to pollen (0.60; 0.41 to 0.87), and of bronchial hyperresponsiveness (0.55;0.34-0.90) was significantly lower in children living in homes where coal or wood was used for heating than in children living in homes with other heating systems. Conclusions-Factors directly or indirectly related to the heating systems used in rural Bavarian homes decrease the susceptibility of children to becoming atopic and to developing bronchial hyperresponsiveness.	UNIV MUNICH,CHILDRENS HOSP,D-80337 MUNICH,GERMANY; UNIV ARIZONA,RESP SCI CTR,DEPT PEDIAT,TUCSON,AZ 85724	University of Munich; University of Arizona					NHLBI NIH HHS [HL15136] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BUTTERFIELD P, 1989, J ENVIRON HEALTH, V52, P172; COLLOFF MJ, 1994, CLIN EXP ALLERGY, V24, P94, DOI 10.1111/j.1365-2222.1994.tb00202.x; GOLD DR, 1992, CLIN CHEST MED, V13, P215; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HONICKY RE, 1985, PEDIATRICS, V75, P587; KOSSOVE D, 1982, S AFR MED J, V61, P622; LARSON TV, 1994, ANNU REV PUBL HEALTH, V15, P133, DOI 10.1146/annurev.pu.15.050194.001025; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MORRIS K, 1990, AM J DIS CHILD, V144, P105, DOI 10.1001/archpedi.1990.02150250117047; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; PANDEY MR, 1987, INDOOR AIR QUALITY 1, V3, P25; SAMET JM, 1991, INDOOR AIR POLLUTION, P170; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	18	82	83	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1448	1450		10.1136/bmj.312.7044.1448	http://dx.doi.org/10.1136/bmj.312.7044.1448			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664621	Green Published			2022-12-28	WOS:A1996UQ29600023
J	Whitworth, AB; Fischer, F; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Fleischhacher, WW				Whitworth, AB; Fischer, F; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Fleischhacher, WW			Comparison of acamprosate and placebo in long-term treatment of alcohol dependence	LANCET			English	Article							CA-ACETYL-HOMOTAURINATE; WEANED ALCOHOLICS; DOUBLE-BLIND; RATS; GABA; NALTREXONE; RECEPTORS; THERAPY; ETHANOL; ACID	Background About 50% of alcoholic patients relapse within 3 months of treatment. Previous studies have suggested that acamprosate may help to prevent such relapse. The aim of our study was to assess the efficacy and safety of long-term acamprosate treatment in alcohol dependence. Methods In this multicentre, double-blind, placebo-controlled study, we recruited 455 patients, aged 18-65 years, with chronic or episodic alcohol dependence. Patients were randomly allocated treatment with acamprosate (1998 mg daily for bodyweight >60 kg; 1332 mg daily for less than or equal to 60 kg) or placebo for 360 days. Patients were assessed on the day treatment started and on days 30, 90, 180, 270, and 360 by interview, self-report, questionnaire, and laboratory screening. Patients were classified as abstinent, relapsing, or non-attending Time to first treatment failure (relapse or non-attendance) was the primary outcome measure. Findings Seven patients were excluded from the intention-to-treat analysis because they did not attend on the first treatment day and therefore received no medication. The acamprosate (n=224) and placebo (n=224) groups were well matched in terms of baseline demographic and alcohol-related variables. 94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase: of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness, three (two vs one) died, ten (six vs four) had adverse side-effects, one (acamprosate treated) received the wrong medication, and three (placebo treated) were non-compliant. The proportion without treatment failure was higher in the acamprosate than in the placebo group throughout the treatment period (p<0.001, Mantel-Cox). At the end of treatment, 41 (18.3%) acamprosate-treated and 16 (7.1%) placebo-treated patients had been continuously abstinent (p=0.007). Mean cumulative abstinence significantly greater in the acamprosate in the placebo group (138.8 [SD 137.5] vs 103.8 [11.0] days; p=0.012). 148 patients (79 acamprosate, 69 placebo) completed 27 months' follow-up: 27 (11.9%) acamprosate-treated and 11 (4.9%) placebo-treated patients remained continuously abstinent, and the mean cumulative abstinence duration was 230.8 days (259.1) and 183.0 days (235.2), respectively. Apart from occasional diarrhoea, there was no difference in side-effects between groups. Interpretation Acamprosate is an effective and well-tolerated pharmacological adjunct to psychosocial and behavioural treatment programmes for treatment of alcohol-dependent patients.	UNIV INNSBRUCK CLIN, DEPT PSYCHIAT, A-6020 INNSBRUCK, AUSTRIA; VIENNA UNIV CLIN, DEPT PSYCHIAT, VIENNA, AUSTRIA; ANTON PROKSCH INST, VIENNA, AUSTRIA; LANDESNERVENKRANKENHAUS, KLAGENFURT, AUSTRIA; GENESUNGSHEIM LANDES OBEROESTERREICH, TRAUN, AUSTRIA; GRP LIPHA, LYON, FRANCE	Medical University of Innsbruck								*AM PSYCH ASS, 1980, DIAGN STAT MAN MENT, P163; BOISMARE F, 1984, PHARMACOL BIOCHEM BE, V21, P787, DOI 10.1016/S0091-3057(84)80020-9; BORG V, 1983, ACTA PSYCHIAT SCAND, V68, P100, DOI 10.1111/j.1600-0447.1983.tb06987.x; BURKE TR, 1988, PUBLIC HEALTH REP, V103, P564; CROFTON J, 1987, ALCOHOL ALCOHOLISM, V22, P321; DAOUST M, 1992, PHARMACOL BIOCHEM BE, V41, P669, DOI 10.1016/0091-3057(92)90210-7; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FAWCETT J, 1987, ARCH GEN PSYCHIAT, V44, P248; GALLIMBERTI L, 1992, ALCOHOL CLIN EXP RES, V16, P673, DOI 10.1111/j.1530-0277.1992.tb00658.x; GERRA G, 1992, CURR THER RES CLIN E, V52, P291, DOI 10.1016/S0011-393X(05)80480-1; GRANT KA, 1989, PHARMACOL BIOCHEM BE, V32, P607, DOI 10.1016/0091-3057(89)90005-1; GREB J, IN PRESS NCDEU 1995; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391; Lehert P, 1993, Alcohol Alcohol Suppl, V2, P157; LEMAGNEN J, 1987, ALCOHOL, V4, P97, DOI 10.1016/0741-8329(87)90005-X; LHUINTRE JP, 1990, ALCOHOL ALCOHOLISM, V25, P613, DOI 10.1093/oxfordjournals.alcalc.a045057; LHUINTRE JP, 1985, LANCET, V1, P1014, DOI 10.1016/S0140-6736(85)91615-0; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; Miller W. R., 1986, TREATING ADDICTIVE B, P121; NARANJO CA, 1991, ALCOHOL ALCOHOLISM, P523; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PAILLE FM, 1995, ALCOHOL ALCOHOLISM, V30, P239; RASSNICK S, 1992, ANN NY ACAD SCI, V654, P502; SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SHAW GK, 1994, BRIT J PSYCHIAT, V165, P515, DOI 10.1192/bjp.165.4.515; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; ZEISE ML, 1993, EUR J PHARMACOL, V231, P47, DOI 10.1016/0014-2999(93)90682-8	29	231	235	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1996	347	9013					1438	1442		10.1016/S0140-6736(96)91682-7	http://dx.doi.org/10.1016/S0140-6736(96)91682-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676626				2022-12-28	WOS:A1996UM48500009
J	Sproul, WD				Sproul, WD			New routes in the preparation of mechanically hard films	SCIENCE			English	Article							TIN/NBN SUPERLATTICE COATINGS; DEPOSITION; GROWTH	Superhard nitride superlattice coatings with nanometer-scale multilayers have hardnesses exceeding 50 gigapascals, making these films highly resistant to abrasion. The nitride superlattice films can be deposited economically by reactive sputtering in production-size equipment on a variety of substrates. A model for the superlattice strength enhancement has been developed that accurately predicts which materials can be used together to produce the enhanced hardness. Advancements in sputtering technology-specifically, pulsed dc power and reactive-gas partial-pressure control-make it possible to reactively deposit nonconducting oxide films at high deposition rates. This technology is being used along with the superlattice strength model in the development of oxide superlattice films.			Sproul, WD (corresponding author), NORTHWESTERN UNIV,BIRL,EVANSTON,IL 60201, USA.		Way, James Douglas/A-9408-2010	Way, James Douglas/0000-0001-9612-8508				Barnett S. A., 1993, PHYS THIN FILMS, V17, P1; CHU X, 1995, J APPL PHYS, V77, P4403, DOI 10.1063/1.359467; CHU X, 1992, J VAC SCI TECHNOL A, V10, P1604, DOI 10.1116/1.578030; CHU X, 1993, SURF COAT TECH, V57, P13, DOI 10.1016/0257-8972(93)90331-H; CHU X, 1995, THESIS NW U EVANSTON; FRACH P, 1993, SURF COAT TECH, V59, P177, DOI 10.1016/0257-8972(93)90079-4; GRAHAM ME, 1994, 37 ANN TECHN C P SOC, P275; HELMERSSON U, 1987, J APPL PHYS, V62, P481, DOI 10.1063/1.339770; MIRKARIMI PB, 1990, APPL PHYS LETT, V57, P2654, DOI 10.1063/1.104189; MIRKARIMI PB, 1993, THESIS NW U EVANSTON; SCHILLER S, 1993, SURF COAT TECH, V61, P331, DOI 10.1016/0257-8972(93)90248-M; SCHILLER S, 1995, 38 ANN TECHN P SOC V, P293; SCHNEIDER JA, UNPUB; SELLERS J, 1995, ASYMMETRIC BIPOLAR P; SHINN M, 1994, APPL PHYS LETT, V64, P61, DOI 10.1063/1.110922; SHINN M, 1992, J MATER RES, V7, P901, DOI 10.1557/JMR.1992.0901; SPROUL WD, 1989, SURF COAT TECH, V39, P499, DOI 10.1016/S0257-8972(89)80011-8; SPROUL WD, 1995, J VAC SCI TECHNOL A, V13, P1188, DOI 10.1116/1.579859; SPROUL WD, 1990, SURF COAT TECH, V43-4, P270, DOI 10.1016/0257-8972(90)90080-V; THOM R, 1993, SURF COAT TECH, V62, P423, DOI 10.1016/0257-8972(93)90278-V; WONG MS, IN PRESS SURF COAT T; YANG WMC, 1977, J APPL PHYS, V48, P876, DOI 10.1063/1.323749	22	252	265	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					889	892		10.1126/science.273.5277.889	http://dx.doi.org/10.1126/science.273.5277.889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688063				2022-12-28	WOS:A1996VC67000035
J	Russell, SS; Srinivasan, G; Huss, GR; Wasserburg, GJ; MacPherson, GJ				Russell, SS; Srinivasan, G; Huss, GR; Wasserburg, GJ; MacPherson, GJ			Evidence for widespread Al-26 in the solar nebula and constraints for nebula time scales	SCIENCE			English	Article							ORDINARY CHONDRITES; REFRACTORY INCLUSIONS; ISOTOPIC ANOMALIES; ALLENDE; RICH; PLAGIOCLASE; METEORITES; MAGNESIUM; HIBONITE; ORIGIN	qA search was made for Mg-26 (Mg-26*) from the decay of Al-26 (half-life = 0.73 million years) in Al-rich objects from unequilibrated ordinary chondrites. Two Ca-Al-rich inclusions (CAls) and two Al-rich chondrules (not CAls) were found that contained Al-26 when they formed. Internal isochrons for the CAls yielded an initial Al-26/Al-27 ratio [(Al-26/Al-27)(0)] of 5 x 10(-5), indistinguishable from most CAls in carbonaceous chondrites. This result shows that CAls with this level of Al-26 are present throughout the classes of chondrites and strengthens the notion that Al-26 was widespread in the early solar system. The two Al-rich chondrules have lower Mg-26*, corresponding to a (Al-26/Al-27)(0) ratio of similar to 9 x 10(-6). Five other Al-rich chondrules contain no resolvable Mg-26*. If chondrules and CAls formed from an isotopically homogeneous reservoir, then the chondrules with Al-26 must have formed or been last altered similar to 2 million years after CAls formed; the Mg-26*-free chondrules formed > 1 to 3 million years later still, Because Mg-26*-containing and Mg-26*-free chondrules are both found in Chainpur, which was not heated to more than similar to 400 degrees C, it follows that parent body metamorphism cannot explain the absence of Mg-26* in some of these chondrules. Rather, its absence indicates that the lifetime of the solar nebula over which CAls and chondrules formed extended over similar to 5 million years.	CALTECH,DIV GEOL & PLANETARY SCI,LUNAT ASYLUM,PASADENA,CA 91125	California Institute of Technology	Russell, SS (corresponding author), SMITHSONIAN INST,NATL MUSEUM NAT HIST,DEPT MINERAL SCI,MRC NHB-119,WASHINGTON,DC 20560, USA.		WASSERBURG, GERALD J/F-6247-2011	Huss, Gary/0000-0003-4281-7839; Russell, Sara/0000-0001-5531-7847				BERNIUS MT, 1991, LUNAR PLANET SCI, V22, P93; BISCHOFF A, 1984, GEOCHIM COSMOCHIM AC, V48, P693, DOI 10.1016/0016-7037(84)90096-6; BRIGHAM CA, 1990, THESIS CALTECH; CAMERON AGW, 1995, METEORITICS, V30, P133, DOI 10.1111/j.1945-5100.1995.tb01110.x; CATANZAR.EJ, 1966, J RES NBS A PHYS CH, VA 70, P453, DOI 10.6028/jres.070A.037; CHERNIAK DJ, 1992, EARTH PLANET SC LETT, V113, P411, DOI 10.1016/0012-821X(92)90142-I; CLAYTON DD, 1995, ASTROPHYS J, V451, pL87, DOI 10.1086/309684; CLAYTON RN, 1988, PHILOS T R SOC A, V325, P483, DOI 10.1098/rsta.1988.0062; DIEHL R, 1994, ASTROPHYS J SUPPL S, V92, P429, DOI 10.1086/191990; FAHEY AJ, 1987, GEOCHIM COSMOCHIM AC, V51, P3215, DOI 10.1016/0016-7037(87)90130-X; Hewins R., 1996, CHONDRULES PROTOPLAN, P55; HINTON RW, 1984, NATURE, V308, P169, DOI 10.1038/308169a0; HINTON RW, 1988, GEOCHIM COSMOCHIM AC, V52, P2573, DOI 10.1016/0016-7037(88)90028-2; HUTCHEON ID, 1989, NATURE, V337, P238, DOI 10.1038/337238a0; HUTCHEON ID, 1995, LUNAR PLANET SCI, V26, P647; HUTCHEON ID, 1989, LUNAR PLANET SCI, V20, P434; HUTCHEON ID, 1994, LUNAR PLANET SCI, V25, P587; Jones R., 1989, P LUNAR PLANET SCI C, V19, P523; LEE T, 1976, GEOPHYS RES LETT, V3, P109, DOI 10.1029/GL003i002p00109; LEE T, 1979, ASTROPHYS J, V228, pL93, DOI 10.1086/182911; MacPherson G.J, 1988, METEORITES EARLY SOL; MACPHERSON GJ, 1984, GEOCHIM COSMOCHIM AC, V48, P29, DOI 10.1016/0016-7037(84)90347-8; MACPHERSON GJ, 1983, GEOCHIM COSMOCHIM AC, V47, P823, DOI 10.1016/0016-7037(83)90116-3; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MAHONEY WA, 1984, ASTROPHYS J, V286, P578, DOI 10.1086/162632; SEARS DWG, 1991, P LUNAR PLANET SCI, V21, P493; SHENG YJ, 1991, GEOCHIM COSMOCHIM AC, V55, P581, DOI 10.1016/0016-7037(91)90014-V; SHENG YJ, 1991, THESIS CALTECH; SRINIVASAN G, 1996, LUNAR PLANET SCI, V27, P1257; UREY HC, 1955, P NATL ACAD SCI USA, V41, P127, DOI 10.1073/pnas.41.3.127; WASSERBURG GJ, 1977, GEOPHYS RES LETT, V4, P299, DOI 10.1029/GL004i007p00299; ZINNER E, 1992, METEORITICS, V27, P311; [No title captured]	35	212	217	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					757	762		10.1126/science.273.5276.757	http://dx.doi.org/10.1126/science.273.5276.757			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670407				2022-12-28	WOS:A1996VB42900030
J	Kaneshima, S; Kawakatsu, H; Matsubayashi, H; Sudo, Y; Tsutsui, T; Ohminato, T; Ito, H; Uhira, K; Yamasato, H; Oikawa, J; Takeo, M; Iidaka, T				Kaneshima, S; Kawakatsu, H; Matsubayashi, H; Sudo, Y; Tsutsui, T; Ohminato, T; Ito, H; Uhira, K; Yamasato, H; Oikawa, J; Takeo, M; Iidaka, T			Mechanism of phreatic eruptions at Aso volcano inferred from near-field broadband seismic observations	SCIENCE			English	Article							SAKURAJIMA VOLCANO; JAPAN; TREMOR; CRACK	Broadband seismometers deployed at Aso volcano in Japan have detected a hydrothermal reservoir 1 to 1.5 kilometers beneath the crater that is continually resonating with periods as long as 15 seconds. When phreatic eruptions are observed, broadband seismograms elucidate a dynamic interplay between the reservoir and discharging flow along the conduit: gradual pressurization and long-period (similar to 20 seconds) pulsations of the reservoir during the 100 to 200 seconds before the initiation of the discharge, followed by gradual deflation of the reservoir concurrent with the discharging flow. The hydrothermal reservoir, where water and heat from the deeper magma chamber probably interact, appears to help control the surface activity at Aso volcano.	UNIV TOKYO,EARTHQUAKE RES INST,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT EARTH & PLANETARY PHYS,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC SCI,ASO VOLCANOL LAB,ASO,KUMAMOTO 86914,JAPAN; GEOL SURVEY JAPAN,TSUKUBA,IBARAKI 305,JAPAN; JAPAN METEOROL AGCY,CHIYODA KU,TOKYO 110,JAPAN; METEOROL RES INST,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; University of Tokyo; Kyoto University; Japan Meteorological Agency; Meteorological Research Institute - Japan			Ohminato, Takao/L-1562-2014	Tsutsui, Tomoki/0000-0002-7036-0533				CHOUET B, 1986, J GEOPHYS RES-SOLID, V91, P13967, DOI 10.1029/JB091iB14p13967; Chouet BA, 1996, NATURE, V380, P309, DOI 10.1038/380309a0; CHUREI M, 1985, B VOLCANOL SOC JPN, V30, P71; Dreier R., 1994, ACTA VULCANOL, V5, P165; FALSAPERLA S, 1994, ACTA VULCANOL, V5, P173; FERRAZZINI V, 1987, J GEOPHYS RES-SOLID, V92, P9215, DOI 10.1029/JB092iB09p09215; GOLD T, 1985, PURE APPL GEOPHYS, V122, P492; Hashida T., 1990, B VOLCANOLOGICAL SOC, V35, P323; HELLWEG P, 1994, EOS, V75, P313; KAMO K, 1986, B DISASTER PREV RES, V29, P1; KANAMORI H, 1982, J GEOPHYS RES, V87, P5422, DOI 10.1029/JB087iB07p05422; KAWAKATSU H, 1992, GEOPHYS RES LETT, V19, P1959, DOI 10.1029/92GL01964; KAWAKATSU H, 1994, GEOPHYS RES LETT, V21, P1963, DOI 10.1029/94GL01683; KIEFER SW, 1984, J GEOPHYS RES, V89, P8523; KIEFFER SW, 1977, J GEOPHYS RES, V82, P2895, DOI 10.1029/JB082i020p02895; KIKUCHI S, 1974, B DISASTER PREV RE B, V17, P1; KOYANAGI RY, 1987, VOLCANISM HAWAII, P1221; LINDE AT, 1993, NATURE, V365, P737, DOI 10.1038/365737a0; MATSUBAYASHI H, 1995, THESIS TOKYO U; NEIDEL N, 1971, GEOPHYSICS, V36, P483; NEUBERG J, 1994, GEOPHYS RES LETT, V21, P749, DOI 10.1029/94GL00377; OHMINATO T, 1993, EOS, V74, P648; Sassa K, 1935, MEM COLL SCI KYOTO I, P255; STEINBERG GS, 1975, J GEOPHYS RES, V80, P1600, DOI 10.1029/JB080i011p01600; TANAKA Y, 1993, J VOLCANOL GEOTHERM, V2, P319; UHIRA K, 1994, J GEOPHYS RES-SOL EA, V99, P17775, DOI 10.1029/94JB00990; Wohletz K., 1992, VOLCANOLOGY GEOTHERM	28	83	83	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					642	645		10.1126/science.273.5275.642	http://dx.doi.org/10.1126/science.273.5275.642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662554				2022-12-28	WOS:A1996VA24900046
J	Nelson, KE; Celentano, DD; Eiumtrakol, S; Hoover, DR; Beyrer, C; Suprasert, S; Kuntolbutra, S; Khamboonruang, C				Nelson, KE; Celentano, DD; Eiumtrakol, S; Hoover, DR; Beyrer, C; Suprasert, S; Kuntolbutra, S; Khamboonruang, C			Changes in sexual behavior and a decline in HIV infection among young men in Thailand	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; CHIANG-MAI; TRANSMITTED DISEASES; NORTHERN THAILAND; COMMERCIAL SEX; WORKERS	Background In Thailand the epidemic of human immunodeficiency virus (HIV) infection is of recent origin. Because of the high seroprevalence of HIV among sex workers, the Ministry of Public Health began a program in 1990 and 1991 to promote the use of condoms during commercial sex. We evaluated the effect of this and other programs to prevent HIV infection in Thailand. Methods Using direct interviews, we studied five cohorts of 21-year-old men from northern Thailand who were conscripted into the army by a lottery in 1991, 1993, and 1995. In all, 4311 men were tested for HIV antibodies by enzyme-linked immunosorbent assay, with confirmation by Western blot assay. Results In the 1991 and 1993 cohorts, the prevalence of HIV infection was 10.4 to 12.5 percent. In 1995, it fell to 6.7 percent (P<0.001). The seroprevalence was only 0.7 percent among men who did not have sexual relations with a sex worker before 1992. Over the study period, the proportion of men who reported having sexual relations with a sex worker fell from 81.4 percent to 63.8 percent (P<0.001). From 1991 to 1995, the men's reported use of condoms during the most recent sexual contacts with sex workers increased from 61.0 percent to 92.5 percent (P<0.001); and in 1995, 15.2 percent of men had a history of a sexually transmitted disease, as compared with 42.2 percent in 1991 (P<0.001). Conclusions Public health programs in Thailand have led to substantial changes in sexual behavior among young men, especially an increased use of condoms, and the rate of new HIV infections has declined. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; ROYAL THAI ARMY,KAVILA ARMY HOSP,CHIANG MAI,THAILAND; CHIANG MAI UNIV,FAC MED,DEPT FAMILY MED,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,RES INST HLTH SCI,CHIANG MAI 50000,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University	Nelson, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI35173] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEYRER C, 1995, AIDS, V9, P171, DOI 10.1097/00002030-199509020-00009; Beyrer C, 1996, AIDS, V10, P113, DOI 10.1097/00002030-199601000-00023; BEYRER C, 1994, 10 INT C AIDS INT C, V2, P25; BROWN T, 1994, AIDS, V8, pS131; CARAEL M, 1995, AIDS, V9, P1171, DOI 10.1097/00002030-199510000-00009; Celentano DD, 1996, JAMA-J AM MED ASSOC, V275, P122, DOI 10.1001/jama.275.2.122; CELENTANO DD, 1994, AIDS, V8, P533, DOI 10.1097/00002030-199404000-00018; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HOOVER DR, 1991, AM J EPIDEMIOL, V134, P1190, DOI 10.1093/oxfordjournals.aje.a116022; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LIMANONDA B, 1994, AM J PUBLIC HEALTH, V84, P2026, DOI 10.2105/AJPH.84.12.2026; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; MORRIS M, 1995, AIDS, V9, P507, DOI 10.1097/00002030-199509050-00014; NELSON KE, 1994, AIDS RES HUM RETROV, V10, pS243; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NELSON KE, 1994, AIDS, V8, P951, DOI 10.1097/00002030-199407000-00012; PYNE HH, 1992, THESIS MIT CAMBRIDGE; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; RUGPAO S, 1993, CONTRACEPTION, V48, P537, DOI 10.1016/0010-7824(93)90116-O; Shilts R., 1987, BAND PLAYED POLITICS; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; STONE AB, 1994, AIDS S1, V8, pS285; Strickler Howard, 1995, Annals of Epidemiology, V5, P447, DOI 10.1016/1047-2797(95)00070-4; Sweat M D, 1995, AIDS, V9 Suppl A, pS251; TAWIL O, 1995, AIDS, V9, P1299, DOI 10.1097/00002030-199512000-00001; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; Vanichseni S., 1989, Thai AIDS Journal, V1, P75; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	32	277	282	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					297	303		10.1056/NEJM199608013350501	http://dx.doi.org/10.1056/NEJM199608013350501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663861				2022-12-28	WOS:A1996UY98200001
J	Planes, A; Vochelle, N; Darmon, JY; Fagola, M; Bellaud, M; Huet, Y				Planes, A; Vochelle, N; Darmon, JY; Fagola, M; Bellaud, M; Huet, Y			Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; VEIN THROMBOSIS; UNFRACTIONATED HEPARIN; PREVENTION; ARTHROPLASTY; PHLEBOGRAPHY; PROPHYLAXIS; SURGERY	Background The risk of deep-vein thrombosis (DVT) and pulmonary embolism after total hip replacement (THR) surgery may persist after hospital discharge, but the extent of the risk is not known. We carried out a single-centre, prospective, randomised, double-blind trial with the aims of quantifying this risk and assessing the efficacy of continued prophylactic treatment. Methods At hospital discharge 13-15 days after surgery, we recruited 179 consecutive THR patients who had no DVT visible on bilateral ascending venography of the legs. The patients were randomly assigned subcutaneous enoxaparin (40 mg, once daily; n=90) or placebo (n=89) for 21 (19-23) days. The primary endpoint was the occurrence of DVT or pulmonary embolism. Venography was repealed at the end of 21 days' treatment or earlier if necessary. Findings There were no deaths and no symptomatic pulmonary embolisms during the study or follow-up periods. Of 173 patients with evaluable venograms, intention-to-treat analysis of efficacy showed that the rate of DVT at day 21 after discharge was significantly lower in the enoxaparin group than in the placebo group (6 [7.1%] vs 17 [19.3%], p=0.018). Distal DVT was detected in one (1.2%) patient in the enoxaparin group and in ten (11.4%) patients in the placebo group (p=0.006). Proximal PVT was observed in five (5.9%) patients in the enoxaparin group and in seven (7.9%) patients in the placebo group (p=0.592). A perprotocol analysis of efficacy in 155 patients confirmed these findings. Safety was good; three minor bleeding episodes occurred in the enoxaparin group and one in the placebo group, but none of these episodes necessitated withdrawal from the study. Interpretation In patients who have undergone THR surgery, are without venogram-proven DVT at hospital discharge, and do not receive antithrombotic prophylaxis after discharge, the risk of tale-occurring DVT remains high at least until day 35 after surgery. Continued prophylaxis with enoxaparin is effective and safe in reducing this risk.	RHONE POULENC RORER PHARMA INC,NEUILLY SUR SEINE,FRANCE		Planes, A (corresponding author), CLIN RADIOCHIRURG MAIL,F-17028 LA ROCHELLE,FRANCE.							ALBRECHTSSON U, 1976, LANCET, V1, P723; AMSTUTZ HC, 1989, J BONE JOINT SURG AM, V71A, P321, DOI 10.2106/00004623-198971030-00002; ANGNELLI G, 1995, THROMB HAEMOSTASIS, V74, P1042; BETTMANN MA, 1980, AM J ROENTGENOL, V134, P1169, DOI 10.2214/ajr.134.6.1169; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; ERIKSSON BI, 1989, ACTA ORTHOP SCAND, V60, P159, DOI 10.3109/17453678909149244; HOEK JA, 1992, THROMB HAEMOSTASIS, V67, P28; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; JOHNSON R, 1977, CLIN ORTHOP RELAT R, V127, P123; KAKKAR VV, 1985, J BONE JOINT SURG BR, V67, P538, DOI 10.1302/0301-620X.67B4.4030846; KRISTIANSEN P, 1981, ACTA RADIOL DIAGN, V22, P577, DOI 10.1177/028418518102200511; LAERUM F, 1981, RADIOLOGY, V140, P651, DOI 10.1148/radiology.140.3.7025090; LAVERICK MD, 1991, BRIT MED J, V303, P549, DOI 10.1136/bmj.303.6802.549; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LOTKE PA, 1994, CLIN ORTHOP RELAT R, V299, P25; MCNALLY MA, 1993, J BONE JOINT SURG BR, V75, P640, DOI 10.1302/0301-620X.75B4.8331123; PAIEMENT GD, 1993, J BONE JOINT SURG AM, V75A, P893, DOI 10.2106/00004623-199306000-00010; PAIEMENT GD, 1987, CLIN ORTHOP RELAT R, V223, P188; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SHARROCK NE, 1990, J BONE JOINT SURG AM, V72A, P1456, DOI 10.2106/00004623-199072100-00005; SIKORSKI JM, 1981, J BONE JOINT SURG BR, V63, P171, DOI 10.1302/0301-620X.63B2.7217137; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; SWIERSTRA BA, 1988, ACTA ORTHOP SCAND, V59, P139; TREMAINE MD, 1991, J VASC TECHNOLOGY, V15, P205; TROWBRIDGE A, 1994, CLIN ORTHOP RELAT R, V299, P203; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WILSON J, 1988, THROMB RES, V51, P439, DOI 10.1016/0049-3848(88)90379-9; WOOLSON ST, 1990, J BONE JOINT SURG AM, V72A, P983, DOI 10.2106/00004623-199072070-00004; 1991, ARCH INTERN MED, V151, P1621; 1992, INT ANGIOL, V11, P151	35	405	416	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					224	228		10.1016/S0140-6736(96)01453-5	http://dx.doi.org/10.1016/S0140-6736(96)01453-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684199				2022-12-28	WOS:A1996UZ28600010
J	Yang, XJ; Ogryzko, VV; Nishikawa, J; Howard, BH; Nakatani, Y				Yang, XJ; Ogryzko, VV; Nishikawa, J; Howard, BH; Nakatani, Y			A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A	NATURE			English	Article							NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ADAPTERS; ACTIVATION; YEAST; CREB; DNA; NUCLEOSOME; DOMAINS; CELLS; P300	The adenoviral oncoprotein E1A induces progression through the cell cycle by binding to the products of the p300/CBP and retinoblastoma gene families. A new cellular p300/CBP-associated factor (P/CAF) having intrinsic histone acetylase activity has been identified that competes with E1A. Exogenous expression of P/CAF in HeLa cells inhibits cell-cycle progression and counteracts the mitogenic activity of E1A. E1A disturbs the normal cellular interaction between p300/CBP and its associated histone acetylase.	NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANISTER AJ, 1995, EMBO J, V14, P4758; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOWNELL JE, 1996, CELL, V84, P843; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, MOL CELL BIOL, V16, P593; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2063; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; OGRYZKO VV, 1994, J VIROL, V68, P3724, DOI 10.1128/JVI.68.6.3724-3732.1994; ROCHETTEEGLY C, 1990, GENE DEV, V5, P1200; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	36	1302	1340	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					319	324		10.1038/382319a0	http://dx.doi.org/10.1038/382319a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684459				2022-12-28	WOS:A1996UY95000041
J	Harding, SM				Harding, SM			Racing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					176	176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667547				2022-12-28	WOS:A1996UW46900001
J	McConnell, J				McConnell, J			The message, the medium, and The Lancet	LANCET			English	Editorial Material														McConnell, John/0000-0002-9928-6568					0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					74	74		10.1016/S0140-6736(05)64597-7	http://dx.doi.org/10.1016/S0140-6736(05)64597-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676719				2022-12-28	WOS:A1996UW67300007
J	Riggs, NR; Lehman, TM; Gehrels, GE; Dickinson, WR				Riggs, NR; Lehman, TM; Gehrels, GE; Dickinson, WR			Detrital zircon link between headwaters and terminus of the upper Triassic Chinle-Dockum paleoriver system	SCIENCE			English	Article							SOUTHERN	New detrital-zircon geochronologic data reveal that a through-going paleoriver connected Texas with Nevada in Late Triassic time. Sandstone from the Upper Triassic Santa Rosa Sandstone (Dockum Group) from northwestern Texas contains a detrital zircon suite nearly identical to that found in western Nevada in the Upper Triassic Osobb Formation (Auld Lang Syne Group, correlative with the Chinle Formation). The Santa Rosa Sandstone was derived in large part from the eroded Cambrian core of the Amarillo-Wichita uplift, as evidenced by abundant zircons with ages of 515 to 525 million years. Other zircon grains in the sandstone are Permian, Devonian, Proterozoic, and Archean in age and, with the exception of the Archean grain, are also matched by the population in the Nevada strata.	TEXAS TECH UNIV,DEPT GEOSCI,LUBBOCK,TX 79409; UNIV ARIZONA,DEPT GEOSCI,TUCSON,AZ 85721	Texas Tech University System; Texas Tech University; University of Arizona	Riggs, NR (corresponding author), NO ARIZONA UNIV,DEPT GEOL,BOX 4099,FLAGSTAFF,AZ 86011, USA.							ABBOTT PL, 1989, GEOLOGY, V17, P329, DOI 10.1130/0091-7613(1989)017<0329:SMSFTE>2.3.CO;2; Bickford M.E., 1989, PROTEROZOIC GEOLOGY, V235, P49; Bickford M.E., 1989, GEOL SOC AM SPEC PAP, V235, P33, DOI DOI 10.1130/SPE235-P33; DENISON RE, 1969, GEOL SOC AM BULL, V80, P245, DOI 10.1130/0016-7606(1969)80[245:IAOIAM]2.0.CO;2; Dickinson W.R., 1981, ARIZ GEOL SOC DIG, V14, P113; Dubiel R.F., 1994, MESOZOIC SYSTEMS ROC, P133; DUNAY RE, 1979, REV PALAEOBOT PALYNO, V28, P61, DOI 10.1016/0034-6667(79)90025-3; ELISON MW, 1988, GEOL SOC AM BULL, V100, P185, DOI 10.1130/0016-7606(1988)100<0185:TFOTFA>2.3.CO;2; Fracasso M. A., 1985, W TEXAS GEOLOGICAL S, V24, P5; FRITZ T, 1991, THESIS TEXAS TU; GEHRELS GE, 1995, AM J SCI, V295, P18, DOI 10.2475/ajs.295.1.18; GLEASON JD, 1995, GEOL SOC AM BULL, V107, P1192, DOI 10.1130/0016-7606(1995)107<1192:NICOSS>2.3.CO;2; HAM WE, 1964, OKLA GEOL SURV B, V95; Harland W.B., 1990, GEOLOGIC TIME SCALE; Jacobo A.J., 1986, REV I MEXICANO PETRO, V18, P5; JOHNSON EA, 1993, GEOL SOC AM ABSTR, V25, P57; Lawton T.F., 1994, MESOZOIC SYSTEMS ROC, P1; LEHMAN TH, UNPUB; LEHMAN TM, 1994, NM BUR MINES MIN RES, V34, P37; LEHMAN TM, 1994, W TEXAS GEOLOGICAL S, V34, P5; LONG LE, 1994, US GEOL SURV CIRC, V1107, P197; Lucas S.G., 1987, J ARIZ-NEV ACAD SCI, V22, P21; LUCAS SG, 1993, GEOL SOC AM ABSTR, V25, P111; LUCAS SG, 1991, NEW MEXICO BUREAU MI, V137, P47; LUDWIG KR, 1991, 88542 US GEOL SURV O; LUPE R, 1985, TECTONOSTRATIGRAPHIC, P263; MAY B, 1988, THESIS TEXAS TU, P8; RUIZCASTELLANOS M, 1976, THESIS U TEXAS; SCHARER U, 1982, NATURE, V295, P585, DOI 10.1038/295585a0; SCHNABLE J, 1994, THESIS TEXAS TU; SCHNABLE JG, UNPUB; Slingerland R., 1989, GEOMORPHOLOGY, V2, P23, DOI DOI 10.1016/0169-555X(89)90004-4; STACEY JS, 1975, EARTH PLANET SC LETT, V26, P207, DOI 10.1016/0012-821X(75)90088-6; Stewart J.H., 1972, US GEOL SURV PROF PA, V690; Stewart J.H., 1980, NEVADA BUREAU MINES, V4; STEWART JH, 1986, GEOLOGY, V14, P567, DOI 10.1130/0091-7613(1986)14<567:LTPOTS>2.0.CO;2; TORRES VR, 1992, GEOL SOC AM ABSTR, V24, pA64; TWETO O, 1987, US GEOL SURV PROF A, V1321, P54	38	98	104	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					97	100		10.1126/science.273.5271.97	http://dx.doi.org/10.1126/science.273.5271.97			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8688060				2022-12-28	WOS:A1996UV47800047
J	Simon, DA; Freak, L; Kinsella, A; Walsh, J; Lane, C; Groarke, L; McCollum, C				Simon, DA; Freak, L; Kinsella, A; Walsh, J; Lane, C; Groarke, L; McCollum, C			Community leg ulcer clinics: A comparative study in two health authorities	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the outcome and cost of care for leg ulcers in community leg ulcer clinics in Stockport District Health Authority with Trafford District Health Authority as a control. Design-Detailed cost and efficacy studies conducted prospectively over a three month period in both districts both before and one year after the introduction of five leg ulcer clinics in Stockport. Setting-Two large district health authorities of broad-socioeconomic mix and total population of 540 000. Patients-All patients receiving treatment for an active leg ulcer, irrespective of the profession or location of their carer. Main outcome measures-The proportion of ulcerated limbs completely healed within three months and total cost of leg ulcer care. Results-The introduction of community clinics in Stockport improved healing of leg ulcers from 66/252 (26%) in 1993 to 99/233 (42%) in 1994 (P<0.001) compared with in Trafford, where 47/203 (23%) healed in 1993 and only 43/213 (20%) in 1994. This improved result in Stockport was achieved while the annual expenditure on care of leg ulcers was reduced from pound 409 991 to only pound 253 371. In the same year the cost of leg ulcer care in Trafford increased from pound 556 039 to pound 673 318. Conclusion-In the first year after the introduction of community clinics, before most patients in Stockport had access to these clinics, healing of leg ulcers was already improved whereas costs were reduced.	UNIV MANCHESTER,UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND; STEPPING HILL HOSP,STOCKPORT DIST HLTH AUTHOR COMMUNITY UNIT,FOURTH FLOOR MATERN UNIT,STOCKPORT SK2 7JE,CHESHIRE,ENGLAND; STRETFORD MEM HOSP,TRAFFORD DIST HLTH AUTHOR COMMUNITY UNIT,MANCHESTER M16 0DU,LANCS,ENGLAND	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAIR SD, 1987, BRIT MED J, V294, P1389; CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; CULLUM N, 1994, NURSING MANAGEMENT L; FREAK L, 1996, HLTH TRENDS, V27, P133; Moffatt C J, 1995, J Wound Care, V4, P57; MOFFATT CJ, 1992, BRIT MED J, V305, P1389, DOI 10.1136/bmj.305.6866.1389; MOFFATT CJ, 1994, P 3 EUR C ADV WOUND	7	88	88	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1648	1651		10.1136/bmj.312.7047.1648	http://dx.doi.org/10.1136/bmj.312.7047.1648			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664719	Green Published			2022-12-28	WOS:A1996UV48900025
J	Armstrong, L; Bell, PM				Armstrong, L; Bell, PM			Addison's disease presenting as reduced insulin requirement in insulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA HOSP,SIR GEORGE E CLARK METAB UNIT,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND									BEAVEN DW, 1959, NEW ENGL J MED, V261, P443, DOI 10.1056/NEJM195908272610909; DAGOGOJACK S, 1994, DIABETES, V43, P1426, DOI 10.2337/diabetes.43.12.1426; DUNLOP D, 1963, Br Med J, V2, P887; Irvine W. J., 1972, CLINICS ENDOCRINOLOG, V1, P549; MAISEY M N, 1969, Guy's Hospital Reports, V118, P363; RILEY WJ, 1980, J PEDIATR-US, V97, P191, DOI 10.1016/S0022-3476(80)80472-0; 1993, NEW ENGL J MED, V329, P977	7	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1601	1602		10.1136/bmj.312.7046.1601	http://dx.doi.org/10.1136/bmj.312.7046.1601			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664674	Green Published			2022-12-28	WOS:A1996UU80600027
J	Forterre, P				Forterre, P			A hot topic: The origin of hyperthermophiles	CELL			English	Review											Forterre, P (corresponding author), UNIV PARIS 11,INST MICROBIOL & GENET,UNITE RECH ASSOCIEE 1354,CTR NATL RECH SCI,BATIMENT 409,F-91405 ORSAY,FRANCE.							BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; FORTERRE P, 1995, ORIGINS LIFE EVOL B, V25, P235, DOI 10.1007/BF01581587; FORTERRE P, 1995, CR ACAD SCI III-VIE, V318, P415; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GOGARTENBOEKELS M, 1995, ORIGINS LIFE EVOL B, V25, P251, DOI 10.1007/BF01581588; KENGEN S, 1994, J BIOL CHEM, V17, P17537; KLENK HP, 1994, SYST APPL MICROBIOL, V16, P638; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; Krah R, 1996, P NATL ACAD SCI USA, V93, P106, DOI 10.1073/pnas.93.1.106; Lilley DMJ., 1995, NUCL ACIDS MOL BIOL, P84; Miller SL, 1995, J MOL EVOL, V41, P689; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PEAK MJ, 1995, J BACTERIOL, V177, P6316, DOI 10.1128/jb.177.21.6316-6318.1995; Pond JL, 1986, THERMOPHILES GEN MOL, P107; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Stetter KO, 1994, EARLY LIFE EARTH, V84, P143; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	20	107	114	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					789	792		10.1016/S0092-8674(00)81262-3	http://dx.doi.org/10.1016/S0092-8674(00)81262-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681374	Bronze			2022-12-28	WOS:A1996UR60400003
J	Burnstock, G				Burnstock, G			A unifying purinergic hypothesis for the initiation of pain	LANCET			English	Article							RHEUMATOID-ARTHRITIS; ATP; STIMULATION; ADENOSINE; GUANETHIDINE; MECHANISMS; RECEPTORS; NEURONS; TISSUES; TUMOR	There have been hints over the years about the involvement of purines in pain, and we now have direct evidence with the cloning and characterisation of extracellular receptors for ATP (P2X-purinoceptors) on nociceptive sensory neurons. In this article, a hypothesis is put forward about the sources of ATP released to activate these receptors in three different pain conditions-as a cotransmitter from sympathetic nerves in causalgia and reflex sympathetic dystrophy; from endothelial cells in vascular pain, including migraine and angina; and from tumour cells in cancer. These findings are leading to an active search for selective PZ-purinoceptor antagonists to alleviate pain.			Burnstock, G (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.							ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BLEEHEN T, 1978, BRIT J PHARMACOL, V62, P573, DOI 10.1111/j.1476-5381.1978.tb07764.x; BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; BOULTON AJM, 1986, CLIN ENDOCRINOL META, V15, P917, DOI 10.1016/S0300-595X(86)80080-9; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P31; BURNSTOCK G, 1989, BIOMED PHARMACOTHER, V43, P727, DOI 10.1016/0753-3322(89)90161-3; BURNSTOCK G, 1990, NEUROCHEM INT, V17, P357, DOI 10.1016/0197-0186(90)90158-P; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; BURNSTOCK G, 1981, LANCET, V1, P1397; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; COUTTS AA, 1981, EUR J PHARMACOL, V76, P391, DOI 10.1016/0014-2999(81)90110-2; CREA F, 1990, CIRCULATION, V81, P164, DOI 10.1161/01.CIR.81.1.164; DRIESSEN B, 1994, BRAIN RES, V666, P182, DOI 10.1016/0006-8993(94)90770-6; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HANNINGTONKIFF JG, 1974, LANCET, V1, P1019; HILTON BP, 1971, J CLIN PATHOL, V24, P250, DOI 10.1136/jcp.24.3.250; JANIG W, 1984, RECENT RESULTS CANC, V89, P45; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; LEVINE JD, 1987, RHEUM DIS CLIN N AM, V13, P369; LEVINE JD, 1986, J RHEUMATOL, V13, P1040; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MAEHARA Y, 1987, CLIN CHIM ACTA, V169, P341, DOI 10.1016/0009-8981(87)90337-8; MCMAHON SB, 1991, BRIT MED BULL, V47, P584, DOI 10.1093/oxfordjournals.bmb.a072494; NEEDLEMAN P, 1974, CIRC RES, V34, P455, DOI 10.1161/01.RES.34.4.455; SAWYNOK J, 1989, NEUROSCIENCE, V32, P557, DOI 10.1016/0306-4522(89)90278-9; SCHOTT GD, 1992, AUTONOMIC FAILURE TX, P904; SIEMS WG, 1993, CANCER RES, V53, P5143; SYLVEN C, 1993, CARDIOVASC DRUG THER, V7, P745, DOI 10.1007/BF00878926; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; WANG YT, 1991, ARCH INT PHARMACOD T, V309, P160; YASUDA JM, 1994, ANN PHARMACOTHER, V28, P338	34	205	213	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1604	1605		10.1016/S0140-6736(96)91082-X	http://dx.doi.org/10.1016/S0140-6736(96)91082-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667873				2022-12-28	WOS:A1996UP66100016
J	MacGowan, AP; Feeney, R; Brown, I; McCulloch, S; Lovering, A				MacGowan, AP; Feeney, R; Brown, I; McCulloch, S; Lovering, A			Routine feedback to GPs who request microbiological tests is effective	BRITISH MEDICAL JOURNAL			English	Letter											MacGowan, AP (corresponding author), SOUTHMEAD HLTH SERV NHS TRUST,DEPT MED MICROBIOL,BRISTOL BS10 5NB,AVON,ENGLAND.		MacGowan, Alasdair/AAM-1582-2020; Lovering, Andrew/AAV-4419-2021	MacGowan, Alasdair/0000-0002-6720-5268; Lovering, Andrew/0000-0001-7826-4290				FRASER CG, 1987, ANN CLIN BIOCHEM, V24, P223, DOI 10.1177/000456328702400301; WINKELMAN JW, 1984, HUM PATHOL, V15, P499, DOI 10.1016/S0046-8177(84)80002-7; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093; Winkens RAG, 1996, BRIT MED J, V312, P490, DOI 10.1136/bmj.312.7029.490; YOUNG DW, 1988, POSTGRAD MED J, V64, P283, DOI 10.1136/pgmj.64.750.283	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1481	1481		10.1136/bmj.312.7044.1481b	http://dx.doi.org/10.1136/bmj.312.7044.1481b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664656	Green Published			2022-12-28	WOS:A1996UQ29600072
J	Navarro, B; Sayas, MJ; Atienza, A; Leon, P				Navarro, B; Sayas, MJ; Atienza, A; Leon, P			An unhappily married man with thick soles	LANCET			English	Article									HOSP DR PESET,DEPT HAEMATOL,E-46017 VALENCIA,SPAIN; HOSP DR PESET,DEPT INTERNAL MED,E-46017 VALENCIA,SPAIN									BRUNNING RD, 1994, ATLAS TUMOR PATHOL, P143; HUTTON JT, 1982, NEW ENGL J MED, V307, P1080; KEW J, 1993, BRIT MED J, V306, P506, DOI 10.1136/bmj.306.6876.506; KYLE RA, 1965, NEW ENGL J MED, V273, P18, DOI 10.1056/NEJM196507012730104; PYE KG, 1992, LANCET, V339, P1540, DOI 10.1016/0140-6736(92)91305-R	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1596	1596		10.1016/S0140-6736(96)91079-X	http://dx.doi.org/10.1016/S0140-6736(96)91079-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667870				2022-12-28	WOS:A1996UP66100013
J	Calman, K; Downie, R				Calman, K; Downie, R			Why arts courses for medical curricula	LANCET			English	Editorial Material									UNIV GLASGOW,DEPT PHILOSOPHY,GLASGOW G12 8QQ,LANARK,SCOTLAND; DEPT HLTH,LONDON SE1 6TE,ENGLAND	University of Glasgow			Calman, Kenneth C/C-9855-2010					CALMAN KC, 1988, MED EDUC, V22, P488, DOI 10.1111/j.1365-2923.1988.tb00790.x; CALMAN KC, 1898, MED EDUC, V22, P265; DOWNIE RS, 1994, HEALING ARTS ILLUSTR; MACNAUGHTON J, 1995, BRIT J GEN PRACT, V45, P571; Osier W., 1920, OLD HUMANITIES NEW S, P26; PIRSIG R, 1974, ZEN ART MOTORCYCLE M, P27; WEATHERALL D, 1994, BRIT MED J, V39, P24	7	34	34	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1499	1500		10.1016/S0140-6736(96)90665-0	http://dx.doi.org/10.1016/S0140-6736(96)90665-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684096				2022-12-28	WOS:A1996UN47300004
